

Dexamethasone in Hospitalized Patients with Covid-19

New England Journal of Medicine

384, 693-704

DOI: [10.1056/nejmoa2021436](https://doi.org/10.1056/nejmoa2021436)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa345.	0.4	28
2	Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa040.	0.3	12
3	The Phosphodiesterase Inhibitor Ensifentrine Reduces Production of Proinflammatory Mediators in Well Differentiated Bronchial Epithelial Cells by Inhibiting PDE4. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 414-429.	1.3	12
4	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). <i>European Respiratory Review</i> , 2020, 29, 200287.	3.0	82
5	Inflammatory phenotyping predicts clinical outcome in COVID-19. <i>Respiratory Research</i> , 2020, 21, 245.	1.4	72
6	Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art. <i>Frontiers in Immunology</i> , 2020, 11, 577442.	2.2	27
7	Cell-Free Therapies: Novel Approaches for COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 583017.	2.2	6
8	Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences. <i>Frontiers in Medicine</i> , 2020, 7, 546.	1.2	5
9	The Coronaviruses of Animals and Birds: Their Zoonosis, Vaccines, and Models for SARS-CoV and SARS-CoV2. <i>Frontiers in Veterinary Science</i> , 2020, 7, 582287.	0.9	60
10	Trajectories of Hospitalization in COVID-19 Patients: An Observational Study in France. <i>Journal of Clinical Medicine</i> , 2020, 9, 3148.	1.0	48
11	COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics. <i>Pharmaceutics</i> , 2020, 12, 945.	2.0	14
12	Do cross-reactive antibodies cause neuropathology in COVID-19?. <i>Nature Reviews Immunology</i> , 2020, 20, 645-646.	10.6	58
13	Endothelial Cell Contributions to COVID-19. <i>Pathogens</i> , 2020, 9, 785.	1.2	17
14	Impact of Covid-19 on Hematological Practice: Challenges and Opportunities. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 603-604.	0.3	2
15	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. <i>Drugs</i> , 2020, 80, 1929-1946.	4.9	74
16	Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients. <i>European Journal of Pharmacology</i> , 2020, 889, 173556.	1.7	30
17	Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness. <i>International Journal of Infectious Diseases</i> , 2020, 101, 290-297.	1.5	33
18	Immunotherapeutic approaches to curtail COVID-19. <i>International Immunopharmacology</i> , 2020, 88, 106924.	1.7	57

#	ARTICLE	IF	CITATIONS
19	Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. <i>Scientific Reports</i> , 2020, 10, 17073.	1.6	31
20	Clinical characteristics and survival analysis in critical and non-critical patients with COVID-19 in Wuhan, China: a single-center retrospective case control study. <i>Scientific Reports</i> , 2020, 10, 17524.	1.6	21
21	Genetic Risk of Severe Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 1590-1591.	13.9	22
22	COVID-19 in an Infant with Congenital Adrenal Hyperplasia: A Case Report. <i>Global Pediatric Health</i> , 2020, 7, 2333794X2095893.	0.3	2
23	Reflections on the Collaborative Fight Against COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 565.	1.2	1
24	Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2020, 7, 586221.	1.2	46
25	The Inhibition of NLRP3 Inflammasome and IL-6 Production by Hibiscus noldeae Baker f. Derived Constituents Provides a Link to Its Anti-Inflammatory Therapeutic Potentials. <i>Molecules</i> , 2020, 25, 4693.	1.7	15
26	Treatment for COVID-19: An overview. <i>European Journal of Pharmacology</i> , 2020, 889, 173644.	1.7	226
27	Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1999-2010.	1.2	23
28	SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit. <i>Frontiers in Oncology</i> , 2020, 10, 1722.	1.3	5
29	Research Progress of Genetic Structure, Pathogenic Mechanism, Clinical Characteristics, and Potential Treatments of Coronavirus Disease 2019. <i>Frontiers in Pharmacology</i> , 2020, 11, 1327.	1.6	4
30	SARS-CoV-2: recommendations for treatment in intensive care medicine. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 664-670.	1.0	8
31	Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. <i>Lancet Microbe</i> , The, 2020, 1, e290-e299.	3.4	422
32	Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. <i>Clinical Immunology</i> , 2020, 220, 108598.	1.4	191
33	COVID-19 and Microvascular Disease: Pathophysiology of SARS-CoV-2 Infection With Focus on the Renin-Angiotensin System. <i>Heart Lung and Circulation</i> , 2020, 29, 1596-1602.	0.2	30
34	Presence of hyaluronan in lung alveoli in severe Covid-19: An opening for new treatment options?. <i>Journal of Biological Chemistry</i> , 2020, 295, 15418-15422.	1.6	71
35	Severe COVID-19: what have we learned with the immunopathogenesis?. <i>Advances in Rheumatology</i> , 2020, 60, 50.	0.8	53
36	Molecular Features of Non-Selective Small Molecule Antagonists of the Bradykinin Receptors. <i>Pharmaceuticals</i> , 2020, 13, 259.	1.7	10

#	ARTICLE	IF	CITATIONS
37	Data monitoring committees for clinical trials evaluating treatments of COVID-19. <i>Contemporary Clinical Trials</i> , 2020, 98, 106154.	0.8	7
38	Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence. <i>International Journal of Surgery</i> , 2020, 82, 179-181.	1.1	57
39	Acute Kidney Injury in COVID-19: The Chinese Experience. <i>Seminars in Nephrology</i> , 2020, 40, 430-442.	0.6	27
40	Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study. <i>European Respiratory Journal</i> , 2020, 56, 2003498.	3.1	145
41	Mining the past to treat the present, ever mindful of the future: Low-dose radiotherapy and COVID-19 pneumonia. <i>Cancer</i> , 2020, 126, 5017-5021.	2.0	4
42	COVID-19 in the Pediatric Population—Review and Current Evidence. <i>Current Infectious Disease Reports</i> , 2020, 22, 29.	1.3	32
43	Immune Thrombocytopenia Secondary to COVID-19: a Systematic Review. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2048-2058.	0.3	215
44	Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. <i>Critical Care</i> , 2020, 24, 589.	2.5	47
45	SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus. <i>Frontiers in Pharmacology</i> , 2020, 11, 1224.	1.6	30
46	Coronavirus Disease 2019 Related Clinical Studies: A Cross-Sectional Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 540187.	1.6	3
47	Photodynamic and sonodynamic therapy of acute hypoxemic respiratory failure in patients with COVID-19. <i>Photodiagnosis and Photodynamic Therapy</i> , 2020, 31, 101961.	1.3	7
48	The BAS2IC Score: A Useful Tool to Identify Patients at High Risk of Early Progression to Severe Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa405.	0.4	8
49	Antiviral Drug Discovery To Address the COVID-19 Pandemic. <i>MBio</i> , 2020, 11, .	1.8	7
50	The use of remdesivir outside of clinical trials during the COVID-19 pandemic. <i>Journal of Pharmaceutical Policy and Practice</i> , 2020, 13, 61.	1.1	3
51	Anakinra for severe forms of COVID-19 — Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e587-e588.	2.2	3
52	Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e754-e763.	2.2	237
53	Encephalopathy in COVID-19 patients; viral, parainfectious, or both?. <i>ENeurologicalSci</i> , 2020, 21, 100275.	0.5	36
54	COVID-19 in children: what did we learn from the first wave?. <i>Paediatrics and Child Health (United Kingdom)</i> , 2020, 11, 100275.	0.2	11

#	ARTICLE	IF	CITATIONS
55	SARS-CoV-2 challenge studies: ethics and risk minimisation. <i>Journal of Medical Ethics</i> , 2020, , medethics-2020-106504.	1.0	15
56	The Important Role of Volatile Components From a Traditional Chinese Medicine Dayuan-Yin Against the COVID-19 Pandemic. <i>Frontiers in Pharmacology</i> , 2020, 11, 583651.	1.6	15
57	May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?. <i>Antioxidants</i> , 2020, 9, 971.	2.2	9
58	Early management of critically ill patients with COVID-19. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1418-1426.	0.4	2
59	Critically Ill Patients with COVID-19: A Narrative Review on Prone Position. <i>Pulmonary Therapy</i> , 2020, 6, 233-246.	1.1	30
60	Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2131-2136.	0.3	1
61	A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. <i>Cell</i> , 2020, 183, 1058-1069.e19.	13.5	305
62	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2333-2344.	13.9	1,102
63	Transcriptional and proteomic insights into the host response in fatal COVID-19 cases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28336-28343.	3.3	149
64	COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. <i>Digestive Diseases</i> , 2021, 39, 119-139.	0.8	88
65	The Possible Dual Role of the ACE2 Receptor in Asthma and Coronavirus (SARS-CoV2) Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 550571.	1.8	24
66	Invasive Pulmonary Aspergillosis in Patients with SARS-CoV-2 Infection: A Systematic Review of the Literature. <i>Diagnostics</i> , 2020, 10, 807.	1.3	49
67	Critical Care Demand and Intensive Care Supply for Patients in Japan with COVID-19 at the Time of the State of Emergency Declaration in April 2020: A Descriptive Analysis. <i>Medicina (Lithuania)</i> , 2020, 56, 530.	0.8	6
68	Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. <i>European Journal of Immunology</i> , 2020, 50, 2025-2040.	1.6	188
69	Lessons from COVID-19: How human behaviour may influence the science. <i>Diabetes Research and Clinical Practice</i> , 2020, 169, 108491.	1.1	3
70	Strategies and Advances in Combating COVID-19 in China. <i>Engineering</i> , 2020, 6, 1076-1084.	3.2	16
71	COVID-19 in a patient with a flare of systemic lupus erythematosus: A rare case-report. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101252.	0.2	12
72	A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. <i>Nature Communications</i> , 2020, 11, 5284.	5.8	66

#	ARTICLE	IF	CITATIONS
73	Clinical Risk Prediction Scores in Coronavirus Disease 2019: Beware of Low Validity and Clinical Utility. , 2020, 2, e0253.		12
74	Attenuating COVID-19 infection and inflammation: Lessons from asthma. <i>Respirology</i> , 2020, 25, 1233-1234.	1.3	2
75	Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2096408.	0.2	15
76	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCOVID-19 prospective trial. <i>Journal of Translational Medicine</i> , 2020, 18, 405.	1.8	98
77	COVID-19 and Acute Sarcopenia. , 2020, 11, 1345.		103
78	SARS-CoV-2 infection in the COPD population is associated with increased healthcare utilization: An analysis of Cleveland clinic's COVID-19 registry. <i>EClinicalMedicine</i> , 2020, 26, 100515.	3.2	50
79	The cardiac effects of SARS-CoV2: COVID-19 special issue. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-2.	0.3	1
80	Effects of Short-Term Low-Dose Glucocorticoids for Patients with Mild COVID-19. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	11
81	Considerations for cancer immunotherapy during the COVID -19 pandemic. <i>Medical Journal of Australia</i> , 2020, 213, 390.	0.8	3
84	Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis. <i>Digestive and Liver Disease</i> , 2020, 52, 1383-1389.	0.4	69
85	Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 63, 101942.	1.1	66
86	Metallo drug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. <i>Nature Microbiology</i> , 2020, 5, 1439-1448.	5.9	140
87	Repurposing existing drugs for COVID-19: an endocrinology perspective. <i>BMC Endocrine Disorders</i> , 2020, 20, 149.	0.9	36
88	Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1192-1200.	5.2	99
90	The transmission modes and sources of COVID-19: A systematic review. <i>International Journal of Surgery Open</i> , 2020, 26, 125-136.	0.2	84
91	A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Réunion Island. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 23, 1-3.	0.9	10
92	Clinical characteristics and manifestations in older patients with COVID-19. <i>BMC Geriatrics</i> , 2020, 20, 395.	1.1	46
93	Reactivation of SARS-CoV-2 after Asymptomatic Infection while on High-Dose Corticosteroids. Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2402-2405.	0.3	10

#	ARTICLE	IF	CITATIONS
94	Obesity, Diabetes and COVID-19: An Infectious Disease Spreading From the East Collides With the Consequences of an Unhealthy Western Lifestyle. <i>Frontiers in Endocrinology</i> , 2020, 11, 582870.	1.5	43
95	Clinical considerations in patients with diabetes during times of COVID19: An update on lifestyle factors and antihyperglycemic drugs with focus on India. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1777-1781.	1.8	6
96	Projected supportive effects of Pycnogenol [®] in patients suffering from multi-dimensional health impairments after a SARS-CoV2 infection. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106191.	1.1	6
97	Correlation between premorbid IL-6 levels and COVID-19 mortality: Potential role for Vitamin D. <i>International Immunopharmacology</i> , 2020, 88, 106995.	1.7	28
98	How Canada can better embed randomized trials into clinical care. <i>Cmaj</i> , 2020, 192, E928-E929.	0.9	9
99	Remdesivir against COVID-19 and Other Viral Diseases. <i>Clinical Microbiology Reviews</i> , 2020, 34, .	5.7	181
100	COVID-19 and ethnicity: Does reduced responsiveness to glucocorticoids explain the more aggressive nature of disease among minorities?. <i>Medical Hypotheses</i> , 2020, 144, 110220.	0.8	6
101	COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. <i>Nature Reviews Nephrology</i> , 2020, 16, 747-764.	4.1	466
102	Defining the scourge of COVID-19 hyperinflammatory syndrome. <i>Lancet Rheumatology</i> , The, 2020, 2, e727-e729.	2.2	6
103	Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). <i>EClinicalMedicine</i> , 2020, 28, 100591.	3.2	74
104	Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>European Journal of Cancer</i> , 2020, 140, 86-104.	1.3	33
105	A materials-science perspective on tackling COVID-19. <i>Nature Reviews Materials</i> , 2020, 5, 847-860.	23.3	228
106	Pandemic and promise: progress towards finding an effective treatment for Novel Coronavirus 19. <i>Australian and New Zealand Journal of Public Health</i> , 2020, 44, 437-439.	0.8	1
107	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. <i>Science</i> , 2020, 370, .	6.0	508
108	Association of smoking status with outcomes in hospitalised patients with COVID-19. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000716.	1.2	20
109	Convalescent Blood Products in COVID-19: A Narrative Review. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612096064.	1.1	3
110	Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider. <i>Critical Care</i> , 2020, 24, 603.	2.5	5
111	The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. <i>Intensive Care Medicine</i> , 2020, 46, 2067-2070.	3.9	38

#	ARTICLE	IF	CITATIONS
112	Glucocorticoid excess and COVID-19 disease. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 703-714.	2.6	36
113	Management Considerations for the COVID-19 Patient with Severe Disease: a Case Scenario and Literature Review. <i>HSS Journal</i> , 2020, 16, 153-159.	0.7	2
114	Elderly as a High-risk Group during COVID-19 Pandemic: Effect of Circadian Misalignment, Sleep Dysregulation and Melatonin Administration. <i>Sleep and Vigilance</i> , 2020, 4, 81-87.	0.4	48
115	ICU re-organisation to face the first COVID-19 epidemic wave in a tertiary hospital. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 731-732.	0.6	10
116	Statin Treatment of COVID-19. <i>American Journal of Cardiology</i> , 2020, 136, 171-173.	0.7	9
117	Cytokine Storms in Cancer and COVID-19. <i>Cancer Cell</i> , 2020, 38, 598-601.	7.7	66
118	Sarilumab use in severe SARS-CoV-2 pneumonia. <i>EClinicalMedicine</i> , 2020, 27, 100553.	3.2	66
119	A case of corticosteroid-responsive SARS-CoV-2 related massive rhabdomyolysis. <i>IDCases</i> , 2020, 22, e00946.	0.4	4
120	Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106144.	1.1	104
121	Finding the right time for anti-inflammatory therapy in COVID-19. <i>International Journal of Infectious Diseases</i> , 2020, 101, 247-248.	1.5	6
122	COVID-19, myocardial edema and dexamethasone. <i>Medical Hypotheses</i> , 2020, 145, 110307.	0.8	10
123	Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review. <i>New Microbes and New Infections</i> , 2020, 38, 100776.	0.8	25
124	Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. <i>Nature Immunology</i> , 2020, 21, 1506-1516.	7.0	563
125	Interferon Beta-1b and Lopinavir/Ritonavir for Middle East Respiratory Syndrome. <i>New England Journal of Medicine</i> , 2020, 383, 1645-1656.	13.9	61
126	Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 739-741.	1.4	22
127	Reply to Hasford and to Spinola et al. <i>Journal of Infectious Diseases</i> , 2020, 222, 1574-1575.	1.9	0
128	Repurposing Existing Drugs for the Treatment of COVID-19. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1186-1194.	1.5	19
129	Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. <i>Drug Safety</i> , 2020, 43, 691-698.	1.4	102

#	ARTICLE	IF	CITATIONS
130	Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning. <i>Journal of Proteome Research</i> , 2020, 19, 4624-4636.	1.8	183
131	Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1120-1131.	0.3	19
132	Risk to health from COVID-19 for anaesthetists and intensivists – a narrative review. <i>Anaesthesia</i> , 2020, 75, 1494-1508.	1.8	32
133	Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106101.	1.1	83
134	Alternative Pathways of IL-1 Activation, and Its Role in Health and Disease. <i>Frontiers in Immunology</i> , 2020, 11, 613170.	2.2	83
135	Current and Future Direct-Acting Antivirals Against COVID-19. <i>Frontiers in Microbiology</i> , 2020, 11, 587944.	1.5	16
136	First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia. <i>Frontiers in Medicine</i> , 2020, 7, 596916.	1.2	5
137	Cardiovascular Disease and SARS-CoV-2: the Role of Host Immune Response Versus Direct Viral Injury. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8141.	1.8	4
138	Phenotypes and personalized medicine in the acute respiratory distress syndrome. <i>Intensive Care Medicine</i> , 2020, 46, 2136-2152.	3.9	106
139	COVID-19-Induced ARDS Is Associated with Decreased Frequency of Activated Memory/Effector T Cells Expressing CD11a ⁺⁺ . <i>Molecular Therapy</i> , 2020, 28, 2691-2702.	3.7	35
140	A Dexamethasone-Eluting Porous Scaffold for Bone Regeneration Fabricated by Selective Laser Sintering. <i>ACS Applied Bio Materials</i> , 2020, 3, 8739-8747.	2.3	21
141	The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8612.	1.8	19
142	Is the Frequency of Candidemia Increasing in COVID-19 Patients Receiving Corticosteroids?. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 286.	1.5	50
143	Risk Factors for Invasive Pulmonary Aspergillosis in Critically Ill Patients With Coronavirus Disease 2019-Induced Acute Respiratory Distress Syndrome. , 2020, 2, e0244.		30
144	The unusual experience of managing a severe COVID-19 case at home: what can we do and where do we go?. <i>BMC Infectious Diseases</i> , 2020, 20, 862.	1.3	5
145	Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions. <i>Clinical Infectious Diseases</i> , 2021, 72, e1130-e1143.	2.9	34
146	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 434-441.	0.6	5
147	Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model. <i>Viruses</i> , 2020, 12, 1325.	1.5	24

#	ARTICLE	IF	CITATIONS
148	Comparison of deep learning with regression analysis in creating predictive models for SARS-CoV-2 outcomes. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 299.	1.5	28
149	Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. <i>Critical Care</i> , 2020, 24, 653.	2.5	67
150	Rapidly progressive organizing pneumonia associated with COVID-19. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101295.	0.2	9
151	Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury. <i>Cell Reports Medicine</i> , 2020, 1, 100145.	3.3	12
152	Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management. , 2020, 8, e001019.		13
153	Peripheral neuropathy in severe COVID-19 resolved with therapeutic plasma exchange. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3233-3238.	0.2	21
154	Sepsis and Coronavirus Disease 2019: Common Features and Anti-Inflammatory Therapeutic Approaches. <i>Critical Care Medicine</i> , 2020, 48, 1841-1844.	0.4	70
155	Safe and effective medication utilization in pediatric patients requiring rehabilitation services during the Coronavirus pandemic of 2019. <i>Journal of Pediatric Rehabilitation Medicine</i> , 2020, 13, 221-223.	0.3	2
156	Outcomes and clinical practice in patients with COVID-19 admitted to the intensive care unit in Montr�al, Canada: a descriptive analysis. <i>CMAJ Open</i> , 2020, 8, E788-E795.	1.1	21
157	Treatment of COVID-19 patients with the anti-�CD6 antibody itolizumab. <i>Clinical and Translational Immunology</i> , 2020, 9, e1218.	1.7	13
158	Impact of COVID-19 on the thyroid gland: an update. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 803-815.	2.6	165
160	Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8803.	1.8	7
161	Recommendations for treatment of critically ill patients with COVID-19. <i>Der Anaesthetist</i> , 2020, , 1.	0.5	22
162	Recommendations for the Diagnosis, Prevention, and Control of Coronavirus Disease-19 in Children�The Chinese Perspectives. <i>Frontiers in Pediatrics</i> , 2020, 8, 553394.	0.9	26
163	Biomimetic Nanoparticles Potentiate the Anti-Inflammatory Properties of Dexamethasone and Reduce the Cytokine Storm Syndrome: An Additional Weapon against COVID-19?. <i>Nanomaterials</i> , 2020, 10, 2301.	1.9	33
164	COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. <i>Journal of Biosciences</i> , 2020, 45, 1.	0.5	79
165	Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: Guidance From the Canadian Society of Transplantation Pediatric Group. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096784.	0.6	17
166	Management of Canadian Pediatric Patients With Glomerular Diseases During the COVID-19 Pandemic: Recommendations From the Canadian Association of Pediatric Nephrologists COVID-19 Rapid Response Team. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812097071.	0.6	5

#	ARTICLE	IF	CITATIONS
167	Effectiveness and safety of noninvasive positive pressure ventilation in the treatment of COVID-19-associated acute hypoxemic respiratory failure: a single center, non-ICU setting experience. Internal and Emergency Medicine, 2021, 16, 1183-1190.	1.0	23
168	Predictors of Mortality and Effect of Drug Therapies in Mechanically Ventilated Patients With Coronavirus Disease 2019: A Multicenter Cohort Study. , 2020, 2, e0305.		3
169	Risk factors for mortality in hospitalized patients with COVID-19 at the start of the pandemic in Belgium: a retrospective cohort study. BMC Infectious Diseases, 2020, 20, 897.	1.3	39
170	Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study. Open Forum Infectious Diseases, 2020, 7, ofaa563.	0.4	48
171	Lung transplantation for patients with severe COVID-19. Science Translational Medicine, 2020, 12, .	5.8	246
172	Perinatal Maternal-Fetal/Neonatal Transmission of COVID-19: A Guide to Safe Maternal and Neonatal Care in the Era of COVID-19 and Physical Distancing. NeoReviews, 2020, 21, e783-e794.	0.4	9
173	Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. Frontiers in Molecular Biosciences, 2020, 7, 605236.	1.6	159
174	Comparing and Contrasting MERS, SARS-CoV, and SARS-CoV-2: Prevention, Transmission, Management, and Vaccine Development. Pathogens, 2020, 9, 985.	1.2	1
175	Prone positioning and convalescent plasma therapy in a critically ill pregnant woman with COVID-19. Clinical Case Reports (discontinued), 2020, 8, 3352-3358.	0.2	6
176	A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19. Scientific Reports, 2020, 10, 20935.	1.6	32
177	Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19?. Journal of Personalized Medicine, 2020, 10, 217.	1.1	25
178	Metallo drugs are unique: opportunities and challenges of discovery and development. Chemical Science, 2020, 11, 12888-12917.	3.7	354
179	COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrology Dialysis Transplantation, 2020, 35, 1973-1983.	0.4	312
180	Cytokine Storm. New England Journal of Medicine, 2020, 383, 2255-2273.	13.9	1,911
181	Targeting progesterone signaling prevents metastatic ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31993-32004.	3.3	29
182	A year in our understanding of COVID-19. Clinical and Experimental Immunology, 2020, 202, 146-148.	1.1	2
183	Corticosteroid injections during the COVID-19 pandemic. Bone & Joint Open, 2020, 1, 605-611.	1.1	19
184	Can Melatonin Be a Potential "Silver Bullet" in Treating COVID-19 Patients?. Diseases (Basel), Tj ETQq1 1 0.784314 rgBT /Overlook	1.0	55

#	ARTICLE	IF	CITATIONS
185	COVID-19: Short and Long-Term Effects of Hospitalization on Muscular Weakness in the Elderly. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8715.	1.2	38
186	GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 267.	7.1	8
187	Remdesivir: a pendulum in a pandemic. <i>BMJ, The</i> , 2020, 371, m4560.	3.0	4
188	Translating scientific discoveries during pandemics: ensuring equity for people affected by COVID-19 and tuberculosis. <i>ERJ Open Research</i> , 2020, 6, 00562-2020.	1.1	0
189	The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome. <i>Journal of Translational Medicine</i> , 2020, 18, 457.	1.8	61
190	Harnessing the Neural Stem Cell Secretome for Regenerative Neuroimmunology. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 590960.	1.8	27
191	USA stockpiling of remdesivir: How should the world respond?. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 1243-1246.	0.6	1
192	Lessons Learned Comparing Immune System Alterations of Bacterial Sepsis and SARS-CoV-2 Sepsis. <i>Frontiers in Immunology</i> , 2020, 11, 598404.	2.2	18
193	SARS-CoV-2 Inhibition by Sulfonated Compounds. <i>Microorganisms</i> , 2020, 8, 1894.	1.6	19
194	<p>Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic</p>. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 2707-2728.	1.2	14
195	Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. <i>Frontiers in Medicine</i> , 2020, 7, 581521.	1.2	42
196	Associations between COVID-19-Related Digital Health Literacy and Online Information-Seeking Behavior among Portuguese University Students. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8987.	1.2	61
198	Vitamin C–An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19. <i>Nutrients</i> , 2020, 12, 3760.	1.7	123
199	Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab. <i>Immunology Letters</i> , 2020, 228, 122-128.	1.1	14
200	In fatal COVID-19, the immune response can control the virus but kill the patient. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 30009-30011.	3.3	24
201	Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients. , 2020, 2, e0232.		7
202	Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis. <i>Critical Care</i> , 2020, 24, 643.	2.5	42
203	Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 723-730.	0.6	22

#	ARTICLE	IF	CITATIONS
204	Does hydroxychloroquine reduce mortality for COVID-19?. <i>European Journal of Internal Medicine</i> , 2020, 82, 21-22.	1.0	4
205	Severe Acute Respiratory Syndrome Coronavirus 2 Lethality Did not Change Over Time in Two Italian Provinces. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa556.	0.4	8
206	Antiviral Dosing Modification for Coronavirus Disease 2019â€“Infected Patients Receiving Extracorporeal Therapy. , 2020, 2, e0242.		8
207	Coronavirus Infection of the Central Nervous System: Animal Models in the Time of COVID-19. <i>Frontiers in Veterinary Science</i> , 2020, 7, 584673.	0.9	3
208	SARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020078.	0.5	5
209	Structured ICU resource management in a pandemic is associated with favorable outcome in critically ill COVIDâ€“19 patients. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 653-663.	1.0	19
210	Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. <i>European Journal of Cancer</i> , 2020, 141, 171-184.	1.3	65
211	Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. <i>Science Advances</i> , 2020, 6, .	4.7	204
212	Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 768-770.	0.7	27
213	Hydroxychloroquine in COVID-19: Taking care of statistics to take care of patients. <i>International Journal of Infectious Diseases</i> , 2020, 99, 324.	1.5	1
214	Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1738-1748.	0.6	36
215	Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 147, 12-17.	0.9	29
216	The trade-off dilemma in pharmacotherapy of COVID-19: systematic review, meta-analysis, and implications. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1821-1849.	0.9	6
217	After 62 years of regulating immunity, dexamethasone meets COVID-19. <i>Nature Reviews Immunology</i> , 2020, 20, 587-588.	10.6	108
218	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARSâ€“CoVâ€“2 and Hyperinflammation in Pediatric COVIDâ€“19: Version 1. <i>Arthritis and Rheumatology</i> , 2020, 72, 1791-1805.	2.9	323
219	Pyruvate affects inflammatory responses of macrophages during influenza A virus infection. <i>Virus Research</i> , 2020, 286, 198088.	1.1	19
220	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.	7.7	108
221	Sexâ€“related differences in COVIDâ€“19 lethality. <i>British Journal of Pharmacology</i> , 2020, 177, 4375-4385.	2.7	69

#	ARTICLE	IF	CITATIONS
222	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. <i>Biochemical Pharmacology</i> , 2020, 180, 114169.	2.0	26
223	Radiation Therapy as a Treatment for COVID-19?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1140-1142.	0.4	6
224	Blood nitrate and nitrite modulating nitric oxide bioavailability: Potential therapeutic functions in COVID-19. <i>Nitric Oxide - Biology and Chemistry</i> , 2020, 103, 29-30.	1.2	27
225	Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1983-1994.	2.0	54
227	Uncontrolled interventions during pandemics: a missed learning opportunity?. <i>Intensive Care Medicine</i> , 2020, 46, 1930-1931.	3.9	3
228	Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. <i>Nature Reviews Rheumatology</i> , 2020, 16, 581-589.	3.5	203
229	Drug treatments for covid-19: living systematic review and network meta-analysis. <i>BMJ</i> , The, 2020, 370, m2980.	3.0	592
230	COVID-19 and Dexamethasone. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 623.	3.8	93
231	Mortality in COVID-19 is not merely a question of resource availability. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 832-833.	5.2	15
232	Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 846-847.	5.2	48
233	Desperate times call for evidence-based measures: Prioritizing science during the COVID-19 pandemic. <i>Jammi</i> , 2020, 5, 127-129.	0.3	0
234	The "Infodemic" of COVID-19. <i>Arthritis and Rheumatology</i> , 2020, 72, 1806-1808.	2.9	52
235	Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. <i>Cell</i> , 2020, 182, 1419-1440.e23.	13.5	1,162
236	Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy. <i>Clinical Immunology</i> , 2020, 219, 108550.	1.4	9
237	The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 1991.	2.2	124
238	Racial Disparities-Associated COVID-19 Mortality among Minority Populations in the US. <i>Journal of Clinical Medicine</i> , 2020, 9, 2442.	1.0	232
239	COVID-19 -Tuberculosis interactions: When dark forces collide. <i>Indian Journal of Tuberculosis</i> , 2020, 67, S155-S162.	0.3	47
240	Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 813-834.	2.5	25

#	ARTICLE	IF	CITATIONS
241	To immunosuppress: whom, when and how? That is the question with COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1129-1131.	0.5	16
242	Dexamethasone nanomedicines for COVID-19. <i>Nature Nanotechnology</i> , 2020, 15, 622-624.	15.6	138
243	Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 810-813.	0.4	10
244	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
245	Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. <i>Lancet Rheumatology</i> , The, 2020, 2, e603-e612.	2.2	228
246	Severe immune thrombocytopenia in a critically ill COVID-19 patient. <i>International Journal of Infectious Diseases</i> , 2020, 99, 269-271.	1.5	22
247	Coronavirus Disease 2019 (COVID-19), Organ Transplantation, and the Nuances of Immunomodulation: Lessons Learned and What Comes Next. <i>Clinical Infectious Diseases</i> , 2020, 73, e4100-e4102.	2.9	1
248	Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity. <i>Obesity Facts</i> , 2020, 13, 439-452.	1.6	49
249	High-dose intravenous vitamin C may help in cytokine storm in severe SARS-CoV-2 infection. <i>Critical Care</i> , 2020, 24, 500.	2.5	11
250	Immunosuppressive Drugs and COVID-19: A Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 1333.	1.6	89
251	Second Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management. <i>Journal of Clinical Medicine</i> , 2020, 9, 2542.	1.0	2
252	Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. <i>Kidney International</i> , 2020, 98, 1530-1539.	2.6	203
253	Ongoing non-industry-sponsored COVID-19 clinical trials in the first trimester of the pandemic: significant differences between the European and the USA approaches. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1067-1072.	1.3	1
254	Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study. <i>Emerging Microbes and Infections</i> , 2020, 9, 1869-1877.	3.0	23
255	Treatment of pemphigus patients in the COVID-19 era: A specific focus on rituximab. <i>Dermatologic Therapy</i> , 2020, 33, e14188.	0.8	4
256	Understanding COVID-19: From Origin to Potential Therapeutics. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5904.	1.2	13
257	COVID-19 and multisystem inflammatory syndrome in children and adolescents. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e276-e288.	4.6	590
258	Tocilizumab for severe COVID-19 pneumonia. <i>Lancet Rheumatology</i> , The, 2020, 2, e659.	2.2	2

#	ARTICLE	IF	CITATIONS
259	Early Treatment of COVID-19 Disease: A Missed Opportunity. <i>Infectious Diseases and Therapy</i> , 2020, 9, 715-720.	1.8	18
260	Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2637-2646.	0.3	149
261	Addition of Corticosteroids to Immunoglobulins Is Associated With Recovery of Cardiac Function in Multi-Inflammatory Syndrome in Children. <i>Circulation</i> , 2020, 142, 2282-2284.	1.6	89
262	Corticosteroids in severe COVID-19: a critical view of the evidence. <i>Critical Care</i> , 2020, 24, 627.	2.5	32
263	Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country. <i>Contemporary Clinical Trials</i> , 2020, 99, 106189.	0.8	14
264	<p>Current Options in the Treatment of COVID-19: A Review</p>. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 1999-2010.	1.2	8
265	SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 570927.	2.2	28
266	Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic. <i>Frontiers in Medicine</i> , 2020, 7, 562142.	1.2	14
267	Epidemiology of the First Wave of COVID-19 ICU Admissions in South Walesâ”The Interplay Between Ethnicity and Deprivation. <i>Frontiers in Medicine</i> , 2020, 7, 569714.	1.2	20
268	Mesenchymal Stem Cells and Their Extracellular Vesicles: A Potential Game Changer for the COVID-19 Crisis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 587866.	1.8	14
269	Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19. <i>BMJ, The</i> , 2020, 371, m3869.	3.0	16
270	Successful management of SARS-CoV-2 acute respiratory distress syndrome and newly diagnosed acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020, 4, 4358-4361.	2.5	16
271	SARS-CoV-2 infection as a risk factor for herpesviridae reactivation: consider the potential influence of corticosteroid therapy. <i>Critical Care</i> , 2020, 24, 623.	2.5	9
272	Thrombosis and COVID-19: The Potential Role of Nutrition. <i>Frontiers in Nutrition</i> , 2020, 7, 583080.	1.6	33
274	Catecholamine physiology and its implications in patients with COVID-19. <i>Lancet Diabetes and Endocrinology,the</i> , 2020, 8, 978-986.	5.5	49
275	Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19. <i>Gerontology</i> , 2020, 66, 553-561.	1.4	20
276	Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 580202.	1.8	20
277	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 562264.	2.2	8

#	ARTICLE	IF	CITATIONS
278	Loss of Olfactory Functionâ€”Early Indicator for Covid-19, Other Viral Infections and Neurodegenerative Disorders. <i>Frontiers in Neurology</i> , 2020, 11, 569333.	1.1	42
279	Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients. <i>Current Transplantation Reports</i> , 2020, 7, 379-389.	0.9	12
280	COVID-19, steroids and other immunomodulators: The jigsaw is not complete. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 699-701.	0.6	7
281	Clinical care of pregnant and postpartum women with COVIDâ€“19: Living recommendations from the National COVIDâ€“19 Clinical Evidence Taskforce. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020, 60, 840-851.	0.4	36
282	The role of nicotinic receptors in SARS-CoV-2 receptor ACE2 expression in intestinal epithelia. <i>Bioelectronic Medicine</i> , 2020, 6, 20.	1.0	5
283	A â€œWindow of Therapeutic Opportunityâ€”for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019. <i>Frontiers in Immunology</i> , 2020, 11, 572635.	2.2	11
284	Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis Leading the Outcome. <i>Journal of Clinical Medicine</i> , 2020, 9, 3487.	1.0	63
285	Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1170-1172.	5.2	98
286	Therapeutic modalities and novel approaches in regenerative medicine for COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106208.	1.1	22
287	Prognostic Impact of Prior Heartâ€“Failure in Patients Hospitalized With COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2334-2348.	1.2	157
288	Photodynamic therapy for COVID-19. <i>Nature Photonics</i> , 2020, 14, 651-652.	15.6	45
289	Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study. <i>Pharmaceuticals</i> , 2020, 13, 317.	1.7	40
290	Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies. <i>International Journal of Infectious Diseases</i> , 2020, 101, 59-64.	1.5	12
291	Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1407-1412.	1.9	15
292	Prolonged viral shedding in an immunocompetent patient with COVID-19. <i>BMJ Case Reports</i> , 2020, 13, e237357.	0.2	12
293	How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. <i>BMJ Open</i> , 2020, 10, e044566.	0.8	11
294	Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009. <i>BMC Medicine</i> , 2020, 18, 265.	2.3	15
295	Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa319.	0.4	16

#	ARTICLE	IF	CITATIONS
296	Clinical Significance of Timing of Intubation in Critically Ill Patients with COVID-19: A Multi-Center Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2847.	1.0	43
297	Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1298.	3.8	388
298	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1317.	3.8	671
299	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1330.	3.8	1,855
300	Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study. <i>Infectious Diseases and Therapy</i> , 2020, 9, 823-836.	1.8	65
301	Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2020, 28, 625-634.	0.9	21
302	Mass Spectrometry Techniques in Emerging Pathogens Studies: COVID-19 Perspectives. <i>Journal of the American Society for Mass Spectrometry</i> , 2020, 31, 2013-2024.	1.2	62
303	Correspondence on "Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study" by Potere et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e194-e194.	0.5	1
304	Caring for patients with COPD and COVID-19: a viewpoint to spark discussion. <i>Thorax</i> , 2020, 75, 1035-1039.	2.7	15
305	SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2020, 19, 40.	1.7	93
306	Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1307.	3.8	983
307	Late i.v. steroid treatment for severe COVID-19-induced acute respiratory distress syndrome: a case report. <i>Acute Medicine & Surgery</i> , 2020, 7, e569.	0.5	2
308	Rapid Real-time Tracking of Nonpharmaceutical Interventions and Their Association With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Positivity: The Coronavirus Disease 2019 (COVID-19) Pandemic Pulse Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e1822-e1829.	2.9	28
309	A living WHO guideline on drugs for covid-19. <i>BMJ, The</i> , 2020, 370, m3379.	3.0	664
310	Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. <i>European Respiratory Journal</i> , 2020, 56, 2003006.	3.1	172
311	COVID-19: In the Eye of the Cytokine Storm. <i>Frontiers in Immunology</i> , 2020, 11, 558898.	2.2	107
312	Steroids in ARDS: more light is being shed. <i>Intensive Care Medicine</i> , 2020, 46, 2108-2110.	3.9	8
313	Drug repurposing approach to fight COVID-19. <i>Pharmacological Reports</i> , 2020, 72, 1479-1508.	1.5	323

#	ARTICLE	IF	CITATIONS
314	Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. <i>Lancet, The</i> , 2020, 396, 959-967.	6.3	278
315	Perioperative management of patients with suspected or confirmed COVID-19: review and recommendations for perioperative management from a retrospective cohort study. <i>British Journal of Anaesthesia</i> , 2020, 125, 895-911.	1.5	18
316	Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2-Induced Cytokine Storm. <i>Journal of Immunology</i> , 2020, 205, 2566-2575.	0.4	16
317	Antimicrobial mouthwashes (gargling) and nasal sprays to protect healthcare workers when undertaking aerosol-generating procedures (AGPs) on patients without suspected or confirmed COVID-19 infection. <i>The Cochrane Library</i> , 2020, 2020, CD013628.	1.5	19
318	Reply to Corticosteroid-Induced Osteonecrosis in COVID-19: A Call for Caution. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 2084-2085.	3.1	0
319	The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13412.	1.7	21
320	Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis. <i>BMJ Open</i> , 2020, 10, e041276.	0.8	29
321	The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019. <i>Journal of Translational Medicine</i> , 2020, 18, 359.	1.8	20
322	Towards characterized convalescent plasma for COVID-19: The dose matters. <i>EClinicalMedicine</i> , 2020, 26, 100545.	3.2	10
323	COVID-19 in COPD: A growing concern. <i>EClinicalMedicine</i> , 2020, 26, 100546.	3.2	23
325	Putative invasive pulmonary aspergillosis in critically ill patients with COVID-19: An observational study from New York City. <i>Mycoses</i> , 2020, 63, 1368-1372.	1.8	32
327	Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data. <i>PLoS ONE</i> , 2020, 15, e0239401.	1.1	54
328	Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and New Old Friends. <i>Frontiers in Immunology</i> , 2020, 11, 2059.	2.2	18
329	Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 6845.	1.2	4
330	Induction of the Antiviral Immune Response and Its Circumvention by Coronaviruses. <i>Viruses</i> , 2020, 12, 1039.	1.5	7
331	COVID-19 clinical trials: learning from exceptions in the research chaos. <i>Nature Medicine</i> , 2020, 26, 1671-1672.	15.2	42
332	Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. <i>PLoS ONE</i> , 2020, 15, e0239799.	1.1	217
333	The role of Interleukin 6 inhibitors in therapy of severe COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110698.	2.5	77

#	ARTICLE	IF	CITATIONS
334	SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. <i>Cancer Cell</i> , 2020, 38, 661-671.e2.	7.7	193
335	Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 203, 105751.	1.2	538
336	Respiratory management of adult patients with acute respiratory distress syndrome due to COVID-19. <i>Respirology</i> , 2020, 25, 1133-1135.	1.3	3
337	Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study. <i>American Journal of Transplantation</i> , 2020, 20, 3198-3205.	2.6	48
338	Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). <i>PLoS Medicine</i> , 2020, 17, e1003293.	3.9	73
339	Co-diagnoses of acute myeloid leukaemia and COVID-19: presentation and management implications. <i>Respirology Case Reports</i> , 2020, 8, e00650.	0.3	4
341	Artificial intelligence in COVID-19 drug repurposing. <i>The Lancet Digital Health</i> , 2020, 2, e667-e676.	5.9	349
342	SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence. <i>American Journal of Emergency Medicine</i> , 2020, 38, 2405-2415.	0.7	12
343	A Systematic Review of COVID-19 Infection in Kidney Transplant Recipients: A Universal Effort to Preserve Patients' Lives and Allografts. <i>Journal of Clinical Medicine</i> , 2020, 9, 2986.	1.0	44
344	Remdesivir: an antiviral for the treatment of COVID-19. <i>The Prescriber</i> , 2020, 31, 31-33.	0.1	1
345	MS, pregnancy and COVID-19. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1137-1146.	1.4	10
346	Clinical trials of disease stages in COVID 19: complicated and often misinterpreted. <i>The Lancet Global Health</i> , 2020, 8, e1249-e1250.	2.9	28
347	Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. <i>EBioMedicine</i> , 2020, 59, 102969.	2.7	116
348	An inflammatory cytokine signature predicts COVID-19 severity and survival. <i>Nature Medicine</i> , 2020, 26, 1636-1643.	15.2	1,860
349	A Pediatric Infectious Diseases Perspective of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Novel Coronavirus Disease 2019 (COVID-19) in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 596-608.	0.6	29
350	Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C) Tj ETQq1 10x7843143gBT /Ove		
352	High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review. <i>Clinical Rheumatology</i> , 2020, 39, 3171-3175.	1.0	65
353	The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. <i>Nature Immunology</i> , 2020, 21, 1146-1151.	7.0	82

#	ARTICLE	IF	CITATIONS
354	Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report. BMC Cardiovascular Disorders, 2020, 20, 389.	0.7	28
356	Obesity: A critical risk factor in the COVID-19 pandemic. Clinical Obesity, 2020, 10, e12403.	1.1	191
357	A public health perspective of aging: do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging?. Immunity and Ageing, 2020, 17, 23.	1.8	61
358	Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. Critical Care, 2020, 24, 525.	2.5	125
359	Monocyte activation in systemic Covid-19 infection: Assay and rationale. EBioMedicine, 2020, 59, 102964.	2.7	80
361	An Ounce of Prevention and a Pound of Cure: Randomized Clinical Trials of Therapeutics Against COVID-19 and an Assessment of Personal Protective Equipment and Distancing. International Journal of Radiation Oncology Biology Physics, 2020, 108, 333-336.	0.4	1
362	Autophagy Inhibits Grass Carp Reovirus (GCRV) Replication and Protects Ctenopharyngodon idella Kidney (CIK) Cells from Excessive Inflammatory Responses after GCRV Infection. Biomolecules, 2020, 10, 1296.	1.8	23
363	Cortisol concentrations and mortality from COVID-19 – Authors' reply. Lancet Diabetes and Endocrinology, 2020, 8, 809-810.	5.5	6
364	Inpatient use of glucocorticoids may mediate the detrimental effect of new-onset hyperglycemia on COVID-19 severity. Diabetes Research and Clinical Practice, 2020, 168, 108441.	1.1	7
365	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thrombosis and Haemostasis, 2020, 120, 1597-1628.	1.8	131
366	Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?. Clinical and Molecular Allergy, 2020, 18, 17.	0.8	27
367	Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. Diabetology and Metabolic Syndrome, 2020, 12, 80.	1.2	63
368	Managing rheumatoid arthritis during COVID-19. Clinical Rheumatology, 2020, 39, 3237-3244.	1.0	43
369	Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia. Open Forum Infectious Diseases, 2020, 7, ofaa421.	0.4	101
370	Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection. The Cochrane Library, 2020, CD013626.	1.5	25
371	Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them. The Cochrane Library, 2020, 2020, CD013627.	1.5	47
372	Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All. Infectious Diseases and Therapy, 2020, 9, 701-705.	1.8	23
373	Case 29-2020: A 66-Year-Old Man with Fever and Shortness of Breath after Liver Transplantation. New England Journal of Medicine, 2020, 383, 1168-1180.	13.9	9

#	ARTICLE	IF	CITATIONS
374	Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines. <i>Frontiers in Pharmacology</i> , 2020, 11, 582025.	1.6	14
375	Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 2961.	1.0	65
376	Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2. <i>Clinical and Translational Science</i> , 2021, 14, 2146-2151.	1.5	15
377	Convalescent plasma for covid-19. <i>BMJ, The</i> , 2020, 370, m3516.	3.0	27
378	Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. <i>European Respiratory Journal</i> , 2020, 56, 2002808.	3.1	278
379	Prognostic factors in patients admitted to an urban teaching hospital with COVID-19 infection. <i>Journal of Translational Medicine</i> , 2020, 18, 354.	1.8	41
380	Psychiatric presentation of patients with acute SARS-CoV-2 infection: a retrospective review of 50 consecutive patients seen by a consultation-liaison psychiatry team. <i>BJPsych Open</i> , 2020, 6, e109.	0.3	44
381	Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2020, 11, 572870.	1.6	72
382	COVID-19: getting to the heart of the matter. <i>European Journal of Heart Failure</i> , 2020, 22, 2216-2218.	2.9	1
383	SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities. <i>IUBMB Life</i> , 2020, 72, 2313-2330.	1.5	10
384	Implications of COVID-19 for an ageing population. <i>Medical Journal of Australia</i> , 2020, 213, 342.	0.8	33
385	How severe COVID-19 infection is changing ARDS management. <i>Intensive Care Medicine</i> , 2020, 46, 2184-2186.	3.9	13
386	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 6145-6157.	1.0	14
387	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716.	0.6	43
388	Remdesivir, a remedy or a ripple in severe COVID-19?. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1195-1198.	1.9	9
389	Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095524.	0.7	11
390	Bacterial and fungal superinfections in critically ill patients with COVID-19. <i>Intensive Care Medicine</i> , 2020, 46, 2071-2074.	3.9	79
392	Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. <i>International Journal of Infectious Diseases</i> , 2020, 100, 327-332.	1.5	219

#	ARTICLE	IF	CITATIONS
393	Impact of Early Pandemic Stage Mutations on Molecular Dynamics of SARS-CoV-2 M ^{pro} . Journal of Chemical Information and Modeling, 2020, 60, 5080-5102.	2.5	62
394	Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa. Nature Reviews Microbiology, 2020, 18, 690-704.	13.6	42
395	Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region. PLoS ONE, 2020, 15, e0238827.	1.1	32
396	Efficacy and Safety of Corticosteroid Treatment in Patients With COVID-19: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2020, 11, 571156.	1.6	26
397	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. Frontiers in Pharmacology, 2020, 11, 1205.	1.6	143
398	Haemoperfusion should only be used for COVID-19 in the context of Randomized trials. Nature Reviews Nephrology, 2020, 16, 697-699.	4.1	10
399	Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. , 2020, 8, e001089.		72
400	Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review. Advances in Therapy, 2020, 37, 4107-4131.	1.3	3
401	Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial. Critical Care, 2020, 24, 502.	2.5	54
402	COVID-19 Therapeutic Options Under Investigation. Frontiers in Pharmacology, 2020, 11, 1196.	1.6	65
403	A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes. Frontiers in Pharmacology, 2020, 11, 1214.	1.6	40
404	Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?. European Journal of Cancer, 2020, 137, 235-239.	1.3	7
405	Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. Respiratory Medicine, 2020, 171, 106114.	1.3	23
406	Integrative Modeling of Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan Pathological Signature of SARS-CoV-2 Infection. Journal of Proteome Research, 2020, 19, 4442-4454.	1.8	142
407	Tocilizumab for severe COVID-19 pneumonia. Lancet Rheumatology, The, 2020, 2, e660.	2.2	4
408	Deciphering SARS-CoV-2 Virologic and Immunologic Features. International Journal of Molecular Sciences, 2020, 21, 5932.	1.8	28
409	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1048.	3.8	1,032
410	Apples and oranges: international comparisons of COVID-19 observational studies in ICUs. Lancet Respiratory Medicine, the, 2020, 8, 952-953.	5.2	22

#	ARTICLE	IF	CITATIONS
411	A Narrative Review of Emerging Therapeutics for COVID-19. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 745-758.	1.2	7
412	Shepherding preprints through a pandemic. BMJ, The, 2020, 371, m4703.	3.0	7
413	Case Report: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Relapse With COVID-19. Frontiers in Neurology, 2020, 11, 598531.	1.1	30
414	Modulation of Autophagy by SARS-CoV-2: A Potential Threat for Cardiovascular System. Frontiers in Physiology, 2020, 11, 611275.	1.3	17
415	Blockage of interleukin-1 β with canakinumab in patients with Covid-19. Scientific Reports, 2020, 10, 21775.	1.6	58
416	Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review. Journal of Clinical Medicine, 2020, 9, 4021.	1.0	13
417	Coronavirus vaccine development: from SARS and MERS to COVID-19. Journal of Biomedical Science, 2020, 27, 104.	2.6	287
418	Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease. Critical Care, 2020, 24, 699.	2.5	93
419	Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study. Critical Care, 2020, 24, 698.	2.5	34
420	COVID-19-Induced Modifications in the Tumor Microenvironment: Do They Affect Cancer Reawakening and Metastatic Relapse?. Frontiers in Oncology, 2020, 10, 592891.	1.3	22
421	Rationale for COVID-19 Treatment by Nebulized Interferon- β -Literature Review and Personal Preliminary Experience. Frontiers in Pharmacology, 2020, 11, 592543.	1.6	11
422	Dexamethasone Treatment for Covid-19, a Curious Precedent Highlighting a Regulatory Gap. Frontiers in Pharmacology, 2020, 11, 621934.	1.6	11
423	Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients?. Molecules, 2020, 25, 5888.	1.7	25
424	Care bundles for improving outcomes in patients with COVID-19 or related conditions in intensive care - a rapid scoping review. The Cochrane Library, 2020, 2020, CD013819.	1.5	8
425	A manifesto for the future of ICU trials. Critical Care, 2020, 24, 686.	2.5	7
426	Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology. Frontiers in Cardiovascular Medicine, 2020, 7, 568720.	1.1	5
427	SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. Frontiers in Immunology, 2020, 11, 569760.	2.2	30
428	NF- κ B Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients. Frontiers in Immunology, 2020, 11, 598444.	2.2	153

#	ARTICLE	IF	CITATIONS
429	The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective. <i>Frontiers in Medicine</i> , 2020, 7, 596587.	1.2	12
430	COVID-19 Induced Acute Respiratory Distress Syndrome—A Multicenter Observational Study. <i>Frontiers in Medicine</i> , 2020, 7, 599533.	1.2	18
431	Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. <i>Microorganisms</i> , 2020, 8, 1885.	1.6	39
432	COVID-19 and African rheumatology: progress in adversity. <i>Lancet Rheumatology</i> , The, 2020, 2, e732-e734.	2.2	5
433	Managing hyperglycemia during the COVID-19 pandemic: Improving outcomes using new technologies in intensive care. <i>SAGE Open Medicine</i> , 2020, 8, 205031212097417.	0.7	7
434	Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. <i>Scientific Reports</i> , 2020, 10, 21291.	1.6	32
435	Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. <i>Critical Care</i> , 2020, 24, 696.	2.5	265
436	What Open-Lung Biopsy Teaches Us about ARDS in COVID-19 Patients: Mechanisms, Pathology, and Therapeutic Implications. <i>BioMed Research International</i> , 2020, 2020, 1-11.	0.9	7
437	Effects of Tocilizumab in COVID-19 patients: a cohort study. <i>BMC Infectious Diseases</i> , 2020, 20, 964.	1.3	30
438	Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2. <i>Frontiers in Chemistry</i> , 2020, 8, 590263.	1.8	24
439	COVID-19 care in India: the course to self-reliance. <i>The Lancet Global Health</i> , 2020, 8, e1359-e1360.	2.9	16
440	Preferential use of dexamethasone for fetal lung maturation in severe coronavirus disease 2019. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2020, 2, 100218.	1.3	3
441	Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series. <i>Annals of Medicine and Surgery</i> , 2020, 60, 417-424.	0.5	20
442	Editorial from the new editor-in-chief. <i>Contemporary Clinical Trials</i> , 2020, 96, 106127.	0.8	0
443	Should I use steroid injections to treat shoulder pain during the COVID-19 pandemic?. <i>JSES International</i> , 2020, 4, 709-712.	0.7	4
444	Leadership to prevent COVID-19: is it the most important mitigation factor?. <i>Travel Medicine and Infectious Disease</i> , 2020, 38, 101925.	1.5	5
445	A real-world study of glucocorticoid treatment in COVID-19 patients with different disease severities. <i>Clinical and Translational Medicine</i> , 2020, 10, e235.	1.7	2
446	Community hospital experience in the emergency management of COVID-19: Preventing morbidity and preserving resources. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1386-1391.	0.4	0

#	ARTICLE	IF	CITATIONS
448	A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019. , 2020, 2, e0283.		17
449	Colorectal Surgery in the time of Covid 19. Colorectal Disease, 2020, 22, 983-984.	0.7	0
450	The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. Med, 2020, 1, 90-102.	2.2	87
451	Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection. Nature Communications, 2020, 11, 6319.	5.8	203
452	Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. Scientific Reports, 2020, 10, 21447.	1.6	70
453	Tocilizumab for Covid-19 â€” The Ongoing Search for Effective Therapies. New England Journal of Medicine, 2020, 383, 2387-2388.	13.9	36
454	Severe asthma and COVID-19: lessons from the first wave. Journal of Asthma, 2020, , 1-7.	0.9	9
455	An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Review of Anti-Infective Therapy, 2021, 19, 877-888.	2.0	184
456	COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019â€”Associated Hospitalization Surveillance Network, March 1â€”June 30, 2020. Open Forum Infectious Diseases, 2020, 7, ofaa528.	0.4	8
457	Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019. , 2020, 2, e0280.		39
458	Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Critical Care, 2020, 24, 688.	2.5	100
459	Corticosteroid treatment for early acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials. Journal of Intensive Care, 2020, 8, 91.	1.3	17
460	Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019. Journal of Comparative Effectiveness Research, 2020, 9, 1247-1254.	0.6	18
461	Multidisciplinary Approach to the Diagnosis and In-Hospital Management of COVID-19 Infection: A Narrative Review. Frontiers in Pharmacology, 2020, 11, 572168.	1.6	17
462	Diagnosis and Management of Acute Respiratory Distress Syndrome in a Time of COVID-19. Diagnostics, 2020, 10, 1053.	1.3	13
463	COVID-19â€”related skin manifestations: Update on therapy. Clinics in Dermatology, 2021, 39, 920-926.	0.8	10
464	Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes. Signal Transduction and Targeted Therapy, 2020, 5, 287.	7.1	72
465	<p>COVID-19 and Obesity: Epidemiology, Pathogenesis and Treatment</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 4953-4959.	1.1	13

#	ARTICLE	IF	CITATIONS
466	Effectiveness of Steroid Treatment for SARS-CoV-2 Pneumonia With Cryptogenic Organizing Pneumonia-Like Reaction: A Case Report. <i>Disaster Medicine and Public Health Preparedness</i> , 2022, 16, 491-494.	0.7	5
467	Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1185-1204.	1.3	23
468	Case Report of Patients with Acute Respiratory Distress Syndrome Caused by COVID-19: Successfully Treated by Venovenous Extracorporeal Membrane Oxygenation and an Ultra-Protective Ventilation. <i>Medicina (Lithuania)</i> , 2020, 56, 570.	0.8	1
469	The Neat Dance of COVID-19: NEAT1, DANCR, and Co-Modulated Cholinergic RNAs Link to Inflammation. <i>Frontiers in Immunology</i> , 2020, 11, 590870.	2.2	37
470	Timing of Intubation and In-Hospital Mortality in Patients With Coronavirus Disease 2019. , 2020, 2, e0254.		48
471	<p>A Dangerous Consequence of the Recent Pandemic: Early Lung Fibrosis Following COVID-19 Pneumonia â€œ Case Reports</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 1039-1046.	0.9	18
472	Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics. <i>Cell Host and Microbe</i> , 2020, 28, 638-645.	5.1	30
473	CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ARDS. <i>Critical Care</i> , 2020, 24, 632.	2.5	67
474	Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8118.	1.8	148
475	Factores pronÃ³sticos en pacientes hospitalizados con diagnÃ³stico de infecciÃ³n por SARS-CoV-2 en BogotÃ¡, Colombia. <i>Biomedica</i> , 2020, 40, 116-130.	0.3	6
476	Current and evolving standards of care for patients with ARDS. <i>Intensive Care Medicine</i> , 2020, 46, 2157-2167.	3.9	55
477	Innovation in the design of large-scale hybrid randomized clinical trials. <i>Contemporary Clinical Trials</i> , 2020, 99, 106178.	0.8	4
478	Macrophage responses associated with COVID-19: A pharmacological perspective. <i>European Journal of Pharmacology</i> , 2020, 887, 173547.	1.7	27
479	Host â€œ virus â€œ drug interactions as determinants of COVID-19â€™s phenotypes: A data-driven hypothesis. <i>Medical Hypotheses</i> , 2020, 144, 110275.	0.8	2
480	COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19) Tj ETQq0 0 0 rgBT /Overlock 10 2020, 12, 175883592097114.	1.4	12
481	The Impact of Science-Unbased Measures Against COVID-19 in Clinical Decision-Making Process. <i>AAPS PharmSciTech</i> , 2020, 21, 293.	1.5	2
482	Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndromeâ€™An Observational Pilot Study. <i>Frontiers in Immunology</i> , 2020, 11, 581338.	2.2	75
483	Application of Humanized Zebrafish Model in the Suppression of SARS-CoV-2 Spike Protein Induced Pathology by Tri-Herbal Medicine Coronil via Cytokine Modulation. <i>Molecules</i> , 2020, 25, 5091.	1.7	35

#	ARTICLE	IF	CITATIONS
484	A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection. <i>Infection, Genetics and Evolution</i> , 2020, 86, 104610.	1.0	25
485	Risk factors associated with disease aggravation among 126 hospitalized patients with COVID-19 in different places in China. <i>Medicine (United States)</i> , 2020, 99, e22971.	0.4	3
486	Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology. <i>Frontiers in Immunology</i> , 2020, 11, 581076.	2.2	6
487	Revisiting the Immune Balance Theory: A Neurological Insight Into the Epidemic of COVID-19 and Its Alike. <i>Frontiers in Neurology</i> , 2020, 11, 566680.	1.1	11
488	Hereditary haemochromatosis, haemophagocytic lymphohistiocytosis and COVID-19. <i>Clinical Infection in Practice</i> , 2020, 7-8, 100052.	0.2	8
489	Transplant Drugs against SARS, MERS and COVID-19. <i>Transplantation</i> , 2020, 1, 71-84.	0.3	5
490	Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. <i>Intensive Care Medicine</i> , 2020, 46, 2284-2296.	3.9	79
491	General Approach to the Clinical Care of Solid Organ Transplant Recipients with COVID-19 Infection. <i>Current Transplantation Reports</i> , 2020, 7, 366-378.	0.9	8
492	Strategy, coordinated implementation, and sustainable financing needed for COVID-19 innovations. <i>Lancet, The</i> , 2020, 396, 1469-1471.	6.3	12
493	New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	59
494	Epidemiological and Clinical Characteristics of COVID-19 in Children: A Systematic Review and Meta-Analysis. <i>Frontiers in Pediatrics</i> , 2020, 8, 591132.	0.9	86
495	Similar Clinical Course and Significance of Circulating Innate and Adaptive Immune Cell Counts in STEMI and COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 3484.	1.0	8
496	Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 3488.	1.0	59
497	Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 559-570.	1.0	7
498	An observational cohort study of hydroxychloroquine and azithromycin for COVID-19: (Canâ€™t Get No) Satisfaction. <i>International Journal of Infectious Diseases</i> , 2020, 98, 216-217.	1.5	18
499	Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. <i>American Heart Journal</i> , 2021, 232, 105-115.	1.2	15
500	Sepsis in the critically ill patient: current and emerging management strategies. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 635-647.	2.0	12
501	Delayed hospital admission and high-dose corticosteroids potentially prolong SARS-CoV-2 RNA detection duration of patients with COVID-19. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 841-848.	1.3	14

#	ARTICLE	IF	CITATIONS
502	Impact of late administration of corticosteroids in COVID-19 ARDS. <i>Intensive Care Medicine</i> , 2021, 47, 110-112.	3.9	25
503	The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients. <i>Inflammopharmacology</i> , 2021, 29, 91-100.	1.9	215
504	Clinical trials of inhaled beclomethasone and mometasone for COVID-19 should be conducted. <i>Journal of Medical Virology</i> , 2021, 93, 637-638.	2.5	12
505	Updates on community acquired pneumonia management in the ICU. , 2021, 217, 107663.		68
506	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2021, 73, 36-47.	2.9	52
507	Are All Patients with Cancer at Heightened Risk for Severe Coronavirus Disease 2019 (COVID-19)?. <i>Clinical Infectious Diseases</i> , 2021, 72, 351-356.	2.9	24
508	The proper use of corticosteroids for 2019-nCov pneumonia: Towards promising results?. <i>Journal of Infection</i> , 2021, 82, e6-e7.	1.7	5
509	The RECOVERY Platform. <i>New England Journal of Medicine</i> , 2021, 384, 757-758.	13.9	47
510	Research in the Context of a Pandemic. <i>New England Journal of Medicine</i> , 2021, 384, 755-757.	13.9	50
511	Covid-19.bioreproducibility.org: A web resource for <scp>SARS-CoV</scp>-related structural models. <i>Protein Science</i> , 2021, 30, 115-124.	3.1	15
512	Low-Dose Dexamethasone Following IVIG in Pediatric Inflammatory Multisystem Syndrome in Temporal Association with COVID-19 (PIMS-TC). <i>Indian Journal of Pediatrics</i> , 2021, 88, 301-302.	0.3	2
513	Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 112-117.	2.8	33
514	Characteristics of SARS-CoV-2 and COVID-19. <i>Nature Reviews Microbiology</i> , 2021, 19, 141-154.	13.6	3,334
515	The increasing importance of the novel Coronavirus. <i>Hospital Practice (1995)</i> , 2021, 49, 1-11.	0.5	8
516	Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. <i>Rheumatology</i> , 2021, 60, 399-407.	0.9	103
517	Modifications to mobile chest radiography technique during the COVID-19 pandemic – implications of X-raying through side room windows. <i>Radiography</i> , 2021, 27, 193-199.	1.1	9
518	COVID-19: Discovery, diagnostics and drug development. <i>Journal of Hepatology</i> , 2021, 74, 168-184.	1.8	302
519	Pregnancy and COVID-19. <i>Physiological Reviews</i> , 2021, 101, 303-318.	13.1	406

#	ARTICLE	IF	CITATIONS
520	Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2021, 102, 397-411.	1.5	9
521	Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia. <i>JAMA Internal Medicine</i> , 2021, 181, 24.	2.6	593
522	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia. <i>JAMA Internal Medicine</i> , 2021, 181, 32.	2.6	654
523	Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 657-662.	1.0	48
524	Global Impact of Coronavirus Disease 2019 Infection Requiring Admission to the ICU. <i>Chest</i> , 2021, 159, 524-536.	0.4	121
525	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. <i>Nature Reviews Nephrology</i> , 2021, 17, 46-64.	4.1	444
526	Anti-IFN γ R Mabs for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 519-528.	1.4	9
527	Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 41.	2.6	385
528	Mechanisms of COVID-19-induced cardiovascular disease: Is sepsis or exosome the missing link?. <i>Journal of Cellular Physiology</i> , 2021, 236, 3366-3382.	2.0	21
530	Pacientes craticos COVID-19 atendidos por anestesiologos en el Noroeste de Espaa: estudio multicentrico, prospectivo, observacional. <i>Revista Espaola De Anestesiologa Y Reanimacion</i> , 2021, 68, 10-20.	0.1	15
531	System-Wide Strategies Were Associated With Improved Outcome in Critically Ill Patients With Coronavirus Disease 2019. <i>Chest</i> , 2021, 159, 1072-1075.	0.4	5
532	SARS-CoV-2 (COVID-19) in patients with some degree of immunosuppression. <i>Reumatologa Clnica (English Edition)</i> , 2021, 17, 408-419.	0.2	17
533	Anesthetic Considerations for Recovered COVID-19 Patients. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 376-377.	0.6	4
534	Severe acute respiratory syndrome-2 spike (S) protein based vaccine candidates: State of the art and future prospects. <i>Reviews in Medical Virology</i> , 2021, 31, e2183.	3.9	43
535	Multisystem Inflammatory Syndrome in Children: Survey of Protocols for Early Hospital Evaluation and Management. <i>Journal of Pediatrics</i> , 2021, 229, 33-40.	0.9	58
536	Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System. <i>Gastroenterology</i> , 2021, 160, 919-921.e3.	0.6	29
537	EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic. <i>European Journal of Neurology</i> , 2021, 28, 7-14.	1.7	27
538	Bone marrow haemophagocytosis indicates severe infection with severe acute respiratory syndrome coronavirus 2. <i>Histopathology</i> , 2021, 78, 727-737.	1.6	11

#	ARTICLE	IF	CITATIONS
539	Treatment of immunocompromised COVID-19 patients with convalescent plasma. <i>Transplant Infectious Disease</i> , 2021, 23, e13477.	0.7	47
540	Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 384-391.	0.5	269
541	Safety of Remdesivir in Patients With Acute Kidney Injury or CKD. <i>Kidney International Reports</i> , 2021, 6, 206-210.	0.4	79
542	Role of the inflammatory response in community-acquired pneumonia: clinical implications. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1261-1274.	2.0	4
543	Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2. <i>Cytotherapy</i> , 2021, 23, 101-110.	0.3	14
544	Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 107-119.	1.1	32
545	C4 article: Implications of COVID-19 in transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 1801-1815.	2.6	15
546	Review on therapeutic targets for COVID-19: insights from cytokine storm. <i>Postgraduate Medical Journal</i> , 2021, 97, 391-398.	0.9	25
547	Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis. <i>Journal of Clinical Immunology</i> , 2021, 41, 303-314.	2.0	41
548	Factors significantly associated with COVID-19 severity in symptomatic patients: A retrospective single-center study. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 76-82.	0.8	13
549	Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019. <i>Chest</i> , 2021, 159, 1182-1196.	0.4	361
550	Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: A case series. <i>Artificial Organs</i> , 2021, 45, E101-E112.	1.0	54
551	New Horizons: Does Mineralocorticoid Receptor Activation by Cortisol Cause ATP Release and COVID-19 Complications?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 622-635.	1.8	17
552	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	3.0	23
553	Nanotechnology for virus treatment. <i>Nano Today</i> , 2021, 36, 101031.	6.2	58
554	The COVID-19 pandemic: consequences for nephrology. <i>Nature Reviews Nephrology</i> , 2021, 17, 81-82.	4.1	81
555	Use of dexamethasone, remdesivir, convalescent plasma and prone positioning in the treatment of severe COVID-19 infection in pregnancy: A case report. <i>Case Reports in Women's Health</i> , 2021, 29, e00273.	0.2	21
556	Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 578-584.	0.6	73

#	ARTICLE	IF	CITATIONS
557	One year update on the COVID-19 pandemic: Where are we now?. <i>Acta Tropica</i> , 2021, 214, 105778.	0.9	142
558	Outcome of hospitalized patients with COVID-19 pneumonia treated with high-dose immunoglobulin therapy in a prospective case series. <i>Clinical Microbiology and Infection</i> , 2021, 27, 651-652.	2.8	5
559	The Urgency of Justice in Research: Beyond COVID-19. <i>Trends in Molecular Medicine</i> , 2021, 27, 97-100.	3.5	29
560	Repurposed Antiviral Drugs for Covid-19 " Interim WHO Solidarity Trial Results. <i>New England Journal of Medicine</i> , 2021, 384, 497-511.	13.9	2,014
561	Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 7-12.	0.1	7
563	Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease: A pilot study. <i>Journal of Internal Medicine</i> , 2021, 289, 906-920.	2.7	40
564	Host genetics and infectious disease: new tools, insights and translational opportunities. <i>Nature Reviews Genetics</i> , 2021, 22, 137-153.	7.7	98
565	SARS-CoV-2 and the COVID-19 pandemic. , 2021, , 445-467.		1
566	SARS-CoV-2: Targeted managements and vaccine development. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 16-29.	3.2	44
567	Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study. <i>EBioMedicine</i> , 2021, 63, 103154.	2.7	143
568	Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia. <i>Leukemia</i> , 2021, 35, 635-638.	3.3	30
569	Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data. <i>Clinical Microbiology and Infection</i> , 2021, 27, 603-610.	2.8	12
570	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. <i>Medicinal Research Reviews</i> , 2021, 41, 1375-1426.	5.0	28
571	SARS-CoV-2 and ECMO: early results and experience. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 37, 53-60.	0.2	12
572	Implementing Delirium Prevention in the Era of COVID-19. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 31-36.	1.2	5
573	Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. <i>Annals of Internal Medicine</i> , 2021, 174, 93-95.	2.0	38
574	Arginine depletion as a therapeutic approach for patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 102, 566-570.	1.5	45
575	Combining Antivirals and Immunomodulators to Fight COVID-19. <i>Trends in Immunology</i> , 2021, 42, 31-44.	2.9	46

#	ARTICLE	IF	CITATIONS
576	Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 561-566.e4.	1.5	90
577	High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13458.	1.7	44
578	Corticosteroid therapy in COVID-19 patients: Don't forget venous thromboembolism. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100783.	0.6	3
579	Risk factors of mortality and contribution of treatment in patients infected with COVID-19: a retrospective propensity score matched study. <i>Current Medical Research and Opinion</i> , 2021, 37, 13-19.	0.9	12
580	Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L301-L330.	1.3	26
581	The place for remdesivir in COVID-19 treatment. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 20-21.	4.6	91
582	A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. <i>New England Journal of Medicine</i> , 2021, 384, 619-629.	13.9	741
583	Corticosteroids for COVID-19: the search for an optimum duration of therapy. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, e8.	5.2	76
584	Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 110982.	2.5	65
585	Multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 pandemic in Brazil: a multicenter, prospective cohort study. <i>Jornal De Pediatria</i> , 2021, 97, 354-361.	0.9	60
587	Sports Medicine Considerations During the COVID-19 Pandemic. <i>American Journal of Sports Medicine</i> , 2021, 49, 512-521.	1.9	35
588	<sc>Identif</sc>. <sc>Al</sc>: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) with digital drug development. <i>Bioengineering and Translational Medicine</i> , 2021, 6, e10196.	3.9	27
589	Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. <i>Intensive Care Medicine</i> , 2021, 47, 60-73.	3.9	597
590	Thrombocytopeny and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. <i>Nature Reviews Cardiology</i> , 2021, 18, 194-209.	6.1	304
591	Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 49-64.	10.6	126
592	COVID-19 and education: restructuring after the pandemic. <i>Transplant International</i> , 2021, 34, 220-223.	0.8	22
593	The Role of Glucocorticoids in the Management of COVID-19. <i>Hormone and Metabolic Research</i> , 2021, 53, 9-15.	0.7	28
594	Proposed Use of Continuous Glucose Monitoring for Care of Critically Ill COVID-19 Patients. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 174-176.	1.3	0

#	ARTICLE	IF	CITATIONS
595	Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 196-206.	5.2	370
596	Genetic influences on viral-induced cytokine responses in the lung. <i>Mucosal Immunology</i> , 2021, 14, 14-25.	2.7	34
597	COVID-19 and diabetes mellitus: from pathophysiology to clinical management. <i>Nature Reviews Endocrinology</i> , 2021, 17, 11-30.	4.3	653
598	Coronavirus disease 2019 vaccines in pregnancy. <i>American Journal of Obstetrics & Gynecology</i> MFM, 2021, 3, 100295.	1.3	51
599	Early Outpatient Treatment of SARS-CoV-2 (COVID-19): A Comment. <i>American Journal of Medicine</i> , 2021, 134, e220-e221.	0.6	0
600	Zoonotic coronavirus epidemics. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 321-337.	0.5	8
601	COVID19- clinical presentation and therapeutic considerations. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 125-131.	1.0	26
602	Reporting and design of randomized controlled trials for COVID-19: A systematic review. <i>Contemporary Clinical Trials</i> , 2021, 101, 106239.	0.8	9
603	Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill Patients With COVID-19 With Hyperinflammatory Phenotype. <i>Chest</i> , 2021, 159, 1793-1802.	0.4	51
604	Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 886-890.	0.4	13
605	COVID-19: neonatal—perinatal perspectives. <i>Journal of Perinatology</i> , 2021, 41, 940-951.	0.9	62
606	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 795-807.	13.9	1,398
607	Repurposing drugs for the management of COVID-19. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 295-307.	2.4	49
608	A comprehensive review on sarilumab in COVID-19. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 615-626.	1.4	31
609	Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 301-324.	1.0	41
610	Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 550-557.	0.5	109
611	Effect of COVID-19 on Kidney Disease Incidence and Management. <i>Kidney360</i> , 2021, 2, 141-153.	0.9	23
612	Risk and Management of Venous Thromboembolism in Patients with COVID-19. <i>Annals of Vascular Surgery</i> , 2021, 73, 78-85.	0.4	8

#	ARTICLE	IF	CITATIONS
613	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e149-e162.	4.6	586
614	COVID-19 vaccines: one step towards the beginning of the end of the global impact of the pandemic. <i>Anaesthesia</i> , 2021, 76, 435-443.	1.8	4
615	Can the hyperthermia-mediated heat shock factor/heat shock protein 70 pathway dampen the cytokine storm during SARS-CoV-2 infection?. <i>British Journal of Pharmacology</i> , 2022, 179, 4910-4916.	2.7	6
616	Intellectual Integrity in Government-Funded Research. <i>Israel Journal of Chemistry</i> , 2021, 61, 6-10.	1.0	0
617	Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106265.	1.1	6
618	Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. <i>JACC: Heart Failure</i> , 2021, 9, 65-73.	1.9	93
619	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. <i>Biotechnology and Biotechnological Equipment</i> , 2021, 35, 74-102.	0.5	13
620	A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa617.	0.4	2
621	Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia. <i>European Respiratory Journal</i> , 2021, 57, 2003545.	3.1	25
622	Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 7-8.	12.5	7
623	COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. <i>Translational Research</i> , 2021, 232, 13-36.	2.2	69
624	SARS CoV2 infection in a young subject affected by arginosuccinate synthase deficiency: A case report of epilepsy worsening. <i>Molecular Genetics and Metabolism Reports</i> , 2021, 26, 100698.	0.4	2
625	Conflicts over calcium and the treatment of COVID-19. <i>Evolution, Medicine and Public Health</i> , 2021, 9, 149-156.	1.1	49
626	IL-6 in inflammation, autoimmunity and cancer. <i>International Immunology</i> , 2021, 33, 127-148.	1.8	500
627	Dexamethasone vs COVID-19: An experimental study in line with the preliminary findings of a large trial. <i>International Journal of Clinical Practice</i> , 2021, 75, e13943.	0.8	18
628	Impact of COVID-19 on COPD and asthma admissions, and the pandemic from a patient's perspective. <i>ERJ Open Research</i> , 2021, 7, 00822-2020.	1.1	34
629	Selective Pressure-Free Treatments for COVID-19. <i>Radiation</i> , 2021, 1, 18-32.	0.6	6
630	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of <i>in vitro</i> , <i>in vivo</i> , and clinical trials. <i>Theranostics</i> , 2021, 11, 1207-1231.	4.6	24

#	ARTICLE	IF	CITATIONS
631	The management of hematologic malignancies during the COVID-19 pandemic. Expert Opinion on Pharmacotherapy, 2021, 22, 565-582.	0.9	9
632	Can drug repurposing strategies be the solution to the COVID-19 crisis?. Expert Opinion on Drug Discovery, 2021, 16, 605-612.	2.5	19
633	Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. Open Forum Infectious Diseases, 2021, 8, ofaa588.	0.4	27
634	Future dermatology clinical research in the post-COVID era. Clinical and Experimental Dermatology, 2021, 46, 189-190.	0.6	0
635	Science in the Spotlight: A Crisis of Confidence?. Journal of Dental Research, 2021, 100, 5-7.	2.5	0
636	Dupilumab maintenance therapy in an asthmatic patient with coronavirus disease 2019 pneumonia. Allergology International, 2021, 70, 274-276.	1.4	5
637	Do Systemic Corticosteroids Reduce Mortality in Critically Ill Adult Patients With COVID-19?. Annals of Emergency Medicine, 2021, 77, 407-409.	0.3	0
638	Diamond Light Source: contributions to SARS-CoV-2 biology and therapeutics. Biochemical and Biophysical Research Communications, 2021, 538, 40-46.	1.0	6
639	Trials in pandemics: here we go again?. British Journal of Anaesthesia, 2021, 126, e42-e44.	1.5	1
640	Lower Respiratory Tract Myeloid Cells Harbor SARS-Cov-2 and Display an Inflammatory Phenotype. Chest, 2021, 159, 963-966.	0.4	10
641	Prevalence of diabetes, management and outcomes among Covid-19 adult patients admitted in a specialized tertiary hospital in Riyadh, Saudi Arabia. Diabetes Research and Clinical Practice, 2021, 172, 108538.	1.1	29
642	COVID-19 in Brazil: 150,000 deaths and the Brazilian underreporting. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115258.	0.8	42
643	Widespread testing, case isolation and contact tracing may allow safe school reopening with continued moderate physical distancing: A modeling analysis of King County, WA data. Infectious Disease Modelling, 2021, 6, 24-35.	1.2	29
644	Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies—need for data validation of the completed trials and to improve ongoing and future randomised trial designs. International Journal of Antimicrobial Agents, 2021, 57, 106222.	1.1	20
645	Compartmental immunophenotyping in COVID-19 ARDS: A case series. Journal of Allergy and Clinical Immunology, 2021, 147, 81-91.	1.5	70
646	Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients. Journal of Infection, 2021, 82, 414-451.	1.7	8
647	The under-representation of BAME patients in the COVID-19 Recovery trial at a major London NHS Trust. Journal of Infection, 2021, 82, 84-123.	1.7	9
648	Can dexamethasone prevent the seizures induced by SARS-CoV-2 infection?. Multiple Sclerosis and Related Disorders, 2021, 47, 102606.	0.9	0

#	ARTICLE	IF	CITATIONS
649	Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsorâ€™s Perspective. <i>Drug Safety</i> , 2021, 44, 95-105.	1.4	12
650	The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium. <i>Lancet Regional Health - Europe</i> , The, 2021, 2, 100019.	3.0	53
651	An early experience on the effect of solid organ transplant status on hospitalized COVID-19 patients. <i>American Journal of Transplantation</i> , 2021, 21, 2522-2531.	2.6	43
652	Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients. <i>Cancer Cell</i> , 2021, 39, 276-283.e3.	7.7	54
653	Biomarkers for the clinical development of antiviral therapies. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 19-32.	0.7	2
654	A snapshot of COVID-19 infection in patients with solid tumors. <i>International Journal of Cancer</i> , 2021, 148, 2389-2397.	2.3	9
655	Pathways to Severe COVID-19 for People with Obesity. <i>Obesity</i> , 2021, 29, 645-653.	1.5	36
657	Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases. <i>Archivos De Bronconeumologia</i> , 2021, 57, 13-20.	0.4	27
658	Biocatalytic routes to anti-viral agents and their synthetic intermediates. <i>Chemical Society Reviews</i> , 2021, 50, 1968-2009.	18.7	39
659	Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. <i>New England Journal of Medicine</i> , 2021, 384, 20-30.	13.9	1,022
660	REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 238-251.	13.9	1,483
661	COVID-19. <i>Critical Care Nursing Quarterly</i> , 2021, 44, 128-137.	0.4	17
662	Anaesthesia research capacity: time for a rethink in light of the COVID-19 pandemic. <i>Anaesthesia</i> , 2021, 76, 574-575.	1.8	1
663	Favorable outcome of COVID-19 among African American (AA) renal transplant recipients in Detroit. <i>Clinical Transplantation</i> , 2021, 35, e14169.	0.8	5
664	Evidence-Based Management of the Critically Ill Adult With SARS-CoV-2 Infection. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 18-41.	1.3	7
665	COVID-19 discharge and follow-up recommendations. <i>Baylor University Medical Center Proceedings</i> , 2021, 34, 73-75.	0.2	7
666	Paired Nasopharyngeal and Deep Lung Testing for Severe Acute Respiratory Syndrome Coronavirus-2 Reveals a Viral Gradient in Critically Ill Patients. <i>Chest</i> , 2021, 159, 1387-1390.	0.4	13
667	Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes. <i>Chest</i> , 2021, 159, 1019-1040.	0.4	140

#	ARTICLE	IF	CITATIONS
668	Pathogenesis guided therapeutic management of COVID-19: an immunological perspective. <i>International Reviews of Immunology</i> , 2021, 40, 54-71.	1.5	10
669	T cell immunobiology and cytokine storm of COVID-19. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12989.	1.3	77
670	Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector. <i>Advanced Therapeutics</i> , 2021, 4, 2000172.	1.6	24
671	Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19. <i>Journal of Infection</i> , 2021, 82, 414-451.	1.7	10
673	Ostracizing Children from Research in COVID-19: Is it Ethical?. <i>Indian Journal of Pediatrics</i> , 2021, 88, 305-306.	0.3	0
674	Case report: a fatal combination of hemophagocytic lymphohistiocytosis with extensive pulmonary microvascular damage in COVID-19 pneumonia. <i>Journal of Hematopathology</i> , 2021, 14, 79-83.	0.2	6
675	DGI recommendations for COVID-19 pharmacotherapy. <i>Infection</i> , 2021, 49, 369-370.	2.3	3
676	Personal View: Low-Dose Lung Radiotherapy Should be Evaluated as a Treatment for Severe COVID-19 Lung Disease. <i>Clinical Oncology</i> , 2021, 33, e64-e68.	0.6	2
677	Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e66-e75.	0.2	22
678	Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies. <i>Acta Haematologica</i> , 2021, 144, 246-249.	0.7	4
679	Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia. <i>Infection</i> , 2021, 49, 539-542.	2.3	56
680	Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 626-628.	2.7	51
681	Regen med therapeutic opportunities for fighting COVID-19. <i>Stem Cells Translational Medicine</i> , 2021, 10, 5-13.	1.6	12
682	Clinical features and outcomes of adults with coronavirus disease 2019: A systematic review and pooled analysis of the literature. <i>International Journal of Clinical Practice</i> , 2021, 75, e13725.	0.8	21
683	Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report. <i>Journal of Medical Virology</i> , 2021, 93, 1678-1686.	2.5	37
684	Azithromycin in viral infections. <i>Reviews in Medical Virology</i> , 2021, 31, e2163.	3.9	89
685	Pregnancy and COVID-19: pharmacologic considerations. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 57, 195-203.	0.9	57
686	Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 105-111.	2.8	55

#	ARTICLE	IF	CITATIONS
687	Asociación entre el tratamiento esteroideo a dosis alta, la función respiratoria y el tiempo hasta el alta en pacientes con COVID-19: Estudio de cohortes. Medicina Clínica, 2021, 156, 7-12.	0.3	5
688	The association between corticosteroid uses and mortality among severe COVID-19 patients. Journal of Infection, 2021, 82, e24.	1.7	4
689	Diabetes in COVID-19: Steroid effect. Journal of Medical Virology, 2021, 93, 4166-4166.	2.5	5
690	Azithromycin in the treatment of COVID-19: a review. Expert Review of Anti-Infective Therapy, 2021, 19, 147-163.	2.0	167
691	What we have to know about corticosteroids use during Sars-Cov-2 infection. Journal of Endocrinological Investigation, 2021, 44, 693-701.	1.8	30
692	Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine. OMICS A Journal of Integrative Biology, 2021, 25, 13-22.	1.0	16
693	Declining Intensive Care Unit Mortality of COVID-19: A Multi-Center Study. Journal of Clinical Medicine Research, 2021, 13, 184-190.	0.6	7
694	History and Recent Advances in Coronavirus Discovery. Methods in Pharmacology and Toxicology, 2021, , 3-24.	0.1	3
695	Effect of Methylprednisolone on Inflammation and Coagulation in Patients with Severe COVID-19: A Retrospective Cohort Study. Biomarker Insights, 2021, 16, 117727192110216.	1.0	4
697	Fears and Hopes. , 2021, , 1-24.		0
698	COVID-19: Imbalanced Immune Responses and Potential Immunotherapies. Frontiers in Immunology, 2020, 11, 607583.	2.2	12
699	Advanced care planning during the COVID-19 pandemic: ceiling of care decisions and their implications for observational data. BMC Palliative Care, 2021, 20, 10.	0.8	18
700	Emerging from the COVID-19 pandemic: the numbers and lessons that will stay with us forever. Einstein (Sao Paulo, Brazil), 2021, 19, eED6207.	0.3	2
701	Continuous hemodiafiltration with the oxiris filter ameliorates cytokine storm and induces rapid clinical improvement in COVID-19 " A case report. Indian Journal of Nephrology, 2021, 31, 555-558.	0.2	2
702	COVID-19: What Should the General Practitioner Know?. Clinical Interventions in Aging, 2021, Volume 16, 43-56.	1.3	7
703	Legionella and SARS-CoV-2 Coinfection in a Patient With Pneumonia " An Outbreak in Northern Portugal. Cureus, 2021, 13, e12476.	0.2	4
704	The Current Understanding and Potential Therapeutic Options to Combat COVID-19. SSRN Electronic Journal, 0, , .	0.4	0
705	Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection. Pharmaceuticals, 2021, 14, 44.	1.7	12

#	ARTICLE	IF	CITATIONS
707	Risk factors for mortality of critically ill patients with COVID-19 receiving invasive ventilation. <i>International Journal of Medical Sciences</i> , 2021, 18, 1198-1206.	1.1	12
710	Management of allergic patients during severe acute respiratory syndrome coronavirus-2 pandemic. <i>Allergy Asthma & Respiratory Disease</i> , 2021, 9, 115.	0.3	0
711	Diagnosis and management considerations in steroid-related hyperglycemia in COVID-19: A position statement from the endocrine society of India. <i>Indian Journal of Endocrinology and Metabolism</i> , 2021, 25, 4.	0.2	7
712	Safety and Efficacy of Low-Dose Corticosteroids in Patients With Non-severe Coronavirus Disease 2019: A Retrospective Cohort Study. <i>Cureus</i> , 2021, 13, e12544.	0.2	9
713	Management of COVID-19 in an adolescent demonstrates lasting effects of extreme prematurity on pulmonary function. <i>Respiratory Medicine Case Reports</i> , 2021, 33, 101394.	0.2	0
714	COVID-19: A game of drugs, vaccines, hope and death!. <i>Indian Journal of Anaesthesia</i> , 2021, 65, 434.	0.3	9
715	Chest Imaging of Patients with Sarcoidosis and SARS-CoV-2 Infection. Current Evidence and Clinical Perspectives. <i>Diagnostics</i> , 2021, 11, 183.	1.3	11
716	Endogenous fungal endophthalmitis following intensive corticosteroid therapy in severe COVID-19 disease. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 1909.	0.5	32
717	COVID-19, steroids, and mucormycosis: What an ophthalmologist should know. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 1970.	0.5	7
718	Association of Early-Phase In-Hospital Glycemic Fluctuation With Mortality in Adult Patients With Coronavirus Disease 2019. <i>Diabetes Care</i> , 2021, 44, 865-873.	4.3	22
719	Re-engineering The Clinical Research Enterprise in Response to COVID-19: The Clinical Translational Science Award (CTSA) experience and proposed playbook for future pandemics. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e96.	0.3	11
720	Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1322, 219-260.	0.8	5
721	Effectiveness of corticosteroids on chest high-resolution computed tomography features of COVID-19 pneumonia. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662110425.	1.0	3
722	Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study. <i>Internal and Emergency Medicine</i> , 2021, 16, 843-852.	1.0	30
723	Identification of 37 Heterogeneous Drug Candidates for Treatment of COVID-19 via a Rational Transcriptomics-Based Drug Repurposing Approach. <i>Pharmaceuticals</i> , 2021, 14, 87.	1.7	5
726	Anti-IL6 treatment of serious COVID-19 disease. <i>Medicine (United States)</i> , 2021, 100, e23582.	0.4	38
728	COVID-19-neutralizing antibodies predict disease severity and survival. <i>Cell</i> , 2021, 184, 476-488.e11.	13.5	586
729	Conservative management of COVID-19 associated hypoxaemia. <i>ERJ Open Research</i> , 2021, 7, 00026-2021.	1.1	22

#	ARTICLE	IF	CITATIONS
731	QTc Prolongation in COVID-19 Patients Using Chloroquine. <i>Cardiovascular Toxicology</i> , 2021, 21, 314-321.	1.1	5
732	Safety in Endoscopy for Patients and Healthcare Workers During the COVID-19 Pandemic. <i>Techniques and Innovations in Gastrointestinal Endoscopy</i> , 2021, 23, 170-178.	0.4	9
733	Immunosuppression in kidney transplant recipients with COVID-19 infection “ where do we stand and where are we heading?. <i>Renal Failure</i> , 2021, 43, 273-280.	0.8	8
734	Therapeutic options for COVID-19: a quick review. <i>Journal of Chemotherapy</i> , 2021, 33, 67-84.	0.7	10
735	Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. <i>Emerging Microbes and Infections</i> , 2021, 10, 291-304.	3.0	48
736	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. <i>Lancet Rheumatology</i> , The, 2021, 3, e71-e82.	2.2	18
737	Current treatment in COVID-19 disease: a rapid review. <i>Drugs in Context</i> , 2021, 10, 1-8.	1.0	51
738	Influence of patient characteristics and immunosuppressant management on mortality in kidney transplant recipients hospitalized with coronavirus disease 2019 (COVID-19). <i>Clinical Transplantation</i> , 2021, 35, e14221.	0.8	21
739	Hyperosmolarity Deserves More Attention in Critically Ill COVID-19 Patients with Diabetes: A Cohort-Based Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 47-58.	1.1	4
740	Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 495-502.	1.3	193
741	The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis. <i>Infection and Chemotherapy</i> , 2021, 53, 221.	1.0	15
742	Adverse outcomes in COVID-19 and diabetes: a retrospective cohort study from three London teaching hospitals. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001858.	1.2	52
743	Serum Prealbumin Concentrations, COVID-19 Severity, and Mortality: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 638529.	1.2	22
744	Structures of the glucocorticoid-bound adhesion receptor GPR97“Go complex. <i>Nature</i> , 2021, 589, 620-626.	13.7	90
745	Perceptions of Romanian Physicians on Lockdowns for COVID-19 Prevention. <i>Healthcare (Switzerland)</i> , 2021, 9, 95.	1.0	6
746	Post-discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission. <i>Respiratory Research</i> , 2021, 22, 29.	1.4	64
747	COVID-19 among nursing home residents: results of an urgent pre-hospital intervention by a multidisciplinary task force. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101039.	0.3	9
748	Granulomatous interstitial nephritis in a patient with SARS-CoV-2 infection. <i>BMC Nephrology</i> , 2021, 22, 19.	0.8	19

#	ARTICLE	IF	CITATIONS
749	Clinical characteristics and risk factors for 28-day mortality in critically ill patients with COVID-19: a retrospective cohort study. Turkish Journal of Medical Sciences, 2021, 51, 2285-2295.	0.4	2
750	Post COVID-19 fibrosis, an emerging complication of SARS-CoV-2 infection. IDCases, 2021, 23, e01041.	0.4	38
751	Response to comments on: Neuro-ophthalmic presentation of COVID-19 disease: A case report. Indian Journal of Ophthalmology, 2021, 69, 2555.	0.5	0
752	COVID-19: What we've done well and what we could or should have done better—the 4 Ps. Critical Care, 2021, 25, 40.	2.5	14
753	Update: Drug treatment options for coronavirus disease 2019 (COVID-19). BioScience Trends, 2021, 15, 345-349.	1.1	5
754	Tocilizumab Plus Dexamethasone in Patients with Moderate-to-Severe COVID-19 Pneumonia: a Randomized Clinical Trial of the CORIMUNO-19 Study Group. SSRN Electronic Journal, 0, , .	0.4	1
755	COVID-19 epidemiology in Canada from January to December 2020: the pre-vaccine era. Facets, 2021, 6, 760-822.	1.1	11
756	Repression of transcription by the glucocorticoid receptor: A parsimonious model for the genomics era. Journal of Biological Chemistry, 2021, 296, 100687.	1.6	27
757	COVID 19 infection: Pediatric perspectives. Journal of the American College of Emergency Physicians Open, 2021, 2, e12375.	0.4	32
758	Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine, 2020, 7, 599334.	1.1	15
759	Drugs in Context Editorial: Review of 2020 and what lies ahead in therapeutic interventions. Drugs in Context, 2021, 10, 1-5.	1.0	0
760	Chronic Active Hepatitis B with COVID-19 in Pregnancy: A Case Report. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	1
761	Pharmacologic Treatment of COVID-19: Evidence-Based Update. Indian Journal of Respiratory Care, 2021, 10, S34-S38.	0.1	3
762	Corticosteroids in acute respiratory distress syndrome: outcomes obscured by mortality. Korean Journal of Internal Medicine, 2021, 36, 65-66.	0.7	3
763	Case Report: Emergency CABG Following Failure of PTCA in a COVID-19 Patient. Frontiers in Cardiovascular Medicine, 2020, 7, 620610.	1.1	11
765	A Novel Report on the Compassionate Use of Baricitinib in Treating a Pediatric Patient With Severe Symptoms of COVID-19 Infection. Journal of Medical Cases, 2021, 12, 94-98.	0.4	2
766	Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study. Clinical Medicine Insights: Oncology, 2021, 15, 117955492110434.	0.6	1
767	A Case Series of Severe Hospitalized COVID-19 Patients Treated with Tocilizumab and Glucocorticoids: A Report from Saudi Arabian Hospital. Journal of Epidemiology and Global Health, 2021, 11, 233.	1.1	8

#	ARTICLE	IF	CITATIONS
768	Emerging therapeutics in the management of COVID-19. <i>World Journal of Virology</i> , 2021, 10, 1-29.	1.3	7
769	Two Cases of Severe COVID-19 Pneumonia Effectively Treated with Extracorporeal Membrane Oxygenation in Addition to Favipiravir and Corticosteroid. <i>Internal Medicine</i> , 2021, 60, 123-130.	0.3	3
771	Current Evidence on Coronavirus Disease-2019: A Comprehensive Review. <i>Pediatric Infectious Disease</i> , 2021, 3, 65-73.	0.0	1
772	A distinct innate immune signature marks progression from mild to severe COVID-19. <i>Cell Reports Medicine</i> , 2021, 2, 100166.	3.3	102
773	Impact of the use of digital devices on e of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 1670.	0.5	274
774	Japanese rapid/living recommendations on drug management for COVID-19. <i>Acute Medicine & Surgery</i> , 2021, 8, e664.	0.5	12
775	Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882199648.	1.4	33
776	Effects of Environmental Factors on Severity and Mortality of COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 607786.	1.2	40
777	Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort. <i>Clinical Infectious Diseases</i> , 2022, 75, e450-e458.	2.9	84
778	Impact of Corticosteroid Administration within 7 Days of the Hospitalization for Influenza Pneumonia with Respiratory Failure: A Propensity Score Analysis Using a Nationwide Administrative Database. <i>Journal of Clinical Medicine</i> , 2021, 10, 494.	1.0	8
782	Mucosal immune responses in COVID19 - a living review. <i>Oxford Open Immunology</i> , 2021, 2, iqab002.	1.2	14
783	Are Patients With Autoimmune Cytopenias at Higher Risk of COVID-19 Pneumonia? The Experience of a Reference Center in Northern Italy and Review of the Literature. <i>Frontiers in Immunology</i> , 2020, 11, 609198.	2.2	22
784	Cardiovascular Health and Disease in the Context of COVID-19. <i>Cardiology Research</i> , 2021, 12, 67-79.	0.5	16
785	Respiratory Disease with SARS-COV2 Infection. , 2021, , 145-158.		0
786	Influence of Confinement on Patients with Autoimmune and Immune-Mediated Inflammatory Disease Receiving Biological Treatment for COVID-19 Infection. <i>The BIOCOVID Study. SSRN Electronic Journal</i> , 0, , .	0.4	0
787	COVID-19: An overview and a clinical update. <i>World Journal of Clinical Cases</i> , 2021, 9, 8-23.	0.3	38
788	Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. <i>Endocrine Journal</i> , 2021, 68, 477-484.	0.7	15
789	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46

#	ARTICLE	IF	CITATIONS
791	Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study. <i>Critical Care</i> , 2021, 25, 2.	2.5	58
792	Environmental effects of stratospheric ozone depletion, UV radiation, and interactions with climate change: UNEP Environmental Effects Assessment Panel, Update 2020. <i>Photochemical and Photobiological Sciences</i> , 2021, 20, 1-67.	1.6	93
793	Early mortality benefit with COVID-19 convalescent plasma: a matched control study. <i>British Journal of Haematology</i> , 2021, 192, 706-713.	1.2	45
794	NCATS Inxight Drugs: a comprehensive and curated portal for translational research. <i>Nucleic Acids Research</i> , 2022, 50, D1307-D1316.	6.5	16
795	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.	2.6	167
796	COVID-19 and SARS-CoV-2: Everything we know so far – a comprehensive review. <i>Open Chemistry</i> , 2021, 19, 548-575.	1.0	6
797	Lesson of the month: Severe granulomatosis with polyangiitis (GPA): a diagnostic challenge during the COVID-19 pandemic. <i>Clinical Medicine</i> , 2021, 21, 79-80.	0.8	8
798	Cancer patients with COVID-19: a retrospective study of 51 patients in the district of Piacenza, Northern Italy. <i>Future Science OA</i> , 2021, 7, FSO645.	0.9	19
799	COVID-19 and Sepsis. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 3301-3311.	0.4	37
800	A single-cell mathematical model of SARS-CoV-2 induced pyroptosis and the effects of anti-inflammatory intervention. <i>AIMS Mathematics</i> , 2021, 6, 6050-6086.	0.7	2
801	COVID-19: treatments and the potential for cardiotoxicity. <i>British Journal of Cardiology</i> , 2021, , .	0.7	3
802	Unilateral inferior altitudinal visual field defect related to COVID-19. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 989.	0.5	17
803	Outcome of early short-course corticosteroids in hospitalized patients with coronavirus disease-2019 (COVID-19): A report from a Saudi Arabian hospital. <i>Journal of Family and Community Medicine</i> , 2021, 28, 125.	0.5	2
804	Adjunctive treatments for the management of septic shock – a narrative review of the current evidence. <i>Anaesthesia</i> , 2021, 76, 1245-1258.	1.8	4
805	Dexamethasone Ameliorates Severe Pneumonia But Slightly Enhances Viral Replication in Lung of SARS-CoV-2-Infected Syrian Hamster. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
806	Corticosteroids and COVID-19: What Could Be the Best Bet in Treating Active Glomerular Diseases in Patients With Concomitant Early COVID-19?. <i>American Journal of Kidney Diseases</i> , 2021, 77, 154-155.	2.1	0
807	Is high-dose glucocorticoid beneficial in COVID-19?. <i>European Respiratory Journal</i> , 2021, 57, 2100065.	3.1	2
808	Transbronchial biopsies™ histopathological findings leading to successful late steroid therapy in Covid-19 acute respiratory failure. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 827-833.	1.4	4

#	ARTICLE	IF	CITATIONS
809	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. <i>Frontiers in Physiology</i> , 2021, 12, 593223.	1.3	113
810	Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e297.	1.7	90
811	Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100048.	1.7	6
812	Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. <i>International Journal of Risk and Safety in Medicine</i> , 2021, 32, 3-17.	0.3	4
813	Red Blood Cell Distribution Width, Disease Severity, and Mortality in Hospitalized Patients with SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 286.	1.0	19
814	BJS commission on surgery and perioperative care post-COVID-19. <i>British Journal of Surgery</i> , 2021, 108, 1162-1180.	0.1	12
815	Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110125.	1.4	7
816	Three hemodialysis patients who experienced worsening respiratory failure during treatment for COVID-19. <i>Nihon Toseki Igakkai Zasshi</i> , 2021, 54, 315-324.	0.2	0
817	Covid-19 controversies: the tocilizumab chapter. <i>BMJ, The</i> , 2021, 372, n244.	3.0	17
818	Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. <i>Annual Review of Microbiology</i> , 2021, 75, 19-47.	2.9	52
819	Viral infections in lung transplantation. <i>Journal of Thoracic Disease</i> , 2021, 13, 6673-6694.	0.6	9
820	Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662110072.	1.0	12
821	SARS-CoV-2 and Systemic Lupus Erythematosus. <i>Current Rheumatology Reports</i> , 2021, 23, 8.	2.1	18
822	Potential of Immune-Related Therapy in COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 609212.	1.6	3
823	Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. <i>Nature Computational Science</i> , 2021, 1, 33-41.	3.8	88
824	Pulmonary cavitation: an under-recognized late complication of severe COVID-19 lung disease. <i>BMC Pulmonary Medicine</i> , 2021, 21, 24.	0.8	43
825	Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave?. <i>Critical Care</i> , 2021, 25, 3.	2.5	94
826	A comprehensive review of COVID-19 treatment. <i>Acta Facultatis Medicae Naissensis</i> , 2021, 38, 105-115.	0.1	3

#	ARTICLE	IF	CITATIONS
827	Non-recommended medical interventions and their possible harm in patients with COVID-19. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110340.	1.1	2
828	Ligand-based approach for predicting drug targets and for virtual screening against COVID-19. <i>Briefings in Bioinformatics</i> , 2021, 22, 1053-1064.	3.2	27
829	Interactions of Influenza and SARS-CoV-2 with the Lung Endothelium: Similarities, Differences, and Implications for Therapy. <i>Viruses</i> , 2021, 13, 161.	1.5	17
830	NF- κ B signalling as a pharmacological target in COVID-19: potential roles for IKK β inhibitors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 561-567.	1.4	49
831	OUP accepted manuscript. <i>European Heart Journal</i> , 2021, , .	1.0	1
832	JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2021, 21, 47.	1.3	57
833	Management of COVID-19 at the pandemic's first wave in Ecuador. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110452.	0.2	2
834	Diagnosis and management of coronavirus disease-associated immune thrombocytopenia: a case series. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2021, 54, e0029 2021.	0.4	6
835	Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 539-560.	3.3	62
836	Observational cohort study of IP-10's potential as a biomarker to aid in inflammation regulation within a clinical decision support protocol for patients with severe COVID-19. <i>PLoS ONE</i> , 2021, 16, e0245296.	1.1	48
837	COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation. <i>Mediators of Inflammation</i> , 2021, 2021, 1-18.	1.4	215
838	Pulmonary complications due to COVID-19 – a literature review. <i>Polish Annals of Medicine</i> , 0, , .	0.3	5
839	An immune-based biomarker signature is associated with mortality in COVID-19 patients. <i>JCI Insight</i> , 2021, 6, .	2.3	269
841	Modulating the host immune response to fight against COVID-19: Where are we in 2021?. <i>Virulence</i> , 2021, 12, 1732-1736.	1.8	8
842	CJEM journal club: corticosteroids use for critically ill COVID-19 patients. <i>Canadian Journal of Emergency Medicine</i> , 2021, 23, 162-163.	0.5	1
843	The emergence of post-COVID-19 mucormycosis in India: Can we prevent it?. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 1645.	0.5	21
845	Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 583777.	1.6	73
846	Recent biotechnological advances as potential intervention strategies against COVID-19. <i>3 Biotech</i> , 2021, 11, 41.	1.1	10

#	ARTICLE	IF	CITATIONS
847	ECMO complications in COVID-19: A new insight of a controversial disease. <i>International Journal of Case Reports and Images</i> , 2021, 12, 1-7.	0.0	0
848	Changes in availability, utilization, and prices of medicines and protection equipment for COVID-19 in an Urban population of Northern Nigeria. <i>Journal of Research in Pharmacy Practice</i> , 2021, 10, 17.	0.2	19
849	The COVID-19 Epidemic: Management and Outcomes of Hemodialysis and Peritoneal Dialysis Patients in Stockholm, Sweden. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 250-256.	0.9	12
850	SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications. <i>Global Heart</i> , 2021, 16, 18.	0.9	4
852	Coronavirus Disease-Associated Pulmonary Aspergillosis: A Devastating Complication of COVID-19. <i>Cureus</i> , 2021, 13, e13004.	0.2	5
854	Clinical and therapeutic outcomes of COVID-19 intensive care units (ICU) patients: a retrospective study in Ghana. <i>Pan African Medical Journal</i> , 2021, 38, 107.	0.3	5
856	Cyclosporine A and COVID19 â€“ The COQUIMA cohort â€“ Author's reply. <i>EClinicalMedicine</i> , 2021, 31, 100682.	3.2	0
858	SARS-CoV-2 viral load: Implication in COVID-19 pathogenesis, clinical presentation, diagnosis, treatment, prognosis and infectivity. <i>Journal of Medical Evidence</i> , 2021, .	0.2	0
860	Functional capacity and rehabilitation strategies in Covid-19 patients: current knowledge and challenges. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2021, 54, e07892020.	0.4	26
861	Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862199887.	1.0	5
862	A case series of presumed fungal endogenous endophthalmitis in post COVID-19 patients. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 1322.	0.5	31
863	The Many Faces of Cytokine Release Syndrome-Related Coagulopathy. <i>Clinical Hematology International</i> , 2021, 3, 3.	0.7	16
864	Rapid GMP-Compliant Expansion of SARS-CoV-2â€“Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 598402.	2.2	25
866	Evaluation of patient characteristics, management and outcomes for COVID-19 at district hospitals in the Western Cape, South Africa: descriptive observational study. <i>BMJ Open</i> , 2021, 11, e047016.	0.8	32
867	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. <i>Comparative Medicine</i> , 2021, 71, 342-358.	0.4	3
868	Annals for Hospitalists Inpatient Notes - Corticosteroids and COVID-19â€“Calming the Storm?. <i>Annals of Internal Medicine</i> , 2021, 174, HO2-HO3.	2.0	1
869	Convalescent plasma therapy in COVID-19 critically ill patients during advanced phases of clinical trials and their preliminary results. <i>Einstein (Sao Paulo, Brazil)</i> , 2021, 19, eRW6186.	0.3	8
871	Haemophagocytic syndrome and COVID-19. <i>Clinical Rheumatology</i> , 2021, 40, 1233-1244.	1.0	53

#	ARTICLE	IF	CITATIONS
872	Glucocorticoids and the Brain after Critical Illness. <i>Endocrinology</i> , 2021, 162, .	1.4	40
873	Increasing recruitment into covid-19 trials. <i>BMJ, The</i> , 2021, 372, n235.	3.0	12
874	Organizing pneumonia and COVID-19: A report of two cases. <i>Respiratory Medicine Case Reports</i> , 2021, 32, 101359.	0.2	9
875	Emerging Evidence on Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 Infection: a Systematic Review with Meta-analysis. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 38-47.	0.3	46
876	Efficacy of synthetic glucocorticoids in COVID-19 endothelites. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 1003-1007.	1.4	38
877	Simple prognostic factors and change of inflammatory markers in patients with severe coronavirus disease 2019: a single-center observational study. <i>Acute Medicine & Surgery</i> , 2021, 8, e683.	0.5	8
878	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2 "care pathways, treatment, and follow-up. <i>European Heart Journal</i> , 2022, 43, 1059-1103.	1.0	111
879	Clinical Features and Outcome of Low and High Corticosteroids in Admitted COVID-19 Patients. <i>Journal of Epidemiology and Global Health</i> , 2021, 11, 316.	1.1	6
880	COVID-19 associated mucormycosis: the urgent need to reconsider the indiscriminate use of immunosuppressive drugs. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110270.	1.1	36
881	Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. <i>Genome Medicine</i> , 2021, 13, 7.	3.6	193
882	Ventilator-associated pneumonia in critically ill patients with COVID-19. <i>Critical Care</i> , 2021, 25, 25.	2.5	217
883	C-reactive protein and clinical outcomes in patients with COVID-19. <i>European Heart Journal</i> , 2021, 42, 2270-2279.	1.0	255
884	Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial. <i>Frontiers in Physiology</i> , 2020, 11, 624657.	1.3	51
885	Treatment of Severe COVID-19 with Convalescent Plasma in Bronx, NYC. <i>JCI Insight</i> , 2021, 6, .	2.3	36
886	Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. <i>Respiration</i> , 2021, 100, 116-126.	1.2	99
887	How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 181-190.	1.0	29
888	Cost-effectiveness of intensive care for hospitalized COVID-19 patients: experience from South Africa. <i>BMC Health Services Research</i> , 2021, 21, 82.	0.9	83
889	Association of Intensive Care Unit Patient Load and Demand With Mortality Rates in US Department of Veterans Affairs Hospitals During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2021, 4, e2034266.	2.8	214

#	ARTICLE	IF	CITATIONS
890	Worsening of heart failure by coronavirus disease 2019 is associated with high mortality. ESC Heart Failure, 2021, 8, 943-952.	1.4	12
891	Judicious use of low-dosage corticosteroids for non-severe COVID-19: A case report. Open Medicine (Poland), 2021, 16, 440-445.	0.6	2
892	Host directed therapies: COVID-19 and beyond. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100058.	1.7	19
893	Lessons Learned from COVID-19 Trials “Should We Be Doing Clinical Trials Differently?”. SSRN Electronic Journal, 0, , .	0.4	1
894	Effect of Convalescent Plasma in Critically Ill Patients With COVID-19: An Observational Study. Frontiers in Medicine, 2021, 8, 630982.	1.2	15
895	A review on the advancements in the development of vaccines to combat coronavirus disease 2019. Clinical and Experimental Vaccine Research, 2021, 10, 6.	1.1	45
896	Reply: Is high-dose glucocorticoid beneficial in COVID-19?. European Respiratory Journal, 2021, 57, 2100324.	3.1	0
897	Kidney involvement in coronavirus-associated diseases (Review). Experimental and Therapeutic Medicine, 2021, 21, 361.	0.8	3
899	Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis. RMD Open, 2021, 7, e001235.	1.8	20
901	Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. PLoS ONE, 2021, 16, e0247275.	1.1	7
902	Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19. European Journal of Hospital Pharmacy, 2021, , ejhpharm-2020-002669.	0.5	13
903	Glucocorticoids Should Be Used With Caution in Patients With SARS-CoV-2. Frontiers in Medicine, 2021, 8, 564943.	1.2	0
904	Immune cartography of macrophage activation syndrome in the COVID-19 era. Nature Reviews Rheumatology, 2021, 17, 145-157.	3.5	75
905	Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19. International Journal of Molecular Sciences, 2021, 22, 1986.	1.8	37
906	Therapeutic Strategies in the Management of COVID-19. Frontiers in Molecular Biosciences, 2020, 7, 636738.	1.6	10
907	Migratory pulmonary infiltrates in a patient with COVID-19 and lymphoma. Jornal Brasileiro De Pneumologia, 2021, 47, e20200528.	0.4	6
908	““““““ type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDS““““““ Wellcome Open Research, 2021, 6, 38.	0.9	29
909	An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19. Frontiers in Medicine, 2021, 8, 630209.	1.2	16

#	ARTICLE	IF	CITATIONS
910	Should We Prescribe Antibiotics in Older Patients Presenting COVID-19 Pneumonia?. Journal of the American Medical Directors Association, 2021, 22, 258-259.	1.2	3
911	Colonic Ileus, Distension, and Ischemia Due to COVID-19-Related Colitis: A Case Report and Literature Review. Cureus, 2021, 13, e13236.	0.2	5
912	Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia. Journal of Clinical Immunology, 2021, 41, 926-929.	2.0	10
913	Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy. Leukemia Research, 2021, 101, 106514.	0.4	4
914	Ozone-Induced Oxidative Stress, Neutrophilic Airway Inflammation, and Glucocorticoid Resistance in Asthma. Frontiers in Immunology, 2021, 12, 631092.	2.2	25
915	A review on the effect of COVID-19 in type 2 asthma and its management. International Immunopharmacology, 2021, 91, 107309.	1.7	17
916	Azithromycin, RECOVERY, and the power of large, simple trials. Lancet, The, 2021, 397, 559-560.	6.3	7
917	Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications. Antioxidants, 2021, 10, 272.	2.2	47
918	Clinical course of severe COVID19 treated with tocilizumab and antivirals postâ€œallogeneic stem cell transplant with extensive chronic GVHD. Transplant Infectious Disease, 2021, 23, e13576.	0.7	5
919	Does COVIDâ€œ19â€œrelated cachexia mimic cancerâ€œrelated cachexia? Examining mechanisms, clinical biomarkers, and potential targets for clinical management. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 519-522.	2.9	9
920	The SARS-CoV-2-Inactivating Activity of Hydroxytyrosol-Rich Aqueous Olive Pulp Extract (HIDROXÂ®) and Its Use as a Virucidal Cream for Topical Application. Viruses, 2021, 13, 232.	1.5	24
921	The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment. Genetic Testing and Molecular Biomarkers, 2021, 25, 85-101.	0.3	6
922	Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study. Lancet Rheumatology, The, 2021, 3, e131-e137.	2.2	61
923	Methodological quality of COVID-19 clinical research. Nature Communications, 2021, 12, 943.	5.8	101
924	Clinical trials in a COVID-19 pandemic: Shared infrastructure for continuous learning in a rapidly changing landscape. Clinical Trials, 2021, 18, 324-334.	0.7	7
926	Tissue Lipidomic Alterations Induced by Prolonged Dexamethasone Treatment. Journal of Proteome Research, 2021, 20, 1558-1570.	1.8	11
927	Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma. Allergy, Asthma and Clinical Immunology, 2021, 17, 14.	0.9	22
928	Epidemiology and microbiology of ventilator-associated pneumonia in COVID-19 patients: a multicenter retrospective study in 188 patients in an un-inundated French region. Critical Care, 2021, 25, 72.	2.5	83

#	ARTICLE	IF	CITATIONS
929	Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARS-CoV-2 Spike Protein**. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 7098-7110.	7.2	77
930	The effects of wearing facemasks on oxygenation and ventilation at rest and during physical activity. <i>PLoS ONE</i> , 2021, 16, e0247414.	1.1	55
931	Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 803-815.	0.5	31
932	Open Science Resources for the Mass Spectrometry-Based Analysis of SARS-CoV-2. <i>Journal of Proteome Research</i> , 2021, 20, 1464-1475.	1.8	11
933	Four Cases of Coronavirus Disease 2019 Transferred from a Cruise Ship. <i>Internal Medicine</i> , 2021, 60, 479-485.	0.3	0
934	COVID-19 and Dentistry in 72 Questions: An Overview of the Literature. <i>Journal of Clinical Medicine</i> , 2021, 10, 779.	1.0	21
935	Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e22483.	1.2	2
936	Just the facts: updates in COVID-19 therapeutics. <i>Canadian Journal of Emergency Medicine</i> , 2021, 23, 283-285.	0.5	0
937	COVID-19 patients with hypertension are at potential risk of worsened organ injury. <i>Scientific Reports</i> , 2021, 11, 3779.	1.6	12
938	There are similarities between rheumatic disease with lung involvement and COVID-19 pneumonia. <i>Irish Journal of Medical Science</i> , 2022, 191, 1-5.	0.8	9
939	Characteristics, Treatment, and Outcomes of Patients With Severe or Life-threatening COVID-19 at a Military Treatment Facility—A Descriptive Cohort Study. <i>Military Medicine</i> , 2022, 187, e1043-e1046.	0.4	3
941	To Curb the Progression of Fatal COVID-19 Course—Dream or Reality. <i>Current Hypertension Reports</i> , 2021, 23, 12.	1.5	3
942	Is There an Effect of Fetal Mesenchymal Stem Cells in the Mother-Fetus Dyad in COVID-19 Pregnancies and Vertical Transmission?. <i>Frontiers in Physiology</i> , 2020, 11, 624625.	1.3	1
943	Letter to the Editor: Evolving evidence for immunosuppressants in COVID-19. <i>Australian Prescriber</i> , 2021, 44, 7.	0.5	0
945	Clinical Features, Inpatient Trajectories and Frailty in Older Inpatients with COVID-19: A Retrospective Observational Study. <i>Geriatrics (Switzerland)</i> , 2021, 6, 11.	0.6	19
946	Why Is COVID-19 More Severe in Patients With Diabetes? The Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 629933.	1.1	43
947	Evolution of COVID-19 management in critical care: review and perspective from a hospital in the United Kingdom. <i>Acute and Critical Care</i> , 2021, 36, 1-14.	0.6	6
948	An ethics framework for consolidating and prioritizing COVID-19 clinical trials. <i>Clinical Trials</i> , 2021, 18, 226-233.	0.7	13

#	ARTICLE	IF	CITATIONS
949	COVID-19-associated pulmonary aspergillosis: a prospective single-center dual case series. <i>Mycoses</i> , 2021, 64, 457-464.	1.8	48
950	Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19. <i>Viruses</i> , 2021, 13, 309.	1.5	35
951	A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. <i>IScience</i> , 2021, 24, 102021.	1.9	66
952	Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. <i>Science</i> , 2021, 371, 926-931.	6.0	247
953	Methylprednisolone in adults hospitalized with COVID-19 pneumonia. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 303-311.	1.0	126
954	Urological cancer patients receiving treatment during COVID-19: a single-centre perspective. <i>British Journal of Cancer</i> , 2021, 124, 1513-1515.	2.9	2
955	Development and validation of an online model to predict critical COVID-19 with immune-inflammatory parameters. <i>Journal of Intensive Care</i> , 2021, 9, 19.	1.3	7
956	SARS-CoV-2 infection: molecular mechanisms of severe outcomes to suggest therapeutics. <i>Expert Review of Proteomics</i> , 2021, 18, 105-118.	1.3	10
957	Hallmarks and detection techniques of cellular senescence and cellular ageing in immune cells. <i>Aging Cell</i> , 2021, 20, e13316.	3.0	54
958	SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 620730.	1.8	40
959	Musculoskeletal involvement of COVID-19: review of imaging. <i>Skeletal Radiology</i> , 2021, 50, 1763-1773.	1.2	88
960	2021 Acute Respiratory Distress Syndrome Update, With Coronavirus Disease 2019 Focus. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 1188-1195.	0.6	32
961	Therapeutic Features and Updated Clinical Trials of Mesenchymal Stem Cell (MSC)-Derived Exosomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 711.	1.0	84
962	Angiotensin-converting enzyme 2 (ACE2) expression increases with age in patients requiring mechanical ventilation. <i>PLoS ONE</i> , 2021, 16, e0247060.	1.1	73
964	Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia. <i>Journal of Clinical Immunology</i> , 2021, 41, 536-544.	2.0	62
965	COVID-19 mortality in the UK Biobank cohort: revisiting and evaluating risk factors. <i>European Journal of Epidemiology</i> , 2021, 36, 299-309.	2.5	88
966	A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 2312-2338.	2.9	145
967	Intensive care management of patients with COVID-19: a practical approach. <i>Annals of Intensive Care</i> , 2021, 11, 36.	2.2	73

#	ARTICLE	IF	CITATIONS
968	Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. <i>Frontiers in Oncology</i> , 2021, 11, 625707.	1.3	7
969	COVID-19 first anniversary review of cases, hospitalization, and mortality in the UK. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 973-978.	1.0	8
970	Real-time prediction of COVID-19 related mortality using electronic health records. <i>Nature Communications</i> , 2021, 12, 1058.	5.8	41
971	Management of inflammatory bowel disease in the COVID-19 era. <i>Intestinal Research</i> , 2022, 20, 3-10.	1.0	19
972	Managing COVID-19 in patients with inflammatory bowel disease: navigating unprecedented challenges. <i>Internal Medicine Journal</i> , 2021, 51, 284-287.	0.5	3
974	Severe coronavirus disease pneumonia in a pregnant woman at 25 weeks' gestation: A case report. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 1583-1588.	0.6	5
975	Neurological Disorders Associated With COVID-19 Hospital Admissions: Experience of a Single Tertiary Healthcare Center. <i>Frontiers in Neurology</i> , 2021, 12, 640017.	1.1	6
976	Increased TLR/MyD88 signaling in patients with obesity: is there a link to COVID-19 disease severity?. <i>International Journal of Obesity</i> , 2021, 45, 1152-1154.	1.6	15
978	Neurohormonal treatment in tako-tsubo cardiomyopathy precipitated by COVID-19. Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 201.	0.4	0
979	Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review. <i>Current Respiratory Medicine Reviews</i> , 2021, 16, 165-183.	0.1	0
982	An Updated Systematic Review and Network Meta-Analysis of 25 Randomized Trials Assessing the Efficacy and Safety of Treatments in Covid-19 Disease. <i>Journal of Public Health Research</i> , 2021, 10, jphr.2021.1945.	0.5	5
983	The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time. <i>Frontiers in Medicine</i> , 2021, 8, 604087.	1.2	1
984	Update in Viral Infections in the Intensive Care Unit. <i>Frontiers in Medicine</i> , 2021, 8, 575580.	1.2	14
985	Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID) Tj ETQq1 1 0.784314 rg3T 702-710.	0.7	13
986	Less Severe Cases of COVID-19 in Sub-Saharan Africa: Could Co-infection or a Recent History of Plasmodium falciparum Infection Be Protective?. <i>Frontiers in Immunology</i> , 2021, 12, 565625.	2.2	18
987	Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. <i>Frontiers in Immunology</i> , 2020, 11, 616595.	2.2	20
988	Evidence-Based Guidelines Should Be Used To Inform COVID-19 Management. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	0
990	PDE3-inhibitor enoximone prevented mechanical ventilation in patients with SARS-CoV-2 pneumonia. <i>Experimental Lung Research</i> , 2021, 47, 1-12.	0.5	4

#	ARTICLE	IF	CITATIONS
991	Clinical features and outcomes of hospitalized COVID-19 patients in a low burden region. <i>Pathogens and Global Health</i> , 2021, 115, 243-249.	1.0	8
993	Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients. <i>European Respiratory Journal</i> , 2021, 58, 2002724.	3.1	34
994	Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. <i>Nature Communications</i> , 2021, 12, 915.	5.8	40
995	Clinical Characteristics and Outcome of Patients With Severe COVID-19 Pneumonia at a Public Sector Hospital in Karachi, Pakistan. <i>Cureus</i> , 2021, 13, e13107.	0.2	12
996	How Do Inflammatory Mediators, Immune Response and Air Pollution Contribute to COVID-19 Disease Severity? A Lesson to Learn. <i>Life</i> , 2021, 11, 182.	1.1	11
998	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 698-706.	0.5	37
999	Multistate Modeling of COVID-19 Patients Using a Large Multicentric Prospective Cohort of Critically Ill Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 544.	1.0	10
1000	Trends in Risk-Adjusted 28-Day Mortality Rates for Patients Hospitalized with COVID-19 in England. <i>Journal of Hospital Medicine</i> , 2021, 16, 290-293.	0.7	17
1001	Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19. <i>Clinical Microbiology Newsletter</i> , 2021, 43, 23-32.	0.4	29
1002	Clonal expansion and activation of tissue-resident memory-like T _H 17 cells expressing GM-CSF in the lungs of patients with severe COVID-19. <i>Science Immunology</i> , 2021, 6, .	5.6	125
1003	Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 83.	7.1	57
1004	Consensus on the referral and admission of patients with severe respiratory failure to the NHS ECMO service. <i>Lancet Respiratory Medicine</i> , 2021, 9, e16-e17.	5.2	32
1005	COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine. <i>Mayo Clinic Proceedings</i> , 2021, 96, 446-463.	1.4	62
1006	The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 – A systematic review of the literature. <i>Journal of Autoimmunity</i> , 2021, 117, 102592.	3.0	72
1007	Notable Developments for Vitamin D Amid the COVID-19 Pandemic, but Caution Warranted Overall: A Narrative Review. <i>Nutrients</i> , 2021, 13, 740.	1.7	25
1008	Editorial: COVID-19 immunology and organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2021, 26, 258-265.	0.8	0
1009	Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients. <i>Internal and Emergency Medicine</i> , 2021, 16, 1593-1603.	1.0	32
1010	Point-of-care lung ultrasound assessment for risk stratification and therapy guiding in COVID-19 patients: a prospective noninterventional study. <i>European Respiratory Journal</i> , 2021, 58, 2004283.	3.1	40

#	ARTICLE	IF	CITATIONS
1011	When to call it off: Defining the role of low-dose corticosteroids in thwarting the progression of non-severe COVID-19. <i>Annals of Medicine and Surgery</i> , 2021, 62, 236-238.	0.5	1
1012	The great pretenderâ€™s Bellâ€™s palsy secondary to SARSâ€™CoVâ€™2?. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 1175-1177.	0.2	11
1015	Treatment of Critically Ill Patients with Coronavirus Disease 2019. <i>Korean Journal of Medicine</i> , 2021, 96, 22-29.	0.1	1
1017	Combination of convalescent plasma therapy and repurposed drugs to treat severe COVIDâ€™19 patient with multimorbidity. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 2132-2137.	0.2	3
1018	Scientific effort in combating COVID â€™19 in obstetrics and gynecology. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 57, 189-194.	0.9	2
1019	COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?. <i>Journal of Ovarian Research</i> , 2021, 14, 28.	1.3	17
1020	A matched cohort study of convalescent plasma therapy for COVID-19. <i>Journal of Clinical Apheresis</i> , 2021, 36, 523-532.	0.7	14
1021	Current understanding of the impact of COVID-19 on gastrointestinal disease: Challenges and openings. <i>World Journal of Gastroenterology</i> , 2021, 27, 449-469.	1.4	18
1022	Epithelial Cells and Inflammation in Pulmonary Wound Repair. <i>Cells</i> , 2021, 10, 339.	1.8	33
1023	Comparison of COVID-19 and influenza characteristics. <i>Journal of Zhejiang University: Science B</i> , 2021, 22, 87-98.	1.3	27
1025	Infection, inflammation and intervention: mechanistic modelling of epithelial cells in COVID-19. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20200950.	1.5	22
1026	Convalescent plasma therapy for COVID-19 patients: a protocol of a prospective meta-analysis of randomized controlled trials. <i>Trials</i> , 2021, 22, 112.	0.7	3
1027	In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation. <i>PLoS ONE</i> , 2021, 16, e0245772.	1.1	94
1028	SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets. <i>BMC Genomics</i> , 2021, 22, 125.	1.2	21
1029	Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. <i>Frontiers in Immunology</i> , 2021, 12, 613422.	2.2	228
1030	Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital. <i>Infectious Diseases</i> , 2021, 53, 291-302.	1.4	21
1031	Baricitinib and dexamethasone for hospitalized patients with COVID-19. <i>Cleveland Clinic Journal of Medicine</i> , 2021, , .	0.6	18
1032	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. <i>Frontiers in Immunology</i> , 2021, 12, 631139.	2.2	117

#	ARTICLE	IF	CITATIONS
1033	Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. <i>RMD Open</i> , 2021, 7, e001455.	1.8	183
1034	The swedish covid-19 intensive care cohort: Risk factors of ICU admission and ICU mortality. <i>Acta Anaesthesiologica Scandinavica</i> , 2021, 65, 525-533.	0.7	59
1035	Adjunctive Nutraceutical Therapies for COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1963.	1.8	33
1036	Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies. <i>Anaesthesia</i> , 2021, 76, 537-548.	1.8	117
1037	The Rheumatology Drugs for COVID-19 Management: Which and When?. <i>Journal of Clinical Medicine</i> , 2021, 10, 783.	1.0	18
1038	Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs. <i>Pharmacogenomics Journal</i> , 2021, 21, 275-284.	0.9	32
1040	Chemokine Regulation During Epidemic Coronavirus Infection. <i>Frontiers in Pharmacology</i> , 2020, 11, 600369.	1.6	15
1041	Adverse Outcomes Associated With Corticosteroid Use in Critical COVID-19: A Retrospective Multicenter Cohort Study. <i>Frontiers in Medicine</i> , 2021, 8, 604263.	1.2	10
1042	Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?. <i>European Respiratory Review</i> , 2021, 30, 200346.	3.0	24
1044	Effects of Methylprednisolone on Ventilator-Free Days in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome and COVID-19: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 760.	1.0	12
1045	SARS-CoV-2 pneumonia-angiotensin receptor binding and lung immunopathology: a narrative review. <i>Critical Care</i> , 2021, 25, 53.	2.5	14
1046	COVID-19: Reasons for Guarded Optimism. <i>Pharmaceutical Medicine</i> , 2021, 35, 67-69.	1.0	0
1047	Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19. <i>PLoS ONE</i> , 2021, 16, e0247665.	1.1	5
1049	Corticosteroids in COVID-19: A double-edged sword – a retrospective study. <i>Medicina Intensiva</i> , 2022, 46, 229-231.	0.4	3
1050	Balancing clinical evidence in the context of a pandemic. <i>Nature Biotechnology</i> , 2021, 39, 270-274.	9.4	6
1051	Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology. <i>Oncology Reviews</i> , 2021, 15, 510.	0.8	2
1052	Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?. <i>Croatian Medical Journal</i> , 2021, 62, 95-100.	0.2	10
1053	Characteristics and outcomes of hospital admissions for COVID-19 and influenza in the Toronto area. <i>Cmaj</i> , 2021, 193, E410-E418.	0.9	66

#	ARTICLE	IF	CITATIONS
1054	Gestione del Covid-19 in età pediatrica: documento di consenso. <i>Medico E Bambino</i> , 2021, 40, 85-101.	0.1	5
1055	Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 816-828.	2.3	29
1056	Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease. <i>Frontiers in Pharmacology</i> , 2021, 12, 636989.	1.6	28
1058	Corticosteroids in COVID-19: one size does not fit all. <i>European Respiratory Journal</i> , 2021, 57, 2100224.	3.1	11
1059	The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation. <i>Vaccines</i> , 2021, 9, 109.	2.1	97
1060	Steroid harms if given early in COVID-19 viraemia. <i>BMJ Case Reports</i> , 2021, 14, e241105.	0.2	16
1061	Corticosteroids Treatment of Patients with Coronavirus Disease 2019: A Propensity Score Matching Study. <i>Current Medical Science</i> , 2021, 41, 24-30.	0.7	9
1062	Role of the Sphingosin-1-phosphate pathway in invasion of the nervous system by SARS-CoV-2 infection. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2021, 48, 637-650.	0.9	10
1063	The impact of COVID-19 on kidney transplantation and the kidney transplant recipient – One year into the pandemic. <i>Transplant International</i> , 2021, 34, 612-621.	0.8	40
1064	Diagnostic tool or screening programme? Asymptomatic testing for SARS-CoV-2 needs clear goals and protocols. <i>Lancet Regional Health - Europe</i> , The, 2021, 1, 100002.	3.0	19
1066	Bacterial Superinfections Among Persons With Coronavirus Disease 2019: A Comprehensive Review of Data From Postmortem Studies. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab065.	0.4	54
1067	Antimicrobial Resistance Patterns and Antibiotic Use during Hospital Conversion in the COVID-19 Pandemic. <i>Antibiotics</i> , 2021, 10, 182.	1.5	31
1068	Lombardy, Northern Italy: COVID-19 second wave less severe and deadly than the first? A preliminary investigation. <i>Infectious Diseases</i> , 2021, 53, 370-375.	1.4	38
1069	The cytokine storm and thyroid hormone changes in COVID-19. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 891-904.	1.8	63
1070	Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 58.	7.1	178
1071	The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19. <i>Life</i> , 2021, 11, 144.	1.1	21
1072	Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. <i>BMJ</i> , The, 2021, 372, n311.	3.0	166
1073	Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 919-923.	0.3	26

#	ARTICLE	IF	CITATIONS
1074	A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. <i>Nature Medicine</i> , 2021, 27, 659-667.	15.2	188
1075	Precision medicine in acute respiratory distress syndrome: workshop report and recommendations for future research. <i>European Respiratory Review</i> , 2021, 30, 200317.	3.0	34
1076	COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. <i>British Journal of Haematology</i> , 2021, 193, 43-51.	1.2	49
1077	Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19. <i>Journal of Neurology</i> , 2021, 268, 3125-3128.	1.8	12
1079	Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone. <i>Current Pharmacology Reports</i> , 2021, 7, 49-54.	1.5	11
1080	Food Safety Concerns in "COVID-19 Era". <i>Microbiology Research</i> , 2021, 12, 53-68.	0.8	20
1081	Not COVID-19, Don't Overlook Pneumocystis in Patients on Gefitinib!. <i>Current Oncology</i> , 2021, 28, 961-964.	0.9	8
1082	Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation: a Soci�t� Francophone de Greffe de Moelle et de Th�rapie cellulaire (SFGM�C) multicentre cohort study. <i>British Journal of Haematology</i> , 2021, 192, e121-e124.	1.2	36
1083	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021, 397, 605-612.	6.3	234
1084	A Timely Call to Arms: COVID-19, the Circadian Clock, and Critical Care. <i>Journal of Biological Rhythms</i> , 2021, 36, 55-70.	1.4	22
1085	Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 185-203.	0.6	41
1086	Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. <i>Blood Advances</i> , 2021, 5, 913-925.	2.5	11
1087	IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression. <i>Heliyon</i> , 2021, 7, e06155.	1.4	126
1088	The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19. <i>Cell Metabolism</i> , 2021, 33, 258-269.e3.	7.2	87
1089	Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A Valid Option to Control SARS-CoV-2-Associated Neuroinflammation?. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 213-218.	2.1	14
1090	Long-term outcome after intensive care for COVID-19: differences between men and women" a nationwide cohort study. <i>Critical Care</i> , 2021, 25, 86.	2.5	20
1091	Early and Significant Reduction in C-reactive Protein Levels After Corticosteroid Therapy Is Associated With Reduced Mortality in Patients With COVID-19. <i>Journal of Hospital Medicine</i> , 2021, 16, 142-148.	0.7	21
1092	Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility. <i>Journal of Translational Medicine</i> , 2021, 19, 79.	1.8	24

#	ARTICLE	IF	CITATIONS
1093	High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China. <i>Frontiers in Immunology</i> , 2021, 12, 627844.	2.2	40
1094	Impact of the coronavirus (COVID-19) pandemic on scientific research and implications for clinical academic training – A review. <i>International Journal of Surgery</i> , 2021, 86, 57-63.	1.1	92
1095	A specialised cardiorespiratory team approach in the intensive care management of COVID-19 patients: benefit on mortality, diagnosis and management. <i>Clinical Medicine</i> , 2021, 21, 101-106.	0.8	6
1096	An automated approach to determine antibody endpoint titers for COVID-19 by an enzyme-linked immunosorbent assay. <i>Immunohematology</i> , 2021, 37, 33-43.	0.2	0
1097	The Potential Role of Radiogenomics in Precision Medicine for COVID-19. <i>Journal of Thoracic Imaging</i> , 2021, 36, W34-W34.	0.8	2
1098	Surveillance of diabetes with inpatients on glucocorticoids: are the JBDS audit standards being met?. <i>Practical Diabetes</i> , 2021, 38, 9-12.	0.1	1
1099	Characteristics of viral pneumonia in the COVID-19 era: an update. <i>Infection</i> , 2021, 49, 607-616.	2.3	39
1100	Corticosteroid Pulses for Hospitalized Patients with COVID-19: Effects on Mortality. <i>Mediators of Inflammation</i> , 2021, 2021, 1-10.	1.4	15
1101	A Critical Appraisal of the Effects of Anesthetics on Immune-system Modulation in Critically Ill Patients With COVID-19. <i>Clinical Therapeutics</i> , 2021, 43, e57-e70.	1.1	6
1102	“Tocilizumab-an option for patients with COVID-19 associated cytokine release syndrome: A single center experience”, a retrospective study-original article. <i>Annals of Medicine and Surgery</i> , 2021, 63, 102165.	0.5	6
1103	Assessment of the Temporal Trajectory of Clinical Trials for COVID-19 Interventions After Highly Publicized Lay and Medical Attention. <i>JAMA Network Open</i> , 2021, 4, e210689.	2.8	3
1104	Metal-Bound Methisazone; Novel Drugs Targeting Prophylaxis and Treatment of SARS-CoV-2, a Molecular Docking Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2977.	1.8	4
1106	Use of IFN γ /IL10 Ratio for Stratification of Hydrocortisone Therapy in Patients With Septic Shock. <i>Frontiers in Immunology</i> , 2021, 12, 607217.	2.2	15
1107	Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients. <i>Current Problems in Cancer Case Reports</i> , 2021, 3, 100057.	0.1	7
1108	Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection. <i>Pharmaceutics</i> , 2021, 13, 342.	2.0	8
1109	Serum β 2-microglobulin levels in Coronavirus disease 2019 (Covid-19): Another prognosticator of disease severity?. <i>PLoS ONE</i> , 2021, 16, e0247758.	1.1	12
1110	Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method. <i>Critical Care</i> , 2021, 25, 106.	2.5	121
1111	Acute and Post-Acute Neurological Complications of COVID-19. <i>Neurology International</i> , 2021, 13, 102-119.	1.3	65

#	ARTICLE	IF	CITATIONS
1112	Optimizing Management to Reduce the Mortality of COVID-19: Experience From a Designated Hospital for Severely and Critically Ill Patients in China. <i>Frontiers in Medicine</i> , 2021, 8, 582764.	1.2	4
1113	Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2. , 2021, 3, e0395.		13
1115	Clinical Management of Hypertension, Inflammation and Thrombosis in Hospitalized COVID-19 Patients: Impact on Survival and Concerns. <i>Journal of Clinical Medicine</i> , 2021, 10, 1073.	1.0	6
1116	Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations. <i>European Journal of Pharmacology</i> , 2021, 894, 173836.	1.7	51
1117	Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system. <i>Antiviral Research</i> , 2021, 187, 105015.	1.9	33
1118	COVID-19 Cliff Notes: A COVID-19 Multidisciplinary Care Compendium. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 474.e1-474.e3.	0.6	1
1119	The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. Author's reply. <i>Intensive Care Medicine</i> , 2021, 47, 357-358.	3.9	0
1120	Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients. <i>Health Care Management Science</i> , 2021, 24, 339-355.	1.5	8
1122	Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis. <i>BMC Medicine</i> , 2021, 19, 75.	2.3	40
1123	A perspective on the potential detrimental role of inflammation in pig orthotopic heart xenotransplantation. <i>Xenotransplantation</i> , 2021, 28, e12687.	1.6	11
1124	Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 607408.	1.6	15
1125	Review of studies of severe acute respiratory syndrome related coronavirusâ€² pathogenesis in human organoid models. <i>Reviews in Medical Virology</i> , 2021, 31, e2227.	3.9	10
1126	Treatment of COVID-19: a review of current and prospective pharmacotherapies. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2021, 82, 1-9.	0.2	14
1127	Potential COVIDâ€² Therapeutic Agents and Vaccines: An Evidenceâ€²Based Review. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 429-460.	1.0	22
1128	ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. <i>PLoS ONE</i> , 2021, 16, e0249038.	1.1	97
1129	A randomised trial of <i>Mycobacterium w</i> in critically ill patients with COVID-19: ARMY-1. <i>ERJ Open Research</i> , 2021, 7, 00059-2021.	1.1	14
1130	Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults. <i>Trials</i> , 2021, 22, 221.	0.7	14
1131	Systemic corticosteroids in coronavirus disease 2019 (COVIDâ€²)â€²related smell dysfunction: an international view. <i>International Forum of Allergy and Rhinology</i> , 2021, 11, 1041-1046.	1.5	45

#	ARTICLE	IF	CITATIONS
1132	Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID) Tj ETQg, 0, 0 rgBT, /Overlock	0.7	21
1133	Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 1015-1027.	13.9	438
1134	Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. <i>Nature Medicine</i> , 2021, 27, 401-410.	15.2	127
1135	A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. <i>European Journal of Pharmacology</i> , 2021, 895, 173890.	1.7	86
1136	Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities. <i>Frontiers in Immunology</i> , 2021, 12, 663586.	2.2	26
1137	The impact of viremia on organ failure, biomarkers and mortality in a Swedish cohort of critically ill COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 7163.	1.6	27
1139	Clinical Course and Risk Factors of Disease Deterioration in Critically Ill Patients with COVID-19. <i>Human Gene Therapy</i> , 2021, 32, 310-315.	1.4	23
1140	Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection. <i>Journal of Virology</i> , 2021, 95, .	1.5	97
1142	El cuidado cr�tico en el paciente con COVID-19.. <i>Revista Colombiana De Neumolog�a</i> , 2021, 32, 115-123.	0.1	0
1143	High dimensional profiling identifies specific immune types along the recovery trajectories of critically ill COVID19 patients. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 3987-4002.	2.4	13
1144	Successful use of CPAP in a pregnant patient with COVID-19 pneumonia. <i>BMJ Case Reports</i> , 2021, 14, e238055.	0.2	2
1147	Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective study. <i>Medicina Intensiva</i> , 2022, 46, 179-191.	0.4	17
1148	COVID-19 at 1 Year. <i>Circulation</i> , 2021, 143, e746-e748.	1.6	0
1149	Nitric oxide and COVID-19: Dose, timing and how to administer it might be crucial. <i>Acta Anaesthesiologica Scandinavica</i> , 2021, 65, 576-577.	0.7	9
1150	COVID-19 and rheumatology: A year later. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 31-36.	0.2	7
1151	Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics. <i>International Journal of Obesity</i> , 2021, 45, 1163-1169.	1.6	48
1152	Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1160-1168.	0.4	38
1153	Prone Position in Mechanically Ventilated COVID-19 Patients: A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1046.	1.0	17

#	ARTICLE	IF	CITATIONS
1154	Easing COVID-19 lockdown measures while protecting the older restricts the deaths to the level of the full lockdown. <i>Scientific Reports</i> , 2021, 11, 5839.	1.6	14
1155	Clinical evidence of an interferon- α –glucocorticoid therapeutic synergy in COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 107.	7.1	10
1156	The Theoretical Value of Whole-Lung Irradiation for COVID-19 Pneumonia: A Reasonable and Safe Solution until Targeted Treatments are Developed. <i>Radiation Research</i> , 2021, 195, 474-479.	0.7	2
1157	Does inhaled corticosteroid use affect the risk of COVID-19-related death?. <i>Breathe</i> , 2021, 17, 200275.	0.6	4
1158	Glycemic Profile of Intravenous Dexamethasone-Induced Hyperglycemia Using Continuous Glucose Monitoring. <i>American Journal of Case Reports</i> , 2021, 22, e930733.	0.3	9
1159	Characteristics and outcomes in hospitalized COVID-19 patients during the first 28 days of the spring and autumn pandemic waves in Milan: An observational prospective study. <i>Respiratory Medicine</i> , 2021, 178, 106323.	1.3	20
1160	The utility of a local multidisciplinary working group to oversee the establishment of rapidly evolving standards of care and to support trial recruitment during the COVID-19 pandemic. <i>Clinical Medicine</i> , 2021, 21, e287-e289.	0.8	1
1161	Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India. <i>BMC Infectious Diseases</i> , 2021, 21, 241.	1.3	22
1162	Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics. <i>Scientific Reports</i> , 2021, 11, 6725.	1.6	25
1163	Beware of Steroid-Induced Avascular Necrosis of the Femoral Head in the Treatment of COVID-19—Experience and Lessons from the SARS Epidemic. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 983-995.	2.0	43
1164	Coronavirus disease 2019 (COVID-19) and autoimmunity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 5-30.	0.2	28
1165	Clinical course and outcome of patients with ACTH-dependent Cushing's syndrome infected with novel coronavirus disease-19 (COVID-19): case presentations. <i>Endocrine</i> , 2021, 72, 12-19.	1.1	20
1166	Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e213071.	2.8	113
1167	Outcomes of extracorporeal membrane oxygenation in acute respiratory distress syndrome due to COVID-19: The lessons learned from the first wave of COVID-19. <i>Journal of Cardiac Surgery</i> , 2021, 36, 2219-2224.	0.3	8
1168	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. <i>Wellcome Open Research</i> , 2021, 6, 71.	0.9	5
1169	COVID-19 and liver disease: mechanistic and clinical perspectives. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 348-364.	8.2	272
1170	Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. <i>EClinicalMedicine</i> , 2021, 33, 100773.	3.2	55
1171	Factors associated with myocardial SARS-CoV-2 infection, myocarditis, and cardiac inflammation in patients with COVID-19. <i>Modern Pathology</i> , 2021, 34, 1345-1357.	2.9	90

#	ARTICLE	IF	CITATIONS
1172	Is an EAA>>0.6 in severe COVID-19 patients synonymous with a toxic and pro-inflammatory endotoxin profile, and should we treat it?. <i>Intensive Care Medicine Experimental</i> , 2021, 9, 16.	0.9	2
1180	Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis. <i>International Journal of Infectious Diseases</i> , 2021, 104, 671-676.	1.5	21
1181	The effect of the timing of dexamethasone administration in patients with COVID-19 pneumonia. <i>Tuberculosis and Respiratory Diseases</i> , 2021, 84, 217-225.	0.7	13
1182	The struggle of a good friend getting old: cellular senescence in viral responses and therapy. <i>EMBO Reports</i> , 2021, 22, e52243.	2.0	38
1183	Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death. <i>ELife</i> , 2021, 10, .	2.8	58
1184	Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e115-e115.	0.5	4
1185	High-dose glucocorticoid treatment of near-fatal bocavirus lung infection results in rapid recovery. <i>ERJ Open Research</i> , 2021, 7, 00060-2021.	1.1	1
1186	COVID-19: Overview. <i>Health Evaluation and Promotion</i> , 2021, 48, 220-228.	0.0	0
1187	Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality. <i>ERJ Open Research</i> , 2021, 7, 00018-2021.	1.1	5
1188	How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician. <i>World Journal of Gastroenterology</i> , 2021, 27, 1022-1042.	1.4	26
1189	Current evidence for COVID-19 therapies: a systematic literature review. <i>European Respiratory Review</i> , 2021, 30, 200384.	3.0	37
1190	Performance of national COVID-19 "symptom checkers": a comparative case simulation study. <i>BMJ Health and Care Informatics</i> , 2021, 28, e100187.	1.4	13
1192	Anti-IL5 Drugs in COVID-19 Patients: Role of Eosinophils in SARS-CoV-2-Induced Immunopathology. <i>Frontiers in Pharmacology</i> , 2021, 12, 622554.	1.6	27
1193	Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists. <i>Rheumatology International</i> , 2021, 41, 911-920.	1.5	3
1194	SARS"CoV"2 and pediatric solid organ transplantation: Current knowns and unknowns. <i>Pediatric Transplantation</i> , 2021, 25, e13986.	0.5	6
1195	Endothelial dysfunction in COVID-19 calls for immediate attention: the emerging roles of the endothelium in inflammation caused by SARS-CoV-2. <i>Frontiers of Medicine</i> , 2021, 15, 638-643.	1.5	9
1196	Sex matters: COVID-19 in kidney transplantation. <i>Kidney International</i> , 2021, 99, 555-558.	2.6	6
1197	Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. <i>Intensive Care Medicine</i> , 2021, 47, 355-356.	3.9	3

#	ARTICLE	IF	CITATIONS
1198	Biomarkers of Cardiac Stress and Cytokine Release Syndrome in COVID-19: A Review. <i>Current Heart Failure Reports</i> , 2021, 18, 163-168.	1.3	9
1199	Musculoskeletal Corticosteroid Injection during COVID-19 Pandemic in Sabah: Is It Safe?. <i>Advances in Orthopedics</i> , 2021, 2021, 1-6.	0.4	4
1200	Time course of endothelial dysfunction markers and mortality in COVID-19 patients: A pilot study. <i>Clinical and Translational Medicine</i> , 2021, 11, e283.	1.7	41
1201	Renal Manifestations of Covid-19: Physiology and Pathophysiology. <i>Journal of Clinical Medicine</i> , 2021, 10, 1216.	1.0	27
1202	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. <i>Cell Reports Medicine</i> , 2021, 2, 100208.	3.3	115
1203	Molecular and Cellular Biomarkers of COVID-19 Prognosis: Protocol for the Prospective Cohort TARGET Study. <i>JMIR Research Protocols</i> , 2021, 10, e24211.	0.5	3
1204	Risk factors for mortality in hospitalized patients with COVID-19 from three hospitals in Peru: a retrospective cohort study. <i>F1000Research</i> , 2021, 10, 224.	0.8	18
1205	Impact of Systemic Corticosteroids on Mortality in Older Adults With Critical COVID-19 Pneumonia. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, e127-e132.	1.7	13
1206	Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study. <i>PLoS ONE</i> , 2021, 16, e0248276.	1.1	29
1207	Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 1207-1216.	1.6	16
1208	Secondary haemophagocytic lymphohistiocytosis in COVID-19: correlation of the autopsy findings of bone marrow haemophagocytosis with HScore. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2020-207337.	1.0	18
1209	COVID-19 Hastalarında Akut Solunum Sıkıntısı Sendromu Yaygınlığı ve İyileşim Sürelerinin Değerlendirilmesi. <i>Yayınlanmamış Demirel Üniversitesi Tıp Fakültesi Dergisi</i> , 2021, 28, 51-56.	0.0	2
1210	Rheumatology and COVID-19 at 1 year: facing the unknowns. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 679-681.	0.5	12
1212	Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. <i>Orbit</i> , 2022, 41, 616-619.	0.5	72
1214	Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. <i>Science Immunology</i> , 2021, 6, .	5.6	161
1215	Twenty articles that critical care clinicians should read about COVID-19. <i>Intensive Care Medicine</i> , 2021, 47, 337-341.	3.9	4
1216	Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1801-1814.	1.8	67
1217	Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients. <i>Current Transplantation Reports</i> , 2021, 8, 127-139.	0.9	31

#	ARTICLE	IF	CITATIONS
1218	COVID-19 in early 2021: current status and looking forward. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 114.	7.1	191
1219	Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. <i>Cell Metabolism</i> , 2021, 33, 479-498.	7.2	179
1220	Neutrophils in COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 652470.	2.2	206
1221	Pandemics and maternal health: the indirect effects of COVID-19. <i>Anaesthesia</i> , 2021, 76, 69-75.	1.8	33
1222	Post COVID-19 Organizing Pneumonia: The Right Time to Interfere. <i>Medicina (Lithuania)</i> , 2021, 57, 283.	0.8	20
1223	Current trends and geographical differences in therapeutic profile and outcomes of COVID-19 among pregnant women - a systematic review and meta-analysis. <i>BMC Pregnancy and Childbirth</i> , 2021, 21, 247.	0.9	19
1224	COVID-19 and Diabetic Ketoacidosis: Report of Eight Cases. <i>Cureus</i> , 2021, 13, e14223.	0.2	5
1226	How Can Immuno suppression After Organ Transplantation be Made More Effective and Safer? â€“ A Review on Liposomal Formulations with Consideration of Archaean Tetraetherlipid. <i>Biomedical and Pharmacology Journal</i> , 2021, 14, 33-52.	0.2	0
1227	COMPARATIVE ANALYSIS OF DRUG EFFICACY IN THE TREATMENT FOR COVID-19 SEVERE FORMS, BASED ON ATTRIBUTE-BASED STATISTIC METHODS AND ANALYSIS OF DRUG INTERACTIONS. <i>Farmatsiya I Farmakologiya</i> , 2021, 8, 316-324.	0.2	0
1228	Uptake of treatment practice standards during a pandemic in an academic medical system. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-2.	1.0	0
1229	Will the COVID-19 Pandemic Finally Fuel Drug Repurposing Efforts?. <i>American Journal of Medical Quality</i> , 2021, 36, 122-124.	0.2	0
1230	Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies. <i>Reviews in Medical Virology</i> , 2021, 31, e2228.	3.9	6
1231	Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. <i>Drugs and Aging</i> , 2021, 38, 341-346.	1.3	8
1232	Warm Autoimmune Hemolytic Anemia Associated With Asymptomatic SARS-CoV-2 Infection. <i>Cureus</i> , 2021, 13, e14101.	0.2	11
1233	Lung Ultrasound Patterns and Clinical-Laboratory Correlates during COVID-19 Pneumonia: A Retrospective Study from North East Italy. <i>Journal of Clinical Medicine</i> , 2021, 10, 1288.	1.0	10
1234	Non-invasive ventilation for SARS-CoV-2 acute respiratory failure: a subanalysis from the HOPE COVID-19 registry. <i>Emergency Medicine Journal</i> , 2021, 38, 359-365.	0.4	36
1235	Plitidepsin: a Repurposed Drug for the Treatment of COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	28
1237	Telehealth follow up in emergency department patients discharged with COVID-like illness and exertional hypoxia. <i>American Journal of Emergency Medicine</i> , 2021, 49, 426-430.	0.7	7

#	ARTICLE	IF	CITATIONS
1238	Divergent effects of acute versus chronic glucocorticoids in COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e168-e170.	2.2	24
1239	First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus, Spain. <i>PLoS ONE</i> , 2021, 16, e0248029.	1.1	206
1240	Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. <i>Reviews in Medical Virology</i> , 2021, 31, e2231.	3.9	128
1241	Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, 67.	1.1	39
1242	Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing. <i>Viruses</i> , 2021, 13, 532.	1.5	18
1243	Do COVID-19 Infections Result in a Different Form of Secondary Hemophagocytic Lymphohistiocytosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2967.	1.8	10
1244	Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?. <i>Stem Cell Research and Therapy</i> , 2021, 12, 155.	2.4	13
1245	Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting. <i>Inflammopharmacology</i> , 2021, 29, 343-366.	1.9	9
1246	A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing. <i>3 Biotech</i> , 2021, 11, 198.	1.1	15
1247	Gastrointestinal manifestations in COVID-19. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2021, 115, 1362-1388.	0.7	76
1248	Network Meta-Analysis on the Mechanisms Underlying Alcohol Augmentation of COVID-19 Pathologies. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 675-688.	1.4	31
1249	Does hydroxychloroquine still have any role in the COVID-19 pandemic?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1257-1266.	0.9	8
1250	Kidney transplantation and COVID-19 renal and patient prognosis. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, i21-i29.	1.4	32
1251	Navigating the Uncertainties of COVID-19-associated Aspergillosis: A Comparison With Influenza-associated Aspergillosis. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	50
1252	State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia. <i>Infection</i> , 2021, 49, 591-605.	2.3	112
1253	Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101657.	1.4	28
1254	Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). <i>PLoS ONE</i> , 2021, 16, e0248132.	1.1	41
1255	Reactive arthritis after COVID-19. <i>BMJ Case Reports</i> , 2021, 14, e241375.	0.2	42

#	ARTICLE	IF	CITATIONS
1256	SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids—An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis. <i>Journal of Maxillofacial and Oral Surgery</i> , 2021, 20, 418-425.	0.6	217
1257	Deciphering the state of immune silence in fatal COVID-19 patients. <i>Nature Communications</i> , 2021, 12, 1428.	5.8	107
1258	COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 33, 100789.	3.2	160
1259	Diabetes mellitus in combination with COVID-19: modern views on therapy. <i>Reproductive Endocrinology</i> , 2021, , 8-20.	0.0	0
1260	Does Macrophage Migration Inhibitory Factor predict the prognosis of COVID-19 disease?. <i>Journal of Infection in Developing Countries</i> , 2021, 15, 398-403.	0.5	8
1261	Pulmonary Fibrosis After COVID-19 Pneumonia. <i>Cureus</i> , 2021, 13, e13923.	0.2	10
1262	A Retrospective Study Assessing the Effect of Diabetes on Mortality in Patients With COVID-19 at a Teaching Hospital in the United Kingdom. <i>Cureus</i> , 2021, 13, e13902.	0.2	4
1263	Intensive care physicians'™ perceptions of the diagnosis & management of patients with acute hypoxic respiratory failure associated with COVID-19: A UK based survey. <i>Journal of the Intensive Care Society</i> , 2022, 23, 285-292.	1.1	4
1264	Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19. <i>BMC Pharmacology & Toxicology</i> , 2021, 22, 14.	1.0	7
1265	COVID-19 and HIV-Associated Immune Reconstitution Inflammatory Syndrome: Emergence of Pathogen-Specific Immune Responses Adding Fuel to the Fire. <i>Frontiers in Immunology</i> , 2021, 12, 649567.	2.2	14
1266	One hundred eighteen days on a ventilator: a COVID-19 success story against all odds. <i>BMJ Case Reports</i> , 2021, 14, e239631.	0.2	2
1267	Exertional hypoxia in patients without resting hypoxia is an early predictor of moderate to severe COVID-19. <i>Internal and Emergency Medicine</i> , 2021, 16, 2097-2103.	1.0	2
1268	La crisis de la pandemia por el SARS-CoV-2 desde el punto de vista de los neumólogos.. <i>Revista Colombiana De Neumología</i> , 2021, 32, 6-7.	0.1	0
1270	COVID-19 in Children: Respiratory Involvement and Some Differences With the Adults. <i>Frontiers in Pediatrics</i> , 2021, 9, 622240.	0.9	15
1271	Management Issues of Sarcoidosis in the Time of Coronavirus Disease 2019. <i>Chest</i> , 2021, 159, 1306-1307.	0.4	7
1272	The Centrality of Obesity in the Course of Severe COVID-19. <i>Frontiers in Endocrinology</i> , 2021, 12, 620566.	1.5	14
1273	Protecting the role of the intensive care research coordinator during pandemics. <i>Australian Critical Care</i> , 2021, 34, 119.	0.6	2
1275	The protective effect of rheumatic disease agents in COVID-19. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101659.	1.4	9

#	ARTICLE	IF	CITATIONS
1277	Cysteinyl-specialized proresolving mediators link resolution of infectious inflammation and tissue regeneration via TRAF3 activation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	18
1278	The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19. Frontiers in Medicine, 2021, 8, 637647.	1.2	25
1279	Trends in 30-day mortality from COVID-19 among older adults in the Veterans Affairs system. Journal of the American Geriatrics Society, 2021, 69, 1448-1450.	1.3	7
1280	Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective. Journal of Pharmaceutical Sciences, 2021, 110, 1002-1017.	1.6	14
1281	Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions. Biomedicines, 2021, 9, 279.	1.4	20
1282	Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment. Frontiers in Immunology, 2021, 12, 635371.	2.2	46
1283	The Quest for System-Theoretical Medicine in the COVID-19 Era. Frontiers in Medicine, 2021, 8, 640974.	1.2	13
1284	Postintensive Care Syndrome in Survivors of Critical Illness Related to Coronavirus Disease 2019: Cohort Study From a New York City Critical Care Recovery Clinic*. Critical Care Medicine, 2021, 49, 1427-1438.	0.4	93
1285	The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. Drugs in Context, 2021, 10, 1-10.	1.0	3
1286	Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study. British Journal of Clinical Pharmacology, 2021, 87, 3766-3775.	1.1	30
1287	Acute covid-19 and multisystem inflammatory syndrome in children. BMJ, The, 2021, 372, n385.	3.0	57
1288	Are Some COVID-19 Vaccines Better Than Others? Interpreting and Comparing Estimates of Efficacy in Vaccine Trials. Clinical Infectious Diseases, 2022, 74, 352-358.	2.9	36
1289	Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. PLoS Medicine, 2021, 18, e1003415.	3.9	72
1290	COVID-19 vaccines: The status and perspectives in delivery points of view. Advanced Drug Delivery Reviews, 2021, 170, 1-25.	6.6	262
1291	Colchicine and SARS-CoV-2: Management of the hyperinflammatory state. Respiratory Medicine, 2021, 178, 106322.	1.3	44
1292	Drug repurposing for COVID-19 via knowledge graph completion. Journal of Biomedical Informatics, 2021, 115, 103696.	2.5	102
1293	Germline Genetic Variants of Viral Entry and Innate Immunity May Influence Susceptibility to SARS-CoV-2 Infection: Toward a Polygenic Risk Score for Risk Stratification. Frontiers in Immunology, 2021, 12, 653489.	2.2	10
1294	Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Nature Genetics, 2021, 53, 435-444.	9.4	162

#	ARTICLE	IF	CITATIONS
1295	Characteristics and Outcomes of Heart Transplant Recipients With Coronavirus-19 Disease in a High-volume Transplant Center. <i>Transplantation</i> , 2022, 106, 641-647.	0.5	14
1296	Immune reactivity during COVID-19: Implications for treatment. <i>Immunology Letters</i> , 2021, 231, 28-34.	1.1	45
1297	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2021, 57, 2100048.	3.1	152
1298	Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1096-1110.	2.5	101
1299	A physician's approach and experience of managing patients with diabetes during COVID-19. <i>Practical Diabetes</i> , 2021, 38, 23.	0.1	2
1301	Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. <i>Trials</i> , 2021, 22, 224.	0.7	8
1302	COVID-19 and inhaled corticosteroids—another piece in an expanding puzzle. <i>Lancet Respiratory Medicine</i> , 2021, 9, 674-675.	5.2	5
1303	COVID-19 and obesity: what is known about the features of pathogenesis and treatment?. <i>Arhivno-Rossijskij Žurnal Terapevtičeskoj Praktiki</i> , 2021, 2, 17-23.	0.1	5
1304	Primera y segunda oleada de enfermedad por coronavirus-19: un estudio comparativo en pacientes hospitalizados en una UCI de un hospital universitario de tercer nivel. <i>Medicina Intensiva</i> , 2021, , .	0.4	4
1305	Terapia combinada de tocilizumab y corticoides en la enfermedad grave por SARS-CoV-2. <i>Medicina Intensiva</i> , 2021, , .	0.4	2
1306	Nowcasting epidemics of novel pathogens: lessons from COVID-19. <i>Nature Medicine</i> , 2021, 27, 388-395.	15.2	32
1308	Mutant glucocorticoid receptor binding elements on the interleukin-6 promoter regulate dexamethasone effects. <i>BMC Immunology</i> , 2021, 22, 24.	0.9	8
1309	Recovery From COVID-19 Pneumonia in a Heart Transplant Recipient. <i>Infectious Diseases in Clinical Practice</i> , 2021, Publish Ahead of Print, e401-e403.	0.1	2
1310	Testimonies From the Pandemic Shore. <i>American Journal of Critical Care</i> , 2021, 30, 88-90.	0.8	1
1311	Clinical Features and Prognostic Factors of 245 Portuguese Patients Hospitalized With COVID-19. <i>Cureus</i> , 2021, 13, e13687.	0.2	1
1312	COVID-19, adrenal gland, glucocorticoids, and adrenal insufficiency. <i>Biomedical Papers of the Medical Faculty of the University Palacký&#x0301;, Olomouc, Czechoslovakia</i> , 2021, 165, 1-7.	0.2	12
1314	An A-E assessment of post-ICU COVID-19 recovery. <i>Journal of Intensive Care</i> , 2021, 9, 29.	1.3	2
1316	Renal Involvement in COVID-19: A Review of the Literature. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 895-903.	1.1	21

#	ARTICLE	IF	CITATIONS
1317	Assessing inflammatory status in COVID-19: a role in the pandemic?. <i>Internal and Emergency Medicine</i> , 2021, 16, 1423-1425.	1.0	2
1318	Colonic Epithelial Angiotensin-Converting Enzyme 2 (ACE2) Expression in Blacks and Whites: Potential Implications for Pathogenesis Covid-19 Racial Disparities. <i>Journal of Racial and Ethnic Health Disparities</i> , 2022, 9, 691-697.	1.8	4
1319	Oncologic immunomodulatory agents in patients with cancer and COVID-19. <i>Scientific Reports</i> , 2021, 11, 4814.	1.6	11
1321	CRISPR systems: Novel approaches for detection and combating COVID-19. <i>Virus Research</i> , 2021, 294, 198282.	1.1	36
1323	Secondary infections in mechanically ventilated patients with COVID-19: An overlooked matter?. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 330-336.	0.5	30
1324	Severe covid-19 pneumonia: pathogenesis and clinical management. <i>BMJ, The</i> , 2021, 372, n436.	3.0	240
1325	Pituitary Disorders and COVID-19, Reimagining Care: The Pandemic A Year and Counting. <i>Frontiers in Endocrinology</i> , 2021, 12, 656025.	1.5	9
1326	Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 315-322.	1.3	3
1327	Precision therapeutic targets for COVID-19. <i>Virology Journal</i> , 2021, 18, 66.	1.4	40
1328	COVID-19 research in critical care: the good, the bad, and the ugly. <i>Intensive Care Medicine</i> , 2021, 47, 470-472.	3.9	11
1329	<scp>COVID</scp>â€19: immunopathology, pathophysiological mechanisms, and treatment options. <i>Journal of Pathology</i> , 2021, 254, 307-331.	2.1	86
1330	Why Havenâ€™t We Found an Effective Treatment for COVID-19?. <i>Frontiers in Immunology</i> , 2021, 12, 644850.	2.2	9
1331	Identifying Clinical Phenotypes in Moderate to Severe Acute Respiratory Distress Syndrome Related to COVID-19: The COVADIS Study. <i>Frontiers in Medicine</i> , 2021, 8, 632933.	1.2	19
1332	Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with Coronavirus Disease 2019-Related Pneumonia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 867-879.	0.4	42
1333	A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. <i>ACS Central Science</i> , 2021, 7, 512-533.	5.3	217
1334	Beyond knowledge: Evaluating the practices and precautionary measures towards COVIDâ€19 amongst medical doctors in Jordan. <i>International Journal of Clinical Practice</i> , 2021, 75, e14122.	0.8	24
1335	COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa. <i>Globalization and Health</i> , 2021, 17, 24.	2.4	40
1336	An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. <i>Frontiers in Pharmacology</i> , 2021, 12, 632677.	1.6	65

#	ARTICLE	IF	CITATIONS
1338	The first 12 months of COVID-19: a timeline of immunological insights. <i>Nature Reviews Immunology</i> , 2021, 21, 245-256.	10.6	325
1339	Vitamin D ³ to Treat COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1047.	3.8	30
1340	Baricitinib Therapy in Covid-19 Pneumonia – An Unmet Need Fulfilled. <i>New England Journal of Medicine</i> , 2021, 384, 867-869.	13.9	56
1341	Systemic lupus erythematosus and coronavirus disease 2019. <i>Rheumatology and Immunology Research</i> , 2021, 2, 15-18.	0.2	1
1342	Corticosteroids for COVID-19 Therapy: Potential Implications on Tuberculosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3773.	1.8	52
1343	Cellular Immune Response to COVID-19 and Potential Immune Modulators. <i>Frontiers in Immunology</i> , 2021, 12, 646333.	2.2	47
1344	Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts. <i>MSphere</i> , 2021, 6, .	1.3	11
1345	COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?. <i>Infectious Disease Reports</i> , 2021, 13, 259-284.	1.5	27
1346	Circulating Adaptive Immune Cells Expressing the Gut Homing Marker $\alpha 4 \beta 7$ Integrin Are Decreased in COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 639329.	2.2	8
1347	Visual lung damage CT score at hospital admission of COVID-19 patients and 30-day mortality. <i>European Radiology</i> , 2021, 31, 8354-8363.	2.3	20
1348	Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C. <i>Medical Hypotheses</i> , 2021, 149, 110537.	0.8	5
1349	A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1865-1873.	1.3	9
1352	PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021032.	0.5	17
1353	Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials. <i>Reviews in Medical Virology</i> , 2022, 32, e2239.	3.9	9
1354	High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 675679.	2.2	19
1355	New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals. <i>BioScience Trends</i> , 2021, 15, 126-128.	1.1	32
1357	Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter. <i>TH Open</i> , 2021, 05, e134-e138.	0.7	10
1358	Absence of ‘‘Cytokine Storm’’ in Hospitalized COVID-19 Patients: A Retrospective Cohort Study. <i>Infectious Disease Reports</i> , 2021, 13, 377-387.	1.5	3

#	ARTICLE	IF	CITATIONS
1359	Is butyrate a natural alternative to dexamethasone in the management of CoVID-19?. F1000Research, 2021, 10, 273.	0.8	16
1360	Perinatal SARS-CoV-2 Infection and Neonatal COVID-19: A 2021 Update. NeoReviews, 2021, 22, e284-e295.	0.4	23
1361	Adrenal insufficiency in the COVID-19 era. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E784-E785.	1.8	15
1362	Management and Prevention of COVID-19 in Pregnancy and Pandemic Obstetric Care: A Review of Current Practices. Healthcare (Switzerland), 2021, 9, 467.	1.0	16
1363	Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	6
1364	Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infectious Diseases, 2021, 21, 337.	1.3	161
1365	Common variants at 21q22.3 locus influence MX1 and TMPRSS2 gene expression and susceptibility to severe COVID-19. IScience, 2021, 24, 102322.	1.9	60
1366	Probable Interaction Between Warfarin and the Combination of Remdesivir With Dexamethasone for Coronavirus Disease 2019 (COVID-19) Treatment: A 2 Case Report. Journal of Pharmacy Practice, 2022, 35, 1039-1043.	0.5	4
1367	Neutralizing monoclonal antibodies for treatment of COVID-19. Nature Reviews Immunology, 2021, 21, 382-393.	10.6	568
1368	2020 Year in Review: Pharmacologic Treatments for COVID-19. Respiratory Care, 2021, 66, 1167-1172.	0.8	2
1369	Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech). Viruses, 2021, 13, 756.	1.5	130
1370	Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic. JAMA Network Open, 2021, 4, e216842.	2.8	35
1371	Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. Journal of Laryngology and Otology, 2021, 135, 442-447.	0.4	272
1372	Corticosteroids May Have Negative Effects on the Management of Patients with Severe Fever with Thrombocytopenia Syndrome: A Caseâ€“Control Study. Viruses, 2021, 13, 785.	1.5	13
1373	Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19. Lancet Respiratory Medicine, the, 2021, 9, 682-683.	5.2	12
1374	Clinical and Virologic Characteristics and Outcomes of Coronavirus Disease 2019 at a Cancer Center. Open Forum Infectious Diseases, 2021, 8, ofab193.	0.4	4
1376	<sc>QTc</sc> prolongation in <sc>COVID</sc>â€“19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and metaâ€“analysis. Pharmacoepidemiology and Drug Safety, 2021, 30, 694-706.	0.9	30
1377	COPD in the time of COVID-19. EClinicalMedicine, 2021, 34, 100832.	3.2	0

#	ARTICLE	IF	CITATIONS
1378	COVID-19-Induced Hypoxia With Accompanying Syncope Event and Traumatic Injury. <i>Cureus</i> , 2021, 13, e14602.	0.2	0
1379	Hypoxia and viral infectious diseases. <i>JCI Insight</i> , 2021, 6, .	2.3	15
1381	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). <i>Internal and Emergency Medicine</i> , 2021, 16, 1005-1015.	1.0	37
1382	Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.. <i>European Journal of Internal Medicine</i> , 2021, 86, 34-40.	1.0	61
1383	Reconciling estimates of global spread and infection fatality rates of COVID-19: An overview of systematic evaluations. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13554.	1.7	83
1384	Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. <i>American Journal of Therapeutics</i> , 2021, 28, e299-e318.	0.5	103
1385	Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. <i>Nature Medicine</i> , 2021, 27, 668-676.	15.2	120
1386	The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response. <i>International Journal of Infectious Diseases</i> , 2021, 105, 756-762.	1.5	16
1387	COVID -19 complicated by Acute Respiratory Distress Syndrome, Myocarditis, and Pulmonary Embolism. A case report. <i>The Journal of Critical Care Medicine</i> , 2021, 7, 123-129.	0.3	5
1388	The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection. <i>Journal of General Virology</i> , 2021, 102, .	1.3	95
1389	Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab. <i>Frontiers in Immunology</i> , 2021, 12, 665522.	2.2	10
1391	Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease. <i>Open Heart</i> , 2021, 8, e001526.	0.9	22
1392	Complement cascade in severe forms of COVID-19: Recent advances in therapy. <i>European Journal of Immunology</i> , 2021, 51, 1652-1659.	1.6	46
1393	Prone Positioning of Nonintubated Patients With Coronavirus Disease 2019—A Systematic Review and Meta-Analysis. <i>Critical Care Medicine</i> , 2021, 49, e1001-e1014.	0.4	32
1394	Convalescent plasma treatment of critically ill intensive care COVID-19 patients. <i>Transfusion</i> , 2021, 61, 1394-1403.	0.8	15
1395	Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup. <i>New England Journal of Medicine</i> , 2021, 384, 1564-1565.	13.9	118
1396	Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone. <i>Inflammation</i> , 2021, 44, 1865-1877.	1.7	46
1397	Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e216468.	2.8	111

#	ARTICLE	IF	CITATIONS
1398	An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 9023.	1.6	42
1399	Elucidating the Neuropathologic Mechanisms of SARS-CoV-2 Infection. <i>Frontiers in Neurology</i> , 2021, 12, 660087.	1.1	46
1400	Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital. <i>International Journal of Infectious Diseases</i> , 2021, 105, 532-539.	1.5	20
1401	Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4067.	1.8	27
1402	Paediatric research in the times of COVID-19. <i>Pediatric Research</i> , 2021, 90, 267-271.	1.1	8
1403	A <sc>COVID</sc>-ready public health surveillance system: The Food and Drug Administration's Sentinel System. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 827-837.	0.9	26
1404	Neutralizing Antibody Therapeutics for COVID-19. <i>Viruses</i> , 2021, 13, 628.	1.5	99
1405	Guidelines should not pool evidence from uncomplicated and severe COVID-19. <i>Lancet, The</i> , 2021, 397, 1262-1263.	6.3	11
1406	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 1491-1502.	13.9	1,419
1407	The effect of COVID-19 on liver transplantation: impact, practice patterns, therapeutics, and next steps. <i>Current Opinion in Organ Transplantation</i> , 2021, 26, 339-345.	0.8	1
1410	Potential Role of the Galectin-9/TIM-3 Axis in the Disparate Progression of SARS-CoV-2 in a Married Couple: A Case Report. <i>Biomedicine Hub</i> , 2021, 6, 48-58.	0.4	12
1411	Clinical course of COVID-19 disease in immunosuppressed renal transplant patients. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 428-434.	0.4	8
1414	Pulmonary fibrosis secondary to COVID-19: a narrative review. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 791-803.	1.0	64
1415	Estimating the impact of COVID-19-induced coagulopathy. <i>Annals of the Academy of Medicine, Singapore</i> , 2021, 50, 294-296.	0.2	0
1417	Dexametasona en COVID-19: ¿un medicamento para todos?. <i>Medicina Intensiva</i> , 2021, , .	0.4	1
1419	MSC-derived exosomes carrying a cocktail of exogenous interfering RNAs an unprecedented therapy in era of COVID-19 outbreak. <i>Journal of Translational Medicine</i> , 2021, 19, 164.	1.8	16
1420	Reply to "ivermectin Treatment May Improve the Prognosis of Patients With COVID-19". <i>Archivos De Bronconeumologia</i> , 2021, 57, 65-66.	0.4	1
1421	The Management of Immunosuppression in Kidney Transplant Recipients with COVID-19 Disease: An Update and Systematic Review of the Literature. <i>Medicina (Lithuania)</i> , 2021, 57, 435.	0.8	23

#	ARTICLE	IF	CITATIONS
1422	Quest for a Cure: Potential Small-Molecule Treatments for COVID-19, Part 2. Organic Process Research and Development, 2021, 25, 1089-1111.	1.3	13
1423	Clinical and Immunological Factors That Distinguish COVID-19 From Pandemic Influenza A(H1N1). Frontiers in Immunology, 2021, 12, 593595.	2.2	32
1424	Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6. Journal of Clinical Medicine, 2021, 10, 1583.	1.0	21
1426	The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis. PLoS ONE, 2021, 16, e0249481.	1.1	35
1429	Diabetes Mellitus and COVID-19: Associations and Possible Mechanisms. International Journal of Endocrinology, 2021, 2021, 1-10.	0.6	18
1430	Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease. Journal of Medicinal Chemistry, 2021, 64, 5632-5644.	2.9	26
1431	Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine, 2021, 9, 763-772.	5.2	301
1432	Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nature Communications, 2021, 12, 2295.	5.8	130
1433	Understanding the Co-Epidemic of Obesity and COVID-19: Current Evidence, Comparison with Previous Epidemics, Mechanisms, and Preventive and Therapeutic Perspectives. Current Obesity Reports, 2021, 10, 214-243.	3.5	50
1434	Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. Autoimmunity Reviews, 2021, 20, 102778.	2.5	47
1435	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. Journal of the American College of Cardiology, 2021, 77, 1903-1921.	1.2	150
1436	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. JAMA - Journal of the American Medical Association, 2021, 325, 1620.	3.8	515
1437	Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia. AIDS Research and Human Retroviruses, 2021, 37, 283-291.	0.5	4
1438	Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus. Molecules, 2021, 26, 2593.	1.7	29
1439	Ivermectin for preventing and treating COVID-19. The Cochrane Library, 0, , .	1.5	25
1440	Selective Vagus Nerve Stimulation as a Therapeutic Approach for the Treatment of ARDS: A Rationale for Neuro-Immunomodulation in COVID-19 Disease. Frontiers in Neuroscience, 2021, 15, 667036.	1.4	23
1441	SARS-CoV-2 Infection in Hereditary Hemorrhagic Telangiectasia Patients Suggests Less Clinical Impact Than in the General Population. Journal of Clinical Medicine, 2021, 10, 1884.	1.0	8
1442	COVID-19 and ARDS: Update on Preventive and Therapeutic Venues. Current Molecular Medicine, 2022, 22, 312-324.	0.6	5

#	ARTICLE	IF	CITATIONS
1443	Rapid clinical evolution for COVID-19 translates into early hospital admission and unfavourable outcome: A preliminary report. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 744.	0.6	0
1445	From bedside to bench: regulation of host factors in SARS-CoV-2 infection. <i>Experimental and Molecular Medicine</i> , 2021, 53, 483-494.	3.2	6
1446	No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison. <i>Frontiers in Pharmacology</i> , 2021, 12, 621676.	1.6	6
1447	SIADH and severe COVID-19 pneumonia in elderly patients: a therapeutic challenge in developing countries. <i>Internal and Emergency Medicine</i> , 2021, 16, 2023-2025.	1.0	5
1448	Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM). <i>Archives of Endocrinology and Metabolism</i> , 2021, 65, 368-375.	0.3	13
1451	Correlation of Low Levels of Î±1 Antitrypsin and Elevation of Neutrophil to Lymphocyte Ratio with Higher Mortality in Severe COVID-19 Patients. <i>Mediators of Inflammation</i> , 2021, 2021, 1-7.	1.4	7
1452	The treatment of SARS-CoV2 with antivirals and mitigation of the cytokine storm syndrome: the role of gene expression. <i>Genome</i> , 2021, 64, 400-415.	0.9	0
1453	Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review. <i>Science Progress</i> , 2021, 104, 003685042110169.	1.0	15
1454	Effectiveness of potential antiviral treatments in COVID-19 transmission control: a modelling study. <i>Infectious Diseases of Poverty</i> , 2021, 10, 53.	1.5	13
1455	Coronavirus Disease 2019 in Children. <i>Journal of the Nihon University Medical Association</i> , 2021, 80, 49-54.	0.0	0
1456	Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. <i>Cancer Discovery</i> , 2021, 11, 1336-1344.	7.7	20
1457	COVID-19, a tale of two peaks: patientsâ€™ characteristics, treatments, and clinical outcomes. <i>Internal and Emergency Medicine</i> , 2021, 16, 1629-1639.	1.0	5
1458	Effect of Corticosteroids on Mortality in Hospitalized COVID-19 Patients Not Receiving Invasive Mechanical Ventilation. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1660-1667.	2.3	10
1459	Modelling intensive care unit capacity under different epidemiological scenarios of the COVID-19 pandemic in three Western European countries. <i>International Journal of Epidemiology</i> , 2021, 50, 753-767.	0.9	24
1460	Outcomes of non-COVID-19 critically ill patients during the COVID-19 pandemic. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 942-950.	1.0	14
1461	A Perspective on COVID-19 Management. <i>Journal of Clinical Medicine</i> , 2021, 10, 1586.	1.0	8
1462	Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units. <i>Critical Care</i> , 2021, 25, 155.	2.5	23
1463	Managing Pandemics with Health Informatics: Successes and Challenges. <i>Yearbook of Medical Informatics</i> , 2021, 30, 017-025.	0.8	13

#	ARTICLE	IF	CITATIONS
1464	Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID-19: Systematic review and meta-analysis. <i>Journal of Asthma</i> , 2022, 59, 866-879.	0.9	78
1465	Association Between Lack of Blinding and Mortality Results in Critical Care Randomized Controlled Trials: A Meta-Epidemiological Study*. <i>Critical Care Medicine</i> , 2021, 49, 1800-1811.	0.4	21
1466	Racial and Ethnic Differences and Clinical Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) Presenting to the Emergency Department. <i>Clinical Infectious Diseases</i> , 2022, 74, 387-394.	2.9	23
1467	Endothelial cells and SARS-CoV-2: An intimate relationship. <i>Vascular Pharmacology</i> , 2021, 137, 106829.	1.0	45
1468	Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain. <i>Lancet Regional Health - Europe</i> , The, 2021, 3, 100041.	3.0	35
1469	Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 545-547.	2.3	19
1470	A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis. <i>Microorganisms</i> , 2021, 9, 806.	1.6	12
1472	Pneumonia. <i>Nature Reviews Disease Primers</i> , 2021, 7, 25.	18.1	230
1473	RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19. <i>Contemporary Clinical Trials</i> , 2021, 103, 106330.	0.8	9
1475	COVID-19 and the human innate immune system. <i>Cell</i> , 2021, 184, 1671-1692.	13.5	524
1476	Systemic Inflammation May Induce Cardiac Injury in COVID-19 Patients Including Children and Adolescents Without Underlying Cardiovascular Diseases: A Systematic Review. <i>Cardiovascular Revascularization Medicine</i> , 2022, 35, 169-178.	0.3	20
1477	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e253-e261.	2.2	140
1478	Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. <i>New England Journal of Medicine</i> , 2021, 384, 1503-1516.	13.9	762
1479	Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases. <i>Rheumatology International</i> , 2021, 41, 1097-1103.	1.5	21
1481	Risk Factors and a Scoring System to Predict ARDS in Patients with COVID-19 Pneumonia in Korea: A Multicenter Cohort Study. <i>Disease Markers</i> , 2021, 2021, 1-7.	0.6	7
1482	Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	0
1483	Emergency Medicine Journal COVID-19 monthly top five. <i>Emergency Medicine Journal</i> , 2021, 38, 398-400.	0.4	0
1485	Ethical dimensions in randomized trials and off-label use of investigational drugs for COVID-19 treatment. <i>Clinical Ethics</i> , 2022, 17, 95-104.	0.5	1

#	ARTICLE	IF	CITATIONS
1486	Care Systems COVID-19 Impact Assessment: Lessons Learned and Compelling Needs. <i>NAM Perspectives</i> , 2021, 2021, .	1.3	9
1487	Cytokine Storm. <i>New England Journal of Medicine</i> , 2021, 384, e59.	13.9	19
1489	Respuesta. <i>Medicina Clínica</i> , 2021, 156, 361.	0.3	0
1490	Is it safe to start steroids at home for a COPD exacerbation after virtual assessment in the COVID-19 era?. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 213-215.	0.6	0
1491	COVID-19 cytokine storm: targeting the appropriate cytokine. <i>Lancet Rheumatology</i> , The, 2021, 3, e236-e237.	2.2	39
1492	Biological Stress Responses to Acute Respiratory Distress Syndrome and Treatment Strategy. <i>The Japanese Journal of Rehabilitation Medicine</i> , 2021, 58, 352-356.	0.0	0
1493	Improving the management of suspected tonsillitis and peritonsillar abscess referred to ENT â€“ a coronavirus disease 2019 service improvement. <i>Journal of Laryngology and Otology</i> , 2021, 135, 584-588.	0.4	3
1495	IL-6 modulation for COVID-19: the right patients at the right time?. , 2021, 9, e002285.		32
1496	Adhatoda Vasica attenuates inflammatory and hypoxic responses in preclinical mouse models: potential for repurposing in COVID-19-like conditions. <i>Respiratory Research</i> , 2021, 22, 99.	1.4	24
1498	Time-to-Death Longitudinal Characterization of Clinical Variables and Longitudinal Prediction of Mortality in COVID-19 Patients: A Two-Center Study. <i>Frontiers in Medicine</i> , 2021, 8, 661940.	1.2	15
1499	Current COVID-19 treatments: Rapid review of the literature. <i>Journal of Global Health</i> , 2021, 11, 10003.	1.2	26
1500	Risk factors for COVID-19 mortality: The effect of convalescent plasma administration. <i>PLoS ONE</i> , 2021, 16, e0250386.	1.1	12
1501	High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool?. <i>Internal and Emergency Medicine</i> , 2021, 16, 1329-1330.	1.0	5
1502	Practical recommendations for the prevention and management of COVID-19 in low-income and middle-income settings: adapting clinical experience from the field. <i>Family Medicine and Community Health</i> , 2021, 9, e000930.	0.6	2
1503	Combination therapy with plasma exchange and glucocorticoid may be effective for severe COVID-19 infection: A retrospective observational study. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 390-400.	0.4	8
1504	Clinical characteristics and risk factors for the isolation of multi-drug-resistant Gram-negative bacteria from critically ill patients with COVID-19. <i>Journal of Hospital Infection</i> , 2021, 110, 165-171.	1.4	49
1505	Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	185
1506	Viral epidemiology and SARS-CoV-2 co-infections with other respiratory viruses during the first COVID-19 wave in Paris, France. <i>Influenza and Other Respiratory Viruses</i> , 2021, 15, 425-428.	1.5	14

#	ARTICLE	IF	CITATIONS
1507	Neurological update: COVID-19. <i>Journal of Neurology</i> , 2021, 268, 4379-4387.	1.8	25
1508	Stratifying Deterioration Risk by Acuity at Admission Offers Triage Insights for Coronavirus Disease 2019 Patients. , 2021, 3, e0400.		8
1509	A COVID-19 Drug Repurposing Strategy through Quantitative Homological Similarities Using a Topological Data Analysis-Based Framework. <i>Pharmaceutics</i> , 2021, 13, 488.	2.0	13
1510	Emergency Airway Management in Patients with COVID-19: A Prospective International Multicenter Cohort Study. <i>Anesthesiology</i> , 2021, 135, 292-303.	1.3	30
1511	Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. <i>Circulation: Heart Failure</i> , 2021, 14, e007957.	1.6	24
1512	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <i>Nature Communications</i> , 2021, 12, 2349.	5.8	194
1513	The time to offer treatments for COVID-19. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 505-518.	1.9	20
1514	Interferon β for patients with moderate to severe COVID-19 in the inflammatory phase of the disease. <i>Journal of Medical Virology</i> , 2021, 93, 4102-4107.	2.5	7
1515	2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. <i>European Journal of Cancer</i> , 2021, 147, 154-160.	1.3	34
1516	Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 675678.	2.2	35
1517	Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1217-1225.	1.5	61
1518	Second versus first wave of COVID-19 deaths: Shifts in age distribution and in nursing home fatalities. <i>Environmental Research</i> , 2021, 195, 110856.	3.7	97
1522	Clinical Variants, Characteristics, and Outcomes Among COVID-19 Patients: A Case Series Analysis at a Tertiary Care Hospital in Karachi, Pakistan. <i>Cureus</i> , 2021, 13, e14761.	0.2	7
1524	Chemotherapy During Active SARS-CoV2 Infection: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2021, 11, 662211.	1.3	7
1525	Antibiotic prescribing for respiratory tract infection in patients with suspected and proven COVID-19: results from an antibiotic point prevalence survey in Scottish hospitals. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab078.	0.9	6
1526	The UK Foot and Ankle COVID-19 National (FALCoN) audit. <i>Bone & Joint Open</i> , 2021, 2, 216-226.	1.1	6
1527	COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. <i>Current Medical Research and Opinion</i> , 2021, 37, 929-938.	0.9	9
1528	Comments on "Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations" by Amato et al.. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 757.	0.6	2

#	ARTICLE	IF	CITATIONS
1529	Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study. <i>International Journal of Infectious Diseases</i> , 2021, 105, 487-494.	1.5	11
1531	Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. <i>Intensive Care Medicine</i> , 2021, 47, 521-537.	3.9	148
1532	A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 675-686.	1.4	22
1533	Use of Remdesivir in Myasthenia gravis and COVID-19. <i>Pharmacotherapy</i> , 2021, 41, 546-550.	1.2	5
1534	The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 615333.	1.2	22
1535	Characteristics and Risk Factors Associated With Mortality in Critically Ill Patients With COVID-19. <i>Cureus</i> , 2021, 13, e14442.	0.2	6
1536	Lessons from the pandemic on the value of research infrastructure. <i>Health Research Policy and Systems</i> , 2021, 19, 54.	1.1	10
1537	Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes. <i>Infectious Diseases in Clinical Practice</i> , 2021, 29, e282-e286.	0.1	13
1538	Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1098-1100.	0.6	28
1539	Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 153, 72-85.	0.9	12
1540	Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 1487-1510.	1.6	50
1541	RBD-specific polyclonal F(ab) ² fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial. <i>EClinicalMedicine</i> , 2021, 34, 100843.	3.2	41
1542	Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom. <i>Journal of Clinical Medicine</i> , 2021, 10, 1607.	1.0	21
1543	Impact of corticosteroids in hospitalised COVID-19 patients. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000766.	1.2	27
1544	COVID-19 Management in the Pediatric Age: Consensus Document of the COVID-19 Working Group in Paediatrics of the Emilia-Romagna Region (RE-CO-Ped), Italy. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3919.	1.2	25
1545	How Are Emerging Data Translated Into Clinical Practice? A Mixed Methods Investigation of Coronavirus Disease 2019 Institutional Treatment Protocols. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab072.	0.4	7
1546	Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. <i>Nature Reviews Microbiology</i> , 2021, 19, 425-441.	13.6	202
1547	COVID-19 associated thrombotic thrombocytopenic purpura (TTP) ; A case series and mini-review. <i>International Immunopharmacology</i> , 2021, 93, 107397.	1.7	26

#	ARTICLE	IF	CITATIONS
1548	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 271-281.	3.7	23
1549	Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. <i>European Journal of Ophthalmology</i> , 2022, 32, NP11-NP16.	0.7	97
1550	COVID-19 and Cardiovascular Disease. <i>Circulation Research</i> , 2021, 128, 1214-1236.	2.0	232
1551	Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry. <i>American Journal of Transplantation</i> , 2021, 21, 2573-2582.	2.6	53
1552	Fast prototyping of a local fuzzy search system for decision support and retraining of hospital staff during pandemic. <i>Health Information Science and Systems</i> , 2021, 9, 21.	3.4	1
1553	ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 204.	1.2	11
1554	Acuity level of care as a predictor of case fatality and prolonged hospital stay in patients with COVID-19: a hospital-based observational follow-up study from Pakistan. <i>BMJ Open</i> , 2021, 11, e045414.	0.8	5
1555	Review of Pharmacotherapy Tried for Management of the Coronavirus Disease-19. <i>Eurasian Journal of Medicine</i> , 2021, 53, 137-143.	0.2	5
1556	Effects of early corticosteroid use in patients with severe coronavirus disease 2019. <i>BMC Infectious Diseases</i> , 2021, 21, 506.	1.3	9
1557	MECHANISMS OF CYTOKINE STORM DEVELOPMENT IN COVID-19 AND NEW POTENTIAL TARGETS OF PHARMACOTHERAPY. <i>Farmatsiya I Farmakologiya</i> , 2021, 8, 380-391.	0.2	3
1559	Metabolomics and computational analysis of the role of monoamine oxidase activity in delirium and SARS-COV-2 infection. <i>Scientific Reports</i> , 2021, 11, 10629.	1.6	20
1560	COVID-19 Outcomes in Underserved Populations: Reaping What One Sows. <i>Respiratory Care</i> , 2021, 66, 1041-1043.	0.8	0
1561	COVID-19-Associated Pneumonia: Radiobiological Insights. <i>Frontiers in Pharmacology</i> , 2021, 12, 640040.	1.6	4
1563	High plasma concentration of non-esterified polyunsaturated fatty acids is a specific feature of severe COVID-19 pneumonia. <i>Scientific Reports</i> , 2021, 11, 10824.	1.6	17
1564	Practical Advices for Treating Chronic Pain in the Time of COVID-19: A Narrative Review Focusing on Interventional Techniques. <i>Journal of Clinical Medicine</i> , 2021, 10, 2303.	1.0	7
1565	Convalescent plasma to treat COVID-19: Following the Argentinian lead. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103161.	0.5	1
1566	COVID-19 in People With Schizophrenia: Potential Mechanisms Linking Schizophrenia to Poor Prognosis. <i>Frontiers in Psychiatry</i> , 2021, 12, 666067.	1.3	22
1567	Cryptococcal Meningoencephalitis During Convalescence From Severe COVID-19 Pneumonia. <i>Neurohospitalist, The</i> , 2022, 12, 96-99.	0.3	14

#	ARTICLE	IF	CITATIONS
1569	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab278.	0.4	31
1570	When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 30-34.	2.3	6
1572	A case report of COVID-19 in refractory myasthenia. <i>Medicine (United States)</i> , 2021, 100, e25701.	0.4	3
1574	Year in Review 2020: Noteworthy Literature in Cardiothoracic Critical Care. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2021, 25, 128-137.	0.4	2
1575	Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON) Tj ETQq0 0.0 rgBT /Oyerklock 10	0.4	3
1576	Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2. <i>Pathogens</i> , 2021, 10, 636.	1.2	2
1577	All That Coughs Is Not COVID-19: A Delayed Diagnosis of Disseminated Coccidioidomycosis Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab246.	0.4	8
1578	SARS-CoV-2 prevalence and maternal-perinatal outcomes among pregnant women admitted for delivery: Experience from COVID-19-dedicated maternity hospital in Jammu, Jammu and Kashmir (India). <i>Journal of Medical Virology</i> , 2021, 93, 5505-5514.	2.5	31
1579	Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials. <i>Lung</i> , 2021, 199, 239-248.	1.4	24
1580	Strongyloidiasis in the COVID era: a warning for an implementation of the screening protocol. <i>Infection</i> , 2021, 49, 1065-1067.	2.3	4
1581	Outpatient Management of Patients With COVID-19. <i>Chest</i> , 2021, 160, 1222-1231.	0.4	11
1582	Caspases and therapeutic potential of caspase inhibitors in moderate-severe SARS-CoV-2 infection and long COVID. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 118-129.	2.7	43
1583	Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1362-1363.	0.5	2
1584	Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. <i>Intensive Care Medicine</i> , 2021, 47, 641-652.	3.9	57
1585	Blood DNA methylation and COVID-19 outcomes. <i>Clinical Epigenetics</i> , 2021, 13, 118.	1.8	68
1586	Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2. <i>Clinical and Translational Science</i> , 2021, 14, 1123-1132.	1.5	12
1587	Nanobased Platforms for Diagnosis and Treatment of COVID-19: From Benchtop to Bedside. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 2150-2176.	2.6	27
1588	Perspective: the nose and the stomach play a critical role in the NZACE2-Pärtari* (modified ACE2) drug treatment project of SARS-CoV-2 infection. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 553-560.	1.3	10

#	ARTICLE	IF	CITATIONS
1589	Patients with COVID-19: in the dark-NETs of neutrophils. <i>Cell Death and Differentiation</i> , 2021, 28, 3125-3139.	5.0	189
1590	Predicting recurrence of respiratory failure in critically ill patients with COVID-19: A preliminary study. <i>Journal of Infection</i> , 2021, 82, e33-e35.	1.7	5
1591	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 522-532.	5.2	195
1592	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.5	151
1593	Clinical Olfactory Working Group consensus statement on the treatment of postinfectious olfactory dysfunction. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1704-1719.	1.5	85
1594	Machine Learning as a Precision-Medicine Approach to Prescribing COVID-19 Pharmacotherapy with Remdesivir or Corticosteroids. <i>Clinical Therapeutics</i> , 2021, 43, 871-885.	1.1	14
1596	Standard Dose Ivermectin for COVID-19. <i>Chest</i> , 2021, 159, 2111-2112.	0.4	6
1597	Tailored modulation of the inflammatory balance in COVID-19 patients admitted to the ICU—a viewpoint. <i>Critical Care</i> , 2021, 25, 178.	2.5	4
1598	Efficacy of corticosteroid in patients with COVID-19: A multicenter retrospective study and meta-analysis. <i>Journal of Medical Virology</i> , 2021, 93, 4292-4302.	2.5	18
1599	Prognostic Factors in Hospitalized COVID-19 Patients at the Start of the Pandemic in Colombia: A Retrospective Cohort Study. <i>Cureus</i> , 2021, 13, e14865.	0.2	2
1601	Are We Forgetting About IgA? A Re-examination of Coronavirus Disease 2019 Convalescent Plasma. <i>Transfusion</i> , 2021, 61, 1740-1748.	0.8	16
1602	Characteristics and pharmacological management of COVID-19 patients admitted at a hospital in Nairobi, Kenya. <i>African Journal of Pharmacy and Pharmacology</i> , 2021, 15, 92-100.	0.2	1
1603	Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses. <i>Pathogens</i> , 2021, 10, 565.	1.2	57
1605	Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 498-510.	5.2	180
1606	Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection. <i>Frontiers in Microbiology</i> , 2021, 12, 675419.	1.5	25
1607	Key Factors Fuelling India's Second COVID Surge. <i>The Physician</i> , 2021, 7, 1-6.	0.2	1
1608	Epidemiology, clinical characteristics, and virologic features of COVID-19 patients in Kazakhstan: A nation-wide retrospective cohort study. <i>Lancet Regional Health - Europe</i> , 2021, 4, 100096.	3.0	26
1609	Comparative incidence and outcomes of COVID-19 in kidney or kidney-pancreas transplant recipients versus kidney or kidney-pancreas waitlisted patients: A single-center study. <i>Clinical Transplantation</i> , 2021, 35, e14362.	0.8	6

#	ARTICLE	IF	CITATIONS
1610	Incidence and mortality of COVID-19-associated pulmonary aspergillosis: A systematic review and meta-analysis. <i>Mycoses</i> , 2021, 64, 993-1001.	1.8	76
1611	Factors influencing risk perception and nosocomial infection prevention practices of frontline nurses during the COVID-19 pandemic. <i>BMC Nursing</i> , 2021, 20, 78.	0.9	10
1612	Management of severe covid-19: progress and promise. <i>BMJ, The</i> , 2021, 373, n1147.	3.0	6
1613	Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?. <i>Clinics in Dermatology</i> , 2021, 39, 430-445.	0.8	2
1614	Reactivación de <i>Strongyloides stercoralis</i> en pacientes con neumonía por SARS-CoV-2 en tratamiento con dexametasona. <i>Medicina Clínica</i> , 2022, 158, 242-243.	0.3	7
1616	Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity. <i>Frontiers in Immunology</i> , 2021, 12, 665329.	2.2	26
1617	Characterization of Bacterial and Fungal Infections in Hospitalized Patients With Coronavirus Disease 2019 and Factors Associated With Health Care-Associated Infections. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab201.	0.4	92
1618	The characteristics and outcomes of critically ill patients with COVID-19 who received systemic thrombolysis for presumed pulmonary embolism: an observational study. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 1061-1067.	1.0	12
1619	A clinical staging proposal of the disease course over time in non-severe patients with coronavirus disease 2019. <i>Scientific Reports</i> , 2021, 11, 10681.	1.6	9
1621	Does methylprednisolone affect time to recovery in COVID-19 Pneumonia?. <i>Marmara Medical Journal</i> , 0, , .	0.2	1
1622	Practicing With Uncertainty: Kidney Transplantation During the COVID-19 Pandemic. <i>American Journal of Kidney Diseases</i> , 2021, 77, 777-785.	2.1	39
1623	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) coinfection: A unique case series. <i>Travel Medicine and Infectious Disease</i> , 2021, 41, 102026.	1.5	18
1624	The intersection of COVID-19 and cancer: signaling pathways and treatment implications. <i>Molecular Cancer</i> , 2021, 20, 76.	7.9	42
1625	Influenza- and COVID-19-Associated Pulmonary Aspergillosis: Are the Pictures Different?. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 388.	1.5	26
1626	Characteristics, management, and prognosis of elderly patients with COVID-19 admitted in the ICU during the first wave: insights from the COVID-ICU study. <i>Annals of Intensive Care</i> , 2021, 11, 77.	2.2	44
1628	Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy. <i>Transplant Infectious Disease</i> , 2021, 23, e13625.	0.7	24
1629	Therapeutic strategies to fight COVID-19: Which is the <i>status artis</i> ?. <i>British Journal of Pharmacology</i> , 2022, 179, 2128-2148.	2.7	33
1630	COVID-19 is not "just another flu": a real-life comparison of severe COVID-19 and influenza in hospitalized patients in Vienna, Austria. <i>Infection</i> , 2021, 49, 907-916.	2.3	7

#	ARTICLE	IF	CITATIONS
1631	Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. <i>Nature Communications</i> , 2021, 12, 3189.	5.8	139
1632	Impact of dexamethasone on the incidence of ventilator-associated pneumonia and blood stream infections in COVID-19 patients requiring invasive mechanical ventilation: a multicenter retrospective study. <i>Annals of Intensive Care</i> , 2021, 11, 87.	2.2	45
1633	Characteristics, Comorbidities, Complications, and Outcomes Among 802 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 in a Community Hospital in Florida. , 2021, 3, e0416.		5
1634	A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection. <i>Science Immunology</i> , 2021, 6, .	5.6	96
1635	One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses. <i>ImmunoHorizons</i> , 2021, 5, 322-335.	0.8	19
1636	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021, 397, 1637-1645.	6.3	1,374
1637	A systematic review and meta-analysis of regional risk factors for critical outcomes of COVID-19 during early phase of the pandemic. <i>Scientific Reports</i> , 2021, 11, 9784.	1.6	29
1638	Unproven Therapy Algorithms for Early SARS-CoV-2 Infection Are Dangerous. <i>American Journal of Medicine</i> , 2021, 134, e345.	0.6	0
1639	Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia. <i>Medicina Clínica</i> , 2022, 158, 301-307.	0.3	4
1640	type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDS. Wellcome Open Research, 2021, 6, 38.	0.9	35
1641	Rapid Clinical and Radiological Improvement in a Patient with Severe COVID-19 Infection Treated with Convalescent Plasma. <i>Reports</i> , 2021, 4, 15.	0.2	0
1642	Notes from the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient with Severe COVID-19 and Cytokine Release Syndrome. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e27609.	1.2	2
1643	Superior ophthalmic vein thrombosis secondary to COVID-19: an index case. <i>Radiology Case Reports</i> , 2021, 16, 1138-1143.	0.2	6
1644	Care pathway and prioritization of rapid testing for COVID-19 in UK hospitals: a qualitative evaluation. <i>BMC Health Services Research</i> , 2021, 21, 532.	0.9	8
1645	How we approach thrombosis risk in children with COVID-19 infection and MIS. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29049.	0.8	25
1646	Relating Ventilatory Support and Drug Treatment Strategies to the Fundamental Pathophysiology in COVID-19 Illness. <i>European Medical Journal (Chelmsford, England)</i> , 0, , .	3.0	0
1647	Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multicentre study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1488-1493.	2.8	16
1648	Pitfalls and perils of survival analysis under incorrect assumptions: the case of COVID-19 data. <i>Biomedica</i> , 2021, 41, 21-28.	0.3	4

#	ARTICLE	IF	CITATIONS
1649	Coronavirus Disease 2019 in Children. <i>Frontiers in Pediatrics</i> , 2021, 9, 668484.	0.9	56
1650	No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients. <i>Medicine (United States)</i> , 2021, 100, e26023.	0.4	4
1651	A Biochemical and Structural Understanding of TOM Complex Interactions and Implications for Human Health and Disease. <i>Cells</i> , 2021, 10, 1164.	1.8	14
1652	Practice of adjunctive treatments in critically ill COVID-19 patients: rational for the multicenter observational PROACT-COVID study in The Netherlands. <i>Annals of Translational Medicine</i> , 2021, 9, 813-813.	0.7	6
1654	A review of Covid-19 and acute kidney injury: from pathophysiology to clinical results. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2021, 43, 551-571.	0.4	20
1656	Prognostic value of static and dynamic biomarkers in COVID-19 patients: a prospective cohort study. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 308-314.	0.5	1
1657	Outcome Improvement Between the First Two Waves of the Coronavirus Disease 2019 Pandemic in a Single Tertiary-Care Hospital in Belgium. , 2021, 3, e0438.		27
1658	Adjuvant Inhaled Corticosteroids in Community-Acquired Pneumonia: A Review Article. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 34.	1.3	0
1659	Systemic Corticosteroid Administration in Coronavirus Disease 2019 Outcomes: An Umbrella Meta-Analysis Incorporating Both Mild and Pulmonary Fibrosis-Manifested Severe Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 670170.	1.6	8
1661	Impact of tocilizumab on clinical outcomes in severe covid-19 patients and risk of secondary infection: A case-control study. <i>Marmara Medical Journal</i> , 0, , .	0.2	0
1662	A flow cytometric approach to study glucocorticoid receptor expression in immune cell subpopulations of genetically engineered mice. <i>Immunology Letters</i> , 2021, 233, 68-79.	1.1	4
1663	Daily multidisciplinary COVID-19 meeting: Experiences from a French university hospital. <i>Respiratory Medicine and Research</i> , 2021, 79, 100828.	0.4	0
1665	One Year of Coronavirus Disease 2019 (COVID-19) in Brazil: A Political and Social Overview. <i>Annals of Global Health</i> , 2021, 87, 44.	0.8	54
1667	Existing Drugs Considered as Promising in COVID-19 Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5434.	1.8	24
1668	SARS-CoV-2 Infection Is Associated with Reduced KrÄ¼ppel-like Factor 2 in Human Lung Autopsy. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 65, 222-226.	1.4	5
1669	Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1323-1330.	1.8	26
1670	Tocilizumab in COVID-19: some clarity amid controversy. <i>Lancet, The</i> , 2021, 397, 1599-1601.	6.3	29
1671	Successful Management of COVID-19 Infection in 2 Early Post-Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2021, 53, 1175-1179.	0.3	8

#	ARTICLE	IF	CITATIONS
1672	Clinical features and prognostic factors in Covid-19: A prospective cohort study. EBioMedicine, 2021, 67, 103378.	2.7	79
1674	Successful heart transplantation for COVID-19-associated post-infectious fulminant myocarditis. ESC Heart Failure, 2021, 8, 2625-2630.	1.4	16
1675	Admission respiratory status predicts mortality in COVID-19. Influenza and Other Respiratory Viruses, 2021, 15, 569-572.	1.5	42
1676	Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Current Medical Research and Opinion, 2021, 37, 1085-1097.	0.9	21
1677	COVID-19 Vasculopathy: Mounting Evidence for an Indirect Mechanism of Endothelial Injury. American Journal of Pathology, 2021, 191, 1374-1384.	1.9	78
1678	Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation. EBioMedicine, 2021, 67, 103382.	2.7	61
1679	Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV, the, 2021, 8, e294-e305.	2.1	129
1680	Demonstrating the ascendancy of COVID-19 research using acronyms. Scientometrics, 2021, 126, 6127-6130.	1.6	11
1681	Severe hyperglycemia and insulin resistance in patients with SARS-CoV-2 infection: a report of two cases. Clinical Diabetes and Endocrinology, 2021, 7, 8.	1.3	17
1682	Coronavirus Disease 2019 in Kidney Transplant Recipients: Single-Center Experience and Case-Control Study. Transplantation Proceedings, 2021, 53, 1187-1193.	0.3	8
1683	HGF, IL-1 β , and IL-27 Are Robust Biomarkers in Early Severity Stratification of COVID-19 Patients. Journal of Clinical Medicine, 2021, 10, 2017.	1.0	34
1684	Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study. Nutrients, 2021, 13, 1760.	1.7	71
1685	Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infectious Diseases of Poverty, 2021, 10, 71.	1.5	42
1686	COVID-19 in Solid Organ Transplantation: Disease Severity and Clinical Update. Transplantation Proceedings, 2021, 53, 1227-1236.	0.3	13
1687	Endogenous Endophthalmitis A Complication of COVID-19 Pandemic: A Case Series. Ocular Immunology and Inflammation, 2021, 29, 726-729.	1.0	20
1688	Sino-orbital mucormycosis in a COVID-19 patient: A case report. International Journal of Surgery Case Reports, 2021, 82, 105957.	0.2	130
1691	Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study. Multidisciplinary Respiratory Medicine, 2021, 16, 737.	0.6	3
1692	Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). American Heart Journal, 2021, 235, 54-64.	1.2	11

#	ARTICLE	IF	CITATIONS
1693	Outcomes of COVID-19 in solid organ transplant recipients: A matched cohort study. <i>Transplant Infectious Disease</i> , 2021, 23, e13637.	0.7	47
1694	Good Clinical Trials by removing defensive interpretation of Good Clinical Practice guidelines. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4552-4559.	1.1	4
1695	Comments on the Pathophysiological Basis and Rationale for Early Treatment of COVID-19. <i>American Journal of Medicine</i> , 2021, 134, e341-e342.	0.6	0
1696	Critical care survival rates in COVID-19 patients improved as the first wave of the pandemic developed. <i>Evidence-based Nursing</i> , 2021, , ebnurs-2020-103370.	0.1	6
1697	Outcomes of acute respiratory distress syndrome in COVID-19 patients compared to the general population: a systematic review and meta-analysis. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1347-1354.	1.0	16
1698	Dynamic albumin values as clinical surrogate for COVID-19 therapeutics. <i>Journal of Investigative Medicine</i> , 2021, 69, 1260-1260.	0.7	1
1699	Predictors of the prolonged recovery period in COVID-19 patients: a cross-sectional study. <i>European Journal of Medical Research</i> , 2021, 26, 41.	0.9	32
1700	A simple and readily available inflammation-based risk scoring system on admission predicts the need for mechanical ventilation in patients with COVID-19. <i>Inflammation Research</i> , 2021, 70, 731-742.	1.6	7
1701	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021, 128, 1780-1801.	2.0	48
1702	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. <i>Lancet, The</i> , 2021, 397, 2049-2059.	6.3	391
1703	COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. <i>Immunological Reviews</i> , 2021, 302, 228-240.	2.8	126
1704	Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2. <i>Klinische Monatsblätter Für Augenheilkunde</i> , 2021, 238, 569-578.	0.3	6
1705	Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2841-2850.	1.4	15
1706	Management of patients with severe acute respiratory failure due to SARS-CoV-2 pneumonia with noninvasive ventilatory support outside Intensive Care Unit. <i>Minerva Medica</i> , 2021, 112, 329-337.	0.3	14
1707	Functional and Radiological Improvement in a COVID-19 Pneumonia Patient Treated With Steroids. <i>Cureus</i> , 2021, 13, e15257.	0.2	0
1708	Risk Categories in COVID-19 Based on Degrees of Inflammation: Data on More Than 17,000 Patients from the Spanish SEMI-COVID-19 Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 2214.	1.0	15
1709	The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. <i>Antioxidants</i> , 2021, 10, 881.	2.2	20
1710	Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review. <i>Nutrients</i> , 2021, 13, 1550.	1.7	26

#	ARTICLE	IF	CITATIONS
1711	Expression of Surfactant Protein D Distinguishes Severe Pandemic Influenza A(H1N1) from Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 224, 21-30.	1.9	15
1712	Advances of nanomaterialsâ€based strategies for fighting against COVIDâ€™19. <i>View</i> , 2021, 2, 20200180.	2.7	16
1713	Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 601-621.	1.3	144
1715	Current Strategies of Antiviral Drug Discovery for COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671263.	1.6	75
1716	Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 511-521.	5.2	174
1717	Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome. <i>Molecular Medicine</i> , 2021, 27, 48.	1.9	7
1718	COVID-19: The therapeutic landscape. <i>Med</i> , 2021, 2, 493-497.	2.2	20
1719	Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: A national retrospective registry study. <i>Phytomedicine</i> , 2021, 85, 153531.	2.3	53
1720	Increased Glucocorticoid Receptor Alpha Expression and Signaling in Critically Ill Coronavirus Disease 2019 Patients*. <i>Critical Care Medicine</i> , 2021, 49, 2131-2136.	0.4	10
1721	Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 251-252.	5.5	7
1722	Corticosteroid therapy for COVID-19. <i>Medicine (United States)</i> , 2021, 100, e25719.	0.4	37
1723	When Are Treatment Blinding and Treatment Standardization Necessary in Realâ€™World Clinical Trials?. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 116-121.	2.3	4
1724	Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives. <i>World Journal of Clinical Cases</i> , 2021, 9, 2951-2968.	0.3	8
1725	The Volunteers in Research programme: supporting COVID-19 research and improving medical training in parallel. <i>Clinical Medicine</i> , 2021, 21, 182-188.	0.8	5
1726	Longitudinal Clinical Profiles of Hospital vs. Community-Acquired Acute Kidney Injury in COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 647023.	1.2	20
1727	Evidence and the Main Adverse Effects Regarding Drug Therapies in the War Against COVID-19. <i>Current Medicinal Chemistry</i> , 2021, 28, 3147-3157.	1.2	0
1728	Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e1397-e1401.	2.9	44
1730	Clinical characteristics and outcomes of 1,331 patients with COVID-19: HM Spanish Cohort. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 342-352.	0.5	1

#	ARTICLE	IF	CITATIONS
1731	FAVPIRAVIR AND DEXAMETHASONE IN MANAGEMENT OF SARS-COV2 INFECTION. International Journal of Medicine and Medical Research, 2021, 6, 77-81.	0.0	0
1733	COVID-2019 fundamentals. Journal of the American Dental Association, 2021, 152, 354-363.	0.7	10
1734	Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19. Vascular Medicine, 2021, 26, 626-632.	0.8	26
1735	Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2. EMBO Molecular Medicine, 2021, 13, e14045.	3.3	36
1736	Development and validation of early warning score systems for COVID-19 patients. Healthcare Technology Letters, 2021, 8, 105-117.	1.9	11
1737	Differential Cytokine Signatures of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Influenza Infection Highlight Key Differences in Pathobiology. Clinical Infectious Diseases, 2022, 74, 254-262.	2.9	28
1738	AIDS and COVID: A tale of two pandemics and the role of statisticians. Statistics in Medicine, 2021, 40, 2499-2510.	0.8	9
1739	Salvaging the endothelium in acute respiratory distress syndrome: a druggable intersection between TLR4 and NAD+ signalling. European Respiratory Journal, 2021, 57, 2004588.	3.1	0
1740	SARS CoV-2 (COVID-19) Current Pharmacotherapy for Mother and Infant. Neonatal Network: NN, 2021, 40, 175-182.	0.1	0
1741	Normal Adrenal and Thyroid Function in Patients Who Survive COVID-19 Infection. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2208-2220.	1.8	50
1742	Integrating New Effectiveness Data Into US Food and Drug Administration-Approved Drug Labeling. JAMA Internal Medicine, 2021, 181, 897-898.	2.6	5
1743	The Emerging Role of Neutrophils in the Pathogenesis of Thrombosis in COVID-19. International Journal of Molecular Sciences, 2021, 22, 5368.	1.8	21
1744	Ethical reflections on Covid-19 vaccines. Acta Clinica Belgica, 2022, 77, 600-605.	0.5	8
1745	Dynamic changes in gene-to-gene regulatory networks in response to SARS-CoV-2 infection. Scientific Reports, 2021, 11, 11241.	1.6	3
1746	Vitamin C and corticosteroids in viral pneumonia. Acute and Critical Care, 2021, 36, 169-171.	0.6	1
1747	Counseling in maternal-fetal medicine: SARS-CoV-2 infection in pregnancy. Ultrasound in Obstetrics and Gynecology, 2021, 57, 687-697.	0.9	44
1748	Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: a single-center retrospective cohort study. Virology Journal, 2021, 18, 101.	1.4	11
1749	Management of COVID-19: current status and future prospects. Microbes and Infection, 2021, 23, 104832.	1.0	18

#	ARTICLE	IF	CITATIONS
1750	Convalescent Plasma Efficacy in Life-Threatening COVID-19 Patients Admitted to the ICU: A Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2113.	1.0	7
1751	Pharmacological strategies used to manage symptoms of patients dying of COVID-19: A rapid systematic review. <i>Palliative Medicine</i> , 2021, 35, 1099-1107.	1.3	11
1752	The prognostic role of hyperglycemia and glucose variability in covid-related acute respiratory distress Syndrome. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108789.	1.1	12
1753	Características clínicas, laboratoriales y predictores de mortalidad de pacientes con COVID-19 internados en el Hospital Nacional. <i>Revista Científica Ciencias De La Salud</i> , 2021, 3, 26-37.	0.1	0
1754	COVID-19 and Heart Transplant: A Case Series and Review of the Literature. <i>Transplantation Proceedings</i> , 2021, 53, 1219-1223.	0.3	6
1755	Insights into SARS-CoV-2 Persistence and Its Relevance. <i>Viruses</i> , 2021, 13, 1025.	1.5	37
1756	Dexamethasone and COVID-19: Strategies in Low- and Middle-Income Countries to Tackle Steroid-Related Strongyloides Hyperinfection. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1611-1612.	0.6	9
1757	Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned. <i>Viruses</i> , 2021, 13, 963.	1.5	11
1758	JAK inhibitors: Ten years after. <i>European Journal of Immunology</i> , 2021, 51, 1615-1627.	1.6	49
1759	2019 Coronavirus disease (COVID-19): contribution of rheumatology. <i>Terapevticheskii Arkhiv</i> , 2021, 93, .	0.2	6
1760	Comparative Effectiveness of Pharmacological Interventions for Covid-19: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 649472.	1.6	11
1761	Corticosteroids for treating mild COVID-19: opening the floodgates of therapeutic misadventure. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, 114, 541-542.	0.2	13
1762	Determinants of IgG antibodies kinetics after severe and critical COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 5416-5424.	2.5	13
1763	Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study. <i>Lancet</i> , The, 2021, 397, 1885-1894.	6.3	142
1764	Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 733-745.	0.9	24
1765	Characteristics and outcomes of patients with COVID-19 supported by extracorporeal membrane oxygenation: A retrospective multicenter study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 2107-2116.e6.	0.4	32
1766	Clinical Characteristics of Patients With Re-admitted of Novel Coronavirus 2019 (nCOVID-19) in Wenzhou, China. <i>Frontiers in Public Health</i> , 2021, 9, 649178.	1.3	2
1767	Endothelial Dysfunction and SARS-CoV-2 Infection: Association and Therapeutic Strategies. <i>Pathogens</i> , 2021, 10, 582.	1.2	17

#	ARTICLE	IF	CITATIONS
1768	A specific low-density neutrophil population correlates with hypercoagulation and disease severity in hospitalized COVID-19 patients. <i>JCI Insight</i> , 2021, 6, .	2.3	79
1771	Respiratory Support During the COVID-19 Pandemic. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1723.	3.8	14
1772	Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. <i>PLoS ONE</i> , 2021, 16, e0252057.	1.1	126
1773	Integration of Equipoise into Eligibility Criteria in the STARRT-AKI Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 234-237.	2.5	5
1774	COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE). <i>Bulletin Du Cancer</i> , 2021, 108, 490-500.	0.6	8
1775	Low Serum Albumin Predicts Severe Outcomes in COVID-19 Infection: A Single-Center Retrospective Case-Control Study. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 258-267.	0.6	15
1776	COVID-19 patient care experience in the United Kingdom. <i>Vnitřni Lekarství</i> , 2021, 67, e35-e40.	0.1	0
1777	Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study. <i>Annals of Intensive Care</i> , 2021, 11, 73.	2.2	9
1778	A Practical Guide for the Management of Steroid Induced Hyperglycaemia in the Hospital. <i>Journal of Clinical Medicine</i> , 2021, 10, 2154.	1.0	35
1779	Drug combination therapy for emerging viral diseases. <i>Drug Discovery Today</i> , 2021, 26, 2367-2376.	3.2	65
1780	Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. <i>Oncologist</i> , 2021, 26, 685-693.	1.9	3
1781	Limited utility of the HScore in detecting secondary haemophagocytic lymphohistiocytosis in COVID-19. <i>British Journal of Haematology</i> , 2021, 194, 686-688.	1.2	1
1782	Complementary and alternative medicines use in COVID-19: A global perspective on practice, policy and research. <i>Research in Social and Administrative Pharmacy</i> , 2022, 18, 2524-2528.	1.5	61
1783	Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5672.	1.8	16
1784	Overview of COVID-19 Disease: Virology, Epidemiology, Prevention Diagnosis, Treatment, and Vaccines. <i>Biologics</i> , 2021, 1, 2-40.	2.3	16
1785	International COVID-19 trial to restart with focus on immune responses. <i>Nature</i> , 2021, , .	13.7	11
1786	One Size Does Not Fit All. <i>Chest</i> , 2021, 159, 1693-1695.	0.4	7
1787	Monitoring clinical trials in infectious diseases. , 2021, 2, 29-32.		0

#	ARTICLE	IF	CITATIONS
1788	Phagocytosis, Degranulation and Extracellular Traps Release by Neutrophilsâ€”The Current Knowledge, Pharmacological Modulation and Future Prospects. <i>Frontiers in Pharmacology</i> , 2021, 12, 666732.	1.6	41
1789	Reparations for Black American descendants of persons enslaved in the U.S. and their potential impact on SARS-CoV-2 transmission. <i>Social Science and Medicine</i> , 2021, 276, 113741.	1.8	29
1791	Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106334.	1.1	58
1792	High-dose steroids for the treatment of severe COVID-19: comment. <i>Internal and Emergency Medicine</i> , 2021, 16, 1415-1416.	1.0	0
1793	Immune Modulation in Critically Ill Septic Patients. <i>Medicina (Lithuania)</i> , 2021, 57, 552.	0.8	12
1794	LSEâ€”Lancet Commission on the future of the NHS: re-laying the foundations for an equitable and efficient health and care service after COVID-19. <i>Lancet, The</i> , 2021, 397, 1915-1978.	6.3	49
1795	Severe T cell hyporeactivity in ventilated COVID-19 patients correlates with prolonged virus persistence and poor outcomes. <i>Nature Communications</i> , 2021, 12, 3006.	5.8	11
1796	A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test. <i>International Journal of Infectious Diseases</i> , 2021, 106, 33-35.	1.5	9
1797	Case Report: Successful Response to Intravenous Immunoglobulin and Steroid Pulses in a Renal Transplant Recipient With Severe Covid-19 Disease and Associated Acute Allograft Failure. <i>Frontiers in Immunology</i> , 2021, 12, 671013.	2.2	5
1798	Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVIDâ€”19 outbreak?. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04249.	0.2	4
1799	Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. <i>BMJ, The</i> , 2021, 373, n1038.	3.0	50
1800	Dexamethasone and COVID-19 in a developing country: Appropriate use?. <i>Tuberculosis and Respiratory Diseases</i> , 2021, 84, 248-249.	0.7	1
1801	A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis. <i>International Journal of Infectious Diseases</i> , 2021, 106, 71-77.	1.5	32
1802	Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. <i>Pharmaceuticals</i> , 2021, 14, 520.	1.7	24
1803	Impact of COVIDâ€”19 in Liver Disease Progression. <i>Hepatology Communications</i> , 2021, 5, 1138-1150.	2.0	39
1804	Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020. <i>Journal of Clinical Medicine</i> , 2021, 10, 2274.	1.0	19
1805	COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis?. <i>Rheumatology International</i> , 2021, 41, 1515-1521.	1.5	7
1806	Comparing machine learning algorithms for predicting ICU admission and mortality in COVID-19. <i>Npj Digital Medicine</i> , 2021, 4, 87.	5.7	97

#	ARTICLE	IF	CITATIONS
1808	Psychosocial Risk Factors, Noncommunicable Diseases, and Animal Models for COVID-19. <i>Biological Psychiatry</i> , 2021, 89, e67-e71.	0.7	1
1809	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.	3.9	106
1811	Broad antiviral and anti-inflammatory efficacy of nafamostat against SARS-CoV-2 and seasonal coronaviruses in primary human bronchiolar epithelia. <i>Nano Select</i> , 2022, 3, 437-449.	1.9	8
1812	COVID-19 pneumonia in Galicia (Spain): Impact of prognostic factors and therapies on mortality and need for mechanical ventilation. <i>PLoS ONE</i> , 2021, 16, e0253465.	1.1	1
1813	Controversies clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages. <i>World Journal of Clinical Cases</i> , 2021, 9, 5135-5178.	0.3	3
1814	The Many Faces of Innate Immunity in SARS-CoV-2 Infection. <i>Vaccines</i> , 2021, 9, 596.	2.1	10
1815	Vaccination against SARS-COV-2 in oncology. <i>Oncogematologiya</i> , 2021, 16, 70-80.	0.1	2
1816	Extracorporeal Membrane Oxygenation instead of Invasive Mechanical Ventilation in a Patient with Severe COVID-19-associated Acute Respiratory Distress Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1571-1573.	2.5	15
1817	The Global Case-Fatality Rate of COVID-19 Has Been Declining Since May 2020. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 2176-2184.	0.6	51
1818	Prior immunosuppressive therapy is associated with mortality in COVID-19 patients: A retrospective study of 835 patients. <i>Journal of Medical Virology</i> , 2021, 93, 5768-5776.	2.5	15
1819	Prevalence and predictors of in-hospital mortality of patients hospitalized with COVID-19 infection. <i>Journal of Infection and Public Health</i> , 2021, 14, 759-765.	1.9	32
1821	New Evidence of Potential Benefits of Dexamethasone and Added on Therapy of Fludrocortisone on Clinical Outcomes of Corticosteroid in Sepsis Patients: A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 544.	1.1	4
1822	Use of monoclonal antibodies to IL-6 in patients with severe COVID-19. <i>Pulmonologiya</i> , 2021, 31, 263-271.	0.2	1
1823	Therapeutic Targeting of Transcription Factors to Control the Cytokine Release Syndrome in COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 673485.	1.6	10
1824	Short durations of corticosteroids for hospitalised COVID-19 patients are associated with a high readmission rate. <i>Journal of Infection</i> , 2021, 82, 276-316.	1.7	16
1825	Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening. <i>Cell Reports</i> , 2021, 35, 109218.	2.9	38
1826	Prevalence and outcome of patients with acute myocarditis and positive viral search on nasopharyngeal swab. <i>European Journal of Heart Failure</i> , 2021, 23, 1242-1245.	2.9	11
1828	Efficacy and safety of convalescent plasma therapy in SARS-CoV2 patients on hemodialysis. <i>Hemodialysis International</i> , 2021, 25, 515-522.	0.4	6

#	ARTICLE	IF	CITATIONS
1830	Investigation of Coagulation Biomarkers to Assess Clinical Deterioration in SARS-CoV-2 Infection. <i>Frontiers in Medicine</i> , 2021, 8, 670694.	1.2	16
1833	The role of antirheumatics in patients with COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e447-e459.	2.2	36
1834	How we secured a <scp>COVID</scp>â€19 convalescent plasma procurement scheme in Japan. <i>Transfusion</i> , 2021, 61, 1998-2007.	0.8	21
1835	COVID-19 pathophysiology and pharmacology: what do we know and how did Canadians respond? A review of Health Canada authorized clinical vaccine and drug trials. <i>Canadian Journal of Physiology and Pharmacology</i> , 2021, 99, 577-588.	0.7	2
1836	Biomarkers for severe COVID-19. <i>EBioMedicine</i> , 2021, 68, 103405.	2.7	5
1837	Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled Trial. <i>Frontiers in Medicine</i> , 2021, 8, 691712.	1.2	11
1838	Serum Complement C3 and C4 and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression. <i>Frontiers in Immunology</i> , 2021, 12, 696085.	2.2	58
1840	Serum uric acid, disease severity and outcomes in COVID-19. <i>Critical Care</i> , 2021, 25, 212.	2.5	22
1842	Characteristics and Survival of Intensive Care Unit Patients with Coronavirus Disease in Osaka, Japan: A Retrospective Observational Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2477.	1.0	10
1843	Interleukin-6: obstacles to targeting a complex cytokine in critical illness. <i>Lancet Respiratory Medicine</i> ,the, 2021, 9, 643-654.	5.2	120
1844	Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. <i>Pharmacological Reviews</i> , 2021, 73, 924-967.	7.1	359
1845	Colchicine Treatment in SARS-CoV-2 Infection. <i>American Journal of Therapeutics</i> , 2021, Publish Ahead of Print, .	0.5	4
1846	Clinical Management of COVID-19 Patients â€ An Update. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 4-10.	2.5	33
1848	The 1918 influenza and <scp>COVID</scp>â€19 pandemics: The effect of age on outcomes. <i>Respirology</i> , 2021, 26, 840-841.	1.3	6
1849	A lethal mouse model using a mouse-adapted SARS-CoV-2 strain with enhanced binding to mouse ACE2 as an important platform for COVID-19 research. <i>EBioMedicine</i> , 2021, 68, 103406.	2.7	4
1850	Future developments in the prevention, diagnosis and treatment of COVID-19. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021, 73, 56-80.	1.4	4
1851	Characteristics and Clinical Course of Adult Inpatients with SARS-CoV-2 Pneumonia at High Altitude. <i>Canadian Respiratory Journal</i> , 2021, 2021, 1-9.	0.8	4
1853	IL-13 is a driver of COVID-19 severity. <i>JCI Insight</i> , 2021, 6, .	2.3	80

#	ARTICLE	IF	CITATIONS
1854	Leukocytes Parameters, CRP, and Ferritin in Iranian Patients with COVID-19 Infection; A Cross-sectional Study. Iranian Journal of Medical Microbiology, 2021, 15, 361-368.	0.1	1
1855	Ivermectin as a potential treatment for COVID-19?. PLoS Neglected Tropical Diseases, 2021, 15, e0009446.	1.3	8
1856	Histopathological features in fatal COVID-19 acute respiratory distress syndrome. Medicina Intensiva, 2021, 45, 261-270.	0.4	17
1858	Could Exogenous Insulin Ameliorate the Metabolic Dysfunction Induced by Glucocorticoids and COVID-19?. Frontiers in Endocrinology, 2021, 12, 649405.	1.5	1
1859	Role of arachidonic cascade in COVID-19 infection: A review. Prostaglandins and Other Lipid Mediators, 2021, 154, 106539.	1.0	32
1860	Predictors of severity and mortality among patients hospitalized with COVID-19 in Rhode Island. PLoS ONE, 2021, 16, e0252411.	1.1	12
1861	Differential Cytokine Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir. Frontiers in Immunology, 2021, 12, 680188.	2.2	8
1863	Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials. Reviews in Medical Virology, 2022, 32, e2258.	3.9	32
1864	Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19 patients. Mycoses, 2021, 64, 1083-1091.	1.8	62
1865	Clinical Characteristics and Outcomes of Liver Transplantation Recipients With COVID-19 Pneumonia. Transplantation Proceedings, 2021, 53, 2481-2489.	0.3	2
1866	Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice. Expert Review of Anti-Infective Therapy, 2021, 19, 1553-1562.	2.0	12
1867	COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system. PLoS ONE, 2021, 16, e0252591.	1.1	16
1868	COVID-19: Innovative Antiviral Drugs Required for Long-Term Prevention and Control of Coronavirus Diseases. Current Medicinal Chemistry, 2021, 28, 3554-3567.	1.2	2
1869	COVID-19 chemoprevention. International Journal of Infectious Diseases, 2021, 107, 31-33.	1.5	0
1871	Patient trust in plans to share primary care data. BMJ, The, 2021, 373, n1413.	3.0	4
1872	Vitamin A Plasma Levels in COVID-19 Patients: A Prospective Multicenter Study and Hypothesis. Nutrients, 2021, 13, 2173.	1.7	40
1873	Not all that glitters is COVID-19: a case series demonstrating the need for histopathology when skin findings accompany SARS-CoV-2 infection. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1865-1873.	1.3	11
1874	Disputes over the production and dissemination of misinformation in the time of COVID-19. Respiratory Medicine, 2021, 182, 106380.	1.3	4

#	ARTICLE	IF	CITATIONS
1875	Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab335.	0.4	13
1877	Impact of intermediate to high doses of methylprednisolone on mortality rate in patients with COVID-19 pneumonia-induced severe systemic inflammation. <i>International Journal of Clinical Practice</i> , 2021, 75, e14479.	0.8	6
1878	Planning for the Next Pandemic: Ethics and Innovation Today for Improved Clinical Trials Tomorrow. <i>Statistics in Biopharmaceutical Research</i> , 2022, 14, 22-27.	0.6	4
1879	Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk. <i>Annals of Pharmacotherapy</i> , 2021, , 106002802110288.	0.9	7
1880	COVID-19-Associated Pulmonary Aspergillosis at an Academic Medical Center in the Midwestern United States. <i>Mycopathologia</i> , 2021, 186, 499-505.	1.3	8
1881	Realising the full potential of data-enabled trials in the UK: a call for action. <i>BMJ Open</i> , 2021, 11, e043906.	0.8	23
1882	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. <i>Current HIV/AIDS Reports</i> , 2021, 18, 261-270.	1.1	5
1883	Is rapid scientific publication also high quality? Bibliometric analysis of highly disseminated COVID-19 research papers. <i>Learned Publishing</i> , 2021, 34, 568-577.	0.8	27
1884	Impact of Prophylactic Hydroxychloroquine on People at High Risk of COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2609.	1.0	5
1885	A Multidisciplinary Approach to Coronavirus Disease (COVID-19). <i>Molecules</i> , 2021, 26, 3526.	1.7	14
1886	Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey. <i>United European Gastroenterology Journal</i> , 2021, 9, 797-808.	1.6	12
1887	SARS-CoV-2 infection in patients with autoimmune hepatitis. <i>Journal of Hepatology</i> , 2021, 74, 1335-1343.	1.8	90
1888	Closed-Loop Versus Conventional Mechanical Ventilation in COVID-19 ARDS. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 1184-1193.	1.3	12
1889	Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy?. <i>Frontiers in Public Health</i> , 2021, 9, 664108.	1.3	19
1890	Efficient Identification of High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Plasma Samples by Pooling Method. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1221-1227.	1.2	0
1891	Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 648005.	1.2	25
1892	Glycophosphopeptical AM3 Food Supplement: A Potential Adjuvant in the Treatment and Vaccination of SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 698672.	2.2	11
1894	Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. <i>American Journal of Therapeutics</i> , 2021, 28, e434-e460.	0.5	160

#	ARTICLE	IF	CITATIONS
1895	Poor nutritional status, risk of sarcopenia and nutrition related complaints are prevalent in COVID-19 patients during and after hospital admission. <i>Clinical Nutrition ESPEN</i> , 2021, 43, 369-376.	0.5	69
1896	Improved outcomes over time for adult COVID-19 patients with acute respiratory distress syndrome or acute respiratory failure. <i>PLoS ONE</i> , 2021, 16, e0253767.	1.1	18
1897	Evolution of outcomes for patients hospitalised during the first 9 months of the SARS-CoV-2 pandemic in France: A retrospective national surveillance data analysis. <i>Lancet Regional Health - Europe, The</i> , 2021, 5, 100087.	3.0	35
1898	Lupus, vaccinations and COVID-19: What we know now. <i>Lupus</i> , 2021, 30, 1541-1552.	0.8	21
1899	Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	113
1900	Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19. <i>IScience</i> , 2021, 24, 102752.	1.9	9
1901	COVID-19: Sleep, Circadian Rhythms and Immunity – Repurposing Drugs and Chronotherapeutics for SARS-CoV-2. <i>Frontiers in Neuroscience</i> , 2021, 15, 674204.	1.4	8
1903	Comparison of Patient Clinical characteristics and Outcomes Between Different COVID-19 Peak Periods: A Single Center Retrospective Propensity Matched Analysis. <i>Cureus</i> , 2021, 13, e15777.	0.2	6
1905	Back to the future with machine learning. <i>Nature Machine Intelligence</i> , 2021, 3, 464-465.	8.3	0
1907	Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19. <i>CJC Open</i> , 2021, 3, 1257-1272.	0.7	18
1909	An Immunoinformatics Approach for SARS-CoV-2 in Latam Populations and Multi-Epitope Vaccine Candidate Directed Towards the World's Population. <i>Vaccines</i> , 2021, 9, 581.	2.1	9
1910	Response to: –Correspondence on –Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study – by Klopfenstein et al. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-220787.	0.5	0
1911	Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review). <i>Sovremennyye Tehnologii V Medicine</i> , 2021, 13, 81.	0.4	4
1912	Imaging in the COVID-19 era: Lessons learned during a pandemic. <i>World Journal of Radiology</i> , 2021, 13, 193-223.	0.5	0
1913	Identification of patients with COVID-19 who are optimal for methylprednisolone pulse therapy. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 781.	0.6	11
1914	Appendicitis with concurrent COVID-19 infection in a patient during the third trimester of pregnancy. <i>BMJ Case Reports</i> , 2021, 14, e242651.	0.2	3
1915	The Fight against COVID-19 on the Multi-Protease Front and Surroundings: Could an Early Therapeutic Approach with Repositioning Drugs Prevent the Disease Severity?. <i>Biomedicines</i> , 2021, 9, 710.	1.4	7
1916	Evaluation of Strategies to Fight COVID-19: The French Paradigm. <i>Journal of Clinical Medicine</i> , 2021, 10, 2942.	1.0	4

#	ARTICLE	IF	CITATIONS
1918	Secondary bacterial infections in patients with COVID-19. <i>Pneumon</i> , 2021, , 1-7.	0.6	1
1919	Dexamethasone in the Treatment of COVID-19: Primus Inter Pares?. <i>Journal of Personalized Medicine</i> , 2021, 11, 556.	1.1	14
1920	Confronting COVID-19: Current Issues of SARS-CoV-2 Therapeutic Drug/Vaccine Development. <i>Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku</i> , 2021, 26, 91-97.	0.0	0
1921	Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection. <i>ELife</i> , 2021, 10, .	2.8	21
1922	Australia needs a prioritised national research strategy for clinical trials in a pandemic: lessons learned from COVID-19. <i>Medical Journal of Australia</i> , 2021, 215, 56.	0.8	5
1924	Relative COVID-19 Viral Persistence and Antibody Kinetics. <i>Pathogens</i> , 2021, 10, 752.	1.2	9
1926	Preventing Infectious Complications of Immunomodulation in COVID-19 in Foreign-Born Patients. <i>Journal of Immigrant and Minority Health</i> , 2021, 23, 1343-1347.	0.8	2
1927	Risk factors, treatment and outcomes of subacute thyroiditis secondary to COVID-19: a systematic review. <i>Internal Medicine Journal</i> , 2022, 52, 522-529.	0.5	46
1929	COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2094-2105.	0.4	65
1931	COVID-19 in pregnancy: where are we now?. <i>Journal of Perinatal Medicine</i> , 2021, 49, 637-642.	0.6	1
1932	COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes. <i>JCI Insight</i> , 2021, 6, .	2.3	35
1933	Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True?. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab318.	0.4	4
1934	The Effect of COVID-19 on NF- κ B and Neurological Manifestations of Disease. <i>Molecular Neurobiology</i> , 2021, 58, 4178-4187.	1.9	31
1935	Hospital-Acquired Bloodstream Infections in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019): Association With Immunosuppressive Therapies. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab339.	0.4	22
1936	COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 705-715.	8.2	26
1937	Systematic literature search, review and dissemination methodology for the COVID-19 pandemic. <i>BMJ Simulation and Technology Enhanced Learning</i> , 2021, 7, 524-527.	0.7	3
1938	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 547-560.	1.3	37
1939	Dexamethasone in hospitalized patients with COVID-19 preliminary report: Discussions from the respirology and sleep Twitter journal club @respandsleepjc (#rsjc). <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2021, 5, 270-272.	0.2	1

#	ARTICLE	IF	CITATIONS
1940	COVID-19 and the Endocrine System: A Comprehensive Review on the Theme. <i>Journal of Clinical Medicine</i> , 2021, 10, 2920.	1.0	57
1941	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. <i>Hepatology</i> , 2021, 74, 1750-1765.	3.6	41
1942	Zinc supplementation as an adjunct therapy for COVID-19: Challenges and opportunities. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3737-3746.	1.1	37
1943	Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 105, 107904.	1.3	49
1944	Distinct cytokine profiles associated with COVID-19 severity and mortality. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2098-2107.	1.5	47
1945	Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions. <i>Molecules and Cells</i> , 2021, 44, 408-421.	1.0	18
1946	Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. <i>Lancet Respiratory Medicine</i> , 2021, 9, 655-664.	5.2	88
1947	Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. <i>Current Opinion in Rheumatology</i> , 2021, 33, 412-418.	2.0	6
1948	Critical care after the COVID-19 outbreak in China: lessons and renaissance. <i>Intensive Care Medicine</i> , 2021, 47, 1017-1020.	3.9	3
1949	In Reply. <i>Deutsches A&#x0308;rztblatt International</i> , 2021, 118, 376-377.	0.6	1
1950	Insights from a Prospective Follow-up of Thyroid Function and Autoimmunity among COVID-19 Survivors. <i>Endocrinology and Metabolism</i> , 2021, 36, 582-589.	1.3	40
1951	Characteristics and outcomes of older patients with coronavirus disease 2019 in Japan. <i>Geriatrics and Gerontology International</i> , 2021, 21, 629-635.	0.7	4
1952	Soluble Suppression of Tumorigenicity-2 Associates With Ventilator Dependence in Coronavirus Disease 2019 Respiratory Failure. , 2021, 3, e0480.		5
1953	Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients â€“ a safe but futile intervention. A comparative cohort study. <i>Infectious Diseases</i> , 2021, 53, 820-829.	1.4	7
1954	Dexamethasone for Severe COVID-19: How Does It Work at Cellular and Molecular Levels?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6764.	1.8	25
1955	Management of diabetes in elderly patients during the COVID-19 pandemic: current and future perspectives. <i>Expert Review of Endocrinology and Metabolism</i> , 2021, 16, 181-189.	1.2	7
1956	Initial prehospital Rapid Emergency Medicine Score (REMS) to predict outcomes for COVID-19 patients. <i>Journal of the American College of Emergency Physicians Open</i> , 2021, 2, e12483.	0.4	8
1957	COVID-19 Treatment Agents: Do They Pose an Environmental Risk?. <i>ACS ES&T Water</i> , 2021, 1, 1555-1565.	2.3	8

#	ARTICLE	IF	CITATIONS
1958	Antibiotic resistance during and beyond COVID-19. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, i5-i16.	0.9	23
1960	COVID-19 impact on the liver. <i>World Journal of Clinical Cases</i> , 2021, 9, 3814-3825.	0.3	15
1961	Glucose control using an artificial pancreas in a severe COVID-19 patient on extracorporeal membrane oxygenation: a case report. <i>Journal of Anesthesia</i> , 2021, 35, 586-590.	0.7	2
1962	Why electronic health records can do something big for clinical research. <i>Brain</i> , 2021, 144, 1615-1616.	3.7	1
1963	Mortality in critically ill patients with coronavirus disease 2019-associated pulmonary aspergillosis: A systematic review and meta-analysis. <i>Mycoses</i> , 2021, 64, 1015-1027.	1.8	27
1964	Strategies to DAMPen COVID-19-mediated lung and systemic inflammation and vascular injury. <i>Translational Research</i> , 2021, 232, 37-48.	2.2	30
1965	Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial. <i>Clinical Therapeutics</i> , 2021, 43, 1007-1019.	1.1	52
1966	Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial. <i>European Respiratory Journal</i> , 2022, 59, 2100752.	3.1	31
1967	Is there any role of intermittent fasting in the prevention and improving clinical outcomes of COVID-19?: intersection between inflammation, mTOR pathway, autophagy and calorie restriction. <i>VirusDisease</i> , 2021, 32, 625-634.	1.0	13
1970	Prone Position in COVID-19 Patients With Severe Acute Respiratory Distress Syndrome Receiving Conventional Oxygen Therapy: A Retrospective Study. <i>Archivos De Bronconeumologia</i> , 2021, 58, 277-277.	0.4	5
1971	Les facteurs pronostiques dans la Covid-19. <i>NPG Neurologie - Psychiatrie - Geriatrie</i> , 2021, 21, 304-312.	0.1	2
1974	Integrin: An Intriguing Target for COVID-19 and Related Diseases. <i>ChemBioChem</i> , 2021, 22, 2516-2520.	1.3	10
1975	Predication of oxygen requirement in COVID-19 patients using dynamic change of inflammatory markers: CRP, hypertension, age, neutrophil and lymphocyte (CHANeL). <i>Scientific Reports</i> , 2021, 11, 13026.	1.6	10
1976	Dose-Related Aberrant Inhibition of Intracellular Perforin Expression by S1 Subunit of Spike Glycoprotein That Contains Receptor-Binding Domain from SARS-CoV-2. <i>Microorganisms</i> , 2021, 9, 1303.	1.6	2
1977	Infecção por SARS-CoV-2 en pacientes trasplantados de corazón. Experiencia en México. <i>Cirugia Cardiovascular</i> , 2021, 29, 21-21.	0.1	0
1978	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. <i>Frontiers in Medicine</i> , 2021, 8, 684151.	1.2	50
1979	Camphor impairs SARS-CoV-2 and Influenza A (H1N1) viral replication: <i>in silico</i> predicted interaction with SARS-CoV-2 nucleocapsid protein and H1N1 nucleoprotein. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00798.	1.1	15
1980	Usefulness of Respiratory Mechanics and Laboratory Parameter Trends as Markers of Early Treatment Success in Mechanically Ventilated Severe Coronavirus Disease: A Single-Center Pilot Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2513.	1.0	8

#	ARTICLE	IF	CITATIONS
1981	Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay. <i>ACS Central Science</i> , 2021, 7, 1245-1260.	5.3	115
1982	Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19. <i>Scientific Reports</i> , 2021, 11, 12310.	1.6	31
1983	Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID-19. <i>British Journal of Pharmacology</i> , 2021, 178, 3864-3868.	2.7	24
1984	Pneumothorax/pneumomediastinum in non-intubated COVID-19 patients: Differences between first and second Italian pandemic wave. <i>European Journal of Internal Medicine</i> , 2021, 88, 144-146.	1.0	32
1985	Thromboinflammation in coronavirus disease 2019: The clot thickens. <i>British Journal of Pharmacology</i> , 2022, 179, 2100-2107.	2.7	14
1986	Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 2031-2036.	2.9	68
1987	Determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 100, 115347.	0.8	36
1988	Inhibition of the lipoxin A4 and resolvin D1 receptor impairs host response to acute lung injury caused by pneumococcal pneumonia in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L1085-L1092.	1.3	12
1989	Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient—Case report and review of literature. <i>Journal De Mycologie Medicale</i> , 2021, 31, 101125.	0.7	88
1991	In-Hospital Cardiac Arrest (IHCA) and Outcomes in Patients Admitted With COVID-19 Infection. <i>Cureus</i> , 2021, 13, e15365.	0.2	0
1992	Relating Ventilatory Support and Drug Treatment Strategies to the Fundamental Pathophysiology in COVID-19 Illness. <i>European Medical Journal (Chelmsford, England)</i> , 0, , .	3.0	0
1993	COVID-19 pneumothorax in the UK: a prospective observational study using the ISARIC WHO clinical characterisation protocol. <i>European Respiratory Journal</i> , 2021, 58, 2100929.	3.1	21
1994	The Right Ventricle in COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 2535.	1.0	21
1995	Predictive performance of emergency department-specific variables on COVID-19 pneumonia. <i>Singapore Medical Journal</i> , 2022, 63, 715.	0.3	1
1996	COVID-19: step-by-step treatment strategies. <i>Problemy Zdorov'ia i Ākologii</i> , 2021, , 155-162.	0.0	1
1997	PEP-CoV protocol: a PEP flute-self-care randomised controlled trial to prevent respiratory deterioration and hospitalisation in early COVID-19. <i>BMJ Open</i> , 2021, 11, e050582.	0.8	2
1998	Tailoring management and immunosuppression regimen in kidney transplant recipients with COVID-19 infection—lessons from Singapore. <i>Singapore Medical Journal</i> , 2021, , .	0.3	0
1999	Histopathological features in fatal COVID-19 acute respiratory distress syndrome. <i>Medicina Intensiva (English Edition)</i> , 2021, 45, 261-270.	0.1	4

#	ARTICLE	IF	CITATIONS
2000	Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1407-1418.	1.8	5
2001	Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab329.	0.4	7
2002	Promising effects of atorvastatin on mortality and need for mechanical ventilation in patients with severe COVID-19; a retrospective cohort study. <i>International Journal of Clinical Practice</i> , 2021, 75, e14434.	0.8	10
2003	Analysis of clinical symptoms, radiological changes and pulmonary function data 4 months after COVID-19. <i>Clinical Respiratory Journal</i> , 2021, 15, 992-1002.	0.6	20
2004	COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico. <i>Journal of Clinical Immunology</i> , 2021, 41, 1463-1478.	2.0	40
2005	Hospitalization Outcomes and Mortality Predictors of SARS-Cov-2 Infection in the Elderly: A Single Center Experience from India. <i>Archives of Clinical Infectious Diseases</i> , 2021, 16, .	0.1	1
2006	Covid-19 vaccine trials: Ethnic diversity and immunogenicity. <i>Vaccine</i> , 2021, 39, 3541-3543.	1.7	16
2008	COVID-19 and Cardiovascular Diseases: Challenges and Solutions. <i>Cardiology Research</i> , 2021, 12, 149-155.	0.5	2
2010	Glucocorticoides solos versus tocilizumab solo o glucocorticoides más tocilizumab en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada. <i>Medicina Clínica</i> , 2021, 156, 602-605.	0.3	7
2011	The impact of atherosclerotic cardiovascular disease, dyslipidaemia and lipid lowering therapy on Coronavirus disease 2019 outcomes. <i>Current Opinion in Lipidology</i> , 2021, Publish Ahead of Print, 231-243.	1.2	2
2012	Antibody and viral RNA kinetics in SARS-CoV2 infected patients admitted to a Romanian University Hospital of Infectious Diseases. <i>International Journal of Infectious Diseases</i> , 2021, 107, 205-211.	1.5	4
2013	Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1520.e7-1520.e10.	2.8	13
2015	Steroid use in elderly critically ill COVID-19 patients. <i>European Respiratory Journal</i> , 2021, 58, 2100979.	3.1	44
2016	Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition?. <i>Drug Discovery Today</i> , 2021, 26, 1473-1481.	3.2	20
2017	An intra-host SARS-CoV-2 dynamics model to assess testing and quarantine strategies for incoming travelers, contact management, and de-isolation. <i>Patterns</i> , 2021, 2, 100262.	3.1	15
2018	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021, 150, 190-202.	1.3	37
2019	Inhaled Dry Powder Formulation of Tamibarotene, a Broad-Spectrum Antiviral against Respiratory Viruses Including SARS-CoV-2 and Influenza Virus. <i>Advanced Therapeutics</i> , 2021, 4, 2100059.	1.6	12
2021	Update in COVID-19 2020. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1462-1471.	2.5	13

#	ARTICLE	IF	CITATIONS
2023	Distinct clinical and immunological profiles of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa. <i>Nature Communications</i> , 2021, 12, 3554.	5.8	21
2024	Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	1.4	6
2025	Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113848.	6.6	6
2026	COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome?. <i>Translational Research</i> , 2021, 232, 1-12.	2.2	45
2027	Corticosteroids in patients with COVID-19: use and misuse. <i>Minerva Anestesiologica</i> , 2021, 87, 1042-1048.	0.6	2
2028	An Impaired Inflammatory and Innate Immune Response in COVID-19. <i>Molecules and Cells</i> , 2021, 44, 384-391.	1.0	13
2029	Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e410-e418.	2.2	57
2030	COVID-19 and thrombotic microangiopathies. <i>Thrombosis Research</i> , 2021, 202, 191-198.	0.8	57
2031	Effect of dexamethasone on complications or all cause mortality after major non-cardiac surgery: multicentre, double blind, randomised controlled trial. <i>BMJ</i> , The, 2021, 373, n1162.	3.0	19
2032	Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs. <i>Science Advances</i> , 2021, 7, .	4.7	107
2033	SARS-CoV-2 and hypertension. <i>Physiological Reports</i> , 2021, 9, e14800.	0.7	11
2034	Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. <i>Scientific Reports</i> , 2021, 11, 13208.	1.6	24
2035	Calcifediol Treatment and COVID-19-Related Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4017-e4027.	1.8	60
2036	Diabetes and COVID19: a bidirectional relationship. <i>Nutrition and Diabetes</i> , 2021, 11, 21.	1.5	40
2037	COVID-19: A Redox Disease-What a Stress Pandemic Can Teach Us About Resilience and What We May Learn from the Reactive Species Interactome About Its Treatment. <i>Antioxidants and Redox Signaling</i> , 2021, 35, 1226-1268.	2.5	28
2038	Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic. <i>Metabolism Open</i> , 2021, 10, 100096.	1.4	27
2039	Anti-Inflammatory Treatment of COVID-19 Pneumonia With Tofacitinib Alone or in Combination With Dexamethasone is Safe and Possibly Superior to Dexamethasone as a Single Agent in a Predominantly African American Cohort. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 605-613.	1.2	26
2040	A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?. <i>Arthritis and Rheumatology</i> , 2021, 73, 2166-2178.	2.9	43

#	ARTICLE	IF	CITATIONS
2041	A Role for Steroids in COVID-19-associated Pneumonitis at Six-Week Follow-Up?. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1082-1083.	1.5	6
2042	A severe case of human coronavirus 229E pneumonia in an elderly man with diabetes mellitus: a case report. <i>BMC Infectious Diseases</i> , 2021, 21, 524.	1.3	4
2043	Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current Pandemic. <i>Journal of Clinical Medicine</i> , 2021, 10, 2452.	1.0	77
2044	Asthma in the era of SARS CoV-2 virus. <i>Journal of Asthma</i> , 2022, 59, 1501-1508.	0.9	3
2045	Validation of the Acute Physiology and Chronic Health Evaluation (APACHE) II and IV Score in COVID-19 Patients. <i>Critical Care Research and Practice</i> , 2021, 2021, 1-9.	0.4	13
2046	Digestive involvement in COVID-19: what we have learned in the past 12 months. <i>Medicine and Pharmacy Reports</i> , 0, , .	0.2	0
2049	Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group. <i>Pediatric Research</i> , 2022, 91, 1069-1077.	1.1	8
2050	COVID-19 Summary Guidelines. <i>Sushruta Journal of Health Policy & Opinions</i> , 2021, 14, 1-5.	0.1	0
2051	Exposure to dexamethasone modifies transcriptomic responses of free-living stages of <i>Strongyloides stercoralis</i> . <i>PLoS ONE</i> , 2021, 16, e0253701.	1.1	4
2052	Lessons from a local effort to screen for SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2108044118.	3.3	1
2053	Factors associated with mortality in patients with COVID-19 admitted to intensive care: a systematic review and meta-analysis. <i>Anaesthesia</i> , 2021, 76, 1224-1232.	1.8	61
2054	Editorial: Rheumatology at the center of coronavirus disease 2019: pathogenesis, treatment, and clinical care. <i>Current Opinion in Rheumatology</i> , 2021, 33, 409-411.	2.0	0
2055	Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): Evidence base for practise and implications for research. <i>Transfusion Medicine</i> , 2021, 31, 409-420.	0.5	12
2056	Rationale for a New Outpatient Drug Therapy Algorithm in COVID-19 Patients Based on the Principle of «Multi-hit» Approach. <i>Antibiotiki I Khimioterapiya</i> , 2021, 66, 49-61.	0.1	2
2057	Roles and Interplay of SARS-CoV-2 Serology With Clinical Stages of Disease in COVID-19. <i>Cureus</i> , 2021, 13, e15953.	0.2	1
2058	Imaging in the COVID-19 era: Lessons learned during a pandemic. <i>World Journal of Radiology</i> , 2021, 13, 192-222.	0.5	9
2059	Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	89
2062	Therapeutic approaches to tackle COVID-19: An overview. <i>Indian Journal of Pharmacy and Pharmacology</i> , 2021, 8, 121-135.	0.1	0

#	ARTICLE	IF	CITATIONS
2063	Time to positivity in bloodstream infection is not a prognostic marker for mortality: analysis of a prospective multicentre randomized control trial. <i>Clinical Microbiology and Infection</i> , 2022, 28, 136.e7-136.e13.	2.8	6
2064	EMJ COVID-19 monthly top five. <i>Emergency Medicine Journal</i> , 2021, 38, 558-560.	0.4	0
2065	Post-acute COVID-19 Syndrome (PACS): A public health emergency. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100882.	0.6	13
2067	Molecular mechanisms of Na,K-ATPase dysregulation driving alveolar epithelial barrier failure in severe COVID-19. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L1186-L1193.	1.3	24
2068	The impact of COVID-19 on pregnancy and therapeutic drug development. <i>British Journal of Pharmacology</i> , 2022, 179, 2108-2120.	2.7	11
2069	Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19. <i>Cell Discovery</i> , 2021, 7, 42.	3.1	23
2070	Gender issues during the times of COVID-19 pandemic. <i>European Journal of Neurology</i> , 2021, 28, e73-e77.	1.7	6
2071	American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2. <i>Arthritis and Rheumatology</i> , 2021, 73, e46-e59.	2.9	9
2073	Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study. <i>Critical Care</i> , 2021, 25, 223.	2.5	23
2074	Direct Comparison of Clinical Characteristics, Outcomes, and Risk Prediction in Patients with COVID-19 and Controls: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2672.	1.0	4
2075	Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. <i>Scientific Reports</i> , 2021, 11, 12414.	1.6	14
2076	SARS-CoV-2 infection and paediatric endocrine disorders: Risks and management considerations. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00262.	1.0	5
2077	Clinical Trials of COVID-19 Therapies Should Account for Diabetes and Hyperglycemia. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 1181-1187.	1.3	0
2078	Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13662.	0.7	22
2079	Diabetes and COVID19: a bidirectional relationship. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 1332-1336.	1.3	12
2080	The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 211-229.	2.0	10
2081	Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2. <i>ACS Infectious Diseases</i> , 2021, 7, 2337-2351.	1.8	23
2082	Convalescent plasma therapy in patients with moderate-to-severe COVID-19: A study from Indonesia for clinical research in low- and middle-income countries. <i>EClinicalMedicine</i> , 2021, 36, 100931.	3.2	21

#	ARTICLE	IF	CITATIONS
2083	The solid organ transplant recipient with SARS-CoV-2 infection. <i>Current Opinion in Organ Transplantation</i> , 2021, 26, 412-418.	0.8	5
2084	Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. <i>Science</i> , 2021, 373, 541-547.	6.0	148
2085	Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. <i>Nature Communications</i> , 2021, 12, 3309.	5.8	81
2087	Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN- β . <i>Journal of Clinical Immunology</i> , 2021, 41, 1425-1442.	2.0	39
2088	Multisystem Inflammatory Syndrome in Children – Initial Therapy and Outcomes. <i>New England Journal of Medicine</i> , 2021, 385, 23-34.	13.9	273
2089	COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave?. <i>Transplantation</i> , 2021, 105, 2146-2155.	0.5	25
2090	Glucocorticoid-Glucocorticoid Receptor Response to Severe Acute Respiratory Syndrome Coronavirus 2. <i>Critical Care Medicine</i> , 2021, Publish Ahead of Print, 2157-2160.	0.4	1
2091	Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19. <i>Bioscience Reports</i> , 2021, 41, .	1.1	18
2092	Advancing precision medicine for acute respiratory distress syndrome. <i>Lancet Respiratory Medicine</i> , 2022, 10, 107-120.	5.2	83
2093	Methylprednisolone Induces Extracellular Trap Formation and Enhances Bactericidal Effect of Canine Neutrophils. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7734.	1.8	5
2094	A Kidney Transplant Patient Who Died of COVID-19-associated Severe Acute Respiratory Distress Syndrome. <i>Internal Medicine</i> , 2021, 60, 2297-2300.	0.3	3
2095	Comparative effectiveness and safety of 32 pharmacological interventions recommended by guidelines for coronavirus disease 2019: a systematic review and network meta-analysis combining 66 trials. <i>Chinese Medical Journal</i> , 2021, 134, 1920-1929.	0.9	6
2096	Maternal Death Caused by Severe-Critical COVID-19 in Jakarta: Case Series. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2021, 9, 103-108.	0.1	2
2097	The effect of the outbreak of COVID-19 on respiratory physicians and healthcare in Japan: Serial nationwide surveys by the Japanese Respiratory Society. <i>Respiratory Investigation</i> , 2021, 59, 792-798.	0.9	2
2098	Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3419-3428.	1.6	25
2099	Coronavirus disease 2019 respiratory failure: what is the best supportive care for patients who require ICU admission?. <i>Current Opinion in Critical Care</i> , 2021, 27, 462-467.	1.6	5
2100	A retrospective multi-center experience of renal transplants from India during COVID-19 pandemic. <i>Clinical Transplantation</i> , 2021, 35, e14423.	0.8	13
2101	A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study. <i>EClinicalMedicine</i> , 2021, 37, 100941.	3.2	40

#	ARTICLE	IF	CITATIONS
2102	Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19. <i>Journal of Personalized Medicine</i> , 2021, 11, 668.	1.1	16
2103	Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients. <i>Journal of Nephrology</i> , 2021, 34, 1025-1037.	0.9	6
2104	The Anti-Viral Applications of Marine Resources for COVID-19 Treatment: An Overview. <i>Marine Drugs</i> , 2021, 19, 409.	2.2	18
2105	The Role of Glucocorticoids in the Treatment of ARDS: A Multicenter Retrospective Study Based on the eICU Collaborative Research Database. <i>Frontiers in Medicine</i> , 2021, 8, 678260.	1.2	2
2106	COVID-19 and endocrine and metabolic disorders: critical points and suggestions for a correct therapeutic management from a tertiary endocrine center in Italy. <i>Minerva Endocrinology</i> , 2022, 47, .	0.6	4
2107	Evaluation of Rocuronium Continuous Infusion in Critically Ill Patients During the COVID-19 Pandemic and Drug Shortages. <i>Journal of Pharmacy Practice</i> , 2023, 36, 249-255.	0.5	3
2108	Infectious disease-associated encephalopathies. <i>Critical Care</i> , 2021, 25, 236.	2.5	34
2109	Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence. <i>World Journal of Gastroenterology</i> , 2021, 27, 3748-3761.	1.4	14
2110	ÐœyastheniaÂgravis complicated by comorbid pathology. <i>Ukrainian Neurological Journal</i> , 2021, , .	0.0	0
2111	Awake Prone Positioning in Non-Intubated Patients With Acute Hypoxemic Respiratory Failure Due to COVID-19. <i>Respiratory Care</i> , 2022, 67, 102-114.	0.8	28
2112	The influence of leprosy-related clinical and epidemiological variables in the occurrence and severity of COVID-19: A prospective real-world cohort study. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009635.	1.3	17
2113	Differences in Inflammatory Marker Kinetics between the First and Second Wave of COVID-19 Patients Admitted to the ICU: A Retrospective, Single-Center Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3290.	1.0	7
2114	Famotidine and Mortality in Coronavirus Disease 2019. <i>Gastroenterology</i> , 2021, 161, 361-362.	0.6	1
2115	Impact of COVID-19 on a brain damage unit. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102163.	1.8	0
2116	Trends in COVID-19 cases and clinical management in Veterans Health Administration medical facilities: A national cohort study. <i>PLoS ONE</i> , 2021, 16, e0246217.	1.1	4
2119	Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 233-250.	2.6	13
2121	Discovery of potential imaging and therapeutic targets for severe inflammation in COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 14151.	1.6	8
2122	Current Understanding of Clinical Manifestations of COVID-19 in Glomerular Disease. <i>Glomerular Diseases</i> , 2021, 1, 250-264.	0.2	6

#	ARTICLE	IF	CITATIONS
2123	Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 239-254.	0.2	40
2124	Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3359-3366.	1.6	17
2125	Tocilizumab in patients with COVID-19: which patient, time, and dose?. <i>Journal of Anesthesia</i> , 2021, 35, 896-902.	0.7	7
2126	Residual respiratory impairment after COVID-19 pneumonia. <i>BMC Pulmonary Medicine</i> , 2021, 21, 241.	0.8	23
2127	COVID-19 during Early Phase of Autologous Stem Cell Transplantation. <i>Medicina (Lithuania)</i> , 2021, 57, 724.	0.8	1
2129	Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: An observational study. <i>Mycoses</i> , 2021, 64, 1366-1377.	1.8	37
2130	Gastroenterology and liver disease during COVID-19 and in anticipation of post-COVID-19 era: Current practice and future directions. <i>World Journal of Clinical Cases</i> , 2021, 9, 4918-4938.	0.3	3
2131	Pulmonary function, computerized tomography features and six-minute walk test at three months in severe COVID-19 patients treated with intravenous pulsed methylprednisolone: a preliminary report. <i>Monaldi Archives for Chest Disease</i> , 2021, , .	0.3	3
2132	Critical Review of the Scientific Evidence and Recommendations in COVID-19 Management Guidelines. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab376.	0.4	8
2133	Editorial policy regarding the citation of preprints in the <i>British Journal of Pharmacology</i> (<i>BJP</i>). <i>British Journal of Pharmacology</i> , 2021, 178, 3605-3610.	2.7	2
2134	Single-nucleus transcriptome analysis of human brain immune response in patients with severe COVID-19. <i>Genome Medicine</i> , 2021, 13, 118.	3.6	81
2135	Environmental impact assessment of COVID-19 therapeutic solutions. A prospective analysis. <i>Science of the Total Environment</i> , 2021, 778, 146257.	3.9	35
2136	Inferring molecular mechanisms of dexamethasone therapy in severe COVID-19 from existing transcriptomic data. <i>Gene</i> , 2021, 788, 145665.	1.0	17
2137	Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111642.	2.5	50
2138	Variation in therapeutic strategies for the management of severe COVID-19 in India: A nationwide cross-sectional survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14574.	0.8	3
2139	A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. <i>EClinicalMedicine</i> , 2021, 37, 100957.	3.2	56
2140	Spectrum of Endocrine Dysfunction and Association With Disease Severity in Patients With COVID-19: Insights From a Cross-Sectional, Observational Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 645787.	1.5	39
2141	Diabetes, Obesity, COVID-19, Insulin, and Other Antidiabetes Drugs. <i>Diabetes Care</i> , 2021, 44, 1929-1933.	4.3	12

#	ARTICLE	IF	CITATIONS
2142	Impact of COVID-19 on cancer care in India: a cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 970-976.	5.1	108
2143	Persistence of Disparities Among Racially/Ethnically Marginalized Groups in the Coronavirus Disease 2019 Pandemic Regardless of Statewide Shelter-in-Place Policies: An Analysis From Northern California. <i>American Journal of Epidemiology</i> , 2021, 190, 2300-2313.	1.6	5
2144	Pharmacological management of COVID-19 in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107927.	1.2	14
2145	Mucormycosis and COVID-19: An epidemic within a pandemic in India. <i>Mycoses</i> , 2021, 64, 1253-1260.	1.8	117
2146	Association of COVID-19 transmission with high levels of ambient pollutants: Initiation and impact of the inflammatory response on cardiopulmonary disease. <i>Science of the Total Environment</i> , 2021, 779, 146464.	3.9	15
2147	Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. <i>Current Opinion in Rheumatology</i> , 2021, 33, 419-430.	2.0	53
2148	Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 1382-1392.	13.9	534
2150	Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021, 89, 1425-1441.	1.5	30
2152	Endothelial, Immunothrombotic, and Inflammatory Biomarkers in the Risk of Mortality in Critically Ill COVID-19 Patients: The Role of Dexamethasone. <i>Diagnostics</i> , 2021, 11, 1249.	1.3	18
2153	Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?. <i>Stem Cell Research and Therapy</i> , 2021, 12, 425.	2.4	15
2154	The RECOVERY trial: cardiovascular implications of a large, simple randomized trial in COVID-19. <i>Cardiovascular Research</i> , 2021, 117, e110-e113.	1.8	3
2155	Influence of Prednisone on Inflammatory Biomarkers in Community-Acquired Pneumonia: Secondary Analysis of a Randomized Trial. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1406-1414.	1.0	9
2156	Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 593-596.	0.1	1
2158	SARS-CoV-2 and Autoimmune Cytopenia. <i>Hemato</i> , 2021, 2, 463-476.	0.2	7
2159	The Controversy About the Effects of Different Doses of Corticosteroid Treatment on Clinical Outcomes for Acute Respiratory Distress Syndrome Patients: An Observational Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 722537.	1.6	2
2160	Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection. <i>Personalized Medicine</i> , 2021, 18, 389-398.	0.8	13
2161	The role of immunomodulatory medications in the treatment of COVID-19. <i>Current Opinion in Rheumatology</i> , 2021, 33, 431-445.	2.0	4
2162	Incidence of Secondary Hemophagocytic Lymphohistiocytosis in Critically-Ill COVID-19 Patients. <i>Cureus</i> , 2021, 13, e16735.	0.2	2

#	ARTICLE	IF	CITATIONS
2163	Diabetes Mellitus and SARS-CoV-2 Infection: Pathophysiologic Mechanisms and Implications in Management. <i>Current Diabetes Reviews</i> , 2021, 17, e123120189797.	0.6	19
2164	Acute Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review and Meta-Analysis. <i>Clinical Endoscopy</i> , 2021, 54, 534-541.	0.6	14
2165	A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. <i>European Respiratory Journal</i> , 2021, 58, 2100673.	3.1	32
2166	Genetic Susceptibility of ACE2 and TMPRSS2 in Six Common Cancers and Possible Impacts on COVID-19. <i>Cancer Research and Treatment</i> , 2021, 53, 650-656.	1.3	13
2168	<i>Strongyloides</i> in bronchoalveolar lavage fluid: practical implications in the COVID-19 era. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	5
2169	COVID-19 Severity: Lung-Heart Interplay. <i>Current Cardiology Reviews</i> , 2021, 17, e230421189016.	0.6	11
2171	A Periaortitis Patient Who Succumbed to COVID-19 While Undergoing Systemic Steroid Therapy: A Case Report and Literature Review. <i>American Journal of Case Reports</i> , 2021, 22, e932733.	0.3	1
2172	Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e801-e809.	0.2	17
2173	Full-Length Recombinant hSP-D Binds and Inhibits SARS-CoV-2. <i>Biomolecules</i> , 2021, 11, 1114.	1.8	13
2174	Dexamethasone may improve severe COVID-19 via ameliorating endothelial injury and inflammation: A preliminary pilot study. <i>PLoS ONE</i> , 2021, 16, e0254167.	1.1	41
2175	Glucocorticoid and mineralocorticoid receptor expression in critical illness: A narrative review. <i>World Journal of Critical Care Medicine</i> , 2021, 10, 102-111.	0.8	5
2177	Risk Based Decision Algorithms for Management of COVID-19 Associated Rhino-orbital Mucormycosis. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2022, 74, 3447-3454.	0.3	7
2179	Subcutaneous and mediastinal emphysema, uncommon complications of COVID-19 ARDS: a case series. <i>Journal of Emergency and Critical Care Medicine</i> , 0, 5, 26-26.	0.7	0
2180	Outcomes among patients with COVID-19 and asthma: A systematic review and meta-analysis. <i>Allergy and Asthma Proceedings</i> , 2021, 42, 267-273.	1.0	18
2181	Point-of-care COVID-19 antigen testing in German emergency rooms – a cost-benefit analysis. <i>Pulmonology</i> , 2022, 28, 164-172.	1.0	21
2182	Does dehydroepiandrosterone sulfate have a role in COVID-19 prognosis and treatment?. <i>Endocrine Regulations</i> , 2021, 55, 174-181.	0.5	7
2183	Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity. <i>Cells</i> , 2021, 10, 1756.	1.8	19
2184	High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 704767.	1.6	8

#	ARTICLE	IF	CITATIONS
2185	Neutralizing Anti-interferon- β Autoantibodies: an Ameliorating Factor in COVID-19 Infection?. <i>Journal of Clinical Immunology</i> , 2021, 41, 1531-1535.	2.0	5
2186	Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. <i>BMC Infectious Diseases</i> , 2021, 21, 635.	1.3	75
2187	Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. <i>Immunity</i> , 2021, 54, 1463-1477.e11.	6.6	179
2188	COVID-19 versus Non-COVID-19 Acute Respiratory Distress Syndrome: Comparison of Demographics, Physiologic Parameters, Inflammatory Biomarkers, and Clinical Outcomes. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1202-1210.	1.5	100
2189	Diagnostic accuracy of screening tests for patients suspected of COVID-19, a retrospective cohort study. <i>Infectious Diseases</i> , 2021, 53, 855-864.	1.4	6
2190	COVID-19 versus SARS: A comparative review. <i>Journal of Infection and Public Health</i> , 2021, 14, 967-977.	1.9	5
2191	Chest CT severity score and radiological patterns as predictors of disease severity, ICU admission, and viral positivity in COVID-19 patients. <i>Respiratory Investigation</i> , 2021, 59, 436-445.	0.9	17
2192	N-acetylcysteine for the treatment of COVID-19 among hospitalized patients. <i>Journal of Infection</i> , 2022, 84, 94-118.	1.7	17
2193	N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 2993-3013.	1.6	31
2195	Reply to: “Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients”. <i>Journal of Hepatology</i> , 2021, 75, 228-229.	1.8	0
2196	Cholesterol Recognition Motifs (CRAC) in the S Protein of Coronavirus: A Possible Target for Antiviral Therapy?. 0, , .		1
2197	Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. <i>Cell Reports</i> , 2021, 36, 109432.	2.9	24
2198	SARS-CoV-2 and Tacrolimus Blood Concentration in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2021, 6, 2694-2697.	0.4	4
2199	Asthma and COVID-19: a dangerous liaison?. <i>Asthma Research and Practice</i> , 2021, 7, 9.	1.2	37
2200	Corticosteroids May Be Indicated in Children with Severe COVID-19 Disease. <i>Pediatric Annals</i> , 2021, 50, e270-e271.	0.3	0
2201	Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) – United States, March–June and October–December 2020: Implications for the Potential Effects of COVID-19 Tier-1 Vaccination on Future Hospitalizations and Outcomes. <i>Clinical Infectious Diseases</i> , 2021, 73, S32-S37.	2.9	2
2202	Neutrophilia, lymphopenia and myeloid dysfunction: a living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology. <i>Oxford Open Immunology</i> , 2021, 2, .	1.2	7
2203	Use of placebo in clinical trials in COVID-19 pandemic times: considerations on pros, cons, challenges and limitations. <i>Minerva Medica</i> , 2021, , .	0.3	3

#	ARTICLE	IF	CITATIONS
2204	Impact of dexamethasone use to prevent from severe COVID-19-induced acute kidney injury. <i>Critical Care</i> , 2021, 25, 249.	2.5	9
2205	Therapeutic Application of Corticosteroids in COVID-19: A Focus on Optimum Dose and Duration of Therapy. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1145-1148.	1.0	11
2206	Editorial: Hemostatic Challenges in Pediatric Critical Care Medicine. <i>Frontiers in Pediatrics</i> , 2021, 9, 697921.	0.9	0
2207	From advanced disease to transplantation: an overview of the liver at the time of COVID-19 pandemic. <i>Internal and Emergency Medicine</i> , 2021, , 1.	1.0	2
2208	Opportunities for the use of routinely collected data for the generation of large randomized evidence in Colombia. <i>Wellcome Open Research</i> , 0, 6, 182.	0.9	0
2209	Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai Health System COVID-19 patients. <i>PLoS ONE</i> , 2021, 16, e0253660.	1.1	18
2210	COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion. <i>Lancet Respiratory Medicine</i> , 2021, 9, 795-802.	5.2	56
2211	Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review. <i>Life</i> , 2021, 11, 753.	1.1	14
2212	Delirium and Associated Factors in a Cohort of Hospitalized Patients With Coronavirus Disease 2019. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2022, 63, 3-13.	0.2	9
2214	GRP78: THE CONNECTING LINK BETWEEN COVID-19 AND MUCORMYCOSIS?. , 2021, , 53-53.		0
2215	Criptococosis diseminada en paciente positivo para COVID-19. <i>Repertorio De Medicina Y Cirugia</i> , 0, , 46-50.	0.0	1
2216	Collective aeromedical evacuations of SARS-CoV-2-related ARDS patients in a military tactical plane: a retrospective descriptive study. <i>BMJ Military Health</i> , 2023, 169, 443-447.	0.4	2
2217	The Impact of SARS-CoV-2 Viral Load on the Mortality of Hospitalized Patients: A Retrospective Analysis. <i>Cureus</i> , 2021, 13, e16540.	0.2	1
2218	Tocilizumab and SARS-CoV-2 (COVID-19): An Evolving Story, the Picture Is Clearer. <i>Infectious Diseases in Clinical Practice</i> , 2021, 29, e199-e201.	0.1	0
2219	Efficacy and Safety of Leflunomide for Refractory COVID-19: A Pilot Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 581833.	1.6	5
2220	Up-regulation of ACE2, the SARS-CoV-2 receptor, in asthmatics on maintenance inhaled corticosteroids. <i>Respiratory Research</i> , 2021, 22, 200.	1.4	10
2221	Potential impact of intervention strategies on COVID-19 transmission in Malawi: a mathematical modelling study. <i>BMJ Open</i> , 2021, 11, e045196.	0.8	8
2222	Is continuous positive airway pressure therapy in COVID-19 associated with an increased rate of pulmonary barotrauma?. <i>ERJ Open Research</i> , 2021, 7, 00886-2020.	1.1	4

#	ARTICLE	IF	CITATIONS
2223	COVID-19 pneumonia. Nurse Practitioner, 2021, 46, 22-28.	0.2	0
2224	Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk. Annals of Pharmacotherapy, 2021, , 106002802110360.	0.9	1
2226	Hypotheses and facts for genetic factors related to severe COVID-19. World Journal of Virology, 2021, 10, 137-155.	1.3	12
2227	Mitigating the Emerging Threat of Mucormycosis in COVID-19. Proceedings of Singapore Healthcare, 0, 201010582110349.	0.2	0
2228	Targeting cytokine storm in COVID-19: what have we learned?. European Heart Journal Open, 2021, 1, .	0.9	3
2229	Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study. Virology Journal, 2021, 18, 142.	1.4	9
2230	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infectious Diseases and Therapy, 2021, 10, 1837-1885.	1.8	28
2231	Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. Cell Host and Microbe, 2021, 29, 1052-1062.	5.1	185
2232	Increased Secondary Infection in COVID-19 Patients Treated with Steroids in New York City. Japanese Journal of Infectious Diseases, 2021, 74, 307-315.	0.5	48
2233	SARS-CoV-2 in children with cancer in Brazil: Results of a multicenter national registry. Pediatric Blood and Cancer, 2021, 68, e29223.	0.8	14
2234	Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections. F1000Research, 0, 10, 536.	0.8	6
2235	COVID-19 and mucormycosis superinfection: the perfect storm. Infection, 2021, 49, 833-853.	2.3	112
2236	Corticosteroids for COVID-19. Journal of Intensive Medicine, 2021, 1, 14-25.	0.8	40
2237	Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. New England Journal of Medicine, 2021, 385, 406-415.	13.9	342
2238	Cytokine adsorption during ECMO for COVID-19-related ARDS. Lancet Respiratory Medicine, the, 2021, 9, 680-682.	5.2	3
2239	Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nature Communications, 2021, 12, 4117.	5.8	170
2240	Trends in ICU Mortality From Coronavirus Disease 2019: A Tale of Three Surges. Critical Care Medicine, 2022, 50, 245-255.	0.4	28
2241	Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis*. Critical Care Medicine, 2021, 49, 2042-2057.	0.4	88

#	ARTICLE	IF	CITATIONS
2242	Pathophysiology of COVID-19-associated acute kidney injury. <i>Nature Reviews Nephrology</i> , 2021, 17, 751-764.	4.1	280
2243	Epidemiology and Incidence of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1779-1792.	1.8	17
2244	How trustworthy guidelines can impact outcomes. <i>Current Opinion in Critical Care</i> , 2021, 27, 544-550.	1.6	4
2245	COVID-19 infection in patients with sarcoidosis: susceptibility and clinical outcomes. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 463-471.	1.2	7
2246	Distinctive features of severe SARS-CoV-2 pneumonia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	49
2247	Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? A meta-analysis of randomized control trials. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1049-1055.	1.0	17
2248	Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation. <i>European Heart Journal Open</i> , 2021, 1, .	0.9	19
2249	Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 108, 270-273.	1.5	6
2250	Association of hypothermia with increased mortality rate in SARS-CoV-2 infection. <i>International Journal of Infectious Diseases</i> , 2021, 108, 167-170.	1.5	7
2251	Clinical features of multisystem inflammatory syndrome in children. <i>Current Opinion in Rheumatology</i> , 2021, 33, 378-386.	2.0	4
2252	Ivermectin for preventing and treating COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD015017.	1.5	101
2253	Antiviral Effect of Budesonide against SARS-CoV-2. <i>Viruses</i> , 2021, 13, 1411.	1.5	13
2254	Target Groups for a Short Dexamethasone Course among Critically Ill COVID-19 Patients. <i>Critical Care Research and Practice</i> , 2021, 2021, 1-10.	0.4	2
2255	Hyperglycaemia increases mortality risk in non-diabetic patients with COVID-19 even more than in diabetic patients. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00291.	1.0	15
2256	Remdesivir shifts circadian rhythmicity to eveningness; similar to the most prevalent chronotype in ADHD. <i>Journal of Neural Transmission</i> , 2021, 128, 1159-1168.	1.4	5
2258	Large airway complications in COVID-19 pneumonia. <i>Monaldi Archives for Chest Disease</i> , 2021, , .	0.3	2
2259	Analysis of COVID-19 Guideline Quality and Change of Recommendations: A Systematic Review. <i>Health Data Science</i> , 2021, 2021, .	1.1	9
2260	Not all COVID-19 pandemic waves are alike. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1040.e7-1040.e10.	2.8	33

#	ARTICLE	IF	CITATIONS
2265	Systemic corticosteroids in the management of covid-19 ARDS. <i>Anesteziologie A Intenzivni Medicina</i> , 2021, 32, 150-155.	0.1	0
2266	Development of a Risk Prediction Score to Identify High-Risk Groups for the Critical Coronavirus Disease 2019 (COVID-19) in Japan. <i>Japanese Journal of Infectious Diseases</i> , 2021, 74, 344-351.	0.5	5
2267	COVID-19-associated ischaemic stroke despite use of anticoagulation. <i>BMJ Case Reports</i> , 2021, 14, e243741.	0.2	2
2268	Patient-level and hospital-level variation and related time trends in COVID-19 case fatality rates during the first pandemic wave in England: multilevel modelling analysis of routine data. <i>BMJ Quality and Safety</i> , 2022, 31, 211-220.	1.8	14
2269	Macrodiolide Diversification Reveals Broad Immunosuppressive Activity That Impairs the cGAS-εSTING Pathway. <i>Angewandte Chemie</i> , 2021, 133, 18882-18889.	1.6	0
2270	Viral-Induced Inflammatory Coagulation Disorders: Preparing for Another Epidemic. <i>Thrombosis and Haemostasis</i> , 2022, 122, 008-019.	1.8	11
2272	Ivermectin as a multifaceted drug in COVID-19: Current insights. <i>Medical Journal Armed Forces India</i> , 2021, 77, S254-S256.	0.3	1
2274	Pneumothorax in otherwise healthy non-intubated patients suffering from COVID-19 pneumonia: a systematic review. <i>Journal of Thoracic Disease</i> , 2021, 13, 4519-4529.	0.6	9
2275	Steroid therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>Monaldi Archives for Chest Disease</i> , 2021, 91, .	0.3	6
2276	Daily glucose variation influenced by the use of corticosteroids in COVID-19 patients treated in Lima-Peru. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102188.	1.8	4
2277	Pharmacotherapy in Coronavirus Disease 2019 and Risk of Secondary Infections: A Single-Center Case Series and Narrative Review. , 2021, 3, e0492.		6
2278	Fulminant Myocarditis With ST Elevation and Cardiogenic Shock in a SARS-CoV-2 Patient. <i>Cureus</i> , 2021, 13, e16149.	0.2	8
2279	Critical care outcomes from COVID-19: patients, interventions, healthcare systems and the need for core datasets. <i>Anaesthesia</i> , 2021, 76, 1155-1158.	1.8	1
2280	Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab-induced arthritis by methylprednisolone, baricitinib, and remdesivir. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04459.	0.2	2
2281	Laboratory parameters related to severe disease and death in SARS-CoV-2 pneumonia: Retrospective analysis. <i>Journal of Medical Virology</i> , 2021, 93, 5886-5895.	2.5	6
2282	Contemporary narrative review of treatment options for COVID -19. <i>Respirology</i> , 2021, 26, 745-767.	1.3	12
2284	Dexamethasone treatment may mitigate adverse effects of vitamin D deficiency in hospitalized Covid-19 patients. <i>Journal of Medical Virology</i> , 2021, 93, 6605-6610.	2.5	8
2285	Corticosteroid treatment for acute/acute-on-chronic experimental and naturally occurring pancreatitis in several species: a scoping review to inform possible use in dogs. <i>Acta Veterinaria Scandinavica</i> , 2021, 63, 28.	0.5	5

#	ARTICLE	IF	CITATIONS
2286	Peculiarities of the course of multisystem inflammatory syndrome associated with COVID-19 in children: from literature review to own clinical observations. <i>Aktualna Infektologija</i> , 2021, 9, 31-38.	0.1	0
2287	The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis. <i>Clinical Epidemiology and Global Health</i> , 2021, 11, 100755.	0.9	32
2288	Global health security as it pertains to Zika, Ebola, and COVID-19. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 401-408.	1.3	5
2289	Benefits of Steroid Therapy in COVID-19 Patients with Different PaO ₂ /FiO ₂ Ratio at Admission. <i>Journal of Clinical Medicine</i> , 2021, 10, 3236.	1.0	4
2290	Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms. <i>Experimental and Molecular Medicine</i> , 2021, 53, 1116-1123.	3.2	116
2291	Basic mechanisms of SARS-CoV-2 infection. What endocrine systems could be implicated?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 137-150.	2.6	15
2293	50-gene risk profiles in peripheral blood predict COVID-19 outcomes: A retrospective, multicenter cohort study. <i>EBioMedicine</i> , 2021, 69, 103439.	2.7	20
2294	Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody. <i>Journal of Physical Chemistry B</i> , 2021, 125, 7368-7379.	1.2	25
2295	The Impact of Corticosteroids on Secondary Infection and Mortality in Critically Ill COVID-19 Patients. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 1201-1208.	1.3	31
2296	The Effect of COVID-19 on Adult Cardiac Surgery in the United States in 717%103 Patients. <i>Annals of Thoracic Surgery</i> , 2022, 113, 738-746.	0.7	32
2297	Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2291-2307.	1.8	12
2298	High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients. <i>Life Science Alliance</i> , 2021, 4, e202001009.	1.3	8
2300	Surfactant for the Treatment of ARDS in a Patient With COVID-19. <i>Chest</i> , 2021, 160, e9-e12.	0.4	22
2301	The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients. <i>Respiratory Medicine</i> , 2021, 183, 106433.	1.3	31
2302	Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID-19: A Binational, Registry-Based Cohort Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1713-1719.	2.9	35
2303	COVID-19 Associated Rhino-Orbital Mucormycosis Complicated by Gangrenous and Bone Necrosis: A Case Report from Honduras. <i>Vaccines</i> , 2021, 9, 826.	2.1	15
2304	What every intensivist should know about Tocilizumab. <i>Critical Care</i> , 2021, 25, 262.	2.5	10
2305	Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 709856.	1.6	23

#	ARTICLE	IF	CITATIONS
2306	Low mortality in SARS-CoV-2 infected heart transplant recipients at a single center. <i>Clinical Transplantation</i> , 2022, 36, .	0.8	5
2307	Clinical characteristics and outcomes of COVID-19 in a low-prevalence, well resourced setting, Sydney, Australia. <i>Internal Medicine Journal</i> , 2021, 51, 1605-1613.	0.5	4
2308	Effects of Immune System-Related Medications on COVID-19 Outcome in a Cohort of Iranian Patients: Preliminary Report of a Data Mining Study. <i>Journal of Immunology Research</i> , 2021, 2021, 1-21.	0.9	3
2309	What we learned in the past year in managing our COVID-19 patients in intensive care units?. <i>World Journal of Critical Care Medicine</i> , 2021, 10, 81-101.	0.8	5
2310	In-hospital complications associated with COVID-19. <i>Lancet, The</i> , 2021, 398, 188-190.	6.3	6
2311	Acute Pericarditis Due to SARS-COV-2 in a Kidney Transplant Recipient. <i>Cureus</i> , 2021, 13, e16547.	0.2	0
2312	Mortality risk factors in a Spanish cohort of oldest-old patients hospitalized with COVID-19 in an acute geriatric unit: the OCTA-COVID study. <i>European Geriatric Medicine</i> , 2021, 12, 1169-1180.	1.2	20
2313	Chemotherapy resumption in breast cancer patient after COVID-19. <i>Surgical Case Reports</i> , 2021, 7, 170.	0.2	2
2314	Roles of steroid receptors in the lung and COVID-19. <i>Essays in Biochemistry</i> , 2021, 65, 1025-1038.	2.1	11
2315	Forecasting COVID-19 Severity by Intelligent Optical Fingerprinting of Blood Samples. <i>Diagnostics</i> , 2021, 11, 1309.	1.3	5
2316	Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 151-170.	2.6	20
2317	Toxin-like peptides in plasma, urine and faecal samples from COVID-19 patients. <i>F1000Research</i> , 2021, 10, 550.	0.8	16
2318	Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany. <i>Infection</i> , 2021, 49, 1313-1318.	2.3	10
2320	Risk Factors for Fungal Co-Infections in Critically Ill COVID-19 Patients, with a Focus on Immunosuppressants. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 545.	1.5	35
2321	Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin. <i>EMBO Molecular Medicine</i> , 2021, 13, e14122.	3.3	38
2322	Single-cell transcriptome of bronchoalveolar lavage fluid reveals sequential change of macrophages during SARS-CoV-2 infection in ferrets. <i>Nature Communications</i> , 2021, 12, 4567.	5.8	43
2323	The quest to find genes that drive severe COVID. <i>Nature</i> , 2021, 595, 346-348.	13.7	15
2324	Could pulmonary low-dose radiation therapy be an alternative treatment for patients with COVID-19 pneumonia? Preliminary results of a multicenter SEOR-GICOR nonrandomized prospective trial (IPACOVID trial). <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1010-1020.	1.0	24

#	ARTICLE	IF	CITATIONS
2325	Do We have the Evidence to Repurpose Levamisole for Treatment of COVID 19?. <i>Current Drug Therapy</i> , 2021, 16, 142-147.	0.2	0
2326	Clinical subphenotypes in COVID-19: derivation, validation, prediction, temporal patterns, and interaction with social determinants of health. <i>Npj Digital Medicine</i> , 2021, 4, 110.	5.7	18
2327	Drug Policies Skyline during COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2021, 10, 3117.	1.0	1
2328	COVID-19: Failure of the DisCoVeRy Clinical Trial, and Nowâ€œNew Hopes?. <i>Pharmaceuticals</i> , 2021, 14, 664.	1.7	3
2329	Validation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3049.	1.0	12
2330	The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2. <i>Journal of Osteopathic Medicine</i> , 2021, 121, 705-714.	0.4	6
2331	The role of Tâ€œcell immunity in COVIDâ€œ19 severity amongst people living with type II diabetes. <i>FEBS Journal</i> , 2021, 288, 5042-5054.	2.2	9
2332	Treating the endotheliopathy of <scp>SARSâ€œCoV</scp>â€œ2 infection with plasma: Lessons learned from optimized trauma resuscitation with blood products. <i>Transfusion</i> , 2021, 61, S336-S347.	0.8	2
2333	What can a learning healthcare system teach us about improving outcomes?. <i>Current Opinion in Critical Care</i> , 2021, 27, 527-536.	1.6	5
2334	In-hospital fatality and venous thromboembolism during the first and second COVID-19 waves at a center opting for standard-dose thromboprophylaxis. <i>Thrombosis Research</i> , 2021, 203, 82-84.	0.8	10
2335	Moving forward in clinical research with master protocols. <i>Contemporary Clinical Trials</i> , 2021, 106, 106438.	0.8	4
2336	Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates. <i>Acta Pharmacologica Sinica</i> , 2021, , .	2.8	18
2337	Care without a compass: Including patients with cancer in COVID-19 studies. <i>Cancer Cell</i> , 2021, 39, 895-896.	7.7	14
2338	Key summary of German national treatment guidance for hospitalized COVID-19 patients. <i>Infection</i> , 2022, 50, 93-106.	2.3	30
2339	Longitudinal Outcomes for Multisystem Inflammatory Syndrome in Children. <i>Pediatrics</i> , 2021, 148, .	1.0	75
2341	The Impact of Age on Mortality in Chronic Haemodialysis Population with COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 3022.	1.0	8
2342	Radiologically Undetectable Latent Pulmonary Lymphocyte Infiltration Suggesting the Need for Early Glucocorticoid Therapy: An Autopsy Case of Rapidly Progressive COVID-19 Pneumonia with Lymphopenia. <i>Internal Medicine</i> , 2021, 60, 2145-2148.	0.3	0
2343	Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2021, 21, 663.	1.3	121

#	ARTICLE	IF	CITATIONS
2344	A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital. <i>Journal of Emergency Medicine</i> , 2022, 62, 83-91.	0.3	5
2345	Potential Adverse Effects of Dexamethasone Therapy on COVID-19 Patients: Review and Recommendations. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1907-1931.	1.8	38
2347	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021, 138, 1768-1773.	0.6	53
2348	Prognostic Factors and Predictors of In-Hospital Mortality Among COVID-19 Patients Admitted to the Intensive Care Unit: An Aid for Triage, Counseling, and Resource Allocation. <i>Cureus</i> , 2021, 13, e16577.	0.2	3
2349	Cold agglutinin disease and COVID-19 requiring therapeutic plasma exchange. <i>BMJ Case Reports</i> , 2021, 14, e244227.	0.2	4
2350	Dysregulated liver function in SARS-CoV-2 infection: Current understanding and perspectives. <i>World Journal of Gastroenterology</i> , 2021, 27, 4358-4370.	1.4	5
2352	High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome: a retrospective study. <i>Internal and Emergency Medicine</i> , 2021, 16, 1913-1919.	1.0	12
2353	Risk factors and outcomes of ventilator-associated pneumonia in COVID-19 patients: a propensity score matched analysis. <i>Critical Care</i> , 2021, 25, 235.	2.5	19
2354	COVID-19 in liver transplant recipients. <i>Journal of Liver Transplantation</i> , 2021, 3, 100026.	0.2	6
2355	Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. <i>JAMA Network Open</i> , 2021, 4, e2116901.	2.8	179
2356	Contextualising evidence-based recommendations for the second wave of the COVID-19 pandemic in India. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 905-907.	4.6	5
2358	On-admission SARS-CoV-2 RNAemia as a single potent predictive marker of critical condition development and mortality in COVID-19. <i>PLoS ONE</i> , 2021, 16, e0254640.	1.1	16
2359	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993.	1.8	136
2360	COVID-19 and Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 328-333.	1.0	7
2361	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	1.7	86
2362	JAK Inhibitors â€” More Than Just Glucocorticoids. <i>New England Journal of Medicine</i> , 2021, 385, 463-465.	13.9	15
2363	Do not just sit there, do something â€” but do no harm: the worrying aspects of COVID-19 experimental interventions. <i>Intensive Care Medicine</i> , 2021, 47, 896-898.	3.9	6
2364	Mechanisms of Myocardial Injury in COVID-19. <i>Clinical Chemistry</i> , 2021, 67, 1044-1046.	1.5	7

#	ARTICLE	IF	CITATIONS
2365	Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19. <i>Medical Science Monitor</i> , 2021, 27, e933973.	0.5	6
2366	COVID-19 multidisciplinary working group. <i>Clinical Medicine</i> , 2021, 21, e429-e430.	0.8	0
2367	Efficacy of tocilizumab in COVID-19: A review of the current evidence. <i>Science Progress</i> , 2021, 104, 003685042110303.	1.0	6
2368	In COVID-19 patients, low 25-hydroxyvitamin D level in serum is associated with longer viral clearance time and higher risk of intensive care unit admission. <i>Nutrition and Food Science</i> , 2021, ahead-of-print, .	0.4	1
2369	Biomedical Research COVID-19 Impact Assessment: Lessons Learned and Compelling Needs. <i>NAM Perspectives</i> , 2021, 2021, .	1.3	4
2370	Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, e41-e45.	0.5	9
2372	Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3050-3055.	1.4	16
2373	Commentary: Why Haven't We Found an Effective Treatment for COVID-19?. <i>Frontiers in Immunology</i> , 2021, 12, 714175.	2.2	2
2374	Clinical Outcomes of Severe COVID-19 Patients Admitted to an Intermediate Respiratory Care Unit. <i>Frontiers in Medicine</i> , 2021, 8, 711027.	1.2	5
2375	Impact of Tocilizumab on Clinical Outcomes in COVID-19-Associated Cytokine Release Syndrome: A Single-Center Experience. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002110282.	0.5	1
2377	Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 706431.	1.3	1
2378	Beyond the physical risk: Psychosocial impact and coping in healthcare professionals during the COVID-19 pandemic. <i>Journal of Clinical Nursing</i> , 2021, , .	1.4	17
2379	Methylprednisolone and 60 Days in Hospital Survival in Coronavirus Disease 2019 Pneumonia. , 2021, 3, e0493.		9
2380	Prevention of Thromboembolic Events in Patients with COVID-19. <i>TH Open</i> , 2021, 05, e415-e419.	0.7	0
2383	Lung transplantation for coronavirus disease 2019 (COVID-19): The who, what, where, when, and why. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 865-868.	0.4	13
2384	Precision Medicine and Heterogeneity of Treatment Effect in Therapies for ARDS. <i>Chest</i> , 2021, 160, 1729-1738.	0.4	24
2385	Convalescent plasma in the management of COVID-19 pneumonia. <i>European Journal of Internal Medicine</i> , 2021, 89, 121-123.	1.0	1
2386	Learning from past respiratory failure patients to triage COVID-19 patient ventilator needs: A multi-institutional study. <i>Journal of Biomedical Informatics</i> , 2021, 119, 103802.	2.5	7

#	ARTICLE	IF	CITATIONS
2387	External validation and update of prediction models for unfavorable outcomes in hospitalized patients with COVID-19 in Japan. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1043-1050.	0.8	4
2389	Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2021, 18, 1281-1289.	1.9	3
2390	Therapeutic anticoagulation in COVID-19 patients. <i>Thrombosis Research</i> , 2021, 203, 72-73.	0.8	1
2391	Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research. <i>Cancer Cell</i> , 2021, 39, 897-899.	7.7	1
2392	From severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) to coronavirus disease 2019 (COVID-19): a systematic review of the quality and responsiveness of clinical management guidelines in outbreak settings. <i>Wellcome Open Research</i> , 0, 6, 170.	0.9	4
2393	Outpatient Management of COVID-19 Disease: A Holistic Patient-Centered Proposal Based on the Greek Experience. <i>Journal of Personalized Medicine</i> , 2021, 11, 709.	1.1	1
2394	Worldwide Early Impact of COVID-19 on Dialysis Patients and Staff and Lessons Learned: A DOPPS Roundtable Discussion. <i>Kidney Medicine</i> , 2021, 3, 619-634.	1.0	18
2395	Coronavirus disease 2019 in children. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 500-509.	1.3	8
2396	Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine. <i>Frontiers in Immunology</i> , 2021, 12, 701273.	2.2	5
2397	Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. <i>PLoS ONE</i> , 2021, 16, e0254453.	1.1	27
2399	Randomised, controlled, open label, multicentre clinical trial to explore safety and efficacy of hyperbaric oxygen for preventing ICU admission, morbidity and mortality in adult patients with COVID-19. <i>BMJ Open</i> , 2021, 11, e046738.	0.8	10
2401	Coronavirus Disease 2019 in a Patient With a Systemic Autoinflammatory Syndrome due to an NLRC4 Inflammasomopathy. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab362.	0.4	4
2402	Macrolide Diversification Reveals Broad Immunosuppressive Activity That Impairs the cGAS-εSTING Pathway. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 18734-18741.	7.2	5
2403	Diagnostic Challenges of Pneumocystis Pneumonia during the COVID-19 Pandemic: A Case of a Young Patient with Ground Glass Opacities and Pulmonary Embolism on Chest CT. <i>Case Reports in Infectious Diseases</i> , 2021, 2021, 1-6.	0.2	1
2404	What the HEC happens around the heart during COVID-19?. <i>Basic Research in Cardiology</i> , 2021, 116, 43.	2.5	0
2405	Making trials part of good clinical care: lessons from the RECOVERY trial. <i>Future Healthcare Journal</i> , 2021, 8, e243-e250.	0.6	32
2407	Relationship between Built Environment and COVID-19 Dispersal Based on Age Stratification: A Case Study of Wuhan. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7563.	1.2	13
2408	The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence. <i>Frontiers in Immunology</i> , 2021, 12, 677957.	2.2	6

#	ARTICLE	IF	CITATIONS
2409	Leveraging a Preexisting Global Infectious Disease Network for Local Decision Making During a Pandemic. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	2
2410	Tocilizumab Induces Rapid, Sustained Improvement of Inflammatory Markers in COVID-19, With Clinical Improvement in Most Patients. <i>American Journal of Therapeutics</i> , 2021, 28, e592-e596.	0.5	0
2411	Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2114741.	2.8	73
2412	High mortality among kidney transplant recipients diagnosed with coronavirus disease 2019: Results from the Brazilian multicenter cohort study. <i>PLoS ONE</i> , 2021, 16, e0254822.	1.1	51
2413	Proven COVID-19-associated pulmonary aspergillosis in patients with severe respiratory failure. <i>Mycoses</i> , 2021, 64, 1223-1229.	1.8	32
2414	Myocarditis associated with Covid-19 disease: A systematic review of published case reports and case series. <i>International Journal of Clinical Practice</i> , 2021, 75, e14470.	0.8	55
2415	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e498-e506.	2.2	58
2416	Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102196.	1.8	66
2417	Trends in 28-Day Mortality of Critical Care Patients With Coronavirus Disease 2019 in the United Kingdom: A National Cohort Study, March 2020 to January 2021*. <i>Critical Care Medicine</i> , 2021, 49, 1895-1900.	0.4	18
2418	The signal pathways and treatment of cytokine storm in COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 255.	7.1	355
2419	In Reply to Bevelacqua et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1551.	0.4	0
2420	The Elephant in the Room. <i>Chest</i> , 2021, 160, 387-388.	0.4	4
2421	Deconstructing improvements and hospital variation in COVID-19 mortality rates during the early pandemic wave: the effects of wave evolution and advances in testing, treatment, and hospital care quality. <i>BMJ Quality and Safety</i> , 2022, 31, 168-171.	1.8	0
2422	Test it earlier, result it faster, makes us stronger: how rapid viral diagnostics enable therapeutic success. <i>Current Opinion in Virology</i> , 2021, 49, 111-116.	2.6	7
2423	Structural Insight into the Binding of Cyanovirin-N with the Spike Glycoprotein, Mpro and PLpro of SARS-CoV-2: Protein-Protein Interactions, Dynamics Simulations and Free Energy Calculations. <i>Molecules</i> , 2021, 26, 5114.	1.7	11
2424	Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study. <i>Antibiotics</i> , 2021, 10, 1031.	1.5	7
2425	SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients. <i>Frontiers in Immunology</i> , 2021, 12, 720205.	2.2	16
2426	Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. <i>Frontiers in Pharmacology</i> , 2021, 12, 699949.	1.6	15

#	ARTICLE	IF	CITATIONS
2427	Revisiting Old Friends: Adjunctive Therapies in Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 473-475.	2.5	0
2428	Non-Coding RNAs in COVID-19: Emerging Insights and Current Questions. Non-coding RNA, 2021, 7, 54.	1.3	24
2429	Practical scenarios and day-to-day challenges in the management of diabetes in COVID-19 "Dealing with the "double trouble"™. Primary Care Diabetes, 2021, 15, 737-739.	0.9	8
2430	Analysis of primary care prescription trends in England during the COVID-19 pandemic compared against a predictive model. Family Medicine and Community Health, 2021, 9, e001143.	0.6	20
2431	Admission NT-proBNP and outcomes in patients without history of heart failure hospitalized with COVID-19. ESC Heart Failure, 2021, 8, 4278-4287.	1.4	20
2433	Identification of COVID-19 prognostic markers and therapeutic targets through meta-analysis and validation of Omics data from nasopharyngeal samples. EBioMedicine, 2021, 70, 103525.	2.7	27
2434	Effects of Steroids and Tocilizumab on the Immune Response Profile of Patients with COVID-19-Associated ARDS Requiring or Not Venovenous Extracorporeal Membrane Oxygenation. Membranes, 2021, 11, 603.	1.4	3
2435	Four consecutive yearly point-prevalence studies in Wales indicate lack of improvement in sepsis care on the wards. Scientific Reports, 2021, 11, 16222.	1.6	2
2436	Outcomes of Patients Denied Extracorporeal Membrane Oxygenation during the COVID-19 Pandemic in Greater Paris, France. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 994-997.	2.5	14
2437	Effect of prone positioning on oxygenation and static respiratory system compliance in COVID-19 ARDS vs. non-COVID ARDS. Respiratory Research, 2021, 22, 220.	1.4	23
2438	A moral dilemma: The use of zinc in patients hospitalized with COVID pneumonia. Clinical Research in Practice the Journal of Team Hippocrates, 2021, 7, .	0.0	0
2439	Comparative effectiveness research in COVID-19 using real-world data: methodological considerations. Journal of Comparative Effectiveness Research, 2021, 10, 1259-1264.	0.6	2
2440	The Airway Microbiome: Present and Future Applications. Archivos De Bronconeumologia, 2022, 58, 8-10.	0.4	19
2441	Physician experiences in management of COVID-19-associated coagulopathy in pregnancy: Communication from the ISTH SSC Subcommittee on Women's Health Issues in Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2021, 19, 2539-2545.	1.9	16
2442	India and management of COVID-19: A case study on published guidelines. Drug Discoveries and Therapeutics, 2021, 15, 171-179.	0.6	0
2443	Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study. Frontiers in Immunology, 2021, 12, 673693.	2.2	9
2444	Case Report: Steroid-induced Ocular Hypertension in a 6-year-old Boy. Optometry and Vision Science, 2021, 98, 867-869.	0.6	3
2445	Hypertriglyceridemia during hospitalization independently associates with mortality in patients with COVID-19. Journal of Clinical Lipidology, 2021, 15, 724-731.	0.6	14

#	ARTICLE	IF	CITATIONS
2446	The Care of the Leukemic Patients in Times of SARS-CoV-2. <i>Current Oncology Reports</i> , 2021, 23, 114.	1.8	2
2447	Kidney implications of SARS-CoV2 infection in children. <i>Pediatric Nephrology</i> , 2021, , 1.	0.9	9
2449	The prognostic value of the SOFA score in patients with COVID-19. <i>Medicine (United States)</i> , 2021, 100, e26900.	0.4	41
2450	Invasive mould disease in fatal COVID-19: a systematic review of autopsies. <i>Lancet Microbe</i> , The, 2021, 2, e405-e414.	3.4	62
2451	Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111785.	2.5	14
2452	Lessons Learned in Managing Patients with Colorectal Cancer During the COVID-19 Pandemic. <i>Current Treatment Options in Oncology</i> , 2021, 22, 93.	1.3	5
2453	SARS-CoV-2 Myocarditis: Insights Into Incidence, Prognosis, and Therapeutic Implications. <i>Current Cardiology Reports</i> , 2021, 23, 129.	1.3	17
2454	Clinical outcomes in cancer patients with COVID-19. <i>Cancer Reports</i> , 2021, 4, e1413.	0.6	9
2455	Fundamental challenges in assessing the impact of research infrastructure. <i>Health Research Policy and Systems</i> , 2021, 19, 119.	1.1	8
2456	What's Next in Pneumonia?. <i>Archivos De Bronconeumologia</i> , 2022, 58, 208-210.	0.4	1
2457	Pathogenesis and treatment of cytokine storm in COVID-19. <i>Turkish Journal of Biology</i> , 2021, 45, 372-389.	2.1	18
2458	Validation of The 4C Deterioration Model for COVID-19 in a UK Teaching Hospital During Wave 2. <i>American Journal of the Medical Sciences</i> , 2021, 362, 512-515.	0.4	3
2459	Clinical experience of coronavirus disease 2019 in hematopoietic cell transplant and chimeric antigen receptor T-cell recipients. <i>Current Opinion in Hematology</i> , 2021, Publish Ahead of Print, 394-400.	1.2	4
2460	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	3.4	149
2461	COVID-19: Inflammatory Profile. <i>Annual Review of Medicine</i> , 2022, 73, 65-80.	5.0	43
2462	Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients. <i>Clinical and Experimental Nephrology</i> , 2022, 26, 75-85.	0.7	13
2463	Systemic corticosteroids for the treatment of COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD014963.	1.5	119
2464	Clinical Implications of IL-32, IL-34 and IL-37 in Atherosclerosis: Speculative Role in Cardiovascular Manifestations of COVID-19. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 630767.	1.1	18

#	ARTICLE	IF	CITATIONS
2465	Burden and characteristics of COVID-19 in the United States during 2020. <i>Nature</i> , 2021, 598, 338-341.	13.7	126
2466	COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. <i>Cytokine and Growth Factor Reviews</i> , 2021, 60, 28-45.	3.2	21
2467	French multicentre observational study on SARS-CoV-2 infections intensive care initial management: the FRENCH CORONA study. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100931.	0.6	19
2468	The Evolution of Clinical Knowledge During COVID-19: Towards a Global Learning Health System. <i>Yearbook of Medical Informatics</i> , 2021, 30, 176-184.	0.8	7
2469	Hospital-Level Variation in Death for Critically Ill Patients with COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 403-411.	2.5	39
2470	Optimal Timing of Remdesivir Initiation in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Administered With Dexamethasone. <i>Clinical Infectious Diseases</i> , 2022, 75, e499-e508.	2.9	20
2472	COVID-19 Vaccination Issues in Solid Organ Transplant Recipients. <i>Vestnik Medicinskoga Instituta REAVIZ ReabilitaciÅc, VraÅd ZdorovĚe</i> , 2021, 11, 5-14.	0.1	0
2473	Clinical Trends Among U.S. Adults Hospitalized With COVID-19, March to December 2020. <i>Annals of Internal Medicine</i> , 2021, 174, 1409-1419.	2.0	45
2474	Change in patterns of hospitalization for influenza during COVID-19 surges. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 72-78.	1.5	6
2475	First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1467-1477.	2.3	25
2477	Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic. <i>Pharmaceuticals</i> , 2021, 14, 819.	1.7	12
2479	Significant Publications on Infectious Diseases Pharmacotherapy in 2020. <i>Journal of Pharmacy Practice</i> , 2023, 36, 394-406.	0.5	1
2480	Outcomes of renal replacement therapy in the critically ill with COVID-19. <i>Medicina Intensiva (English)</i> Tj ETQq0 0 0 rgBT /Overlock 10 T	0.1	1
2481	COVID-19 in Africa: Current difficulties and future challenges considering the ACCCOS study. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100912.	0.6	5
2482	Drug Repurposing Against SARS-CoV-2: Targeting NSP16-NSP10 Interaction. <i>Journal of the Turkish Chemical Society, Section A: Chemistry</i> , 0, , 933-940.	0.4	1
2483	Comprehensive Immunologic Evaluation of Bronchoalveolar Lavage Samples from Human Patients with Moderate and Severe Seasonal Influenza and Severe COVID-19. <i>Journal of Immunology</i> , 2021, 207, 1229-1238.	0.4	21
2484	Remdesivir and Mortality in Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2022, 74, 1812-1820.	2.9	25
2485	Steroids use in non-oxygen requiring COVID-19 patients: a systematic review and meta-analysis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, 114, 455-463.	0.2	18

#	ARTICLE	IF	CITATIONS
2486	Challenges in interpreting cytokine data in COVID-19 affect patient care and management. <i>PLoS Biology</i> , 2021, 19, e3001373.	2.6	7
2487	Predictors of Hypoxemia and Related Adverse Outcomes in Patients Hospitalized with COVID-19: A Double-Center Retrospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3581.	1.0	4
2488	Low-dose spinal and opioid-free anesthesia in patient with Severe Aortic Stenosis and SARS-CoV-2 infection: Case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04192.	0.2	3
2489	Fourteen-day survival among older adults with severe infection with severe acute respiratory syndrome coronavirus 2 treated with corticosteroid: a cohort study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1145-1150.	2.8	9
2490	Intranasal Corticosteroids Are Associated with Better Outcomes in Coronavirus Disease 2019. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3934-3940.e9.	2.0	20
2491	Fever management in critically ill COVID-19 patients: a retrospective analysis. <i>Minerva Anestesiologica</i> , 2021, 87, 1217-1225.	0.6	3
2492	Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. <i>European Respiratory Journal</i> , 2022, 59, 2101724.	3.1	38
2493	Long COVID-19 Pulmonary Sequelae and Management Considerations. <i>Journal of Personalized Medicine</i> , 2021, 11, 838.	1.1	36
2494	Risk of COVID-19 in shielded and nursing care home patients: a cohort study in general practice. <i>BJGP Open</i> , 2021, 5, BJGPO.2021.0081.	0.9	4
2495	The "cytokine storm": molecular mechanisms and therapeutic prospects. <i>Trends in Immunology</i> , 2021, 42, 681-705.	2.9	156
2496	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients: a multinational observational study by the European Confederation of Medical Mycology. <i>Clinical Microbiology and Infection</i> , 2022, 28, 580-587.	2.8	133
2497	Tailoring glucocorticoids in patients with severe COVID-19: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 1261-1261.	0.7	3
2498	Inhaled bronchodilators use and clinical course of adult inpatients with Covid-19 pneumonia in Spain: A retrospective cohort study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 69, 102007.	1.1	5
2499	Anti-SARS-CoV-2 Strategies and the Potential Role of miRNA in the Assessment of COVID-19 Morbidity, Recurrence, and Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8663.	1.8	18
2500	Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 3545.	1.0	28
2501	Cardiac arrhythmias in patients presenting with COVID-19 treated in Portuguese hospitals: A national registry from the Portuguese Association of Arrhythmology, Pacing and Electrophysiology. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 573-580.	0.2	13
2502	We Know the Prognosis but can We Change It?. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 835-836.	0.3	0
2503	Clinical characteristics and outcomes of critically ill COVID-19 patients in Sfax, Tunisia. <i>Acute and Critical Care</i> , 2022, 37, 84-93.	0.6	3

#	ARTICLE	IF	CITATIONS
2504	The organisational response of a hospital critical care service to the COVID-19 pandemic: The Groote Schuur Hospital experience. <i>Southern African Journal of Critical Care</i> , 2021, 37, 63.	0.2	3
2505	Vitamin D and acute and severe illness – a mechanistic and pharmacokinetic perspective. <i>Nutrition Research Reviews</i> , 2023, 36, 23-38.	2.1	4
2506	Duplex Ultrasound Screening for Deep and Superficial Vein Thrombosis in COVID-19 Patients. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 1095-1100.	0.8	7
2507	Tuberculosis lymph node granulomas: using transcriptomics to discover immunopathology paradigms and guide host-directed therapy. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	1
2508	Aplicación de escalas pronósticas de gravedad en la neumonía por SARS-CoV-2. <i>Medicina Clínica</i> , 2021, 157, 99-105.	0.3	6
2509	ACE2 Netlas: In silico Functional Characterization and Drug-Gene Interactions of ACE2 Gene Network to Understand Its Potential Involvement in COVID-19 Susceptibility. <i>Frontiers in Genetics</i> , 2021, 12, 698033.	1.1	4
2510	High-dose intravenous immunoglobulins as a therapeutic option in critical illness polyneuropathy accompanying SARS-CoV-2 infection: A case-based review of the literature (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1182.	0.8	10
2511	Effect of time and titer in convalescent plasma therapy for COVID-19. <i>IScience</i> , 2021, 24, 102898.	1.9	16
2512	A high-resolution temporal atlas of the SARS-CoV-2 translome and transcriptome. <i>Nature Communications</i> , 2021, 12, 5120.	5.8	57
2513	Coronavirus disease (COVID-19) complicated by rhino-orbital-cerebral mucormycosis presenting with neurovascular thrombosis: a case report and review of literature. <i>Journal of NeuroVirology</i> , 2021, 27, 644-649.	1.0	11
2514	Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 109, 261-268.	1.5	14
2515	Experimental and Compassionate Drug Use During the First Wave of the COVID-19 Pandemic: A Retrospective Single-Center Study. <i>Advances in Therapy</i> , 2021, 38, 5165-5177.	1.3	3
2516	Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients. <i>Critical Care</i> , 2021, 25, 281.	2.5	50
2517	Daily monitoring of viral load measured as SARS-CoV-2 antigen and RNA in blood, IL-6, CRP and complement C3d predicts outcome in patients hospitalized with COVID-19. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1988-1997.	1.4	31
2518	Caution When Comparing the Impact of Corticosteroids in COVID-19. <i>Chest</i> , 2021, 160, e243-e244.	0.4	1
2519	Disrupted Resolution Mechanisms Favor Altered Phagocyte Responses in COVID-19. <i>Circulation Research</i> , 2021, 129, e54-e71.	2.0	46
2520	Innovative treatment as a precursor to clinical research. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	5
2521	Inflammation, a common mechanism in frailty and COVID19 , and stem cells as a therapeutic approach. <i>Stem Cells Translational Medicine</i> , 2021, 10, 1482-1490.	1.6	8

#	ARTICLE	IF	CITATIONS
2522	Triple challenge of diabetes, COVID-19, and mucormycosis. International Journal of Diabetes in Developing Countries, 2021, , 1-2.	0.3	2
2523	Low-Dose Lung Radiation Therapy for COVID-19 Lung Disease: A Preclinical Efficacy Study in a Bleomycin Model of Pneumonitis. International Journal of Radiation Oncology Biology Physics, 2022, 112, 197-211.	0.4	13
2524	Extracorporeal Blood Purification Is Appropriate in Critically Ill Patients with COVID-19 and Multiorgan Failure: COMMENTARY. Kidney360, 2022, 3, 423-425.	0.9	1
2525	Diagnosing Disseminated Nocardiosis in a Patient With COVID-19 Pneumonia. Journal of Medical Cases, 2021, 12, 319-324.	0.4	6
2526	One year on: Are we ready for COVID?. Archivos De Bronconeumologia, 2021, 57, 517-518.	0.4	0
2527	Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. Journal of Medical Virology, 2021, 93, 6737-6749.	2.5	13
2528	Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure. Respiratory Medicine, 2021, 185, 106477.	1.3	9
2529	Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. Annals of Internal Medicine, 2021, 174, 1151-1158.	2.0	16
2530	The clinical spectrum of SARS-CoV-2 infection in Gaucher disease: Effect of both a pandemic and a rare disease that disrupts the immune system. Molecular Genetics and Metabolism, 2022, 135, 115-121.	0.5	3
2531	COVID-19 Vaccines in Patients with Maintenance Hemodialysis. Journal of Personalized Medicine, 2021, 11, 789.	1.1	14
2532	Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection. Cell Death and Differentiation, 2022, 29, 156-166.	5.0	38
2533	Corticosteroids and RCTs against the supposed undervaluation of real data evidence. Critical Care, 2021, 25, 297.	2.5	0
2534	Pressing Questions and Challenges in the HIV-1 and SARS-CoV-2 Syndemic. AIDS Research and Human Retroviruses, 2021, 37, 589-600.	0.5	5
2535	Application of validated severity scores for pneumonia caused by SARS-CoV-2. Medicina Clínica (English Edition), 2021, 157, 99-105.	0.1	9
2536	Antirheumatic drugs and COVID-19: frustrations and hopes. Meditsinskiy Sovet, 2021, , 134-139.	0.1	0
2537	AAÿÄ±r COVÄ°D- 19 PnÃ¶monisinde Pulse Steroid Tedavisinin Mortalite Äœezerine Etkisi. SÃ¼leyman Demirel Äœeniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.0	0
2538	Caring for nursing home residents with COVID-19: a âœehospital-at-nursing homeâœ-intermediate care intervention. Aging Clinical and Experimental Research, 2021, 33, 2917-2924.	1.4	10
2539	Response to: Correspondence on âœAssociations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registryâœby Sparks<i>et al</i>. Annals of the Rheumatic Diseases, 2023. 82. e158-e158.	0.5	3

#	ARTICLE	IF	CITATIONS
2540	Association between obesity and hospital mortality in critical COVID-19: a retrospective cohort study. <i>International Journal of Obesity</i> , 2021, 45, 2617-2622.	1.6	5
2541	Asthma and COVID-19: Emphasis on Adequate Asthma Control. <i>Canadian Respiratory Journal</i> , 2021, 2021, 1-12.	0.8	9
2542	COVID-19: The Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation. <i>Cells</i> , 2021, 10, 2212.	1.8	4
2543	COVID-19 Disease, Women's Predominant Non-Heparin Vaccine-Induced Thrombotic Thrombocytopenia and Kounis Syndrome: A Passepourtout Cytokine Storm Interplay. <i>Biomedicines</i> , 2021, 9, 959.	1.4	14
2544	SARS-CoV-2 and Cystic Fibrosis: Expectations Versus Reality, a Literature Review. <i>European Medical Journal Respiratory</i> , 0, , .	1.0	0
2545	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	7.1	68
2546	Recent advances in potential drug therapies combating COVID-19 and related coronaviruses-A perspective. <i>Food and Chemical Toxicology</i> , 2021, 154, 112333.	1.8	5
2547	Vaccination and their importance for lung transplant recipients in a COVID-19 world. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1413-1425.	1.3	13
2548	Genomic and Non-Genomic Actions of Glucocorticoids on Adipose Tissue Lipid Metabolism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8503.	1.8	22
2549	Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2021, , .	0.4	7
2550	Acute kidney injury prevalence, progression and long-term outcomes in critically ill patients with COVID-19: a cohort study. <i>Annals of Intensive Care</i> , 2021, 11, 123.	2.2	47
2551	MANAGEMENT OF ENDOCRINE DISEASE: Dysnatraemia in COVID-19: prevalence, prognostic impact, pathophysiology, and management. <i>European Journal of Endocrinology</i> , 2021, 185, R103-R111.	1.9	13
2553	Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19. <i>Advances in Biological Regulation</i> , 2021, 81, 100818.	1.4	10
2554	SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020. <i>Transplantation Proceedings</i> , 2021, 53, 2421-2434.	0.3	6
2555	Rhino-orbital mucormycosis following COVID-19 in previously non-diabetic, immunocompetent patients. <i>Orbit</i> , 2021, 40, 499-504.	0.5	20
2556	Obesity, inflammatory and thrombotic markers, and major clinical outcomes in critically ill patients with COVID-19 in the US. <i>Obesity</i> , 2021, 29, 1719-1730.	1.5	11
2557	Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDS. <i>Nature Communications</i> , 2021, 12, 5152.	5.8	47
2558	Inflammasome activation at the crux of severe COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 694-703.	10.6	210

#	ARTICLE	IF	CITATIONS
2559	Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 368-380.e3.	1.5	59
2560	Reflections on Critical Care's Past, Present, and Future. <i>Critical Care Medicine</i> , 2021, 49, 1855-1865.	0.4	13
2561	Exploiting an early immunological window of opportunity in COVID-19. <i>Lancet Respiratory Medicine</i> , 2021, 9, 811-812.	5.2	1
2562	Y un año después, ¿estamos preparados para la COVID?. <i>Archivos De Bronconeumología</i> , 2021, 57, 517-518.	0.4	0
2563	Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis. <i>World Journal of Gastroenterology</i> , 2021, 27, 4763-4783.	1.4	9
2564	SARS-CoV-2: Understanding the Transcriptional Regulation of ACE2 and TMPRSS2 and the Role of Single Nucleotide Polymorphism (SNP) at Codon 72 of p53 in the Innate Immune Response against Virus Infection. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8660.	1.8	14
2565	Elevated inflammatory markers are associated with poor outcomes in COVID-19 patients treated with remdesivir. <i>Journal of Medical Virology</i> , 2022, 94, 384-387.	2.5	14
2566	Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19. <i>Thorax</i> , 2022, 77, 203-209.	2.7	90
2567	Hepatitis E virus infection activates NOD-like receptor family pyrin domain-containing 3 inflammasome antagonizing interferon response but therapeutically targetable. <i>Hepatology</i> , 2022, 75, 196-212.	3.6	19
2570	Immunological map in COVID-19. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 547-556.	1.5	9
2571	Virtual Peer-to-Peer Learning to Enhance and Accelerate the Health System Response to COVID-19: The HHS ASPR Project ECHO COVID-19 Clinical Rounds Initiative. <i>Annals of Emergency Medicine</i> , 2021, 78, 223-228.	0.3	11
2572	Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and Meta-Analysis. <i>JCO Global Oncology</i> , 2021, 7, 1286-1305.	0.8	30
2573	Defining Potential Therapeutic Targets in Coronavirus Disease 2019: A Cross-Sectional Analysis of a Single-Center Cohort. , 2021, 3, e0488.		2
2574	Liver transplantation during global COVID-19 pandemic. <i>World Journal of Clinical Cases</i> , 2021, 9, 6608-6623.	0.3	3
2575	Compassionate use of anti-IL6 receptor antibodies in critically ill patients with acute respiratory distress syndrome due to SARS-COV-2. <i>Minerva Anestesiologica</i> , 2021, 87, 1080-1090.	0.6	3
2576	COVID-19 vulnerabilities are intensified by declining human serum albumin levels. <i>Experimental Physiology</i> , 2022, 107, 674-682.	0.9	10
2577	Blunt and penetrating chest trauma with concomitant COVID-19 infections: Two case reports. <i>Trauma Case Reports</i> , 2021, 34, 100507.	0.2	1
2578	The impact of primary care supported shielding on the risk of mortality in people vulnerable to COVID-19: English sentinel network matched cohort study. <i>Journal of Infection</i> , 2021, 83, 228-236.	1.7	7

#	ARTICLE	IF	CITATIONS
2579	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. <i>Journal of Neuroimmunology</i> , 2021, 357, 577627.	1.1	33
2581	The Need for a US National Clinical Trial Infrastructure in a Public Health Crisis. <i>JAMA Health Forum</i> , 2021, 2, e213223.	1.0	5
2582	Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19. <i>BioScience Trends</i> , 2021, 15, 205-210.	1.1	8
2583	Case Report: COVID-19-associated Rhinosinusitis Mucormycosis Caused by <i>Rhizopus arrhizus</i> : A Rare but Potentially Fatal Infection Occurring After Treatment with Corticosteroids. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 449-453.	0.6	26
2584	Sex differences in immunological responses to COVID-19: a cross-sectional analysis of a single-centre cohort. <i>British Journal of Anaesthesia</i> , 2021, 127, e75-e78.	1.5	4
2585	Outcomes of renal replacement therapy in the critically ill with COVID-19. <i>Medicina Intensiva</i> , 2021, 45, 325-331.	0.4	10
2587	Protocol for the Controlled evaluation of Angiotensin Receptor blockers for COVID-19 respiratory disease (CLARITY): a randomised controlled trial. <i>Trials</i> , 2021, 22, 573.	0.7	7
2588	DAMPening Severe COVID-19 with Dexamethasone. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, .	0.4	5
2589	Low Levels of Few Micronutrients May Impact COVID-19 Disease Progression: An Observational Study on the First Wave. <i>Metabolites</i> , 2021, 11, 565.	1.3	25
2590	ANCA Vasculitis Induction Management During the COVID-19 Pandemic. <i>Kidney International Reports</i> , 2021, 6, 2903-2907.	0.4	8
2591	Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0123721.	1.4	13
2592	Reducing SARS-CoV-2 pathological protein activity with small molecules. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 383-397.	2.4	11
2593	Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study. <i>Wellcome Open Research</i> , 0, 6, 216.	0.9	0
2594	Outcomes of extracorporeal membrane oxygenation in influenza versus COVID-19 during the first wave of COVID-19. <i>Journal of Cardiac Surgery</i> , 2021, 36, 3740-3746.	0.3	12
2595	Severe acute respiratory syndrome (SARS) coronavirus-2 infection (COVID-19) in pregnancy – An overview. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 263, 106-116.	0.5	8
2596	Secondary haemophagocytic lymphohistiocytosis in hospitalised COVID-19 patients as indicated by a modified HScore is infrequent and high scores do not associate with increased mortality. <i>Clinical Medicine</i> , 2021, 21, e543-e547.	0.8	3
2597	Acute respiratory distress syndrome. <i>Lancet, The</i> , 2021, 398, 622-637.	6.3	426
2598	Combating the progression of novel coronavirus SARS-CoV-2 infectious Disease: Current state and future prospects in molecular diagnostic and drug discovery. <i>Current Molecular Medicine</i> , 2021, 21, .	0.6	6

#	ARTICLE	IF	CITATIONS
2599	Extracorporeal membrane oxygenation for COVID-19 during first and second waves. <i>Lancet Respiratory Medicine</i> , 2021, 9, e80-e81.	5.2	52
2600	In-hospital mortality among immunosuppressed patients with COVID-19: Analysis from a national cohort in Spain. <i>PLoS ONE</i> , 2021, 16, e0255524.	1.1	42
2601	Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection. <i>Life Science Alliance</i> , 2021, 4, e202101049.	1.3	14
2602	Efficacy and Safety of Corticosteroid Use in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2447-2463.	1.8	16
2603	Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia: A Randomized Double-Blind Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1274-1282.	0.4	41
2604	Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19. <i>American Journal of Therapeutics</i> , 2021, 28, e616-e619.	0.5	4
2605	Evidence-based public policy making for medicines across countries: findings and implications for the future. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1019-1052.	0.6	30
2608	Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity. <i>Science Advances</i> , 2021, 7, .	4.7	49
2609	Experience of Treating COVID-19 With Remdesivir and Convalescent Plasma in a Resource-Limited Setting: A Prospective, Observational Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab391.	0.4	11
2610	Observed risk of recurrent bleeding and thromboembolic disease in COVID-19 patients with gastrointestinal bleeding. <i>Endoscopy International Open</i> , 2021, 09, E1435-E1444.	0.9	0
2612	Risk, Course, and Effect of SARS-CoV-2 Infection in Children and Adults with Chronic Inflammatory Bowel Diseases. <i>Children</i> , 2021, 8, 753.	0.6	3
2613	The obstetric patient in the Covid pandemic: anaesthesia and perioperative care. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 361-369.	0.9	3
2614	A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients. <i>Viruses</i> , 2021, 13, 1706.	1.5	9
2616	Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 69, 102035.	1.1	9
2617	Cardiac arrhythmias in patients presenting with COVID-19 treated in Portuguese hospitals: A national registry from the Portuguese Association of Arrhythmology, Pacing and Electrophysiology. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 573-580.	0.2	4
2618	Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes. <i>Journal of Infection and Public Health</i> , 2021, 14, 1021-1027.	1.9	6
2619	Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19. <i>Respiratory Investigation</i> , 2021, 59, 799-803.	0.9	24
2620	Association between inhaled corticosteroid use and COVID-19 outcomes. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1486-1492.	0.9	4

#	ARTICLE	IF	CITATIONS
2621	COVID-19 clinical phenotypes and short-term outcomes: differences between the first and the second wave of pandemic in Italy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1-7.	1.0	11
2622	Importance of nationally coordinated data collection and quality improvement networks. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2022, 6, 6-8.	0.2	1
2623	ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO). <i>European Heart Journal Supplements</i> , 2021, 23, C128-C153.	0.0	7
2624	Vigilance in selection of low-dose versus high-dose steroids in COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 109, 54-55.	1.5	1
2625	Cytokine adsorption and ECMO in patients with COVID-19 – Author's reply. <i>Lancet Respiratory Medicine</i> , 2021, 9, e72-e74.	5.2	7
2626	Specific Risk Factors for Fatal Outcome in Critically Ill COVID-19 Patients: Results from a European Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3855.	1.0	12
2627	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. <i>The Lancet Regional Health Americas</i> , 2021, 2, 100062.	1.5	33
2628	A review on the COVID-19: Facts and current situation. <i>NeuroPharmac Journal</i> , 0, , 180-191.	0.1	3
2629	Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. <i>Brain</i> , 2021, 144, 3576-3588.	3.7	101
2630	Studying SARS-CoV-2 infectivity and therapeutic responses with complex organoids. <i>Nature Cell Biology</i> , 2021, 23, 822-833.	4.6	21
2631	Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 921-932.	2.5	108
2632	Comparison of clinical and echocardiographic features of first and second waves of COVID-19 at a large, tertiary medical center serving a predominantly African American patient population. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 3181-3190.	0.7	5
2633	Sex and Gender Differences in Testing, Hospital Admission, Clinical Presentation, and Drivers of Severe Outcomes From COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab448.	0.4	41
2634	SARS-CoV-2 Treatment: Current Therapeutic Options and the Pursuit of Tailored Therapy. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 7457.	1.3	11
2635	CT of Post-Acute Lung Complications of COVID-19. <i>Radiology</i> , 2021, 301, E383-E395.	3.6	115
2636	The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models. <i>Frontiers in Pharmacology</i> , 2021, 12, 660490.	1.6	31
2638	Outcome measures in solid organ donor management research: a systematic review. <i>British Journal of Anaesthesia</i> , 2021, 127, 745-759.	1.5	0
2639	COVID-19-associated opportunistic infections: a snapshot on the current reports. <i>Clinical and Experimental Medicine</i> , 2022, 22, 327-346.	1.9	78

#	ARTICLE	IF	CITATIONS
2640	Challenges and Opportunities for Osteoporosis Care During the COVID-19 Pandemic. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4795-e4808.	1.8	7
2641	Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial. <i>Contemporary Clinical Trials</i> , 2021, 110, 106547.	0.8	4
2642	COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 713560.	1.1	76
2643	Clinical Study of Surge of Mucormycosis in COVID-19 Pandemic: A Tertiary Care Center Study. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2022, 74, 3455-3462.	0.3	11
2644	Impact of early corticosteroids on 60-day mortality in critically ill patients with COVID-19: A multicenter cohort study of the OUTCOMEREA network. <i>PLoS ONE</i> , 2021, 16, e0255644.	1.1	27
2645	Phase III Clinical Trial of Combination Therapy with Favipiravir and Methylprednisolone for COVID-19 with Non-Critical Respiratory Failure. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2353-2369.	1.8	5
2646	Antimicrobial Consumption among 66 Acute Care Hospitals in Catalonia: Impact of the COVID-19 Pandemic. <i>Antibiotics</i> , 2021, 10, 943.	1.5	36
2647	Progress and pitfalls of a year of drug repurposing screens against COVID-19. <i>Current Opinion in Virology</i> , 2021, 49, 183-193.	2.6	25
2649	Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation. <i>In Silico Pharmacology</i> , 2021, 9, 49.	1.8	8
2650	May mesenchymal stem cell transplantation be a solution for COVID-19 induced cytokine storm?. <i>World Journal of Transplantation</i> , 2021, 11, 344-355.	0.6	1
2651	Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study. <i>Frontiers in Immunology</i> , 2021, 12, 709861.	2.2	13
2652	Invasive pulmonary aspergillosis associated with viral pneumonitis. <i>Current Opinion in Microbiology</i> , 2021, 62, 21-27.	2.3	39
2653	Decreased Mortality Over Time During the First Wave in Patients With COVID-19 in Geriatric Care: Data From the Stockholm GeroCovid Study. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1565-1573.e4.	1.2	9
2654	Bacterial infections in patients hospitalized with COVID-19. <i>Internal and Emergency Medicine</i> , 2022, 17, 431-438.	1.0	33
2655	Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in Vigibase During 2020. <i>Drug Safety</i> , 2021, 44, 987-998.	1.4	9
2656	Immune System Disequilibrium—Neutrophils, Their Extracellular Traps, and COVID-19-Induced Sepsis. <i>Frontiers in Medicine</i> , 2021, 8, 711397.	1.2	6
2657	Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States. <i>Annals of Internal Medicine</i> , 2021, 174, 1395-1403.	2.0	24
2658	Recurrent Sweet syndrome presenting in a figurate pattern in a patient with Fanconi anemia. <i>International Journal of Dermatology</i> , 2021, , .	0.5	2

#	ARTICLE	IF	CITATIONS
2659	JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3752.	1.0	7
2660	The microbiota-related coinfections in COVID-19 patients: a real challenge. Beni-Suef University <i>Journal of Basic and Applied Sciences</i> , 2021, 10, 47.	0.8	9
2661	Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 3784.	1.0	12
2662	Effectiveness of Natural Antioxidants against SARS-CoV-2? Insights from the In-Silico World. <i>Antibiotics</i> , 2021, 10, 1011.	1.5	41
2663	Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era. <i>Frontiers in Medicine</i> , 2021, 8, 706482.	1.2	23
2664	Alveolar Nitric Oxide as a Biomarker of COVID-19 Lung Sequelae: A Pivotal Study. <i>Antioxidants</i> , 2021, 10, 1350.	2.2	11
2665	Risk factors for SARS-CoV-2 infection and epidemiological profile of Brazilian anesthesiologists during the COVID-19 pandemic: cross-sectional study. <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2021, , .	0.2	3
2666	Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients. <i>PLoS ONE</i> , 2021, 16, e0256226.	1.1	34
2667	Secondary infections in critically ill patients with COVID-19. <i>Critical Care</i> , 2021, 25, 317.	2.5	31
2668	Management of infectious complications associated with coronavirus infection in severe patients admitted to ICU. <i>Medicina Intensiva (English Edition)</i> , 2021, 45, 485-500.	0.1	6
2669	Emergency medical admissions and COVID-19: impact on 30-day mortality and hospital length of stay. <i>Irish Journal of Medical Science</i> , 2021, , 1.	0.8	3
2670	Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibufrofenate in a Compassionate Use Program. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2511-2524.	1.8	5
2671	A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol. <i>Gates Open Research</i> , 0, 5, 117.	2.0	2
2672	Human Disease Phenotypes Associated with Loss and Gain of Function Mutations in STAT2: Viral Susceptibility and Type I Interferonopathy. <i>Journal of Clinical Immunology</i> , 2021, 41, 1446-1456.	2.0	22
2673	Exercise-induced hypoxia among emergency department patients admitted for suspected COVID-19. <i>Emergency Medicine Journal</i> , 2021, 38, 794-797.	0.4	0
2674	The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 1-9.	2.3	31
2675	Mucormycosis in CAPA, a Possible Fungal Super-Infection. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 708.	1.5	5
2676	Adrenal hemorrhage and hemorrhagic masses; diagnostic workup and imaging findings. <i>British Journal of Radiology</i> , 2021, 94, 20210753.	1.0	15

#	ARTICLE	IF	CITATIONS
2677	Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2455-2474.	0.9	2
2678	IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 483.	3.8	31
2679	S100A8 may govern hyperinflammation in severe COVID-19. <i>FASEB Journal</i> , 2021, 35, e21798.	0.2	15
2680	Relationship of D-dimer and prediction of pulmonary embolism in hospitalized COVID-19 patients: a multicenter study. <i>Future Microbiology</i> , 2021, 16, 863-870.	1.0	6
2681	Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study. <i>Arthritis Care and Research</i> , 2021, 73, 1322-1331.	1.5	12
2682	Potential Immunomodulatory Properties of Biologically Active Components of Spices Against SARS-CoV-2 and Pan Î ² -Coronaviruses. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 729622.	1.8	11
2683	Epicardial fat inflammation response to COVID-19 therapies. <i>Obesity</i> , 2021, 29, 1427-1433.	1.5	13
2684	The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). <i>Leukemia</i> , 2021, 35, 2917-2923.	3.3	16
2685	Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients. <i>Cancers</i> , 2021, 13, 4312.	1.7	11
2686	Non-toxic polymer nanovectors for improved delivery of dexamethasone. <i>Scientific Reports</i> , 2021, 11, 17263.	1.6	3
2687	A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance. <i>ELife</i> , 2021, 10, .	2.8	23
2688	Combining IL-6 and SARS-CoV-2 RNAemia-based risk stratification for fatal outcomes of COVID-19. <i>PLoS ONE</i> , 2021, 16, e0256022.	1.1	12
2689	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 924-932.	5.2	218
2690	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 777-789.	13.9	712
2691	Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2. <i>Antiviral Research</i> , 2021, 193, 105137.	1.9	32
2692	Use of Corticosteroid in Persistent Post-COVID-19 Interstitial Lung Disease. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1599-1599.	1.5	2
2693	Corticosteroid Administration and Impaired Glycemic Control in Mechanically Ventilated COVID-19 Patients. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2022, 26, 32-40.	0.4	4
2694	Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust. <i>Leukemia and Lymphoma</i> , 2021, , 1-4.	0.6	1

#	ARTICLE	IF	CITATIONS
2695	Lectin from <i>Triticum vulgare</i> (WGA) Inhibits Infection with SARS-CoV-2 and Its Variants of Concern Alpha and Beta. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10205.	1.8	17
2697	Bacterial and fungal growth in sputum cultures from 165 COVID-19 pneumonia patients requiring intubation: evidence for antimicrobial resistance development and analysis of risk factors. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021, 20, 69.	1.7	11
2698	TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2. <i>Cellular Signalling</i> , 2021, 85, 110064.	1.7	15
2699	Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission. <i>Journal of Medical Virology</i> , 2022, 94, 205-210.	2.5	23
2700	Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis. <i>Advances in Medical Sciences</i> , 2021, 66, 262-268.	0.9	3
2701	Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019. <i>Respiratory Investigation</i> , 2021, 59, 596-601.	0.9	15
2702	Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients. <i>Journal of Personalized Medicine</i> , 2021, 11, 891.	1.1	5
2704	Mesenchymal stem cell therapy for severe COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 339.	7.1	58
2705	<i>Aspergillus</i> Test Profiles and Mortality in Critically Ill COVID-19 Patients. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0122921.	1.8	50
2706	Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases. <i>Med</i> , 2021, 2, 1093-1109.e6.	2.2	6
2707	CORonavirus-19 mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR) multicentric prospective randomized clinical trial. <i>International Immunopharmacology</i> , 2021, 98, 107874.	1.7	7
2708	A systematic review on the effects of Echinacea supplementation on cytokine levels: Is there a role in COVID-19?. <i>Metabolism Open</i> , 2021, 11, 100115.	1.4	15
2709	SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response. <i>MBio</i> , 2021, 12, e0233521.	1.8	57
2710	SARS-CoV-2 Infection in the Immunodeficient Host: Necessary and Dispensable Immune Pathways. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3237-3248.	2.0	4
2711	Herpes Simplex Virus Re-Activation in Patients with SARS-CoV-2 Pneumonia: A Prospective, Observational Study. <i>Microorganisms</i> , 2021, 9, 1896.	1.6	28
2712	Prolonged SARS-CoV-2 Viral Shedding in Patients with COVID-19 was Associated with Delayed Initiation of Arbidol Treatment and Consulting Doctor Later: A Retrospective Cohort Study. <i>Current Medical Science</i> , 2021, 41, 1096-1104.	0.7	8
2713	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 209-221.	4.6	233
2714	Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study. <i>Journal of Infection and Public Health</i> , 2021, 14, 1247-1253.	1.9	10

#	ARTICLE	IF	CITATIONS
2715	Strongyloidiasis: An Important Coinfection in the COVID-19 Era. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 1134-1135.	0.6	4
2716	Guidance for a New Clinical Challenge. <i>Anesthesia and Analgesia</i> , 2021, 133, 873-875.	1.1	0
2717	COVID-19 Outbreak Management and Vaccination Strategy in The United States of America. <i>Epidemiologia</i> , 2021, 2, 426-453.	1.1	1
2718	Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. <i>Science Immunology</i> , 2021, 6, eabd0205.	5.6	26
2719	The RECOVERY trial platform: a milestone in the development and execution of treatment evaluation during an epidemic. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 443-446.	1.1	3
2720	Early Detection of Symptom Exacerbation in Patients With SARS-CoV-2 Infection Using the Fitbit Charge 3 (DEXTERITY): Pilot Evaluation. <i>JMIR Formative Research</i> , 2021, 5, e30819.	0.7	8
2721	Clinical outcome of patients with COVID-19 Pneumonia treated with corticosteroids and colchicine in Colombia. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021, 20, 66.	1.7	17
2722	Clinical characteristics and in-hospital mortality of patients with COVID-19 in Chile: A prospective cohort study. <i>International Journal of Clinical Practice</i> , 2021, 75, e14919.	0.8	5
2723	A descriptive study of the surge response and outcomes of ICU patients with COVID-19 during first wave in Nordic countries. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, 66, 56-64.	0.7	14
2724	Comparing the clinical characteristics and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review and meta-analysis. <i>Infection</i> , 2022, 50, 43-56.	2.3	53
2725	Does Vitamin D have a role to play in Covid-19 in the dexamethasone era?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102237.	1.8	2
2726	Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity?. <i>Infectious Disease Reports</i> , 2021, 13, 855-864.	1.5	9
2727	Comparison of the impact of chronic corticosteroid therapy on critical care outcomes of COVID-19 patients with and without history of chronic liver disease. <i>Scientific Reports</i> , 2021, 11, 19245.	1.6	4
2728	Defending Antiviral Cationic Amphiphilic Drugs That May Cause Drug-Induced Phospholipidosis. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4125-4130.	2.5	14
2729	Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. <i>Lancet</i> , The, 2021, 398, 843-855.	6.3	204
2730	Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. <i>The Lancet Global Health</i> , 2021, 9, e1216-e1225.	2.9	131
2731	Public health concerns and increased risk of severe COVID-19 disease through androgen use. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, Publish Ahead of Print, 625-629.	1.2	3
2732	Challenges and Lessons Learned From COVID-19 Trials: Should We Be Doing Clinical Trials Differently?. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1353-1364.	0.8	34

#	ARTICLE	IF	CITATIONS
2733	Clinical Characteristics of Patients with Coronavirus Disease (COVID-19): Preliminary Baseline Report of Japan COVID-19 Task Force, a Nationwide Consortium to Investigate Host Genetics of COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 113, 74-81.	1.5	24
2734	The BMJ Awards 2021: Research paper of the year. <i>BMJ, The</i> , 2021, 374, n2350.	3.0	1
2735	The BMJ Awards 2021: "Landmark" study on dexamethasone wins paper of the year. <i>BMJ, The</i> , 2021, 374, n2389.	3.0	0
2736	Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. <i>Kidney International Reports</i> , 2021, 6, 2305-2315.	0.4	26
2737	Potential drug development and therapeutic approaches for clinical intervention in COVID-19. <i>Biorganic Chemistry</i> , 2021, 114, 105016.	2.0	11
2738	The use of inhaled corticosteroids in early-stage COVID-19. <i>Lancet, The</i> , 2021, 398, 818-819.	6.3	3
2739	Perioperative use of intra-articular steroids during the COVID-19 pandemic. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2021, , 1.	0.6	0
2740	Treatment Options for COVID-19-Related Guillain-Barré Syndrome. <i>Neurologist</i> , 2021, 26, 196-224.	0.4	7
2741	The impact of specific cytokine directed treatment on severe COVID-19. <i>Leukemia</i> , 2021, 35, 3613-3615.	3.3	3
2742	Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 796.e1-796.e7.	0.6	42
2743	Peripheral nerve stimulation and immunity: the expanding opportunities for providing mechanistic insight and therapeutic intervention. <i>International Immunology</i> , 2022, 34, 107-118.	1.8	22
2744	Interleukin-1RA Mitigates SARS-CoV-2-Induced Inflammatory Lung Vascular Leakage and Mortality in Humanized K18-hACE-2 Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2773-2785.	1.1	20
2745	Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry. <i>Molecular Medicine</i> , 2021, 27, 105.	1.9	18
2746	Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis. <i>EClinicalMedicine</i> , 2021, 40, 101125.	3.2	53
2747	COVID-19: Pulmonary and Extra Pulmonary Manifestations. <i>Frontiers in Public Health</i> , 2021, 9, 711616.	1.3	75
2748	Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	39
2749	In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. <i>PLoS Pathogens</i> , 2021, 17, e1009929.	2.1	108
2751	The FDA's latest move to expand eligibility for oncology trials "a double-edged sword?". <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 745-746.	12.5	1

#	ARTICLE	IF	CITATIONS
2752	Current status of therapeutic alternatives for COVID-19: A narrative review. <i>Infezioni in Medicina</i> , 2021, 29, 312-327.	0.7	8
2753	Network-based analysis revealed significant interactions between risk genes of severe COVID-19 and host genes interacted with SARS-CoV-2 proteins. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	4
2754	Effect of mortality from COVID-19 on inpatient outcomes. <i>Journal of Medical Virology</i> , 2022, 94, 318-326.	2.5	9
2755	Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2022, 28, 93-112.	0.7	15
2756	The Binary Model of Chronic Diseases Applied to COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 716084.	2.2	6
2757	Aspirin Is Related to Worse Clinical Outcomes of COVID-19. <i>Medicina (Lithuania)</i> , 2021, 57, 931.	0.8	9
2758	Outpatient Management of COVID-19 With Monoclonal Antibody Therapy in a Young Renal Transplant Patient. <i>Cureus</i> , 2021, 13, e17672.	0.2	2
2759	Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute Cardiovascular Care (ACVC), in collaboration with the European Heart Rhythm Association (FHRA). <i>Cardiovascular Research</i> , 2021, 117, 2705-2729.	1.8	95
2760	Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome. <i>European Respiratory Review</i> , 2021, 30, 210059.	3.0	16
2761	Plasmapheresis: a feasible choice for bullous pemphigoid patients infected with SARS-CoV-2. <i>International Journal of Dermatology</i> , 2022, 61, 252-256.	0.5	0
2762	Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an "old" strategy. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000867.	1.2	17
2763	Learning from the global response to COVID-19 to accelerate innovation in mental health trials. <i>World Psychiatry</i> , 2021, 20, 358-359.	4.8	9
2764	Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection. <i>Respiratory Care</i> , 2021, 66, 1805-1814.	0.8	8
2767	Steroids in severe COVID-19 patients: A retrospective analysis on the first pandemics in Lombardy. <i>Emergency Care Journal</i> , 2021, 17, .	0.2	1
2768	The Use of Telemonitoring in Managing the COVID-19 Pandemic: Pilot Implementation Study. <i>JMIR Formative Research</i> , 2021, 5, e20131.	0.7	14
2769	Protein requirements for critically ill ventilator-dependent patients with COVID-19. <i>Nutrition in Clinical Practice</i> , 2021, 36, 984-992.	1.1	8
2770	A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis. <i>Current Issues in Molecular Biology</i> , 2021, 43, 1212-1225.	1.0	9
2771	COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control. <i>International Journal of Infectious Diseases</i> , 2021, 112, 300-317.	1.5	21

#	ARTICLE	IF	CITATIONS
2773	Clinical aspects of SARS-CoV-2 infection and vitamin D. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 287-291.	2.6	9
2774	Risk factors associated with bloodstream infections among critically ill patients with COVID-19. <i>Journal of Infection</i> , 2021, 83, e1-e3.	1.7	3
2776	The Paradox of Choice in Hemostatic Resuscitation: Still More Options Than Evidence, But a Good Start. <i>Transfusion Medicine Reviews</i> , 2021, 35, 71-72.	0.9	0
2777	COVID-19 in Patients with Active Tuberculosis. <i>Diagnostics</i> , 2021, 11, 1768.	1.3	5
2778	Clinical and operational impact of rapid point-of-care SARS-CoV-2 detection in an emergency department. <i>American Journal of Emergency Medicine</i> , 2021, 50, 713-718.	0.7	9
2779	Women's Lives Matter—The Critical Need for Women to Prioritize Optimal Physical Activity to Reduce COVID-19 Illness Risk and Severity. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10271.	1.2	1
2780	Effects of different corticosteroid therapy on severe COVID-19 patients: a meta-analysis of randomized controlled trials. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 79-89.	1.0	7
2781	Use of corticosteroids in COVID-19 patients vs. acute respiratory distress syndrome of other etiologies: Are there any differences?. <i>Qatar Medical Journal</i> , 2021, 2021, 30.	0.2	0
2783	The Impact of COVID-19 on Kidney Transplant Recipients in Pre-Vaccination and Delta Strain Era: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4533.	1.0	9
2784	Secondary Bacterial Pneumonias and Bloodstream Infections in Patients Hospitalized with COVID-19. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1584-1587.	1.5	10
2785	Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1349-1351.	5.2	28
2786	High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern. <i>Frontiers in Medicine</i> , 2021, 8, 735853.	1.2	7
2787	Uric acid as a prognostic factor and critical marker of COVID-19. <i>Scientific Reports</i> , 2021, 11, 17791.	1.6	18
2788	Declining Mortality Rate of Hospitalised Patients in the Second Wave of the COVID-19 Epidemics in Italy: Risk Factors and the Age-Specific Patterns. <i>Life</i> , 2021, 11, 979.	1.1	10
2789	The role of endotheliitis in COVID-19: Real-world experience of 11190 patients and literature review for a pathophysiological map to clinical categorisation. <i>International Journal of Clinical Practice</i> , 2021, 75, e14843.	0.8	7
2790	Early versus late awake prone positioning in non-intubated patients with COVID-19. <i>Critical Care</i> , 2021, 25, 340.	2.5	39
2791	Systemic Human Neutrophil Lipocalin Associates with Severe Acute Kidney Injury in SARS-CoV-2 Pneumonia. <i>Journal of Clinical Medicine</i> , 2021, 10, 4144.	1.0	3
2792	Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 515-523.	4.5	6

#	ARTICLE	IF	CITATIONS
2793	COVID-19 and pregnancy: Lessons from 2020. <i>Early Human Development</i> , 2021, 162, 105460.	0.8	6
2794	Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells. <i>PLoS Pathogens</i> , 2021, 17, e1009840.	2.1	17
2795	Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID). <i>International Journal of General Medicine</i> , 2021, Volume 14, 5517-5526.	0.8	25
2797	Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e491-e498.	2.9	34
2798	Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0257376.	1.1	6
2799	Steroid resistance and rebound phenomena in patients with COVID-19. <i>Respiratory Investigation</i> , 2021, 59, 608-613.	0.9	12
2800	Identification of Immune Activation Markers in the Early Onset of COVID-19 Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 651484.	1.8	12
2801	BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review. <i>Clinical Immunology</i> , 2021, 230, 108816.	1.4	17
2803	Previous Vitamin D Supplementation and Morbidity and Mortality Outcomes in People Hospitalised for COVID19: A Cross-Sectional Study. <i>Frontiers in Public Health</i> , 2021, 9, 758347.	1.3	8
2804	Covid-19 infection in pregnant women in Dubai: a case-control study. <i>BMC Pregnancy and Childbirth</i> , 2021, 21, 658.	0.9	10
2805	Extracorporeal Membrane Oxygenation for Secondary Organizing Pneumonia after Severe SARS-CoV-2 Infection: A Case Report. <i>Medicina (Lithuania)</i> , 2021, 57, 1013.	0.8	0
2806	An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19. <i>Cellular Immunology</i> , 2021, 367, 104398.	1.4	5
2807	Isolation of <i>Rhizopus microsporus</i> and <i>Lichtheimia corymbifera</i> from tracheal aspirates of two immunocompetent critically ill patients with COVID-19. <i>Medical Mycology Case Reports</i> , 2021, 33, 32-37.	0.7	4
2808	Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: A propensity score-matched analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2814-2824.	1.9	27
2809	Development and validation of a simple web-based tool for early prediction of COVID-19-associated death in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 610-625.	2.6	16
2810	Bronchoscopy During Coronavirus Disease 2019 Pandemic: A Bronchoscopist's Perspective. , 2021, 3, e0522.		4
2811	Clinical Subphenotypes in Critically Ill Patients With COVID-19. <i>Chest</i> , 2021, 160, 795-796.	0.4	3
2812	COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 584-595.	0.6	10

#	ARTICLE	IF	CITATIONS
2813	Case Report: Successful Treatment of Five Critically Ill Coronavirus Disease 2019 Patients Using Combination Therapy With Etoposide and Corticosteroids. <i>Frontiers in Medicine</i> , 2021, 8, 718641.	1.2	4
2814	Caution with the use of dexamethasone in patients with COVID-19 in its initial phases. <i>Revista Colombiana de Medicina y Salud Pública</i> , 2021, 221, 592-595.	0.3	5
2815	Extreme immunotherapy: emergency immunology to defeat pandemics. <i>Molecular Medicine</i> , 2021, 27, 112.	1.9	0
2816	Coronavirus disease 2019 and renal transplantation. <i>World Journal of Clinical Cases</i> , 2021, 9, 7986-7997.	0.3	3
2817	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. <i>PLoS Pathogens</i> , 2021, 17, e1009804.	2.1	39
2818	Is asthma associated with COVID-19 infection? A UK Biobank analysis. <i>ERJ Open Research</i> , 2021, 7, 00309-2021.	1.1	8
2819	COVID-19 Critical Illness: A Data-Driven Review. <i>Annual Review of Medicine</i> , 2022, 73, 95-111.	5.0	20
2820	Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls. <i>Rheumatology International</i> , 2022, 42, 457-467.	1.5	4
2821	SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses. <i>Future Microbiology</i> , 2021, 16, 1105-1133.	1.0	11
2822	Fewer COVID-19-associated strokes and reduced severity during the second COVID-19 wave: The Madrid Stroke Network. <i>European Journal of Neurology</i> , 2021, 28, 4078-4089.	1.7	7
2823	Adaptive Trials in Cardiology: Some Considerations and Examples. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1428-1437.	0.8	2
2824	Immune Responses against SARS-CoV-2: Questions and Experiences. <i>Biomedicines</i> , 2021, 9, 1342.	1.4	10
2825	The Effect of Anakinra in Hospitalized Patients with COVID-19: An Updated Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4462.	1.0	16
2826	COVID-19, Suffering and Palliative Care: A Review. <i>American Journal of Hospice and Palliative Medicine</i> , 2022, 39, 986-995.	0.8	9
2827	Coronavirus disease 2019 in solid organ transplant recipients in the setting of proactive screening and contact tracing of Qatar. <i>Qatar Medical Journal</i> , 2021, 2021, 23.	0.2	2
2829	High-Dose Methylprednisolone Pulses for 3 Days vs. Low-Dose Dexamethasone for 10 Days in Severe, Non-Critical COVID-19: A Retrospective Propensity Score Matched Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4465.	1.0	7
2830	GAPDH, Interferon β , and Nitric Oxide: Inhibitors of Coronaviruses. <i>Frontiers in Virology</i> , 2021, 1, .	0.7	5
2831	Increased Incidence of Ventilator-Acquired Pneumonia in Coronavirus Disease 2019 Patients: A Multicentric Cohort Study*. <i>Critical Care Medicine</i> , 2022, 50, 449-459.	0.4	37

#	ARTICLE	IF	CITATIONS
2832	Role of total lung stress on the progression of early COVID-19 pneumonia. <i>Intensive Care Medicine</i> , 2021, 47, 1130-1139.	3.9	51
2833	Protocol and statistical analysis plan for the phase 3 randomised controlled Treatment of Invasively Ventilated Adults with Early Activity and Mobilisation (TEAM III) trial. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2021, 23, 262-272.	0.0	1
2834	COVID-19 and Cancer. <i>JAMA Oncology</i> , 2021, 7, 1882.	3.4	42
2835	The immune response to SARS-CoV-2 and COVID-19 immunopathology â€“ Current perspectives. <i>Pulmonology</i> , 2021, 27, 423-437.	1.0	118
2836	Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial. <i>Journal of Medical Virology</i> , 2022, 94, 263-271.	2.5	45
2837	Antibiotic Use and Bacterial Infection among Inpatients in the First Wave of COVID-19: a Retrospective Cohort Study of 64,691 Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0134121.	1.4	37
2838	Microbial Metabolites: The Emerging Hotspot of Antiviral Compounds as Potential Candidates to Avert Viral Pandemic Alike COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 732256.	1.6	15
2839	Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 989-998.	5.2	79
2840	Willingness to Treat with Therapies of Unknown Effectiveness in Severe COVID-19: A Survey of Intensivist Physicians. <i>Annals of the American Thoracic Society</i> , 2021, , .	1.5	3
2841	Impact of SARS-CoV-2 Infection (COVID-19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1358-1367.	2.3	36
2842	Predictors of Mortality in COVID-19 Patients in Southern California â€“ Retrospective Multicenter Study. <i>Cureus</i> , 2021, 13, e18137.	0.2	1
2843	Impact of COVID-19 on the Endocrine System: A Mini-review. <i>Endocrinology</i> , 2022, 163, .	1.4	63
2844	The role and place of glucocorticosteroids in treatment of COVID-19 pneumonia without hypoxemia. <i>Meditinskiy Sovet</i> , 2021, , 162-172.	0.1	9
2845	Predisposing factors of rhino-orbital-cerebral mucormycosis in patients with COVID 19 infection. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2021, , 1-7.	0.3	7
2846	Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?. <i>International Immunopharmacology</i> , 2021, 101, 108200.	1.7	20
2847	Systemic inflammation in COVID-19 patients may induce various types of venous and arterial thrombosis: A systematic review. <i>Scandinavian Journal of Immunology</i> , 2021, 94, e13097.	1.3	24
2848	Focused Management of Patients With Severe Acute Brain Injury and ARDS. <i>Chest</i> , 2022, 161, 140-151.	0.4	13
2849	Is glucose-6-phosphatase dehydrogenase deficiency associated with severe outcomes in hospitalized COVID-19 patients?. <i>Scientific Reports</i> , 2021, 11, 19213.	1.6	5

#	ARTICLE	IF	CITATIONS
2850	Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis. <i>Pharmacotherapy</i> , 2021, 41, 884-906.	1.2	27
2851	Clinical Course and Outcome of Patients with SARS-CoV-2 Alpha Variant Infection Compared to Patients with SARS-CoV-2 Wild-Type Infection Admitted to the ICU. <i>Microorganisms</i> , 2021, 9, 1944.	1.6	8
2852	Clinical characteristics of COVID-19 in Osaka, Japan: Comparison of the first–third waves with the fourth wave. <i>Respiratory Investigation</i> , 2021, 59, 810-818.	0.9	16
2854	eARDS: A multi-center validation of an interpretable machine learning algorithm of early onset Acute Respiratory Distress Syndrome (ARDS) among critically ill adults with COVID-19. <i>PLoS ONE</i> , 2021, 16, e0257056.	1.1	28
2855	Increased Autotaxin Levels in Severe COVID-19, Correlating with IL-6 Levels, Endothelial Dysfunction Biomarkers, and Impaired Functions of Dendritic Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10006.	1.8	15
2856	Immunotherapy Summary for Cytokine Storm in COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 731847.	1.6	9
2857	Corticosteroid Protection Against COVID-19: Begin with the Nose. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3941-3943.	2.0	5
2858	Multisystem Inflammatory Syndrome in Children. <i>Journal of Emergency Medicine</i> , 2022, 62, 28-37.	0.3	22
2859	Searching for scientific evidence in a pandemic: An overview of TREC-COVID. <i>Journal of Biomedical Informatics</i> , 2021, 121, 103865.	2.5	11
2860	Effectiveness and safety of ivermectin in the treatment of COVID-19: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e050532.	0.8	4
2861	Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease. <i>Scandinavian Journal of Immunology</i> , 2021, 94, e13101.	1.3	16
2862	Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort. <i>Frontiers in Immunology</i> , 2021, 12, 700921.	2.2	26
2863	Clinical characteristics, management practices, and outcomes among lung transplant patients with COVID-19. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 936-947.	0.3	19
2865	Will Auranofin Become a Golden New Treatment Against COVID-19?. <i>Frontiers in Immunology</i> , 2021, 12, 683694.	2.2	12
2866	COVID-19: an “extraterrestrial” disease?. <i>International Journal of Infectious Diseases</i> , 2021, 110, 155-159.	1.5	3
2867	<sc><i>Mycobacterium avium</i></sc> infection associated with sterile polyarthritis in a dog. <i>Journal of Small Animal Practice</i> , 2022, 63, 154-158.	0.5	1
2869	Management of Patients With Glucocorticoid-Related Diseases and COVID-19. <i>Frontiers in Endocrinology</i> , 2021, 12, 705214.	1.5	15
2870	Virus-induced senescence is a driver and therapeutic target in COVID-19. <i>Nature</i> , 2021, 599, 283-289.	13.7	195

#	ARTICLE	IF	CITATIONS
2872	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Public Health</i> , 2021, 9, 729559.	1.3	27
2873	Antiviral, immunomodulatory, and anticoagulant effects of quercetin and its derivatives: Potential role in prevention and management of COVID-19. <i>Journal of Pharmaceutical Analysis</i> , 2022, 12, 29-34.	2.4	34
2874	Anti-inflammatory activity of lefamulin versus azithromycin and dexamethasone in vivo and in vitro in a lipopolysaccharide-induced lung neutrophilia mouse model. <i>PLoS ONE</i> , 2021, 16, e0237659.	1.1	3
2875	Lower blood pH as a strong prognostic factor for fatal outcomes in critically ill COVID-19 patients at an intensive care unit: A multivariable analysis. <i>PLoS ONE</i> , 2021, 16, e0258018.	1.1	7
2876	The “Black Fungus” in India: The Emerging Syndemic of COVID-19-Associated Mucormycosis. <i>Annals of Internal Medicine</i> , 2021, 174, 1301-1302.	2.0	33
2877	The use of Tofacitinib in the Management of COVID-19 Pneumonia. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 1087-1088.	0.3	0
2878	Hyaluronic Acid-Dexamethasone Nanoparticles for Local Adjunct Therapy of Lung Inflammation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10480.	1.8	6
2879	Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 586-594.	5.5	145
2881	Latent Class Analysis Reveals COVID-19-related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1274-1285.	2.5	121
2882	Society for Maternal-Fetal Medicine Special Statement: COVID-19 research in pregnancy: progress and potential. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, B19-B31.	0.7	14
2883	Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1250-1261.	2.8	69
2884	Interplay between endocrinology, metabolism and COVID-19 infection. <i>Clinical Medicine</i> , 2021, 21, e499-e504.	0.8	9
2885	Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study. <i>BMC Health Services Research</i> , 2021, 21, 986.	0.9	13
2886	Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. <i>Lancet Rheumatology</i> , 2021, 3, e638-e647.	2.2	30
2887	SARS-CoV-2 epidemiology, prevention, risk factors, evaluation, diagnosis, management and vaccines. <i>Osteopathic Family Physician</i> , 2021, 13, .	0.2	0
2888	Solumedrol Treatment for Severe Sepsis in Humans with a Blunted Adrenocorticotrophic Hormone-Cortisol Response: A Prospective Randomized Double-Blind Placebo-Controlled Pilot Clinical Trial. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 693-697.	1.3	3
2889	Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study. <i>PLoS ONE</i> , 2021, 16, e0256903.	1.1	8
2890	Monoclonal antibodies as antibacterial therapies: thinking outside of the box. <i>Lancet Infectious Diseases</i> , 2021, 21, 1201-1202.	4.6	7

#	ARTICLE	IF	CITATIONS
2891	Considering opportunistic parasitic infections in COVID-19 policies and recommendations. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 1345-1347.	0.7	5
2892	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. Wellcome Open Research, 2021, 6, 71.	0.9	4
2893	Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration: protocol for an exploratory, multicentre, open-label, randomised controlled trial (CAME COVID-19 study). BMJ Open, 2021, 11, e053325.	0.8	4
2894	Management of acute kidney injury associated with Covid-19. Current Opinion in Nephrology and Hypertension, 2021, Publish Ahead of Print, 563-570.	1.0	3
2895	Severe COVID-19 pneumonia complicated by cardiomyopathy and a small anterior pneumothorax. BMJ Case Reports, 2021, 14, e245900.	0.2	0
2896	Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine, 2021, 9, 1407-1418.	5.2	501
2897	Calming the cytokine storm in COVID-19. Nature Medicine, 2021, 27, 1674-1675.	15.2	97
2898	The Immunology of SARS-CoV-2 Infection and Vaccines in Solid Organ Transplant Recipients. Viruses, 2021, 13, 1879.	1.5	16
2899	Understanding the Potential Impact of Different Drug Properties on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission and Disease Burden: A Modelling Analysis. Clinical Infectious Diseases, 2022, 75, e224-e233.	2.9	10
2900	Circadian Rhythms, Disease and Chronotherapy. Journal of Biological Rhythms, 2021, 36, 503-531.	1.4	55
2901	Cytometric analysis of patients with COVID-19: what is changed in the second wave?. Journal of Translational Medicine, 2021, 19, 403.	1.8	5
2902	A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. IScience, 2021, 24, 103040.	1.9	19
2903	Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis. International Journal of Infectious Diseases, 2021, 110, 320-329.	1.5	13
2904	Comparison of baseline characteristics, treatment and clinical outcomes of critically ill COVID-19 patients admitted in the first and second waves in Australia. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2021, 23, 308-319.	0.0	5
2905	Combination therapy for COVID-19 in hemodialysis patients: Pharmacological treatments and renal replacement therapy based on the severity. Therapeutic Apheresis and Dialysis, 2022, 26, 475-477.	0.4	2
2906	A hitchhiker's guide through the COVID-19 galaxy. Clinical Immunology, 2021, 232, 108849.	1.4	3
2907	Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. Pharmacoeconomics, 2021, 39, 1201-1208.	1.7	8
2908	Do high-dose corticosteroids improve outcomes in hospitalized COVID-19 patients?. Journal of Medical Virology, 2022, 94, 372-379.	2.5	16

#	ARTICLE	IF	CITATIONS
2909	Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19. <i>Pharmaceuticals</i> , 2021, 14, 955.	1.7	12
2910	Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, 114, 721-732.	0.2	28
2912	COVID-19-Associated Subacute Thyroiditis: Evidence-Based Data From a Systematic Review. <i>Frontiers in Endocrinology</i> , 2021, 12, 707726.	1.5	50
2913	An internally validated prediction model for critical COVID-19 infection and intensive care unit admission in symptomatic pregnant women. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 403.e1-403.e13.	0.7	23
2914	Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 708848.	2.2	7
2915	Therapeutic Approaches in Modulating the Inflammatory and Immunological Response in Patients With Sepsis, Acute Respiratory Distress Syndrome, and Pancreatitis: An Expert Opinion Review. <i>Cureus</i> , 2021, 13, e18393.	0.2	7
2916	Successful treatment of COVID-19-related acute respiratory distress syndrome with a rare blood type: A case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04859.	0.2	0
2917	Defining COVID-19-associated hyperinflammatory syndrome in specific populations. <i>Lancet Rheumatology, The</i> , 2021, 3, e609-e611.	2.2	1
2918	Restricted access to the NHS during the COVID-19 pandemic: Is it time to move away from the rationed clinical response?. <i>Lancet Regional Health - Europe, The</i> , 2021, 8, 100201.	3.0	10
2919	Antenatal corticosteroids in COVID-19 perspective. <i>World Journal of Experimental Medicine</i> , 2021, 11, 37-43.	0.9	1
2920	Self-sustaining IL-8 loops drive a prothrombotic neutrophil phenotype in severe COVID-19. <i>JCI Insight</i> , 2021, 6, .	2.3	71
2921	Understanding the Link Between Obesity and Severe COVID-19 Outcomes: Causal Mediation by Systemic Inflammatory Response. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e698-e707.	1.8	21
2922	Comparison of pulse-dose and high-dose corticosteroids with no corticosteroid treatment for COVID-19 pneumonia in the intensive care unit. <i>Journal of Medical Virology</i> , 2022, 94, 349-356.	2.5	18
2923	Ruxolitinib en COVID-19 grave. <i>Revista De La Facultad De Ciencias Medicas De Cordoba</i> , 2021, 78, 294-302.	0.1	11
2924	An Intriguing Case of Multisystem Inflammatory Syndrome in an Adult Patient with Remote Infection with COVID-19 and Acute Chlamydia. <i>Case Reports in Infectious Diseases</i> , 2021, 2021, 1-7.	0.2	0
2925	Comment on "Predictive factors for a severe course of COVID-19 infection in Myasthenia gravis patients with an overall impact on myasthenic status and survival" by Jakub Kováčik et al. <i>European Journal of Neurology</i> , 2022, 29, e5-e6.	1.7	2
2926	Assessment of Alveolar Macrophage Dysfunction Using an in vitro Model of Acute Respiratory Distress Syndrome. <i>Frontiers in Medicine</i> , 2021, 8, 737859.	1.2	4
2928	The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience. <i>European Journal of Cancer</i> , 2021, 154, 30-34.	1.3	45

#	ARTICLE	IF	CITATIONS
2929	Therapeutic potential of melatonin and melatonergic drugs on K18â€‹i>hACE2</i> mice infected with SARSâ€‹CoVâ€‹2. <i>Journal of Pineal Research</i> , 2022, 72, e12772.	3.4	20
2930	Inpatient use of metformin and acarbose is associated with reduced mortality of COVIDâ€‹19 patients with type 2 diabetes mellitus. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00301.	1.0	15
2931	SARSâ€‹CoVâ€‹2 vaccination in solidâ€‹organ transplant recipients: What the clinician needs to know. <i>Transplant International</i> , 2021, 34, 1776-1788.	0.8	32
2932	Emerging potential mechanisms and predispositions to the neurological manifestations of COVID-19. <i>Journal of the Neurological Sciences</i> , 2021, 428, 117608.	0.3	16
2933	Fortyâ€‹fifth ASPEN Presidential Address: Research in a pandemicâ€‹”Why, what, how?. <i>Journal of Parenteral and Enteral Nutrition</i> , 2021, 45, 1690-1702.	1.3	1
2934	Emerging and Established Histological Techniques for the Analysis of Thrombosis in COVID-19 Lungs. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 745906.	1.1	1
2935	Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses. <i>JCI Insight</i> , 2021, 6, .	2.3	26
2936	Eosinophil-mediated lung inflammation associated with elevated natural killer T cell response in COVID-19 patients. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 201-209.	0.7	6
2937	Management of COVID-19 Patients in the Emergency Department. <i>Journal of Personalized Medicine</i> , 2021, 11, 961.	1.1	9
2938	Identifying molecular insight of synergistic complexities for SARS-CoV-2 infection with pre-existing type 2 diabetes. <i>Computers in Biology and Medicine</i> , 2021, 136, 104668.	3.9	12
2939	Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	2
2940	Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. <i>World Journal of Gastroenterology</i> , 2021, 27, 5520-5535.	1.4	10
2941	The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection. <i>European Respiratory Journal</i> , 2022, 59, 2100769.	3.1	17
2942	Possibility of deterioration of respiratory status when steroids precede antiviral drugs in patients with COVID-19 pneumonia: A retrospective study. <i>PLoS ONE</i> , 2021, 16, e0256977.	1.1	14
2943	Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. <i>Cell Metabolism</i> , 2021, 33, 2174-2188.e5.	7.2	127
2944	Seroconversion in septic ICU patients presenting with COVID-19: necessary but not sufficient. <i>Archives of Medical Research</i> , 2021, 52, 850-857.	1.5	1
2945	COVID outcome prediction in the emergency department (COPE): using retrospective Dutch hospital data to develop simple and valid models for predicting mortality and need for intensive care unit admission in patients who present at the emergency department with suspected COVID-19. <i>BMJ Open</i> , 2021, 11, e051468.	0.8	12
2946	The rise in cases of mucormycosis, candidiasis and aspergillosis amidst COVID19. <i>Fungal Biology Reviews</i> , 2021, 38, 67-91.	1.9	22

#	ARTICLE	IF	CITATIONS
2947	Use of CytoSorb therapy to treat critically ill coronavirus disease 2019 patients: a case series. <i>Journal of Medical Case Reports</i> , 2021, 15, 476.	0.4	4
2948	Evaluation of the efficacy of anticoagulation therapy in reducing mortality in a nationwide cohort of hospitalized patients with coronavirus disease in Japan. <i>International Journal of Infectious Diseases</i> , 2021, 112, 111-116.	1.5	4
2949	Beyond the Extra Respiration of Phagocytosis: NADPH Oxidase 2 in Adaptive Immunity and Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 733918.	2.2	20
2950	Variation in Clinical Characteristics, Outcomes, and Mortality of Hospitalized Patients with COVID-19 during the Second Wave of the Pandemic: A Single-Center Experience. <i>Journal of Investigative Medicine</i> , 2021, 69, 1479-1482.	0.7	3
2951	Scientific evidence in the COVID-19 treatment: A comprehensive review. <i>World Journal of Virology</i> , 2021, 10, 217-228.	1.3	6
2952	Risk factors for invasive aspergillosis in ICU patients with COVID-19: current insights and new key elements. <i>Annals of Intensive Care</i> , 2021, 11, 136.	2.2	31
2953	ERS International Congress 2020 virtual: highlights from the Respiratory Intensive Care Assembly. <i>ERJ Open Research</i> , 2021, 7, 00214-2021.	1.1	0
2954	Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital. <i>World Journal of Critical Care Medicine</i> , 2021, 10, 244-259.	0.8	2
2955	A symptomatic near-term pregnant woman recovered from SARS-CoV-2 infection. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2021, 60, 945-948.	0.5	8
2956	Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 4019.	1.0	11
2957	Prospective Study of Policies and Use of Therapies for COVID-19 Amongst Australian Health Services during 2020. <i>Internal Medicine Journal</i> , 2021, , .	0.5	1
2958	Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis. <i>Scientific Reports</i> , 2021, 11, 17787.	1.6	16
2960	SGLT2-inhibition reverts urinary peptide changes associated with severe COVID-19: An in-silico proof-of-principle of proteomics-based drug repurposing. <i>Proteomics</i> , 2021, 21, e2100160.	1.3	3
2962	External validation of the 4C mortality score among COVID-19 patients admitted to hospital in Ontario, Canada: a retrospective study. <i>Scientific Reports</i> , 2021, 11, 18638.	1.6	25
2963	Association Between Caseload Surge and COVID-19 Survival in 558 U.S. Hospitals, March to August 2020. <i>Annals of Internal Medicine</i> , 2021, 174, 1240-1251.	2.0	133
2964	Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study. <i>Scientific Reports</i> , 2021, 11, 17648.	1.6	28
2966	Prompt Reduction in CRP, IL-6, IFN- γ , IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 734838.	1.2	13
2967	Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: A case series. <i>Med</i> , 2021, 2, 1163-1170.e2.	2.2	31

#	ARTICLE	IF	CITATIONS
2968	Tofacitinib Associated with Reduced Intubation Rates in the Management of Severe COVID-19 Pneumonia: A Preliminary Experience. <i>Indian Journal of Critical Care Medicine</i> , 2022, 25, 1108-1112.	0.3	8
2969	Repurposing Cardio-Metabolic Drugs to Fight Covid19. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 419-423.	1.0	1
2972	Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?. <i>Current Opinion in Virology</i> , 2021, 50, 119-127.	2.6	32
2973	Study of Thoracic CT in COVID-19: The STOIC Project. <i>Radiology</i> , 2021, 301, E361-E370.	3.6	26
2974	Distinctive pseudopalisaded histiocytic hyperplasia characterizes the transition of exudative to proliferative phase of diffuse alveolar damage in patients dying of COVID-19. <i>Human Pathology</i> , 2021, 116, 49-62.	1.1	2
2975	Bacterial Coinfections in Coronavirus Disease 2019. <i>Trends in Microbiology</i> , 2021, 29, 930-941.	3.5	128
2976	In silico drug repurposing in COVID-19: A network-based analysis. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 111954.	2.5	17
2977	Preface. <i>Critical Care Clinics</i> , 2021, 37, xiii-xv.	1.0	0
2978	Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. <i>ESMO Open</i> , 2021, 6, 100274.	2.0	75
2979	Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1130-1140.	5.2	65
2980	Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study. <i>Anesthesiology</i> , 2021, 135, 1076-1090.	1.3	3
2981	Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics. <i>Frontiers in Immunology</i> , 2021, 12, 752227.	2.2	25
2982	Have we improved the management of COVID-19 patients admitted in intensive care between the two waves?. <i>Journal of Critical Care</i> , 2021, 65, 84-85.	1.0	3
2983	Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India. <i>Radiotherapy and Oncology</i> , 2021, 163, 83-90.	0.3	19
2984	Impact of COVID-19 on Pediatric Immunocompromised Patients. <i>Pediatric Clinics of North America</i> , 2021, 68, 1029-1054.	0.9	16
2985	Pharmacologic Treatments for Acute Respiratory Distress Syndrome. <i>Critical Care Clinics</i> , 2021, 37, 877-893.	1.0	8
2986	The Epidemiology of Acute Respiratory Distress Syndrome Before and After Coronavirus Disease 2019. <i>Critical Care Clinics</i> , 2021, 37, 703-716.	1.0	35
2987	Intubation timing as determinant of outcome in patients with acute respiratory distress syndrome by SARS-CoV-2 infection. <i>Journal of Critical Care</i> , 2021, 65, 164-169.	1.0	22

#	ARTICLE	IF	CITATIONS
2988	Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2021, 111, 267-270.	1.5	40
2989	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology</i> , The, 2021, 3, e690-e697.	2.2	121
2990	COVID-19-related outcomes in immunocompromised patients: A nationwide study in Korea. <i>PLoS ONE</i> , 2021, 16, e0257641.	1.1	36
2991	Cardiac Abnormalities Depicted with MRI in COVID-19: Ongoing Concern for Myocardial Injury. <i>Radiology</i> , 2021, 301, E371-E372.	3.6	3
2992	Group IIA secreted phospholipase A2 is associated with the pathobiology leading to COVID-19 mortality. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	70
2993	One year on: The impact of COVID-19 on clinical research. <i>European Journal of Internal Medicine</i> , 2021, 92, 24-27.	1.0	2
2994	COVID-19: A Review of Potential Treatments (Corticosteroids, Remdesivir, Tocilizumab,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 507 Td (B Pharmacy Practice, 2023, 36, 407-417.	0.5	27
2995	Management of SARS-CoV-2 pneumonia in intensive care unit: An observational retrospective study comparing two bundles. <i>Journal of Critical Care</i> , 2021, 65, 200-204.	1.0	3
2996	Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives. <i>International Immunopharmacology</i> , 2021, 99, 108036.	1.7	10
2997	IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients. <i>International Immunopharmacology</i> , 2021, 99, 107998.	1.7	4
2998	Risk factors for isolation of multi-drug resistant organisms in coronavirus disease 2019 pneumonia: A multicenter study. <i>American Journal of Infection Control</i> , 2021, 49, 1256-1261.	1.1	18
2999	COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. <i>Lancet Rheumatology</i> , The, 2021, 3, e724-e736.	2.2	76
3000	Azithromycin: can its benefit be ruled out in mild COVID-19?. <i>Lancet Respiratory Medicine</i> ,the, 2021, 9, 1079-1081.	5.2	1
3001	COVID-19 in Children. <i>Pediatric Clinics of North America</i> , 2021, 68, 961-976.	0.9	21
3002	SARS-CoV-2 attenuates corticosteroid sensitivity by suppressing DUSP1 expression and activating p38 MAPK pathway. <i>European Journal of Pharmacology</i> , 2021, 908, 174374.	1.7	14
3003	Impact of the COVID-19 pandemic on corticosteroid injection services: A National Survey of Members of the British Society of Skeletal Radiologists (BSSR). <i>British Journal of Radiology</i> , 2021, 94, 20210327.	1.0	1
3004	Platelets in the perspective of COVID-19; pathophysiology of thrombocytopenia and its implication as prognostic and therapeutic opportunity. <i>International Immunopharmacology</i> , 2021, 99, 107995.	1.7	27
3005	The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells. <i>IScience</i> , 2021, 24, 103144.	1.9	34

#	ARTICLE	IF	CITATIONS
3006	COVID-19 and adult-onset Still's disease as part of hyperferritinemic syndromes. <i>Modern Rheumatology Case Reports</i> , 2022, 6, 101-105.	0.3	5
3007	Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry. <i>Lancet</i> , The, 2021, 398, 1230-1238.	6.3	257
3008	Incidence and risk factors for pneumomediastinum in COVID-19 patients in the intensive care unit. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2022, 34, 236-244.	0.5	8
3009	Efficacy and safety of pegylated interferon- β in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study. <i>International Journal of Infectious Diseases</i> , 2021, 111, 281-287.	1.5	21
3010	Outcomes of Covid-19 organizing pneumonia in critically ill patients. <i>Journal of Infection</i> , 2021, 83, 496-522.	1.7	7
3011	Effectiveness of corticosteroids to treat severe COVID-19: A systematic review and meta-analysis of prospective studies. <i>International Immunopharmacology</i> , 2021, 100, 108121.	1.7	38
3012	Qualitative and quantitative muscle ultrasound changes in patients with COVID-19-related ARDS. <i>Nutrition</i> , 2021, 91-92, 111449.	1.1	26
3013	Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: An observational study. <i>International Immunopharmacology</i> , 2021, 100, 108163.	1.7	9
3014	COVID-19 and mucormycosis in Latin America – An emerging concern. <i>Travel Medicine and Infectious Disease</i> , 2021, 44, 102156.	1.5	4
3015	Mandibular mucormycosis following SARS-CoV-2 infection – A case report and review of literature. <i>Clinical Infection in Practice</i> , 2021, 12, 100099.	0.2	19
3016	Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis. <i>Respiratory Medicine</i> , 2021, 188, 106602.	1.3	38
3017	Recent advances in management of COVID-19: A review. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112107.	2.5	55
3018	Cell death and pathological findings of the spleen in COVID-19 patients. <i>Pathology Research and Practice</i> , 2021, 227, 153610.	1.0	11
3019	The critical care literature 2020. <i>American Journal of Emergency Medicine</i> , 2021, 50, 683-692.	0.7	1
3020	SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166264.	1.8	5
3021	Randomized trial drug controlled compendious transcriptome analysis supporting broad and phase specific therapeutic potential of multiple candidates in COVID-19. <i>Cytokine</i> , 2021, 148, 155719.	1.4	4
3022	COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us?. <i>Cytokine</i> , 2021, 148, 155628.	1.4	12
3023	The role of CD71+ erythroid cells in the regulation of the immune response. , 2021, 228, 107927.		37

#	ARTICLE	IF	CITATIONS
3024	Drug repurposing for COVID-19: Approaches, challenges and promising candidates. , 2021, 228, 107930.		85
3025	Respiratory and peripheral muscular ultrasound characteristics in ICU COVID 19 ARDS patients. Journal of Critical Care, 2022, 67, 14-20.	1.0	21
3027	Management of Coronavirus Disease 2019 (COVID-19) Pneumonia. , 2022, , 342-349.		4
3028	Mucormycosis (black fungus) ensuing COVID-19 and comorbidity meets - Magnifying global pandemic grievance and catastrophe begins. Science of the Total Environment, 2022, 805, 150355.	3.9	26
3029	COVID-19 in a Patient with Liver Cirrhosis. American Journal of Case Reports, 2021, 22, e929948.	0.3	2
3030	Cytokine storms, evolution and COVID-19. Evolution, Medicine and Public Health, 2021, 9, 83-92.	1.1	12
3031	Dalbavancin: novel candidate for COVID-19 treatment. Cell Research, 2021, 31, 243-244.	5.7	8
3032	A Comparison Study of Coronavirus Disease 2019 Outcomes in Hospitalized Kidney Transplant Recipients. Kidney360, 2021, 2, 494-506.	0.9	2
3033	Research shows racial disparity, mortality data for patients with cancer and COVID-19. Cancer, 2021, 127, 333-333.	2.0	2
3034	Can GPR4 Be a Potential Therapeutic Target for COVID-19?. Frontiers in Medicine, 2020, 7, 626796.	1.2	7
3035	Myocarditis in SARS-CoV-2 negative patients with suspected preceding infection. BMJ Case Reports, 2021, 14, e239513.	0.2	2
3036	Demographic characteristics, acute care resource use and mortality by age and sex in patients with COVID-19 in Ontario, Canada: a descriptive analysis. CMAJ Open, 2021, 9, E271-E279.	1.1	2
3037	Drugs for the Treatment of COVID-19. , 2021, , 193-204.		0
3038	Ongoing trials on COVID-19 treatments: please, don't forget Venous Thromboembolism!. Journal of Thrombosis and Thrombolysis, 2021, 51, 1170-1171.	1.0	0
3039	Resolutive Results with Oral Corticosteroids for Patients with COVID-19 in Pulmonary Inflammatory Phase. Successful Outpatient Experience during the Collapse of Belem Do Para Health System- Brazil. Health, 2021, 13, 830-838.	0.1	0
3040	Infectious disease immunotherapies - An update: Revisiting an age-old adage in times of COVID-19. Journal of Marine Medical Society, 2021, 23, 10.	0.0	0
3042	Latest Evidence. , 2021, , 219-227.		0
3043	Downhill Zagreb Topological Indices and M-polynomial of Some Chemical Structures Applied for the Treatment of COVID-19 Patients. Open Journal of Applied Sciences, 2021, 10, 395-413.	0.2	2

#	ARTICLE	IF	CITATIONS
3044	Risk of in-hospital death associated with Covid-19 lung consolidations on chest computed tomography – A novel translational approach using a radiation oncology contour software. European Journal of Radiology Open, 2021, 8, 100322.	0.7	6
3045	A New SARS-CoV-2 Variant Poorly Detected by RT-PCR on Nasopharyngeal Samples, with High Lethality. SSRN Electronic Journal, 0, , .	0.4	2
3046	Research Status of Aerosol Inhalation Drugs in COVID-19 Outbreak. Advances in Clinical Medicine, 2021, 11, 3487-3492.	0.0	0
3047	Effectiveness of Convalescent Plasma Therapy in Severe or Critically Ill COVID-19 Patients: A Retrospective Cohort Study. Yonsei Medical Journal, 2021, 62, 799.	0.9	2
3048	Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial. SSRN Electronic Journal, 0, , .	0.4	51
3049	Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?. Open Forum Infectious Diseases, 2021, 8, ofab013.	0.4	4
3051	Clinical Profile and Outcomes of Confirmed COVID 19 at Manila Doctors Hospital. Asian Journal of Epidemiology, 2021, 14, 1-10.	0.5	0
3052	Role of dexamethasone on oxygen requirement, mortality, and survival incidence among COVID-19 patients: Quasi-experimental study. Anesthesia: Essays and Researches, 2021, 15, 62.	0.2	1
3053	COVID-19 pandemic and the answer of science: a year in review. Anais Da Academia Brasileira De Ciencias, 2021, 93, e20210543.	0.3	4
3054	Novel coronavirus disease (COVID-19) pandemic: A recent mini review. Computational and Structural Biotechnology Journal, 2021, 19, 612-623.	1.9	35
3055	Tocilizumab for Severe and Critical COVID-19 Pneumonia in Queens, NYC. Infectious Diseases in Clinical Practice, 2021, Publish Ahead of Print, e215-e220.	0.1	4
3056	Clinical trial enrollment at a rural satellite hospital during COVID-19 pandemic. Journal of Clinical and Translational Science, 2021, 5, e136.	0.3	6
3057	Immunosuppression minimization in kidney transplant recipients hospitalized for COVID-19. CKJ: Clinical Kidney Journal, 2021, 14, 1229-1235.	1.4	22
3058	Knowledge, attitude and perception of Pakistanis towards COVID-19; a large cross-sectional survey. BMC Public Health, 2021, 21, 21.	1.2	31
3059	HYPERGLYCEMIA ON THE BACKGROUND OF TREATMENT OF COVID-19-ASSOCIATED PNEUMONIA USING GLUCOCORTICOIDS. Juvenis Scientia, 2021, 7, 5-11.	0.1	1
3060	COVID-19-associated familial acute disseminated encephalomyelitis (ADEM): A case report. IDCases, 2021, 26, e01264.	0.4	5
3061	COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. Internal and Emergency Medicine, 2021, 16, 281-308.	1.0	46
3062	Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110466.	1.1	5

#	ARTICLE	IF	CITATIONS
3063	Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact. <i>Immunotherapy Advances</i> , 2021, 1, .	1.2	14
3064	Extracorporeal membrane oxygenation in patients with COVID-19: 1-year experience. <i>Journal of Thoracic Disease</i> , 2021, 13, 5911-5924.	0.6	3
3065	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. <i>BMC Infectious Diseases</i> , 2021, 21, 72.	1.3	39
3066	Recommendations on Inpatient Treatment of Patients With COVID-19. <i>Deutsches A&#x0308;rztblatt International</i> , 2021, 118, .	0.6	35
3067	The current therapeutic strategies of COVID-19. <i>E3S Web of Conferences</i> , 2021, 308, 02013.	0.2	0
3068	More skilled clinical management of COVID-19 patients modified mortality in an intermediate respiratory intensive care unit in Italy. <i>Respiratory Research</i> , 2021, 22, 16.	1.4	11
3069	Predictors of negative first SARS-CoV-2 RT-PCR despite final diagnosis of COVID-19 and association with outcome. <i>Scientific Reports</i> , 2021, 11, 2388.	1.6	25
3070	Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 3113-3117.	0.8	76
3071	Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. <i>Cell Research</i> , 2021, 31, 272-290.	5.7	229
3072	Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients. <i>Frontiers in Medicine</i> , 2020, 7, 603961.	1.2	49
3073	COVID-19 Repeated Convalescent Plasma Collection: Analysis of 149 Donations from 88 French Military Health Workers. <i>Transfusion Medicine and Hemotherapy</i> , 2021, 48, 284-289.	0.7	0
3074	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. <i>BMJ, The</i> , 2021, 372, n84.	3.0	309
3075	Emerging Fungal Infections: New Species, New Names, and Antifungal Resistance. <i>Clinical Chemistry</i> , 2021, 68, 83-90.	1.5	28
3076	A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13556.	0.7	17
3077	Tocilizumab for the treatment of COVID-19. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 431-434.	1.4	8
3078	COVID-19 THERAPEUTICAL OPTIONS: OVERVIEW ON CURRENTLY ANTI-INFLAMMATORY AND ANTICOAGULANT DRUGS USED. <i>Health and Society</i> , 2021, 1, .	0.0	0
3079	Experience of International Air Transportation and Subsequent Lung Transplant in a Patient with COVID-19-associated Acute Respiratory Distress Syndrome: a Case Report. <i>Journal of Korean Medical Science</i> , 2021, 36, e123.	1.1	7
3080	TeX-Graph: Coupled tensor-matrix knowledge-graph embedding for COVID-19 drug repurposing. , 2021, , 603-611.		7

#	ARTICLE	IF	CITATIONS
3082	COVID-19 Antiviral and Treatment Candidates: Current Status. <i>Immune Network</i> , 2021, 21, e7.	1.6	8
3083	COVID-19 and fatal renal mucormycosis: Contributory or coincidental?. <i>Indian Journal of Urology</i> , 2021, 37, 270.	0.2	10
3084	Case Management of COVID-19 (Secondary Version). <i>JMA Journal</i> , 2021, 4, 191-197.	0.6	18
3086	Post-Acute COVID-19 Sequelae â€œâ€ COVID Long Haulerâ€™. <i>Wits Journal of Clinical Medicine</i> , 2021, 3, 117.	0.0	0
3087	Common Variants at 21q22.3 Locus Influence <i>MX1</i> Gene Expression and Susceptibility to Severe COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3088	Severe COVID-19: A distinct entity. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 84.	0.3	5
3090	COVID-19 and rheumatology: Reflecting on the first wave and preparing for the second wave. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 7-9.	0.9	4
3091	An Atypical Case of COVID-19 Induced Pancytopenia, Rhabdomyolysis and Myocarditis. <i>Cureus</i> , 2021, 13, e12455.	0.2	3
3092	Inflammation and Hyperinflammation. , 2021, , 233-243.		0
3093	Effect of neuromuscular electrical stimulation on the recovery of people with COVID-19 admitted to the intensive care unit: A narrative review. <i>Journal of Rehabilitation Medicine</i> , 2021, 53, jrm00164.	0.8	23
3094	COVID-19: What Do Rheumatologists Need to Know?. <i>Current Rheumatology Reports</i> , 2021, 23, 5.	2.1	8
3095	Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF \pm -antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e146.	0.3	25
3096	Multidimensional Evaluation of All-Cause Mortality Risk and Survival Analysis for Hospitalized Patients with COVID-19. <i>International Journal of Medical Sciences</i> , 2021, 18, 3140-3149.	1.1	6
3097	Spectroscopic Investigations, Computational Analysis and Molecular Docking to SAR-Cov-2 Targets Studies of 5,8-Quinolinedione Attached to Betulin Derivatives. <i>Crystals</i> , 2021, 11, 76.	1.0	5
3098	Spontaneous conversion of prenyl halides to acids: application in metal-free preparation of deuterated compounds under mild conditions. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 7390-7402.	1.5	6
3099	COVID-19, COPD, and AECOPD: Immunological, Epidemiological, and Clinical Aspects. <i>Frontiers in Medicine</i> , 2020, 7, 627278.	1.2	24
3100	Antiviral Activity of Azithromycin (A Synthetic Macrolide) for Next Step of COVID-19. <i>Asian Journal of Chemistry</i> , 2021, 33, 1594-1602.	0.1	0
3101	SARS-CoV-2 therapeutics: how far do we stand from a remedy?. <i>Pharmacological Reports</i> , 2021, 73, 750-768.	1.5	17

#	ARTICLE	IF	CITATIONS
3102	Emerging evidence for serum procalcitonin estimation at point-of-care and advancement in quantitative sensing strategies over the past decade. <i>Sensors International</i> , 2021, 2, 100107.	4.9	5
3103	Rhino-orbito-cerebral mycosis and COVID-19: From bad to worse?. <i>Annals of Indian Academy of Neurology</i> , 2021, 25, 68-75.	0.2	11
3104	Treatment Approach, Pharmacological Agents and Vaccines. , 2021, , 145-162.		0
3105	New Scoring System for Predicting Mortality in Patients with COVID-19. <i>Yonsei Medical Journal</i> , 2021, 62, 806.	0.9	10
3106	Adrenocortical System Hormones in Non-Critically ill Covid-19 Patients. <i>Acta Endocrinologica</i> , 2021, 17, 83-89.	0.1	6
3107	SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 817-819.	0.5	37
3108	Recent progress in the development of potential drugs against SARS-CoV-2. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100057.	1.7	7
3109	Development and application of therapeutic antibodies against COVID-19. <i>International Journal of Biological Sciences</i> , 2021, 17, 1486-1496.	2.6	47
3110	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. <i>Infection and Chemotherapy</i> , 2021, 53, 166.	1.0	21
3112	The immune dysregulations in COVID-19: Implications for the management of rheumatic diseases. <i>Modern Rheumatology</i> , 2021, 31, 927-932.	0.9	4
3113	Rationale for azithromycin in COVID-19: an overview of existing evidence. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000806.	1.2	49
3114	Management of Patients with SARS-CoV-2 Infection. In <i>Clinical Practice</i> , 2021, , 125-135.	0.1	0
3115	COVID-19-associated Eosinopenia in a Patient With Chronic Eosinophilia Due to Chronic Strongyloidiasis. <i>Infectious Diseases in Clinical Practice</i> , 2021, 29, e305-e306.	0.1	9
3116	When Does the Cytokine Storm Begin in COVID-19 Patients? A Quick Score to Recognize It. <i>Journal of Clinical Medicine</i> , 2021, 10, 297.	1.0	36
3117	Vitamin-D levels and intensive care unit outcomes of a cohort of critically ill COVID-19 patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1155-1163.	1.4	31
3118	Sex differences in response to adjunctive corticosteroid treatment for patients with septic shock. <i>Intensive Care Medicine</i> , 2021, 47, 246-248.	3.9	13
3119	Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients infected with SARS-CoV-2. <i>ELife</i> , 2021, 10, .	2.8	21
3120	Secondary Infections in Critically Ill Patients with COVID-19. <i>Annual Update in Intensive Care and Emergency Medicine</i> , 2021, , 43-52.	0.1	0

#	ARTICLE	IF	CITATIONS
3121	A simple model for the total number of SARS-CoV-2 infections on a national level. <i>Epidemiology and Infection</i> , 2021, 149, e80.	1.0	6
3122	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. <i>Emerging Microbes and Infections</i> , 2021, 10, 507-535.	3.0	202
3123	Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. <i>Cardiovascular Pathology</i> , 2021, 50, 107278.	0.7	55
3124	Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. <i>Nature</i> , 2021, 590, 635-641.	13.7	524
3125	Network machine learning maps phytochemically rich "Hyperfoods" to fight COVID-19. <i>Human Genomics</i> , 2021, 15, 1.	1.4	28
3126	Global pandemics interconnected " obesity, impaired metabolic health and COVID-19. <i>Nature Reviews Endocrinology</i> , 2021, 17, 135-149.	4.3	326
3127	Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 105-110.	1.0	18
3129	Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS-CoV-2 in the respiratory tract. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00698.	1.1	14
3130	Estimated Impact of Public and Private Sector COVID-19 Diagnostics and Treatments on US Healthcare Resource Utilization. <i>Advances in Therapy</i> , 2021, 38, 1212-1226.	1.3	6
3131	2020: The Year of the COVID-19 Pandemic. <i>Journal of Nutrition, Health and Aging</i> , 2021, 25, 1-4.	1.5	5
3132	Tele-medicine versus face-to-face consultation in Endocrine Outpatients Clinic during COVID-19 outbreak: a single-center experience during the lockdown period. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1689-1698.	1.8	19
3133	Practical considerations for pregnant women with diabetes and severe acute respiratory syndrome coronavirus 2 infection. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2020, 2, 100210.	1.3	3
3134	COVID-19 and Cancer: Current Challenges and Perspectives. <i>Cancer Cell</i> , 2020, 38, 629-646.	7.7	196
3135	Consenso del Comit� de Psiquiatr�a de Enlace de la Asociaci�n Colombiana de Psiquiatr�a sobre el diagn�stico y tratamiento del delirium en el contexto de la pandemia por COVID-19. <i>Revista Colombiana De Psiquiatr�a</i> , 2022, 51, 245-255.	0.1	2
3136	Successful treatment with methyl-prednisolone pulses for the late phase of COVID-19 with respiratory failure: A single-center case series. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101318.	0.2	9
3137	Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. <i>Thrombosis Research</i> , 2020, 196, 382-394.	0.8	62
3138	Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 1742-1764.	2.6	16
3139	Progress report on the coronavirus pandemic. <i>Nature</i> , 2020, 584, 325-325.	13.7	12

#	ARTICLE	IF	CITATIONS
3140	Why decoding the immune response to COVID matters for vaccines. <i>Nature</i> , 2020, 586, 473-474.	13.7	4
3141	Why do COVID death rates seem to be falling?. <i>Nature</i> , 2020, 587, 190-192.	13.7	46
3142	Genetic mechanisms of critical illness in COVID-19. <i>Nature</i> , 2021, 591, 92-98.	13.7	1,014
3143	Dynamic data-driven meta-analysis for prioritisation of host genes implicated in COVID-19. <i>Scientific Reports</i> , 2020, 10, 22303.	1.6	31
3144	Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide. <i>Bioscience Reports</i> , 2020, 40, .	1.1	29
3145	Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study. <i>Bioscience Reports</i> , 2020, 40, .	1.1	24
3146	Specialized pro-resolving mediator network: an update on production and actions. <i>Essays in Biochemistry</i> , 2020, 64, 443-462.	2.1	231
3147	Remdesivir for the Treatment of Covid-19 – Final Report. <i>New England Journal of Medicine</i> , 2020, 383, 1813-1826.	13.9	5,834
3148	COVID-19, host response treatment, and the need for political leadership. <i>Journal of Public Health Policy</i> , 2021, 42, 6-14.	1.0	12
3149	Therapeutics for COVID-19: established and in development. <i>Microbiology Australia</i> , 2020, 41, 217.	0.1	2
3150	Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1009-1027.	2.0	23
3151	Natural history of COVID-19 and therapeutic options. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1159-1184.	1.3	101
3152	Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality. <i>Journal of Cell Biology</i> , 2020, 219, .	2.3	20
3153	The Clinical Course of Coronavirus Disease 2019 in a US Hospital System: A Multistate Analysis. <i>American Journal of Epidemiology</i> , 2021, 190, 539-552.	1.6	17
3154	COVID 19: in the eye of the cytokine storm. <i>European Heart Journal</i> , 2021, 42, 150-151.	1.0	15
3155	COVID-19: patients with stroke or risk of stroke. <i>European Heart Journal Supplements</i> , 2020, 22, P25-P28.	0.0	15
3156	End-stage heart failure patients should be treated instantly despite a pandemic with all-time available technology to ensure best outcomes. <i>European Heart Journal Supplements</i> , 2020, 22, P33-P37.	0.0	3
3157	The Effect of IL-6 Inhibitors on Mortality Among Hospitalized COVID-19 Patients: A Multicenter Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 581-588.	1.9	6

#	ARTICLE	IF	CITATIONS
3158	Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. <i>Journal of Infectious Diseases</i> , 2021, 223, 981-984.	1.9	62
3159	Low-Dose Radiation Therapy for COVID-19: Promises and Pitfalls. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa103.	1.4	15
3160	Histological Evidence of Pulmonary Microthrombosis and Vasculitis in Life-Threatening Respiratory Virus Diseases. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa640.	0.4	6
3161	COVID-19: a pan-organ pandemic. <i>Oxford Medical Case Reports</i> , 2020, 2020, omaa107.	0.2	4
3162	Acute Respiratory Distress Syndrome. <i>Anesthesiology</i> , 2021, 134, 270-282.	1.3	44
3163	Improving Survival of Critical Care Patients With Coronavirus Disease 2019 in England: A National Cohort Study, March to June 2020*. <i>Critical Care Medicine</i> , 2021, 49, 209-214.	0.4	162
3164	Fatal SARS-CoV-2 Inflammatory Syndrome and Myocarditis in an Adolescent: A Case Report. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, e72-e76.	1.1	10
3165	Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2021, 37, e40-e80.	0.4	184
3225	Molecular determinants of vascular transport of dexamethasone in COVID-19 therapy. <i>IUCr</i> , 2020, 7, 1048-1058.	1.0	12
3226	COVID-19 with dengue shock syndrome in a child: coinfection or cross-reactivity?. <i>BMJ Case Reports</i> , 2020, 13, e239315.	0.2	14
3227	Retrospective cohort study of admission timing and mortality following COVID-19 infection in England. <i>BMJ Open</i> , 2020, 10, e042712.	0.8	42
3228	Manipulation of ACE2 expression in COVID-19. <i>Open Heart</i> , 2020, 7, e001424.	0.9	55
3229	Open drug discovery of anti-virals critical for Canada's pandemic strategy. <i>Facets</i> , 2020, 5, 1019-1036.	1.1	2
3230	Sex differences in COVID-19 course and outcome: progesterone should not be neglected. <i>Journal of Applied Physiology</i> , 2020, 129, 1007-1008.	1.2	9
3231	High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19. <i>JCI Insight</i> , 2020, 5, .	2.3	97
3232	Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. <i>Journal of Clinical Investigation</i> , 2020, 130, 6417-6428.	3.9	96
3233	Antituberculosis BCG vaccination: more reasons for varying innate and adaptive immune responses. <i>Journal of Clinical Investigation</i> , 2020, 130, 5121-5123.	3.9	7
3234	Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome. <i>Journal of Clinical Investigation</i> , 2020, 130, 6218-6221.	3.9	50

#	ARTICLE	IF	CITATIONS
3235	Early Experience With Methylprednisolone on SARS-CoV-2 Infection in the African American Population, a Retrospective Analysis. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2020, 14, 117954842098069.	0.5	8
3236	Pandemic trials: evidence-based medicine on steroids. <i>European Respiratory Journal</i> , 2020, 56, 2004116.	3.1	6
3237	Targeting coagulation activation in severe COVID-19 pneumonia: lessons from bacterial pneumonia and sepsis. <i>European Respiratory Review</i> , 2020, 29, 200240.	3.0	16
3238	The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?. <i>ERJ Open Research</i> , 2021, 7, 00768-2020.	1.1	14
3239	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 290.	1.6	37
3240	Cognitive impact of COVID-19: looking beyond the short term. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 170.	3.0	149
3241	Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study. <i>Annals of Intensive Care</i> , 2020, 10, 131.	2.2	39
3242	Airway Hygiene in COVID-19 Pneumonia: Treatment Responses of 3 Critically Ill Cruise Ship Employees. <i>American Journal of Case Reports</i> , 2020, 21, e926596.	0.3	17
3243	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. <i>F1000Research</i> , 2020, 9, 1109.	0.8	8
3244	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. <i>F1000Research</i> , 2020, 9, 1193.	0.8	41
3245	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. <i>F1000Research</i> , 2020, 9, 1193.	0.8	38
3246	Novel respiratory infectious diseases in Korea. <i>Yeungnam University Journal of Medicine</i> , 2020, 37, 286-295.	0.7	4
3247	Trends in COVID-19 Risk-Adjusted Mortality Rates. <i>Journal of Hospital Medicine</i> , 2021, 16, 90-92.	0.7	188
3248	Understanding the immunopathogenesis of COVID-19: Its implication for therapeutic strategy. <i>World Journal of Clinical Cases</i> , 2020, 8, 5835-5843.	0.3	11
3250	A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19. <i>PLoS Biology</i> , 2020, 18, e3000970.	2.6	139
3251	Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection. <i>PLoS Computational Biology</i> , 2020, 16, e1008461.	1.5	106
3252	Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. <i>PLoS Medicine</i> , 2020, 17, e1003501.	3.9	155
3253	Association between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients. <i>PLoS ONE</i> , 2020, 15, e0239571.	1.1	53

#	ARTICLE	IF	CITATIONS
3254	Continuous Positive Airway Pressure (CPAP) face-mask ventilation is an easy and cheap option to manage a massive influx of patients presenting acute respiratory failure during the SARS-CoV-2 outbreak: A retrospective cohort study. PLoS ONE, 2020, 15, e0240645.	1.1	52
3255	Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS ONE, 2020, 15, e0241955.	1.1	453
3256	Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS ONE, 2020, 15, e0242184.	1.1	48
3257	C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19. PLoS ONE, 2020, 15, e0242400.	1.1	104
3258	Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic (March-April 2020). PLoS ONE, 2020, 15, e0242760.	1.1	36
3259	Blood test dynamics in hospitalized COVID-19 patients: Potential utility of D-dimer for pulmonary embolism diagnosis. PLoS ONE, 2020, 15, e0243533.	1.1	10
3260	Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0243705.	1.1	62
3261	The use of methylprednisolone in COVID-19 patients: A propensity score matched retrospective cohort study. PLoS ONE, 2020, 15, e0244128.	1.1	14
3262	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis. PLoS ONE, 2020, 15, e0244627.	1.1	9
3263	Infection of human Nasal Epithelial Cells with SARS-CoV-2 and a 382-nt deletion isolate lacking ORF8 reveals similar viral kinetics and host transcriptional profiles. PLoS Pathogens, 2020, 16, e1009130.	2.1	98
3264	Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia. Annals of Hepato-biliary-pancreatic Surgery, 2020, 24, 526-532.	0.1	10
3265	A COVID-19 Case Complicated by Candida dubliniensis and Klebsiella pneumoniae-Carbapenem-Resistant Enterobacteriaceae. Journal of Medical Cases, 2020, 11, 403-406.	0.4	7
3266	COVID-19 therapy and prevention. Discoveries, 2020, 8, e113.	1.5	4
3267	A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO Molecular Medicine, 2021, 13, e13105.	3.3	62
3268	Assessment of patients with Covid-19 hospitalized in southern Santa Catarina. Revista Da Sociedade Brasileira De Medicina Tropical, 2020, 53, e20200579.	0.4	6
3269	Pneumothorax as a late complication of COVID-19. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2020, 62, e61.	0.5	16
3270	Commonalities Between COVID-19 and Radiation Injury. Radiation Research, 2020, 195, 1-24.	0.7	23
3271	All-cause mortality among patients treated with repurposed antivirals and antibiotics for COVID-19 in Mexico City: A real-world observational study. EXCLI Journal, 2021, 20, 199-222.	0.5	12

#	ARTICLE	IF	CITATIONS
3272	Testosterone in COVID-19 –“ Foe, Friend or Fatal Victim?. <i>European Endocrinology</i> , 2020, 16, 88.	0.8	11
3274	Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. <i>Pulmonologiya</i> , 2020, 30, 629-644.	0.2	7
3275	Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study. <i>Aging</i> , 2021, 13, 27-60.	1.4	49
3276	Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned. <i>Annals of Gastroenterology</i> , 2020, 33, 591-602.	0.4	13
3277	COVID-19 in cancer patients: risk, clinical features, and management. <i>Cancer Biology and Medicine</i> , 2020, 17, 519-527.	1.4	135
3282	Correlation of Influenza Vaccination and the COVID-19 Severity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	13
3283	<p>An Up-to-Date Overview of Therapeutic Agents for the Treatment of COVID-19 Disease</p>. <i>Clinical Pharmacology: Advances and Applications</i> , 2020, Volume 12, 203-212.	0.8	7
3284	The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial Registries. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4577-4587.	1.1	9
3285	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4673-4695.	1.1	43
3286	COVID-19 Pneumonia Resembling an Acute Exacerbation of Interstitial Pneumonia. <i>Internal Medicine</i> , 2020, 59, 3207-3211.	0.3	9
3287	Pneumothorax in a COVID-19 Pneumonia Patient without Underlying Risk Factors. <i>Internal Medicine</i> , 2020, 59, 2921-2925.	0.3	19
3288	COVID-19: A Therapeutic Approach Based on Pathophysiological Staging. <i>Open Respiratory Medicine Journal</i> , 2020, 14, 32-37.	1.3	1
3289	Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach. <i>JMIR Medical Informatics</i> , 2020, 8, e21648.	1.3	9
3290	Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review. <i>Journal of Medical Internet Research</i> , 2020, 22, e21758.	2.1	14
3291	Prospective data linkage to facilitate COVID-19 trials –“ A call to action. <i>International Journal of Population Data Science</i> , 2020, 5, 1383.	0.1	1
3292	Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. <i>Life Science Alliance</i> , 2021, 4, e202000955.	1.3	56
3293	Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	82
3294	Covid-19 Effects on ARTERial Stiffness and Vascular AgeiNg: CARTESIAN Study Rationale and Protocol. <i>Artery Research</i> , 2021, 27, 59.	0.3	19

#	ARTICLE	IF	CITATIONS
3295	COVID-19 and haematology services in a cancer centre from a middle-income country: adapting service delivery, balancing the known and unknown during the pandemic. <i>Ecancermedicalsecience</i> , 2020, 14, 1110.	0.6	4
3296	COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis. <i>Journal of Korean Medical Science</i> , 2020, 35, e343.	1.1	156
3297	Triggers, Timescales, and Treatments for Cytokine-Mediated Tissue Damage. <i>European Medical Journal Innovations</i> , 2021, 5, 52-62.	2.0	4
3298	Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitis—A Critical Review of Its Pathogenesis and Treatment. <i>Frontiers in Pediatrics</i> , 2020, 8, 626182.	0.9	120
3299	Cinnamon and Hop Extracts as Potential Immunomodulators for Severe COVID-19 Cases. <i>Frontiers in Plant Science</i> , 2021, 12, 589783.	1.7	20
3300	Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 Across Asia: Findings and Public Health Implications for the Future. <i>Frontiers in Public Health</i> , 2020, 8, 585832.	1.3	62
3301	Discovery of a Bradykinin B2 Partial Agonist Profile of Raloxifene in a Drug Repurposing Campaign. <i>International Journal of Molecular Sciences</i> , 2021, 22, 257.	1.8	3
3302	Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19. <i>Pharmaceuticals</i> , 2021, 14, 15.	1.7	28
3303	Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19. <i>Viruses</i> , 2021, 13, 29.	1.5	118
3304	Niacinamide May Be Associated with Improved Outcomes in COVID-19-Related Acute Kidney Injury: An Observational Study. <i>Kidney360</i> , 2021, 2, 33-41.	0.9	23
3305	Public Risk-Taking and Rewards During the COVID-19 Pandemic - A Case Study of Remdesivir in the Context of Global Health Equity. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.5	6
3306	Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2). <i>International Journal of Occupational and Environmental Medicine</i> , 2020, 11, 157-178.	4.1	16
3307	Cytokine storm in COVID-19: Potential therapeutics for immunomodulation. <i>Journal of Research in Clinical Medicine</i> , 2020, 8, 38-38.	0.3	11
3308	Tocilizumab and corticosteroids for COVID-19 treatment in elderly patients. <i>Journal of Gerontology and Geriatrics</i> , 2020, 68, 197-203.	0.2	11
3309	COVID-19 treatment : a growing (anti)body of evidence. <i>South African General Practitioner</i> , 2020, 1, 172-174.	0.0	2
3310	COVID-19: What We Know So Far. <i>International Journal of Clinical Research</i> , 2020, 1, 73-108.	0.1	1
3311	Convalescent Plasma Therapy for Coronavirus Disease 2019. <i>Infection and Chemotherapy</i> , 2020, 52, 307.	1.0	10
3312	SARS-CoV-2 and myocardial injury: Few answers, many questions. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 521-525.	0.6	13

#	ARTICLE	IF	CITATIONS
3313	Steroids in COVID-19: An overview. Cleveland Clinic Journal of Medicine, 2020, , .	0.6	34
3314	COVID-19 in patients with IBD and pancreaticobiliary disorders. Cleveland Clinic Journal of Medicine, 2020, , .	0.6	4
3315	The hospitalized patient with COVID-19 on the medical ward: Cleveland Clinic approach to management. Cleveland Clinic Journal of Medicine, 2020, , .	0.6	4
3316	Management of COVID-19 in special populations with kidney disease. Cleveland Clinic Journal of Medicine, 2020, , .	0.6	2
3317	COVID-19: general overview, pharmacological options and ventilatory support strategies. Multidisciplinary Respiratory Medicine, 2020, 15, 708.	0.6	2
3318	COVID-19 and heart failure: The big challenge. Heart Views, 2020, 21, 187.	0.1	5
3319	Endocrine involvement in COVID-19: Mechanisms, clinical features, and implications for care. Indian Journal of Endocrinology and Metabolism, 2020, 24, 381.	0.2	39
3320	Clinical profile of hospitalized COVID-19 patients in first & second wave of the pandemic: Insights from an Indian registry based observational study. Indian Journal of Medical Research, 2021, 153, 619.	0.4	51
3321	Demographic & clinical profile of patients with COVID-19 at a tertiary care hospital in north India. Indian Journal of Medical Research, 2021, 153, 115.	0.4	34
3322	Retinal vein occlusion in COVID-19: A novel entity. Indian Journal of Ophthalmology, 2020, 68, 2291.	0.5	119
3323	Co-infection of COVID-19 with dengue fever and acute graft dysfunction in a kidney transplant recipient - A case report. Indian Journal of Transplantation, 2020, 14, 363.	0.0	2
3324	Efficacy and safety of steroid therapy in COVID-19: A rapid systematic review and Meta-analysis. Indian Journal of Pharmacology, 2020, 52, 535.	0.4	20
3325	Case Report: Adrenal Pathology Findings in Severe COVID-19: An Autopsy Study. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1604-1607.	0.6	80
3326	Case Report: Multidrug-Resistant Tuberculosis and COVID-19 Coinfection in Port-au-Prince, Haiti. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1986-1988.	0.6	24
3327	Case Report: COVID-19 Associated Renal Infarction and Ascending Aortic Thrombosis. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1989-1992.	0.6	25
3328	How Do We Combat Bogus Medicines in the Age of the COVID-19 Pandemic?. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1360-1363.	0.6	18
3329	Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1364-1366.	0.6	23
3330	Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Low- and Middle-Income Countries. American Journal of Tropical Medicine and Hygiene, 2020, , .	0.6	3

#	ARTICLE	IF	CITATIONS
3331	Factors of Severity in Patients with COVID-19: Cytokine/Chemokine Concentrations, Viral Load, and Antibody Responses. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 2412-2418.	0.6	60
3332	Clinical Challenges and Considerations in Management of Chronic Pain Patients During a COVID-19 Pandemic. <i>Annals of the Academy of Medicine, Singapore</i> , 2020, 49, 669-673.	0.2	11
3333	Coronavirus Disease 2019 (COVID-19): The Singapore Experience. A Review of the First Eight Months. <i>Annals of the Academy of Medicine, Singapore</i> , 2020, 49, 764-778.	0.2	27
3334	SARS-CoV-2 and Advanced HIV Infection. <i>Annals of the Academy of Medicine, Singapore</i> , 2020, 49, 1042-1043.	0.2	1
3335	Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 353-367.	0.2	33
3336	Coronavirus Disease 2019 (COVID-19) in Children: Lessons from Pediatric Rheumatology. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 469-479.	0.2	10
3337	Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers. <i>Indian Journal of Critical Care Medicine</i> , 2020, 24, 771-776.	0.3	12
3338	Kidney injury in COVID-19. <i>World Journal of Nephrology</i> , 2020, 9, 18-32.	0.8	19
3339	COVID-19 Pandemic and Children: A Review. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2020, 25, 574-585.	0.3	25
3340	Update on the diagnosis and management of COVID-19 in pediatric patients. <i>Clinics</i> , 2020, 75, e2353.	0.6	11
3341	COVID-19 research risks ignoring important host genes due to pre-established research patterns. <i>ELife</i> , 2020, 9, .	2.8	14
3342	Positive association between COVID-19 deaths and influenza vaccination rates in elderly people worldwide. <i>PeerJ</i> , 0, 8, e10112.	0.9	15
3343	Icosapent Ethyl â€œ A Successful Treatment for Symptomatic COVID-19 Infection. <i>Cureus</i> , 2020, 12, e10211.	0.2	11
3344	Overview of the Pathogenesis and Treatment of SARS-CoV-2 for Clinicians: A Comprehensive Literature Review. <i>Cureus</i> , 2020, 12, e10357.	0.2	7
3345	Rhino-Orbital Mucormycosis Associated With COVID-19. <i>Cureus</i> , 2020, 12, e10726.	0.2	341
3346	Immune Thrombocytopenic Purpura â€œ Different Presentations in Two COVID-19 Patients. <i>Cureus</i> , 2020, 12, e11202.	0.2	7
3347	Activities of Serum Ferritin and Treatment Outcomes Among COVID-19 Patients Treated With Vitamin C and Dexamethasone: An Uncontrolled Single-Center Observational Study. <i>Cureus</i> , 2020, 12, e11442.	0.2	17
3348	V.I.T.A.M. in COVID 19: A Systematic Approach to a Global Pandemic. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2021, 15, 117954842110474.	0.5	0

#	ARTICLE	IF	CITATIONS
3349	Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 568-573.	1.3	4
3350	Immunology of SARS-CoV-2 infections and vaccines. <i>Advances in Immunology</i> , 2021, 151, 49-97.	1.1	12
3352	Identification of fragments binding to SARS-CoV-2 nsp10 reveals ligand-binding sites in conserved interfaces between nsp10 and nsp14/nsp16. <i>RSC Chemical Biology</i> , 2022, 3, 44-55.	2.0	23
3353	Diabetes, COVID-19 and mucormycosis: Unanswered questions!. <i>Indian Journal of Endocrinology and Metabolism</i> , 2021, 25, 191.	0.2	1
3354	A case of acquired immunodeficiency syndrome-related Kaposi sarcoma in a patient with COVID-19 – A brief review of HIV-COVID Co-infection and its Therapeutic challenges!. <i>Respiratory Medicine Case Reports</i> , 2021, 34, 101524.	0.2	2
3355	Topics of thrombosis with COVID-19 from a viewpoint of infectious disease specialist. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2021, 32, 628-631.	0.1	0
3356	Ultrasound-Guided Minimally Invasive Tissue Sampling: A Minimally Invasive Autopsy Strategy During the COVID-19 Pandemic in Brazil, 2020. <i>Clinical Infectious Diseases</i> , 2021, 73, S442-S453.	2.9	8
3357	Impact of computational approaches in the fight against COVID-19: an AI guided review of 17 000 studies. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	20
3358	Commentary: The daunting enigma of post-COVID-19 endogenous endophthalmitis. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 2871.	0.5	1
3359	Enfermedad por coronavirus 2019 (COVID-19). <i>Medicina UPB</i> , 2021, 40, 41-49.	0.1	0
3360	Incidence and prognosis of COVID-19 amongst heart transplant recipients: a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e224-e226.	0.8	17
3361	Chest computed tomography in the diagnosis of COVID-19 in patients with false negative RT-PCR. <i>Einstein (Sao Paulo, Brazil)</i> , 2021, 19, eAO6363.	0.3	3
3362	SARS-CoV-2 mechanisms of action and impact on human organism, risk factors and potential treatments. An exhaustive survey. <i>International Journal of Transgender Health</i> , 2021, 14, 894-947.	1.1	0
3363	Anti-Inflammatory Therapy of Infections. , 2022, , 791-797.		1
3364	COVID-19 Treatments Sold Online Without Prescription Requirements in the United States: Cross-sectional Study Evaluating Availability, Safety and Marketing of Medications. <i>Journal of Medical Internet Research</i> , 2022, 24, e27704.	2.1	16
3365	Incidence of Venous Thromboembolism and Effect of Anticoagulant Dosing in Hospitalized COVID-19 Patients. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021, 10, 162-170.	0.4	3
3366	Anti-inflammatory agents other than corticosteroid in SARS-CoV-2 pneumonia. <i>Clinical Critical Care</i> , 2021, , .	0.0	0
3367	Antiviral therapy and immunotherapy of COVID-19. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 53-59.	0.5	0

#	ARTICLE	IF	CITATIONS
3368	Ventilatory support and corticosteroid therapy in SARS-CoV-2. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 52-56.	0.5	0
3369	Phenotyping in COVID-19: Making the case for why science needs philosophy. <i>Annals of the Academy of Medicine, Singapore</i> , 2021, 50, 669-670.	0.2	0
3370	C-reactive protein levels associated with COVID-19 outcomes in the United States. <i>Journal of Osteopathic Medicine</i> , 2021, 121, 869-873.	0.4	17
3371	COVID-19 Induced New-onset Psychosis: A Case Report from Oman. <i>Oman Medical Journal</i> , 2021, 36, e303-e303.	0.3	12
3372	Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States. <i>Clinical Therapeutics</i> , 2021, 43, 1877-1893.e4.	1.1	6
3373	COVID-19 hospital prevalence as a risk factor for mortality: an observational study of a multistate cohort of 62 hospitals. <i>BMJ Quality and Safety</i> , 2022, 31, 45-53.	1.8	13
3374	Fewer Intubations but Higher Mortality Among Intubated Coronavirus Disease 2019 Patients During the Second Than the First Wave. , 2021, 3, e531.		7
3375	Utility of conventional clinical risk scores in a low-risk COVID-19 cohort. <i>BMC Infectious Diseases</i> , 2021, 21, 1094.	1.3	6
3376	Phenotyping in acute respiratory distress syndrome: state of the art and clinical implications. <i>Current Opinion in Critical Care</i> , 2022, 28, 1-8.	1.6	18
3377	COVID-19â€™Associated Bone Marrow Necrosisâ€™A Case Report. <i>Indian Journal of Radiology and Imaging</i> , 2021, 31, 725-728.	0.3	7
3378	Uso de aminoquinolinas (Cloroquina e Hidroxicloroquina) no tratamento da COVID-19: uma revisÃ£o sistemÃ¡tica. <i>Research, Society and Development</i> , 2021, 10, e569101220907.	0.0	0
3379	Non-invasive Ventilation (NIV) in the Management of Respiratory Failure Due to COVID-19 Infection: Experience From a Resource Limited Setting. <i>Mayo Clinic Proceedings</i> , 2021, , .	1.4	5
3380	Interactions between diabetes and COVID-19: A narrative review. <i>World Journal of Diabetes</i> , 2021, 12, 1674-1692.	1.3	9
3381	Corticosteroid Management of Coronavirus 2019 (COVID-19) in Patients with Bilateral Adrenalectomy. <i>Case Reports in Infectious Diseases</i> , 2021, 2021, 1-3.	0.2	0
3382	Use of extracorporeal blood purification therapy (ECBPT) as an adjuvant to high-dose corticosteroids in a severely ill COVID-19 patient with concomitant bacterial infection. <i>BMJ Case Reports</i> , 2021, 14, e245639.	0.2	2
3383	Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 231-247.	1.6	9
3384	Treatment of COVID-19 in pregnant women: A systematic review and meta-analysis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 267, 120-128.	0.5	19
3385	The Evolving Concept of Neuro-Thromboinflammation for Neurodegenerative Disorders and Neurotrauma: A Rationale for PAR1-Targeting Therapies. <i>Biomolecules</i> , 2021, 11, 1558.	1.8	1

#	ARTICLE	IF	CITATIONS
3387	The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section. <i>Journal of Infection and Public Health</i> , 2022, 15, 142-151.	1.9	10
3388	COVID-19 and dexamethasone-induced hyperglycaemia: Workload implications for diabetes inpatient teams. <i>Diabetic Medicine</i> , 2022, 39, e14716.	1.2	3
3389	Efficacy and Safety of Sarilumab in patients with COVID19 Pneumonia: A Randomized, Phase III Clinical Trial (SARTRE Study). <i>Infectious Diseases and Therapy</i> , 2021, 10, 2735-2748.	1.8	17
3390	Overview of potential drugs for the treatment of new coronavirus Infection (COVID-19). <i>Acta Biomedica Scientifica</i> , 2021, 6, 74-86.	0.1	0
3391	Age and genotype dependent erythropoietin protection in COVID-19. <i>World Journal of Stem Cells</i> , 2021, 13, 1513-1529.	1.3	11
3392	Worldwide epidemiology of neuro-coronavirus disease in children: lessons for the next pandemic. <i>Current Opinion in Pediatrics</i> , 2021, 33, 580-590.	1.0	6
3394	Artificial intelligence in cardiology: the debate continues. <i>European Heart Journal Digital Health</i> , 2021, 2, 721-726.	0.7	6
3395	Corticosteroid use in ARDS and its application to evolving therapeutics for coronavirus disease 2019 (COVID-19): A systematic review. <i>Pharmacotherapy</i> , 2022, 42, 71-90.	1.2	14
3396	Ferritin as prognostic marker in COVID-19: the FerVid study. <i>Postgraduate Medicine</i> , 2021, , 1-6.	0.9	30
3397	Haemorrhagic ulcerative duodenitis in a patient with COVID-19 infection: clinical improvement following treatment with budesonide. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000757.	1.1	4
3398	A multicentric observational study of imaging findings in COVID-19-related rhino-orbito-cerebral mucormycosis: a new Pandora's box. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2021, 52, .	0.3	8
3399	To study the clinical course of rhino orbital mucormycosis in post COVID-19 patients: A case series. <i>IP International Journal of Ocular Oncology and Oculoplasty</i> , 2021, 7, 328-332.	0.0	1
3400	Antiviral and Immunomodulatory Effects of Pelargonium sidoides DC. Root Extract EPs® 7630 in SARS-CoV-2-Infected Human Lung Cells. <i>Frontiers in Pharmacology</i> , 2021, 12, 757666.	1.6	23
3401	Comprehensive Review of Cardiovascular Complications of Coronavirus Disease 2019 and Beneficial Treatments. <i>Cardiology in Review</i> , 2022, 30, 145-157.	0.6	11
3402	Pneumonia rebound after stopping steroid in a patient with COVID -19: A case report. <i>Respirology Case Reports</i> , 2021, 9, e0869.	0.3	5
3403	Diagnostic Tests and Procedures During the COVID-19 Pandemic. <i>Springer Actuarial</i> , 2022, , 191-216.	0.2	1
3404	Importance of antiviral Hâ,S in treatment protocols for COVID-19. <i>Pulmonologiya</i> , 2021, 31, 636-644.	0.2	1
3405	Effect of Different Corticosteroid Regimens on the Outcome of Severe COVID-19-Related Acute Respiratory Failure. A Retrospective Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4847.	1.0	5

#	ARTICLE	IF	CITATIONS
3406	Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). <i>Clinical Trials</i> , 2022, 19, 52-61.	0.7	16
3407	Comorbidity-associated glutamine deficiency is a predisposition to severe COVID-19. <i>Cell Death and Differentiation</i> , 2021, 28, 3199-3213.	5.0	37
3408	Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry. <i>European Journal of Medical Research</i> , 2021, 26, 117.	0.9	18
3409	Dexamethasone in Treatment of Comorbid SARS-CoV-2 Patients Aged over 50 Years with Lung Injury over 50 %. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2021, 31, 43-50.	0.2	0
3410	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021, 6, 1433-1442.	5.9	94
3411	A comprehensive review of pharmacokinetic and pharmacodynamic in animals: exploration of interaction with antibiotics of Shuang-Huang-Lian preparations. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, .	1.0	1
3412	Tocilizumab in HIV patient with severe COVID-19: case report. <i>AIDS Research and Therapy</i> , 2021, 18, 73.	0.7	2
3415	Challenges to manage pandemic of coronavirus disease (COVID-19) in Iran with a special situation: a qualitative multi-method study. <i>BMC Public Health</i> , 2021, 21, 1919.	1.2	28
3416	Diabetes patients with comorbidities had unfavorable outcomes following COVID-19: A retrospective study. <i>World Journal of Diabetes</i> , 2021, 12, 1789-1808.	1.3	6
3417	A Retrospective Analysis of Risk Factors of COVID-19 Associated Mucormycosis and Mortality Predictors: A Single-Center Study. <i>Cureus</i> , 2021, 13, e18718.	0.2	6
3418	Impact of Living Donor Liver Transplantation on COVID-19 Clinical Outcomes from a Quaternary Care Centre in Delhi. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	0
3419	Pharmacotherapy for SARS-CoV-2 and Seizures for Drug Repurposing Presumed on Mechanistic Targets. <i>Current Molecular Pharmacology</i> , 2022, 15, 832-845.	0.7	1
3420	Remdesivir-Associated Significant Bradycardia: A Report of Three Cases. <i>Journal of Tehran University Heart Center</i> , 2021, 16, 79-83.	0.2	5
3421	Colchicine treatment in COVID-19: the remaining unsolved question. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 1351-1353.	5.2	1
3422	COVID-19 Presentation and Outcomes among Cancer Patients: A Matched Case-Control Study. <i>Cancers</i> , 2021, 13, 5283.	1.7	10
3423	Use of steroids in COVID-19 patients: A meta-analysis. <i>European Journal of Pharmacology</i> , 2022, 914, 174579.	1.7	32
3424	Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis. <i>Respirology</i> , 2021, 26, 1027-1040.	1.3	22
3425	Outcomes of tocilizumab therapy in severe or critical COVID-19 patients: A retrospective cohort, single-centre study. <i>Tropical Medicine and International Health</i> , 2021, 26, 1689-1699.	1.0	3

#	ARTICLE	IF	CITATIONS
3427	Practical management of patients with hematological diseases during the COVID-19 pandemic in Japan. <i>International Journal of Hematology</i> , 2021, 114, 709-718.	0.7	5
3428	Lung transplantation for post-COVID-19 pulmonary fibrosis. <i>Respirology Case Reports</i> , 2021, 9, e0862.	0.3	6
3429	Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion. <i>Seminars in Immunology</i> , 2021, 55, 101508.	2.7	37
3430	Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. <i>European Journal of Neurology</i> , 2022, 29, e7-e8.	1.7	3
3431	Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report. <i>European Journal of Case Reports in Internal Medicine</i> , 2021, 8, 002821.	0.2	3
3432	Old Problem, New Concerns: Hypercortisolemia in the Time of COVID-19. <i>Frontiers in Endocrinology</i> , 2021, 12, 711612.	1.5	7
3433	A new SARS-CoV-2 variant with high lethality poorly detected by RT-PCR on nasopharyngeal samples: an observational study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 298.e9-298.e15.	2.8	13
3434	The effect of glucocorticoids on mortality in severe COVID-19 patients. <i>Medicine (United States)</i> , 2021, 100, e27373.	0.4	10
3435	Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study. <i>Scientific Reports</i> , 2021, 11, 19728.	1.6	27
3436	Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1690.	3.8	169
3437	Diabetes, Heart Failure, and COVID-19: An Update. <i>Frontiers in Physiology</i> , 2021, 12, 706185.	1.3	7
3438	Treatment of children with COVID-19: update of the Italian Society of Pediatric Infectious Diseases position paper. <i>Italian Journal of Pediatrics</i> , 2021, 47, 199.	1.0	11
3439	Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. <i>Brain Communications</i> , 2021, 3, fcab242.	1.5	32
3440	Results of an early second PCR test performed on SARS-CoV-2 positive patients may support risk assessment for severe COVID-19. <i>Scientific Reports</i> , 2021, 11, 20463.	1.6	1
3441	How can we increase participation in pandemic research in Canada?. <i>Canadian Journal of Anaesthesia</i> , 2022, 69, 293-297.	0.7	2
3442	The Impact of Severe Acute Respiratory Syndrome Coronavirus Type 2 on Children With Liver Diseases. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2022, 74, 159-170.	0.9	13
3443	Cardiopulmonary Phenotypes of Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Cardiology in Review</i> , 2021, Publish Ahead of Print, .	0.6	2
3444	Oral dexamethasone for COVID-19 patients at the initial recognition of hypoxia: Can an early dose herald a better outcome?. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 170-171.	1.5	1

#	ARTICLE	IF	CITATIONS
3446	Evolving outcomes of extracorporeal membrane oxygenation support for severe COVID-19 ARDS in Sorbonne hospitals, Paris. <i>Critical Care</i> , 2021, 25, 355.	2.5	50
3447	SARS-CoV-2 Psychiatric Sequelae: A Review of Neuroendocrine Mechanisms and Therapeutic Strategies. <i>International Journal of Neuropsychopharmacology</i> , 2021, , .	1.0	8
3448	COVID-19 pandemic. What have we learned?. <i>Anales De PediatrÃa (English Edition)</i> , 2021, 95, 382.e1-382.e8.	0.1	2
3449	Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 206-210.	0.8	4
3450	The potential role of ICU capacity strain in COVID-19 mortality: comparison between first and second waves in Pavia, Italy. <i>Journal of Anesthesia, Analgesia and Critical Care</i> , 2021, 1, .	0.5	1
3451	COVID-19-associated mucormycosis, diabetes and steroid therapy: Experience in a single centre in Western Mexico. <i>Mycoses</i> , 2022, 65, 65-70.	1.8	17
3452	COVID-19 associated myocarditis: A systematic review. <i>American Journal of Emergency Medicine</i> , 2022, 51, 150-155.	0.7	46
3453	Interhospital Transfer Outcomes for Critically Ill Patients With Coronavirus Disease 2019 Requiring Mechanical Ventilation. , 2021, 3, e0559.		9
3454	Successful use of Impella 5.5 to manage cardiogenic shock complicated by COVID-19. <i>Journal of Cardiac Surgery</i> , 2021, 36, 4783-4785.	0.3	4
3455	The Impact of SARS-CoV-2 Infection, and Application of Immunosuppressive Agents in Kidney Transplant Recipients Suffering from COVID-19. <i>Pharmaceuticals</i> , 2021, 14, 1054.	1.7	5
3456	Effects of dexamethasone on immune dysfunction and ventilator-associated pneumonia in COVID-19 acute respiratory distress syndrome: an observational study. <i>Journal of Intensive Care</i> , 2021, 9, 64.	1.3	15
3457	Changes in characteristics and outcomes of critically ill COVID-19 patients in Tyrol (Austria) over 1 year. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1237-1247.	1.0	15
3458	Results from a national survey on COVID-19-associated mucormycosis in Germany: 13 patients from six tertiary hospitals. <i>Mycoses</i> , 2022, 65, 103-109.	1.8	38
3459	Endogenous endophthalmitis due to methicillin-resistant <i>Staphylococcus aureus</i> bacteremia in a patient with COVID-19. <i>Baylor University Medical Center Proceedings</i> , 2022, 35, 1-2.	0.2	0
3460	A Low-Producing Haplotype of Interleukin-6 Disrupting CTCF Binding Is Protective against Severe COVID-19. <i>MBio</i> , 2021, 12, e0137221.	1.8	22
3461	One year later: The case of tocilizumab in COVID-19. <i>European Journal of Internal Medicine</i> , 2022, 95, 5-6.	1.0	7
3462	Host methylation predicts SARS-CoV-2 infection and clinical outcome. <i>Communications Medicine</i> , 2021, 1, 42.	1.9	35
3463	Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis. <i>Frontiers in Immunology</i> , 2021, 12, 741061.	2.2	62

#	ARTICLE	IF	CITATIONS
3464	Feasibility of CPAP application and variables related to worsening of respiratory failure in pregnant women with SARS-CoV-2 pneumonia: Experience of a tertiary care centre. <i>PLoS ONE</i> , 2021, 16, e0258754.	1.1	1
3465	Imaging in Post-COVID Lung Disease: Does ¹⁸ F-FDG PET/CT Have the Key?. <i>Journal of Nuclear Medicine</i> , 2022, 63, 268-269.	2.8	0
3466	Prediction of in-hospital mortality with machine learning for COVID-19 patients treated with steroid and remdesivir. <i>Journal of Medical Virology</i> , 2022, 94, 958-964.	2.5	25
3467	Effectiveness of methylprednisolone therapy in patients with a high-risk common type of COVID-19 pneumonia: a retrospective cohort study. <i>Clinical and Experimental Medicine</i> , 2022, 22, 487-497.	1.9	1
3468	Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing. <i>Ageing Research Reviews</i> , 2022, 73, 101494.	5.0	11
3469	Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections. <i>F1000Research</i> , 0, 10, 536.	0.8	10
3470	COVID-19, children, clinical trials and compassion: The ethical case for using innovative or compassionate treatments. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, , .	0.7	4
3471	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	1.2	42
3472	Complications of Critical COVID-19. <i>Chest</i> , 2022, 161, 989-998.	0.4	14
3473	Impact of COVID-19 on Patients with Inflammatory Bowel Disease. <i>Journal of Exploratory Research in Pharmacology</i> , 2022, 7, 37-44.	0.2	4
3474	CytoSorb® Hemoadsorption as a Promising Tool to Handle COVID-19-Induced Cytokine Storm. <i>Case Reports in Critical Care</i> , 2021, 2021, 1-5.	0.2	1
3475	Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis. <i>Sao Paulo Medical Journal</i> , 2021, 139, 657-661.	0.4	7
3476	Clinical research methodology process: what is changing with COVID-19?. <i>European Heart Journal Supplements</i> , 2021, 23, E161-E167.	0.0	1
3477	How COVID-19 has changed medical research funding. <i>Interface Focus</i> , 2021, 11, 20210025.	1.5	10
3478	Endothelial dysfunction and COVID-19 (Review). <i>Biomedical Reports</i> , 2021, 15, 102.	0.9	7
3480	Glucocorticoids Induce Partial Remission of Focal Segmental Glomerulosclerosis but Not Interstitial Nephritis in COVID-19 Acute Kidney Injury in an APOL1 Low-Risk Genotype White Patient. <i>American Journal of Case Reports</i> , 2021, 22, e933462.	0.3	6
3482	Assessing relative COVID-19 mortality during the second wave: a prospective Swiss population-based study. <i>BMJ Open</i> , 2021, 11, e051164.	0.8	4
3483	High-Risk Outreach for COVID-19 Mortality Reduction in an Indigenous Community. <i>American Journal of Public Health</i> , 2021, 111, 1939-1941.	1.5	9

#	ARTICLE	IF	CITATIONS
3485	The role of ventilatory support for long-term outcomes after critical infection with COVID-19: A prospective cohort study. <i>Clinical Respiratory Journal</i> , 2022, 16, 63-71.	0.6	6
3486	The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers. <i>Journal of General Internal Medicine</i> , 2021, , 1.	1.3	7
3487	Toxin-like peptides in plasma, urine and faecal samples from COVID-19 patients. <i>F1000Research</i> , 0, 10, 550.	0.8	3
3488	Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study. <i>Critical Care</i> , 2021, 25, 363.	2.5	19
3489	Visible blue light inhibits infection and replication of SARS-CoV-2 at doses that are well-tolerated by human respiratory tissue. <i>Scientific Reports</i> , 2021, 11, 20595.	1.6	15
3490	COVID-19-Associated Pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the Intensive Care Unit: a Retrospective Multicenter Observational Cohort during the First French Pandemic Wave. <i>Microbiology Spectrum</i> , 2021, 9, e0113821.	1.2	32
3491	Reliability of COVID-19 symptom checkers as national triage tools: an international case comparison study. <i>BMJ Health and Care Informatics</i> , 2021, 28, e100448.	1.4	7
3492	Antibiotics for the treatment of COVID-19. <i>The Cochrane Library</i> , 2022, 2022, CD015025.	1.5	49
3493	Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2022, 160, 243-260.	1.3	93
3494	Pituitary Adrenal Responses and Glucocorticoid Receptor Expression in Critically Ill Patients with COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11473.	1.8	8
3495	Acute Hypoxemic Respiratory Failure with High Clinical Suspicion of COVID-19 Despite Negative PCR: a Case for Empiric Corticosteroids and Role of Serum Antibody in Diagnosis. <i>Journal of General Internal Medicine</i> , 2021, 37, 232.	1.3	0
3496	The therapeutic dilemma of immunosuppressive drugs for refractory cardiac sarcoidosis in COVID-19 infection. <i>ESC Heart Failure</i> , 2021, 8, 5577-5582.	1.4	3
3497	Real-Life Impact of Glucocorticoid Treatment in COVID-19 Mortality: A Multicenter Retrospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4678.	1.0	3
3498	Venovenous extracorporeal membrane oxygenation in patients with COVID-19 respiratory failure. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 212-217.	0.4	11
3499	Whole-lung low-dose radiation therapy (LD-RT) for non-intubated oxygen-dependent patients with COVID-19-related pneumonia receiving dexamethasone and/or remdesivir. <i>Radiotherapy and Oncology</i> , 2021, 165, 20-31.	0.3	13
3501	Coronavirus Disease (COVID-19) Associated Rhinocerebral Mucormycosis and Complications: A Case Report. <i>International Journal of Clinical Research</i> , 2021, 2, 93-99.	0.1	1
3502	Formal and informal science advice in emergencies: COVID-19 in the UK. <i>Interface Focus</i> , 2021, 11, 20210059.	1.5	5
3503	Hemoperfusion and blood purification strategies in patients with COVID-19: A systematic review. <i>Artificial Organs</i> , 2021, 45, 1466-1476.	1.0	20

#	ARTICLE	IF	CITATIONS
3504	Open-label randomized controlled trial of ultra-low tidal ventilation without extracorporeal circulation in patients with COVID-19 pneumonia and moderate to severe ARDS: study protocol for the VT4COVID trial. <i>Trials</i> , 2021, 22, 692.	0.7	1
3505	Personal observations on COVID-19 and the conduct and application of biomedical science. <i>Interface Focus</i> , 2021, 11, 20210053.	1.5	1
3506	Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 4610.	1.0	4
3507	The Role of Surface in the Pathogenesis and Treatment of COVID-19. <i>Covid</i> , 2021, 1, 465-471.	0.7	1
3508	Management Challenge of Rhino-Orbito-Cerebral Mucormycosis in Covid 19 Era: A Prospective Observational Study. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2022, 74, 3485-3491.	0.3	12
3509	Influenza and RSV incidence during COVID-19 pandemic – an observational study from in-hospital point-of-care testing. <i>Medical Microbiology and Immunology</i> , 2021, 210, 277-282.	2.6	44
3510	Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 271-284.	0.4	48
3511	Aspergillosis: Emerging risk groups in critically ill patients. <i>Medical Mycology</i> , 2021, 60, .	0.3	17
3512	Coronavirus disease 2019 in kidney transplant recipients: a systematic review and meta-analysis. <i>Singapore Medical Journal</i> , 2023, 64, 593-602.	0.3	8
3513	The relationship between Covid-19 and mucociliary clearance. <i>Acta Oto-Laryngologica</i> , 2021, 141, 989-993.	0.3	4
3514	Incidence and Risk Factors of COVID-19-Associated Pulmonary Aspergillosis in Intensive Care Unit – A Monocentric Retrospective Observational Study. <i>Pathogens</i> , 2021, 10, 1370.	1.2	11
3515	Association of Serum Ferritin Levels and Methylprednisolone Treatment With Outcomes in Nonintubated Patients With Severe COVID-19 Pneumonia. <i>JAMA Network Open</i> , 2021, 4, e2127172.	2.8	10
3516	Cardiac SARS-CoV-2 infection is associated with pro-inflammatory transcriptomic alterations within the heart. <i>Cardiovascular Research</i> , 2022, 118, 542-555.	1.8	42
3517	COVID-19 survivors with calcineurin-inhibitors-treated rheumatoid arthritis. <i>Modern Rheumatology Case Reports</i> , 2021, , .	0.3	1
3518	Acute Kidney Disease and Mortality in Acute Kidney Injury Patients with COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 4599.	1.0	18
3519	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1365-1376.	5.2	119
3521	Extracorporeal Membrane Oxygenation for COVID 2019-Acute Respiratory Distress Syndrome: Comparison between First and Second Waves (Stage 2). <i>Journal of Clinical Medicine</i> , 2021, 10, 4839.	1.0	10
3522	Role of neutrophils, platelets, and extracellular vesicles and their interactions in COVID-19 associated thrombopathy. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 17-31.	1.9	45

#	ARTICLE	IF	CITATIONS
3523	Dexamethasone in COVID-19: Should we consider a "golden hour" practice?. International Journal of Clinical Practice, 2021, 75, e14672.	0.8	0
3524	Glucocorticoid Dose in COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1801.	3.8	8
3525	Double Trouble—COVID-19 and the Widespread Use of Corticosteroids: Are We Staring at an Osteonecrosis Epidemic?. Indian Journal of Orthopaedics, 2022, 56, 226-236.	0.5	14
3526	Influence of Geopolitics on Severity and Outcome in Coronavirus Disease 2019. Critical Care Medicine, 2021, Publish Ahead of Print, .	0.4	2
3527	Evaluation of Hospitalized Patient Outcomes in COVID-19 Infection for Continued versus Discontinued Use of Preadmission Antiplatelet Regimen. Journal of Pharmacy Practice, 2023, 36, 508-513.	0.5	0
3528	Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases. Frontiers in Cellular and Infection Microbiology, 2021, 11, 753249.	1.8	6
3529	Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Expert Review of Anti-Infective Therapy, 2022, 20, 585-609.	2.0	5
3530	Extracorporeal membrane oxygenation for coronavirus disease 2019-related acute respiratory distress syndrome. Current Opinion in Critical Care, 2022, 28, 90-97.	1.6	7
3531	Cancer and Covid-19: Collectively catastrophic. Cytokine and Growth Factor Reviews, 2022, 63, 78-89.	3.2	10
3532	Corticosteroids for COVID-19: worth it or not?. Molecular Biology Reports, 2022, 49, 567-576.	1.0	21
3533	COVID-19 Advanced Care. Journal of Personalized Medicine, 2021, 11, 1082.	1.1	1
3534	Neurotropism of SARS-CoV-2 and neurological diseases of the central nervous system in COVID-19 patients. Experimental Brain Research, 2022, 240, 9-25.	0.7	38
3535	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respiratory Medicine, 2021, 9, 1419-1426.	5.2	123
3536	Post-covid condition in adults and children. Pulmonologiya, 2021, 31, 562-570.	0.2	5
3537	<i>Garcinia kola</i> and garcinoic acid suppress SARS-CoV-2 spike glycoprotein S1-induced hyperinflammation in human PBMCs through inhibition of NF- κ B activation. Phytotherapy Research, 2021, 35, 6963-6973.	2.8	10
3538	Increased risk of death in COVID-19 hospital admissions during the second wave as compared to the first epidemic wave: a prospective, single-centre cohort study in London, UK. Infection, 2022, 50, 457-465.	2.3	11
3539	Coronavirus disease 2019 in liver transplant patients: Clinical and therapeutic aspects. World Journal of Hepatology, 2021, 13, 1299-1315.	0.8	1
3540	Impact of COVID-19 pandemic on liver, liver diseases, and liver transplantation programs in intensive care units. World Journal of Hepatology, 2021, 13, 1215-1233.	0.8	3

#	ARTICLE	IF	CITATIONS
3541	Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia. JAMA - Journal of the American Medical Association, 2021, 326, 1807.	3.8	174
3542	Infection, Inflammation and Immunity in Covid-19 Infection. Acta Medica Bulgarica, 2021, 48, 77-82.	0.0	0
3543	Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study. Open Heart, 2021, 8, e001785.	0.9	18
3544	Vitamins, supplements and COVID-19: a review of currently available evidence. Drugs in Context, 2021, 10, 1-15.	1.0	24
3545	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respiratory Medicine, 2021, 9, 1275-1287.	5.2	394
3546	A review of the evidence for and against the use of steroids in renal transplant patients with COVID-19. Journal of King Abdulaziz University, Islamic Economics, 2021, 42, 1149-1152.	0.5	1
3547	COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	26
3548	Combating Oxidative Stress and Inflammation in COVID-19 by Molecular Hydrogen Therapy: Mechanisms and Perspectives. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-17.	1.9	63
3549	Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies. Current Medical Science, 2021, 41, 1065.	0.7	3
3550	Mega randomized clinical trials: a definitive solution or a double-edged sword?. European Journal of Clinical Pharmacology, 2021, , 1.	0.8	0
3551	Targeting the Pentose Phosphate Pathway for SARS-CoV-2 Therapy. Metabolites, 2021, 11, 699.	1.3	25
3552	Sex and organ-specific risk of major adverse renal or cardiac events in solid organ transplant recipients with COVID-19. American Journal of Transplantation, 2022, 22, 245-259.	2.6	13
3553	Comparison of characteristics and outcomes of patients admitted to hospital with COVID-19 during wave 1 and wave 2 of the current pandemic. Internal and Emergency Medicine, 2021, , 1.	1.0	8
3554	Corticosteroid therapy in patients with heart failure hospitalized for COVID-19: a multicenter retrospective study. Internal and Emergency Medicine, 2021, 16, 2301-2305.	1.0	8
3555	Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals. Viruses, 2021, 13, 1993.	1.5	70
3556	COVID-19, circadian rhythms and sleep: from virology to chronobiology. Interface Focus, 2021, 11, 20210043.	1.5	12
3557	Clinical Features and Temporal Lung Radiographic Changes in 25 Patients Recovering from COVID-19 Pneumonia: A Retrospective Case-Control Study. Medical Science Monitor, 2021, 27, e933381.	0.5	1
3558	Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target. Frontiers in Immunology, 2021, 12, 687397.	2.2	22

#	ARTICLE	IF	CITATIONS
3559	Case Report: Home-based Management of Severe COVID-19 with Low-dose Tofacitinib. American Journal of Tropical Medicine and Hygiene, 2021, 105, 1472-1475.	0.6	4
3560	Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study. PLoS ONE, 2021, 16, e0258643.	1.1	28
3561	Chronic obstructive pulmonary disease and COVID-19: interrelationships. Current Opinion in Pulmonary Medicine, 2022, 28, 76-83.	1.2	42
3562	Opportunistic mycoses in COVID-19 patients/survivors: Epidemic inside a pandemic. Journal of Infection and Public Health, 2021, 14, 1720-1726.	1.9	12
3563	Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: A phase 1 trial. EClinicalMedicine, 2021, 41, 101167.	3.2	22
3564	Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial. EClinicalMedicine, 2021, 41, 101169.	3.2	52
3565	COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes and Endocrinology, 2021, 9, 786-798.	5.5	155
3566	A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition. Antiviral Research, 2021, 195, 105183.	1.9	8
3567	Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial. EClinicalMedicine, 2021, 41, 101152.	3.2	28
3568	General recommendation for assessment and management on the risk of glucocorticoid-induced osteonecrosis in patients with COVID-19. Journal of Orthopaedic Translation, 2021, 31, 1-9.	1.9	19
3569	Concurrent COVID-19 and Pneumocystis jirovecii pneumonia: The importance of radiological diagnostic and HIV testing. Radiology Case Reports, 2021, 16, 3685-3689.	0.2	11
3570	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. International Immunopharmacology, 2021, 101, 108232.	1.7	14
3571	Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19. Biomedicine and Pharmacotherapy, 2021, 144, 112276.	2.5	9
3572	Comparing the outcomes of treatment with INF- β 1-a (interferon beta-1a) and INF- β 1-b (interferon beta-1b) among COVID-19 inpatients. International Immunopharmacology, 2021, 101, 108241.	1.7	1
3573	Normalization of SARS-CoV-2 viral load via RT-qPCR provides higher-resolution data for comparison across time and between patients. Virus Research, 2021, 306, 198604.	1.1	7
3574	Serology-based therapeutic strategy in SARS-CoV-2-infected patients. International Immunopharmacology, 2021, 101, 108214.	1.7	2
3575	Regulatory approval for COVID-19 across the globe. Indian Journal of Pharmacology, 2020, 52, 457.	0.4	1
3576	Authors' response. Indian Journal of Medical Research, 2020, 152, 151.	0.4	0

#	ARTICLE	IF	CITATIONS
3577	Favorable outcome of COVID-19 in a young woman with severe Crohn's disease on regular use of adalimumab and prednisone: a case report. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2020, 62, e102.	0.5	4
3580	Management of patients with COVID-19 in the MICU. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 526-531.	0.6	0
3582	A new model for clinical trials to address the COVID-19 emergency. <i>Breathe</i> , 2020, 16, 200220.	0.6	0
3583	Síndrome de dificultad respiratoria aguda en el contexto de la pandemia por COVID-19. <i>CES Medicina</i> , 0, 34, 69-77.	0.1	0
3586	Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial. <i>F1000Research</i> , 2020, 9, 1017.	0.8	2
3587	Treatment of Coronavirus Disease 2019: Shooting in the Dark. <i>European Cardiology Review</i> , 2020, 15, e59.	0.7	2
3589	Tratamiento farmacológico para COVID-19 en protocolos latinoamericanos: Una revisión narrativa de la eficacia y seguridad. , 2020, 8, 150-160.		4
3591	Acute Kidney Injury in COVID-19 Pneumonia: A Single-Center Experience in Bahrain. <i>Cureus</i> , 2020, 12, e9693.	0.2	24
3594	Antiviral treatment for COVID-19: the evidence supporting remdesivir. <i>Clinical Medicine</i> , 2020, 20, e215-e217.	0.8	4
3595	Comparison of the Clinical Course of COVID-19 Pneumonia and Acute Respiratory Distress Syndrome in 2 Passengers from the Cruise Ship Diamond Princess in February 2020. <i>American Journal of Case Reports</i> , 2020, 21, e926835.	0.3	3
3598	COVID-19 Pandemic in Women—Rheumatologist's Perspective. <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , 2020, 5, 250-255.	0.1	0
3600	Clinical management and outcome differences between first and second waves among COVID-19 hospitalized patients: A regional prospective observational cohort. <i>PLoS ONE</i> , 2021, 16, e0258918.	1.1	6
3601	The intersection of COVID-19 and autoimmunity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	138
3602	COVID-19-related Acute Respiratory Distress Syndrome Subphenotypes and Differential Response to Corticosteroids: Time for More Precision?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1241-1243.	2.5	6
3603	Tissue Proteomic Analysis Identifies Mechanisms and Stages of Immunopathology in Fatal COVID-19. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 66, 196-205.	1.4	26
3604	Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. <i>Infectious Diseases and Therapy</i> , 2021, , 1.	1.8	6
3605	Hospitalization and mortality trends among patients with confirmed COVID-19 in the United States, April through August 2020. <i>Journal of Public Health Research</i> , 2021, , .	0.5	2
3606	Clinical use of antiviral, antibiotic and immunomodulatory drugs in hospitalized COVID-19 patients: a retrospective study in Bandung, Indonesia. <i>F1000Research</i> , 0, 10, 1091.	0.8	1

#	ARTICLE	IF	CITATIONS
3607	Dysregulated Inflammation During Obesity: Driving Disease Severity in Influenza Virus and SARS-CoV-2 Infections. <i>Frontiers in Immunology</i> , 2021, 12, 770066.	2.2	26
3608	Mucormycosis in COVID Diabetic Patients: A Horrifying Triad!. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 1314-1317.	0.3	4
3609	A Case Series of Amoebic Liver Abscess in Patients With COVID-19 Infection. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1017-1020.	0.4	1
3610	Organising pneumonia manifesting as a late-phase complication of COVID-19. <i>BMJ Case Reports</i> , 2021, 14, e246119.	0.2	14
3611	Immune interventions in COVID-19: a matter of time?. <i>Mucosal Immunology</i> , 2022, 15, 198-210.	2.7	14
3612	Cytokine Storm and Immunomodulation in COVID-19. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 1288-1291.	0.3	5
3613	The Role of Glucocorticoids in Inflammatory Diseases. <i>Cells</i> , 2021, 10, 2921.	1.8	44
3614	Dexamethasone therapy and rates of secondary pulmonary and bloodstream infections in critically ill COVID-19 patients. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 793.	0.6	12
3615	COVID-19 in lung transplant recipients: an overview of the Swedish national experience. <i>Transplant International</i> , 2021, 34, 2597-2608.	0.8	8
3616	COVID-19 ASSOCIATED MUCORMYCOSIS (CAM) AND IT'S MANAGEMENT. , 2021, , 35-37.		0
3617	Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19. <i>Case Reports in Medicine</i> , 2021, 2021, 1-5.	0.3	6
3618	Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets. <i>Molecular Systems Biology</i> , 2021, 17, e10260.	3.2	26
3619	The risk factors potentially influencing risk of serious illness/death in people with diabetes, following SARS-CoV-2 infection. <i>Cardiovascular Endocrinology and Metabolism</i> , 2021, Publish Ahead of Print, 231-232.	0.5	1
3620	Rehabilitation of peripheral facial palsy associated with COVID-19 in a child: A case report. <i>Annals of Physical and Rehabilitation Medicine</i> , 2022, 65, 101600.	1.1	6
3621	The course of action for effective anti-cytokine treatment in COVID-19. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1353-1354.	5.2	4
3622	Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1955-1963.	1.1	22
3623	Divergent COVID-19 Disease Trajectories Predicted by a DAMP-Centered Immune Network Model. <i>Frontiers in Immunology</i> , 2021, 12, 754127.	2.2	10
3624	Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. <i>Clinical and Translational Science</i> , 2022, 15, 501-513.	1.5	21

#	ARTICLE	IF	CITATIONS
3625	Occurrence, Fate, Effects, and Risks of Dexamethasone: Ecological Implications Post-COVID-19. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11291.	1.2	18
3626	Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001899.	1.8	8
3627	Characteristics and Outcomes of US Patients Hospitalized With COVID-19. <i>American Journal of Critical Care</i> , 2022, 31, 146-157.	0.8	16
3628	Early warning scores to assess the probability of critical illness in patients with COVID-19. <i>Emergency Medicine Journal</i> , 2021, 38, 901-905.	0.4	13
3629	Prolonged corticosteroid therapy and cytomegalovirus infection in patients with severe COVID-19. <i>Journal of Medical Virology</i> , 2022, 94, 1067-1073.	2.5	12
3630	<i>Pneumocystis jirovecii</i> Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11399.	1.2	24
3631	Colchicine, COVID-19 and hematological parameters: A meta-analysis. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e24057.	0.9	6
3632	Did our pharmacological strategy for COVID-19 fail?. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00866.	1.1	2
3633	The Structured Process to Identify Fit-for-Purpose Data: A Data Feasibility Assessment Framework. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 122-134.	2.3	25
3634	Expert Consensus Statements on the Use of Corticosteroids in Non-severe COVID-19. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 1280-1285.	0.3	5
3635	Smoking status related to Covid-19 mortality and disease severity in a veteran population. <i>Respiratory Medicine</i> , 2021, 190, 106668.	1.3	2
3636	The COVID-19 pandemic and ANCA-associated vasculitis – reports from the EUVAS meeting and EUVAS education forum. <i>Autoimmunity Reviews</i> , 2021, 20, 102986.	2.5	25
3637	Possible harm from glucocorticoid drugs misuse in the early phase of SARS-CoV-2 infection: a narrative review of the evidence. <i>Internal and Emergency Medicine</i> , 2022, 17, 329-338.	1.0	13
3638	Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000774.	1.1	20
3640	Transcutaneous retrobulbar injection of amphotericin B in rhino-orbital-cerebral mucormycosis: a review. <i>Orbit</i> , 2022, 41, 275-286.	0.5	16
3641	The impact of the hypoxia-induced vascular permeability on COVID-19-infected patients. <i>Exploration</i> , 2021, 1, 20210051.	5.4	20
3642	Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1427-1438.	5.2	86
3643	Phytochemicals for the treatment of COVID-19. <i>Journal of Microbiology</i> , 2021, 59, 959-977.	1.3	19

#	ARTICLE	IF	CITATIONS
3644	Health Indicators in Hospitalized Patients With SARS-CoV-2 Pneumonia: A Comparison Between the First and Second Wave. <i>Archivos De Bronconeumologia</i> , 2021, 57, 717-719.	0.4	5
3645	Caring for Hospitalized COVID-19 Patients: From Hypes and Hopes to Doing the Simple Things First. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	1
3646	Impact of immunosuppression on the immune response to SARS-CoV-2 infection: A mechanistic study. <i>Transplant Infectious Disease</i> , 2021, 23, e13743.	0.7	5
3647	The Role of HLA Antigens and Steroid Dose on the Course of COVID-19 of Patients After Kidney Transplantation. <i>Frontiers in Medicine</i> , 2021, 8, 730156.	1.2	0
3648	Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. <i>Frontiers in Pediatrics</i> , 2021, 9, 723532.	0.9	32
3650	Inovação, propriedade intelectual e acesso a medicamentos e vacinas: o debate internacional na pandemia da Covid-19. <i>Liinc Em Revista</i> , 2020, 16, e5338.	0.1	4
3651	COVID-19 therapy: from myths to reality and hopes. <i>Medical Immunology (Russia)</i> , 2020, 22, 827-836.	0.1	0
3652	Clinical characteristics and predictors of the duration of hospital stay in COVID-19 patients in Jordan. <i>F1000Research</i> , 0, 9, 1439.	0.8	3
3656	U-shaped-aggressiveness of SARS-CoV-2: Period between initial symptoms and clinical progression to COVID-19 suspicion. A population-based cohort study. <i>PLoS ONE</i> , 2020, 15, e0243268.	1.1	5
3657	COVID-19 Treatment at a Glance. <i>Turkish Thoracic Journal</i> , 2020, 21, 438-445.	0.2	2
3658	Corticosteroids in the treatment of SARS-CoV-2 related lung disease. <i>SeĖnovskij Vestnik</i> , 2020, 11, 19-28.	0.3	3
3659	Virus-Induced Wheezing With COVID-19. <i>Indian Pediatrics</i> , 2020, 57, 1183-1185.	0.2	0
3662	High Dose Steroid Therapy to Prevent Severe Hypoxia in COVID-19 Patients: A Potential Solution for Low Resource Clinical Setting. <i>Cureus</i> , 2020, 12, e12330.	0.2	4
3663	Outcomes of COVID-19 Patients Hospitalized at Acute Care Services. <i>Infectious Diseases in Clinical Practice</i> , 2021, 29, e88-e96.	0.1	0
3664	Randomised placebo-controlled multicentre effectiveness trial of adjunct betamethasone therapy in hospitalised children with community-acquired pneumonia: a trial protocol for the KIDS-STEP trial. <i>BMJ Open</i> , 2020, 10, e041937.	0.8	1
3665	A case report on transient cardiomyopathy with cytokine storm in SARS-CoV-2. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytaa519.	0.3	4
3666	COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 33-43.	0.5	8
3669	Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial. <i>F1000Research</i> , 2020, 9, 1017.	0.8	8

#	ARTICLE	IF	CITATIONS
3673	Cascaded deep transfer learning on thoracic CT in COVID-19 patients treated with steroids. <i>Journal of Medical Imaging</i> , 2020, 8, 014501.	0.8	6
3675	Acute Ischemic Stroke as Complication in COVID-19 with Acute Respiratory Distress Syndrome in Intensive Care Unit: A Review. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 604-609.	0.1	1
3676	Profile and outcomes of hospitalized patients with COVID-19 at a tertiary institution hospital in Ghana. <i>Ghana Medical Journal</i> , 2021, 54, 39-45.	0.1	8
3677	A narrative review of non-pharmacological management of SARS-CoV-2 respiratory failure: a call for an evidence based approach. <i>Annals of Translational Medicine</i> , 2020, 8, 1599-1599.	0.7	1
3678	Statin use is associated with reduced mortality after respiratory viral infection. <i>ERJ Open Research</i> , 2021, 7, 00365-2020.	1.1	4
3679	Core warming of coronavirus disease 2019 (COVID-19) patients undergoing mechanical ventilation—A protocol for a randomized controlled pilot study. <i>PLoS ONE</i> , 2020, 15, e0243190.	1.1	3
3681	Successful Treatment with High-dose Steroids for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Triggered by COVID-19. <i>Internal Medicine</i> , 2022, 61, 233-236.	0.3	6
3682	COVID-19 and antimicrobial resistance: A cross-study. <i>Science of the Total Environment</i> , 2022, 807, 150873.	3.9	79
3683	COVID-19 grave: entenda o papel da imunidade, do endotélio e da coagulação na prática clínica. <i>Jornal Vascular Brasileiro</i> , 2020, 19, e20200131.	0.1	10
3684	Effectiveness and Safety of Methylprednisolone When Treating Patients with COVID-19 Pneumonia-Induced Severe Systemic Inflammation: A Retrospective, Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3686	Intravenous lidocaine infusion in a case of severe COVID-19 infection. <i>Journal of Anaesthesiology Clinical Pharmacology</i> , 2021, 37, 481.	0.2	4
3688	Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100261.	0.7	3
3689	Characteristics, Management and Prognosis of Elderly Patients with COVID-19 Admitted in the ICU During the First Wave: Insights from the COVID-ICU Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
3690	Journal Club—Severe Acute Respiratory Syndrome Coronavirus-2: Impact on COPD Patients. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 7, 413-419.	0.5	2
3691	CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION). <i>Juvenis Scientia</i> , 2020, 6, 41-80.	0.1	0
3692	MATH+ and I-MASK+ Protocols for Prevention and Treatment of All Phases of COVID-19 — A Short Review. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3693	Can Serum Cortisol Be Used To Monitor Patients With COVID-19?. <i>US Endocrinology</i> , 2020, 16, 63.	0.3	1
3696	Critical Care for COVID-19 Affected Patients: Updated Position Statement of the Indian Society of Critical Care Medicine. <i>Indian Journal of Critical Care Medicine</i> , 2020, 24, S225-S230.	0.3	22

#	ARTICLE	IF	CITATIONS
3697	COVID-19: The latest news and views. Libyan Journal of Medical Sciences, 2020, 4, 99.	0.1	0
3698	Impact of Timing of Tocilizumab Use in Hospitalized SARS-CoV-2 Infected Patients. SSRN Electronic Journal, 0, , .	0.4	0
3699	Deep RNA Sequencing of Intensive Care Unit Patients with COVID-19. SSRN Electronic Journal, 0, , .	0.4	2
3700	Pathogenesis Guided Therapeutic Management of COVID-19: An Immunological Perspective. SSRN Electronic Journal, 0, , .	0.4	1
3701	COVID-19â€™Practicing prevention in the workplace. Indian Journal of Occupational and Environmental Medicine, 2020, 24, 133.	0.6	6
3702	Myocarditis Associated with Coronavirus Disease 2019 (COVID-19) in a Pediatric Patient. Advances in Infectious Diseases, 2020, 10, 226-232.	0.0	0
3703	Vitamin C, Thiamine and Steroids: Ménage à Trois or Medical Masala. Indian Journal of Critical Care Medicine, 2020, 24, 619-623.	0.3	0
3705	Clinical Spectrum of Children With Multisystem Inflammatory Syndrome Associated With SARS-CoV-2 Infection. Indian Pediatrics, 2021, 58, 955-958.	0.2	7
3706	Voice Series COVID-19 Special Collection Part 1: Interview with clinicians: COVID-19 mutation and current breakthrough in vaccine development. BIO Integration, 2021, 2, .	0.9	0
3708	Acute Respiratory Distress Syndrome in a Patient With Acute Promyelocytic Leukemia: Overlapping Between Differentiation Syndrome and COVID-19. Journal of Hematology (Brossard, Quebec), 2021, 10, 217-220.	0.4	1
3710	SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients. Kidney360, 2022, 3, 10.34067/KID.0005732021.	0.9	9
3711	SARS-CoV-2 infection in heart transplant recipients: a systematic literature review of clinical outcomes and immunosuppression strategies. Heart Failure Reviews, 2022, 27, 1653-1663.	1.7	5
3712	The Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City. Viruses, 2021, 13, 2182.	1.5	31
3713	Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19. Frontiers in Medicine, 2021, 8, 749657.	1.2	13
3714	Convalescent Plasma Reduces Mortality and Decreases Hospitalization Stay in Patients with Moderate COVID-19 Pneumonia. Metabolites, 2021, 11, 761.	1.3	11
3715	Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. Current Opinion in Nephrology and Hypertension, 2022, 31, 36-46.	1.0	11
3716	PEGylated green halloysite/spinel ferrite nanocomposites for pH sensitive delivery of dexamethasone: A potential pulmonary drug delivery treatment option for COVID-19. Applied Clay Science, 2022, 216, 106333.	2.6	16
3717	SARS-CoV-2 Infection in Kidney Transplant Recipients: A Single-Centre Study of 20 Cases from India. International Journal of Nephrology, 2021, 2021, 1-7.	0.7	4

#	ARTICLE	IF	CITATIONS
3718	Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. <i>BMJ, The</i> , 2021, 375, e068060.	3.0	52
3719	Risk, Clinical Course, and Outcome of Ischemic Stroke in Patients Hospitalized With COVID-19: A Multicenter Cohort Study. <i>Stroke</i> , 2021, 52, 3978-3986.	1.0	18
3720	Host-modifying drugs against COVID-19: some successes, but not yet the breakthrough. <i>Environmental Microbiology</i> , 2021, 23, 7257-7270.	1.8	0
3721	Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent. <i>Beni-Suef University Journal of Basic and Applied Sciences</i> , 2021, 10, 78.	0.8	22
3722	Improving the early identification of COVID-19 pneumonia: a narrative review. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000911.	1.2	7
3723	Intensive care unit hospitalizations and outcomes in patients with severe COVID-19 during summer and fall surges in Georgia. <i>World Journal of Critical Care Medicine</i> , 2021, 10, 369-376.	0.8	2
3724	Clinical Practice in COVID-19: the most frequently asked questions to Infectious Diseases Specialists. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101648.	0.3	1
3725	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12081.	1.8	21
3727	Myeloid dysregulation and therapeutic intervention in COVID-19. <i>Seminars in Immunology</i> , 2021, 55, 101524.	2.7	9
3728	Autoimmune Thrombocytopenia in SLE and COVID-19. <i>European Journal of Case Reports in Internal Medicine</i> , 2021, 8, 002863.	0.2	1
3729	Mortality in Solid Organ Transplant Recipients Hospitalized for Covid-19. <i>American Journal of Transplantation</i> , 2021, 22, 12.	2.6	4
3730	Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities. <i>Seminars in Immunology</i> , 2021, 55, 101522.	2.7	12
3731	A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol. <i>Gates Open Research</i> , 0, 5, 117.	2.0	9
3732	Mortality risk factors in kidney-transplanted patients with COVID-19: A systematic review and regression analysis. <i>Health Science Reports</i> , 2021, 4, e427.	0.6	4
3733	Identification and Development of Therapeutics for COVID-19. <i>MSystems</i> , 2021, 6, e0023321.	1.7	20
3734	Development of an Inactivated Vaccine against SARS CoV-2. <i>Vaccines</i> , 2021, 9, 1266.	2.1	23
3735	COVID-19 in patients with CLL: how can we change the odds?. <i>Blood</i> , 2021, 138, 1652-1653.	0.6	1
3736	Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group. , 2021, 3, e0566.		5

#	ARTICLE	IF	CITATIONS
3737	Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2956-2970.	2.9	46
3738	The evolution of clot strength in critically-ill COVID-19 patients: a prospective observational thromboelastography study. <i>Thrombosis Journal</i> , 2021, 19, 83.	0.9	6
3739	Prevalence and Clinical Implications of COVID-19 Myocarditis. <i>Cardiac Electrophysiology Clinics</i> , 2022, 14, 53-62.	0.7	16
3740	Assessment of 28-Day In-Hospital Mortality in Mechanically Ventilated Patients With Coronavirus Disease 2019: An International Cohort Study. , 2021, 3, e0567.		4
3741	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e855-e864.	2.2	38
3742	Corticosteroid treatment in COVID-19 modulates host inflammatory responses and transcriptional signatures of immune dysregulation. <i>Journal of Leukocyte Biology</i> , 2021, 110, 1225-1239.	1.5	4
3743	Complex immune deregulation in severe COVID-19: More than a mechanism of pathogenesis. <i>EBioMedicine</i> , 2021, 73, 103673.	2.7	6
3744	COVID-19 critical illness in pregnancy. <i>Obstetric Medicine</i> , 2022, 15, 220-224.	0.5	3
3746	Longitudinal validation of an electronic health record delirium prediction model applied at admission in COVID-19 patients. <i>General Hospital Psychiatry</i> , 2022, 74, 9-17.	1.2	7
3747	Mortality comparison between the first and second/third waves among 3,795 critical COVID-19 patients with pneumonia admitted to the ICU: A multicentre retrospective cohort study. <i>Lancet Regional Health - Europe</i> , The, 2021, 11, 100243.	3.0	99
3750	Caring for patients in a new pandemic: the necessity and challenges of observational research. <i>Journal of Clinical Investigation</i> , 2020, 130, 6225-6227.	3.9	5
3751	Drugs of unproven benefit for COVID-19: a pharma perspective on ethical allocation of available therapies. <i>Journal of Clinical Investigation</i> , 2020, 130, 5622-5623.	3.9	1
3752	Implications of COVID-19 for inflammatory bowel disease: Opportunities and challenges amidst the pandemic. <i>World Journal of Meta-analysis</i> , 2020, 8, 383-399.	0.1	0
3756	Evidence and decision-making in times of pandemic. <i>Colombian Journal of Anesthesiology</i> , 2020, 48, .	0.5	1
3757	From Editor-in-Chief: Has everything changed during pandemic: peer-review, science, clinical practices and education, CV diseases?. <i>Heart Vessels and Transplantation</i> , 0, 4, .	0.0	3
3758	Dexamethasone use in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 96-98.	0.2	0
3759	Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa486.	0.4	4
3765	A Hawkes process model for the propagation of COVID-19: Simple analytical results. <i>Europhysics Letters</i> , 2020, 131, 68005.	0.7	5

#	ARTICLE	IF	CITATIONS
3766	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. <i>F1000Research</i> , 0, 9, 1109.	0.8	7
3767	The effects of tocilizumab on clinical and laboratory features of patients with severe COVID-19: a single-center experience. <i>Heart Vessels and Transplantation</i> , 0, 4, .	0.0	2
3769	Recovery From Acute Kidney Injury With Diabetic Ketoacidosis Following SARS-CoV-2 Infection: A Case Report and Literature Review. <i>Cureus</i> , 2020, 12, e11702.	0.2	5
3770	Treatment Experience With Inhaled Corticosteroids in Combination with Remdesivir and Dexamethasone Among COVID-19 Patients Admitted to a Rural Community Hospital: A Case Series. <i>Cureus</i> , 2020, 12, e11787.	0.2	3
3771	Therapeutic options in the treatment of severe acute respiratory syndrome coronavirus 2 in pregnant patient. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2020, 2, 100224.	1.3	1
3772	COVID-19 pandemic: potential phase III vaccines in development. <i>The Applied Biology & Chemistry Journal</i> , 0, , 21-33.	0.0	8
3776	Corticosteroids: A controversial therapy for coronavirus disease 2019. <i>Journal of Translational Internal Medicine</i> , 2020, 8, 115-118.	1.0	1
3777	Let fever do its job. <i>Evolution, Medicine and Public Health</i> , 2021, 9, 26-35.	1.1	24
3784	Systemic microvascular dysfunction in COVID-19. <i>American Journal of Cardiovascular Disease</i> , 2020, 10, 386-391.	0.5	4
3785	Understanding COVID-19: the virus. <i>Community Eye Health Journal</i> , 2020, 33, 5-9.	0.4	1
3786	Is there a place for anti-inflammatory therapy in COVID-19?. <i>Journal of Thoracic Disease</i> , 2020, 12, 7076-7080.	0.6	0
3787	Therapeutic strategies against COVID-19. <i>Acta Biomedica</i> , 2020, 91, e2020038.	0.2	3
3788	The "perfect" storm: Current evidence on pediatric inflammatory multisystem disease during SARS-CoV-2 pandemic. <i>Acta Biomedica</i> , 2020, 91, e2020034.	0.2	3
3789	Knowledge of COVID-19 among Health Care Workers at a Tertiary Care Hospital of Nepal: A Descriptive Cross-sectional Study. <i>Journal of the Nepal Medical Association</i> , 2020, 58, 905-910.	0.1	1
3790	Clinical Experience, Pathophysiology, and Considerations in the Prophylaxis and Treatment of Hypercoagulopathy of COVID-19: A Review Study. <i>Iranian Journal of Medical Sciences</i> , 2021, 46, 1-14.	0.3	8
3791	COVID-19 in underlying COPD Patients. <i>EXCLI Journal</i> , 2021, 20, 248-251.	0.5	2
3792	It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?. <i>Archives of Medical Science</i> , 2021, 17, 546-550.	0.4	0
3793	Coronavirus (SARS-CoV-2) in gastroenterology and its current epidemiological situation: An updated review until January 2021. <i>EXCLI Journal</i> , 2021, 20, 366-385.	0.5	3

#	ARTICLE	IF	CITATIONS
3794	Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. American Journal of Cardiovascular Disease, 2021, 11, 93-107.	0.5	13
3795	Cardiovascular manifestations of COVID-19: An evidence-based narrative review. Indian Journal of Medical Research, 2021, 153, 7-16.	0.4	4
3796	Diabetes and Covid-19: Clinical implications and novel management strategies. Ulster Medical Journal, 2021, 90, 81-85.	0.2	0
3797	Cardiovascular injuries and SARS-COV-2 infection: focus on elderly people. Journal of Geriatric Cardiology, 2021, 18, 534-548.	0.2	2
3798	First case report of a successfully managed severe COVID-19 infection in Malawi. Malawi Medical Journal, 2020, 32, 226-228.	0.2	2
3799	Mechanism and adverse effects of COVID-19 drugs: a basic review. International Journal of Physiology, Pathophysiology and Pharmacology, 2021, 13, 102-109.	0.8	5
3800	Differences in mortality in critically ill elderly patients during the second COVID-19 surge in Europe. Critical Care, 2021, 25, 344.	2.5	7
3801	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. RMD Open, 2021, 7, .	1.8	6
3803	Comparison of tocilizumab and high-dose methylprednisolone pulse on outcomes in severe corona virus disease-2019: TAME-COVID, a retrospective multicentric study. International Journal of Applied & Basic Medical Research, 2021, 11, 263.	0.2	1
3804	Clinical Testing of a New Drug. Springer Series in Pharmaceutical Statistics, 2021, , 1-21.	0.0	0
3805	Sight-threatening intraocular infection in patients with COVID-19 in India. Indian Journal of Ophthalmology, 2021, 69, 3664.	0.5	12
3806	Treatment and therapeutic agents. , 2022, , 121-176.		0
3807	Wave comparisons of clinical characteristics and outcomes of COVID-19 admissions - Exploring the impact of treatment and strain dynamics. Journal of Clinical Virology, 2022, 146, 105031.	1.6	9
3808	COVID-19 & Heart. , 2022, , 105-116.		0
3809	The potential of drug delivery nanosystems to treat COVID-19. , 2022, , 307-337.		0
3810	DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic. Pharmacological Research, 2022, 175, 105982.	3.1	18
3811	Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. Journal of Molecular and Cellular Cardiology, 2022, 164, 69-82.	0.9	34
3812	COVID-19 Associated Thyroid Storm: A Case Report. Clinical Practice and Cases in Emergency Medicine, 2021, 5, 412-414.	0.1	5

#	ARTICLE	IF	CITATIONS
3813	Filtered Tensor Construction and Decomposition for Drug Repositioning. , 2021, , .		1
3814	The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19. Revista Da AssociaçãO MÃ©dica Brasileira, 2021, 67, 1299-1304.	0.3	3
3815	Lessons and Issues of COVID-19 from the Perspective of Pulmonologists. Nihon Ika Daigaku Igakkai Zasshi, 2021, 17, 217-219.	0.0	0
3816	Current Updates on Covid-19 Vaccine Research and an Overview of Therapeutic Drug Research. Biosciences, Biotechnology Research Asia, 2021, 18, 439-457.	0.2	0
3817	Inhaled β_2 Adrenergic Agonists and Other cAMP-Elevating Agents: Therapeutics for Alveolar Injury and Acute Respiratory Disease Syndrome?. Pharmacological Reviews, 2021, 73, 1659-1697.	7.1	8
3818	Immunosuppressants in Liver Transplant Recipients With Coronavirus Disease 2019: Capability or Catastrophe? A Systematic Review and Meta-Analysis. Frontiers in Medicine, 2021, 8, 756922.	1.2	7
3819	A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling. Purinergic Signalling, 2022, 18, 13-59.	1.1	20
3820	A Core Omnigenic Non-coding Trait Governing Dex-Induced Osteoporotic Effects Identified Without DEXA. Frontiers in Pharmacology, 2021, 12, 750959.	1.6	1
3821	Spike protein multiorgan tropism suppressed by antibodies targeting SARS-CoV-2. Communications Biology, 2021, 4, 1318.	2.0	8
3822	What have we learned from the first to the second wave of COVID-19 pandemic? An international survey from the ESCMID Study Group for Infection in the Elderly (ESGIE) group. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 281-288.	1.3	8
3823	Etiological and pathophysiological enigmas of severe coronavirus disease 2019, multisystem inflammatory syndrome in children, and Kawasaki disease. Clinical and Experimental Pediatrics, 2022, 65, 153-166.	0.9	14
3824	Endothelial cell biomarkers in critically ill COVID-19 patients with encephalitis. Journal of Neurochemistry, 2022, 161, 492-505.	2.1	15
3825	Axial spondyloarthritis may protect against poor outcomes in COVID-19: propensity score matched analysis of 9766 patients from a nationwide multi-centric research network. Clinical Rheumatology, 2022, 41, 721-730.	1.0	9
3826	Tocilizumab en casos severos de COVID-19 ¿El tiempo importa?. Revista Medicina E Investigaci3n ClÃnica Guayaquil, 2021, 2, 9-14.	0.1	0
3827	SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma. Microbiology Spectrum, 2021, 9, e0139721.	1.2	15
3828	Time-Dependent COVID-19 Mortality in Patients With Cancer. JAMA Oncology, 2022, 8, 114.	3.4	50
3829	Three-month and six-month outcomes of patients with COVID-19 associated hyperinflammation treated with short-term immunosuppressive therapy: follow-up of the CHIC study. RMD Open, 2021, 7, e001906.	1.8	4
3830	Dismal Survival in COVID-19 Patients Requiring ECMO as Rescue Therapy after Corticosteroid Failure. Journal of Personalized Medicine, 2021, 11, 1238.	1.1	2

#	ARTICLE	IF	CITATIONS
3831	Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001044.	1.2	3
3832	The Second- vs First-wave COVID-19: More of the Same or a Lot Worse? A Comparison of Mortality between the Two Waves in Patients Admitted to Intensive Care Units in Nine Hospitals in Western Maharashtra. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 1343-1348.	0.3	21
3833	Lower Driving Pressure and Neuromuscular Blocker Use Are Associated With Decreased Mortality in Patients With COVID-19 ARDS. <i>Respiratory Care</i> , 2022, 67, 216-226.	0.8	8
3834	The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies. <i>Frontiers in Pharmacology</i> , 2021, 12, 704205.	1.6	89
3835	Invasive fungal rhinosinusitis associated with COVID-19: An observational study. <i>IP International Journal of Medical Microbiology and Tropical Diseases</i> , 2021, 7, 237-241.	0.1	0
3836	Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008477.	1.6	12
3837	COVID-19 in patients aged 80 years and over during the peaks of the first three pandemic waves at a Spanish tertiary hospital. <i>Pneumon</i> , 2021, , 1-6.	0.6	3
3838	Comparative Effectiveness of an Automated Text Messaging Service for Monitoring COVID-19 at Home. <i>Annals of Internal Medicine</i> , 2022, 175, 179-190.	2.0	15
3839	Mortality due to COVID-19 infection: A comparison of first and second waves. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 747-752.	0.4	15
3840	Trilayer microneedle array assisted transdermal and intradermal delivery of dexamethasone. <i>International Journal of Pharmaceutics</i> , 2022, 612, 121295.	2.6	28
3841	Nimotuzumab for COVID-19: case series. <i>Immunotherapy</i> , 2022, 14, 185-193.	1.0	6
3842	Severe COVID-19 is associated with hyperactivation of the alternative complement pathway. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 550-556.e2.	1.5	25
3843	Factors associated with admission to the intensive care unit and mortality in patients with COVID-19, Colombia. <i>PLoS ONE</i> , 2021, 16, e0260169.	1.1	10
3844	COVID-19 associated infections in the ICU setting: A retrospective analysis in a tertiary-care hospital. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2023, 41, 278-283.	0.3	14
3845	COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. <i>Cardiology Discovery</i> , 2021, 1, 233-258.	0.6	6
3846	Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19. <i>JAMA Internal Medicine</i> , 2022, 182, 42.	2.6	78
3847	Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19. <i>Nature Medicine</i> , 2022, 28, 201-211.	15.2	132
3848	Identification of potential pan-coronavirus therapies using a computational drug repurposing platform. <i>Methods</i> , 2021, , .	1.9	1

#	ARTICLE	IF	CITATIONS
3849	COVID-19 hospital activity and in-hospital mortality during the first and second waves of the pandemic in England: an observational study. <i>Thorax</i> , 2022, 77, 1113-1120.	2.7	34
3850	Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?. <i>Life</i> , 2021, 11, 1220.	1.1	8
3851	Do Cost-Effectiveness Analyses Account for Drug Generization? A Literature Review and Assessment of Implications. <i>Value in Health</i> , 2022, 25, 59-68.	0.1	13
3852	A Randomized Controlled Trial to Evaluate the Safety and Efficacy of a Novel Inhaled Biologic Therapeutic in Adults with Respiratory Distress Secondary to COVID-19 Infection. <i>Infectious Diseases and Therapy</i> , 2021, , 1.	1.8	1
3853	COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme ² , Mutual Effects and Pharmacotherapy. <i>Frontiers in Endocrinology</i> , 2021, 12, 772865.	1.5	15
3854	Corticosteroid treatment and mortality in mechanically ventilated COVID-19-associated acute respiratory distress syndrome (ARDS) patients: a multicentre cohort study. <i>Annals of Intensive Care</i> , 2021, 11, 159.	2.2	18
3855	Immunomodulatory and Anti-fibrotic Effects Following the Infusion of Umbilical Cord Mesenchymal Stromal Cells in a Critically Ill Patient With COVID-19 Presenting Lung Fibrosis: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 767291.	1.2	3
3856	Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders. <i>Medical Science Monitor</i> , 2021, 28, e934267.	0.5	1
3857	Roles of host mitochondria in the development of COVID-19 pathology: Could mitochondria be a potential therapeutic target?. <i>Molecular Biomedicine</i> , 2021, 2, 38.	1.7	19
3858	Activating endogenous resolution pathways by soluble epoxide hydrolase inhibitors for the management of COVID-19. <i>Archiv Der Pharmazie</i> , 2022, 355, e2100367.	2.1	9
3859	Regarding management of COVID-19 in acute lymphoblastic leukemia. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, 44, 120-121.	0.1	0
3860	Reactivation of EBV and CMV in Severe COVID-19: Epiphenomena or Trigger of Hyperinflammation in Need of Treatment? A Large Case Series of Critically ill Patients. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 1152-1158.	1.3	39
3861	Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment. <i>Egyptian Heart Journal</i> , 2021, 73, 103.	0.4	0
3862	Ventilator-associated pneumonia among SARS-CoV-2 acute respiratory distress syndrome patients. <i>Current Opinion in Critical Care</i> , 2022, 28, 74-82.	1.6	40
3864	COVID-19 Infections and Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 658-663.	2.0	19
3865	Outcomes Associated with Tocilizumab with or without Corticosteroid versus Dexamethasone for Treatment of Patients with Severe to Critical COVID-19 pneumonia. <i>Journal of Infection and Public Health</i> , 2021, 15, 36-41.	1.9	6
3866	Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. <i>Pharmacological Reports</i> , 2022, 74, 229-240.	1.5	35
3867	ESCMID COVID-19 living guidelines: drug treatment and clinical management. <i>Clinical Microbiology and Infection</i> , 2022, 28, 222-238.	2.8	103

#	ARTICLE	IF	CITATIONS
3868	Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. <i>Respiratory Research</i> , 2021, 22, 304.	1.4	7
3869	Pharmacological Treatment Options for Coronavirus Disease-19 in Renal Patients. <i>International Journal of Nephrology</i> , 2021, 2021, 1-9.	0.7	8
3870	The danger of the single storyline obfuscating the complexities of managing SARS-CoV-2/COVID-19. <i>Journal of Evaluation in Clinical Practice</i> , 2022, 28, 1173-1186.	0.9	11
3871	Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma. <i>Acta Haematologica</i> , 2022, 145, 384-393.	0.7	9
3872	Rhino-Orbito-Cerebral Mucormycosis During the Second Wave of Covid-19: The Indian Scenario. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2021, , 1-6.	0.3	3
3873	Functional decline in hospitalized older patients with coronavirus disease 2019: a retrospective cohort study. <i>BMC Geriatrics</i> , 2021, 21, 638.	1.1	6
3874	Fragility Index and Fragility Quotient in Randomized Controlled Trials on Corticosteroids in ARDS Due to COVID-19 and Non-COVID-19 Etiology. <i>Journal of Clinical Medicine</i> , 2021, 10, 5287.	1.0	7
3875	Current status of therapeutic approaches and vaccines for SARS-CoV-2. <i>Future Microbiology</i> , 2021, 16, 1319-1326.	1.0	2
3876	A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	46
3877	COVID-19 in Children. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 1-14.	1.9	10
3878	Inflammation, ageing and diseases of the lung: Potential therapeutic strategies from shared biological pathways. <i>British Journal of Pharmacology</i> , 2022, 179, 1790-1807.	2.7	8
3879	Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 760-768.	0.4	1
3880	Efficacy and Safety of Immunomodulators in Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Infectious Diseases and Therapy</i> , 2022, 11, 231-248.	1.8	15
3881	Comparison of Clinical Characteristics and Outcome of Critically Ill Patients Admitted to Tertiary Care Intensive Care Units in India during the Peak Months of First and Second Waves of COVID-19 Pandemic: A Retrospective Analysis. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 1349-1356.	0.3	6
3882	Are Mechanically Ventilated Patients with COVID-19 More Likely to Die than Those without COVID-19? Perhaps Not. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 1341-1342.	0.3	0
3883	Pulmonary surfactant as a versatile biomaterial to fight COVID-19. <i>Journal of Controlled Release</i> , 2022, 342, 170-188.	4.8	20
3884	Severe neonatal COVID-19: Challenges in management and therapeutic approach. <i>Journal of Medical Virology</i> , 2022, 94, 1701-1706.	2.5	15
3886	Treatment of SARS-CoV-2 (COVID-19): A safety perspective. <i>World Journal of Pharmacology</i> , 2021, 10, 1-32.	1.3	1

#	ARTICLE	IF	CITATIONS
3887	Retrospective cohort study to evaluate medication use in patients hospitalised with COVID-19 in Scotland: protocol for a national observational study. <i>BMJ Open</i> , 2021, 11, e054861.	0.8	3
3888	Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study. <i>Advances in Therapy</i> , 2021, , 1.	1.3	8
3889	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. <i>Journal of Virology</i> , 2022, 96, JVI0155121.	1.5	18
3891	Complexity of immune responses in COVID-19. <i>Seminars in Immunology</i> , 2021, 55, 101545.	2.7	10
3892	Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study. <i>Wellcome Open Research</i> , 0, 6, 216.	0.9	1
3893	SARS-CoV-2 and the Immune Response in Pregnancy with Delta Variant Considerations. <i>Infectious Disease Reports</i> , 2021, 13, 993-1008.	1.5	24
3894	Changes in SARS-CoV-2 viral load and mortality during the initial wave of the pandemic in New York City. <i>PLoS ONE</i> , 2021, 16, e0257979.	1.1	3
3895	Combination therapy of tocilizumab and steroid for COVID-19 patients: A meta-analysis. <i>Journal of Medical Virology</i> , 2022, 94, 1350-1356.	2.5	14
3896	The paradox of immunosuppressants and COVID-19. <i>European Respiratory Journal</i> , 2022, 59, 2102828.	3.1	8
3897	Reply to: Time to Tailor the One Size Fits All Approach?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, , .	2.5	0
3898	Mutual Pan-African support paradigm to produce scientific evidence of traditional medical practices for use against COVID-19 and emerging pandemics. <i>Scientific African</i> , 2021, 14, e01046.	0.7	1
3899	Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support. <i>European Respiratory Journal</i> , 2022, 60, 2102532.	3.1	47
3900	Nasal therapyâ€”The missing link in optimising strategies to improve prevention and treatment of COVID-19. <i>PLoS Pathogens</i> , 2021, 17, e1010079.	2.1	10
3901	Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial. <i>Intensive Care Medicine</i> , 2022, 48, 36-44.	3.9	22
3902	Intravenous immunoglobulin therapy for COVID-19 ARDS. <i>Lancet Respiratory Medicine</i> , 2021, , .	5.2	5
3903	Prognostic factors and combined use of tocilizumab and corticosteroids in a Spanish cohort of elderly COVID-19 patients. <i>Journal of Medical Virology</i> , 2022, 94, 1540-1549.	2.5	13
3904	Why Females Do Better: The X Chromosomal TLR7 Gene-Dose Effect in COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 756262.	2.2	35
3905	Delayed Immune Reconstitution Inflammatory Syndrome in an Immunosuppressed Patient With SARS-CoV-2. <i>Cureus</i> , 2021, 13, e19481.	0.2	2

#	ARTICLE	IF	CITATIONS
3906	Indications, Clinical Utility, and Safety of Bronchoscopy in COVID-19. <i>Respiratory Care</i> , 2022, 67, 241-251.	0.8	9
3907	GCgx: transcriptome-wide exploration of the response to glucocorticoids. <i>Journal of Molecular Endocrinology</i> , 2021, 68, B1-B4.	1.1	1
3908	Coronavirus disease 2019 in immunocompromised patients. <i>Current Opinion in Critical Care</i> , 2021, Publish Ahead of Print, .	1.6	12
3909	The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 307-316.	1.4	27
3910	Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example. <i>Translational Psychiatry</i> , 2021, 11, 591.	2.4	7
3911	Mucormycosis in COVID-19 patients: predisposing factors, prevention and management. <i>Acta Neurologica Belgica</i> , 2022, 122, 273-280.	0.5	16
3913	Procalcitonin Increase Is Associated with the Development of Critical Care-Acquired Infections in COVID-19 ARDS. <i>Antibiotics</i> , 2021, 10, 1425.	1.5	17
3914	SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. <i>Cell</i> , 2021, 184, 6243-6261.e27.	13.5	277
3915	The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials. <i>Cancers</i> , 2021, 13, 5924.	1.7	19
3916	Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression. <i>Clinical Microbiology and Infection</i> , 2022, 28, 491-501.	2.8	45
3917	Extracorporeal Membrane Oxygenation for COVID-19: some answers and a remaining question. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, , 100986.	0.6	0
3918	Coronavirus Disease 2019-associated Invasive Fungal Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab510.	0.4	75
3919	Who, what, and when-effective therapy for severe COVID-19. <i>Lancet Rheumatology</i> , The, 2022, 4, e2-e3.	2.2	7
3920	Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study. <i>Emerging Microbes and Infections</i> , 2022, 11, 50-59.	3.0	12
3921	Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review. <i>Drug Development Research</i> , 2022, 83, 16-54.	1.4	13
3922	Prostacyclin in Intubated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 324-329.	2.5	16
3923	Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasone. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	25
3924	Coronavirus Disease 2019: Clinics, Treatment, and Prevention. <i>Frontiers in Microbiology</i> , 2021, 12, 761887.	1.5	21

#	ARTICLE	IF	CITATIONS
3925	COVID-19 and Cardiovascular System. Part 3. COVID-19 Current Treatment Approaches: Evidence-Based Review. <i>Sklifosovsky Journal Emergency Medical Care</i> , 2021, 10, 438-451.	0.3	0
3927	The Role of Inhaled Corticosteroids (ICS) in Critically Ill Patients With COVID-19: A Multicenter, Cohort Study. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 248-257.	1.3	7
3928	Discovery of Diverse Natural Products as Inhibitors of SARS-CoV-2 M ^{pro} Protease through Virtual Screening. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 6094-6106.	2.5	14
3929	A Comparative Study on the Outcomes of Mechanically Ventilated COVID-19 vs Non-COVID-19 Patients with Acute Hypoxemic Respiratory Failure. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 1377-1381.	0.3	5
3930	Is It a Wave or a Tsunami: That is the Question. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 1331-1332.	0.3	0
3931	A Review Article on Vaccine Development and Therapeutics Approach Against SARS-CoV-2. <i>The Open Covid Journal</i> , 2021, 1, 117-138.	0.4	0
3932	Long Runs and Higher Incidence of Bleeding Complications in COVID-19 Patients Requiring Venovenous Extracorporeal Membrane Oxygenation: A Case Series from the United Arab Emirates. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 1452-1458.	0.3	5
3933	Clinical outcomes of corticosteroids for COVID-19 patients at the National Center for Global Health and Medicine during the first wave of infections. <i>Respiratory Investigation</i> , 2021, , .	0.9	0
3934	High Mortality During the Second Wave of the Coronavirus Disease 2019 (COVID-19) Pandemic in Uganda: Experience From a National Referral COVID-19 Treatment Unit. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab530.	0.4	13
3935	Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 758-766.	1.3	15
3936	Risk Factors for Invasive Aspergillosis in Patients Admitted to the Intensive Care Unit With Coronavirus Disease 2019: A Multicenter Retrospective Study. <i>Frontiers in Medicine</i> , 2021, 8, 753659.	1.2	23
3937	Treatments for COVID-19: Lessons from 2020 and new therapeutic options. <i>Current Opinion in Pharmacology</i> , 2022, 62, 43-59.	1.7	23
3938	The changing nature of COVID-19 associated AKI: Where are we now?. <i>Nephrology Dialysis Transplantation</i> , 2021, , .	0.4	3
3939	COVID-19 Pandemic Between Severity Facts and Prophylaxis. <i>Natural Product Communications</i> , 2021, 16, 1934578X2110412.	0.2	1
3940	Understanding COVID-19 Pathophysiology – What Defines Progress?. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, , .	1.4	0
3941	A Narrative Review of Existing Options for COVID-19-Specific Treatments. <i>Advances in Virology</i> , 2021, 2021, 1-13.	0.5	0
3942	Role of COVID 19 Inflammatory Markers in Rhino-Orbito-Cerebral Mucormycosis: A Case Study in Predisposed Patients at a Designated Nodal Centre. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2021, , 1-7.	0.3	9
3943	Post-COVID-19 assessment in a specialist clinical service: a 12-month, single-centre, prospective study in 1325 individuals. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001041.	1.2	57

#	ARTICLE	IF	CITATIONS
3944	Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID). <i>Journal of General Internal Medicine</i> , 2022, 37, 4-14.	1.3	20
3945	Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 158-166.	5.2	37
3947	Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells. <i>Nature Immunology</i> , 2022, 23, 62-74.	7.0	105
3948	The Emergence of Cryptococemia in COVID-19 Infection: A Case Report. <i>Cureus</i> , 2021, 13, e19761.	0.2	12
3949	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. <i>Science Advances</i> , 2021, 7, eabj5629.	4.7	32
3950	Multimodal Identification by Transcriptomics and Multiscale Bioassays of Active Components in Xuanfeibaidu Formula to Suppress Macrophage-Mediated Immune Response. <i>Engineering</i> , 2023, 20, 63-76.	3.2	10
3951	Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. <i>Lancet Rheumatology</i> , The, 2022, 4, e33-e41.	2.2	96
3953	Treatment with Fluticasone Propionate Increases Antibiotic Efficacy during Treatment of Late-Stage Primary Pneumonic Plague. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0127521.	1.4	2
3954	DEspRhigh neutrophils are associated with critical illness in COVID-19. <i>Scientific Reports</i> , 2021, 11, 22463.	1.6	18
3955	Advances in the Pharmacological Management of Pediatric Acute Respiratory Distress Syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 349-360.	0.9	1
3957	Pathogenesis of Respiratory Viral and Fungal Coinfections. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0009421.	5.7	64
3958	Promises and challenges of personalized medicine to guide ARDS therapy. <i>Critical Care</i> , 2021, 25, 404.	2.5	35
3959	Acute estradiol and progesterone therapy in hospitalised adults to reduce COVID-19 severity: a randomised control trial. <i>BMJ Open</i> , 2021, 11, e053684.	0.8	19
3960	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet</i> , The, 2022, 399, 143-151.	6.3	199
3961	Global lessons learned from COVID-19 mass casualty incidents. <i>British Journal of Anaesthesia</i> , 2022, 128, e97-e100.	1.5	7
3962	Increased frequency of pneumothorax and pneumomediastinum in COVID-19 patients admitted in the ICU: A multicentre study from Mumbai, India. <i>Clinical Medicine</i> , 2021, 21, e615-e619.	0.8	9
3963	Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India. <i>Cancer Medicine</i> , 2021, 10, 8777.	1.3	4
3964	COVID-lateral damage: cardiovascular manifestations of SARS-CoV-2 infection. <i>Translational Research</i> , 2022, 241, 25-40.	2.2	5

#	ARTICLE	IF	CITATIONS
3965	Clinical determinants of coronavirus disease COVID-19 manifestation. <i>Hypertension</i> , 2021, 14, 29-35.	0.2	0
3966	Pulmonary tuberculosis and COVID-19 coinfection: A new medical challenge. <i>Monaldi Archives for Chest Disease</i> , 2021, , .	0.3	1
3967	Could inhaled corticosteroids be the game changers in the prevention of severe COVID-19? A review of current evidence. <i>Panminerva Medica</i> , 2021, , .	0.2	6
3968	Assessing the evidence on remdesivir. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1630.	4.6	3
3970	Persistent SARS-CoV-2 Nucleocapsid Protein Presence in the Intestinal Epithelium of a Pediatric Patient 3 Months After Acute Infection. <i>JPGN Reports</i> , 2022, 3, e152.	0.2	31
3971	Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19). <i>HIV Medicine</i> , 2021, , .	1.0	0
3972	Post-mortem lung tissue: the fossil record of the pathophysiology and immunopathology of severe COVID-19. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 95-106.	5.2	34
3973	Cytokine Adsorption Therapy during Extracorporeal Membrane Oxygenation in Adult Patients with COVID-19. <i>Blood Purification</i> , 2021, , 1-7.	0.9	9
3974	Versatile neutrophil functions in cancer. <i>Seminars in Immunology</i> , 2021, 57, 101538.	2.7	16
3975	COVID-19 and chronic fatigue syndrome: An endocrine perspective. <i>Journal of Clinical and Translational Endocrinology</i> , 2022, 27, 100284.	1.0	27
3976	People critically ill with COVID-19 exhibit peripheral immune profiles predictive of mortality and reflective of SARS-CoV-2 lung viral burden. <i>Cell Reports Medicine</i> , 2021, 2, 100476.	3.3	11
3977	Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. <i>Future Microbiology</i> , 2021, 16, 1415-1451.	1.0	12
3978	Interstitial lung disease before and after COVID-19: a double threat?. <i>European Respiratory Journal</i> , 2021, 58, 2101956.	3.1	26
3979	Therapeutic implications of ongoing alveolar viral replication in COVID-19. <i>Lancet Rheumatology</i> , The, 2022, 4, e135-e144.	2.2	17
3980	Randomised clinical trials in critical care: past, present and future. <i>Intensive Care Medicine</i> , 2022, 48, 164-178.	3.9	46
3981	The effect of Huashibaidu formula on the blood oxygen saturation status of severe COVID-19: A retrospective cohort study. <i>Phytomedicine</i> , 2022, 95, 153868.	2.3	5
3982	Impact of N-acetyl-L-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study. <i>ERJ Open Research</i> , 2022, 8, 00542-2021.	1.1	7
3983	Systemic Anti-Cancer Therapy and Metastatic Cancer Are Independent Mortality Risk Factors during Two UK Waves of the COVID-19 Pandemic at University College London Hospital. <i>Cancers</i> , 2021, 13, 6085.	1.7	3

#	ARTICLE	IF	CITATIONS
3984	Expected Value of Sample Information to Guide the Design of Group Sequential Clinical Trials. <i>Medical Decision Making</i> , 2022, 42, 461-473.	1.2	4
3985	Safety of Remdesivir for Patients 80 Years of Age or Older with Coronavirus Disease 2019 (COVID-19). <i>Drugs and Aging</i> , 2021, 38, 1067-1074.	1.3	11
3986	A Tale of Two Waves: Changes in the Use of Noninvasive Ventilation and Prone Positioning in Critical Care Management of Coronavirus Disease 2019. , 2021, 3, e0587.		6
3987	Dexamethasone Treatment for COVID-19-Related Lung Injury in an Adult with WHIM Syndrome. <i>Journal of Clinical Immunology</i> , 2021, , 1.	2.0	1
3988	The Immunomodulatory Function of Vitamin D, with Particular Reference to SARS-CoV-2. <i>Medicina (Lithuania)</i> , 2021, 57, 1321.	0.8	2
3989	SARS-CoV-2 Nsp5 Protein Causes Acute Lung Inflammation, A Dynamical Mathematical Model. <i>Frontiers in Systems Biology</i> , 2021, 1, .	0.5	6
3990	Is SARS-CoV-2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody-based therapeutics?. <i>Reviews in Medical Virology</i> , 2022, 32, e2314.	3.9	7
3991	Mucormycosis: A Triple Burden in Patients with Diabetes during COVID-19 Pandemic. <i>Health Sciences Review</i> , 2021, 1, 100005.	0.6	9
3992	HIV Diagnosis and the Clinical Course of COVID-19 Among Patients Seeking Care Within the New York City Public Hospital System During the Initial Pandemic Peak. <i>AIDS Patient Care and STDs</i> , 2021, 35, 457-466.	1.1	7
3993	A Propensity Score-Matched Observational Study of Remdesivir in Patients with COVID-19 and Severe Kidney Disease. <i>Kidney360</i> , 2022, 3, 269-278.	0.9	15
3994	Time Optimal Control Studies on COVID-19 Incorporating Adverse Events of the Antiviral Drugs. <i>Computational and Mathematical Biophysics</i> , 2021, 9, 214-241.	0.6	2
3995	Cardiovascular manifestations of COVID-19: An evidence-based narrative review. <i>Indian Journal of Medical Research</i> , 2021, 153, 7.	0.4	11
3996	Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic. <i>RSC Drug Discovery Series</i> , 2021, , 45-60.	0.2	0
3997	Chapter 4: Individual Leadership, Organizational Planning, and Community Partnerships. , 2021, , .		0
3999	Updates on management of leprosy in the context of COVID-19 pandemic: Recommendations by IADVL SIG Leprosy. <i>Indian Dermatology Online Journal</i> , 2021, 12, 24.	0.2	5
4000	A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality. <i>Emerging Microbes and Infections</i> , 2021, 10, 2256-2263.	3.0	6
4001	Systemic corticosteroids for management of COVID-19: Saving lives or causing harm?. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110639.	1.0	12
4002	MAIT Cells in Respiratory Viral Infections in Mouse and Human. <i>Critical Reviews in Immunology</i> , 2021, 41, 19-35.	1.0	7

#	ARTICLE	IF	CITATIONS
4004	What treatment really make sense for critically ill patients with COVID-19: single-center retrospective cohort study. <i>Alexander Saltanov Intensive Care Herald</i> , 2021, , 69-79.	0.2	1
4005	Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (September 2021). <i>Acute Medicine & Surgery</i> , 2021, 8, e706.	0.5	16
4006	The immunology and immunotherapy for COVID-19. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e24.	1.6	2
4007	Comparison of standard dose with high dose of methylprednisolone in the management of COVID-19 patients admitted in ICU. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 4066.	0.3	1
4008	Clinical profile and outcomes of coronavirus disease 2019 (COVID-19) in patients undergoing hemodialysis. <i>Indian Journal of Nephrology</i> , 2022, 32, 16.	0.2	2
4009	COVID-19 in hemodialysis patients: Experience from a Western Indian center. <i>Indian Journal of Nephrology</i> , 2022, 32, 216.	0.2	3
4010	Arrhythmias in COVID-19. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 17, 73-82.	0.5	7
4011	Short Review of Liposteroid: A Novel Targeted Glucocorticoid Preparation for Treatment of Autoimmune and Inflammatory Diseases. <i>Prague Medical Report</i> , 2021, 122, 257-268.	0.4	9
4012	Blunted sFasL signalling exacerbates TNF-driven neutrophil necroptosis in critically ill COVID-19 patients. <i>Clinical and Translational Immunology</i> , 2021, 10, e1357.	1.7	20
4013	OpiniÃ£o de mÃ©dicos brasileiros sobre o tratamento da COVID-19. <i>Revista Brasileira Em PromoÃ§Ã£o Da SaÃºde</i> , 0, 34, 1-10.	0.1	0
4014	COVID-19 associated cardiac disease: Is there a role of neutrophil extracellular traps in pathogenesis?. <i>AIMS Molecular Science</i> , 2021, 8, 275-290.	0.3	2
4016	Implementation of an Emergency Department-Embedded Infusion Center for the Administration of Monoclonal Antibody Therapy in Patients With Early COVID-19 Infection. <i>Journal of Infusion Nursing</i> , 2022, 45, 41-48.	1.2	1
4018	A Practical Strategy for Exploring the Pharmacological Mechanism of Luteolin Against COVID-19/Asthma Comorbidity: Findings of System Pharmacology and Bioinformatics Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 769011.	2.2	21
4019	Cytomegalovirus reactivation in critically-ill Coronavirus Disease 2019 patients: A case series of 11 patients. <i>IDCases</i> , 2022, 27, e01402.	0.4	4
4021	Use of tocilizumab, remdesivir, and high-dose methylprednisolone prevents intubation in an ESRD patient with COVID-19 pneumonia. <i>SAGE Open Medical Case Reports</i> , 2022, 10, 2050313X2110690.	0.2	2
4022	Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, e0150421.	1.2	17
4023	Combination of Mycological Criteria: a Better Surrogate to Identify COVID-19-Associated Pulmonary Aspergillosis Patients and Evaluate Prognosis?. <i>Journal of Clinical Microbiology</i> , 2022, 60, JCM0216921.	1.8	29
4024	COVID-19 versus Seasonal Influenza: Comparison of Profiles of Older Adults Hospitalized in a Short-Term Geriatric Ward in France. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 108-113.	0.6	0

#	ARTICLE	IF	CITATIONS
4025	Dexamethasone ameliorates severe pneumonia but slightly enhances viral replication in the lungs of SARS-CoV-2-infected Syrian hamsters. <i>Cellular and Molecular Immunology</i> , 2022, 19, 290-292.	4.8	17
4026	Commentary: A case of endogenous candida endophthalmitis with incidental cytomegalovirus infection and optic neuropathy in a patient recovered from severe COVID-19. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 326.	0.5	1
4027	Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection. <i>Scientific Reports</i> , 2022, 12, 536.	1.6	11
4028	Overcoming barriers in the design and implementation of clinical trials for acute kidney injury: a report from the 2020 Kidney Disease Clinical Trialists meeting. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 834-844.	0.4	14
4029	Methylprednisolone accelerate chest computed tomography absorption in COVID-19: A three-centered retrospective case control study from China. <i>World Journal of Clinical Cases</i> , 2022, 10, 426-436.	0.3	0
4030	Repurposing of Medicines in the EU: Launch of a Pilot Framework. <i>Frontiers in Medicine</i> , 2021, 8, 817663.	1.2	7
4031	Point-of-Care Lung Ultrasound for Differentiating COVID-19 From Influenza. <i>Cureus</i> , 2022, 14, e21116.	0.2	0
4032	Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials. <i>Pharmacological Research</i> , 2022, 176, 106053.	3.1	10
4033	Effects of corticosteroids on Covid-19 patients: A systematic review and meta-analysis on clinical outcomes. <i>Pulmonary Pharmacology and Therapeutics</i> , 2022, 72, 102107.	1.1	21
4034	Preliminary study regarding the predicted body weight-based dexamethasone therapy in patients with COVID-19 pneumonia. <i>Pulmonary Pharmacology and Therapeutics</i> , 2022, 72, 102108.	1.1	3
4035	Implications of WHO COVID-19 interim guideline 2020.5 on the comprehensive care for infected persons in Africa Before, during and after clinical management of cases. <i>Scientific African</i> , 2022, 15, e01083.	0.7	0
4036	Hypertension and COVID-19: Updates from the era of vaccines and variants. <i>Journal of Clinical and Translational Endocrinology</i> , 2022, 27, 100285.	1.0	9
4037	Burden of COVID-19 and case fatality rate in Pune, India: an analysis of the first and second wave of the pandemic. <i>IJID Regions</i> , 2022, 2, 74-81.	0.5	13
4039	Knowledge of COVID-19 among Health Care Workers at a Tertiary Care Hospital of Nepal: A Descriptive Cross-sectional Study. <i>Journal of the Nepal Medical Association</i> , 2020, 58, 905-910.	0.1	4
4040	Lasciate ogni speranza voi che non sperimentate: il Recovery collaborative group e il Recovery fund. <i>Medico E Bambino</i> , 2020, 39, 551-552.	0.1	1
4041	It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?. <i>Archives of Medical Science</i> , 2020, 17, 546-550.	0.4	2
4042	Is there a place for anti-inflammatory therapy in COVID-19?. <i>Journal of Thoracic Disease</i> , 2020, 12, 7076-7080.	0.6	0
4043	Effectiveness of the Use of Dexamethasone in Treatment of Coronavirus Infections: A Systematic Review. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 518-521.	0.1	0

#	ARTICLE	IF	CITATIONS
4044	NK cells at the crossroads in COVID-19: a question of timing. <i>Ciencia, Tecnología Y Salud</i> , 2020, 7, 309-324.	0.0	1
4045	XIII. Pharmacotherapy and Clinical Trials. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 2319-2322.	0.0	0
4046	COVID-19 and Autoimmune/Autoinflammatory Rheumatic Disease Patients: Lessons Learned and Questions Anticipating Answers. <i>Mediterranean Journal of Rheumatology</i> , 2021, 32, 188.	0.3	2
4047	Gastrointestinal symptoms in patients with coronavirus disease 2019 (COVID-19) – friend or foe?. <i>Przegląd Gastroenterologiczny</i> , 0, , .	0.3	0
4048	Formulating Hypotheses for Different Study Designs. <i>Journal of Korean Medical Science</i> , 2021, 36, e338.	1.1	11
4049	Endogenous fungal endophthalmitis treated with intravitreal caspofungin in a COVID-19 recovered patient: A case report. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3759.	0.5	8
4050	Evaluation of I-TAC as a potential early plasma marker to differentiate between critical and non-critical COVID-19. <i>Cell Stress</i> , 2021, 6, 6-16.	1.4	3
4051	Management of Hypertension in Patients with COVID-19: Implication of Angiotensin-Converting Enzyme 2. <i>Cardiology Plus</i> , 2021, 6, 210-217.	0.2	1
4052	Use of corticosteroids in the therapy of COVID-19 infection (corticosteroids in COVID-19 infection). <i>Serbian Journal of Anesthesia and Intensive Therapy</i> , 2021, 43, 85-96.	0.1	2
4053	Favourable outcome of severe COVID-19 patients in hyperinflammatory phase with high dose dexamethasone pulse therapy: A series of 10 cases. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 4598.	0.3	1
4054	Combatting SARS-CoV-2: Potential Therapeutic Candidates Against COVID-19. <i>European Medical Journal Allergy & Immunology</i> , 0, , 61-70.	0.0	1
4055	Comparative efficacy and safety of mycophenolate mofetil and azathioprine in combination with corticosteroids in the treatment of lymphocytic myocarditis. <i>Russian Journal of Cardiology</i> , 2021, 26, 4650.	0.4	2
4056	RESPOSTA DOS PACIENTES COM CORONAVÍRUS A DIFERENTES DOSAGENS DE DEXAMETASONA. <i>Revista Remecs - Revista Multidisciplinar De Estudos Científicos Em Saúde</i> , 0, , 18-28.	0.0	0
4057	New-onset hyperglycaemia and prolonged systemic corticosteroids therapy in mild COVID-19 patients as major risk factors for invasive mucormycosis: a preliminary study. <i>Current Medical Mycology</i> , 2021, 7, 22-28.	0.8	2
4058	COVID-19 Infection and Myocardial Infarction Pathophysiology and Therapy. <i>EMJ Cardiology</i> , 0, , 98-107.	0.0	1
4059	Role of systemic corticosteroids in preventing hypoxia among patients with mild COVID-19: An observational study. <i>Drug Discoveries and Therapeutics</i> , 2021, 15, 273-277.	0.6	6
4060	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. <i>RMD Open</i> , 2021, 7, e001896.	1.8	22
4061	Characteristics and outcomes of 974 COVID-19 patients in intensive care units in Turkey. <i>Annals of Saudi Medicine</i> , 2021, 41, 318-326.	0.5	4

#	ARTICLE	IF	CITATIONS
4062	Single-cell immunology of SARS-CoV-2 infection. <i>Nature Biotechnology</i> , 2022, 40, 30-41.	9.4	78
4063	Hyperglycaemia in COVID-19: improving recognition and management in a single centre. <i>British Journal of Diabetes</i> , 2021, 21, 237-240.	0.1	0
4064	Plasma therapy: a passive resistance against the deadliest. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	5
4065	The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness. <i>Monaldi Archives for Chest Disease</i> , 2022, , .	0.3	2
4066	Clinical Characteristics of COVID-19 Patients in a Regional Population With Diabetes Mellitus: The ACCREDIT Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 777130.	1.5	6
4067	COVID-19 Disease and Dermatomyositis: A Mini-Review. <i>Frontiers in Immunology</i> , 2021, 12, 747116.	2.2	24
4068	COVID-19-Associated Pulmonary Aspergillosis in a Tertiary Hospital. <i>Journal of Fungi (Basel,)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf,50 502 T	1.5	12
4069	Forecasting the Severity of COVID-19 Pandemic Amidst the Emerging SARS-CoV-2 Variants: Adoption of ARIMA Model. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-17.	0.7	7
4070	Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach. <i>Swiss Medical Weekly</i> , 2022, 152, w30088.	0.8	18
4071	Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells. <i>PLoS Pathogens</i> , 2022, 18, e1010171.	2.1	18
4072	Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact. <i>PLoS ONE</i> , 2022, 17, e0262462.	1.1	4
4073	Identification of potentially anti-COVID-19 active drugs using the connectivity MAP. <i>PLoS ONE</i> , 2022, 17, e0262751.	1.1	4
4074	A review of COVID-19 therapeutics in pregnancy and lactation. <i>Obstetric Medicine</i> , 2022, 15, 225-232.	0.5	13
4075	Examination of Medication Use Patterns by Age Group, Comorbidity, and Month in COVID-19 Positive Patients in a Large Statewide Health System During the Pandemic in 2020. <i>Journal of Pharmacy Technology</i> , 2022, 38, 75-87.	0.5	3
4076	Application of a city wide digital population database for outcome analysis in diabetes: SARS-CoV-2, diabetes and hospital admission rate month by month in Greater Manchester, UK. <i>Cardiovascular Endocrinology and Metabolism</i> , 2022, 11, e0257.	0.5	1
4077	Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy. <i>Vaccines</i> , 2022, 10, 192.	2.1	20
4078	Targeted Advanced Home Care for Patients With Moderate or Severe COVID-19. <i>Annals of Family Medicine</i> , 2022, 20, 91-91.	0.9	1
4079	Modulation of Macrophage Immunometabolism: A New Approach to Fight Infections. <i>Frontiers in Immunology</i> , 2022, 13, 780839.	2.2	37

#	ARTICLE	IF	CITATIONS
4080	Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study. <i>Brazilian Journal of Infectious Diseases</i> , 2022, 26, 101702.	0.3	0
4081	Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	28
4082	Low Selectivity Indices of Ivermectin and Macrocyclic Lactones on SARS-CoV-2 Replication In Vitro. <i>Covid</i> , 2022, 2, 60-75.	0.7	10
4083	Potential metal-related strategies for prevention and treatment of COVID-19. <i>Rare Metals</i> , 2022, 41, 1-13.	3.6	5
4084	Clinical and prognostic significance of C-reactive protein to albumin ratio in hospitalized coronavirus disease 2019 (COVID-19) patients. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 377-384.	1.0	17
4085	Experience of Rwanda on COVID-19 Case Management: From Uncertainties to the Era of Neutralizing Monoclonal Antibodies. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1023.	1.2	3
4086	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19. <i>JAMA Network Open</i> , 2022, 5, e2147331.	2.8	38
4087	Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists. <i>PLoS ONE</i> , 2022, 17, e0261843.	1.1	2
4088	COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury. <i>American Journal of Medicine</i> , 2022, 135, S49-S52.	0.6	5
4089	Characteristics and Outcomes of Patients With Frailty Admitted to ICU With Coronavirus Disease 2019: An Individual Patient Data Meta-Analysis. , 2022, 4, e0616.		18
4090	Future directions for the discovery of natural product-derived immunomodulating drugs: an IUPHAR positional review. <i>Pharmacological Research</i> , 2022, 177, 106076.	3.1	23
4091	Early procalcitonin to predict mortality in critically ill COVID-19 patients: a multicentric cohort study. <i>Minerva Anestesiologica</i> , 2022, , .	0.6	2
4092	Severe influenza: is there a role for antiviral combinations?. <i>Lancet Infectious Diseases</i> , The, 2022, , .	4.6	0
4093	Effects of IFIH1 rs1990760 variants on systemic inflammation and outcome in critically ill COVID-19 patients in an observational translational study. <i>ELife</i> , 2022, 11, .	2.8	16
4094	Vasculature-on-a-chip platform with innate immunity enables identification of angiotensin-1 derived peptide as a therapeutic for SARS-CoV-2 induced inflammation. <i>Lab on A Chip</i> , 2022, 22, 1171-1186.	3.1	27
4096	Trauma-induced Necrotizing Soft-tissue Infection following COVID-19 Treatment. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2022, 10, e4108.	0.3	0
4097	Mortality by COVID-19 Before Vaccination - One Year Experience of Hospitalized Patients in Madrid. <i>International Journal of Infectious Diseases</i> , 2022, 116, 339-343.	1.5	8
4098	Clinical outcomes of geriatric patients with COVID-19: review of one-year data. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 465-474.	1.4	9

#	ARTICLE	IF	CITATIONS
4099	Clinical characteristics and treatment outcomes of SARS-CoV-2 delta variant outbreak, Pingtung, Taiwan, June 2021. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1767-1772.	0.8	7
4100	Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology. <i>Journal of Hematology and Oncology</i> , 2022, 15, 5.	6.9	30
4101	Treatment of MIS-C in Children and Adolescents. <i>Current Pediatrics Reports</i> , 2022, 10, 1-10.	1.7	41
4102	Efficacy and Safety of Remdesivir in COVID-19 Positive Dialysis Patients. <i>Antibiotics</i> , 2022, 11, 156.	1.5	11
4103	The Value of Clinical Frailty Scale (CFS) as a Prognostic Tool in Predicting Mortality in COVID-19: A Retrospective Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1104.	1.2	9
4104	SARS-CoV-2 epidemic after social and economic reopening in three U.S. states reveals shifts in age structure and clinical characteristics. <i>Science Advances</i> , 2022, 8, eabf9868.	4.7	10
4106	Asthma and COVID-19 Associations: Focus on IgE-Related Immune Pathology. <i>Life</i> , 2022, 12, 153.	1.1	3
4107	COVID-19: Les thérapeutiques. , 2022, 1, 13-13.		0
4108	Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19. <i>PLoS ONE</i> , 2022, 17, e0261711.	1.1	1
4109	Convalescent plasma for COVID-19. TSUNAMI is not the final word. <i>European Journal of Internal Medicine</i> , 2022, 97, 116-118.	1.0	4
4110	Janus Kinase Signaling Pathway and Its Role in COVID-19 Inflammatory, Vascular, and Thrombotic Manifestations. <i>Cells</i> , 2022, 11, 306.	1.8	15
4111	Metainflammation in COVID-19. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 1154-1166.	0.6	7
4112	Platform trials and the future of evaluating therapeutic behavioural interventions. , 2022, 1, 7-8.		9
4113	Adverse Effects of Anti-Covid-19 Drug Candidates and Alcohol on Cellular Stress Responses of Hepatocytes. <i>Hepatology Communications</i> , 2022, 6, 1262-1277.	2.0	6
4114	Update zu COVID-19 und Diabetes mellitus: SARS-CoV-2-Pandemie " Diabetesinzidenz steigt. , 0, , .		0
4115	Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19. <i>PLoS ONE</i> , 2022, 17, e0262777.	1.1	7
4116	Tocilizumab-Induced Unexpected Increase of Several Inflammatory Cytokines in Critically Ill COVID-19 Patients: The Anti-Inflammatory Side of IL-6. <i>Viral Immunology</i> , 2022, 35, 60-70.	0.6	6
4117	Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e403-e409.	2.9	40

#	ARTICLE	IF	CITATIONS
4118	Implementation of an Electronic Health Record Integrated Clinical Pathway Improves Adherence to COVID-19 Hospital Care Guidelines. <i>American Journal of Medical Quality</i> , 2022, 37, 335-341.	0.2	5
4119	Covid-19, the thyroid and the pituitary—The real state of play. <i>Annales D'Endocrinologie</i> , 2022, 83, 103-108.	0.6	17
4120	Clinical Outcomes of Early Versus Late Intubation in COVID-19 Patients. <i>Cureus</i> , 2022, 14, e21669.	0.2	5
4121	Delirium in hospitalized patients with COVID-19 pneumonia: a prospective, cross-sectional, cohort study. <i>Internal and Emergency Medicine</i> , 2022, 17, 1445-1452.	1.0	11
4122	Therapeutic role of immunomodulators during the COVID-19 pandemic—a narrative review. <i>Postgraduate Medicine</i> , 2022, 134, 160-179.	0.9	9
4123	How to Use and Interpret the Results of a Platform Trial. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 67.	3.8	36
4124	A learning health system approach to the COVID-19 pandemic: System-wide changes in clinical practice and 30-day mortality among hospitalized patients. <i>Learning Health Systems</i> , 2022, 6, .	1.1	7
4125	Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19. <i>SN Comprehensive Clinical Medicine</i> , 2022, 4, 42.	0.3	5
4126	Hip fracture mortality in patients co-infected with coronavirus disease 2019: a comparison of the first two waves of the United Kingdom pandemic during the pre-vaccine era. <i>International Orthopaedics</i> , 2022, 46, 171-178.	0.9	5
4127	Can low-dose aspirin help the RECOVERY of patients hospitalized with COVID-19?. <i>European Heart Journal</i> , 2022, 43, 714-715.	1.0	0
4128	Preclinical Pharmacokinetics and Safety of Intravenous RTD-1. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, aac0212521.	1.4	4
4129	Immune-Guided Therapy of COVID-19. <i>Cancer Immunology Research</i> , 2022, 10, 384-402.	1.6	20
4130	Interleukin-1 blocking agents for treating COVID-19. <i>The Cochrane Library</i> , 2022, 2022, CD015308.	1.5	26
4131	An in silico analysis identifies drugs potentially modulating the cytokine storm triggered by SARS-CoV-2 infection. <i>Scientific Reports</i> , 2022, 12, 1626.	1.6	4
4132	Innate immunological pathways in COVID-19 pathogenesis. <i>Science Immunology</i> , 2022, 7, eabm5505.	5.6	101
4133	Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2. <i>Journal of Biological Chemistry</i> , 2022, 298, 101658.	1.6	12
4134	Remdesivir for pregnancy: A systematic review of antiviral therapy for COVID-19. <i>Heliyon</i> , 2022, 8, e08835.	1.4	14
4135	Relationship Between Myocardial Injury During Index Hospitalization for SARS-CoV-2 Infection and Longer-Term Outcomes. <i>Journal of the American Heart Association</i> , 2022, 11, e022010.	1.6	24

#	ARTICLE	IF	CITATIONS
4136	Answer to the "Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure" correspondence. <i>Revista Clínica Española</i> , 2022, , .	0.3	1
4137	Strategies for drug repurposing against coronavirus targets. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100072.	1.7	11
4138	Equitable Allocation of Remdesivir for the COVID-19 Pandemic in Los Angeles County. <i>Prehospital Emergency Care</i> , 2021, , 1-6.	1.0	0
4139	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. <i>International Journal of Biological Sciences</i> , 2022, 18, 459-472.	2.6	65
4140	OUP accepted manuscript. <i>Brain</i> , 2022, 145, 409-410.	3.7	1
4141	Corticosteroids as risk factor for COVID-19-associated pulmonary aspergillosis in intensive care patients. <i>Critical Care</i> , 2022, 26, 30.	2.5	38
4142	Systemic corticosteroids for COVID-19. <i>Academic Emergency Medicine</i> , 2021, , .	0.8	0
4143	Clinical trial design during and beyond the pandemic: the I-SPY COVID trial. <i>Nature Medicine</i> , 2022, 28, 9-11.	15.2	17
4144	Acute exacerbation of interstitial lung disease in the intensive care unit. <i>World Journal of Critical Care Medicine</i> , 2022, 11, 22-32.	0.8	4
4145	Methylprednisolone Treatment Versus Standard Supportive Care for Adult COVID-19 Mechanically Ventilated, Acute Respiratory Distress Syndrome Patients. <i>SN Comprehensive Clinical Medicine</i> , 2022, 4, 11.	0.3	3
4146	First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy. <i>BMJ Open</i> , 2022, 12, e054069.	0.8	13
4147	Strategies to minimize heterogeneity and optimize clinical trials in Acute Respiratory Distress Syndrome (ARDS): Insights from mathematical modelling. <i>EBioMedicine</i> , 2022, 75, 103809.	2.7	9
4148	Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. <i>Clinical Microbiology and Infection</i> , 2022, 28, 602-608.	2.8	60
4149	Fungal Infections Other Than Invasive Aspergillosis in COVID-19 Patients. <i>Journal of Fungi (Basel)</i> , 2022, 9, 10784314	1.5	16
4150	Pulmonary Aspects of COVID-19. <i>Annual Review of Medicine</i> , 2022, 73, 81-93.	5.0	8
4151	Use of N-Acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19. <i>Science Progress</i> , 2022, 105, 003685042210745.	1.0	29
4152	Orthopaedic long COVID - the unknown unknowns. <i>Bone and Joint Research</i> , 2022, 11, 10-11.	1.3	11
4153	The evolution of knowledge on genes associated with human diseases. <i>IScience</i> , 2022, 25, 103610.	1.9	2

#	ARTICLE	IF	CITATIONS
4154	Steroid and Thyroid Hormone Profiles in Patients Hospitalized With SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	1
4155	Potential and Possible Therapeutic Effects of Melatonin on SARS-CoV-2 Infection. Antioxidants, 2022, 11, 140.	2.2	7
4157	Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. Medicina (Lithuania), 2022, 58, 144.	0.8	126
4158	Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection. Inflammopharmacology, 2022, 30, 23-49.	1.9	8
4159	Effect of dexamethasone in patients with ARDS and COVID-19 (REMED trial)â€”study protocol for a prospective, multi-centre, open-label, parallel-group, randomized controlled trial. Trials, 2022, 23, 35.	0.7	4
4160	Respiratory involvement parameters in hospitalized COVID-19 patients and their association with mortality and length of stay. Canadian Journal of Respiratory Therapy, 0, 58, 1-8.	0.2	1
4162	Effect of a single high dose of vitamin D3 on cytokines, chemokines, and growth factor in patients with moderate to severe COVID-19. American Journal of Clinical Nutrition, 2022, 115, 790-798.	2.2	23
4163	COVID-19 in the Critically Ill Pregnant Patient. Critical Care Clinics, 2022, , .	1.0	5
4165	The Petasites hybridus CO2 Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro. Viruses, 2022, 14, 106.	1.5	4
4166	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet, The, 2022, 399, 530-540.	6.3	48
4167	Stenotrophomonas maltophilia Bacteremia Associated With Severe COVID-19: Successful Treatment With Appropriate Antimicrobial Therapy. Cureus, 2022, 14, e21750.	0.2	1
4168	Alterations in cortisol and interleukin-6 secretion in patients with COVID-19 suggestive of neuroendocrine-immune adaptations. Endocrine, 2022, 75, 317-327.	1.1	20
4169	Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia. Cancers, 2022, 14, 558.	1.7	6
4170	PRCTC: a machine learning model for prediction of response to corticosteroid therapy in COVID-19 patients. Aging, 2022, 14, 54-72.	1.4	1
4171	Utility of severity assessment tools in COVID-19 pneumonia: a multicentre observational study. Clinical Medicine, 2022, 22, 63-70.	0.8	4
4172	Nudging within learning health systems: next generation decision support to improve cardiovascular care. European Heart Journal, 2022, 43, 1296-1306.	1.0	16
4173	Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. Lancet Rheumatology, The, 2022, 4, e24-e32.	2.2	34
4174	The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe, The, 2022, 3, e543-e552.	3.4	255

#	ARTICLE	IF	CITATIONS
4175	Future Perspectives in Drug Repurposing. RSC Drug Discovery Series, 2022, , 301-319.	0.2	0
4176	Methylprednisolone, venous thromboembolism, and association with heparin to 30 days in hospital survival in severe Covid-19 pneumonia. BMC Pulmonary Medicine, 2022, 22, 6.	0.8	5
4177	Critical role of acute hypoxemia on the cognitive impairment after severe COVID-19 pneumonia: a multivariate causality model analysis. Neurological Sciences, 2022, 43, 2217-2229.	0.9	11
4178	Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan. CEN Case Reports, 2022, , 1.	0.5	4
4179	Long-Term Effects of COVID-19. Mayo Clinic Proceedings, 2022, 97, 579-599.	1.4	49
4180	The year in cardiovascular medicine 2021: digital health and innovation. European Heart Journal, 2022, 43, 271-279.	1.0	26
4181	Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure. Revista Clínica Española, 2022, , .	0.3	2
4182	Outcomes of critically ill COVID-19 survivors and caregivers: a case study-centred narrative review. Canadian Journal of Anaesthesia, 2022, 69, 630-643.	0.7	2
4183	Analysis of Critical COVID-19 Cases Among Children in Korea. Journal of Korean Medical Science, 2022, 37, e13.	1.1	27
4184	COVID-19 Pulmonary Pathology: The Experience of European Pulmonary Pathologists throughout the First Two Waves of the Pandemic. Diagnostics, 2022, 12, 95.	1.3	5
4185	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. Frontiers in Medicine, 2021, 8, 806641.	1.2	22
4186	The Association of an Alpha-2 Adrenergic Receptor Agonist and Mortality in Patients With COVID-19. Frontiers in Medicine, 2021, 8, 797647.	1.2	4
4187	Association of vitamin D status with COVID-19 and its severity. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 579-599.	2.6	47
4188	Severe COVID-19 and Multisystem Inflammatory Syndrome in Children in Children and Adolescents. Critical Care Clinics, 2022, 38, 571-586.	1.0	15
4189	Inpatient Management and OBICU Care for Pregnant Patients With Severe COVID-19 Disease. Clinical Obstetrics and Gynecology, 2022, 65, 189-194.	0.6	1
4190	Observational study of changes in utilization and outcomes in mechanical ventilation in COVID-19. PLoS ONE, 2022, 17, e0262315.	1.1	21
4191	A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature. Current Oncology, 2022, 29, 337-349.	0.9	15
4192	Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 – United States, March 2020–August 2021. Morbidity and Mortality Weekly Report, 2022, 71, 96-102.	9.0	86

#	ARTICLE	IF	CITATIONS
4193	The Pathogenetic Dilemma of Post-COVID-19 Mucormycosis in India. , 2022, 13, 24.		9
4194	Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis. <i>Haematologica</i> , 2022, 107, 1914-1921.	1.7	3
4195	Effectiveness of low-dose radiation therapy in COVID-19 patients globally: A systematic review. <i>F1000Research</i> , 2022, 11, 62.	0.8	5
4196	Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. <i>Clinical Trials</i> , 2022, 19, 146-157.	0.7	7
4197	Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. <i>ESMO Open</i> , 2022, 7, 100403.	2.0	32
4198	SARS-CoV-2 Infection Triggers Auto-Immune Response in ARDS. <i>Frontiers in Immunology</i> , 2022, 13, 732197.	2.2	14
4199	Hyperinflammatory environment drives dysfunctional myeloid cell effector response to bacterial challenge in COVID-19. <i>PLoS Pathogens</i> , 2022, 18, e1010176.	2.1	20
4200	Atrial Arrhythmias During Venovenous ECMO: A Cry for Help?. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, , .	0.6	1
4201	Introduction and Historical Overview of Drug Repurposing Opportunities. <i>RSC Drug Discovery Series</i> , 2022, , 1-13.	0.2	4
4202	Safety profile of COVID-19 drugs in a real clinical setting. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 733-753.	0.8	16
4203	COVID-19 Drug Development. <i>Journal of Microbiology and Biotechnology</i> , 2022, 32, 1-5.	0.9	26
4204	Frail Older Adults with Presymptomatic SARS-CoV-2 Infection: Clinical Course and Prognosis. <i>Gerontology</i> , 2022, 68, 1393-1401.	1.4	2
4205	SARS-CoV-2, diabetes and mortality: month by month variation in mortality rate from June 2020 to June 2021. <i>Cardiovascular Endocrinology and Metabolism</i> , 2022, 11, e0258.	0.5	1
4206	A Peek into Pandora's Box: COVID-19 and Neurodegeneration. <i>Brain Sciences</i> , 2022, 12, 190.	1.1	9
4207	SARS-CoV-2 infections in patients with autoimmune blistering disorders: A case series and retrospective analysis. <i>JAAD International</i> , 2022, 7, 38-43.	1.1	7
4208	COVID-19 scenario and recommendations on the continuity of immunobiological therapy in patients with atopic asthma in Brazil and Latin America. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 211-220.	1.0	0
4209	An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic. <i>Brazilian Journal of Medical and Biological Research</i> , 2021, 55, e11631.	0.7	6
4210	Reactivation of <i>Strongyloides stercoralis</i> in patients with SARS-CoV-2 pneumonia receiving dexamethasone. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 242-243.	0.1	3

#	ARTICLE	IF	CITATIONS
4211	Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe Covid-19 pneumonia: a case report. <i>BMC Gastroenterology</i> , 2022, 22, 22.	0.8	3
4212	Characteristics and outcome of tertiary care critically ill COVID-19 patients with multiple comorbidities admitted to the intensive care unit. <i>Annals of Thoracic Medicine</i> , 2022, 17, 59.	0.7	4
4213	Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis. <i>Neurological Sciences</i> , 2022, 43, 1557-1567.	0.9	12
4215	Inhaled corticosteroids reduce senescence in endothelial progenitor cells from patients with COPD. <i>Thorax</i> , 2022, 77, 616-620.	2.7	8
4216	Health Status, Persistent Symptoms, and Effort Intolerance One Year After Acute COVID-19 Infection. <i>Journal of General Internal Medicine</i> , 2022, 37, 1218-1225.	1.3	30
4217	The effect of steroids used in the treatment of COVID-19 on infections in intensive care. <i>Ä°stanbul Kuzey Klinikleri</i> , 2022, 9, 131-139.	0.1	0
4218	Pulmonary Pathology of End-Stage COVID-19 Disease in Explanted Lungs and Outcomes After Lung Transplantation. <i>American Journal of Clinical Pathology</i> , 2022, 157, 908-926.	0.4	14
4219	Renewed rationale for sex- and gender-disaggregated research: A COVID-19 commentary review. <i>Women's Health</i> , 2022, 18, 174550652210767.	0.7	1
4220	Inflammation and Mortality in COVID-19 Hospitalized Patients With and Without Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	1.8	8
4221	Physiotherapy management for COVID-19 in the acute hospital setting and beyond: an update to clinical practice recommendations. <i>Journal of Physiotherapy</i> , 2022, 68, 8-25.	0.7	31
4222	A model of infection and immune response to low dose radiation. <i>International Journal of Radiation Biology</i> , 2022, 98, 1243-1256.	1.0	2
4223	Renin-angiotensin system modulation and outcomes in patients hospitalized for interstitial SARS-CoV2 pneumonia: a cohort study. <i>Internal and Emergency Medicine</i> , 2022, 17, 1335-1341.	1.0	3
4224	Opioids in COVID-19: Two Sides of a Coin. <i>Frontiers in Pharmacology</i> , 2021, 12, 758637.	1.6	3
4225	Early, biomarker-guided steroid dosing in COVID-19 Pneumonia: a pilot randomized controlled trial. <i>Critical Care</i> , 2022, 26, 9.	2.5	7
4226	In regard to Hess et al.. <i>Radiotherapy and Oncology</i> , 2022, , .	0.3	0
4227	The Development and Validation of Simplified Machine Learning Algorithms to Predict Prognosis of Hospitalized Patients With COVID-19: Multicenter, Retrospective Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e31549.	2.1	14
4228	Impact of COVID-19 on Male Fertility. <i>Urology</i> , 2022, 164, 33-39.	0.5	12
4229	A functionally distinct neutrophil landscape in severe COVID-19 reveals opportunities for adjunctive therapies. <i>JCI Insight</i> , 2022, 7, .	2.3	28

#	ARTICLE	IF	CITATIONS
4230	Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?. <i>Experimental Biology and Medicine</i> , 2022, 247, 330-337.	1.1	9
4231	Management of Children Admitted to Hospitals across Bangladesh with Suspected or Confirmed COVID-19 and the Implications for the Future: A Nationwide Cross-Sectional Study. <i>Antibiotics</i> , 2022, 11, 105.	1.5	24
4232	Severe Acute Respiratory Syndrome Type 2â€Causing Coronavirus: Variants and Preventive Strategies. <i>Advanced Science</i> , 2022, 9, e2104495.	5.6	16
4233	Arrhythmias in the COVID-19 patient. <i>Heart Rhythm O2</i> , 2022, 3, 8-14.	0.6	12
4234	Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. <i>Cmaj</i> , 2022, 194, E242-E251.	0.9	103
4235	Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis. <i>Innate Immunity</i> , 2022, 28, 3-10.	1.1	1
4236	A guide to immunotherapy for COVID-19. <i>Nature Medicine</i> , 2022, 28, 39-50.	15.2	206
4237	Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. <i>EClinicalMedicine</i> , 2022, 43, 101242.	3.2	22
4238	Real-world evidence of the use of glucocorticoids for severe COVID-19. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882110727.	1.4	3
4239	Steroid Therapy and Outcome of Parapneumonic Pleural Effusions (STOPPE): A Pilot Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1093-1101.	2.5	8
4240	Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 546.	3.8	229
4241	Early CT and MRI signs of invasive fungal sinusitis complicating COVID-19 infection: case report. <i>The Egyptian Journal of Otolaryngology</i> , 2022, 38, .	0.1	2
4242	Obesity, Inflammation, and Mortality in COVID-19: An Observational Study from the Public Health Care System of New York City. <i>Journal of Clinical Medicine</i> , 2022, 11, 622.	1.0	10
4243	The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 800492.	1.2	20
4245	Association between ILâ€10 systemic low level and highest pain score in patients during symptomatic SARSâ€CoVâ€2 infection. <i>Pain Practice</i> , 2022, 22, 453-462.	0.9	6
4246	Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19. , 2022, 1, .		77
4248	Impact of untreated diabetes and COVID-19-related diabetes on severe COVID-19. <i>Heliyon</i> , 2022, 8, e08801.	1.4	5
4249	Fatal case of disseminated cryptococcal infection and meningoencephalitis in the setting of prolonged glucocorticoid use in a Covid-19 positive patient. <i>IDCases</i> , 2022, 27, e01380.	0.4	7

#	ARTICLE	IF	CITATIONS
4250	Lactate and Lactate-to-Pyruvate Ratio in Critically Ill COVID-19 Patients: A Pilot Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 171.	1.1	2
4252	SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis. <i>Medicine (United States)</i> , 2022, 101, e28722.	0.4	3
4253	Enhanced neutrophil extracellular trap formation in COVID-19 is inhibited by the protein kinase C inhibitor ruboxistaurin. <i>ERJ Open Research</i> , 2022, 8, 00596-2021.	1.1	11
4254	COVID-19 pandemic 2020 – A tertiary Melbourne hospital's experience. <i>Internal Medicine Journal</i> , 2022, , .	0.5	2
4255	Corticosteroids Utilization in the Management of Critically Ill Coronavirus Disease-2019 Pneumonia. <i>Journal of Translational Critical Care Medicine</i> , 2022, 4, 4.	0.0	0
4256	Clinical Characteristics and Outcomes of Patients With COVID-19-Associated Acute Respiratory Distress Syndrome Who Underwent Lung Transplant. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 652.	3.8	64
4257	Clinical outcomes of immunomodulatory therapies in the management of COVID-19: A tertiary-care experience from Pakistan. <i>PLoS ONE</i> , 2022, 17, e0262608.	1.1	2
4258	A review on covid-19: From molecular variability, drug development to status of vaccine clinical trials. <i>International Journal of Pharma and Bio Sciences</i> , 2022, 12, 55-71.	0.1	0
4259	Cytomegalovirus pneumonitis amid COVID-19 chaos: the hidden enemy – a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, 58.	0.4	6
4260	Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 824-837.	1.9	49
4261	Efficacy of lopinavir-ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis. <i>Future Virology</i> , 2022, 17, 169-189.	0.9	13
4262	Predictors of adverse outcome in the first and second waves of the COVID-19 pandemic: results from a UK centre. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612210745.	1.1	1
4263	Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches. <i>BMB Reports</i> , 2022, 55, 11-19.	1.1	7
4264	Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19. <i>Clinical Therapeutics</i> , 2022, 44, 364-373.	1.1	22
4265	Pathogenetic factors fanning the flames of COVID-19 to cause rhino-orbito-cerebral mucormycosis: An observational study. <i>Journal De Mycologie Medicale</i> , 2022, 32, 101252.	0.7	6
4266	The T cell immune response against SARS-CoV-2. <i>Nature Immunology</i> , 2022, 23, 186-193.	7.0	785
4267	Impact of Severity of Maternal COVID-19 Infection on Perinatal Outcome and Vertical Transmission Risk: An Ambispective Study From North India. <i>Cureus</i> , 2022, 14, e21820.	0.2	1
4268	IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19. <i>Annual Review of Immunology</i> , 2022, 40, 323-348.	9.5	50

#	ARTICLE	IF	CITATIONS
4269	Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 435-479.	1.9	11
4270	The Impact of Vaccination on Incidence and Outcomes of SARS-CoV-2 Infection in Patients with Kidney Failure in Scotland. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 677-686.	3.0	38
4271	Mortality due to COVID-19 during the pandemic: A comparison of first, second and third SMAtteo COvid19 REgistry (SMACORE). <i>Heliyon</i> , 2022, 8, e08895.	1.4	2
4272	Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19). <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 623-628.	0.9	5
4273	COVID-19 in Children. <i>Pediatric Clinics of North America</i> , 2022, 69, 547-571.	0.9	12
4274	The Role of Glucocorticoids in the Treatment of Multisystem Inflammatory Syndrome (MIS-C)â€”Data from POLISH MIS-C Registry. <i>Children</i> , 2022, 9, 178.	0.6	2
4275	Coronavirus Disease 2019 Temperature Trajectories Correlate With Hyperinflammatory and Hypercoagulable Subphenotypes. <i>Critical Care Medicine</i> , 2022, 50, 212-223.	0.4	8
4276	Sexual dimorphism in COVID-19: potential clinical and public health implications. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 221-230.	5.5	78
4277	Temporal Reduction in COVID-19-Associated Fatality Among Kidney Transplant Recipients: The Brazilian COVID-19 Registry Cohort Study. <i>Transplant International</i> , 2022, 36, 10205.	0.8	0
4278	Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation. <i>Inflammation Research</i> , 2022, 71, 293-307.	1.6	29
4279	Therapeutic Plasma Exchanges in Combination with High-Dose Steroid-Induced Immunosuppression as an Ultima Ratio Therapy in Severe Coronavirus Disease 2019 (COVID-19): A Case-Series Report. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 715-722.	1.6	1
4280	Therapeutic Effects of Inhaled Nitric Oxide Therapy in COVID-19 Patients. <i>Biomedicines</i> , 2022, 10, 369.	1.4	21
4282	Colchicine Against SARS-CoV-2 Infection: What is the Evidence?. <i>Rheumatology and Therapy</i> , 2022, 9, 379-389.	1.1	12
4283	COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 397-421.	1.9	7
4284	COVID-19-Triggered Acute Exacerbation of IPF, an Underdiagnosed Clinical Entity With Two-Peaked Respiratory Failure: A Case Report and Literature Review. <i>Frontiers in Medicine</i> , 2022, 9, 815924.	1.2	8
4285	COVID-19 Hospitalizations, Intensive Care Unit Stays, Ventilation, and Death Among Patients With Immune-mediated Inflammatory Diseases Compared to Controls. <i>Journal of Rheumatology</i> , 2022, 49, 523-530.	1.0	18
4286	Disruption of Kidneyâ€”Immune System Crosstalk in Sepsis with Acute Kidney Injury: Lessons Learned from Animal Models and Their Application to Human Health. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1702.	1.8	16
4287	Longâ€”term mortality and healthâ€”related quality of life in the COVID STEROID trial. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, 66, 543-545.	0.7	1

#	ARTICLE	IF	CITATIONS
4288	Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	15
4289	The Association Between Proton Pump Inhibitors and COVID-19 is Confounded by Hyperglycemia in a Population-Based Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 791074.	1.6	3
4290	One year into the SARS-CoV-2 pandemic: perinatal outcome and data on the transmission of 116 pregnant women. <i>Journal of Perinatal Medicine</i> , 2022, 50, 404-406.	0.6	4
4291	Innate immunity: the first line of defense against SARS-CoV-2. <i>Nature Immunology</i> , 2022, 23, 165-176.	7.0	303
4292	Dexamethasone Improves Cardiovascular Outcomes in Critically Ill COVID-19, a Real World Scenario Multicenter Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 808221.	1.2	6
4293	Reply letter to: Correspondence on "Coronavirus disease 2019 in patients with cardiovascular disease"™ (J Cardiovasc Med (Hagerstown). 2022 Jan 1;23(1):e42. doi: 10.2459/JCM.0000000000001276. PMID: 34784314 rgBT /Ove		
4294	High-Dose Convalescent Plasma for Treatment of Severe COVID-19. <i>Emerging Infectious Diseases</i> , 2022, 28, 548-555.	2.0	26
4295	Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2022, 5, 100101.	0.6	8
4296	Vascular endotheliitis associated with infections: Its pathogenetic role and therapeutic implication. <i>Biochemical Pharmacology</i> , 2022, 197, 114909.	2.0	19
4297	Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry. <i>International Journal of Infectious Diseases</i> , 2022, 116, 51-58.	1.5	17
4298	Glucocorticoids coordinate macrophage metabolism through the regulation of the tricarboxylic acid cycle. <i>Molecular Metabolism</i> , 2022, 57, 101424.	3.0	18
4299	Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results. <i>Journal of Clinical Epidemiology</i> , 2022, 144, 43-55.	2.4	19
4300	Mechanisms and clinical evidence to support melatonin's use in severe COVID-19 patients to lower mortality. <i>Life Sciences</i> , 2022, 294, 120368.	2.0	16
4301	Efficacy of awake prone positioning for severe illness coronavirus disease 2019 patients: a propensity <sc>score-adjusted</sc> cohort study. <i>Acute Medicine & Surgery</i> , 2022, 9, e734.	0.5	1
4302	COVID-19 with Rapid Progression to Hypoxemia Likely due to Imbalance between Ventilation and Blood Flow: A Case Report. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2022, 16, 117954842110732.	0.5	3
4304	Covid-19 and leptospirosis, pulmonary involvement and response to steroids: A comparative observational study from a rural Tertiary care center in Kerala. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 294.	0.3	7
4306	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. <i>Cell</i> , 2022, 185, 916-938.e58.	13.5	164
4307	Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. <i>European Heart Journal</i> , 2022, 43, 1157-1172.	1.0	297

#	ARTICLE	IF	CITATIONS
4308	The CTSA University of Texas Health Science Center (UTHSC) Northeast Tyler and Rio Grande Valley Success Story: How Rural, Underserved Academic Communities Rapidly Built a Robust Engine for Collaborative COVID-19 Clinical Research. <i>Journal of Health Care for the Poor and Underserved</i> , 2022, 33, 517-527.	0.4	0
4309	COVID-19 in cancer patients. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2022, 116, 767-797.	0.7	11
4310	Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression Modulation. <i>Kidney International Reports</i> , 2022, 7, 983-992.	0.4	12
4311	Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. <i>European Respiratory Journal</i> , 2022, 60, 2102523.	3.1	31
4312	Day-to-day blood pressure variability in COVID-19: A biomarker of disrupted central autonomic network. <i>Journal of Clinical Hypertension</i> , 2022, 24, 234-236.	1.0	4
4313	Children and adolescents in African countries should also be vaccinated for COVID-19. <i>BMJ Global Health</i> , 2022, 7, e008315.	2.0	14
4314	Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection. <i>Pathogens and Global Health</i> , 2022, 116, 297-304.	1.0	7
4315	Characteristics, Outcomes, and Severity Risk Factors Associated With SARS-CoV-2 Infection Among Children in the US National COVID Cohort Collaborative. <i>JAMA Network Open</i> , 2022, 5, e2143151.	2.8	102
4316	Glucocorticoid-Induced Leucine Zipper Alleviates Lung Inflammation and Enhances Bacterial Clearance during Pneumococcal Pneumonia. <i>Cells</i> , 2022, 11, 532.	1.8	4
4317	Candidemia Among Coronavirus Disease 2019 Patients in Turkey Admitted to Intensive Care Units: A Retrospective Multicenter Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac078.	0.4	13
4318	Disulfiram inhibits neutrophil extracellular trap formation and protects rodents from acute lung injury and SARS-CoV-2 infection. <i>JCI Insight</i> , 2022, 7, .	2.3	54
4319	Outcomes of patients with cancer infected with SARS-CoV-2: results from the Ion Chiricu Oncology Institute series. <i>ESMO Open</i> , 2022, 7, 100423.	2.0	3
4320	Descriptive comparison of admission characteristics between pandemic waves and multivariable analysis of the association of the Alpha variant (B.1.1.7 lineage) of SARS-CoV-2 with disease severity in inner London. <i>BMJ Open</i> , 2022, 12, e055474.	0.8	12
4321	The Fight Against Severe COVID-19: Can Parasitic Worms Contribute?. <i>Frontiers in Immunology</i> , 2022, 13, 849465.	2.2	3
4322	Anesthesia and Enhanced Recovery After Surgery in Bariatric Surgery. <i>Anesthesiology Clinics</i> , 2022, 40, 119-142.	0.6	4
4323	Impact of corticosteroid therapy on the survival of critical COVID-19 patients admitted into an intensive care unit. <i>Revista Española De Anestesiología Y Reanimación (English Edition)</i> , 2022, 69, 120-120.	0.1	0
4324	Predictive ability of severity scores and outcomes for mortality in kidney transplant recipients with coronavirus disease 2019 admitted to the intensive care unit: results from a Brazilian single-center cohort study. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2022, 44, 383-394.	0.4	2
4326	Identificação de <i>Lophomonas</i> spp em lavado broncoalveolar de indivíduo portador de SRAG por SARS-CoV-2 associado a tuberculose pulmonar. <i>Research, Society and Development</i> , 2022, 11, e46211222808.	0.0	1

#	ARTICLE	IF	CITATIONS
4327	Repurposing the drug, ivermectin, in COVID-19: toxicological points of view. <i>European Journal of Medical Research</i> , 2022, 27, 21.	0.9	12
4328	Newly diagnosed diabetes vs. pre-existing diabetes upon admission for COVID-19: Associated factors, short-term outcomes, and long-term glycemic phenotypes. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108145.	1.2	41
4329	Oxidation of Aqueous Dexamethasone Solution by Gas-Phase Pulsed Corona Discharge. <i>Water (Switzerland)</i> , 2022, 14, 467.	1.2	1
4331	RT-PCR negative COVID-19. <i>BMC Infectious Diseases</i> , 2022, 22, 149.	1.3	13
4332	The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment. <i>Medicina (Lithuania)</i> , 2022, 58, 261.	0.8	3
4333	Mortality and readmission rates among hospitalized COVID-19 patients with varying stages of chronic kidney disease: a multicenter retrospective cohort. <i>Scientific Reports</i> , 2022, 12, 2258.	1.6	13
4334	Corticosteroids for Pleural Infection: Should We STOPPE Studying?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 987-988.	2.5	1
4335	ECMO during the COVID-19 pandemic: moving from rescue therapy to more reasonable indications. <i>European Respiratory Journal</i> , 2022, 59, 2103262.	3.1	11
4336	Therapeutics for COVID-19 and post COVID-19 complications: An update. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100086.	1.7	55
4337	Analyzing the Effect of Vaccination Over COVID Cases and Deaths in Asian Countries Using Machine Learning Models. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 806265.	1.8	7
4338	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. <i>JAMA Internal Medicine</i> , 2022, 182, 115.	2.6	63
4339	Comparison of SARS-CoV-2 Evolution in Paediatric Primary Airway Epithelial Cell Cultures Compared with Vero-Derived Cell Lines. <i>Viruses</i> , 2022, 14, 325.	1.5	5
4340	Effect of Vitamin C on Clinical Outcomes of Critically Ill Patients With COVID-19: An Observational Study and Subsequent Meta-Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 814587.	1.2	14
4341	Chronic Kidney Disease and COVID-19: Outcomes of hospitalised adults from a tertiary care centre in North India. <i>Medical Journal Armed Forces India</i> , 2022, , .	0.3	3
4342	Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 327-336.	5.2	131
4343	Validation of Respiratory Rate-Oxygenation Index in Patients With COVID-19-Related Respiratory Failure. <i>Critical Care Medicine</i> , 2022, 50, e638-e642.	0.4	15
4344	Factors associated with hospital admission and adverse outcome for COVID-19: Role of social factors and medical care. <i>Infectious Diseases Now</i> , 2022, 52, 130-137.	0.7	6
4345	Remarkable resolution of COVID-19-associated cerebral vasculitis with methylprednisolone. <i>Infectious Diseases Now</i> , 2022, , .	0.7	2

#	ARTICLE	IF	CITATIONS
4346	Pharmacologic Treatment and Management of Coronavirus Disease 2019. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 349-364.	1.9	2
4347	Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. <i>EBioMedicine</i> , 2022, 76, 103856.	2.7	38
4348	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet</i> , The, 2022, 399, 665-676.	6.3	280
4349	ERS International Congress 2021: highlights from the Respiratory Infections Assembly. <i>ERJ Open Research</i> , 0, , 00642-2021.	1.1	0
4351	Plant-Based Support of Respiratory Health during Viral Outbreaks. <i>Journal of Agricultural and Food Chemistry</i> , 2022, , .	2.4	5
4352	An Outpatient Management Strategy Using a Coronataxi Digital Early Warning System Reduces Coronavirus Disease 2019 Mortality. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac063.	0.4	7
4353	Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac043.	0.4	4
4354	Timing of convalescent plasma administration and 28-day mortality in COVID-19 pneumonia. <i>Journal of Investigative Medicine</i> , 2022, 70, 1258-1264.	0.7	7
4355	Severe COVID pneumonia and undetectable B cells after vaccination in patients previously treated with rituximab: a case series. <i>Postgraduate Medicine</i> , 2022, 134, 239-243.	0.9	4
4356	In Patients with Severe COVID-19, the Profound Decrease in the Peripheral Blood T-Cell Subsets Is Correlated with an Increase of QuantiFERON-TB Gold Plus Indeterminate Rates and Reflecting a Reduced Interferon-Gamma Production. <i>Life</i> , 2022, 12, 244.	1.1	6
4357	The Concept Of Repurposing In Covid-19 Infection. <i>Coronaviruses</i> , 2022, 03, .	0.2	0
4358	Prolonged SARS-CoV-2 infection associated with long-term corticosteroid use in a patient with impaired B-cell immunity. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 971-974.	0.8	8
4359	Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial. <i>European Respiratory Journal</i> , 2022, 59, 2103036.	3.1	9
4360	COVID-19 and Lung Mast Cells: The Kallikreinâ€“Kinin Activation Pathway. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1714.	1.8	17
4361	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARSâ€“CoVâ€“2 and Hyperinflammation in Pediatric COVIDâ€“19: Version 3. <i>Arthritis and Rheumatology</i> , 2022, 74, .	2.9	146
4362	Clinical characteristics and outcomes of the first two waves of the COVID-19 pandemic in a community hospital: a retrospective cohort study. <i>IJID Regions</i> , 2022, 3, 1-7.	0.5	2
4363	The Use of Inhaled Glucocorticosteroids (ICS) during the COVID-19 Pandemic. <i>Tuberculosis and Lung Diseases</i> , 2022, 100, 7-18.	0.2	0
4364	Intensive care burden of COVID-19 in tertiary care hospitals during the first year of outbreak in Kawasaki City, Japan: A retrospective cohort study. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	0.8	2

#	ARTICLE	IF	CITATIONS
4365	COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments. <i>Acta Haematologica</i> , 2022, 145, 244-256.	0.7	7
4366	Cell-Free DNA: Potential Application in COVID-19 Diagnostics and Management. <i>Viruses</i> , 2022, 14, 321.	1.5	9
4367	Immunosuppression and SARS-CoV-2 Infection in Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2022, 8, e1292.	0.8	17
4368	COVID-19-associated mucormycosis: an update of anesthetic management. <i>Ain-Shams Journal of Anesthesiology</i> , 2022, 14, .	0.1	2
4369	Deep learning for drug repurposing: Methods, databases, and applications. <i>Wiley Interdisciplinary Reviews: Computational Molecular Science</i> , 2022, 12, .	6.2	48
4370	Association of ventilator type with hospital mortality in critically ill patients with SARS-CoV2 infection: a prospective study. <i>Annals of Intensive Care</i> , 2022, 12, 10.	2.2	4
4371	The Efficacy of Early Additional Hemoperfusion Therapy for Severe COVID-19 Patients: A Prospective Cohort Study. <i>Blood Purification</i> , 2022, 51, 879-888.	0.9	10
4372	Use of Systemic Anticoagulation in COVID-19: Delving Beyond Theoretical Hypothesis. <i>Cureus</i> , 2022, 14, e22061.	0.2	0
4374	Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intensive, phase 2 clinical trial. <i>Gut</i> , 2022, 71, 879-888.	6.1	24
4375	Another piece in the COVID-19 treatment puzzle. <i>Lancet, The</i> , 2022, 399, 609-610.	6.3	6
4376	High-Flow Nasal Cannula in COVID-19 Pneumonia. <i>Critical Care Medicine</i> , 2022, Publish Ahead of Print, .	0.4	1
4377	A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. <i>American Heart Journal</i> , 2022, 247, 76-89.	1.2	12
4378	CytoSorb Rescue for COVID-19 Patients With Vasoplegic Shock and Multiple Organ Failure: A Prospective, Open-Label, Randomized Controlled Pilot Study*. <i>Critical Care Medicine</i> , 2022, 50, 964-976.	0.4	45
4379	Pregnant women with COVID-19. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2022, 61, 197-198.	0.5	4
4380	Clinical outcomes after IL-6 blockade in patients with COVID-19 and HIV: a case series. <i>AIDS Research and Therapy</i> , 2022, 19, 6.	0.7	4
4381	Development of nano structured graphene oxide incorporated dexamethasone with enhanced dissolution. <i>Colloids and Interface Science Communications</i> , 2022, 47, 100599.	2.0	6
4382	Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy. <i>Respiratory Investigation</i> , 2022, 60, 248-255.	0.9	12
4383	AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, India. <i>Complementary Therapies in Medicine</i> , 2022, 66, 102814.	1.3	21

#	ARTICLE	IF	CITATIONS
4384	Imiquimod Boosts Interferon Response, and Decreases ACE2 and Pro-Inflammatory Response of Human Bronchial Epithelium in Asthma. <i>Frontiers in Immunology</i> , 2021, 12, 743890.	2.2	3
4385	Lessons from the COVID-19 pandemic. <i>Therapie</i> , 2021, 77, 3-3.	0.6	1
4386	Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2141328.	2.8	30
4387	<sc>Reverseâ€Bayes</sc> methods for evidence assessment and research synthesis. <i>Research Synthesis Methods</i> , 2022, 13, 295-314.	4.2	12
4388	COVID-19: comprehensive review on mutations and current vaccines. <i>Archives of Microbiology</i> , 2022, 204, 8.	1.0	26
4389	Untargeted metabolomics of COVID-19 patient serum reveals potential prognostic markers of both severity and outcome. <i>Metabolomics</i> , 2022, 18, 6.	1.4	60
4390	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. <i>Current Infectious Disease Reports</i> , 2021, 23, 28.	1.3	5
4391	A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. <i>European Urology</i> , 2022, 81, 285-293.	0.9	40
4392	The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 923-933.e6.	1.5	17
4393	Post-sequelae one year after hospital discharge among older COVID-19 patients: A multi-center prospective cohort study. <i>Journal of Infection</i> , 2022, 84, 179-186.	1.7	31
4394	Risk factors for Coronavirus disease-associated mucormycosis. <i>Journal of Infection</i> , 2022, 84, 383-390.	1.7	45
4395	Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 622-635.	4.6	135
4396	Namulumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. <i>Lancet Respiratory Medicine</i> ,the, 2022, 10, 255-266.	5.2	32
4397	Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> ,the, 2022, 10, 237-246.	5.2	50
4398	Neonates and COVID-19: state of the art. <i>Pediatric Research</i> , 2022, 91, 432-439.	1.1	51
4399	Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 7092.	5.8	65
4400	The state of complement in COVID-19. <i>Nature Reviews Immunology</i> , 2022, 22, 77-84.	10.6	159
4402	Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab588.	0.4	7

#	ARTICLE	IF	CITATIONS
4403	Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm. <i>Interface Focus</i> , 2022, 12, 20210006.	1.5	16
4404	Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. <i>MBio</i> , 2021, 12, e0334721.	1.8	45
4405	Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. <i>European Respiratory Journal</i> , 2022, 60, 2102518.	3.1	46
4406	The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. <i>European Respiratory Review</i> , 2021, 30, 210171.	3.0	20
4407	HSV-1 reactivation is associated with an increased risk of mortality and pneumonia in critically ill COVID-19 patients. <i>Critical Care</i> , 2021, 25, 417.	2.5	39
4409	Comparison of Low-Versus High-Dose Steroids in the Clinical Outcome of Hospitalized COVID-19 Patients. <i>Antibiotics</i> , 2021, 10, 1510.	1.5	8
4410	Increased Kynurenine Indicates a Fatal Course of COVID-19. <i>Antioxidants</i> , 2021, 10, 1960.	2.2	23
4411	Root Causes of Fungal Coinfections in COVID-19 Infected Patients. <i>Infectious Disease Reports</i> , 2021, 13, 1018-1035.	1.5	30
4412	Dexamethasone Attenuates Oncostatin M Production via Suppressing of PI3K/Akt/NF- κ B Signaling in Neutrophil-like Differentiated HL-60 Cells. <i>Molecules</i> , 2022, 27, 129.	1.7	9
4413	Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections. <i>Viruses</i> , 2021, 13, 2489.	1.5	20
4414	Pharmacological treatment of COVID-19: an opinion paper. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 115-130.	0.5	47
4416	Clinical Spectrum of Children With Multisystem Inflammatory Syndrome Associated With SARS-CoV-2 Infection. <i>Indian Pediatrics</i> , 2021, 58, 955-958.	0.2	1
4417	Neutrophil-to-lymphocyte ratio is a powerful predictor of adult patients with acute respiratory distress syndrome who might benefit from corticosteroid therapy. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 11556-11570.	0.0	0
4418	Update to Perinatal-Neonatal Management of COVID-19 Guidelines. <i>Indian Pediatrics</i> , 2021, , .	0.2	0
4419	An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. <i>Drug Resistance Updates</i> , 2021, 59, 100794.	6.5	175
4421	The QTc interval and treatment outcome of inpatients with COVID-19. <i>PONS - Medicinski Casopis</i> , 2021, 18, 63-73.	0.0	0
4422	Use of corticosteroid hormones in patients with moderate COVID-19: what goals can be achieved. <i>Epidemiology and Infectious Diseases (Russian Journal)</i> , 2021, 26, 23-36.	0.1	0
4424	A Complication of COVID-19 in the maxillofacial region. Clinical cases. <i>Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR</i> , 2021, 27, 313-320.	0.1	2

#	ARTICLE	IF	CITATIONS
4425	Response to Glucocorticoid Therapy in Patients with Mild to Moderate Coronavirus Disease 2019 at a Japanese Care Facility. <i>Tohoku Journal of Experimental Medicine</i> , 2022, , .	0.5	6
4426	Nosocomial Infection in Patients with Severe and Critical COVID-19. <i>Obshchaya Reanimatologiya</i> , 2022, 18, 4-10.	0.2	5
4427	Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial. <i>Infection and Chemotherapy</i> , 2022, 54, 102.	1.0	23
4428	Delayed-onset Organizing Pneumonia Emerging after Recovery from Coronavirus Disease 2019: A Report of Three Cases Diagnosed Using Transbronchial Cryobiopsy and a Review of the Literature. <i>Internal Medicine</i> , 2022, 61, 1403-1410.	0.3	3
4429	COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e13.	1.6	12
4430	Treatment of COVID-19-Related Hyperinflammatory Response In Intensive Care Unit: Pulse Steroid, Anticytokines, IVIG, Plasmapheresis.. <i>Journal of Contemporary Medicine</i> , 2022, 12, 228-232.	0.1	0
4431	COVID19 associated mucormycosis: A review. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 418.	0.3	7
4432	Renal mucormycosis presenting during the COVID-19 pandemic: A series of 11 cases from a tertiary care center in India. <i>Indian Journal of Urology</i> , 2022, 38, 115.	0.2	1
4433	Antiviral cyclic peptides targeting the main protease of SARS-CoV-2. <i>Chemical Science</i> , 2022, 13, 3826-3836.	3.7	29
4434	Using National Electronic Health Records for Pandemic Preparedness: Validation of a Parsimonious Model for Predicting Excess Deaths Among Those With COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4436	Assessment of Clinical Efficacy of Dexamethasone in Patients with Moderate COVID-19. <i>Obshchaya Reanimatologiya</i> , 2022, 18, 11-16.	0.2	2
4437	Daphnoretin from <i>Carthamus tinctorius</i> as a Potential Inflammatory Inhibitor in COVID-19 by Binding to Toll-like Receptor-4: An in silico Molecular Docking Study. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 220-227.	0.1	1
4438	Tiroiditis por infecci3n por COVID-19: reporte de caso. <i>Revista Colombiana De EndocrinologÃa, Diabetes & Metabolismo</i> , 2021, 8, .	0.1	0
4439	Educational Impact of #IDJClub, a Twitter-Based Infectious Diseases Journal Club. <i>Clinical Infectious Diseases</i> , 2022, 74, S244-S250.	2.9	7
4441	Monoclonal antibody therapies in the management of SARS-CoV-2 infection. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 41-58.	1.9	26
4442	Osteonecrosis with Concomitant Bacterial Osteomyelitis of Both Hips and a Knee in a Postâ€“COVID-19 Patient. <i>JBJS Case Connector</i> , 2022, 12, .	0.1	2
4443	Safety and Efficacy of Mesenchymal Stem Cells in Severe/Critical COVID-19 Patients: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4444	Acute Hypoxaemic Respiratory Failure and Acute Respiratory Distress Syndrome. , 2022, , 149-163.		2

#	ARTICLE	IF	CITATIONS
4445	Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19. <i>Translational and Clinical Pharmacology</i> , 2022, 30, 24.	0.3	3
4446	Current therapeutic choices for coronavirus disease 2019: a state-of-the-art review. , 2022, , 79-93.		0
4447	Using National Electronic Health Records for Pandemic Preparedness: Validation of a Parsimonious Model for Predicting Excess Deaths Among Those With COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
4448	Osteonecrosis in Patients Recovering from COVID-19: Mechanisms, Diagnosis, and Treatment at Early-Stage Disease (Review). <i>Travmatologija I Ortopediya Rossii</i> , 2022, 28, 128-137.	0.1	4
4449	Sex Differences in Use of Low Tidal Volume Ventilation in COVID-19—Insights From the PROVENT—COVID Study. <i>Frontiers in Medicine</i> , 2021, 8, 780005.	1.2	3
4450	Emerging mucormycosis posing threat to community: Anesthetist's perspective in a tertiary care center. <i>Saudi Journal of Anaesthesia</i> , 2022, 16, 200.	0.2	0
4451	Diabetes - a Consequence of COVID-19 Infection. <i>Materia Socio-medica</i> , 2022, 34, 4.	0.3	5
4452	Health crisis: What opportunities for clinical drug research?. <i>Therapie</i> , 2022, 77, 59-67.	0.6	2
4453	Acute management of COVID-19 in the emergency department: An evidence-based review. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 424.	0.3	2
4454	Demand of COVID-19 medicines without prescription among community pharmacies in Jodhpur, India: Findings and implications. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 503.	0.3	11
4455	COVID-19 and lung involvement. <i>Handbook of Systemic Autoimmune Diseases</i> , 2022, , 189-211.	0.1	0
4457	Pulmonary macrophages and SARS-Cov2 infection. <i>International Review of Cell and Molecular Biology</i> , 2022, 367, 1-28.	1.6	10
4459	Study to assess aetiology, clinical and imaging characteristics of post Covid-19 pulmonary cavitation. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 739.	0.3	2
4460	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. <i>Nature Reviews Rheumatology</i> , 2022, 18, 191-204.	3.5	105
4461	D-dimer, CRP, PCT, and IL-6 Levels at Admission to ICU Can Predict In-Hospital Mortality in Patients with COVID-19 Pneumonia. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-9.	1.9	40
4462	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. <i>Pathogens</i> , 2022, 11, 275.	1.2	9
4463	Clinical features of 162 fatal cases of COVID-19: a multi-center retrospective study. <i>Emergency and Critical Care Medicine</i> , 2022, 2, 109-115.	0.1	1
4464	COVID-19 in a Neuroimmunological Outpatient Cohort: The Bernese Experience. <i>Clinical and Translational Neuroscience</i> , 2022, 6, 6.	0.4	0

#	ARTICLE	IF	CITATIONS
4465	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13763.	1.7	5
4466	The authors reply. <i>Critical Care Medicine</i> , 2022, 50, e335-e336.	0.4	0
4468	Global challenges in preparedness and response to epidemic infectious diseases. <i>Molecular Therapy</i> , 2022, 30, 1801-1809.	3.7	10
4469	A Retrospective Observational Cohort Study on the Efficacy and Safety of Methylprednisolone Pulse Therapy for COVID-19 Pneumonia. <i>Covid</i> , 2022, 2, 244-253.	0.7	2
4470	Potentially effective drugs for the treatment of COVID-19 or MIS-C in children: a systematic review. <i>European Journal of Pediatrics</i> , 2022, 181, 2135-2146.	1.3	19
4471	In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity. <i>Viruses</i> , 2022, 14, 389.	1.5	2
4473	Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. <i>Lancet, The</i> , 2022, 399, 1469-1488.	6.3	165
4474	Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19. <i>Clinical Infectious Diseases</i> , 2024, 78, 711-718.	2.9	6
4476	â€œMATH+â€•Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale. <i>Journal of Clinical Medicine Research</i> , 2022, 14, 53-79.	0.6	4
4477	A year in review in <i>Minerva Anestesiologica</i> 2021. <i>Critical care. Minerva Anestesiologica</i> , 2022, 88, 89-100.	0.6	0
4478	Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis. , 2022, 1, e000036.		13
4479	COVID-19 and Cushingâ€™s disease in a patient with ACTH-secreting pituitary carcinoma. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2022, 2022, .	0.2	4
4480	A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales. <i>Value in Health</i> , 2022, 25, 761-769.	0.1	12
4482	Severe Infections Due to Respiratory Viruses. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 060-074.	0.8	9
4483	Intranasal dexamethasone: a new clinical trial for the control of inflammation and neuroinflammation in COVID-19 patients. <i>Trials</i> , 2022, 23, 148.	0.7	5
4484	Methylprednisolone Pulses in Hospitalized COVID-19 Patients Without Respiratory Failure: A Randomized Controlled Trial. <i>Frontiers in Medicine</i> , 2022, 9, 807981.	1.2	8
4485	Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile. <i>Microbiology Spectrum</i> , 2022, 10, e0256021.	1.2	6
4486	Special Issue â€œPulmonary and Critical Care Practice in the Pandemic of COVID-19â€•. <i>Journal of Clinical Medicine</i> , 2022, 11, 1336.	1.0	0

#	ARTICLE	IF	CITATIONS
4487	Adrenomedullin Therapy in Moderate to Severe COVID-19. <i>Biomedicines</i> , 2022, 10, 533.	1.4	8
4489	Biomarkers during COVID-19: Mechanisms of Change and Implications for Patient Outcomes. <i>Diagnostics</i> , 2022, 12, 509.	1.3	21
4490	Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions. <i>Journal of Personalized Medicine</i> , 2022, 12, 349.	1.1	3
4491	Corticosteroids for acute respiratory distress syndrome. <i>Academic Emergency Medicine</i> , 2022, 29, 255-256.	0.8	0
4492	è»½ç–†ãf»ã,ç%oç–†æ,£è€...ã@ã–ãã...¥ã,CEã,'æCE-ã,Šèž”ã£ã¼. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2022, 18, 47-51.0	1.0	0
4494	Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop. <i>Vaccine</i> , 2022, 40, 3484-3489.	1.7	6
4495	Comparison between methylprednisolone infusion and dexamethasone in COVID-19 ARDS mechanically ventilated patients. <i>The Egyptian Journal of Internal Medicine</i> , 2022, 34, 19.	0.3	13
4496	Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020: an observational cohort study. <i>BMJ Open</i> , 2022, 12, e055137.	0.8	6
4498	Effect of COVID-19 on kidney function in patients with arterial hypertension grade 1-2 and CKD. <i>Nephrology (Saint-Petersburg)</i> , 2022, 26, 34-43.	0.1	5
4499	Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2242.	1.8	17
4500	Investigation Into the Effect of COVID-19 Infection on Length of Hospital Stay and Mortality in Patients With Rheumatoid Arthritis. <i>Cureus</i> , 2022, 14, e22685.	0.2	3
4501	Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0210721.	1.4	22
4502	Multicenter Study of tissue plasminogen activator (alteplase) use in COVID-19 severe respiratory failure (MUST COVID): A retrospective cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12669.	1.0	6
4503	Healthcare Resource Utilization of Patients With COVID-19 Visiting US Hospitals. <i>Value in Health</i> , 2022, 25, 751-760.	0.1	10
4504	Is This the Beginning of the End of Cytokine Adsorption?. <i>Critical Care Medicine</i> , 2022, Publish Ahead of Print, .	0.4	7
4505	COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. <i>Kidney International</i> , 2022, 101, 883-894.	2.6	82
4506	Activating dormant strongyloidiasis secondary to COVID-19 treatment. <i>Global Journal of Medical and Clinical Case Reports</i> , 2022, 9, 015-017.	0.0	2
4507	Hospital Variation in Management and Outcomes of Acute Respiratory Distress Syndrome Due to COVID-19. , 2022, 10, e0638.		9

#	ARTICLE	IF	CITATIONS
4508	Pro-resolving therapies as potential adjunct treatment for infectious diseases: Evidence from studies with annexin A1 and angiotensin-(1-7). <i>Seminars in Immunology</i> , 2022, 59, 101601.	2.7	7
4509	Hospital bed occupancy rate is an independent risk factor for COVID-19 inpatient mortality: a pandemic epicentre cohort study. <i>BMJ Open</i> , 2022, 12, e058171.	0.8	14
4510	PHÃ, N TÃCH Ká³⁴T QUá²³ LÃ, M SÃENG VÃ€ BIá³⁴N Cá»•Bá²T Lá»CI TRÃŠN NGÆá»cel Bá»†NH COVID-19 ÄEá»C Sá»- Dá»NG THUá» KHOA QUá»C Tá³⁴ VINMEC. <i>Y Hoc Viet Nam</i> , 2022, 510, .	0.0	0
4512	Clinical practise of administration of systemic corticosteroids among critically ill patients with COVID-19 in the Czech Republic: survey (ASAPâ€C). <i>Anesteziologie A Intenzivni Medicina</i> , 2022, 33, 7-13.	0.1	0
4513	Clinical and Molecular Relationships between COVID-19 and Feline Infectious Peritonitis (FIP). <i>Viruses</i> , 2022, 14, 481.	1.5	9
4515	Using a Systems Approach to Explore the Mechanisms of Interaction Between Severe Covid-19 and Its Coronary Heart Disease Complications. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 737592.	1.1	1
4516	Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. <i>Frontiers in Pharmacology</i> , 2022, 13, 835136.	1.6	17
4517	Clinical Features and Changes in Insulin Requirements in People with Type 2 Diabetes Requiring Insulin When Hospitalised with SARS-CoV-2 Infection. <i>International Journal of Endocrinology</i> , 2022, 2022, 1-6.	0.6	3
4519	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.5	49
4520	A dangerous duo: spontaneous pneumomediastinum and venous thromboembolism at presentation in a patient with COVID-19 pneumonia. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 12-18.	0.4	1
4521	Tocilizumab and COVID-19: Timing of Administration and Efficacy. <i>Frontiers in Pharmacology</i> , 2022, 13, 825749.	1.6	27
4522	Clinical characteristics and outcomes in a cohort of oncologic patients with <sc>COVID</sc>â€19 during the first year of the pandemic in Mexico. <i>Cancer Medicine</i> , 2022, 11, 1827-1836.	1.3	4
4523	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 57.	7.1	34
4524	Coronavirus disease 2019-associated coronary endotheliitis and thrombotic microangiopathy causing cardiogenic shock: a case report. <i>European Heart Journal - Case Reports</i> , 2022, 6, ytac061.	0.3	6
4525	Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease. <i>Medicina Intensiva (English Edition)</i> , 2022, , .	0.1	1
4526	Antibody therapies to prevent and treat <sc>COVID</sc>â€19. <i>The Prescriber</i> , 2022, 33, 23-28.	0.1	0
4527	NF-â€B Signaling and Inflammationâ€”Drug Repurposing to Treat Inflammatory Disorders?. <i>Biology</i> , 2022, 11, 372.	1.3	19
4528	Efficacy of repurposed antiviral drugs: Lessons from COVID-19. <i>Drug Discovery Today</i> , 2022, 27, 1954-1960.	3.2	24

#	ARTICLE	IF	CITATIONS
4529	Synthetic virions reveal fatty acid-coupled adaptive immunogenicity of SARS-CoV-2 spike glycoprotein. <i>Nature Communications</i> , 2022, 13, 868.	5.8	20
4530	Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. <i>PLoS ONE</i> , 2022, 17, e0263591.	1.1	10
4531	Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 142.	2.4	24
4532	Conversations with individuals on the fence about CV-19 vaccination: Analysis of lives saved by vaccine vs. natural infection mortality and other reflections. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 1-6.	0.4	0
4533	COVID-19 in the Critically Ill Patient. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 365-377.	1.9	5
4534	Chronic Critical Illness in Patients with COVID-19: Characteristics and Outcome of Prolonged Intensive Care Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1049.	1.0	13
4535	Predicting Impact of Prone Position on Oxygenation in Mechanically Ventilated Patients with COVID-19. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 883-889.	1.3	7
4537	Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients. <i>Frontiers in Medicine</i> , 2022, 9, 849222.	1.2	2
4538	Executable network of SARS-CoV-2-host interaction predicts drug combination treatments. <i>Npj Digital Medicine</i> , 2022, 5, 18.	5.7	5
4539	Understanding of COVID-19 from infectionâ€“fatality ratio. <i>Lancet, The</i> , 2022, 399, 1442-1443.	6.3	4
4540	Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac037.	0.4	8
4541	An evidence-based nursing care guide for critically ill patients with COVID-19: A scoping Review. <i>Asian Journal of Nursing Education and Research</i> , 2022, , 144-157.	0.1	3
4542	Les canules nasales Ã haut dÃ©bit comme traitement de premiÃ¨re intention de lâ€™insuffisance respiratoire hypoxÃ©mique associÃ©e Ã la COVID-19 : une Ã©tude de cohorte historique monocentrique.. <i>Canadian Journal of Anaesthesia</i> , 2022, 69, 582-590.	0.7	2
4543	Possible COVID-19-Associated Pulmonary Aspergillosis Due to <i>Aspergillus niger</i> in Greece. <i>Antibiotics</i> , 2022, 11, 300.	1.5	3
4544	Comments on â€œWhole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in Indiaâ€“. <i>Radiotherapy and Oncology</i> , 2022, 167, 323-324.	0.3	1
4545	Effectiveness of Systemic Corticosteroids Therapy for Nonsevere Patients With COVID-19: A Multicenter, Retrospective, Longitudinal Cohort Study. <i>Value in Health</i> , 2022, , .	0.1	6
4546	Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). <i>Scientific Reports</i> , 2022, 12, 2552.	1.6	23
4547	Rate of COVID-19 infection and 30 day mortality between blue and green (dedicated COVID-19 safe) pathways: Results from phase 1 and 2 of the UK foot and ankle COVID-19 national (UK-FAICoN) audit. <i>Foot and Ankle Surgery</i> , 2022, , .	0.8	0

#	ARTICLE	IF	CITATIONS
4548	Pitfalls of Early Systemic Corticosteroids Home Therapy in Older Patients with COVID-19 Pneumonia. <i>Geriatrics (Switzerland)</i> , 2022, 7, 21.	0.6	4
4549	Effect of corticosteroids in patients with COVID-19 early stage pneumonia and risk of disease progression: An uncharted territory. <i>Drug Discoveries and Therapeutics</i> , 2022, 16, 47-48.	0.6	0
4550	LL-37 and Double-Stranded RNA Synergistically Upregulate Bronchial Epithelial TLR3 Involving Enhanced Import of Double-Stranded RNA and Downstream TLR3 Signaling. <i>Biomedicines</i> , 2022, 10, 492.	1.4	1
4551	Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study. <i>PLoS ONE</i> , 2022, 17, e0262564.	1.1	14
4552	Effective and safe profile of mini-pulse corticosteroid among COVID-19 inpatients: a case series. <i>Y Hoc Thanh Pho Ho Chi Minh</i> , 2021, 6, 49-54.	0.1	0
4554	Ofelecin i mi Vlapinâ€™ Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. <i>Medicina (Lithuania)</i> , 2022, 58, 309.	0.8	4
4555	SARS-CoV-2 Infects Red Blood Cell Progenitors and Dysregulates Hemoglobin and Iron Metabolism. <i>Stem Cell Reviews and Reports</i> , 2022, 18, 1809-1821.	1.7	47
4556	MAP2K2 Delays Recovery in Murine Models of Acute Lung Injury and Associates with ARDS Outcome. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, , .	1.4	1
4557	COVID-19 and Chagas Disease in Buenos Aires, Argentina. <i>Frontiers in Tropical Diseases</i> , 2022, 2, .	0.5	1
4558	The Spectrum of Invasive Fungal Sinusitis in COVID-19 Patients: Experience from a Tertiary Care Referral Center in Northern India. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 223.	1.5	9
4559	Clinical outcome of neurological patients with COVID-19: the impact of healthcare organization improvement between waves. <i>Neurological Sciences</i> , 2022, 43, 2923-2927.	0.9	3
4561	Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes. <i>Biomedicines</i> , 2022, 10, 437.	1.4	5
4562	Clinical Evidence Informing Treatment Guidelines on Repurposed Drugs for Hospitalized Patients During the Early COVID-19 Pandemic: Corticosteroids, Anticoagulants, (Hydroxy)chloroquine. <i>Frontiers in Public Health</i> , 2022, 10, 804404.	1.3	2
4563	COVID-19 ARDS: One Pathogen, Multiple Phenotypes. <i>Critical Care Clinics</i> , 2022, , .	1.0	6
4564	Brixia Score in Outcomes of Alpha versus Delta Variant of Infection in Pregnant Critical COVID-19 Patients. <i>International Journal of Translational Medicine</i> , 2022, 2, 66-77.	0.1	2
4565	Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling. <i>Frontiers in Immunology</i> , 2022, 13, 795315.	2.2	35
4566	Targeting Mononuclear Phagocytes to Treat COVID-19. , 0, , .		0
4567	Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patients. <i>PLoS ONE</i> , 2022, 17, e0264301.	1.1	5

#	ARTICLE	IF	CITATIONS
4568	THE DARK SIDE OF THE COVID-19 TREATMENTS ON MYCOBACTERIUM TUBERCULOSIS INFECTION. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022021.	0.5	5
4569	COVID-19 Aortitis: A Review of Published Cases. Cureus, 2022, 14, e22226.	0.2	1
4570	Outcomes of Acute Gastrointestinal Bleeding in Patients With COVID-19: A Case-Control Study. Gastroenterology Research, 2022, 15, 13-18.	0.4	7
4571	Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial. Frontiers in Medicine, 2022, 9, 819621.	1.2	4
4572	Review of Anti-inflammatory and Anti-viral therapeutics for hospitalized patients infected with SARS-CoV-2. Critical Care Clinics, 2022, , .	1.0	3
4573	First and second wave of coronavirus-19 disease: A comparative study in patients hospitalized in an ICU of a third-level university hospital. Medicina Intensiva (English Edition), 2022, 46, 166-168.	0.1	2
4574	CD4 ⁺ T-Cell Dysfunction in Severe COVID-19 Disease Is Tumor Necrosis Factor- α /Tumor Necrosis Factor Receptor 1 α -Dependent. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1403-1418.	2.5	21
4575	The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors. Frontiers in Public Health, 2022, 10, 816848.	1.3	6
4577	Drug repurposing <i>in silico</i> screening platforms. Biochemical Society Transactions, 2022, 50, 747-758.	1.6	14
4578	Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study. The Lancet Regional Health Americas, 2022, 11, 100228.	1.5	2
4579	Intensive Care Unit- α Acquired Weakness in Patients With COVID-19: Occurrence and Associated Factors. Physical Therapy, 2022, 102, .	1.1	6
4580	Kinetics of Severity Biomarkers and Immunological Features of Methylprednisolone Therapy for Severe COVID-19 Patients. Frontiers in Immunology, 2022, 13, 758946.	2.2	0
4581	Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia. Frontiers in Medicine, 2022, 9, 826247.	1.2	4
4582	HSP90 Inhibitors Modulate SARS-CoV-2 Spike Protein Subunit 1-Induced Human Pulmonary Microvascular Endothelial Activation and Barrier Dysfunction. Frontiers in Physiology, 2022, 13, 812199.	1.3	17
4583	Characteristics Associated With Disparities Among Older Adults in Coronavirus Disease 2019 Outcomes in an Academic Health Care System. Medical Care, 2022, 60, 332-341.	1.1	0
4584	Neuraminidase inhibitor treatment is associated with decreased mortality in COVID-19 patients: a retrospective analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 392-401.	1.4	4
4586	In Response to: Corticosteroids in Non-severe COVID-19: Finding Window of Opportunity. Indian Journal of Critical Care Medicine, 2022, 26, 405-405.	0.3	0
4587	Impact of Early Corticosteroids on Preventing Clinical Deterioration in Non-critically Ill Patients Hospitalized with COVID-19: A Multi-hospital Cohort Study. Infectious Diseases and Therapy, 2022, 11, 887-898.	1.8	5

#	ARTICLE	IF	CITATIONS
4588	Cellular therapies for the treatment and prevention of SARS-CoV-2 infection. <i>Blood</i> , 2022, 140, 208-221.	0.6	13
4589	A human pluripotent stem cell-based model of SARS-CoV-2 infection reveals an ACE2-independent inflammatory activation of vascular endothelial cells through TLR4. <i>Stem Cell Reports</i> , 2022, 17, 538-555.	2.3	22
4590	Effect of 12Âmg vs 6Âmg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial. <i>Canadian Journal of Emergency Medicine</i> , 2022, 24, 266-267.	0.5	3
4591	Mining Electronic Health Records for Drugs Associated With 28-day Mortality in COVID-19: Pharmacopoeia-wide Association Study (PharmWAS). <i>JMIR Medical Informatics</i> , 2022, 10, e35190.	1.3	1
4592	First case reported of COVID-19 infection in an adult patient with Ellis-van Creveld syndrome. <i>Progress in Pediatric Cardiology</i> , 2022, , 101508.	0.2	0
4593	Fatal COVID-19 and Nonâ€œCOVID-19 Acute Respiratory Distress Syndrome Is Associated with Incomplete Alveolar Type 1 Epithelial Cell Differentiation from the Transitional State without Fibrosis. <i>American Journal of Pathology</i> , 2022, 192, 454-467.	1.9	18
4594	Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence. <i>Expert Review of Anti-Infective Therapy</i> , 2022, , 1-11.	2.0	2
4595	Programmed cell death: the pathways to severe COVID-19?. <i>Biochemical Journal</i> , 2022, 479, 609-628.	1.7	30
4596	Evolution of prescribing practices and outcomes in the COVID-19 pandemic in metropolitan areas. <i>Infezioni in Medicina</i> , 2022, 30, 86-95.	0.7	1
4597	Factors associated with dexamethasone efficacy in COVIDâ€œ19. A retrospective investigative cohort study. <i>Journal of Medical Virology</i> , 2022, , .	2.5	2
4598	Photodynamic disinfection of SARS-CoV-2 clinical samples using a methylene blue formulation. <i>Photochemical and Photobiological Sciences</i> , 2022, 21, 1101-1109.	1.6	18
4599	Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 91.	7.1	14
4600	Cutting the Gordian knot of heterogeneity: Can integrated systems biology modelling rescue critical care syndromes?. <i>EBioMedicine</i> , 2022, 77, 103884.	2.7	0
4601	IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. <i>JCI Insight</i> , 2022, 7, .	2.3	23
4602	Neuroimmune disorders in COVID-19. <i>Journal of Neurology</i> , 2022, 269, 2827-2839.	1.8	27
4603	Comparison of Outcomes of In-Centre Haemodialysis Patients between the 1st and 2nd COVID-19 Outbreak in England, Wales, and Northern Ireland: A UK Renal Registry Analysis. <i>Nephron</i> , 2022, 146, 469-480.	0.9	9
4604	Therapeutic strategies for COVID-19 patients: An update. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	0
4605	æ°âžžã,³ãfãfŠã, ã,ãf«ã,¹æ,,ÿæÿ“ç—†â€œæ²»ç™,æ^ ç•¥ã•ãf“ã,ãfãf³ã«ãã,ã†â€œ. Nihon Jibi Inkoka Tokeibu Geka Gakkai Kaho, 2022,		

#	ARTICLE	IF	CITATIONS
4606	Experiencing COVID-19 at a large district level hospital in Cape Town: A retrospective analysis of the first wave. <i>Southern African Journal of Infectious Diseases</i> , 2022, 37, 317.	0.3	0
4607	Comparison of clinical characteristics and outcomes of COVID-19 patients undergoing early versus late intubation from initial hospital admission: A systematic review and meta-analysis. <i>Respiratory Investigation</i> , 2022, , .	0.9	5
4609	COVID-19 Risk Stratification and Mortality Prediction in Hospitalized Indian Patients: Harnessing clinical data for public health benefits. <i>PLoS ONE</i> , 2022, 17, e0264785.	1.1	16
4610	COVID-19 Disease in Syrian Patients With Cancer: Clinical Manifestations, Laboratory Findings, Treatment, and Outcomes. <i>JCO Global Oncology</i> , 2022, 8, e2100283.	0.8	2
4611	COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0020021.	5.7	64
4613	Recent Advances in Fungal Infections: From Lung Ecology to Therapeutic Strategies With a Focus on <i>Aspergillus</i> spp.. <i>Frontiers in Medicine</i> , 2022, 9, 832510.	1.2	6
4614	A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 685-715.	2.0	30
4615	Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid. <i>Frontiers in Medicine</i> , 2022, 9, 856891.	1.2	1
4616	Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 611-621.	4.6	22
4617	Fatal Mucormycosis Post COVID-19 Infection in Uncontrolled Diabetes with Misuse of Glucocorticoids and Antibiotics. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 1121-1126.	1.1	4
4618	Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomics. <i>Molecular Therapy</i> , 2022, 30, 1952-1965.	3.7	20
4619	Neurocognitive and psychiatric post-coronavirus disease 2019 conditions. <i>Current Opinion in Neurology</i> , 2022, Publish Ahead of Print, .	1.8	10
4620	Intravenous N-Acetylcysteine in Management of COVID-19: A Case Series. <i>Journal of Pharmacy Practice</i> , 2023, 36, 1008-1014.	0.5	2
4621	Targeting of neutrophil activation in the early phase of the disease for prevention of Coronavirus diseaseâ€™19 severity. <i>Microbiology and Immunology</i> , 2022, 66, 264-276.	0.7	5
4622	Using Explicit Thresholds were valuable for judging Benefits and Harms in partially contextualized GRADE Guidelines. <i>Journal of Clinical Epidemiology</i> , 2022, 147, 69-75.	2.4	3
4623	Inflammaging at the Time of COVID-19. <i>Clinics in Geriatric Medicine</i> , 2022, 38, 473-481.	1.0	14
4624	Inducible Nitric Oxide Synthase (iNOS): Why a Different Production in COVID-19 Patients of the Two Waves?. <i>Viruses</i> , 2022, 14, 534.	1.5	10
4625	Statin use in hospitalized patients with COVID-19: A comprehensive analysis of the New York City Public Hospital System. <i>American Journal of Medicine</i> , 2022, , .	0.6	2

#	ARTICLE	IF	CITATIONS
4626	Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac104.	0.4	6
4627	Does Losartan reduce the severity of COVID-19 in hypertensive patients?. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 116.	0.7	3
4628	Assessing Provider Utilization of COVID-19 Inflammatory Marker Trends in Hospitalized Patients and Implications in Optimizing Value-Based Care During a Pandemic. <i>Kansas Journal of Medicine</i> , 2022, 15, 91-96.	0.1	0
4629	Risk factors for Herpes simplex virus and Cytomegalovirus infections in critically-ill COVID-19 patients. <i>Multidisciplinary Respiratory Medicine</i> , 2022, 17, 815.	0.6	9
4630	Clinical presentation and outcomes of chronic dialysis patients with COVID-19: A single center experience from Greece. <i>World Journal of Nephrology</i> , 2022, 11, 58-72.	0.8	3
4632	Niclosamideâ€”A promising treatment for COVIDâ€™19. <i>British Journal of Pharmacology</i> , 2022, 179, 3250-3267.	2.7	31
4633	Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. <i>EBioMedicine</i> , 2022, 77, 103893.	2.7	48
4634	Effect of polymerised type I collagen on hyperinflammation of adult outpatients with symptomatic COVIDâ€™19. <i>Clinical and Translational Medicine</i> , 2022, 12, e763.	1.7	9
4635	Characteristics and outcomes of older patients hospitalised for COVID-19 in the first and second wave of the pandemic in The Netherlands: the COVID-OLD study. <i>Age and Ageing</i> , 2022, 51, .	0.7	6
4636	Bilateral and Multiple Central Serous Chorioretinopathy Following COVID-19 Infection: A Case Report and Literature Review. <i>Cureus</i> , 2022, 14, e23246.	0.2	5
4637	Progressive pulmonary fibrosis due to diffuse alveolar damage in a <sc>COVID</sc>â€™19â€™infected autopsy case. <i>Respirology Case Reports</i> , 2022, 10, e0934.	0.3	2
4638	Mortality and associated risk factors in patients hospitalized due to COVID-19 in a Peruvian reference hospital. <i>PLoS ONE</i> , 2022, 17, e0264789.	1.1	15
4639	No perfect therapy for the imperfect COVID-19 cytokine storm. <i>Lancet Rheumatology</i> , The, 2022, 4, e308-e310.	2.2	7
4640	Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. <i>Rheumatology</i> , 2022, 61, SI151-SI156.	0.9	7
4642	Evaluation of aerosolized epoprostenol for hypoxemia in non-intubated patients with coronavirus disease 2019. <i>Hospital Practice (1995)</i> , 2022, 50, 118-123.	0.5	5
4643	Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e380-e388.	2.9	27
4644	Multidisciplinary and interprofessional collaboration as a necessity to drive modern oncology research trials in the era of precision oncology. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2022, 53, 179-180.	0.2	0
4645	A Brief Review on Ophthalmic Suspension for Covid-19 Infection. <i>Research Journal of Pharmacology and Pharmacodynamics</i> , 2022, , 29-36.	0.1	0

#	ARTICLE	IF	CITATIONS
4646	C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19. <i>Scientific Reports</i> , 2022, 12, 5250.	1.6	11
4647	Intubation Timing in COVID-19 Based on ROX Index and Association With Patient Outcomes. <i>Respiratory Care</i> , 2022, 67, 1291-1299.	0.8	3
4648	Low-dose radiation therapy in the management of COVID-19 pneumonia (LOWRAD-Cov19). Final results of a prospective phase I-II trial. <i>Radiotherapy and Oncology</i> , 2022, , .	0.3	4
4649	Infection fatality rate of COVID-19 in community-dwelling elderly populations. <i>European Journal of Epidemiology</i> , 2022, 37, 235-249.	2.5	34
4650	SARS-CoV-2 Associated Immune Dysregulation and COVID-Associated Pulmonary Aspergilliosis (CAPA): A Cautionary Tale. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3228.	1.8	3
4651	Corticosteroids for Non-severe COVID-19: Primum Non Nocere. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 403-404.	0.3	2
4652	Comparison of Outcomes and Process of Care for Patients Treated at Hospitals Dedicated for COVID-19 Care vs Other Hospitals. <i>JAMA Network Open</i> , 2022, 5, e220873.	2.8	8
4653	Atraumatic Osteonecrosis of the Humeral Head: Pathophysiology and Current Concepts of Evaluation and Treatment. <i>JSES Reviews, Reports, and Techniques</i> , 2022, , .	0.1	1
4655	Adrenal tropism of SARS-CoV-2 and adrenal findings in a post-mortem case series of patients with severe fatal COVID-19. <i>Nature Communications</i> , 2022, 13, 1589.	5.8	24
4656	ACE2 Expression in Organotypic Human Airway Epithelial Cultures and Airway Biopsies. <i>Frontiers in Pharmacology</i> , 2022, 13, 813087.	1.6	6
4657	Concurrent myopathy and inflammatory cardiac disease in COVID-19 patients: a case series and literature review. <i>Rheumatology International</i> , 2022, 42, 905-912.	1.5	11
4658	Severe and critical COVID-19 in a tertiary center in Colombia, a retrospective cross-sectional study. <i>BMC Infectious Diseases</i> , 2022, 22, 247.	1.3	6
4659	Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry. <i>Internal and Emergency Medicine</i> , 2022, 17, 1115-1127.	1.0	4
4661	Real World Impact of Remdesivir and Dexamethasone on Clinical Outcomes of Severe Coronavirus Disease 2019 in a Community Hospital. <i>Military Medicine</i> , 2023, 188, e1529-e1533.	0.4	3
4662	Pulmonary and Critical Care Considerations for e-Cigarette, or Vaping, Product Use-Associated Lung Injury. <i>Chest</i> , 2022, 162, 256-264.	0.4	8
4663	Corticosteroids in acute respiratory distress syndrome: One size does not fit all. <i>American Journal of Health-System Pharmacy</i> , 2022, , .	0.5	0
4664	One Year Prevalence of Venous Thromboembolism in Hospitalized COVID-19 Patients in France: Patients' Characteristics, Time Trends, and Outcomes. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1532-1541.	1.8	5
4665	Ethnic disparities in hospitalisation and hospital-outcomes during the second wave of COVID-19 infection in east London. <i>Scientific Reports</i> , 2022, 12, 3721.	1.6	13

#	ARTICLE	IF	CITATIONS
4666	The Impact of the Coronavirus (COVID-19) Infection on the Drug- Metabolizing Enzymes Cytochrome P450s. <i>Drug Metabolism Letters</i> , 2022, 15, 71-74.	0.5	2
4667	Whole-genome sequencing reveals host factors underlying critical COVID-19. <i>Nature</i> , 2022, 607, 97-103.	13.7	174
4668	Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1400-1410.	0.4	21
4669	Drug dosing in hospitalized obese patients with COVID-19. <i>Critical Care</i> , 2022, 26, 60.	2.5	3
4670	COVID-19 Oximetry @home: evaluation of patient outcomes. <i>BMJ Open Quality</i> , 2022, 11, e001584.	0.4	8
4671	Part <sc>II</sc>: Statistics in practice: Study design and application of inferential statisticsâ€”Interventional research. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2022, 5, 377-381.	0.5	0
4672	Incidence and risk factors for hyperkalaemia in patients treated for COVIDâ€19 with nafamostat mesylate. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 1070-1078.	0.7	5
4674	Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Antigen in Urine of Hospitalized Patients With Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2022, 226, 812-821.	1.9	5
4675	A Simple Prognostic Score for Critical COVID-19 Derived from Patients without Comorbidities Performs Well in Unselected Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 1810.	1.0	7
4677	Cytological patterns of bronchoalveolar lavage fluid in mechanically ventilated COVIDâ€19 patients on extracorporeal membrane oxygenation. <i>Clinical Respiratory Journal</i> , 2022, , .	0.6	2
4678	Incidence and risk factors for COVIDâ€19 associated candidemia (CAC) in ICU patients. <i>Mycoses</i> , 2022, , .	1.8	12
4679	Racial/ethnic disparities on inflammation and response to methylprednisolone in severe COVID-19 pneumonia. <i>BMC Infectious Diseases</i> , 2022, 22, 254.	1.3	3
4680	The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 51.	0.9	4
4681	Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality. <i>JAMA Network Open</i> , 2022, 5, e221455.	2.8	10
4682	Postextubation Stridor in Severe COVID-19. <i>Respiratory Care</i> , 2022, 67, 638-646.	0.8	2
4683	Relationship Between Endothelial and Angiogenesis Biomarkers Envisage Mortality in a Prospective Cohort of COVID-19 Patients Requiring Respiratory Support. <i>Frontiers in Medicine</i> , 2022, 9, 826218.	1.2	17
4684	Neuroimmunology and Neurological Manifestations of COVID-19. , 0, , .		0
4685	Editorial on pregnancy and the SARS-CoV-2 pandemic. <i>Physiological Reviews</i> , 2022, , .	13.1	0

#	ARTICLE	IF	CITATIONS
4688	Detection, prevention and treatment of COVID-19 and opportunities for nanobiotechnology. <i>View</i> , 2022, 3, .	2.7	8
4689	Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19. <i>Infezioni in Medicina</i> , 2022, 30, 11-21.	0.7	3
4690	Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir. <i>Viruses</i> , 2022, 14, 670.	1.5	3
4691	A Case of Rebound Inflammation in a 38-Year-Old Man with Severe COVID-19 Pneumonia Following Cessation of Dexamethasone Therapy. <i>American Journal of Case Reports</i> , 2022, 23, e935946.	0.3	2
4692	Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists. <i>Diabetes Mellitus</i> , 2022, 25, 27-49.	0.5	13
4693	Influence of perioperative SARS-CoV-2 infection on mortality in orthopaedic inpatients with surgically treated traumatic fractures. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2023, 33, 1043-1049.	0.6	1
4694	Respiratory ECMO Survival Prediction (RESP) Score for COVID-19 Patients Treated with ECMO. <i>ASAIO Journal</i> , 2022, 68, 486-491.	0.9	17
4695	Delayed dexamethasone treatment at initiation of oxygen supplementation for coronavirus disease 2019 is associated with the exacerbation of clinical condition. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	0.8	0
4696	Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0204521.	1.4	6
4697	Mechanically Ventilated Patients Shed High-Titer Live Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for Extended Periods From Both the Upper and Lower Respiratory Tract. <i>Clinical Infectious Diseases</i> , 2022, 75, e82-e88.	2.9	8
4698	Prescription Patterns of Drugs Given to Hospitalized COVID-19 Patients: A Cross-Sectional Study in Colombia. <i>Antibiotics</i> , 2022, 11, 333.	1.5	5
4699	2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1717-1756.	1.2	220
4700	A Retrospective Analysis of Clinical Manifestations, Management and Outcome of Acute Respiratory Distress Syndrome Associated with Coronavirus Disease-2019 Infection in Children. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 331-338.	0.3	3
4701	Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 1412.	1.0	9
4702	Efficacy of early use of remdesivir: a systematic review of subgroup analysis. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 249-259.	0.5	3
4703	Asthma and coronavirus disease 2019-related outcomes in hospitalized patients. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 79-87.e6.	0.5	7
4704	A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19. , 2022, 4, e0662.		23
4705	From Biomedical Applications of Alginate towards CVD Implications Linked to COVID-19. <i>Pharmaceuticals</i> , 2022, 15, 318.	1.7	4

#	ARTICLE	IF	CITATIONS
4706	Importance of Efferocytosis in COVID-19 Mortality. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 995-1007.	1.1	1
4707	Clinical impact of ventilator-associated pneumonia in patients with the acute respiratory distress syndrome: a retrospective cohort study. <i>Annals of Intensive Care</i> , 2022, 12, 24.	2.2	3
4708	Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial. <i>European Respiratory Journal</i> , 2022, 60, 2200025.	3.1	33
4709	Mortality and Pulmonary Embolism in Acute Respiratory Distress Syndrome From COVID-19 vs. Non-COVID-19. <i>Frontiers in Medicine</i> , 2022, 9, 800241.	1.2	9
4710	SARS-CoV-2 infection and children: Insights from the 6th Workshop on Paediatric Virology (Review). <i>World Academy of Sciences Journal</i> , 2022, 4, .	0.4	1
4711	Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India. <i>Mycoses</i> , 2022, 65, 526-540.	1.8	12
4712	Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial. <i>Infectious Disease Reports</i> , 2022, 14, 160-168.	1.5	21
4713	Hundreds of COVID trials could provide a deluge of new drugs. <i>Nature</i> , 2022, 603, 25-27.	13.7	29
4714	A Case of Emergency Partial Small Bowel Resection for a Patient with Novel Coronavirus and Small Bowel Necrosis. <i>Japanese Journal of Gastroenterological Surgery</i> , 2022, 55, 199-206.	0.0	0
4715	Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis. <i>American Journal of Therapeutics</i> , 2022, 29, e298-e304.	0.5	9
4716	Mechanical Circulatory Support in COVID-19. <i>Cardiology Clinics</i> , 2022, , .	0.9	3
4717	Screening Large Population Health Databases for Potential Coronavirus Disease 2019 Therapeutics: A Pharmacopeia-Wide Association Study of Commonly Prescribed Medications. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac156.	0.4	1
4718	Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis. <i>Frontiers in Medicine</i> , 2022, 9, 838564.	1.2	24
4719	Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 123.	0.7	4
4721	Assessing Unexpected Circumstances That Lead to Modifications in Clinical Trial Design, Conduct, or Analysis. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 868.	3.8	0
4722	Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study. <i>Frontiers in Medicine</i> , 2022, 9, 828402.	1.2	5
4723	SARS-CoV-2 pathogenesis. <i>Nature Reviews Microbiology</i> , 2022, 20, 270-284.	13.6	404
4724	Pulmonary embolism after dexamethasone treatment for COVID-19: a case report. <i>BMC Infectious Diseases</i> , 2022, 22, 277.	1.3	3

#	ARTICLE	IF	CITATIONS
4725	Efficacy of pharmacological interventions in COVID-19: A network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	1.1	5
4726	The number of circulating CD26 expressing cells is decreased in critical COVID-19 illness. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2023, 103, 153-161.	1.1	2
4727	Clinicopathologic characteristics of severe COVID-19 patients in Mexico City: A post-mortem analysis using a minimally invasive autopsy approach. <i>PLoS ONE</i> , 2022, 17, e0262783.	1.1	7
4728	Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19. <i>Scientific Reports</i> , 2022, 12, 5207.	1.6	8
4729	The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication <i>In Vitro</i> and Decreases Viral Titers and Disease Progression in Syrian Hamsters. <i>MBio</i> , 2022, 13, e0370521.	1.8	22
4731	Role of Acute Thrombosis in COVID-19. <i>Critical Care Clinics</i> , 2022, , .	1.0	3
4732	SARS-CoV-2 and its variants of concern including Omicron: A never ending pandemic. <i>Chemical Biology and Drug Design</i> , 2022, 99, 769-788.	1.5	37
4734	Selenium in the Prevention of SARS-CoV-2 and Other Viruses. <i>Biological Trace Element Research</i> , 2022, , 1.	1.9	12
4735	Surfing Corona waves instead of breaking them: Rethinking the role of natural immunity in COVID-19 policy. <i>F1000Research</i> , 0, 11, 337.	0.8	0
4737	Coronavirus disease 2019 and the liver. <i>Current Opinion in Gastroenterology</i> , 2022, Publish Ahead of Print, .	1.0	3
4738	Small hospitals in battle against COVID-19: A single-center cohort study. <i>Pneumon</i> , 2022, 35, 1-5.	0.6	1
4739	Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis. <i>Frontiers in Microbiology</i> , 2022, 13, 860931.	1.5	15
4740	Six-Week Hospital-Based Pulmonary Rehabilitation in Covid Pneumonia ICU Survivors: Experience from a Tertiary Care Center in Central India. , 2022, 23, 89-96.		7
4741	A Clustered Case Series of Mucorales Detection in Respiratory Samples from COVID-19 Patients in Intensive Care, France, August to September 2021. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 258.	1.5	7
4742	Pharmacological consideration of COVID-19 infection and vaccines in pregnancy. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 537-542.	0.6	6
4743	High mortality among hospitalized adult patients with COVID-19 pneumonia in Peru: A single centre retrospective cohort study. <i>PLoS ONE</i> , 2022, 17, e0265089.	1.1	13
4744	Use of Antivirals in SARS-CoV-2 Infection. <i>Critical Review of the Role of Remdesivir. Drug Design, Development and Therapy</i> , 2022, Volume 16, 827-841.	2.0	12
4745	Systemic Steroids for Otolaryngology Head and Neck Surgery Disorders: An Evidence-Based Primer for Clinicians. <i>Otolaryngology - Head and Neck Surgery</i> , 2023, 168, 643-657.	1.1	4

#	ARTICLE	IF	CITATIONS
4746	COVID-19 FAQs in Pediatric Cardiac Surgery: 2022 Perspective and Updates. World Journal for Pediatric & Congenital Heart Surgery, 2022, , 215013512210859.	0.3	1
4747	Development and Structure of an Accurate Machine Learning Algorithm to Predict Inpatient Mortality and Hospice Outcomes in the Coronavirus Disease 2019 Era. Medical Care, 2022, 60, 381-386.	1.1	5
4748	Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis. Emerging Microbes and Infections, 2022, 11, 1154-1165.	3.0	25
4749	The Risk Factors Potentially Influencing Hospital Admission in People with Diabetes, Following SARS-CoV-2 Infection: A Population-Level Analysis. Diabetes Therapy, 2022, 13, 1007.	1.2	10
4750	Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial. British Journal of General Practice, 2022, 72, e446-e455.	0.7	19
4751	Clinical Significance of COVID-19 and Diabetes: In the Pandemic Situation of SARS-CoV-2 Variants including Omicron (B.1.1.529). Biology, 2022, 11, 400.	1.3	10
4752	CD24Fc: an emerging COVID-19 therapy. Lancet Infectious Diseases, The, 2022, 22, 565-567.	4.6	4
4753	Reactivation of Tuberculosis in the Setting of COVID-19 Infection. Cureus, 2022, 14, e23417.	0.2	4
4754	Therapeutic Strategies for COVID-19 Lung Disease in Children. Frontiers in Pediatrics, 2022, 10, 829521.	0.9	6
4755	Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19. Drugs in Context, 2022, 11, 1-15.	1.0	0
4756	Caring for older adults during the COVID-19 pandemic. Clinical Microbiology and Infection, 2022, 28, 785-791.	2.8	21
4757	Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series. Current Oncology, 2022, 29, 2312-2325.	0.9	8
4758	Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. Stem Cell Research and Therapy, 2022, 13, 122.	2.4	29
4760	Hospital management of hyperglycemia in the context of COVID-19: evidence-based clinical considerations. Diabetology and Metabolic Syndrome, 2022, 14, 37.	1.2	7
4762	Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study. Scientific Reports, 2022, 12, 5323.	1.6	7
4763	Covid-19 variants of concern and pregnancy. , 2022, 1, e000151.		4
4764	Clinical Features and Mortality of COVID-19-Associated Mucormycosis: A Systematic Review and Meta-Analysis. Mycopathologia, 2022, 187, 271-289.	1.3	20
4765	KLF15 cistromes reveal a hepatocyte pathway governing plasma corticosteroid transport and systemic inflammation. Science Advances, 2022, 8, eabj2917.	4.7	5

#	ARTICLE	IF	CITATIONS
4766	COVID-19 and Mucormycosis Coinfection: How Challenging It Is. Canadian Journal of Infectious Diseases and Medical Microbiology, 2022, 2022, 1-5.	0.7	4
4767	Care of the Hepatology Patient in the COVID-19 Era. Current Hepatology Reports, 2022, , 1-12.	0.4	2
4768	Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism. Scientific Reports, 2022, 12, 5758.	1.6	22
4769	REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan. Journal of Infection and Chemotherapy, 2022, , .	0.8	1
4770	Utilization of Nanoparticles, Nanodevices, and Nanotechnology in the Treatment Course of Cutaneous Melanoma. Advanced Therapeutics, 2022, 5, .	1.6	3
4771	Inhaled corticosteroids: not just for asthma, but for COVID-19?. Lancet Respiratory Medicine,the, 2022, 10, 526-527.	5.2	4
4772	Systemic Corticosteroid Use for COVID-19 in US Outpatient Settings From April 2020 to August 2021. JAMA - Journal of the American Medical Association, 2022, 327, 2015.	3.8	16
4773	The benefit of dexamethasone in patients with COVID-19 infection is preserved in patients with diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 1385-1389.	2.2	4
4774	Anti-COVID-19 potential of Azadirachta indica (Neem) leaf extract. Scientific African, 2022, 16, e01184.	0.7	5
4775	Vive la Résistance: T-cell Immunity in the Protection against SARS-CoV-2 Infection. Cancer Discovery, 2022, 12, 892-894.	7.7	0
4776	Aggregating human judgment probabilistic predictions of the safety, efficacy, and timing of a COVID-19 vaccine. Vaccine, 2022, 40, 2331-2341.	1.7	7
4777	Antiviral Efficacy of Molnupiravir for COVID-19 Treatment. Viruses, 2022, 14, 763.	1.5	8
4778	Lipidomics in Understanding Pathophysiology and Pharmacologic Effects in Inflammatory Diseases: Considerations for Drug Development. Metabolites, 2022, 12, 333.	1.3	14
4779	Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight, 2022, 7, .	2.3	24
4780	Herbal inhibitors of SARS-CoV-2 M ^{pro} effectively ameliorate acute lung injury in mice. IUBMB Life, 2022, 74, 532-542.	1.5	6
4781	Treatment with 3-day methylprednisolone pulses in severe cases of COVID-19 compared with the standard regimen protocol of dexamethasone. Journal of Investigative Medicine, 2022, 70, 1423-1428.	0.7	5
4782	Incidence, Mortality, and Imaging Outcomes of Atrial Arrhythmias in COVID-19. American Journal of Cardiology, 2022, 173, 64-72.	0.7	8
4783	COVID-19 Trials: Who Participates and Who Benefits?. Southern Medical Journal, 2022, 115, 256-261.	0.3	2

#	ARTICLE	IF	CITATIONS
4784	COVID-19-Associated Pulmonary Aspergillosis in a Patient Treated With Remdesivir, Dexamethasone, and Baricitinib: A Case Report. <i>Cureus</i> , 2022, 14, e23755.	0.2	1
4785	Pathogen Species Is Associated With Mortality in Nosocomial Bloodstream Infection in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	6
4786	Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities. <i>JAMA Internal Medicine</i> , 2022, 182, 426.	2.6	69
4787	High-cited favorable studies for COVID-19 treatments ineffective in large trials. <i>Journal of Clinical Epidemiology</i> , 2022, 148, 1-9.	2.4	4
4788	Outcomes of Percutaneous Tracheostomy for Patients With SARS-CoV-2 Respiratory Failure. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2023, 30, 60-65.	0.8	3
4789	COVID-19 and Plethora of Fungal Infections. <i>Current Fungal Infection Reports</i> , 2022, 16, 47-54.	0.9	10
4790	Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia. <i>Journal of Infection and Public Health</i> , 2022, 15, 389-394.	1.9	6
4791	Acute respiratory distress syndrome. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2022, 35, 29-33.	0.1	4
4792	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. <i>Blood Cancer Discovery</i> , 2022, 3, 181-193.	2.6	12
4793	Intensive care-related loss of quality of life and autonomy at 6 months post-discharge: Does COVID-19 really make things worse?. <i>Critical Care</i> , 2022, 26, 94.	2.5	9
4794	Persistent Hiccups as an Atypical Presentation of SARS-CoV-2 Infection: A Systematic Review of Case Reports. <i>Frontiers in Neurology</i> , 2022, 13, 819624.	1.1	9
4796	Grape Phytochemicals and Vitamin D in the Alleviation of Lung Disorders. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 1276-1292.	0.6	6
4797	COVID-19 therapeutics: Challenges and directions for the future. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2119893119.	3.3	92
4798	A critical evaluation of risk to reward ratio of quercetin supplementation for COVID-19 and associated comorbid conditions. <i>Phytotherapy Research</i> , 2022, 36, 2394-2415.	2.8	15
4799	Factors affecting the content of Ig G-antibodies to S-protein SARS-CoV-2 in the blood of convalescents after new coronaviral infection (COVID-19). <i>Meditinskiy Sovet</i> , 2022, , 51-65.	0.1	5
4801	Comparison of Survival and Clinical Profile of Adults with COVID-19 Hospitalized in Two Clinics in Medellín, Colombia. <i>Current Clinical Microbiology Reports</i> , 2022, , 1-9.	1.8	1
4803	In silico Study of Some Dexamethasone Analogs and Derivatives against SARS-CoV-2 Target: A Cost-effective Alternative to Remdesivir for Various COVID Phases. <i>Current Chinese Science</i> , 2022, 2, 294-309.	0.2	15
4804	Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group. <i>EClinicalMedicine</i> , 2022, 46, 101362.	3.2	20

#	ARTICLE	IF	CITATIONS
4805	Characterization of Altered Gene Expression and Histone Methylation in Peripheral Blood Mononuclear Cells Regulating Inflammation in COVID-19 Patients. <i>Journal of Immunology</i> , 2022, 208, 1968-1977.	0.4	8
4806	Autoimmune disease and COVID-19: a multicentre observational study in the United Kingdom. <i>Rheumatology</i> , 2022, 61, 4643-4655.	0.9	4
4807	Clinical characteristics, activity levels and mental health problems in children with long coronavirus disease: a survey of 510 children. <i>Future Microbiology</i> , 2022, 17, 577-588.	1.0	63
4808	Molnupiravir and Its Antiviral Activity Against COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 855496.	2.2	81
4809	Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. <i>The Lancet Digital Health</i> , 2022, 4, e220-e234.	5.9	20
4810	Very late intubation in COVID-19 patients: a forgotten prognosis factor?. <i>Critical Care</i> , 2022, 26, 89.	2.5	14
4811	Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 548-553.	0.8	7
4812	Risk Prediction for Acute Kidney Injury in Patients Hospitalized With COVID-19. <i>Kidney Medicine</i> , 2022, 4, 100463.	1.0	4
4813	Corticosteroid therapy in COVID-19 associated with in-hospital mortality in geriatric patients: a propensity matched cohort study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, , .	1.7	7
4814	The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections. <i>Frontiers in Immunology</i> , 2022, 13, 832394.	2.2	56
4816	Survival After Severe COVID-19: Long-Term Outcomes of Patients Admitted to an Intensive Care Unit. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 1019-1028.	1.3	12
4819	Therapeutic potential of induced iron depletion using iron chelators in Covid-19. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 1947-1956.	1.8	18
4820	Apparent Association of Insulin With Interleukin-6 (IL-6) in Severe COVID-19 Patients Having Chronic Disease Comorbidities. <i>Cureus</i> , 2022, 14, e23790.	0.2	2
4821	Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression. <i>Heliyon</i> , 2022, 8, e09230.	1.4	16
4822	Development of a colorimetric assay for the detection of SARS-CoV-2 3CLpro activity. <i>Biochemical Journal</i> , 2022, 479, 901-920.	1.7	3
4823	TREATMENT PROFILE AND SURVIVAL ANALYSIS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) COVID-19 PATIENTS. <i>International Journal of Applied Pharmaceutics</i> , 0, , 54-56.	0.3	6
4824	High-Dose Pulse Steroids for the Treatment of Acute Hypoxemic Respiratory Failure in COVID-19 Pneumonia: A Simple Case Series. , 2022, 26, 106-118.		1
4825	Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial. <i>Critical Care</i> , 2022, 26, 101.	2.5	19

#	ARTICLE	IF	CITATIONS
4826	WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales. <i>Journal of General Internal Medicine</i> , 2022, 37, 1980-1987.	1.3	27
4827	Airway administration of bisphosphate and dexamethasone inhibits SARS-CoV-2 variant infection by targeting alveolar macrophages. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 116.	7.1	2
4828	Learning hematology while surfing the waves of the COVID-19 pandemic. , 0, .		0
4829	Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13776.	1.7	20
4830	The end of the COVID-19 pandemic. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13782.	1.7	44
4831	Neuropsychiatric manifestation of the drugs used in the treatment of SARS-2-CoV-2019 (COVID-19) infection and their management: An overview and practice implications. <i>Asian Journal of Psychiatry</i> , 2022, 73, 103101.	0.9	4
4832	Handling death as an intercurrent event in time to recovery analysis in COVID-19 treatment clinical trials. <i>Contemporary Clinical Trials</i> , 2022, 119, 106758.	0.8	1
4833	Stress Hyperglycemia, Diabetes Mellitus and COVID-19 Infection: Risk Factors, Clinical Outcomes and Post-Discharge Implications. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 2022, 3, .	0.3	8
4834	Cardiovascular signatures of COVID-19 predict mortality and identify barrier stabilizing therapies. <i>EBioMedicine</i> , 2022, 78, 103982.	2.7	17
4835	A global picture: therapeutic perspectives for COVID-19. <i>Immunotherapy</i> , 2022, 14, 351-371.	1.0	56
4836	Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study. <i>Medicina (Lithuania)</i> , 2022, 58, 513.	0.8	16
4837	Treatments, resource utilization, and outcomes of COVID-19 patients presenting to emergency departments across pandemic waves: an observational study by the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN). <i>Canadian Journal of Emergency Medicine</i> , 2022, 24, 397-407.	0.5	17
4838	A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19. <i>Med</i> , 2022, 3, 233-248.e6.	2.2	17
4839	Factors predicting in-hospital all-cause mortality in COVID 19 patients at the Laquintinie Hospital Douala, Cameroon. <i>Travel Medicine and Infectious Disease</i> , 2022, 47, 102292.	1.5	3
4840	Clinical Presentation and Outcome of Hospitalized Patients With COVID-19 in the First and Second Waves in Saudi Arabia. <i>International Journal of Infectious Diseases</i> , 2022, 118, 104-108.	1.5	8
4841	Sex Differences in Thrombosis and Mortality in Patients Hospitalized for COVID-19. <i>American Journal of Cardiology</i> , 2022, 170, 112-117.	0.7	5
4842	A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors. <i>Antiviral Research</i> , 2022, 201, 105272.	1.9	9
4843	COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. <i>Pharmacological Research</i> , 2022, 179, 106201.	3.1	23

#	ARTICLE	IF	CITATIONS
4844	Covid-19 and its implications for the provision of gynecological services globally. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2022, 272, 58-63.	0.5	0
4845	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management. <i>American Journal of Emergency Medicine</i> , 2022, 56, 158-170.	0.7	13
4846	Adverse effects of prenatal dexamethasone exposure on fetal development. <i>Journal of Reproductive Immunology</i> , 2022, 151, 103619.	0.8	6
4847	Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection?. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159140.	1.2	10
4848	Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 25, 52-73.	1.8	11
4849	Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159139.	1.2	18
4850	Dexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19. <i>Journal of Critical Care</i> , 2022, 69, 154014.	1.0	24
4851	Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19. <i>International Immunopharmacology</i> , 2022, 107, 108689.	1.7	2
4852	Neurological sequela and disruption of neuron-glia homeostasis in SARS-CoV-2 infection. <i>Neurobiology of Disease</i> , 2022, 168, 105715.	2.1	18
4853	A Trans-Agency Workshop on the Pathophysiology of Radiation-Induced Lung Injury. <i>Radiation Research</i> , 2021, 197, .	0.7	3
4854	Short-Course of Methylprednisolone Improves Respiratory Functional Parameters After 120 Days in Hospitalized COVID-19 Patients (Metcovid Trial): A Randomized Clinical Trial. <i>Frontiers in Medicine</i> , 2021, 8, 758405.	1.2	13
4855	Update to Perinatal-Neonatal Management of COVID-19 Guidelines. <i>Indian Pediatrics</i> , 2022, 59, 63-66.	0.2	1
4856	Prognosis of patients hospitalized with a diagnosis of COVID-19 pneumonia in a tertiary hospital in Turkey. <i>Annals of Saudi Medicine</i> , 2021, 41, 327-335.	0.5	4
4857	Follow Your Nose: A Key Clue to Understanding and Treating COVID-19. <i>Frontiers in Endocrinology</i> , 2021, 12, 747744.	1.5	11
4858	The immunologic response to severe acute respiratory syndrome coronavirus 2. <i>Allergy and Asthma Proceedings</i> , 2021, 42, 495-505.	1.0	5
4859	The role and place of pathogenetic therapy with glucocorticosteroid hormones in the treatment of patients with novel coronavirus infection (COVID-19). <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1395-1400.	0.2	1
4860	Using 18F-FDG PET/CT to rule out Richter transformation as cause of deterioration in a patient with chronic lymphatic leukemia and severe COVID-19. <i>Medicine (United States)</i> , 2021, 100, e27545.	0.4	0
4861	COVID-19 and thrombotic microangiopathy. <i>Obstetrics, Gynecology and Reproduction</i> , 2022, 15, 639-657.	0.2	5

#	ARTICLE	IF	CITATIONS
4862	Outcome of Critically Ill COVID-19 Patients According to the Setting of Corticosteroid Initiationâ€”A Retrospective Observational Cohort Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1359.	1.1	1
4864	Postâ€”Intensive Care Unit Syndrome in a Cohort of COVID-19 Survivors in New York City. <i>Annals of the American Thoracic Society</i> , 2022, 19, 1158-1168.	1.5	24
4866	How Would You Treat This Patient Hospitalized With Community-Acquired Pneumonia?. <i>Annals of Internal Medicine</i> , 2021, 174, 1719-1726.	2.0	1
4867	Corticosteroid Use in Otolaryngology: Current Considerations During the COVIDâ€”19 Era. <i>Otolaryngology - Head and Neck Surgery</i> , 2022, 167, 803-820.	1.1	8
4868	Frequently Asked Questions in Patients With Adrenal Insufficiency in the Time of COVID-19. <i>Frontiers in Endocrinology</i> , 2021, 12, 805647.	1.5	7
4869	COVID-19 in patients with glomerular disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 191-198.	1.0	1
4873	Mortality Predictors in Severe COVID-19 Patients from an East European Tertiary Center: A Never-Ending Challenge for a No Happy Ending Pandemic. <i>Journal of Clinical Medicine</i> , 2022, 11, 58.	1.0	15
4874	A Closer Look at Dexamethasone and the SARS-CoV-2-Induced Cytokine Storm: In Silico Insights of the First Life-Saving COVID-19 Drug. <i>Antibiotics</i> , 2021, 10, 1507.	1.5	7
4875	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases. <i>World Journal of Hepatology</i> , 2021, 13, 1850-1874.	0.8	10
4876	Lung pathology in COVID-19. , 2021, , 86-100.		3
4877	Enhancer RNA Expression in Response to Glucocorticoid Treatment in Murine Macrophages. <i>Cells</i> , 2022, 11, 28.	1.8	7
4879	Association between mortality and age among mechanically ventilated COVID-19 patients: a Japanese nationwide COVID-19 database study. <i>Annals of Intensive Care</i> , 2021, 11, 171.	2.2	15
4880	Multisystem inflammatory syndrome in Indian adolescents associated with SARS-CoV-2 infection: a case report. <i>The Egyptian Journal of Internal Medicine</i> , 2021, 33, 51.	0.3	0
4881	Low- Versus High-Dose Methylprednisolone in Adult Patients With Coronavirus Disease 2019: Less Is More. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab619.	0.4	0
4883	Unraveling the Relationship of Asthma and COVID-19. <i>Journal of Personalized Medicine</i> , 2021, 11, 1374.	1.1	7
4884	Predicting 90-day survival of patients with COVID-19: Survival of Severely Ill COVID (SOSIC) scores. <i>Annals of Intensive Care</i> , 2021, 11, 170.	2.2	11
4885	CytoSorb Therapy in COVID-19 (CTC) Patients Requiring Extracorporeal Membrane Oxygenation: A Multicenter, Retrospective Registry. <i>Frontiers in Medicine</i> , 2021, 8, 773461.	1.2	20
4887	Efficacy and Safety of Mesenchymal Stromal Cells Therapy for COVID-19 Infection: A Systematic Review and Meta-analysis. <i>Current Stem Cell Research and Therapy</i> , 2023, 18, 143-152.	0.6	5

#	ARTICLE	IF	CITATIONS
4888	Intelligent Drug Descriptors Analysis: Toward COVID-19 Drug Repurposing. <i>Studies in Computational Intelligence</i> , 2022, , 173-191.	0.7	2
4889	Interim analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity) Tj ETQq1 1 0,784314,rgBT /Ow 0,4 2F	0.4	2
4890	sTREM-1 Predicts Disease Severity and Mortality in COVID-19 Patients: Involvement of Peripheral Blood Leukocytes and MMP-8 Activity. <i>Viruses</i> , 2021, 13, 2521.	1.5	28
4891	Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 3391-3404.	0.4	3
4893	Rhino-orbital mucormycosis: Our experiences with clinical features and management in a tertiary care center. <i>Romanian Journal of Ophthalmology</i> , 2022, 65, 339-353.	0.4	4
4894	Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. , 2021, , 39-68.		0
4895	Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 5815.	1.0	6
4896	<scp>COVIDâ€19</scp> and critical care capacity: Can we mitigate demand?. <i>Respirology</i> , 2022, 27, 107-108.	1.3	3
4897	Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges. <i>PLoS Pathogens</i> , 2021, 17, e1010106.	2.1	12
4898	Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in France: a nationwide study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 569-574.	0.5	16
4899	Invasive pulmonary aspergillosis in critically ill patients with <scp>COVID</scp> â€19 in Australia: implications for screening and treatment. <i>Internal Medicine Journal</i> , 2021, 51, 2129-2132.	0.5	5
4900	Glycemic control is associated with lower odds of mortality and successful extubation in severe COVID-19. <i>Journal of Osteopathic Medicine</i> , 2022, 122, 111-115.	0.4	3
4901	Immune thrombocytopenic purpura worsened by COVID-19. <i>Blood Research</i> , 2021, 56, 347-349.	0.5	0
4902	Early Identification and Diagnostic Approach in Acute Respiratory Distress Syndrome (ARDS). <i>Diagnostics</i> , 2021, 11, 2307.	1.3	6
4903	A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV) Registry. <i>American Journal of Case Reports</i> , 2022, 23, e935263.	0.3	9
4904	Pediatric patients with COVID-19 admitted to a PICU in Southern Brazil, excluding MIS-C. <i>Acta Colombiana De Cuidado Intensivo</i> , 2021, , .	0.1	0
4905	Invasive Pulmonary Aspergillosis and Tuberculosis Complicated by Hemophagocytic Lymphohistiocytosis - Sequelae of COVID-19 in a Liver Transplant Recipient. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1007-1011.	0.4	7
4906	The Interaction of Vitamin D and Corticosteroids: A Mortality Analysis of 26,508 Veterans Who Tested Positive for SARS-CoV-2. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 447.	1.2	10

#	ARTICLE	IF	CITATIONS
4907	An observational study of intermediate- or high-dose thromboprophylaxis for critically ill COVID-19 patients. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, 66, 365-374.	0.7	3
4909	Clinical trials during the COVID-19 pandemic: research design and lessons. , 2021, , 214-231.		0
4910	A COVID-19 field hospital in a conference centre – The Cape Town, South Africa experience. <i>African Journal of Primary Health Care and Family Medicine</i> , 2021, 13, e1-e9.	0.3	2
4911	Clinical features and acute management of COVID-19 in adults. , 2021, , 101-123.		2
4913	A case of effective intravenous methylprednisolone pulse therapy against severe COVID-19 infection after arteriovenous graft surgery. <i>Respirology Case Reports</i> , 2022, 10, e0889.	0.3	0
4914	Remote Hospital Care for Recovering COVID-19 Patients Using Telemedicine: A Randomised Controlled Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 5940.	1.0	12
4916	Minimum Manufacturing Costs, National Prices, and Estimated Global Availability of New Repurposed Therapies for Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab581.	0.4	16
4917	Host Factor Interaction Networks Identified by Integrative Bioinformatics Analysis Reveals Therapeutic Implications in COPD Patients With COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 718874.	1.6	1
4919	SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 428.	7.1	44
4921	Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study. <i>BMC Infectious Diseases</i> , 2021, 21, 1277.	1.3	8
4923	Gene Signature-Based Drug Repositioning. , 0, , .		1
4924	Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study. <i>Respiratory Research</i> , 2021, 22, 317.	1.4	11
4925	Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial. <i>Thrombosis Research</i> , 2022, 216, 125-128.	0.8	10
4926	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2 – care pathways, treatment, and follow-up. <i>Cardiovascular Research</i> , 2022, 118, 1618-1666.	1.8	32
4927	Dysregulated metabolism underpins Zika-virus-infection-associated impairment in fetal development. <i>Cell Reports</i> , 2021, 37, 110118.	2.9	21
4928	Characteristics and definitive outcomes of COVID-19 patients admitted to a secondary hospital intensive care unit in Sweden. <i>Health Science Reports</i> , 2021, 4, e446.	0.6	2
4929	COVID-19: management in the ICU. , 2021, , 124-143.		2
4930	High-Dose Dexamethasone Versus Tocilizumab in Moderate to Severe COVID-19 Pneumonia: A Randomized Controlled Trial. <i>Cureus</i> , 2021, 13, e20353.	0.2	10

#	ARTICLE	IF	CITATIONS
4931	Arctium lappa L. (Asteraceae): uma terapêutica promissora contra a Covid-19. Revista Fitos, 2021, 15, 508-522.	0.0	0
4932	Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study. Clinical Infectious Diseases, 2022, 75, e516-e524.	2.9	44
4933	Targeting Inflammasome Activation in COVID-19: Delivery of RNA Interference-Based Therapeutic Molecules. Biomedicines, 2021, 9, 1823.	1.4	7
4935	Severe Type of COVID-19: Pathogenesis, Warning Indicators and Treatment. Chinese Journal of Integrative Medicine, 2022, 28, 3-11.	0.7	5
4937	Specialized pro-resolving mediators in respiratory diseases. Current Opinion in Clinical Nutrition and Metabolic Care, 2022, 25, 67-74.	1.3	15
4938	Dexamethasone enhances risk of herpes zoster in severe COVID-19 infection. Infection, 2021, , 1.	2.3	0
4942	Severity of Flare Reactions in Diethylenetriamine Pentaacetate Chelations. Investigative Radiology, 2022, 57, 293-300.	3.5	2
4943	Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. Cancer Discovery, 2022, 12, 303-330.	7.7	24
4944	Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. European Respiratory Review, 2021, 30, 210194.	3.0	43
4945	Understanding and Managing Severe Asthma in the Context of COVID-19. ImmunoTargets and Therapy, 2021, Volume 10, 419-430.	2.7	1
4946	Pharmacological Effort and Medication Approaches for the Management of COVID-19 Pandemic in Nepal .. , 2022, 5, 5-12.		0
4947	Respiratory failure in COVID-19: a patient's perspective and clinical cases. , 2021, , 1-13.		0
4948	Epidemiological Characteristics of Hospitalized Patients with Moderate versus Severe COVID-19 Infection: A Retrospective Cohort Single Centre Study. Diseases (Basel, Switzerland), 2022, 10, 1.	1.0	4
4949	Allocation of Opportunities to Participate in Clinical Trials during the Covid-19 Pandemic and Other Public Health Emergencies. Hastings Center Report, 2022, 52, 51-58.	0.7	1
4950	Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19. World Journal of Gastroenterology, 2021, 27, 8370-8373.	1.4	2
4951	The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations. Lancet Infectious Diseases, The, 2022, 22, e153-e158.	4.6	22
4952	Convalescent plasma for treatment of COVID-19: study protocol for an open randomised controlled trial in Sweden. BMJ Open, 2021, 11, e048337.	0.8	2
4953	Comparison between Dexamethasone and Methylprednisolone Therapy in Patients with COVID-19 Pneumonia Admitted to Non-Intensive Medical Units. Journal of Clinical Medicine, 2021, 10, 5812.	1.0	3

#	ARTICLE	IF	CITATIONS
4954	An Analysis of Demographics and Inhaled Corticosteroid Use on COVID-19 Outcomes Among Hospitalized Adult Asthmatics: An Early Experience at a NY Hospital System. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1473-1484.	1.5	3
4956	Finding of the factors affecting the severity of COVID-19 based on mathematical models. <i>Scientific Reports</i> , 2021, 11, 24224.	1.6	7
4959	Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 751869.	2.2	10
4960	Drug discovery to treat COVID-19 two years after its outbreak. <i>Drug Discoveries and Therapeutics</i> , 2021, 15, 281-288.	0.6	6
4961	Asthma and COVID-19: an update. <i>European Respiratory Review</i> , 2021, 30, 210152.	3.0	56
4962	Major Publications in the Critical Care Pharmacotherapy Literature: 2020. , 2021, 3, e0590.		2
4963	Leveraging Drug-Target Interaction Data for the Translation of Computational Models into Clinically Actionable Interventions. , 2021, , .		0
4965	A Visual and Comprehensive Review on COVID-19-Associated Pulmonary Aspergillosis (CAPA). <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 1067.	1.5	52
4966	Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone. <i>Journal of Clinical Medicine</i> , 2022, 11, 198.	1.0	0
4967	Further discussion on glucocorticoid treatment of COVID-19. <i>Chinese Medical Journal</i> , 2021, Publish Ahead of Print, .	0.9	0
4968	COVID-19 Patient Management in Outpatient Setting: A Population-Based Study from Southern Italy. <i>Journal of Clinical Medicine</i> , 2022, 11, 51.	1.0	8
4969	Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists. <i>Pharmaceuticals</i> , 2021, 14, 1256.	1.7	10
4970	Identification of transcriptional regulatory network associated with response of host epithelial cells to SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 23928.	1.6	2
4971	Safety of conventional immunosuppressive therapies for patients with dermatological conditions and coronavirus disease 2019: A review of current evidence. <i>Journal of Dermatology</i> , 2022, 49, 317-329.	0.6	3
4974	Enoxaparin Use in Hospitalized SARS-CoV-2-Positive Patients with Elevated D-Dimer: A Pilot Study. <i>Journal of Pharmacy Practice</i> , 2023, 36, 532-536.	0.5	0
4975	Nursesâ€™ mental health from early COVIDâ€™19 pandemic to vaccination. <i>Journal of Nursing Scholarship</i> , 2021, , .	1.1	8
4976	Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging Infection Consortium WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study. <i>ERJ Open Research</i> , 2022, 8, 00552-2021.	1.1	33
4977	Allosteric Modulation of Small Molecule Drugs on ACE2 Conformational Change upon Binding to SARS-CoV-2 Spike Protein. , 2021, , .		5

#	ARTICLE	IF	CITATIONS
4978	Coronavirus infections from 2002 to 2021: neuropsychiatric manifestations. <i>Sleep Medicine</i> , 2022, 91, 282-288.	0.8	5
4979	High- Versus Low-Dose Dexamethasone for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome: A Multicenter, Randomized Open-Label Clinical Trial. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 491-499.	1.3	37
4980	Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trialâ€“Adjudicated Direct Follow-up Data in the UK. <i>JAMA Network Open</i> , 2021, 4, e2139748.	2.8	15
4982	Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study. <i>Critical Care</i> , 2021, 25, 432.	2.5	11
4983	Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics. <i>Transplantation Direct</i> , 2022, 8, e1268.	0.8	14
4985	Real-world treatment patterns and clinical outcomes for inpatients with COVID-19 in the US from September 2020 to February 2021. <i>PLoS ONE</i> , 2021, 16, e0261707.	1.1	5
4987	Mediterranean Diet a Potential Strategy against SARS-CoV-2 Infection: A Narrative Review. <i>Medicina (Lithuania)</i> , 2021, 57, 1389.	0.8	12
4988	A humanized mouse model of chronic COVID-19. <i>Nature Biotechnology</i> , 2022, 40, 906-920.	9.4	71
4989	The early start of hemoperfusion decreases the mortality rate among severe <sc>COVID</sc>â€“19 patients: A preliminary study. <i>Hemodialysis International</i> , 2022, 26, 176-182.	0.4	9
4990	COVID-19 vs. Classical Myocarditis Associated Myocardial Injury Evaluated by Cardiac Magnetic Resonance and Endomyocardial Biopsy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 737257.	1.1	33
4991	Two Cases of Miliary and Disseminated Coccidioidomycosis Following Glucocorticoid Therapy and Literature Review. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2022, 10, 232470962110519.	0.3	1
4992	Differences in mortality in critically ill elderly patients during the second COVID-19 surge in Europe. <i>Critical Care</i> , 2021, 25, 344.	2.5	21
4995	COVID-19: The question of genetic diversity and therapeutic intervention approaches. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200452.	0.6	1
4996	Overview of clinical trials of drugs for the treatment of patients with new coronavirus infection (COVID-19). <i>Aspirantskiy Vestnik Povolzhiya</i> , 2021, 21, 177-190.	0.0	0
4997	Comparison of Hospitalized Coronavirus Disease 2019 and Influenza Patients Requiring Supplemental Oxygen in a Cohort Study: Clinical Impact and Resource Consumption. <i>Clinical Infectious Diseases</i> , 2022, 75, 2225-2238.	2.9	2
4998	Modified mRNA-Based Vaccines Against Coronavirus Disease 2019. <i>Cell Transplantation</i> , 2022, 31, 096368972210902.	1.2	3
4999	Rural Medical Care and COVID-19. <i>Journal of the Japanese Association of Rural Medicine</i> , 2022, 70, 594-603.	0.0	0
5000	Efficacy of Corticosteroid Therapy in Non-severe COVID-19 Patients with Severe Risk Factors who do not Require Supplemental Oxygen. <i>Journal of Nippon Medical School</i> , 2022, , .	0.3	2

#	ARTICLE	IF	CITATIONS
5001	Severe COVID-19 represents an undiagnosed primary immunodeficiency in a high proportion of infected individuals. <i>Clinical and Translational Immunology</i> , 2022, 11, e1365.	1.7	7
5002	Successful outcome using Tocilizumab in COVID-19 pneumonia with respiratory failure on a ward level. <i>Archive of Clinical Cases</i> , 2022, 9, 29-33.	0.1	0
5003	Combating Viral Diseases in the Era of Systems Medicine. <i>Methods in Molecular Biology</i> , 2022, 2486, 87-104.	0.4	0
5004	Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Nationwide, Multicenter, Retrospective Cohort Study. <i>Journal of Korean Medical Science</i> , 2022, 37, e134.	1.1	14
5005	Emerging Insights on Caspases in COVID-19 Pathogenesis, Sequelae, and Directed Therapies. <i>Frontiers in Immunology</i> , 2022, 13, 842740.	2.2	13
5006	COVID-19... Kyukyu Igakukai Zasshi, 2022, 33, 121-127.	0.0	0
5007	Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems. <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 1763-1790.	2.6	37
5008	Mortality in People with Type 2 Diabetes Following SARS-CoV-2 Infection: A Population Level Analysis of Potential Risk Factors. <i>Diabetes Therapy</i> , 2022, 13, 1037-1051.	1.2	16
5009	Mortality rates among COVID-19 patients hospitalised during the first three waves of the epidemic in Milan, Italy: A prospective observational study. <i>PLoS ONE</i> , 2022, 17, e0263548.	1.1	19
5010	The Vicissitude of Do Not Attempt Cardiopulmonary Resuscitation (DNACPR) Order During COVID-19 Pandemic in Japan – A Retrospective Cohort Study. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3943-3950.	0.8	1
5011	Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients. <i>Frontiers in Pharmacology</i> , 2022, 13, 850583.	1.6	4
5012	Effectiveness of Tocilizumab in Patients with Severe or Critical Lung Involvement in COVID-19: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2286.	1.0	6
5013	We need a new approach to clinical trials in alcohol-associated hepatitis: Is there a lesson in RECOVERY?. <i>Hepatology</i> , 2022, 76, 909-910.	3.6	3
5014	Possible In Utero Transmission of SARS-CoV-2 and Severe Respiratory Disease in a Preterm Infant. <i>Pediatrics</i> , 2022, 150, .	1.0	2
5015	A Case of COVID-19-Induced Delayed-Onset Myocarditis. <i>American Journal of Case Reports</i> , 2022, 23, e935577.	0.3	1
5016	4 th -fluorouridine and its derivatives as potential COVID-19 oral drugs: a review. <i>F1000Research</i> , 0, 11, 410.	0.8	3
5017	A Review of Extracorporeal Blood Purification Techniques for the Treatment of Critically Ill Coronavirus Disease 2019 Patients. <i>ASAIO Journal</i> , 2022, Publish Ahead of Print, .	0.9	10
5018	Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112965.	2.5	20

#	ARTICLE	IF	CITATIONS
5019	Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study. <i>Infection</i> , 2022, 50, 1441-1452.	2.3	10
5020	Single-Cell Landscape of Lungs Reveals Key Role of Neutrophil-Mediated Immunopathology during Lethal SARS-CoV-2 Infection. <i>Journal of Virology</i> , 2022, 96, e0003822.	1.5	7
5021	Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19. <i>Journal of Virology</i> , 2022, 96, e0005722.	1.5	14
5022	Identification of Compounds With Antiviral Activity Against SARS-CoV-2 in the MMV Pathogen Box Using a Phenotypic High-Throughput Screening Assay. <i>Frontiers in Virology</i> , 2022, 2, .	0.7	6
5023	Organ dysfunction and death in patients admitted to hospital with COVID-19 in pandemic waves 1 to 3 in British Columbia, Ontario and Quebec, Canada: a cohort study. <i>CMAJ Open</i> , 2022, 10, E379-E389.	1.1	3
5024	Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis. <i>Circulation</i> , 2022, 145, 1123-1139.	1.6	118
5025	Pneumomediastinum in patients with COVID-19 undergoing CT pulmonary angiography: a retrospective cohort study. <i>Postgraduate Medical Journal</i> , 2023, 99, 570-575.	0.9	1
5026	Cyclosporin A Reveals Potent Antiviral Effects in Preclinical Models of SARS-CoV-2 Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 964-968.	2.5	5
5027	Patient characteristics, management and outcomes in a Nordic subset of the "Large observational study to understand the global impact of severe acute respiratory failure" (LUNG SAFE) study. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, , .	0.7	2
5028	Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19. <i>Microbiology Spectrum</i> , 2022, 10, e0216721.	1.2	5
5029	Assessment of Awake Prone Positioning in Hospitalized Adults With COVID-19. <i>JAMA Internal Medicine</i> , 2022, 182, 612.	2.6	47
5030	Critically Ill Pediatric Patient and SARS-CoV-2 Infection. <i>Children</i> , 2022, 9, 538.	0.6	3
5031	Considerations on Immunization and Immunosuppression of Patients With Autoimmune Blistering Diseases During COVID-19 Pandemic in Brazil: Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 811562.	1.2	1
5032	Outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1029-1032.	0.8	4
5033	Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Frontiers in Medicine</i> , 2022, 9, 844728.	1.2	13
5034	SARS-CoV-2 Infection and Associated Cardiovascular Manifestations and Complications in Children and Young Adults: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 145, 101161CIR0000000000001064.	1.6	34
5035	Muscle dysfunction in the long coronavirus disease 2019 syndrome: Pathogenesis and clinical approach. <i>Reviews in Medical Virology</i> , 2022, 32, e2355.	3.9	22
5036	Community-Acquired Pneumonia. <i>Annals of Internal Medicine</i> , 2022, 175, ITC49-ITC64.	2.0	23

#	ARTICLE	IF	CITATIONS
5037	COVID-19 Infection in Children: Diagnosis and Management. <i>Current Infectious Disease Reports</i> , 2022, 24, 51-62.	1.3	25
5038	Bacterial Ventilator-Associated Pneumonia in COVID-19 Patients: Data from the Second and Third Waves of the Pandemic. <i>Journal of Clinical Medicine</i> , 2022, 11, 2279.	1.0	13
5039	Caring for the Critically Ill Patient with COVID-19. <i>Clinics in Chest Medicine</i> , 2022, 43, 441-456.	0.8	1
5040	New Antivirals and Immune Therapies for COVID-19 Infection. <i>Archivos De Bronconeumologia</i> , 2022, , .	0.4	0
5041	Beneficial ex vivo immunomodulatory and clinical effects of clarithromycin in COVID-19. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	0.8	0
5042	Higher mortality and intubation rate in COVID-19 patients treated with noninvasive ventilation compared with high-flow oxygen or CPAP. <i>Scientific Reports</i> , 2022, 12, 6527.	1.6	9
5043	COVID-19 and kidney disease: insights from epidemiology to inform clinical practice. <i>Nature Reviews Nephrology</i> , 2022, 18, 485-498.	4.1	36
5044	Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: A case-control study. <i>Journal of Medical Virology</i> , 2022, 94, 3653-3660.	2.5	7
5045	Implications of SARS-CoV-2 Infection in Systemic Juvenile Idiopathic Arthritis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4268.	1.8	10
5046	Corticosteroids in COVID-19: A double-edged sword – a retrospective study. <i>Medicina Intensiva (English Edition)</i> , 2022, 46, 229-231.	0.1	2
5048	Identification of Drug Interaction Adverse Events in Patients With COVID-19. <i>JAMA Network Open</i> , 2022, 5, e227970.	2.8	25
5049	COVID-19: Some unresolved issues. <i>Revista Espanola De Quimioterapia</i> , 2022, , .	0.5	1
5051	Timing of Initiation of Methylprednisolone Pulse Therapy in Patients with COVID-19. <i>Covid</i> , 2022, 2, 532-539.	0.7	0
5052	Senicapoc treatment in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, , .	0.7	3
5054	Dexamethasone or prednisone: Which one should be the corticosteroid of choice in patients with pemphigus vulgaris?. <i>Dermatologic Therapy</i> , 2022, 35, e15511.	0.8	3
5055	The Impact of COVID-19 in Bone Metabolism: Basic and Clinical Aspects. <i>Hormone and Metabolic Research</i> , 2022, 54, 540-548.	0.7	4
5056	Comparison of Clinical Features and Outcomes between SARS-CoV-2 and Non-SARS-CoV-2 Respiratory Viruses Associated Acute Respiratory Distress Syndrome: Retrospective Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 2246.	1.0	6
5057	Unethical studies of ivermectin for covid-19. <i>BMJ, The</i> , 2022, 377, o917.	3.0	9

#	ARTICLE	IF	CITATIONS
5058	Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England. <i>ClinicoEconomics and Outcomes Research</i> , 2022, Volume 14, 231-247.	0.7	2
5059	Meta-analysis and systematic review: The administration of glucocorticoids, as a line of treatment for COVID-19 patients, could result in lowering mortality. , 2022, 9, .		1
5060	The effectiveness of dexamethasone as a combination therapy for COVID-19. <i>Acta Pharmaceutica</i> , 2022, 72, 345-358.	0.9	2
5061	Quality and Safety in the Literature: May 2022. <i>BMJ Quality and Safety</i> , 2022, 31, 409-414.	1.8	0
5062	Interaction of Vitamin D and Corticosteroid Use in Hospitalized COVID-19 Patients: A Potential Explanation for Inconsistent Findings in the Literature. <i>Current Pharmaceutical Design</i> , 2022, 28, .	0.9	0
5063	Do Corticosteroids Reduce Mortality or Progression to Severe Disease for Non-Oxygen Requiring Patients Infected With COVID-19?. <i>Annals of Emergency Medicine</i> , 2022, , .	0.3	1
5064	Role of body mass index in outcomes of patients hospitalized with COVID-19 illness. <i>Obesity Science and Practice</i> , 2022, 8, 748-756.	1.0	3
5065	Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review). <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 385.	0.8	4
5066	Role of secondary sepsis in COVID-19 mortality: Observations on patients with preexisting diabetes mellitus and newly diagnosed hyperglycemia. <i>Monaldi Archives for Chest Disease</i> , 2022, , .	0.3	0
5067	The Ameliorative Effect of Dexamethasone on the Development of Autoimmune Lung Injury and Mediastinal Fat-Associated Lymphoid Clusters in an Autoimmune Disease Mouse Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4449.	1.8	2
5068	COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells. <i>Seminars in Immunopathology</i> , 2022, 44, 375-390.	2.8	15
5069	Glucocorticoid-induced hyperglycaemia and diabetes: Call for action. <i>Diabetic Medicine</i> , 2022, 39, e14843.	1.2	5
5070	Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective study. <i>Medicina Intensiva (English Edition)</i> , 2022, 46, 179-191.	0.1	3
5071	Sarilumab administration in patients with severe COVID-19: A report of four cases and a literature review. <i>World Academy of Sciences Journal</i> , 2022, 4, .	0.4	3
5072	Multi-omic approach to identify risk markers specific to COVID-19. <i>EBioMedicine</i> , 2022, 79, 104009.	2.7	2
5073	Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure. <i>Clinical Immunology</i> , 2022, 238, 109016.	1.4	15
5074	Routine laboratory parameters, including complete blood count, predict COVID-19 in-hospital mortality in geriatric patients. <i>Mechanisms of Ageing and Development</i> , 2022, 204, 111674.	2.2	16
5103	Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS-CoV-2 Infection: A Case Study With Imatinib. <i>Journal of Clinical Pharmacology</i> , 2022, , .	1.0	2

#	ARTICLE	IF	CITATIONS
5104	Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022). <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 399-419.	1.0	1
5105	SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets. <i>Inflammation</i> , 2022, 45, 1430-1449.	1.7	16
5106	Gastrointestinal complications (gangrene or perforation) after corona virus disease 2019 " A series of ten patients. <i>Indian Journal of Gastroenterology</i> , 2022, 41, 307-312.	0.7	4
5107	Corticosteroids and Other Treatments Administered to Children Tested for SARS-CoV-2 Infection in Emergency Departments. <i>Academic Pediatrics</i> , 2022, , .	1.0	0
5108	Reducing broad-spectrum antibiotic use in intensive care unit between first and second waves of COVID-19 did not adversely affect mortality. <i>Journal of Hospital Infection</i> , 2022, 124, 37-46.	1.4	7
5109	Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves. <i>Pediatric Research</i> , 2023, 93, 207-216.	1.1	10
5110	Effects of the working experience, educational background, professional titles, and hospital grades of intensive care unit doctors on clinical glucocorticoid use in acute respiratory distress syndrome. <i>Medicine (United States)</i> , 2022, 101, e29021.	0.4	2
5111	Management of pneumonia in critically ill patients. <i>BMJ, The</i> , 2021, 375, e065871.	3.0	27
5112	CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults. <i>BMJ Open</i> , 2021, 11, e050202.	0.8	4
5113	External validation of the 4C Mortality Score for hospitalised patients with COVID-19 in the RECOVER network. <i>BMJ Open</i> , 2022, 12, e054700.	0.8	6
5114	Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial). <i>BMJ Open</i> , 2022, 12, e055189.	0.8	20
5115	Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. <i>Thorax</i> , 2022, 77, 606-615.	2.7	24
5116	Wonder of wonders, miracle of miracles: the unprecedented speed of COVID-19 science. <i>Physiological Reviews</i> , 2022, 102, 1569-1577.	13.1	9
5117	An Adaptive Information Borrowing Platform Design for Testing Drug Candidates of COVID-19. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-13.	0.7	0
5118	A Systematic Review Assessing the Underrepresentation of Cancer Patients in COVID-19 Trials. <i>Acta Haematologica</i> , 2022, 145, 235-243.	0.7	1
5119	A Pandemic Lesson for Global Lung Diseases: Exacerbations Are Preventable. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1271-1280.	2.5	19
5120	SARS-CoV-2 infection associated with aplastic anemia and pure red cell aplasia. <i>Blood Advances</i> , 2022, 6, 3840-3843.	2.5	7
5121	Survival among people hospitalized with COVID-19 in Switzerland: a nationwide population-based analysis. <i>BMC Medicine</i> , 2022, 20, 164.	2.3	6

#	ARTICLE	IF	CITATIONS
5123	Synergistic Effects of Multiple Factors Involved in COVID-19-dependent Muscle Loss. , 2022, 13, 344.		8
5128	SARS-COV-2 " the pandemic of the XXI century, clinical manifestations " neurological implications. Journal of Medicine and Life, 2022, 15, 319-327.	0.4	2
5129	Interleukin-37: A Link Between COVID-19, Diabetes, and the Black Fungus. Frontiers in Microbiology, 2021, 12, 788741.	1.5	5
5130	Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review. Frontiers in Microbiology, 2022, 13, 813358.	1.5	19
5131	Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients. Transplant International, 2022, 35, 10109.	0.8	5
5132	Coronavirus disease 2019 (COVID-19) in special groups: A single-center experience in sickle cell disease patients in Saudi Arabia.. Journal of Family and Community Medicine, 2022, 29, 71-78.	0.5	0
5134	A day in the life of a plague victim. Canadian Family Physician, 2021, 67, 79-79.	0.1	0
5135	Medication use during COVID-19. Canadian Family Physician, 2021, 67, 171-179.	0.1	6
5137	Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches.. BMB Reports, 2021, , .	1.1	0
5139	Too early for admission? A Telemedicine follow up comparison of mild COVID-19 patients from the Emergency Department and Clinics.. International Journal of Health Sciences, 2022, 16, 22-29.	0.4	0
5140	Coronavirus disease 2019 pandemic two years later" What's next?. Croatian Medical Journal, 2022, 63, 1-5.	0.2	0
5141	Unpacking the Drop in COVID-19 Case Fatality Rates: A Study of National and Florida Line-Level Data.. AMIA ... Annual Symposium proceedings, 2021, 2021, 285-294.	0.2	0
5142	Cardiovascular risk factors and clinical outcomes of patients hospitalized with COVID-19 pneumonia in Somalia. Therapeutic Advances in Infectious Disease, 2022, 9, 204993612210957.	1.1	1
5143	Use of flash glucose monitoring for blood glucose control in three diabetes patients undergoing maintenance hemodialysis who were hospitalized for COVID"19 pneumonia. Nihon Toseki Igakkai Zasshi, 2022, 55, 255-264.	0.2	0
5144	Cytokine storm and stem cell activation in unveiling potential targets for diagnosis and therapy. , 2022, , 59-70.		0
5145	Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Stem Cells Translational Medicine, 2022, 11, 688-703.	1.6	13
5147	Effect of High and Low-to-Moderate Dose Corticosteroid Therapy Among Hypoxic COVID-19 Patients at Various Time Intervals: A Multi-Centric Retrospective Cohort Study. SSRN Electronic Journal, 0, , .	0.4	0
5149	Evolving spectrum but persistent high mortality of COVID-19 among patients on kidney replacement therapy in the vaccine era: the Spanish COVID-19 KRT Registry. CKJ: Clinical Kidney Journal, 2022, 15, 1685-1697.	1.4	12

#	ARTICLE	IF	CITATIONS
5150	Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19. <i>Yonsei Medical Journal</i> , 2022, 63, 430.	0.9	6
5151	Higher Education in the UK. , 2022, , 25-40.		1
5153	Current strategies and future perspectives in COVID-19 therapy. , 2022, , 169-227.		0
5154	Validation of Machine Learning Models to Predict Adverse Outcomes in Patients with COVID-19: A Prospective Pilot Study. <i>Yonsei Medical Journal</i> , 2022, 63, 422.	0.9	3
5156	IP-10 and complement activation as friend or foe in COVID-19. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202210962.	1.0	6
5157	Mortality related to COVID-19 in patients with rheumatic and musculoskeletal diseases, first wave of the outbreak: a single-center study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210902.	1.2	2
5158	Therapeutics in the Treatment of COVID-19 for Children and Adolescents. <i>Pediatric Infection and Vaccine</i> , 2022, 29, 1.	0.1	2
5159	Targeting SARS-CoV-2 Infection Through CAR-T Like Bispecific T Cell Engagers Incorporating ACE2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
5160	Unnecessary Use of Corticosteroids for managing early mild symptoms of COVID-19 may lead to Rhino-orbital-cerebral mucormycosis in Patients with Diabetes “ a case series from Lahore, Pakistan. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612210974.	1.1	5
5161	Baseline characteristics and outcome predictors in patients hospitalized with COVID-19 in the University General Hospital of Ioannina, Greece. <i>Pneumon</i> , 2022, 35, 1-10.	0.6	2
5162	National Research Institute of Tuberculosis and Lung Disease (NRITLD) Protocol for the Treatment of Patients with COVID-19. <i>Iranian Journal of Pharmaceutical Research</i> , 2022, 21, .	0.3	3
5163	Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic. <i>Brazilian Journal of Infectious Diseases</i> , 2022, 26, 102353.	0.3	13
5164	A biomedical open knowledge network harnesses the power of AI to understand deep human biology. <i>AI Magazine</i> , 2022, 43, 46-58.	1.4	5
5165	Memory CD4+ T-Cell Lymphocytic Angiopathy in Fatal Forms of COVID-19 Pulmonary Infection. <i>Frontiers in Immunology</i> , 2022, 13, 844727.	2.2	2
5166	Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates. <i>Molecules</i> , 2022, 27, 2723.	1.7	29
5167	The SARS-CoV-2 Pandemic and Cancer Trials Ireland: Impact, Resolution and Legacy. <i>Cancers</i> , 2022, 14, 2247.	1.7	6
5168	Usage of compromised lung volume in monitoring steroid therapy on severe COVID-19. <i>Respiratory Research</i> , 2022, 23, 105.	1.4	1
5169	Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study. <i>Scientific Reports</i> , 2022, 12, 6843.	1.6	12

#	ARTICLE	IF	CITATIONS
5170	pcMSC Modulates Immune Dysregulation in Patients With COVID-19-Induced Refractory Acute Lung Injury. <i>Frontiers in Immunology</i> , 2022, 13, 871828.	2.2	2
5171	The impact of shifting demographics, variants of concern and vaccination on outcomes during the first 3 COVID-19 waves in Alberta and Ontario: a retrospective cohort study. <i>CMAJ Open</i> , 2022, 10, E400-E408.	1.1	16
5172	Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5018.	1.8	1
5173	Toxoplasmosis and Schizophrenia: A Systematic Review and Meta-Analysis of Prevalence and Associations and Future Directions. <i>Psychiatric Research and Clinical Practice</i> , 2022, 4, 48-60.	1.3	12
5174	External validation of the COVID-19 4C mortality score in an urban United States cohort. <i>American Journal of the Medical Sciences</i> , 2022, 364, 409-413.	0.4	5
5175	Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 301-307.	0.1	2
5176	Comparison of Severe Viral Pneumonia Caused by SARS-CoV-2 and Other Respiratory Viruses Among Malaysian Children During the COVID-19 Pandemic. <i>Frontiers in Pediatrics</i> , 2022, 10, 865099.	0.9	4
5177	Finding a chink in the armor: Update, limitations, and challenges toward successful antivirals against flaviviruses. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010291.	1.3	11
5178	The Cytokine Storm in COVID-19: The Strongest Link to Morbidity and Mortality in the Current Epidemic. <i>Covid</i> , 2022, 2, 540-552.	0.7	12
5179	Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study. <i>Japanese Journal of Infectious Diseases</i> , 2022, 75, 484-489.	0.5	4
5180	Marginal Gains and Clinical Trials – Improving and Influencing Practice. <i>Clinical Oncology</i> , 2022, , .	0.6	0
5181	Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials. <i>Value in Health</i> , 2022, , .	0.1	5
5182	SARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation. <i>Frontiers in Immunology</i> , 2022, 13, 871276.	2.2	13
5183	High-flow Nasal Oxygen Therapy in COVID-19 Critically Ill Patients with Acute Hypoxemic Respiratory Failure: A Prospective Observational Cohort Study. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 596-603.	0.3	0
5184	A COVID-19-Related Retinopathy Case Report. <i>Case Reports in Ophthalmology</i> , 2022, 13, 297-304.	0.3	4
5185	Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update. <i>Clinical Immunology</i> , 2022, 239, 109022.	1.4	12
5186	Acute neuromuscular syndromes with respiratory failure during COVID-19 pandemic: Where we stand and challenges ahead. <i>Journal of Clinical Neuroscience</i> , 2022, 101, 264-275.	0.8	5
5187	Heart Failure Relapses in Response to Acute Stresses – Role of Immunological and Inflammatory Pathways. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 809935.	1.1	3

#	ARTICLE	IF	CITATIONS
5188	Duplication and nonregistration of COVID-19 systematic reviews: Bibliometric review. <i>Health Science Reports</i> , 2022, 5, e541.	0.6	4
5189	Modeling Clinical Trajectory Status of Critically Ill COVID-19 Patients Over Time: A Method for Analyzing Discrete Longitudinal and Ordinal Outcomes. <i>Journal of Clinical and Translational Science</i> , 0, , 1-16.	0.3	0
5190	SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality). <i>Infection</i> , 2023, 51, 71-81.	2.3	1
5191	Clinical Characteristics, Risk Factors for Severity and Pharmacotherapy in Hospitalized COVID-19 Patients in the United Arab Emirates. <i>Journal of Clinical Medicine</i> , 2022, 11, 2439.	1.0	2
5192	Hypercortisolism on the background of recovery of COVID-19 (Ñase report). <i>MÃ-Å¼narodnij EndokrinologÃ-Å½urnal</i> , 2022, 18, 133-137.	0.1	0
5193	Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab. <i>BMJ Case Reports</i> , 2022, 15, e242937.	0.2	4
5194	Treatment of COVID-19 in a Patient With Maple Syrup Urine Disease. <i>Cureus</i> , 2022, , .	0.2	0
5195	Post COVID-19: Risk-factors, prevention and management of black fungus. <i>Anti-Infective Agents</i> , 2022, 20, .	0.1	0
5196	Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review. <i>Audiology Research</i> , 2022, 12, 224-248.	0.8	6
5197	Motivating factors, barriers and facilitators of participation in COVID-19 clinical research: A cross-sectional survey of Canadian community intensive care units. <i>PLoS ONE</i> , 2022, 17, e0266770.	1.1	1
5198	Committee report: Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapy. <i>Renal Replacement Therapy</i> , 2022, 8, 18.	0.3	3
5199	Characteristics and Factors Associated With Mortality in Patients With Coronavirus Disease 2019 and Pneumothorax. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2022, 6, 257-268.	1.2	7
5200	Public opinion on sharing data from health services for clinical and research purposes without explicit consent: an anonymous online survey in the UK. <i>BMJ Open</i> , 2022, 12, e057579.	0.8	12
5201	Report of a combination of remdesivir, intravenous methylprednisolone pulse, and tocilizumab for severe coronavirus disease: 20-case series at a single institution. <i>Respiratory Investigation</i> , 2022, 60, 604-606.	0.9	1
5202	The novel concept of "Onco-Immuno-Endocrinology" led to the discovery of new clinical entity "paraneoplastic autoimmune hypophysitis". <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, , 101663.	2.2	4
5203	Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). <i>Leukemia</i> , 2022, 36, 1467-1480.	3.3	63
5204	Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic. <i>Osong Public Health and Research Perspectives</i> , 2022, 13, 84-100.	0.7	0
5205	A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2). <i>Frontiers in Medicine</i> , 2022, 9, 785785.	1.2	15

#	ARTICLE	IF	CITATIONS
5206	Lung function six months after severe COVID-19: Does time, in fact, heal all wounds?. Brazilian Journal of Infectious Diseases, 2022, 26, 102352.	0.3	10
5207	Calprotectin and Imbalances between Acute-Phase Mediators Are Associated with Critical Illness in COVID-19. International Journal of Molecular Sciences, 2022, 23, 4894.	1.8	17
5208	Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature, 2022, 606, 585-593.	13.7	276
5209	Evidence of Continued CD4+ and CD8+ T Cell Activity After SARS-COV-2 Clearance in a Late COVID-19 Pneumonia Heart Transplant Patient. Cureus, 2022, , .	0.2	0
5210	Steroid therapy and antiviral treatment in SARSCoV-2 pneumonia: clinical contexts and indications. Revista Espanola De Quimioterapia, 2022, 35, 54-58.	0.5	1
5211	Acute pericarditis after COVID 19 in a peritoneal dialysis patient. CEN Case Reports, 2022, , 1.	0.5	0
5212	Susceptibility of Patients with Airway Disease to SARS-CoV-2 Infection. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 696-703.	2.5	6
5213	An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19). Cellular and Molecular Biology Letters, 2022, 27, 38.	2.7	11
5214	Statistical significance and its critics: practicing damaging science, or damaging scientific practice?. Synthèse, 2022, 200, 220.	0.6	13
5215	Associations of vaccine status with characteristics and outcomes of hospitalized severe COVID-19 patients in the booster era. PLoS ONE, 2022, 17, e0268050.	1.1	19
5216	COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 573-583.	2.5	16
5217	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. Blood Advances, 2022, 6, 3870-3874.	2.5	8
5218	Treatment strategies of Covid-19. A rheumatology perspective.. European Journal of Internal Medicine, 2022, , .	1.0	3
5219	Intravenous immunoglobulins for treatment of severe COVID-19-related acute encephalopathy. Journal of Neurology, 2022, 269, 4013-4020.	1.8	6
5220	COVID-19 in Kidney Transplant Recipients: A Multicenter Experience from the First Two Waves of Pandemic. BMC Nephrology, 2022, 23, 183.	0.8	16
5221	High-Dose versus Low-Dose Corticosteroids in COVID-19 Patients: a Systematic Review and Meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 3576-3586.	0.6	16
5222	Inhaled antibiotics in critical care: State of the art and future perspectives. Infectious Diseases Now, 2022, 52, 327-333.	0.7	3
5223	Pulse versus nonpulse steroid regimens in patients with coronavirus disease 2019: A systematic review and meta-analysis. Journal of Medical Virology, 2022, 94, 4125-4137.	2.5	6

#	ARTICLE	IF	CITATIONS
5225	The effects of SARS-CoV-2 infection on modulating innate immunity and strategies of combating inflammatory response for COVID-19 therapy. <i>Journal of Biomedical Science</i> , 2022, 29, 27.	2.6	9
5226	Attributable Mortality of Ventilator-associated Pneumonia Among Patients with COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 161-169.	2.5	29
5227	Effectiveness of corticosteroids to treat coronavirus disease 2019 symptoms: A meta-analysis. <i>Medicina Clínica</i> , 2022, 159, 575-583.	0.3	5
5228	HDAC Inhibition as Potential Therapeutic Strategy to Restore the Deregulated Immune Response in Severe COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 841716.	2.2	15
5229	Methylprednisolone pulse therapy for severe COVID-19. <i>Journal of the Japanese Society of Intensive Care Medicine</i> , 2022, 29, 233-235.	0.0	0
5230	Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study. , 2022, 4, e0702.		10
5231	Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. <i>Nature Communications</i> , 2022, 13, 2583.	5.8	25
5233	Pharmacological and non-pharmacological strategies in coronavirus disease 2019: A literature review. <i>Annals of Medicine and Surgery</i> , 2022, 77, 103709.	0.5	0
5234	Clinical outcomes of hospitalized COVID-19 patients treated with remdesivir: a retrospective analysis of a large tertiary care center in Germany. <i>Infection</i> , 2023, 51, 97-108.	2.3	5
5235	COVID-19's Impact on Non-communicable Diseases: What We Do Not Know May Hurt Us. <i>Current Cardiology Reports</i> , 2022, 24, 829-837.	1.3	11
5236	The Genetic Risk for COVID-19 Severity Is Associated With Defective Immune Responses. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4
5237	Finding evidence for treatment decisions in a pandemic. <i>Trends in Molecular Medicine</i> , 2022, 28, 536-541.	3.5	3
5238	Steroid pulse therapy as a treatment for COVID-19. <i>Journal of the Japanese Society of Intensive Care Medicine</i> , 2022, 29, 206-208.	0.0	0
5239	Two Years of the COVID-19 Pandemic: What Lessons Have We Learned?. <i>Annals of Pharmacotherapy</i> , 2022, 56, 1376-1381.	0.9	3
5240	Kidney replacement therapy patients with COVID-19 in the vaccine era: what do we need to know?. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	1.4	0
5241	Low-dose radiotherapy for COVID-19 pneumonia and cancer: summary of a recent symposium and future perspectives. <i>International Journal of Radiation Biology</i> , 2023, 99, 357-371.	1.0	2
5242	Use of Proton Pump Inhibitors With Dexamethasone in Patients With COVID-19 Pneumonia: Contributions to Long-Term Polypharmacy. <i>Cureus</i> , 2022, , .	0.2	0
5243	A Case of COVID-19 With Myasthenic Crisis. <i>Cureus</i> , 2022, , .	0.2	0

#	ARTICLE	IF	CITATIONS
5244	An objective framework for evaluating unrecognized bias in medical AI models predicting COVID-19 outcomes. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2022, 29, 1334-1341.	2.2	12
5245	Favipiravir for treating COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	1
5246	Year in Review 2021: Noteworthy Literature in Cardiothoracic Critical Care. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2022, , 108925322211006.	0.4	1
5247	Mechanisms of Immune Dysregulation in COVID-19 Are Different From SARS and MERS: A Perspective in Context of Kawasaki Disease and MIS-C. <i>Frontiers in Pediatrics</i> , 2022, 10, .	0.9	6
5248	Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. <i>Nature Communications</i> , 2022, 13, 2576.	5.8	21
5249	Relationship between SARS-CoV-2 antibody titer and the severity of COVID-19. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 1094-1100.	1.5	9
5250	18F-FDG PET/CT for the diagnosis of aortic inflammation in COVID-19. <i>Journal of Nuclear Cardiology</i> , 2023, 30, 83-84.	1.4	0
5251	The Existence of at Least Three Genomic Signature Patterns and at Least Seven Subtypes of COVID-19 and the End of the Disease. <i>Vaccines</i> , 2022, 10, 761.	2.1	8
5252	Persistent viral RNA shedding of SARS-CoV-2 is associated with delirium incidence and six-month mortality in hospitalized COVID-19 patients. <i>GeroScience</i> , 2022, 44, 1241-1254.	2.1	12
5253	Clinical and Imaging Features of COVID-19-Associated Pulmonary Aspergillosis. <i>Diagnostics</i> , 2022, 12, 1201.	1.3	10
5254	Introduction of Extracorporeal Membrane Oxygenation on Ninth Day of Ventilator Management for Severe Acute Respiratory Distress Syndrome due to COVID-19: A Case Report. <i>Cureus</i> , 2022, 14, e24869.	0.2	0
5255	Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication. <i>IScience</i> , 2022, 25, 104293.	1.9	9
5256	The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	6
5258	Ventilator-associated pneumonia in critically ill patients with COVID-19 infection: a narrative review. <i>ERJ Open Research</i> , 2022, 8, 00046-2022.	1.1	11
5259	Early Corticosteroid Therapy May Increase Ventilator-Associated Lower Respiratory Tract Infection in Critically Ill Patients with COVID-19: A Multicenter Retrospective Cohort Study. <i>Microorganisms</i> , 2022, 10, 984.	1.6	4
5260	Outcomes of SARS-CoV-2 Infection in Unvaccinated Compared With Vaccinated Solid Organ Transplant Recipients: A Propensity Matched Cohort Study. <i>Transplantation</i> , 2022, 106, 1622-1628.	0.5	15
5261	The Impact of Cytokines on Neutrophils' Phagocytosis and NET Formation during Sepsis: A Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5076.	1.8	7
5262	Corticobulbar tract involvement following COVID-19 infection: Evidence from MRI-tractography and transcranial magnetic stimulation. <i>Clinical Neurophysiology</i> , 2022, 140, 1-3.	0.7	1

#	ARTICLE	IF	CITATIONS
5263	Critical Care Management of Severe COVID-19 in Pregnant Patients. <i>Cureus</i> , 2022, 14, e24885.	0.2	0
5264	Diabetes Mellitus and Other Underlying Conditions in Patients with COVID-19-Associated Rhino-Orbito-Cerebral Mucormycosis: A Systematic Review and Meta-analysis. <i>Journal of Laryngology and Otology</i> , 2022, , 1-33.	0.4	3
5265	A screening study for <sc>COVID</sc> associated pulmonary aspergillosis in critically ill patients during the third wave of the pandemic. <i>Mycoses</i> , 2022, 65, 724-732.	1.8	13
5266	Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician. <i>Current Atherosclerosis Reports</i> , 2022, 24, 563-570.	2.0	35
5267	Molecular dynamic simulations reveal anti-SARS-CoV-2 activity of mitocurcumin by potentially blocking innate immune evasion proteins NSP3 and NSP16. <i>Molecular Diversity</i> , 2023, 27, 635-649.	2.1	2
5268	COVID-19 from emerging global threat to ongoing pandemic crisis. <i>Baylor University Medical Center Proceedings</i> , 2022, 35, 468-475.	0.2	4
5269	Diretrizes Brasileiras para o tratamento farmacol3gico de pacientes hospitalizados com COVID-19. <i>Jornal Brasileiro De Medicina De Emerg4ncia</i> , 2022, 2, e22006.	0.0	1
5270	Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2257-2264.	1.3	17
5271	A Multi-dimensional Review on Severe Acute Respiratory Syndrome CoronaVirus-2. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, .	0.9	1
5272	Elevated Rates of Ventilator-Associated Pneumonia and COVID-19 Associated Pulmonary Aspergillosis in Critically Ill Patients with SARS-CoV2 Infection in the Second Wave: A Retrospective Chart Review. <i>Antibiotics</i> , 2022, 11, 632.	1.5	6
5273	Clinical Characteristics and Outcome of Pediatric COVID-19 Patients in Ethiopia During the Early COVID-19 Pandemic: A Prospective Cohort Study. <i>Pediatric Health, Medicine and Therapeutics</i> , 2022, Volume 13, 165-174.	0.7	4
5274	COVID-19 in patients with hematologic malignancy. <i>Blood</i> , 2022, 140, 236-252.	0.6	69
5275	Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan. <i>Postgraduate Medical Journal</i> , 2023, 99, 463-469.	0.9	19
5277	A Retrospective Global Assessment of Factors Associated With COVID-19 Policies and Health Outcomes. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	4
5278	Automated interpretable discovery of heterogeneous treatment effectiveness: A COVID-19 case study. <i>Journal of Biomedical Informatics</i> , 2022, 130, 104086.	2.5	2
5279	Cytokine response over the course of COVID-19 infection in pregnant women. <i>Cytokine</i> , 2022, 154, 155894.	1.4	9
5280	Antidiabetic activity and metabolite profiles of ascidian <i>Halocynthia roretzi</i> . <i>Journal of Functional Foods</i> , 2022, 93, 105095.	1.6	4
5281	Inheritance of a common androgen synthesis variant allele is associated with female COVID susceptibility in UK Biobank. <i>European Journal of Endocrinology</i> , 2022, 187, 1-14.	1.9	2

#	ARTICLE	IF	CITATIONS
5282	Characterizing the temporal changes in association between modifiable risk factors and acute kidney injury with multi-view analysis. <i>International Journal of Medical Informatics</i> , 2022, 163, 104785.	1.6	1
5283	The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19. <i>Journal of Critical Care</i> , 2022, 70, 154053.	1.0	3
5284	Identification, optimization, and biological evaluation of 3-O- β -chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114426.	2.6	9
5285	Mortality trends and length of stays among hospitalized patients with COVID-19 in Ontario and QuÃ©bec (Canada): a population-based cohort study of the first three epidemic waves. <i>International Journal of Infectious Diseases</i> , 2022, 121, 1-10.	1.5	10
5286	Delayed intubation is associated with mortality in patients with severe COVID-19: A single-centre observational study in Switzerland. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, 41, 101092.	0.6	13
5287	Global effect of COVID-19 pandemic on cancer patients and its treatment: A systematic review. <i>Clinical Complementary Medicine and Pharmacology</i> , 2022, 2, 100041.	0.9	6
5289	Cancer Groundshot: Building a Robust Cancer Control Platform in Addition To Launching the Cancer Moonshot. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 100-115.	1.8	3
5290	Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	26
5291	Remdesivir plus Dexamethasone in COVID-19: A cohort study of severe patients requiring high flow oxygen therapy or non-invasive ventilation. <i>PLoS ONE</i> , 2022, 17, e0267038.	1.1	4
5292	Tocilizumab Accelerates Recovery in Patients With Severe COVID-19 Pneumonia on Venovenous Extracorporeal Membrane Oxygenation. <i>ASAIO Journal</i> , 2022, 68, 1010-1016.	0.9	3
5293	AN OBSERVATIONAL, RETROSPECTIVE STUDY ON THE IMPACT OF CORTICOSTEROIDS AND THEIR OUTCOMES IN COVID-19 PATIENTS. , 2022, , 68-70.		0
5294	Ultraviolet-coupled advanced oxidation processes for anti-COVID-19 drugs treatment: Degradation mechanisms, transformation products and toxicity evolution. <i>Chemosphere</i> , 2022, 303, 134968.	4.2	8
5295	The impact of COVID-19 on the pediatric solid organ transplant population. <i>Seminars in Pediatric Surgery</i> , 2022, 31, 151178.	0.5	8
5296	Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial. <i>Trials</i> , 2022, 23, 401.	0.7	3
5297	Glycyrrhetic acid: A potential drug for the treatment of COVID-19 cytokine storm. <i>Phytomedicine</i> , 2022, 102, 154153.	2.3	10
5298	Rapid and ecofriendly UPLC quantification of Remdesivir, Favipiravir and Dexamethasone for accurate therapeutic drug monitoring in Covid-19 Patient's plasma. <i>Microchemical Journal</i> , 2022, 179, 107580.	2.3	19
5300	Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. <i>Intensive Care Medicine</i> , 2022, 48, 1009-1023.	3.9	66
5301	Androgens and COVID-19. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 3176-3180.	0.8	6

#	ARTICLE	IF	CITATIONS
5302	Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 730-739.	2.5	10
5303	Characteristics and outcomes of sepsis patients with and without COVID-19. Journal of Infection and Public Health, 2022, 15, 670-676.	1.9	12
5304	Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- Covid-19 Registry.. Anti-Infective Agents, 2022, 20, .	0.1	0
5305	Predictors of mortality and morbidity in critically ill COVID-19 patients: An experience from a low mortality country. Health Science Reports, 2022, 5, .	0.6	11
5306	The first detection of Pneumocystis jirovecii in asthmatic patients post COVID-19 in Jordan. Bosnian Journal of Basic Medical Sciences, 0, , .	0.6	11
5307	Paclitaxel and Urolithin A Prevent Histamine-Induced Neurovascular Breakdown Alike, in an <i>Ex Vivo</i> Rat Eye Model. ACS Chemical Neuroscience, 2022, 13, 2092-2098.	1.7	1
5308	Leukotriene Inhibitors with dexamethasone show promise in the prevention of death in COVID-19 patients with low oxygen saturations. Journal of Clinical and Translational Science, 0, , 1-20.	0.3	2
5309	Antidiabetic Drugs and their Potential Use in COVID-19: A Mechanistic Approach. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2022, 22, .	0.6	0
5310	Incidence and predictors of cardiac arrhythmias in patients with COVID-19 induced ARDS. Journal of Cardiology, 2022, 80, 298-302.	0.8	5
5311	Critical Influenza and COVID-19 – A Comparative Nationwide Case-Control Study. , 2022, 4, e0705.		2
5312	Paediatric critical COVID-19 and mortality in a multinational prospective cohort. The Lancet Regional Health Americas, 2022, 12, 100272.	1.5	19
5313	Predicting the Disease Severity of Virus Infection. Advances in Experimental Medicine and Biology, 2022, 1368, 111-139.	0.8	0
5314	SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity. Nature Communications, 2022, 13, 2774.	5.8	21
5315	Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nature Reviews Endocrinology, 2022, 18, 540-557.	4.3	60
5316	A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation*. Critical Care Medicine, 2022, 50, 1348-1359.	0.4	8
5317	Effect of ArtemiC in patients with COVID-19: A Phase II prospective study. Journal of Cellular and Molecular Medicine, 2022, 26, 3281-3289.	1.6	14
5318	ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection. Science Immunology, 2022, 7, eabo6294.	5.6	82
5319	Diagnosis and management of covid-19 in pregnancy. BMJ, The, 2022, 377, e069739.	3.0	25

#	ARTICLE	IF	CITATIONS
5341	The association between pre-exposure to glucocorticoids and other immunosuppressant drugs with severe COVID-19 outcomes. <i>Clinical Microbiology and Infection</i> , 2022, , .	2.8	2
5342	Equipoise, standard of care and consent: responding to the authorisation of new COVID-19 treatments in randomised controlled trials. <i>Journal of Medical Ethics</i> , 2023, 49, 465-470.	1.0	2
5343	SARS-CoV-2 cases reported from long-term residential facilities (care homes) in South Africa: a retrospective cohort study. <i>BMC Public Health</i> , 2022, 22, .	1.2	3
5344	Smartphone-Guided Self-prone Positioning vs Usual Care in Nonintubated Hospital Ward Patients With COVID-19. <i>Chest</i> , 2022, 162, 782-791.	0.4	16
5345	Corticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation. <i>Journal of Infection</i> , 2022, 85, 57-63.	1.7	29
5346	Extracorporeal Immunomodulation Treatment and Clinical Outcomes in ICU COVID-19 Patients. , 2022, 4, e0694.		10
5347	Pathogenetic treatment of patients with COVID-19 at the outpatient stage. <i>Infusion & Chemotherapy</i> , 2022, , 23-31.	0.0	0
5348	Estimating the effectiveness of remdesivir on risk of COVID-19 mortality: The role of observational data. <i>Pharmacological Research</i> , 2022, 181, 106268.	3.1	0
5349	Epigenetic Activation of Antiviral Sensors and Effectors of Interferon Response Pathways During SARS-CoV-2 Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
5350	Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma. <i>Internal Medicine</i> , 2022, 61, 2523-2526.	0.3	11
5351	Addition of Baricitinib to COVID-19 Treatment Does Not Increase Bacterial Infection Compared to Standard Therapy: A Single-center Retrospective Study. <i>Internal Medicine</i> , 2022, 61, 2273-2279.	0.3	3
5352	A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study. <i>ERJ Open Research</i> , 2022, 8, 00129-2022.	1.1	9
5353	Peritonsillar abscess caused by <i>Prevotella bivia</i> during home quarantine for coronavirus disease 2019. <i>Medicine (United States)</i> , 2022, 101, e29469.	0.4	0
5354	Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
5355	Post-COVID Pulmonary Fibrosis: A Medical Quagmire?. <i>The Indian Journal of Chest Diseases & Allied Sciences</i> , 2022, 64, 5-7.	0.1	0
5356	Intensive care clinicians' information acquisition during the first wave of the Covid 19 pandemic. <i>Journal of the Intensive Care Society</i> , 2023, 24, 40-46.	1.1	0
5357	Adjunctive osteopathic therapy for hospitalized COVID-19 patients: A feasibility-oriented chart review study with matched controls. <i>International Journal of Osteopathic Medicine</i> , 2022, 44, 3-8.	0.4	2
5358	Atypical Unilateral SARS-CoV-2 Pneumonia in a Single Lung Re-Transplanted Patient: A Case Report. <i>Transplantation Proceedings</i> , 2022, 54, 1564-1568.	0.3	1

#	ARTICLE	IF	CITATIONS
5359	Declining COVID-19 case-fatality in Georgia, USA, March 2020 to March 2021: a sign of real improvement or a broadening epidemic?. <i>Annals of Epidemiology</i> , 2022, , .	0.9	0
5360	Risk factors associated with COVID-19 severity among patients on maintenance haemodialysis: a retrospective multicentre cross-sectional study in the UK. <i>BMJ Open</i> , 2022, 12, e054869.	0.8	4
5361	Nanomedicine to deliver biological macromolecules for treating COVID-19. <i>Vaccine</i> , 2022, 40, 3931-3941.	1.7	9
5362	Remdesivir in the Treatment of COVID-19: A Propensity Score-Matched Analysis from a Public Hospital in New York City Assessing Renal and Hepatic Safety. <i>Journal of Clinical Medicine</i> , 2022, 11, 3132.	1.0	4
5363	Racial and Ethnic Discrepancy in Pulse Oximetry and Delayed Identification of Treatment Eligibility Among Patients With COVID-19. <i>JAMA Internal Medicine</i> , 2022, 182, 730.	2.6	128
5364	Post-COVID Syndrome: The Research Progress in the Treatment of Pulmonary sequelae after COVID-19 Infection. <i>Pharmaceutics</i> , 2022, 14, 1135.	2.0	15
5365	Impact of Bacterial Infections and Antibiotic Use on Hospitalized COVID-19 Patients: An Emerging Infections Network Survey. <i>Covid</i> , 2022, 2, 649-659.	0.7	0
5366	Risk factors and clinical impact of COVID-19-associated pulmonary aspergillosis: Multicenter retrospective cohort study. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 851-863.	0.7	12
5367	Patients with transplantation have reduced mortality in bacteraemia: Analysis of data from a randomised trial. <i>Journal of Infection</i> , 2022, , .	1.7	4
5368	Post-Covid -19 Pulmonary Hypertension: How it may physiologically affect exercise training. <i>Current Respiratory Medicine Reviews</i> , 2022, 18, .	0.1	0
5369	Prognostic Factors Associated With Mortality of Patients With COVID-19 Requiring Ventilator Management: A Retrospective Cohort Study. <i>Cureus</i> , 2022, , .	0.2	1
5370	Evaluation of models for prognosing mortality in critical care patients with COVID-19: First- and second-wave data from a German university hospital. <i>PLoS ONE</i> , 2022, 17, e0268734.	1.1	1
5371	Early treatment with low-molecular-weight heparin reduces mortality rate in SARS-CoV-2 patients. <i>Panminerva Medica</i> , 0, , .	0.2	5
5372	Un caso fatal de mucormicosis gastrointestinal asociada a Covid-19. <i>Revista Científica Ciencias De La Salud</i> , 2022, 4, 130-134.	0.1	0
5374	Cytokine Profiles as Potential Prognostic and Therapeutic Markers in SARS-CoV-2-Induced ARDS. <i>Journal of Clinical Medicine</i> , 2022, 11, 2951.	1.0	48
5375	The role of kidney dysfunction in COVID-19 and the influence of age. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
5376	Time trends in social contacts of individuals according to comorbidity and vaccination status, before and during the COVID-19 pandemic. <i>BMC Medicine</i> , 2022, 20, .	2.3	6
5377	Gastrointestinal Involvement in SARS-CoV-2 Infection. <i>Viruses</i> , 2022, 14, 1188.	1.5	25

#	ARTICLE	IF	CITATIONS
5378	Dexametasona en COVID-19: ¿un medicamento para todos?. <i>Medicina Intensiva (English Edition)</i> , 2022, 46, 291-292.	0.1	0
5379	Alterations in Immune-Related Defensin Alpha 4 (DEFA4) Gene Expression in Health and Disease. <i>International Journal of Inflammation</i> , 2022, 2022, 1-15.	0.9	3
5380	Assessment of Insulin Infusion Requirements in COVID-19-Infected Patients With Diabetic Ketoacidosis. <i>Endocrine Practice</i> , 2022, 28, 787-794.	1.1	4
5381	COVID-19: A Review of the Pathophysiology and Management. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 1353-1362.	1.3	9
5382	Inhibition of Cyclin-Dependent Kinase 9 Downregulates Cytokine Production Without Detrimentally Affecting Human Monocyte-Derived Macrophage Viability. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	2
5383	2021: Perioperative and critical care year in review for the cardiothoracic surgery team. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, e449-e456.	0.4	1
5384	Immune-Mediated Mechanisms of COVID-19 Neuropathology. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	9
5386	Chronic hepatitis E: Advancing research and patient care. <i>Journal of Hepatology</i> , 2022, 77, 1109-1123.	1.8	37
5387	Incidence, Risk Factors, and Prognosis of Bloodstream Infections in COVID-19 Patients in Intensive Care: A Single-Center Observational Study. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 1353-1362.	1.3	9
5388	Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 888-899.	5.2	62
5389	Prognosis of patients with acute respiratory failure due to the SARS-CoV-2 501Y.V2 variant: a multicenter retrospective matched cohort study. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
5390	Impairment of neutrophil functions and homeostasis in COVID-19 patients: association with disease severity. <i>Critical Care</i> , 2022, 26, .	2.5	18
5391	Comparison of COVID-19 Induced Respiratory Failure and Typical ARDS: Similarities and Differences. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	22
5392	Comparison of Two Waves of COVID-19 in Critically Ill Patients: A Retrospective Observational Study. <i>International Journal of Nephrology</i> , 2022, 2022, 1-6.	0.7	3
5393	A US clinical trial network is needed for the next pandemic. <i>Nature Medicine</i> , 2022, 28, 1330-1331.	15.2	2
5394	Remdesivir: an overview of patenting trends, clinical evidence on COVID-19 treatment, pharmacology and chemistry. <i>Pharmaceutical Patent Analyst</i> , 0, , .	0.4	1
5395	SARS-CoV-2 Attack Rate and Population Immunity in Southern New England, March 2020 to May 2021. <i>JAMA Network Open</i> , 2022, 5, e2214171.	2.8	5
5396	How to tame your genes: mechanisms of inflammatory gene repression by glucocorticoids. <i>FEBS Letters</i> , 2022, 596, 2596-2616.	1.3	6

#	ARTICLE	IF	CITATIONS
5397	Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2. <i>ImmunoTargets and Therapy</i> , 0, Volume 11, 23-35.	2.7	3
5398	Safety and Efficacy Analysis of Apixaban Compared to Heparins in Hospitalized Non-Critically Ill COVID-19 Patients. <i>Hospital Pharmacy</i> , 2022, 57, 727-733.	0.4	3
5399	Evolution of Clinical Care in COVID-Infected Solid Organ Transplant Recipients. <i>Current Transplantation Reports</i> , 2022, 9, 185-198.	0.9	3
5400	Chemokines, soluble PD-L1, and immune cell hypo-responsiveness are distinct features of SARS-CoV-2 critical illness. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 323, L14-L26.	1.3	15
5401	Comparative Clinical Characteristics, Laboratory Findings, and Outcomes of Hypoxemic and Non-Hypoxemic Patients Treated at a Makeshift COVID-19 Unit in Bangladesh: A Retrospective Chart Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 2968.	1.0	2
5402	Diabetes mellitus, glycaemic control, and severe COVID-19 in the Australian critical care setting: A nested cohort study. <i>Australian Critical Care</i> , 2023, 36, 579-585.	0.6	4
5403	A multisystem, cardio-renal investigation of post-COVID-19 illness. <i>Nature Medicine</i> , 2022, 28, 1303-1313.	15.2	39
5404	Concurrent Infection with SARS-CoV-2 and <i>Pneumocystis jirovecii</i> in Immunocompromised and Immunocompetent Individuals. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 585.	1.5	7
5405	Right ventricular dysfunction in patients with COVID-19 pneumonitis whose lungs are mechanically ventilated: a multicentre prospective cohort study. <i>Anaesthesia</i> , 2022, 77, 772-784.	1.8	11
5406	SARS-CoV-2 RNA copy number is a factor associated with the mortality of COVID-19 and improves the predictive performance of mortality in severe cases. <i>Japanese Journal of Infectious Diseases</i> , 2022, , .	0.5	0
5407	An Approach to the Treatment of Children With COVID-19. <i>Pediatric Infectious Disease Journal</i> , 2022, 41, 654-662.	1.1	5
5408	Specialized pro-resolving mediators as modulators of immune responses. <i>Seminars in Immunology</i> , 2022, 59, 101605.	2.7	17
5409	Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era. <i>Antibiotics</i> , 2022, 11, 771.	1.5	23
5410	Predictors of venous thromboembolism in COVID-19 patients: results of the COVID-19 Brazilian Registry. <i>Internal and Emergency Medicine</i> , 0, , .	1.0	3
5411	Tracheomegaly as a Potential Predictor of Severe Tracheal Damage in COVID-19 Patients on Long-Term Mechanical Ventilation. <i>Covid</i> , 2022, 2, 719-730.	0.7	2
5412	A systems biology approach identifies candidate drugs to reduce mortality in severely ill patients with COVID-19. <i>Science Advances</i> , 2022, 8, .	4.7	14
5413	Healing Field: Using Alternating Electric Fields to Prevent Cytokine Storm by Suppressing Clonal Expansion of the Activated Lymphocytes in the Blood Sample of the COVID-19 Patients. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, .	2.0	5
5414	Efficacy and safety of corticosteroid regimens for the treatment of hospitalized COVID-19 patients: a meta-analysis. <i>Future Virology</i> , 2022, 17, 463-489.	0.9	6

#	ARTICLE	IF	CITATIONS
5415	Delirium in Critically Ill Cancer Patients With COVID-19. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2022, 63, 539-547.	0.2	3
5416	Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general ward. <i>Respiratory Research</i> , 2022, 23, .	1.4	6
5417	T-cell immune response predicts the risk of critical SARS-Cov2 infection in hospitalized COVID-19 patients. <i>European Journal of Internal Medicine</i> , 2022, 102, 104-109.	1.0	4
5418	Multiple deadlocks in the development of nonprofit drugs. <i>Drug Discovery Today</i> , 2022, , .	3.2	0
5419	Clinical characteristics and social determinants of health associated with 30-day hospital readmissions of patients with COVID-19. <i>Journal of Investigative Medicine</i> , 2022, 70, 1406-1415.	0.7	4
5420	Duration of SARS-CoV-2 RNA positivity from various specimens and clinical characteristics in patients with COVID-19: a systematic review and meta-analysis. <i>Inflammation and Regeneration</i> , 2022, 42, .	1.5	7
5421	Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trial. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
5424	Low-dose Lung Radiotherapy for COVID-19-related Pneumonia: Preliminary Results of the Italian Mono-institutional COLOR-19 Trial. <i>In Vivo</i> , 2022, 36, 1959-1965.	0.6	3
5425	Factors influencing death in COVID-19 patients treated in the ICU: a single-centre, cross-sectional study. <i>Anaesthesiology Intensive Therapy</i> , 2022, 54, 132-140.	0.4	4
5426	Favipiravir in Early Symptomatic COVID-19, A Randomised Placebo-Controlled Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
5428	Management of Acute Respiratory Distress Syndrome in COVID-19 Patients. <i>Acta Anaesthesiologica Belgica</i> , 2022, 73, 5-14.	0.0	0
5429	SIGNS of COVID-19: Is evidence contagious?. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2022, 52, 10-11.	0.2	0
5430	Calcific aortic valve stenosis and COVID-19: clinical management, valvular damage, and pathophysiological mechanisms. <i>Cardiology Plus</i> , 2022, 7, 3-11.	0.2	0
5431	A scoping review of randomized clinical trials for pain management in pediatric tonsillectomy and adenotonsillectomy. <i>World Journal of Otorhinolaryngology - Head and Neck Surgery</i> , 2023, 9, 9-26.	0.7	1
5432	Severe Neutropenia after Sarilumab Administration in Two COVID-19 Patients: Case Reports and Literature Review. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 142-147.	0.1	1
5433	Prognostic value of radiological index and clinical data in patients with COVID-19 infection. <i>Internal and Emergency Medicine</i> , 2022, 17, 1679-1687.	1.0	3
5434	Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 18, 603-617.	0.9	5
5435	Pathogenesis of pneumonia and acute lung injury. <i>Clinical Science</i> , 2022, 136, 747-769.	1.8	53

#	ARTICLE	IF	CITATIONS
5437	A Rare Case of COVID-19-Induced Chronic Demyelinating Polyneuropathy. <i>Cureus</i> , 2022, , .	0.2	2
5438	Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study. <i>Intensive Care Medicine</i> , 2022, 48, 850-864.	3.9	17
5439	Anti-type I interferon antibodies as a cause of severe COVID-19. , 0, 11, .		2
5440	E-vape and E-Cigarettes-Associated Lung Injury (EVALI) in the COVID-19 Pandemic: A Diagnostic Dilemma and Therapeutic Challenge. <i>Cureus</i> , 2022, , .	0.2	0
5441	Investigating COVID-19 Vaccine Impact on the Risk of Hospitalisation through the Analysis of National Surveillance Data Collected in Belgium. <i>Viruses</i> , 2022, 14, 1315.	1.5	0
5442	PTP \pm promotes fibroproliferative responses after acute lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 323, L69-L83.	1.3	3
5443	Cardiovascular Damage in COVID-19: What We Know Two Years Later. <i>Current Cardiology Reports</i> , 2022, 24, 1085-1091.	1.3	4
5444	Liver Injuries Associated with Coronavirus Disease 2019: View on the Problem. <i>Lviv Clinical Bulletin</i> , 2022, 1-2, 67-74.	0.1	0
5445	Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19â€”Results From a Pilot Open-Label, Randomized Controlled Trial. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	27
5446	Mass cytometry reveals a conserved immune trajectory of recovery in hospitalized COVID-19 patients. <i>Immunity</i> , 2022, , .	6.6	9
5447	Human lungs show limited permissiveness for SARS-CoV-2 due to scarce ACE2 levels but virus-induced expansion of inflammatory macrophages. <i>European Respiratory Journal</i> , 2022, 60, 2102725.	3.1	21
5448	COVID-19 associated mucormycosis in Assiut University Hospitals: a multidisciplinary dilemma. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
5449	The<i>Staphylococcus aureus</i> Network Adaptive Platform Trial Protocol: New Tools for an Old Foe. <i>Clinical Infectious Diseases</i> , 2022, 75, 2027-2034.	2.9	27
5450	COVIDâ€™19 in kidney transplant recipients; a DALMATIAN singleâ€™center experience. <i>Therapeutic Apheresis and Dialysis</i> , 2023, 27, 107-116.	0.4	2
5451	Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. <i>Lancet Respiratory Medicine</i> ,the, 2022, 10, 700-714.	5.2	22
5452	Going Retro, Going Viral: Experiences and Lessons in Drug Discovery from COVID-19. <i>Molecules</i> , 2022, 27, 3815.	1.7	1
5453	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
5454	Key Advances in Intensive Care and the Coronavirus Disease-19 Research and Practice Boost. <i>Journal of Clinical Medicine</i> , 2022, 11, 3370.	1.0	0

#	ARTICLE	IF	CITATIONS
5455	Correspondence: Short- and long-term prognosis of glycemic control in COVID-19 patients with type 2 diabetes. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.2	0
5456	Large scale clinical trials: lessons from the COVID-19 pandemic. BMJ Open Respiratory Research, 2022, 9, e001226.	1.2	7
5457	Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans. Frontiers in Pharmacology, 0, 13, .	1.6	5
5459	A COMPARATIVE STUDY ON THE OUTCOMES OF MECHANICALLY VENTILATED COVID-19 VERSUS NON-COVID-19 PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME AT TERTIARY CARE CENTRE AT SMS MEDICAL COLLEGE JAIPUR. Asian Journal of Pharmaceutical and Clinical Research, 0, , 81-82.	0.3	0
5460	Approach for reporting master protocol study designs on ClinicalTrials.gov: qualitative analysis. BMJ, The, 0, , e067745.	3.0	1
5461	New Insights into Clinical and Mechanistic Heterogeneity of the Acute Respiratory Distress Syndrome: Summary of the Aspen Lung Conference 2021. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, 284-308.	1.4	9
5462	Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels. Immunologic Research, 2022, 70, 714-719.	1.3	3
5463	Co-Infections, Secondary Infections, and Antimicrobial Use in Patients Hospitalized with COVID-19 during the First Five Waves of the Pandemic in Pakistan; Findings and Implications. Antibiotics, 2022, 11, 789.	1.5	23
5464	Redefining critical illness. Nature Medicine, 2022, 28, 1141-1148.	15.2	136
5465	Precision medicine for corticotherapy in COVID-19. Intensive Care Medicine, 2022, 48, 926-929.	3.9	2
5466	Nanomaterials for Photocatalytic Degradations of Analgesic, Mucolytic and Anti-Biotic/Viral/Inflammatory Drugs Widely Used in Controlling SARS-CoV-2. Catalysts, 2022, 12, 667.	1.6	36
5467	Neuromuscular Complications of SARS-CoV-2 and Other Viral Infections. Frontiers in Neurology, 0, 13, .	1.1	9
5468	Post-Coronavirus Disease Mucormycosis: Predisposing factors and Possible Treatment: A Narrative Review. Coronaviruses, 2022, 03, .	0.2	0
5469	Immunometabolic analysis shows a distinct cyto-metabotype in Covid-19 compared to sepsis from other causes. Heliyon, 2022, 8, e09733.	1.4	2
5470	Early dexamethasone use as a protective measure in non-mechanically ventilated critically ill patients with COVID-19: a multicenter, cohort study. Scientific Reports, 2022, 12, .	1.6	4
5471	The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19. Vaccines, 2022, 10, 951.	2.1	8
5472	Nicotine patches in patients on mechanical ventilation for severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial. Intensive Care Medicine, 0, , .	3.9	10
5473	Clinical features and outcomes of COVID-19 admissions in a population with a high prevalence of HIV and tuberculosis: a multicentre cohort study. BMC Infectious Diseases, 2022, 22, .	1.3	10

#	ARTICLE	IF	CITATIONS
5474	Behind the mask. Academic Emergency Medicine, 0, , .	0.8	0
5475	Primer for Designing Main Protease (M ^{pro}) Inhibitors of SARS-CoV-2. Journal of Physical Chemistry Letters, 2022, 13, 5776-5786.	2.1	8
5476	Differential Immune Checkpoint and Ig-like V-Type Receptor Profiles in COVID-19: Associations with Severity and Treatment. Journal of Clinical Medicine, 2022, 11, 3287.	1.0	1
5477	Serum stratifin and presepsin as candidate biomarkers for early detection of COVID-19 disease progression. Journal of Pharmacological Sciences, 2022, 150, 21-30.	1.1	6
5478	No effect of remdesivir or betamethasone on upper respiratory tract SARS-CoV-2 RNA kinetics in hospitalised COVID-19 patients: a retrospective observational study. Infectious Diseases, 2022, 54, 703-712.	1.4	3
5479	Lessons from SARS-CoV-2 in India: A data-driven framework for pandemic resilience. Science Advances, 2022, 8, .	4.7	16
5480	Symptomatic, clinical and biomarker associations for mortality in hospitalized COVID-19 patients enriched for African Americans. BMC Infectious Diseases, 2022, 22, .	1.3	6
5481	Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trial. Clinical and Translational Science, 2022, 15, 1796-1804.	1.5	6
5482	Identification and characterization of the anti-SARS-CoV-2 activity of cationic amphiphilic steroidal compounds. Virulence, 2022, 13, 1031-1048.	1.8	2
5483	Quality of life and persistent symptoms after hospitalization for COVID-19. A prospective observational study comparing ICU with non-ICU patients. Revista Española De Anestesiología Y Reanimación (English Edition), 2022, , .	0.1	0
5484	Risk factors associated with in-hospital mortality patients with COVID-19 in Saudi Arabia. PLoS ONE, 2022, 17, e0270062.	1.1	7
5486	Longitudinal alterations of the gut mycobiota and microbiota on COVID-19 severity. BMC Infectious Diseases, 2022, 22, .	1.3	11
5487	Contemporary Concise Review 2021: COVID-19 and other respiratory infections. Respiriology, 0, , .	1.3	1
5488	The association between frailty risk and COVID-19-associated all-mortality in hospitalised older people: a national cohort study. European Geriatric Medicine, 2022, 13, 1149-1157.	1.2	9
5489	The ratio of serum LL-37 levels to blood leucocyte count correlates with COVID-19 severity. Scientific Reports, 2022, 12, .	1.6	5
5490	A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases. BMC Rheumatology, 2022, 6, .	0.6	4
5491	“No Regrets” Purchasing in a pandemic: making the most of advance purchase agreements. Globalization and Health, 2022, 18, .	2.4	3
5492	Effect of methylprednisolone treatment on COVID-19: An inverse probability of treatment weighting analysis. PLoS ONE, 2022, 17, e0266901.	1.1	2

#	ARTICLE	IF	CITATIONS
5494	Chasing the Ghost: Hyperinflammation Does Not Cause Sepsis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
5495	Current Practice Review in the Management of Acute Respiratory Distress Syndrome. <i>Journal of Pharmacy Practice</i> , 0, , 089719002211087.	0.5	1
5496	Critical care staffing ratio and outcome of COVID-19 patients requiring intensive care unit admission during the first pandemic wave: a retrospective analysis across Switzerland from the RISC-19-ICU observational cohort. <i>Swiss Medical Weekly</i> , 2022, 152, w30183.	0.8	4
5497	Development of ANCA-associated vasculitis after COVID-19 in a patient with Lynch syndrome and atypical hemolytic uremic syndrome. <i>Cukurova Medical Journal</i> , 2022, 47, 898-900.	0.1	0
5498	Prognosis of Old Intensive Care COVID-19 Patients at a Glance: The Senior COVID Study. , 2022, 50, S57-S61.		2
5499	Secondary Organising Pneumonia Among COVID-19 Patients: A Retrospective Case-Control Study. <i>Cureus</i> , 2022, , .	0.2	1
5500	Predicting the response to methylprednisolone pulses in patients with SARS-COV-2 infection. <i>Medicina Cl�nica</i> , 2022, , .	0.3	0
5501	Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia. <i>PLoS ONE</i> , 2022, 17, e0269482.	1.1	5
5502	Outcomes of Heart Failure in COVID-19 Patients: An Appalachian Experience. <i>Cardiology Research</i> , 2022, 13, 162-171.	0.5	2
5503	Clinical course of idiopathic inflammatory myopathies in COVID-19 pandemic: a single-center experience. <i>Future Virology</i> , 0, , .	0.9	0
5504	Post�Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention. <i>Tuberculosis and Respiratory Diseases</i> , 2022, 85, 320-331.	0.7	5
5505	COVID-19 in patients with end stage kidney disease at a large community hospital in Eastern Saudi Arabia. <i>A prospective study</i>. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2022, 43, 633-636.	0.5	0
5506	Longer Steroid Treatment Increases Secondary Bloodstream Infection Risk Among Patients With COVID-19 Requiring Intensive Care. <i>Infectious Diseases in Clinical Practice</i> , 2022, 30, .	0.1	3
5507	A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection. <i>Infectious Disease Reports</i> , 2022, 14, 446-452.	1.5	8
5508	Early Humoral Responses of Hemodialysis Patients After Inactivated SARS-CoV-2 Vaccination. <i>Journal of Inflammation Research</i> , 0, Volume 15, 3467-3475.	1.6	2
5509	I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations. <i>BMJ Open</i> , 2022, 12, e060664.	0.8	15
5510	The Role of Circadian Clock Genes in Critical Illness: The Potential Role of Translational Clock Gene Therapies for Targeting Inflammation, Mitochondrial Function, and Muscle Mass in Intensive Care. <i>Journal of Biological Rhythms</i> , 2022, 37, 385-402.	1.4	9
5511	Mode of methylprednisolone administration and its influence on ARDS dynamics in treatment of hospitalized COVID�19 patients. <i>Medical Alphabet</i> , 2022, , 69-74.	0.0	1

#	ARTICLE	IF	CITATIONS
5513	Multiple Sclerosis Management During the COVID-19 Pandemic. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 537-543.	2.0	8
5514	Neutrophil Extracellular Traps, Sepsis and COVID-19 – A Tripod Stand. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
5515	How COVID-19 Affects Lung Transplantation: A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 3513.	1.0	1
5516	COVID-19 coagulopathy – what should we treat?. <i>Experimental Physiology</i> , 2022, 107, 749-758.	0.9	8
5517	Abnormal antibodies to self-carbohydrates in SARS-CoV-2-infected patients. , 2022, 1, .		5
5518	Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	16
5519	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	28
5520	Longitudinal changes in inflammatory biomarkers among patients with COVID-19: a nationwide study in Iceland. <i>Acta Anaesthesiologica Scandinavica</i> , 0, .	0.7	2
5522	Host-directed immunotherapy of viral and bacterial infections: past, present and future. <i>Nature Reviews Immunology</i> , 2023, 23, 121-133.	10.6	71
5523	Changes in laboratory value improvement and mortality rates over the course of the pandemic: an international retrospective cohort study of hospitalised patients infected with SARS-CoV-2. <i>BMJ Open</i> , 2022, 12, e057725.	0.8	4
5524	Emergency myelopoiesis in critical illness: lessons from the COVID-19 pandemic. <i>Irish Journal of Medical Science</i> , 2023, 192, 831-832.	0.8	4
5525	An Exploratory Study of the Differences in Attitudes and Motives Regarding COVID-19 Plasma Donation. <i>Acta Medica Lituanica</i> , 2022, 29, 14.	0.2	1
5527	Coronavirus disease 2019 (COVID-19) update: From metabolic reprogramming to immunometabolism. <i>Journal of Medical Virology</i> , 2022, 94, 4611-4627.	2.5	18
5528	COVID-19 and the Functionality of Antivirals: The Day After Tomorrow. <i>Health Security</i> , 2022, 20, 270-271.	0.9	0
5529	Characteristics and clinical outcomes of SARS-CoV-2 infection in adult patients with acute leukemia in France. <i>Leukemia Research</i> , 2022, , 106901.	0.4	0
5530	Urine metabolomics links dysregulation of the tryptophan-kynurenine pathway to inflammation and severity of COVID-19. <i>Scientific Reports</i> , 2022, 12, .	1.6	18
5531	Successful Immunomodulatory Treatment of COVID-19 in a Patient With Severe ACTH-Dependent Cushing's Syndrome: A Case Report and Review of Literature. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
5532	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2022, 60, 2200803.	3.1	22

#	ARTICLE	IF	CITATIONS
5533	A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT). <i>Life</i> , 2022, 12, 856.	1.1	4
5534	Glucocorticoids Bind to SARS-CoV-2 S1 at Multiple Sites Causing Cooperative Inhibition of SARS-CoV-2 S1 Interaction With ACE2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
5535	Rise of monkeypox: Lessons from COVID-19 pandemic to mitigate global health crises. <i>Annals of Medicine and Surgery</i> , 2022, 79, .	0.5	20
5536	A multiplex protein panel assay for severity prediction and outcome prognosis in patients with COVID-19: An observational multi-cohort study. <i>EclinicalMedicine</i> , 2022, 49, 101495.	3.2	17
5537	COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records. <i>The Lancet Digital Health</i> , 2022, 4, e542-e557.	5.9	40
5538	Coronavirus disease 2019 and the cardiologist. <i>Current Opinion in Cardiology</i> , 2022, 37, 335-342.	0.8	1
5539	Addressing the global burden of paediatric critical COVID-19 and mortality. <i>The Lancet Regional Health Americas</i> , 2022, 12, 100301.	1.5	0
5540	SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1. <i>Metabolism: Clinical and Experimental</i> , 2022, 133, 155236.	1.5	31
5541	Diretrizes Brasileiras para o tratamento farmacológico de pacientes hospitalizados com COVID-19. <i>Revista Brasileira De Terapia Intensiva</i> , 2022, 34, .	0.1	2
5542	COVID-19 Pandemic and Osteoporosis in Elderly Patients. , 2022, 13, 960.		11
5543	Outcome of COVID-19 in kidney transplant patients from Eastern India: A single center study. <i>Indian Journal of Nephrology</i> , 2022, .	0.2	0
5544	Lung-Function Trajectories in COVID-19 Survivors after Discharge: A Two-Year Longitudinal Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
5545	Overview of coronavirus pandemic. , 2022, , 1-22.		0
5546	Present therapeutic and diagnostic approaches for SARS-CoV-2 infection. , 2022, , 421-449.		0
5547	Clinical characteristics and outcome of patients presenting to emergency department during the second wave of COVID-19. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 2723.	0.3	1
5548	Interaction between Sars-CoV-2 structural proteins and host cellular receptors: From basic mechanisms to clinical perspectives. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, , 243-277.	1.0	4
5549	Treatment of COVID-19. <i>Folia Pharmacologica Japonica</i> , 2022, 157, 214-220.	0.1	0
5550	Recent advancements and nanotechnological interventions in diagnosis, treatment, and vaccination for COVID-19. , 2022, , 279-303.		0

#	ARTICLE	IF	CITATIONS
5551	Clinical Characteristics of COVID-19: Use of Steroids in Mostly Unvaccinated COVID-19 Patients Before the Omicron Variant. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	3
5552	è...1è†œé€æžã*æ—°ãž<ã,3ãfãfŠã, ã,ãf«ã,1æ,,ŸæŸ“ç—‡. <i>Nihon Toseki Igakkai Zasshi</i> , 2022, 55, 371-377.	0.2	0
5553	Estudo nacional sobre recursos da saÃde e prÃticas clÃnicas durante o inÃcio da pandemia da COVID-19 no Brasil. <i>Revista Brasileira De Terapia Intensiva</i> , 2022, 34, .	0.1	0
5554	Currently available drugs for the treatment of Coronavirus-2. , 2022, , 77-95.		0
5555	Thyroid Function During and After COVID-19 Infection: A Review. , 2022, 18, 58.		6
5556	EFFICACY OF REMDESIVIR VERSUS REMDESIVIR PLUS TOCILIZUMAB IN MODERATE TO SEVERE COVID-19 PATIENTS ADMITTED IN THE CRITICAL CARE UNIT OF A TERTIARY CARE HOSPITAL IN WEST BENGAL, INDIA. , 2022, , 24-27.		0
5557	Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge. <i>Transplantation</i> , 2022, 106, 1528-1537.	0.5	23
5558	Gastrointestinal perforation and vascular thrombosis in patients with corona virus disease-19: A life-threatening problem. <i>Indian Journal of Gastroenterology</i> , 2022, 41, 218-223.	0.7	1
5559	The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens. <i>Npj Digital Medicine</i> , 2022, 5, .	5.7	11
5560	Dexamethasone: Therapeutic Applications, Targets and Translation. <i>Nano LIFE</i> , 0, , .	0.6	0
5561	11Î2-Hydroxysteroid Dehydrogenase Type 1 within Osteoclasts Mediates the Bone Protective Properties of Therapeutic Corticosteroids in Chronic Inflammation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7334.	1.8	2
5562	Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza. <i>Journal of Interferon and Cytokine Research</i> , 2022, 42, 369-392.	0.5	9
5563	The Relationship between COVID-19 and Hypothalamicâ€Pituitaryâ€Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excessâ€The CAPISCO International Expert Panel. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7326.	1.8	30
5564	The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis. <i>Neurological Sciences</i> , 0, , .	0.9	2
5565	The influence of physical activity level on the length of stay in hospital in older men survivors of COVID-19. <i>Sport Sciences for Health</i> , 2022, 18, 1483-1490.	0.4	3
5566	Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents. <i>Clinical and Experimental Pediatrics</i> , 2022, 65, 377-386.	0.9	5
5567	COVID-19 and Kidney Transplantation: Epidemiology, Histopathological Presentation, Clinical Presentation and Outcomes, and Therapeutic Strategies. <i>Transplantation</i> , 2022, 3, 219-229.	0.3	0
5568	Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone. <i>Biomedicines</i> , 2022, 10, 1548.	1.4	2

#	ARTICLE	IF	CITATIONS
5569	How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. <i>Blood</i> , 2022, 140, 673-684.	0.6	20
5570	Differences in clinical features and mortality in very old unvaccinated patients (≥80 years) hospitalized with COVID-19 during the first and successive waves from the multicenter SEMI-COVID-19 Registry (Spain). <i>BMC Geriatrics</i> , 2022, 22, .	1.1	6
5571	An autopsy case of COVID-19 with a sudden death: Clinicopathological comparison. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	3
5572	Human cardiac organoids to model COVID-19 cytokine storm induced cardiac injuries. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2022, 16, 799-811.	1.3	15
5573	Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19. <i>Blood Advances</i> , 2022, 6, 4710-4714.	2.5	5
5574	Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity. <i>ACS Infectious Diseases</i> , 2022, 8, 1265-1279.	1.8	3
5575	Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 323, L372-L389.	1.3	9
5576	Cortisol as an Independent Predictor of Unfavorable Outcomes in Hospitalized COVID-19 Patients. <i>Biomedicines</i> , 2022, 10, 1527.	1.4	1
5577	Acetylcholine, Fatty Acids, and Lipid Mediators Are Linked to COVID-19 Severity. <i>Journal of Immunology</i> , 2022, 209, 250-261.	0.4	17
5578	The Impact of Key Secular Trends During the first Three Waves the COVID-19 Pandemic. <i>Annals of Epidemiology</i> , 2022, , .	0.9	2
5579	COVID-19 Mortality and Therapeutics in Nebraska and Southwest Iowa during Early Pandemic. <i>Pharmacy (Basel, Switzerland)</i> , 2022, 10, 69.	0.6	0
5580	Case Report: Post-Partum SARS-CoV-2 Infection After the First French Uterus Transplantation. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	6
5581	A retrospective study of the role of Tocilizumab in preventing or controlling cytokine storm in COVID-19 cases. <i>Journal of Preventive Medicine and Holistic Health</i> , 2022, 8, 30-34.	0.2	0
5582	Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 3769.	1.0	10
5583	Acute Respiratory Distress Syndrome Secondary to Enterovirus-Human-Rhinovirus Infection in an Adult. <i>Cureus</i> , 2022, , .	0.2	4
5584	Comparison of Mental Health among Japanese Healthcare Workers at Two Points during the COVID-19 Pandemic. <i>Journal of Nippon Medical School</i> , 2022, 89, 328-336.	0.3	1
5585	Participants' informed consent in adaptive, platform drug trials in hospitalized COVID-19 patients: Not all approaches are ethically acceptable. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	6
5586	Efficacy and safety of hyperbaric oxygen treatment to treat COVID-19 pneumonia: a living systematic review update. <i>Diving and Hyperbaric Medicine</i> , 2022, 52, 126-135.	0.2	2

#	ARTICLE	IF	CITATIONS
5587	Current Effective Therapeutics in Management of COVID-19. Journal of Clinical Medicine, 2022, 11, 3838.	1.0	23
5588	Pseudoscience and fraudulent products for COVID-19 management. Environmental Science and Pollution Research, 2022, 29, 62887-62912.	2.7	15
5589	High D-glucose levels induce ACE2 expression via GLUT1 in human airway epithelial cell line Calu-3. BMC Molecular and Cell Biology, 2022, 23, .	1.0	2
5590	Attenuation of SARS-CoV-2 replication and associated inflammation by concomitant targeting of viral and host cap 2' O ⁶ -ribose methyltransferases. EMBO Journal, 2022, 41, .	3.5	18
5591	Threshold of increase in oxygen demand to predict mechanical ventilation use in novel coronavirus disease 2019: A retrospective cohort study incorporating restricted cubic spline regression. PLOS ONE, 2022, 17, e0269876.	1.1	2
5592	Inflammation and vascular dysfunction: The negative synergistic combination of diabetes and COVID-19. Diabetes/Metabolism Research and Reviews, 2022, 38, .	1.7	7
5593	Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional Trials. JAMA Network Open, 2022, 5, e2221140.	2.8	12
5594	An Executed Plan to Combat COVID-19 in the United States. Advances in Anesthesia, 2022, 40, 45-62.	0.5	1
5595	An integrated analysis and comparison of serum, saliva and sebum for COVID-19 metabolomics. Scientific Reports, 2022, 12, .	1.6	19
5596	The cross-over of statistical thinking and practices: A pandemic catalyst. Pharmaceutical Statistics, 2022, 21, 778-789.	0.7	1
5597	COVID-19, Mucormycosis and Cancer: The Triple Threat—Hypothesis or Reality?. Journal of Personalized Medicine, 2022, 12, 1119.	1.1	5
5598	Managing endothelial dysfunction in COVID-19 with statins, beta blockers, nicorandil, and oral supplements: A pilot, double-blind, placebo-controlled, randomized clinical trial. Clinical and Translational Science, 2022, 15, 2323-2330.	1.5	9
5599	Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus. International Journal of Molecular Sciences, 2022, 23, 7702.	1.8	2
5600	Recent Progress in the Development of Opaganib for the Treatment of Covid-19. Drug Design, Development and Therapy, 0, Volume 16, 2199-2211.	2.0	9
5601	Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial. Expert Review of Anti-Infective Therapy, 0, , 1-10.	2.0	1
5602	COVID-19-Associated Pulmonary Mucormycosis. Journal of Fungi (Basel, Switzerland), 2022, 8, 711.	1.5	10
5603	COVID-19 in kidney transplant recipients: what have we learned one year later? A cohort study from a tertiary center. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2022, 44, 533-542.	0.4	0
5604	Beneficial Effect of Short-Term Supplementation of High Dose of Vitamin D3 in Hospitalized Patients With COVID-19: A Multicenter, Single-Blinded, Prospective Randomized Pilot Clinical Trial. Frontiers in Pharmacology, 0, 13, .	1.6	7

#	ARTICLE	IF	CITATIONS
5605	Sudden onset hepatitis in children. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 553-554.	8.2	8
5606	Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
5607	Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients. <i>PLoS ONE</i> , 2022, 17, e0269875.	1.1	0
5608	Predictors of mortality among inpatients with COVID-19 infection in a tertiary referral center in the Philippines. <i>IJID Regions</i> , 2022, 4, 134-142.	0.5	4
5609	Use of Tox21 Screening Data to Evaluate the COVID-19 Drug Candidates for Their Potential Toxic Effects and Related Pathways. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
5610	Characteristics of our hypoxemic COVID-19 pneumonia patients receiving corticosteroids and mortality-associated factors. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 953-958.	1.0	0
5611	A review of mass spectrometry-based analyses to understand COVID-19 convalescent plasma mechanisms of action. <i>Proteomics</i> , 0, , 2200118.	1.3	3
5612	Clinical Characteristics and Treatment Outcomes of COVID-19 Patients at Eka Kotebe General Hospital, Addis Ababa, Ethiopia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 107, 252-259.	0.6	1
5613	Dynamics of disease characteristics and clinical management of critically ill COVID-19 patients over the time course of the pandemic: an analysis of the prospective, international, multicentre RISC-19-ICU registry. <i>Critical Care</i> , 2022, 26, .	2.5	11
5614	Low-to-Moderate Dosage and Short-Term Use of Corticosteroids Benefit Patients With Severe COVID-19 Infections. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
5615	Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences. <i>Vaccines</i> , 2022, 10, 1068.	2.1	9
5616	Overstimulation of the ergoreflex—A possible mechanism to explain symptoms in long COVID. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
5617	Clinical Characteristics of Hospitalized COVID-19 Patients Who Have Gastrointestinal Bleeds Requiring Intervention: A Case-Control Study. <i>Cureus</i> , 2022, , .	0.2	2
5618	Tocilizumab Use among Patients Who Developed Pulmonary Embolism in the Course of Cytokine Release Storm and COVID-19 Pneumonia—A Retrospective Study. <i>Biomedicines</i> , 2022, 10, 1581.	1.4	2
5620	Prolonged NHE Activation may be both Cause and Outcome of Cytokine Release Syndrome in COVID-19. <i>Current Pharmaceutical Design</i> , 2022, 28, 1815-1822.	0.9	5
5621	A case of pleural tuberculosis vs latent tuberculosis reactivation as a result of COVID-19 infection and treatment. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 90-94.	0.4	3
5622	When should corticosteroids be used for COVID-19 infection?. <i>European Respiratory Journal</i> , 2022, 60, 2103222.	3.1	0
5623	Optimizing the Design and Analysis of Future AKI Trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1459-1470.	3.0	17

#	ARTICLE	IF	CITATIONS
5626	What, Where, When and How of COVID-19 Patents Landscape: A Bibliometrics Review. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
5627	Potential of outpatient steroid therapy in elderly patients with early COVID-19. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 2585-2590.	1.4	2
5628	Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis. , 2022, 1, .		16
5629	Incidence and severity of SARS-CoV-2 infections in liver and kidney transplant recipients in the post-vaccination era: Real-life data from Denmark. <i>American Journal of Transplantation</i> , 2022, 22, 2637-2650.	2.6	22
5630	Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges. <i>Clinical Trials</i> , 2022, 19, 561-572.	0.7	2
5631	Risk factors for mortality in kidney transplant recipients with COVID-19: a single centre experience and case-control study. <i>BMC Nephrology</i> , 2022, 23, .	0.8	5
5632	Therapeutic approaches for intravascular microthrombi-induced acute respiratory distress syndrome (ARDS) in COVID-19 infection. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, .	0.9	0
5633	The effect of inhaled corticosteroids on the outcomes of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 593-600.	1.3	8
5634	Bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study. <i>Intensive Care Medicine</i> , 2022, 48, 1039-1052.	3.9	33
5635	The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1155-1162.	2.0	3
5636	A practical treatment for COVID-19 and the next pandemic. <i>Pharmacology Research and Perspectives</i> , 2022, 10, .	1.1	9
5637	Management of Severe and Critical COVID-19 Infection with Immunotherapies. <i>Infectious Disease Clinics of North America</i> , 2022, , .	1.9	0
5639	ACE2 and SARS-CoV-2-Main Protease Capillary Columns for Affinity Chromatography: Testimony of the Binding of Dexamethasone and its Carbon Nanotube Nanovector. <i>Chromatographia</i> , 0, , .	0.7	1
5640	Mucormycosis in COVID-19 patients with uncontrolled diabetes - the lethal triangle. <i>Romanian Journal of Rhinology</i> , 2022, 12, 115-123.	0.1	0
5641	Clinical Characteristics and Outcomes of COVID-19 Acute Respiratory Distress Syndrome (ARDS) Survivors in Early Pandemic: A Single Healthcare System Retrospective Study. <i>Cureus</i> , 2022, , .	0.2	0
5642	Pharmacy students' knowledge and confidence of COVID-19 following an interactive didactic class. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2022, 5, 1082-1087.	0.5	3
5643	Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. <i>World Journal of Critical Care Medicine</i> , 2022, 11, 269-297.	0.8	2
5644	A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-8.	0.7	2

#	ARTICLE	IF	CITATIONS
5645	Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 271-279.	1.3	16
5646	Rheumatology research in the post-COVID era—challenges and solutions. <i>Rheumatology</i> , 2023, 62, 489-491.	0.9	1
5647	Clinical and survival differences during separate COVID-19 surges: Investigating the impact of the Sars-CoV-2 alpha variant in critical care patients. <i>PLoS ONE</i> , 2022, 17, e0269244.	1.1	3
5648	Epidemiologic Profile of Severe Acute Respiratory Infection in Brazil During the COVID-19 Pandemic: An Epidemiological Study. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	13
5649	Evaluation of Strongyloides Awareness and Knowledge among Canadian Physicians Caring for Patients At Risk for Severe Strongyloidiasis: A National Cross-sectional Survey. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, , .	0.6	0
5650	Effects of Early Initiation of High-Dose Dexamethasone Therapy on Pro-Inflammatory Cytokines and Mortality in LPS-Challenged Mice. <i>Healthcare (Switzerland)</i> , 2022, 10, 1247.	1.0	0
5651	Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study. <i>The Lancet Digital Health</i> , 2022, 4, e632-e645.	5.9	37
5652	Drug repurposing based on a quantum-inspired method versus classical fingerprinting uncovers potential antivirals against SARS-CoV-2. <i>PLoS Computational Biology</i> , 2022, 18, e1010330.	1.5	7
5653	SARS-CoV-2 Genomic Characteristics and Clinical Impact of SARS-CoV-2 Viral Diversity in Critically Ill COVID-19 Patients: A Prospective Multicenter Cohort Study. <i>Viruses</i> , 2022, 14, 1529.	1.5	4
5654	The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update. <i>Journal of Medical Virology</i> , 2022, 94, 5128-5148.	2.5	12
5655	Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 1336-1352.	2.5	28
5656	65-Year-Old Man With Weight Loss and Dyspnea on Exertion. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1363-1368.	1.4	1
5658	COVID-associated rhinocerebral mucormycosis: a retrospective analysis of presentation and outcomes. <i>European Archives of Oto-Rhino-Laryngology</i> , 2023, 280, 713-721.	0.8	1
5659	The Pitfalls of Mining for QuantiFERON Gold in Severely Ill Patients With COVID-19. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2022, 6, 409-419.	1.2	2
5660	Effect of treatment regimens in severe COVID pneumonia at an Indian tertiary care hospital: An observational, real-world study. <i>Medical Journal Armed Forces India</i> , 2022, 78, 469-474.	0.3	0
5661	A pilot phase Ib/II study of whole-lung low dose radiation therapy (LDRT) for the treatment of severe COVID-19 pneumonia: First experience from Africa. <i>PLoS ONE</i> , 2022, 17, e0270594.	1.1	4
5662	Understanding Immune Responses to Viruses—Do Underlying Th1/Th2 Cell Biases Predict Outcome?. <i>Viruses</i> , 2022, 14, 1493.	1.5	20
5663	Circadian patterns of heart rate, respiratory rate and skin temperature in hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2022, 17, e0268065.	1.1	10

#	ARTICLE	IF	CITATIONS
5664	Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study. <i>Critical Care</i> , 2022, 26, .	2.5	7
5665	Pandemic COVID-19, an update of current status and new therapeutic strategies. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 0, , .	1.4	14
5666	Challenges in hyperglycemia management in critically ill patients with COVID-19. <i>World Journal of Critical Care Medicine</i> , 2022, 11, 219-227.	0.8	1
5667	High-Dose Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute Hypoxemic Respiratory Failure. <i>JAMA Internal Medicine</i> , 2022, 182, 906.	2.6	69
5668	Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy. <i>Pharmacological Research</i> , 2022, 182, 106334.	3.1	2
5669	Maresin-1 and its receptors ROR1/LGR6 as potential therapeutic target for respiratory diseases. <i>Pharmacological Research</i> , 2022, 182, 106337.	3.1	9
5670	In-hospital mortality in SARS-CoV-2 stratified by the use of corticosteroid. <i>Annals of Medicine and Surgery</i> , 2022, 80, .	0.5	1
5671	JAK inhibition as a new treatment strategy for patients with COVID-19. <i>Biochemical Pharmacology</i> , 2022, 202, 115162.	2.0	10
5672	The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges. <i>Thrombosis Update</i> , 2022, 8, 100117.	0.4	1
5673	Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2022, 51, 101545.	3.2	14
5674	Epigenetic activation of antiviral sensors and effectors of interferon response pathways during SARS-CoV-2 infection. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113396.	2.5	5
5675	Core shell stationary phase for a novel separation of some COVID-19 used drugs by UPLC-MS/MS Method: Study of grapefruit consumption impact on their pharmacokinetics in rats. <i>Microchemical Journal</i> , 2022, 181, 107769.	2.3	0
5676	When Should Perioperative Glucocorticoid Replacement Be Administered?. , 2023, , 217-225.		0
5677	Coronaviruses. , 2023, , 277-306.		0
5678	Aspectos clínicos de la COVID-19. <i>Ambiociencias</i> , 0, , 7-22.	0.0	0
5679	The Changes In The AntiHBs Values Following COVID-19 Pneumonia. <i>Journal of Contemporary Medicine</i> , 2022, 12, 537-542.	0.1	0
5680	COVID-19 treatment in elderly. Short Review. <i>Ageing & Longevity</i> , 2022, , 77-85.	0.1	0
5682	Adjunctive Recombinant Human Plasma Gelsolin for Severe COVID-19 Pneumonia. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
5683	ICU strain and outcome in COVID-19 patients—A multicenter retrospective observational study. <i>PLoS ONE</i> , 2022, 17, e0271358.	1.1	5
5684	How to conduct collaborative research studies. <i>Anaesthesia</i> , 2023, 78, 251-255.	1.8	0
5685	COVID-19-Associated Pulmonary Aspergillosis: A Year-Long Retrospective Case Series. <i>Covid</i> , 2022, 2, 976-982.	0.7	4
5687	Renal Mucormycosis: Post-COVID-19 Infection Presenting as Unilateral Hydronephrosis in a Young Immunocompetent Male. <i>Case Reports in Nephrology</i> , 2022, 2022, 1-4.	0.2	2
5688	Oral antiviral treatments for COVID-19: opportunities and challenges. <i>Pharmacological Reports</i> , 2022, 74, 1255-1278.	1.5	31
5689	Outcomes of COVID-19 in a Large Cohort of Lung Transplant Recipients: A Retrospective Study. <i>Transplantology</i> , 2022, 3, 257-266.	0.3	1
5690	Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic. <i>Cancers</i> , 2022, 14, 3598.	1.7	7
5691	Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial. <i>Advances in Biological Regulation</i> , 2022, 86, 100901.	1.4	9
5692	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197.	1.8	46
5693	Corticosteroids showed more efficacy in treating hospitalized patients with COVID-19 than standard care but the effect is minimal: A systematic review and meta-analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	4
5694	New insights on Effects of Glucocorticoids in SARS-CoV-2 infection.. <i>Endocrine Practice</i> , 2022, , .	1.1	2
5695	Cross-talk between SARS-CoV-2 infection and the insulin/IGF signaling pathway: Implications for metabolic diseases in COVID-19 and for post-acute sequelae of SARS-CoV-2 infection. <i>Metabolism: Clinical and Experimental</i> , 2022, 134, 155267.	1.5	4
5696	Definitions matter: Heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis. <i>PLOS Global Public Health</i> , 2022, 2, e0000561.	0.5	10
5697	Critical patients COVID-19 has changed the management and outcomes in the ICU after 1-year of the pandemic? A multicenter, prospective, observational study. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2022, , .	0.2	0
5698	Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studies. <i>Journal of Molecular Modeling</i> , 2022, 28, .	0.8	7
5699	Barriers to COVID-19 Health Products in Low-and Middle-Income Countries During the COVID-19 Pandemic: A Rapid Systematic Review and Evidence Synthesis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	18
5700	Clinical decision analysis of elective delivery vs expectant management for pregnant individuals with COVID-19-related acute respiratory distress syndrome. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2022, 4, 100697.	1.3	1
5701	Antiviral treatment for COVID-19: ensuring evidence is applicable to current circumstances. <i>Cmaj</i> , 2022, 194, E996-E997.	0.9	1

#	ARTICLE	IF	CITATIONS
5702	Recommendations for achieving interoperable and shareable medical data in the USA. <i>Communications Medicine</i> , 2022, 2, .	1.9	3
5703	Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	27
5704	Longitudinal Serum Proteome Characterization of COVID-19 Patients With Different Severities Revealed Potential Therapeutic Strategies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
5705	Diagnostics of messenger ribonucleic acid (mRNA) severe acute respiratory syndrome-corona virusâ€² (SARS-CoVâ€²) vaccination-associated myocarditisâ€”A systematic review. <i>Rechtsmedizin</i> , 0, , .	2.6	1
5707	Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
5708	The adverse effects of highâ€”dose corticosteroid on infectious and nonâ€”infectious sequelae in renal transplant recipients with coronavirus diseaseâ€”19 in India. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	3
5709	Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113459.	2.5	6
5711	Epidemiology, clinical profile, management and outcome in patients of post covid mucormycosis at a tertiary care center in eastern UP. <i>IP International Journal of Ocular Oncology and Oculoplasty</i> , 2022, 8, 125-129.	0.0	0
5712	Anti-ACTH antibodies in critically ill Covid-19 patients: A potential immune evasion mechanism of SARS-CoV-2. <i>Medicina Intensiva (English Edition)</i> , 2022, 46, 472-474.	0.1	2
5713	Systemic sclerosis in the time of COVID-19. <i>Lancet Rheumatology, The</i> , 2022, 4, e566-e575.	2.2	14
5714	Data provenance and integrity of health-care systems data for clinical trials. <i>The Lancet Digital Health</i> , 2022, 4, e567-e568.	5.9	9
5715	Adapt or die: how the pandemic made the shift from EBM to EBM+ more urgent. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 253-260.	1.7	42
5716	Impact of COVID-19 on Rheumatic Diseases in India: Determinants of Mortality and Adverse Outcome: A Retrospective, Cross-Sectional Cohort Study. <i>Indian Journal of Rheumatology</i> , 2023, 18, 134-140.	0.2	0
5717	Outcomes of patients with left ventricular assist device infected with SARS-CoV-2. <i>Turkish Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 30, 199-205.	0.2	1
5718	Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 187-209.	1.0	5
5719	In vitro and in vivo pharmacodynamic activity of the new compound XC221GI in models of the viral inflammation of the respiratory tract. <i>Microbiology Independent Research Journal</i> , 0, 9, .	0.2	4
5720	A fatal case report of invasive pulmonary aspergillosis and mucormycosis coinfection in an immunocompetent patient with coronavirus disease 2019 in Korea. <i>Acute and Critical Care</i> , 2023, 38, 382-388.	0.6	3
5721	Managing COVID-19 in pregnant women. <i>Breathe</i> , 2022, 18, 220019.	0.6	0

#	ARTICLE	IF	CITATIONS
5722	Adoption and Deadoption of Medications to Treat Hospitalized Patients With COVID-19. , 2022, 4, e0727.		3
5723	Prevalencia y factores asociados a infección por SARS-CoV-2 en adultos mayores institucionalizados. Duazary, 2022, 19, 116-128.	0.0	0
5724	COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress. Cancers, 2022, 14, 3711.	1.7	6
5725	Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients. European Respiratory Journal, 2022, 60, 2200780.	3.1	15
5726	Evolution of Respiratory Muscles Thickness in Mechanically Ventilated Patients With COVID-19. Respiratory Care, 2022, 67, 1369-1376.	0.8	1
5727	When to Use Antibiotics in COVID-19: A Proposal Based on Questions. Cureus, 2022, , .	0.2	1
5728	Systemic Autoimmune Diseases in Patients Hospitalized with COVID-19 in Spain: A Nation-Wide Registry Study. Viruses, 2022, 14, 1631.	1.5	10
5729	Prognostic Value of Mid-Region Proadrenomedullin and In Vitro Interferon Gamma Production for In-Hospital Mortality in Patients with COVID-19 Pneumonia and Respiratory Failure: An Observational Prospective Study. Viruses, 2022, 14, 1683.	1.5	5
5730	Lymphocyte Population Changes at Two Time Points during the Acute Period of COVID-19 Infection. Journal of Clinical Medicine, 2022, 11, 4306.	1.0	6
5731	Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19. Journal of Infectious Diseases, 2022, 227, 23-34.	1.9	21
5732	Trends in COVID-19 patient characteristics in a large electronic health record database in the United States: A cohort study. PLoS ONE, 2022, 17, e0271501.	1.1	6
5733	Managing SARS-CoV2 Infections Through Resolution of Inflammation by Eicosanoids: A Review. Journal of Inflammation Research, 0, Volume 15, 4349-4358.	1.6	7
5735	Institutional, therapeutic, and individual factors associated with <scp>30â€¦day</scp> mortality after <scp>COVID</scp>â€¦19 diagnosis in Canadian longâ€¦term care facilities. Journal of the American Geriatrics Society, 2022, 70, 3210-3220.	1.3	7
5736	Therapeutic Approaches to the Neurologic Manifestations of COVID-19. Neurotherapeutics, 2022, 19, 1435-1466.	2.1	22
5737	Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials. Open Forum Infectious Diseases, 2022, 9, .	0.4	6
5738	Patients with myeloproliferative neoplasms and COVIDâ€¦19 have increased rates of arterial thrombosis. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12752.	1.0	3
5739	Are the Current Processes and Regulations Fit for Purpose to Deliver Novel Therapies During Pandemics? A Perspective on COVID-19 from the UK. Pharmaceutical Medicine, 0, , .	1.0	0
5740	Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet, The, 2022, 400, 359-368.	6.3	146

#	ARTICLE	IF	CITATIONS
5741	Iatrogenic Adrenal Insufficiency Following Post COVID-19 Organizing Pneumonia. <i>Archivos De Bronconeumologia</i> , 2023, 59, 63-65.	0.4	1
5742	Proteomic analysis of cardiometabolic biomarkers and predictive modeling of severe outcomes in patients hospitalized with COVID-19. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	0
5743	Multiethnic Investigation of Risk and Immune Determinants of COVID-19 Outcomes. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	1
5745	Severe COVID-19 in a kidney transplant recipient with acquired hypogammaglobulinemia: A case report. <i>Journal of Case Reports and Images in Medicine</i> , 2022, 8, 1-6.	0.0	0
5746	Characteristics and risk factors for mortality in critically ill patients with COVID-19 receiving invasive mechanical ventilation: the experience of a private network in Sao Paulo, Brazil. <i>The Journal of Critical Care Medicine</i> , 2022, 8, 165-175.	0.3	0
5747	Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	15
5748	Predicting Need for Escalation of Care or Death From Repeated Daily Clinical Observations and Laboratory Results in Patients With Severe Acute Respiratory Syndrome Coronavirus 2. <i>American Journal of Epidemiology</i> , 2022, 191, 1944-1953.	1.6	3
5749	Thymosin $\hat{\pm}$ 1 for COVID-19: Look before You Leap!. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 892-893.	0.3	0
5750	COVID-19 Secondary Infections in ICU Patients and Prevention Control Measures: A Preliminary Prospective Multicenter Study. <i>Antibiotics</i> , 2022, 11, 1016.	1.5	1
5751	Metabolomics Markers of COVID-19 Are Dependent on Collection Wave. <i>Metabolites</i> , 2022, 12, 713.	1.3	16
5752	Co-infection and ICU-acquired infection in COVID-19 ICU patients: a secondary analysis of the UNITE-COVID data set. <i>Critical Care</i> , 2022, 26, .	2.5	26
5753	Reversible Tumor Progression Induced by a Dexamethasone Course for Severe COVID-19 during Immune Checkpoint Inhibitor Treatment. <i>Diagnostics</i> , 2022, 12, 1933.	1.3	1
5755	Coagulopathy in COVID-19 and anticoagulation clinical trials. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101377.	0.7	3
5756	Glucocorticoid-Induced Hyperglycemia Including Dexamethasone-Associated Hyperglycemia in COVID-19 Infection: A Systematic Review. <i>Endocrine Practice</i> , 2022, 28, 1166-1177.	1.1	13
5757	Herpes Simplex Virus 1 (HSV-1) Reactivation in Critically Ill COVID-19 Patients: A Brief Narrative Review. <i>Infectious Diseases and Therapy</i> , 2022, 11, 1779-1791.	1.8	16
5758	Dedicated team to ambulatory care for patients with COVID-19 requiring oxygen: Low rate of hospital readmission. <i>International Journal of Infectious Diseases</i> , 2022, 123, 92-96.	1.5	4
5759	Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2022, 17, e0271807.	1.1	10
5760	Is There Any Correlation between Baseline Serum Cortisol Levels and Disease Severity in PCR-Positive COVID-19 Patients with and without Diabetes Mellitus?. <i>Vaccines</i> , 2022, 10, 1361.	2.1	0

#	ARTICLE	IF	CITATIONS
5761	Role of aging in Bloodâ€“Brain Barrier dysfunction and susceptibility to SARS-CoV-2 infection: impacts on neurological symptoms of COVID-19. <i>Fluids and Barriers of the CNS</i> , 2022, 19, .	2.4	10
5762	Natriuretic peptide receptor-C mediates the inhibitory effect of atrial natriuretic peptide on neutrophil recruitment to the lung during acute lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 323, L438-L449.	1.3	2
5763	Combination therapy with remdesivir and immunomodulators improves respiratory status in COVIDâ€“19: A retrospective study. <i>Journal of Medical Virology</i> , 2022, 94, 5702-5712.	2.5	7
5764	COVID-19-associated pulmonary aspergillosis is associated with increased in-hospital mortality and prolonged SARS-CoV-2 viral shedding. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 2617-2625.	0.8	9
5766	Effects of mild obesity on outcomes in Japanese patients with COVID-19: a nationwide consortium to investigate COVID-19 host genetics. <i>Nutrition and Diabetes</i> , 2022, 12, .	1.5	10
5767	Coronavirus Disease-2019 and Implications on the Liver. <i>Clinics in Liver Disease</i> , 2023, 27, 27-45.	1.0	7
5768	Remdesivir in kidney transplant patients with SARS-CoV-2 pneumonia. <i>Nefrologia</i> , 2022, 42, 311-317.	0.2	2
5769	Whether Early Steroid dose is associated with lower mortality in COVID-19 critically ill Patients- An exploratory chart review. <i>Recent Advances in Anti-Infective Drug Discovery</i> , 2022, 17, .	0.4	1
5770	Tracing, Tracking and Treating COVID-19 Associated Rhino-Orbito Cerebral Mucormycosis (ROCM). <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 0, , .	0.3	0
5771	Comparison between the first and second COVID-19 waves in Internal Medicine wards in Milan, Italy: a retrospective observational study. <i>Internal and Emergency Medicine</i> , 2022, 17, 2219-2228.	1.0	7
5773	Should RECOVERY have used response adaptive randomisation? Evidence from a simulation study. <i>BMC Medical Research Methodology</i> , 2022, 22, .	1.4	2
5774	Severity of maternal SARS-CoV-2 infection and perinatal outcomes of women admitted to hospital during the omicron variant dominant period using UK Obstetric Surveillance System data: prospective, national cohort study. , 2022, 1, e000190.		14
5775	Epidemiological profile of COVID-19 in the French overseas department Mayotte, 2020 to 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	1
5776	Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents. <i>Lancet Infectious Diseases</i> , The, 2023, 23, e22-e33.	4.6	38
5778	Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	17
5779	Post COVID-19 Infection Psychosis: Could SARS-CoV-2 Virus Infection Be a Neuropsychiatric Condition That Triggers Psychotic Disorders? â€“ A Case-Based Short Review. <i>Infection and Drug Resistance</i> , 0, Volume 15, 4697-4705.	1.1	13
5780	Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1456-1468.	0.8	10
5781	ARDS in the time of corona: context and perspective. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 323, L431-L437.	1.3	2

#	ARTICLE	IF	CITATIONS
5782	Lidocaine reinforces the anti-inflammatory action of dexamethasone on myeloid and epithelial cells activated by inflammatory cytokines or SARS-CoV-2 infection. <i>Biomedical Journal</i> , 2022, , .	1.4	3
5783	The Low Expression of Fc-Gamma Receptor III (CD16) and High Expression of Fc-Gamma Receptor I (CD64) on Neutrophil Granulocytes Mark Severe COVID-19 Pneumonia. <i>Diagnostics</i> , 2022, 12, 2010.	1.3	1
5784	Identifying inhibitors of NSP16-NSP10 of SARS-CoV-2 from large databases. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 7045-7054.	2.0	2
5785	Strongyloidiasis Hyperinfection Syndrome in COVID-19 Positive Migrants Treated with Corticosteroids. <i>Journal of Immigrant and Minority Health</i> , 2022, 24, 1431-1434.	0.8	5
5786	Characteristics and treatment of hospitalized pregnant women with COVID-19. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2022, 4, 100715.	1.3	8
5787	Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
5788	The Pharmacist's Role in Managing COVID-19 in Chronic Kidney Disease Patients: A Review of Existing Strategies and Future Implications. <i>Pharmacy (Basel, Switzerland)</i> , 2022, 10, 94.	0.6	1
5789	Screening for strongyloidiasis in Spain in the context of the SARS-CoV-2 pandemic: Results of a survey on diagnosis and treatment. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2022, , .	0.2	4
5790	Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients. <i>Transfusion</i> , 2022, 62, 1997-2011.	0.8	7
5791	Predictors of the Outcomes Following the Tocilizumab Treatment for Severe COVID-19. <i>Cureus</i> , 2022, , .	0.2	1
5793	Reduction in risk of death among patients admitted with COVID-19 between first and second epidemic waves in New York City. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	1
5794	Care of the Seriously Ill Patient with SARS CoV-2. <i>Medical Clinics of North America</i> , 2022, , .	1.1	1
5796	Comparative Effectiveness of Dexamethasone in Hospitalized COVID-19 Patients in the United States. <i>Advances in Therapy</i> , 2022, 39, 4723-4741.	1.3	1
5797	I've looked at gut from both sides now: Gastrointestinal tract involvement in the pathogenesis of SARS-CoV-2 and HIV/SIV infections. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
5798	Vitamin D Status and Mortality from SARS CoV-2: A Prospective Study of Unvaccinated Caucasian Adults. <i>Nutrients</i> , 2022, 14, 3252.	1.7	5
5799	An Uncommon Cause of Acute Pancreatitis in a Patient With COVID-19. <i>Cureus</i> , 2022, , .	0.2	1
5800	Bipolar type I diagnosis after a manic episode secondary to SARS-CoV-2 infection: A case report. <i>Medicine (United States)</i> , 2022, 101, e29633.	0.4	2
5801	Immunomodulatory therapies for COVID-19. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3

#	ARTICLE	IF	CITATIONS
5802	Clinical Outcomes and Severity of Acute Respiratory Distress Syndrome in 1154 COVID-19 Patients: An Experience Multicenter Retrospective Cohort Study. <i>Covid</i> , 2022, 2, 1102-1115.	0.7	6
5803	Development of a novel score model to predict hyperinflammation in COVID-19 as a forecast of optimal steroid administration timing. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
5804	Severe <sc>SARSâ€CoV</sc> â€2 infection in a 32â€week pregnant woman treated with Remdesivirâ€Dexamethasone combination therapy: A case report. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	3
5805	Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	76
5806	An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves. <i>Cancers</i> , 2022, 14, 3931.	1.7	2
5808	Cryptococcal Pneumonia: An Unusual Complication in a COVID-19 Patient. <i>Diagnostics</i> , 2022, 12, 1944.	1.3	4
5809	Authorization of COVID-19 clinical trials: lessons from 2 years of experience of a national competent authority. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
5810	Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
5812	Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2023, 76, e82-e89.	2.9	2
5814	Burden of Hyperglycemia in Patients Receiving Corticosteroids for Severe COVID-19. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2022, 6, 484-487.	1.2	4
5815	Unquantifiably low aldosterone concentrations are prevalent in hospitalised COVID-19 patients but may not be revealed by chemiluminescent immunoassay. <i>Endocrine Connections</i> , 2022, , .	0.8	2
5816	Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19. <i>The Lancet Digital Health</i> , 2022, 4, e705-e716.	5.9	11
5817	Early steroids and ventilator-associated pneumonia in COVID-19-related ARDS. <i>Critical Care</i> , 2022, 26, .	2.5	19
5818	Impacts of the COVIDâ€19 pandemic on pharmaceuticals in wastewater treated for beneficial reuse: Two case studies in central Pennsylvania. <i>Journal of Environmental Quality</i> , 2022, 51, 1066-1082.	1.0	11
5819	Brain-Lung Crosstalk: Management of Concomitant Severe Acute Brain Injury and Acute Respiratory Distress Syndrome. <i>Current Treatment Options in Neurology</i> , 2022, 24, 383-408.	0.7	7
5822	The Outcome of High-Dose Corticosteroid Treatment Among Coronavirus Disease 2019 Patients. <i>Infectious Diseases in Clinical Practice</i> , 2022, 30, .	0.1	0
5823	Soluble RAGE as a Prognostic Marker of Worsening in Patients Admitted to the ICU for COVID-19 Pneumonia: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 4571.	1.0	0
5824	Two Years into the COVID-19 Pandemic: Lessons Learned. <i>ACS Infectious Diseases</i> , 2022, 8, 1758-1814.	1.8	47

#	ARTICLE	IF	CITATIONS
5825	COVID-19 and hospital management costs: the Italian experience. BMC Health Services Research, 2022, 22, .	0.9	8
5826	Outcomes of COVID-19 Infections in children: A single-center retrospective study. Pediatric Pulmonology, 2022, 57, 2533-2539.	1.0	3
5827	The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	5
5828	COVID-19-associated pulmonary aspergillosis: an underdiagnosed or overtreated infection?. Current Opinion in Critical Care, 2022, 28, 470-479.	1.6	13
5829	Is hemolysis a novel therapeutic target in COVID-19?. Frontiers in Immunology, 0, 13, .	2.2	1
5830	Covid-19 and alcohol associated liver disease. Digestive and Liver Disease, 2022, 54, 1459-1468.	0.4	20
5831	A Care Step Pathway for the Diagnosis and Treatment of COVID-19-associated Invasive Fungal Infections in the Intensive Care Unit. Critical Care Nurse, 2022, 42, 36-46.	0.5	2
5832	Effect of Insulin Delivery Strategies on Glycemic Control and Nursing Exposure in Critically Ill Patients With COVID-19: An Observational Cohort Study. Diabetes Care, 0, , .	4.3	0
5833	No Impact of Corticosteroid Use During the Acute Phase on Persistent Symptoms Post-COVID-19. International Journal of General Medicine, 0, Volume 15, 6645-6651.	0.8	2
5834	Optimal COVID-19 therapeutic candidate discovery using the CANDO platform. Frontiers in Pharmacology, 0, 13, .	1.6	4
5835	Adrenal Gland Function and Dysfunction During COVID-19. Hormone and Metabolic Research, 2022, 54, 532-539.	0.7	8
5836	Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis. Pharmacological Research, 2022, 184, 106412.	3.1	23
5837	Comparison between first and second wave of COVID-19 outbreak in older people: the COPE multicentre European observational cohort study. European Journal of Public Health, 2022, 32, 807-812.	0.1	6
5838	What Next? New Drugs, Old Drugs, and New Challenges in Choosing Treatments for Covid-19. , 2022, 1, .		0
5839	Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. Annals of the Rheumatic Diseases, 2022, 81, 1742-1749.	0.5	26
5841	The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2878-2888.	2.0	9
5842	Extracorporeal membrane oxygenation for COVID-19: An evolving experience through multiple waves. Artificial Organs, 2022, 46, 2257-2265.	1.0	10
5843	Ventricular Tachycardia or Fibrillation Storm in Coronavirus Disease. Case Reports in Cardiology, 2022, 2022, 1-9.	0.1	3

#	ARTICLE	IF	CITATIONS
5844	Reply to respiratory failure due to neuro-COVID by Finsterer J et al. Journal of Clinical Neuroscience, 2022, , .	0.8	0
5845	Supportive Care in Patients with Critical COVID-19. Infectious Disease Clinics of North America, 2022, , .	1.9	0
5846	Impact of the COVID-19 pandemic on the kidney community: lessons learned and future directions. Nature Reviews Nephrology, 2022, 18, 724-737.	4.1	33
5847	Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study. PLoS ONE, 2022, 17, e0273340.	1.1	12
5848	Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19). Journal of Intensive Medicine, 2022, 2, 199-222.	0.8	3
5850	Does autonomous macrophage-driven inflammation promote alveolar damage in COVID-19?. European Respiratory Journal, 2022, 60, 2201521.	3.1	7
5851	Pneumocystis jirovecii Pneumonia Associated with COVID-19 in Patients with Interstitial Pneumonia. Medicina (Lithuania), 2022, 58, 1151.	0.8	5
5852	Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders. Best Practice and Research in Clinical Haematology, 2022, 35, 101375.	0.7	0
5853	Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization. Cell Reports, 2022, 40, 111214.	2.9	24
5854	The Characteristics of Patients with Severe COVID-19 Pneumonia Treated with Direct Hemoperfusion Using Polymyxin B-Immobilized Fiber Column (PMX-DHP). Infection and Drug Resistance, 0, Volume 15, 4819-4828.	1.1	0
5855	Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis. Stroke, 2022, 53, 3410-3418.	1.0	4
5856	Expression Pattern of Inflammatory and Anti-Inflammatory Cytokines and Key Differential Transcription Factors in Peripheral Blood Mononuclear Cells of Iranian Coronavirus Disease 2019 Patients with Different Disease Severity. Viral Immunology, 2022, 35, 474-482.	0.6	2
5857	Comparison between the persistence of post COVID-19 symptoms on critical patients requiring invasive mechanical ventilation and non-critical patients. PLoS ONE, 2022, 17, e0273041.	1.1	8
5858	Is the Omicron variant truly less virulent in solid organ transplant recipients?. Transplant Infectious Disease, 2022, 24, .	0.7	17
5859	Linear regression model and least square method for experimental identification of AMBU bag in simple ventilator. International Journal of Intelligent Unmanned Systems, 2023, 11, 378-395.	0.6	4
5860	Association between HLA-C alleles and COVID-19 severity in a pilot study with a Spanish Mediterranean Caucasian cohort. PLoS ONE, 2022, 17, e0272867.	1.1	6
5861	Comparative risk assessment of COVID-19 associated mucormycosis and aspergillosis: A systematic review. Health Science Reports, 2022, 5, .	0.6	3
5862	Overweight and obesity are not associated with worse clinical outcomes in COVID-19 patients treated with fixed-dose 6%mg dexamethasone. International Journal of Obesity, 2022, 46, 2000-2005.	1.6	2

#	ARTICLE	IF	CITATIONS
5863	Incidence and risk factors of COVID-19 associated pneumothorax. PLoS ONE, 2022, 17, e0271964.	1.1	13
5864	Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19. American Journal of Respiratory and Critical Care Medicine, 2023, 207, 38-49.	2.5	12
5865	Effect of corticosteroid therapy on mortality in COVID-19 patients: A systematic review and meta-analysis. Reviews in Medical Virology, 2022, 32, .	3.9	13
5866	Estimating incidence of venous thromboembolism in COVID-19: Methodological considerations. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	1.0	3
5867	Pathogenic role of cytokines in COVID-19, its association with contributing co-morbidities and possible therapeutic regimens. Inflammopharmacology, 2022, 30, 1503-1516.	1.9	3
5868	Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry. ACR Open Rheumatology, 2022, 4, 948-953.	0.9	4
5869	COVID-19 and Fungal infections: a double debacle. Microbes and Infection, 2022, 24, 105039.	1.0	10
5870	Nonproductive exposure of PBMCs to SARS-CoV-2 induces cell-intrinsic innate immune responses. Molecular Systems Biology, 2022, 18, .	3.2	7
5871	Nanotechnology-based strategies against SARS-CoV-2 variants. Nature Nanotechnology, 2022, 17, 1027-1037.	15.6	63
5872	Influence of radiologic pattern and the presence of Diffuse Parenchymal Lung Disease on outcome in ventilated patients with COVID 19 pneumonia: impact on prognosis. Internal Medicine Journal, 0, , .	0.5	1
5873	Host and microbiome features of secondary infections in lethal covid-19. IScience, 2022, 25, 104926.	1.9	10
5874	A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.. Biomedicine and Pharmacotherapy, 2022, 153, 113499.	2.5	12
5875	Fatal acute respiratory distress syndrome caused by blastomycosis after recent orthotopic liver transplantation in a non-endemic area. Medical Mycology Case Reports, 2022, 37, 37-40.	0.7	2
5876	Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. International Immunopharmacology, 2022, 111, 109161.	1.7	9
5877	Severe coronavirus disease 2019 in a patient with TAFRO syndrome: A case report. Clinical Infection in Practice, 2022, 16, 100158.	0.2	2
5878	Consequences of COVID-19 on the cardiovascular and renal systems. Sleep Medicine, 2022, 100, 31-38.	0.8	2
5879	Development and validation of an early warning model for hospitalized COVID-19 patients: a multi-center retrospective cohort study. Intensive Care Medicine Experimental, 2022, 10, .	0.9	1
5880	SARS-CoV-2 and COVID-19: A Narrative Review. , 0, 79, .		9

#	ARTICLE	IF	CITATIONS
5881	Clinical features of COVID-19 patients with rebound phenomenon after corticosteroid therapy. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001332.	1.2	7
5882	A Pilot Trial of Thymalfasin (Thymosin- α 1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection. <i>Journal of Infectious Diseases</i> , 2023, 227, 226-235.	1.9	7
5883	Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. <i>Lancet</i> , The, 2022, 400, 1145-1156.	6.3	129
5884	Symptom management in people dying with COVID-19: multinational observational study. <i>BMJ Supportive and Palliative Care</i> , 2022, 12, 439-447.	0.8	1
5885	The Musculoskeletal Manifestations of COVID-19: A Narrative Review Article. <i>Cureus</i> , 2022, , .	0.2	2
5887	Absence of Mortality Differences Between the First and Second COVID-19 Waves in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2022, 7, 2617-2629.	0.4	3
5888	Intravenous immunoglobulin (IVIg) therapy in hospitalised adult COVID-19 patients: A systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , 2022, 32, .	3.9	13
5890	A BRIEF DESCRIPTION OF COVID-19 PULMONARY VIRAL INFECTION AND REPURPOSING OF DRUGS FOR ITS TREATMENT. <i>International Journal of Applied Pharmaceutics</i> , 0, , 22-31.	0.3	1
5891	COVID-19 Therapeutics: Improveâ€”Adaptâ€”Learn. <i>Journal of Clinical Medicine</i> , 2022, 11, 5312.	1.0	0
5892	Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis. <i>Future Microbiology</i> , 2022, 17, 1217-1229.	1.0	0
5893	Cystatin C is associated with adverse COVID-19 outcomes in diverse populations. <i>IScience</i> , 2022, 25, 105040.	1.9	2
5894	COVID-19-associated disseminated mucormycosis: An autopsy case report. <i>World Journal of Clinical Cases</i> , 0, 10, 10358-10365.	0.3	1
5895	Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study. <i>Journal of Infection and Public Health</i> , 2022, 15, 1061-1064.	1.9	0
5896	Two Cases of Lassa Fever Successfully Treated with Ribavirin and Adjunct Dexamethasone for Concomitant Infections. <i>Emerging Infectious Diseases</i> , 2022, 28, 2060-2063.	2.0	1
5897	The hypothalamus-pituitary-adrenal axis in sepsis- and hyperinflammation-induced critical illness: Gaps in current knowledge and future translational research directions. <i>EBioMedicine</i> , 2022, 84, 104284.	2.7	16
5898	TEMPOL inhibits SARS-CoV-2 replication and development of lung disease in the Syrian hamster model. <i>IScience</i> , 2022, 25, 105074.	1.9	5
5899	COVID-19: Vaccines and therapeutics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 75, 128987.	1.0	4
5900	COVID-19 in patients with B cell immune deficiency. <i>Journal of Immunological Methods</i> , 2022, 510, 113351.	0.6	1

#	ARTICLE	IF	CITATIONS
5901	Long-term cognitive performance and its relation to anti-inflammatory therapy in a cohort of survivors of severe COVID-19. <i>Brain, Behavior, & Immunity - Health</i> , 2022, 25, 100513.	1.3	10
5902	Lung-function trajectories in COVID-19 survivors after discharge: A two-year longitudinal cohort study. <i>EClinicalMedicine</i> , 2022, 54, 101668.	3.2	25
5903	Effect of combining anticoagulant and glucocorticoid therapy on mortality in patients with severe COVID-19. <i>European Journal of Inflammation</i> , 2022, 20, 1721727X2211009.	0.2	0
5904	Optimization of Ventilation Therapy Prioritization Strategies Among Patients with COVID-19: Lessons Learned from Real-World Data of Nearly 600,000 Hospitalized Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
5905	Commentary: Fulminant fungal endogenous endophthalmitis following COVID-19. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 3143.	0.5	0
5906	Pulmonary aspergillosis occurred during the acute phase of COVID-19 in a patient on hemodialysis. <i>Nihon Toseki Igakukai Zasshi</i> , 2022, 55, 467-473.	0.2	0
5907	Efficacy of intravenous vitamin C in management of moderate and severe COVID-19: A double blind randomized placebo controlled trial. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 4758.	0.3	2
5908	Unfolding issues of immunity against SARS-CoV-2. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 4878.	0.3	0
5909	Acute-onset respiratory signs in a Labrador Retriever with a positive SARS-CoV-2 rapid antigen test and infection confirmed by RT-PCR analysis: a case report. <i>Journal of Veterinary Science</i> , 0, 23, .	0.5	0
5910	Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2022, 16, 117954842211193.	0.5	5
5911	Circadian Rhythm, Sleep, and Immune Response and the Fight against COVID-19. <i>Oman Medical Journal</i> , 2023, 38, e477-e477.	0.3	2
5912	COVID-19 Impact on Host at Pathophysiological and Cellular Level. , 2022, , 67-111.		1
5913	Pre-hospital Management of COVID-19: Looking for a Future Perspective. , 2022, , 395-419.		0
5914	Medications and Supplements Prescription Patterns during COVID 19 Pandemic in Yemen: A Questionnaire-Based Study. <i>Fortune Journal of Health Sciences</i> , 2022, 05, .	0.1	1
5915	COVID-19 Pandemic and Contamination Response. , 2022, , 19-26.		0
5916	Clinical characteristics and laboratory parameters associated with the risk of severe COVID-19 in patients from two hospitals in Northeast Brazil. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 0, 55, .	0.4	1
5917	Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients. <i>Anais Da Academia Brasileira De Ciencias</i> , 2022, , .	0.3	6
5918	COVID-19 Vaccine Protection Against Mortality in Hospitalized Patients with Oxygen Requirement: A Multicontinental Retrospective Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
5919	Neuropathogenesis and Neurological Manifestations of SARS-CoV-2. , 2022, , 85-100.		0
5920	Methylprednisolone pulse therapy for critically ill patients with coronavirus disease 2019: A retrospective observational study. <i>Acute Medicine & Surgery</i> , 2022, 9, .	0.5	3
5921	COVID-19 in a mosaic trisomy 13 patient with polycystic kidney disease. <i>SAGE Open Medical Case Reports</i> , 2022, 10, 2050313X2211187.	0.2	1
5922	Pharmacotherapeutics of SARS-CoV-2. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 4892.	0.3	0
5923	The Assessment of the Efficacy and Safety of Favipiravir for Patients with SARS-CoV-2 Infection: A Multicenter Non-randomized, Uncontrolled Single-arm Prospective Study. <i>Internal Medicine</i> , 2022, , .	0.3	1
5924	Weaning, Tracheostomy, and Chest Physiotherapy. , 2022, , 71-81.		0
5925	Antibiotics, Antiretroviral, Corticosteroids, Other Therapies Against SARS-CoV-2. , 2022, , 281-293.		0
5926	Mortality and prognostic factors in hospitalized COVID-19 patients with cancer: an analysis from a large healthcare system in the United States. <i>Annals of Translational Medicine</i> , 2022, 10, 1090-1090.	0.7	4
5927	Is Longer Duration or Higher Dose of Steroid Use Effective in Critical COVID-19 Patients: An Area of Uncertainty. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	0
5928	Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2. <i>International Journal of Biological Sciences</i> , 2022, 18, 5591-5606.	2.6	1
5929	Dexamethasone, but Not Vitamin D or A, Dampens the Inflammatory Neutrophil Response to Protect At-risk COVID-19 Patients. <i>Immune Network</i> , 2022, 22, .	1.6	3
5930	COVID-19 Infection: The Virus and Its Origin, the Variants, the Immune Defense, the Multiorgan Autoimmune Reactions, and the Targeted Treatments. <i>Advances in Infectious Diseases</i> , 2022, 12, 568-631.	0.0	1
5931	Uncontrolled diabetes mellitus exacerbated by COVID-19-induced inflammation is the risk factor for COVID-19-associated rhino-orbito-cerebral mucormycosis: A matched pair case-control study. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 3096.	0.5	5
5932	Biomarkers of Sepsis and a Focus on PCSK9. <i>Biomarkers in Disease</i> , 2022, , 1-28.	0.0	0
5933	COVID-19-Associated Acute Kidney Injury. <i>Nephrology Self-assessment Program: NephSAP</i> , 2022, 21, 94-99.	3.0	0
5934	Timeline of Oxygen Demand in Patients with COVID-19 Pneumonia. <i>Internal Medicine</i> , 2023, , .	0.3	0
5935	Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial. <i>CMAJ Open</i> , 2022, 10, E807-E817.	1.1	2
5936	Seronegative immunity to SARS-CoV-2: a case study. <i>Allergy, Asthma and Clinical Immunology</i> , 2022, 18, .	0.9	0

#	ARTICLE	IF	CITATIONS
5937	The The use of corticosteroid therapy for COVID-19 patients: an evidence-based overview. <i>Revista Ciencias Em Saude</i> , 2022, 12, 4-11.	0.0	0
5938	Severity of COVID-19 among solid organ transplant recipients in Canada, 2020â€“2021: a prospective, multicentre cohort study. <i>Cmaj</i> , 2022, 194, E1155-E1163.	0.9	11
5939	Strategies for Cardio-Oncology Care During the COVID-19 Pandemic. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2022, 24, 137-153.	0.4	2
5940	Bismuth subsalicylate as potential treatment for Covid-19 pneumonia: A case series report. <i>Frontiers in Drug Discovery</i> , 0, 2, .	1.1	0
5941	Outcomes of COVID-19 Patients Admitted to the Intermediate Respiratory Care Unit: Non-Invasive Respiratory Therapy in a Sequential Protocol. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10772.	1.2	0
5942	Lung Transplantation in Patients With COVID-19-The Early National Experience. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2023, 35, 822-830.	0.4	4
5943	Does Long-term Oxygen Therapy and Noninvasive Ventilation Predispose Rhino-orbital-cerebral Mucormycosis in COVID-19 Patients?. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 1063-1064.	0.3	0
5944	Changing Critical Care Patterns and Associated Outcomes in Mechanically Ventilated Severe COVID-19 Patients in Different Time Periods: An Explanatory Study from Central India. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 1022-1030.	0.3	1
5945	Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. <i>Nature</i> , 2022, 611, 139-147.	13.7	69
5946	In-Hospital Hyperglycemia Is Associated With Worse Outcomes in Patients Admitted With COVID-19. <i>Diabetes Care</i> , 2022, 45, 2683-2688.	4.3	9
5947	A narrative review of COVID-19-related acute respiratory distress syndrome (CARDS): â€œatypicalâ€•or â€œatypicalâ€•ARDS?. <i>Annals of Translational Medicine</i> , 2022, 10, 908-908.	0.7	4
5948	Early COVID-19 respiratory risk stratification using machine learning. <i>Trauma Surgery and Acute Care Open</i> , 2022, 7, e000892.	0.8	0
5949	Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection. <i>Herald of the Russian Academy of Sciences</i> , 2022, 92, 430-436.	0.2	0
5950	Variation in the risk of death due to COVIDâ€“19: An international multicenter cohort study of hospitalized adults. <i>Journal of Hospital Medicine</i> , 2022, 17, 793-802.	0.7	2
5951	COVID-19: Opportunities to Improve Prognosis. <i>Herald of the Russian Academy of Sciences</i> , 2022, 92, 404-411.	0.2	1
5952	Latent profile analysis identified COVID-19 ARDS phenotypes in Thai patients: Research protocol and preliminary report. <i>Clinical Critical Care</i> , 2022, , .	0.0	0
5953	Risk factors associated with development of coinfection in critically ill patients with COVID-19. <i>Acute and Critical Care</i> , 2022, 37, 312-321.	0.6	3
5954	The fourth wave: vaccination status and intensive care unit mortality at a large hospital system in New York City. <i>Acute and Critical Care</i> , 2022, 37, 339-346.	0.6	4

#	ARTICLE	IF	CITATIONS
5955	Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice. ACS Omega, 2022, 7, 31935-31944.	1.6	11
5956	The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19. Annals of Internal Medicine, 2022, 175, 1401-1410.	2.0	32
5957	A computational approach to drug repurposing using graph neural networks. Computers in Biology and Medicine, 2022, 150, 105992.	3.9	12
5958	Clinical characteristics analysis of COVID-19 patients from the first significant community outbreak by SARS-CoV-2 variant B.1.1.7 in Taiwan as experienced from a single northern medical center. Journal of Microbiology, Immunology and Infection, 2022, 55, 1036-1043.	1.5	7
5959	Outpatient Management of COVID-19: A Primer for the Dermatologist. Current Dermatology Reports, 2022, 11, 318-327.	1.1	1
5960	COVID-19-Related ARDS: Key Mechanistic Features and Treatments. Journal of Clinical Medicine, 2022, 11, 4896.	1.0	15
5961	Development and validation of automated computer-aided risk scores to predict in-hospital mortality for emergency medical admissions with COVID-19: a retrospective cohort development and validation study. BMJ Open, 2022, 12, e050274.	0.8	1
5962	COVID-19 and Kidney Transplantation. Nephrology Self-assessment Program: NephSAP, 2022, 21, 238-245.	3.0	0
5963	Distribution of Pathogens and Predictive Values of Biomarkers of Inflammatory Response at ICU Admission on Outcomes of Critically Ill COVID-19 Patients with Bacterial Superinfections—Observations from National COVID-19 Hospital in Croatia. Diagnostics, 2022, 12, 2069.	1.3	3
5964	Succint review on biological and clinical aspects of Coronavirus disease 2019 (COVID-19)., 2022, 125, 356-365.		0
5965	Mucormycosis in pre- and COVID-19 and COVID-19 era: A study of prevalence, risk factors and clinical features. Laryngoscope Investigative Otolaryngology, 2022, 7, 1343-1350.	0.6	10
5966	Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. European Journal of Clinical Pharmacology, 2022, 78, 1813-1821.	0.8	3
5967	Could Endogenous Glucocorticoids Influence SARS-CoV-2 Infectivity?. Cells, 2022, 11, 2955.	1.8	3
5969	What progress has been made in treatment of immunocompromised COVID-19 patients?. Infectious Diseases Now, 2022, 52, S12-S15.	0.7	2
5970	Association of mortality and early tracheostomy in patients with COVID-19: a retrospective analysis. Scientific Reports, 2022, 12, .	1.6	4
5971	Safety and efficacy of anti-SARS-CoV-2 monoclonal antibodies in pregnancy. Expert Opinion on Drug Safety, 2022, 21, 1137-1141.	1.0	2
5972	Antidepressant use and risk of intubation or death in hospitalized patients with COVID-19: A retrospective cohort study of clinical effectiveness. Frontiers in Psychiatry, 0, 13, .	1.3	2
5973	COVID-19 Related Myocarditis in Adults: A Systematic Review of Case Reports. Journal of Clinical Medicine, 2022, 11, 5519.	1.0	12

#	ARTICLE	IF	CITATIONS
5975	Mortality over time among COVID-19 patients hospitalized during the first surge of the pandemic: A large cohort study. PLoS ONE, 2022, 17, e0275212.	1.1	6
5976	Applicability of Vasopressor Trials in Adult Critical Care: A Prospective Multicentre Meta-Epidemiologic Cohort Study. Clinical Epidemiology, 0, Volume 14, 1087-1098.	1.5	1
5977	Relation of Pulmonary Diffusing Capacity Decline to HRCT and VQ SPECT/CT Findings at Early Follow-Up after COVID-19: A Prospective Cohort Study (The SECURe Study). Journal of Clinical Medicine, 2022, 11, 5687.	1.0	4
5978	Neutrophil-Lymphocyte Ratio Predicting Case Severity in SARS-CoV-2 Infection: A Review. Cureus, 2022, , .	0.2	0
5979	National priority setting partnership using a Delphi consensus process to develop neonatal research questions suitable for practice-changing randomised trials in the United Kingdom. BMJ Open, 2022, 12, e061330.	0.8	2
5980	Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: a nested case-control study. Current Medical Research and Opinion, 0, , 1-15.	0.9	10
5981	Cytokine Storm and Neuropathological Alterations in Patients with Neurological Manifestations of COVID-19. Current Alzheimer Research, 2022, 19, 641-657.	0.7	11
5982	The RECOVERY trial: An analysis and reflection two years on. European Journal of Internal Medicine, 2022, 105, 111-112.	1.0	3
5983	Optimising Precision and Power by Machine Learning in Randomised Trials with Ordinal and Time-to-Event Outcomes with an Application to COVID-19. Journal of the Royal Statistical Society Series A: Statistics in Society, 2022, 185, 2156-2178.	0.6	3
5984	Assessment of the effectiveness of tocilizumab on mortality and progression to mechanical ventilation or intensive care in patients with COVID-19 admitted to a tertiary hospital. European Journal of Hospital Pharmacy, 0, , ejhpharm-2022-003366.	0.5	1
5985	Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes. Diabetes Care, 2022, 45, 2189-2201.	4.3	9
5986	Adult Asthma Management in the Emergency Department during COVID-19 Pandemic: An Expert Opinion Survey. Applied Sciences (Switzerland), 2022, 12, 9460.	1.3	0
5987	Safety and effectiveness of RBD-specific polyclonal equine F(ab ²) fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study. PLoS ONE, 2022, 17, e0274796.	1.1	0
5988	Audio-Vestibular Side Effects of Drugs and Vaccines in Treatment of COVID-19. , 0, , .		0
5989	Impact of hypertension on long-term humoral and cellular response to SARS-CoV-2 infection. Frontiers in Immunology, 0, 13, .	2.2	4
5990	Steroids in the acutely ill: Evolving recommendations and practice. Cleveland Clinic Journal of Medicine, 2022, 89, 505-511.	0.6	2
5991	Race, Ethnicity, and Health Disparities in US Children With COVID-19: A Review of the Evidence and Recommendations for the Future. Journal of the Pediatric Infectious Diseases Society, 2022, 11, S132-S140.	0.6	13
5992	Glucocorticoids mediate transcriptome-wide alternative polyadenylation: Potential mechanistic and clinical implications. Clinical and Translational Science, 2022, 15, 2758-2771.	1.5	1

#	ARTICLE	IF	CITATIONS
5993	Correlating drug prescriptions with prognosis in severe COVID-19: first step towards resource management. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, .	1.5	1
5994	Immunophenotypes of anti-SARS-CoV-2 responses associated with fatal COVID-19. <i>ERJ Open Research</i> , 0, , 00216-2022.	1.1	0
5995	Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial. <i>Trials</i> , 2022, 23, .	0.7	0
5997	Impact of Early Limitation of Therapeutic Effort in Elderly COVID-19 Patients Admitted to the Intensive Care Unit—A Cohort Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 1501.	1.1	2
5998	In Vivo G-CSF treatment activates the GR-SOCS1 axis to suppress IFN- β secretion by natural killer cells. <i>Cell Reports</i> , 2022, 40, 111342.	2.9	3
5999	External validation of a prediction model for CPAP failure in COVID-19 patients with severe pneumonitis. <i>Critical Care</i> , 2022, 26, .	2.5	0
6001	A case of COVID-19-associated fulminant myocarditis successfully treated with mechanical circulatory support. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	7
6002	Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy. <i>Cancers</i> , 2022, 14, 4720.	1.7	9
6003	Endocrine Disorders and COVID-19. <i>Annual Review of Medicine</i> , 2023, 74, 75-88.	5.0	7
6004	Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022). <i>Transplantation and Cellular Therapy</i> , 2022, 28, 810-821.	0.6	9
6005	Transcriptomic clustering of critically ill COVID-19 patients. <i>European Respiratory Journal</i> , 2023, 61, 2200592.	3.1	8
6006	The COVIDTW study: Clinical predictors of COVID-19 mortality and a novel AI prognostic model using chest X-ray. <i>Journal of the Formosan Medical Association</i> , 2022, , .	0.8	2
6007	Evolution of Care and Outcomes Across Surges in Hospitalized Patients with Coronavirus Disease 2019. <i>American Journal of Medicine</i> , 2022, , .	0.6	0
6008	Obesity and coronavirus disease 2019. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 207-218.	1.0	3
6009	Multiple-site decontamination regimen decreases acquired infection incidence in mechanically ventilated COVID-19 patients. <i>Annals of Intensive Care</i> , 2022, 12, .	2.2	6
6010	Psychotic Symptoms After SARS-CoV-2 Infection. <i>Journal of Nervous and Mental Disease</i> , 2022, 210, 724-726.	0.5	0
6011	A Systematic Review on the Emergence of Omicron Variant and Recent Advancement in Therapies. <i>Vaccines</i> , 2022, 10, 1468.	2.1	7
6012	Assessment of Cardiac, Vascular, and Pulmonary Pathobiology In Vivo During Acute COVID-19. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	0

#	ARTICLE	IF	CITATIONS
6013	A practical update on the management of patients with COVID-19. <i>Clinical Medicine</i> , 2022, 22, 468-474.	0.8	2
6014	Effect of Omega-3 fatty acids supplementation on serum level of C-reactive protein in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	10
6015	Deep RNA sequencing of intensive care unit patients with COVID-19. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
6016	Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. <i>Health Research Policy and Systems</i> , 2022, 20, .	1.1	5
6017	Development and validation of COVID-19 associated candidemia score () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 582 Td (<	1.8	3
6018	Systemic Steroids and the Risk of Vasoocclusive Events in Patients with Sickle Cell Disease. <i>Annals of the American Thoracic Society</i> , 2023, 20, 18-20.	1.5	1
6020	Father-Son COVID-19-associated mucormycosis: Important role of genetic susceptibility in combination with environmental factors. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	2
6021	Mycotic infection as a risk factor for COVID-19: A meta-analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
6022	Coronavirus Disease 2019 (COVID-19) Pandemic across Africa: Current Status of Vaccinations and Implications for the Future. <i>Vaccines</i> , 2022, 10, 1553.	2.1	28
6023	Treatment Outcome with High versus low-to-moderate Dosing of Corticosteroids in Early vis-a-vis Late-onset Hypoxic Cases of COVID-19: A Multicentric Retrospective Cohort Study. <i>IJID Regions</i> , 2023, 7, 31-42.	0.5	0
6024	Untargeted saliva metabolomics by liquid chromatography-Mass spectrometry reveals markers of COVID-19 severity. <i>PLoS ONE</i> , 2022, 17, e0274967.	1.1	12
6025	Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2022, 8, e002587.	1.8	21
6026	Clinical Profile of Patients Admitted With Mucormycosis During the COVID-19 Pandemic in Medicine Emergency of a Tertiary Care Hospital in North India. <i>Cureus</i> , 2022, , .	0.2	2
6027	Temporal Trend of COVID-19 Clinical Severity and the Ethnic/Racial Disparity: A Report from the Maryland Study Group. <i>American Journal of Perinatology</i> , 0, , .	0.6	0
6028	Dupilumab Use Is Associated With Protection From Coronavirus Disease 2019 Mortality: A Retrospective Analysis. <i>Clinical Infectious Diseases</i> , 2023, 76, 148-151.	2.9	9
6029	AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021-2022. <i>Jammi</i> , 2022, 7, 163-169.	0.3	0
6030	Comparative Analysis Of Immunosuppressive Therapy Effectiveness In COVID-19 Patients. <i>Russian Open Medical Journal</i> , 2022, 11, .	0.1	0
6031	Treatment of toxic epidermal necrolysis and concurrent COVID-19-associated hyperinflammatory syndrome with systemic corticosteroids and etanercept. <i>JAAD Case Reports</i> , 2022, 29, 139-141.	0.4	2

#	ARTICLE	IF	CITATIONS
6032	Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study. <i>Trials</i> , 2022, 23, .	0.7	3
6033	Temporal Dynamics of Host Immune Response Associated With Disease Severity and Time to Recovery in Patients Hospitalized for COVID-19. , 2022, 4, e0760.		2
6034	Major haemorrhage: past, present and future. <i>Anaesthesia</i> , 2023, 78, 93-104.	1.8	10
6035	Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management. <i>Pediatric Research</i> , 2023, 93, 1499-1508.	1.1	32
6036	COVID-19 Therapies for inpatients: a review and quality assessment of clinical guidelines. <i>ERJ Open Research</i> , 0, , 00236-2022.	1.1	2
6037	An algorithm to predict the need for invasive mechanical ventilation in hospitalized COVID-19 patients: the experience in Sao Paulo. <i>Acute and Critical Care</i> , 0, , .	0.6	0
6038	Microbiological and Clinical Findings of SARS-CoV-2 Infection after 2 Years of Pandemic: From Lung to Gut Microbiota. <i>Diagnostics</i> , 2022, 12, 2143.	1.3	4
6039	Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review. <i>Life</i> , 2022, 12, 1472.	1.1	6
6040	Venovenous extracorporeal membrane oxygenation support in patients with COVID-19 respiratory failure: A multicenter study. <i>JTCVS Open</i> , 2022, 12, 211-220.	0.2	5
6041	Activity of daily life dependency predicts the risk of mortality in patients with COVID-19 undergoing hemodialysis: a retrospective analysis of a single center with nosocomial outbreak. <i>Renal Replacement Therapy</i> , 2022, 8, .	0.3	1
6042	Effect of Hemadsorption Therapy in Critically Ill Patients with COVID-19 (CYTOCOV-19): A Prospective Randomized Controlled Pilot Trial. <i>Blood Purification</i> , 2023, 52, 183-192.	0.9	10
6043	Effect of remdesivir on mortality rate and clinical status of COVID-19 patients: a systematic review with meta-analysis. <i>Journal of Chemotherapy</i> , 2023, 35, 383-396.	0.7	5
6044	COVID-19 associated diabetes mellitus: A review. <i>World Journal of Diabetes</i> , 2022, 13, 729-737.	1.3	8
6045	Disease-Specific Factors Associated with Readmissions or Mortality After Hospital Discharge in COVID-19 Patients: a Retrospective Cohort Study. <i>Journal of General Internal Medicine</i> , 2022, 37, 3973-3978.	1.3	5
6046	COVID-19 immunopathology: From acute diseases to chronic sequelae. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	24
6047	A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2023, 207, 261-270.	2.5	25
6048	Clinical Course and Outcomes among COVID-19 Patients at the Hospital in Bangkok: A Retrospective Study. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 238.	0.9	0
6049	Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20

#	ARTICLE	IF	CITATIONS
6050	Electronic Health Record-based COVID-19 Interprofessional Case Collaboration. <i>Western Journal of Emergency Medicine</i> , 2022, 23, 789-791.	0.6	0
6051	Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study. <i>Gynecologic Oncology</i> , 2022, 167, 146-151.	0.6	2
6052	Development of an In Vitro Model of SARS-CoV-Induced Acute Lung Injury for Studying New Therapeutic Approaches. <i>Antioxidants</i> , 2022, 11, 1910.	2.2	4
6053	Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID-19 pneumonia. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
6055	Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients. <i>Communications Medicine</i> , 2022, 2, .	1.9	5
6056	Managing two waves of the COVID-19 pandemic in northern emergency departments in Paris: COVIDORG II. <i>Journal Europeen Des Urgences Et De Reanimation</i> , 2022, 34, 70-81.	0.1	0
6058	Secondary respiratory early and late infections in mechanically ventilated patients with COVID-19. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	5
6059	Pragmatic platform trials to improve the outcome of patients with acute kidney injury. <i>Current Opinion in Critical Care</i> , 2022, 28, 622-629.	1.6	0
6060	The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECUREAD registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, 365-381.	1.3	7
6061	Analysis of COVID-19 Pandemic on Supplement Usage and Its Combination with Self-Medication within the State of Arkansas. <i>Journal of Dietary Supplements</i> , 2023, 20, 171-198.	1.4	4
6062	Clinical and Radiological Findings of COVID-19 Pneumonia in Immunodeficient Patients: A Single Center Retrospective Analysis. <i>European Archives of Medical Research</i> , 2022, 38, 220-226.	0.0	1
6063	Modelling metabolic diseases and drug response using stem cells and organoids. <i>Nature Reviews Endocrinology</i> , 2022, 18, 744-759.	4.3	30
6064	A systematic review and meta-analysis of the association between the neutrophil, lymphocyte, and platelet count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio and COVID-19 progression and mortality. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 1187-1202.	1.3	15
6065	Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis. <i>Journal of Neurology</i> , 2023, 270, 1-12.	1.8	6
6066	Mortality rates and epidemiological changes in critically ill Coronavirus Disease 2019 patients after a vaccination program in Brazil. <i>Jornal Brasileiro De Pneumologia</i> , 0, , e20220268.	0.4	1
6067	Prophylactic treatment of <i>Glycyrrhiza glabra</i> mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
6068	Efficacy of Dexamethasone and Methylprednisolone in Hospitalization Outcomes of COVID-19 Patients: A Comparative Retrospective Study. <i>Archives of Clinical Infectious Diseases</i> , 2022, 17, .	0.1	0
6069	Relationship between corticosteroid use and incidence of ventilator-associated pneumonia in COVID-19 patients: a retrospective multicenter study. <i>Critical Care</i> , 2022, 26, .	2.5	11

#	ARTICLE	IF	CITATIONS
6070	FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities. <i>Clinical Drug Investigation</i> , 2022, 42, 949-964.	1.1	1
6071	Effect of Corticosteroids on Mortality and Clinical Cure in Community-Acquired Pneumonia. <i>Chest</i> , 2023, 163, 484-497.	0.4	29
6072	COVID-19 outcomes in sickle cell disease and sickle cell trait. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101382.	0.7	1
6073	Demographic and clinical profile of patients suffering prolonged severe hypoxia in COVID-19. <i>Expert Review of Respiratory Medicine</i> , 0, , 1-5.	1.0	0
6074	Computer clinical decision support that automates personalized clinical care: a challenging but needed healthcare delivery strategy. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2022, 30, 178-194.	2.2	5
6075	Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial. <i>Trials</i> , 2022, 23, .	0.7	1
6076	Guidelines for the prevention and management of children and adolescents with COVID-19. <i>European Journal of Pediatrics</i> , 2022, 181, 4019-4037.	1.3	10
6077	Rethinking sepsis after a two-year battle with COVID-19. , 2022, 19, 1317-1318.		5
6078	The effect of immunosuppressive therapy on the development of ventilator-associated pneumonia in patients with COVID-19. <i>Journal of Health Sciences and Medicine</i> , 2022, 5, 1252-1258.	0.0	0
6079	Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort. <i>Infection</i> , 2023, 51, 851-858.	2.3	4
6080	Clinical benefits of inhaled ciclesonide for hospitalized patients with COVID-19 infection: a retrospective study. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	1
6081	When Science Races: the Standard of Care and Medical Negligence in the Times of Covid-19. <i>Wroclaw Review of Law, Administration and Economics</i> , 2022, .	0.0	0
6082	Effect of intravenous pulses of methylprednisolone 250â€%mg versus dexamethasone 6Âmg in hospitalised adults with severe <scp>COVID</scp>â€19 pneumonia: An openâ€label randomised trial. <i>European Journal of Clinical Investigation</i> , 2023, 53, .	1.7	8
6083	Microbiological findings and prescribing trends in SARS- CoV-2 positive patients in two United Kingdom Hospitals. <i>Infection Prevention in Practice</i> , 2022, 4, 100246.	0.6	0
6084	Clinical Consideration for Mesenchymal Stem Cells in Treatment of COVID-19. <i>Current Pharmaceutical Design</i> , 2022, 28, 2991-2994.	0.9	2
6085	A plantâ€derived glucocorticoid receptor modulator with potency to attenuate the side effects of glucocorticoid therapy. <i>British Journal of Pharmacology</i> , 2023, 180, 194-213.	2.7	3
6086	Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?. <i>Journal of Clinical Medicine</i> , 2022, 11, 5559.	1.0	2
6087	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 0, , .	2.9	82

#	ARTICLE	IF	CITATIONS
6088	Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 1119-1128.	5.2	4
6089	Harm of early dexamethasone for COVID-19 and bias in randomized trials. <i>European Journal of Internal Medicine</i> , 2023, 107, 100-101.	1.0	4
6090	Anti-cytokine Therapy in Hospitalized Patients with COVID-19: The Jury is Out. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 1069-1071.	0.3	0
6091	SARS-CoV-2 in immunocompromised individuals. <i>Immunity</i> , 2022, 55, 1779-1798.	6.6	50
6093	Online control of the False Discovery Rate in group-sequential platform trials. <i>Statistical Methods in Medical Research</i> , 2022, 31, 2470-2485.	0.7	8
6094	Extracorporeal membrane oxygenation in COVID-19 associated acute respiratory distress syndrome: A narrative review. <i>Journal of Intensive Medicine</i> , 2023, 3, 4-10.	0.8	2
6095	Approaches to Assessing the Safety of Medicines during the COVID-19 Pandemic Using the Example of Azithromycin. <i>Safety and Risk of Pharmacotherapy</i> , 2022, 10, 283-292.	0.1	0
6096	Druggable targets and therapeutic development for COVID-19. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	4
6097	The Lancet Commission on lessons for the future from the COVID-19 pandemic. <i>Lancet</i> , 2022, 400, 1224-1280.	6.3	307
6098	Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management. <i>Lancet</i> , 2022, 400, 1157-1170.	6.3	78
6099	The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis. <i>Value in Health</i> , 2023, 26, 216-225.	0.1	8
6100	COVID-19-associated AKI. <i>Current Opinion in Critical Care</i> , 2022, 28, 630-637.	1.6	14
6102	COVID-19 in a patient implanted with a total artificial heart: a case report. <i>European Heart Journal - Case Reports</i> , 2022, 6, .	0.3	1
6103	A randomized clinical trial to stimulate the cholinergic anti-inflammatory pathway in patients with moderate COVID-19-pneumonia using a slow-paced breathing technique. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
6104	Mortality of COVID-19 Patients Requiring Extracorporeal Membrane Oxygenation During the Three Epidemic Waves. <i>ASAIO Journal</i> , 2022, 68, 1434-1442.	0.9	7
6105	Educational impact and recommendations from implementation of student-led clinical trial recruitment: a mixed-methods study. <i>Postgraduate Medical Journal</i> , 0, , pmj-2022-142122.	0.9	0
6106	Association of Early Steroid Administration With Outcomes of Children Hospitalized for COVID-19 Without Multisystem Inflammatory Syndrome in Children. <i>JAMA Pediatrics</i> , 2022, 176, 1208.	3.3	2
6107	Mycotic clival osteomyelitis secondary to immunosuppression by SARS-CoV-2. , 0, 13, 459.		1

#	ARTICLE	IF	CITATIONS
6108	Real-world effectiveness of steroids in severe COVID-19: a retrospective cohort study. BMC Infectious Diseases, 2022, 22, .	1.3	1
6109	Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2022, 56, 1460-1474.	1.9	5
6110	Low-dose versus high-dose dexamethasone for hospitalized patients with COVID-19 pneumonia: A randomized clinical trial. PLoS ONE, 2022, 17, e0275217.	1.1	16
6112	COVID-19 and the antiphospholipid syndrome. Autoimmunity Reviews, 2022, 21, 103206.	2.5	12
6114	An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies. Expert Opinion on Pharmacotherapy, 2022, 23, 1695-1700.	0.9	1
6115	Procalcitonin and High APACHE (Acute Physiological and Chronic Health Evaluation) Level Are Associated with the Course of Acute Kidney Injury in Patients with SARS-CoV-2. International Journal of Clinical Practice, 2022, 2022, 1-9.	0.8	0
6116	B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA). Frontiers in Oncology, 0, 12, .	1.3	9
6117	The relationship between pragmatism, timing, and study size on impact of treatment trials: a qualitative, hypothesis generating study of systemic corticosteroids for COVID-19. Journal of Clinical Epidemiology, 2022, , .	2.4	0
6118	Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review. , 2022, 1, e000309.		19
6119	Temporary ICUs during the COVID-19 pandemic first wave: description of the cohort at a French centre. BMC Anesthesiology, 2022, 22, .	0.7	2
6120	Effectiveness of remdesivir with corticosteroids for COVID-19 patients in intensive care unit: A hospital-based observational study. Journal of Medical Virology, 2023, 95, .	2.5	9
6121	Host Biomarkers Reflect Prognosis in Patients Presenting With Moderate Coronavirus Disease 2019: A Prospective Cohort Study. Open Forum Infectious Diseases, 2022, 9, .	0.4	2
6122	Current therapeutic strategies and possible effective drug delivery strategies against COVID-19. Current Drug Delivery, 2022, 19, .	0.8	1
6123	Efficacy of MSC in Patients with Severe COVID-19: Analysis of the Literature and a Case Study. Stem Cells Translational Medicine, 2022, 11, 1103-1112.	1.6	8
6124	Alterations in endothelial nitric oxide synthase activity and their relevance to blood pressure. Biochemical Pharmacology, 2022, 205, 115256.	2.0	17
6125	Clinical effect of early administration of tocilizumab following the initiation of corticosteroid therapy for patients with COVID-19. Journal of Infection and Chemotherapy, 2022, 28, 1639-1644.	0.8	1
6126	Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2022, 6, 511-524.	1.2	3
6128	Targeting SARS-CoV-2 infection through CAR-like bispecific T cell engagers incorporating ACE2. Clinical and Translational Immunology, 2022, 11, .	1.7	6

#	ARTICLE	IF	CITATIONS
6129	Japanese rapid/living recommendations on drug management for <scp>COVID</scp>â€19: updated guidelines (July 2022). <i>Acute Medicine & Surgery</i> , 2022, 9, .	0.5	6
6130	Dynamic Link Prediction for Discovery of New Impactful COVID-19 Research Approaches. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2022, 26, 5883-5894.	3.9	7
6132	Epidemiology and ventilation characteristics of confirmed cases of severe COVID-19 pneumonia admitted in intensive care unit (EPIC19): A multicentre observational study. <i>Indian Journal of Anaesthesia</i> , 2022, 66, 724.	0.3	4
6133	Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211327.	1.0	3
6134	Clinical characteristics and risk factors for mortality of hospitalized cancer patients with COVID-2019 in Mecca, Saudi Arabia. <i>Annals of Thoracic Medicine</i> , 2022, 17, 220.	0.7	0
6135	Glucocorticoid Therapy in Respiratory Illness: Bench to Bedside. <i>Journal of Investigative Medicine</i> , 2022, 70, 1662-1680.	0.7	2
6136	RNA Viruses, Pandemics and Anticipatory Preparedness. <i>Viruses</i> , 2022, 14, 2176.	1.5	4
6137	Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19. <i>Current Issues in Pharmacy and Medical Sciences</i> , 2022, 35, 106-110.	0.1	0
6138	Effect of ozone therapy on the emotional state of a patient after the novel coronavirus infection. <i>Fizioterapevt</i> , 2022, , 49-57.	0.0	0
6139	Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. <i>Nature Communications</i> , 2022, 13, .	5.8	21
6140	Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
6141	Misinformation about medication during the COVIDâ€19 pandemic: A perspective of medical staff. <i>PLoS ONE</i> , 2022, 17, e0276693.	1.1	9
6142	Aspergillus-SARS-CoV-2 Coinfection: What Is Known?. <i>Pathogens</i> , 2022, 11, 1227.	1.2	5
6143	The Effect of Dexamethasone Treatment on COVID-19 Prognosis in Cancer Patients. <i>Vaccines</i> , 2022, 10, 1798.	2.1	3
6144	From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?. <i>Biomedicines</i> , 2022, 10, 2620.	1.4	6
6145	Variation in Clinical Treatment and Outcomes by Race Among US Veterans Hospitalized With COVID-19. <i>JAMA Network Open</i> , 2022, 5, e2238507.	2.8	6
6146	The effects of thymoquinone on steroid-induced femoral head osteonecrosis: An experimental study in rats. <i>Joint Diseases and Related Surgery</i> , 2022, 33, 553-566.	0.6	3
6147	Pressure ulcers in patients with <scp>COVID</scp>â€19 acute respiratory distress syndrome undergoing prone positioning in the intensive care unit: A preâ€and postâ€intervention study. <i>Nursing in Critical Care</i> , 2023, 28, 1115-1123.	1.1	8

#	ARTICLE	IF	CITATIONS
6148	COVID-19 Treatmentâ€™Current Status, Advances, and Gap. <i>Pathogens</i> , 2022, 11, 1201.	1.2	7
6149	Genomic Transcriptome Benefits and Potential Harms of COVID-19 Vaccines Indicated from Optimized Genomic Biomarkers. <i>Vaccines</i> , 2022, 10, 1774.	2.1	3
6150	External Validation of COVID-19 Risk Scores during Three Waves of Pandemic in a German Cohortâ€™A Retrospective Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 1775.	1.1	6
6151	Mandibular Mucormycosis: A Report of Four Cases and a Discussion on Their Management. <i>Cureus</i> , 2022, , .	0.2	1
6152	Does Prophylactic Oral Zinc Reduce the Risk of Contracting COVID-19?. <i>Cureus</i> , 2022, , .	0.2	0
6153	Covid-19 in kidney transplant recipients. <i>Vnitřni Lekarství</i> , 2022, 68, 444-448.	0.1	0
6154	Low expression of EXOSC2 protects against clinical COVID-19 and impedes SARS-CoV-2 replication. <i>Life Science Alliance</i> , 2023, 6, e202201449.	1.3	1
6155	Impact of corticosteroids on the procoagulant profile of critically ill COVID-19 patients: a before-after study. <i>Minerva Anestesiologica</i> , 2023, 89, .	0.6	3
6156	Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 5882.	1.0	20
6157	Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options. <i>Life</i> , 2022, 12, 1605.	1.1	12
6158	El elemento seXo en el COVID-19: Mecanismos diferenciales en la susceptibilidad, severidad y mortalidad de la enfermedad por SARS-CoV-2. <i>Revista Colombiana De EndocrinologAa, Diabetes & Metabolismo</i> , 2022, 9, .	0.1	0
6160	Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19. <i>Current Pharmaceutical Design</i> , 2022, 28, 3658-3670.	0.9	3
6161	High-dose corticosteroids in patients hospitalized for COVID-19 pneumonia: an observational study of comparative effectiveness. <i>International Journal of Infectious Diseases</i> , 2022, 125, 184-191.	1.5	3
6162	The effectiveness of the inclusion of ozone therapy in comprehensive rehabilitation programs for post-COVID syndrome. <i>Russian Journal of Physiotherapy Balneology and Rehabilitation</i> , 2022, 21, 25-34.	0.2	0
6163	Neuroâ€™Immune Interactions in Severe COVID-19 Infection. <i>Pathogens</i> , 2022, 11, 1256.	1.2	1
6164	Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 695-709.	2.8	105
6165	Longitudinal Analysis of Quadriceps Muscle Strength in Patients with Previous COVID-19 Hospitalization and in Patients with Post-Acute Sequelae following Mild COVID-19. <i>Nutrients</i> , 2022, 14, 4319.	1.7	4
6166	Genomic Biomarker Heterogeneities between SARS-CoV-2 and COVID-19. <i>Vaccines</i> , 2022, 10, 1657.	2.1	6

#	ARTICLE	IF	CITATIONS
6167	Early identification of acute respiratory distress syndrome in times of the COVID-19 pandemic. <i>Journal of Intensive Medicine</i> , 2022, , .	0.8	0
6168	Drug repurposing in cardiovascular inflammation: Successes, failures, and future opportunities. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
6169	Considerations for management of patients with diabetes mellitus and acute COVID-19. <i>World Journal of Diabetes</i> , 0, 13, 802-808.	1.3	0
6170	Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19. <i>Biomedicines</i> , 2022, 10, 2628.	1.4	1
6171	Abrogation of neutrophil inflammatory pathways and potential reduction of neutrophil-related factors in COVID-19 by intravenous immunoglobulin. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
6172	Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance. <i>Arthritis Care and Research</i> , 2023, 75, 53-60.	1.5	7
6173	Timing of tofacitinib therapy is critical to improving outcomes in severe-critical COVID-19 infection: A retrospective study from a tertiary care hospital. <i>Medicine (United States)</i> , 2022, 101, e30975.	0.4	2
6174	Surfing Corona waves “ instead of breaking them: Rethinking the role of natural immunity in COVID-19 policy. <i>F1000Research</i> , 0, 11, 337.	0.8	0
6175	Treatment with COLchicine in hospitalized patients affected by COVID-19: The COLVID-19 trial. <i>European Journal of Internal Medicine</i> , 2023, 107, 30-36.	1.0	9
6176	Postoperative systemic inflammatory dysregulation and corticosteroids: a narrative review. <i>Anaesthesia</i> , 2023, 78, 356-370.	1.8	18
6177	Differential Bias for Creatinine- and Cystatin C- Derived Estimated Glomerular Filtration Rate in Critical COVID-19. <i>Biomedicines</i> , 2022, 10, 2708.	1.4	2
6178	Steroid injections in musculoskeletal conditions and COVID infection rates: What is the impact on positive rates following the injection?. <i>Musculoskeletal Care</i> , 0, , .	0.6	1
6179	COVID-19 and HSCT (Hematopoietic stem cell transplant). <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101399.	0.7	8
6180	Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study. <i>International Journal of Infectious Diseases</i> , 2022, 125, 233-240.	1.5	4
6181	Wave of Invasive Fungal Disease on the Shores of COVID-19: A Case Series of COVID-19 Associated Rhino-Orbital Fungal Rhinosinusitis and Literature Review. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 0, , .	0.3	0
6182	Renaissance of glucocorticoids in critical care in the era of COVID-19: ten urging questions. <i>Critical Care</i> , 2022, 26, .	2.5	7
6183	Ventilatory Parameters in Obstetric Patients With COVID-19 and Impact of Delivery. <i>Chest</i> , 2023, 163, 554-566.	0.4	6
6184	Respiratory viruses: their importance and lessons learned from COVID-19. <i>European Respiratory Review</i> , 2022, 31, 220051.	3.0	13

#	ARTICLE	IF	CITATIONS
6185	Levels of soluble complement regulators predict severity of COVID-19 symptoms. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
6186	COVID-19: ACT trials for colchicine and antithrombotic therapies. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 1106-1108.	5.2	1
6187	Assessment of Admission COVID-19 Associated Hyperinflammation Syndrome Score in Critically-Ill COVID-19 Patients. <i>Journal of Intensive Care Medicine</i> , 2023, 38, 70-77.	1.3	2
6188	Adapted tensor decomposition and PCA based unsupervised feature extraction select more biologically reasonable differentially expressed genes than conventional methods. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
6189	Impact of Dexamethasone and Inhaled Nitric Oxide on Severe Acute Kidney Injury in Critically Ill Patients with COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 6130.	1.0	3
6192	Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 1595.	3.8	51
6193	COVID-19 disease and immune dysregulation. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101401.	0.7	26
6194	Intrapulmonary shunting is a key contributor to hypoxia in COVID-19: An update on the pathophysiology. <i>PLoS ONE</i> , 2022, 17, e0273402.	1.1	0
6195	Pharmacologic therapies of ARDS: From natural herb to nanomedicine. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
6196	Fewer COVID-19 Neurological Complications with Dexamethasone and Remdesivir. <i>Annals of Neurology</i> , 2023, 93, 88-102.	2.8	10
6197	On the Recognition of Natural Substrate CTP and Endogenous Inhibitor ddhCTP of SARS-CoV-2 RNA-Dependent RNA Polymerase: A Molecular Dynamics Study. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 4916-4927.	2.5	8
6198	Diabetes hospital Glucose and Outcomes in the COVID-19 pandemic () Tj ETQq1 1 0.784314 rgBT 0.5 1 vaccinations. <i>Internal Medicine Journal</i> , 0, , .	0.5	1
6199	Polyphenolic promiscuity, inflammation-coupled selectivity: Whether PAINS filters mask an antiviral asset. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
6200	Glycemic Gap Predicts Mortality in a Large Multicenter Cohort Hospitalized With COVID-19. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 718-725.	1.8	3
6201	COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 816-832.	1.5	12
6202	COVID-19 and Gut Injury. <i>Nutrients</i> , 2022, 14, 4409.	1.7	8
6203	Outcomes of Extracorporeal Membrane Oxygenation in COVID-19-Induced Acute Respiratory Distress Syndrome: An Inverse Probability Weighted Analysis. , 2022, 4, e0770.		2
6204	Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome*. <i>Critical Care Medicine</i> , 2022, 50, 1701-1713.	0.4	16

#	ARTICLE	IF	CITATIONS
6205	An Observational Study on Unique High Resolution Computed Tomography Pattern of Post-COVID Pulmonary Fibrosis. <i>European Medical Journal Respiratory</i> , 0, , .	1.0	0
6206	Ask the Experts: An International Consensus on Managing Post-Infectious Olfactory Dysfunction Including COVID-19. <i>Current Otorhinolaryngology Reports</i> , 2022, 10, 433-439.	0.2	1
6207	Respiratory support before venovenous ECMO for COVID-19: what is the price?. <i>Lancet Respiratory Medicine</i> , 2023, 11, 214-215.	5.2	1
6208	Targeted delivery of an anti-inflammatory corticosteroid to Ly6C/G-positive cells abates severity of influenza A symptoms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	5
6209	Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19. <i>Trials</i> , 2022, 23, .	0.7	0
6210	Association of early dexamethasone therapy with mortality in critically ill COVID-19 patients: a French multicenter study. <i>Annals of Intensive Care</i> , 2022, 12, .	2.2	5
6211	Treatment of severe COVID-19: an evolving paradigm. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1887-1891.	0.9	5
6212	Chest dual-energy CT to assess the effects of steroids on lung function in severe COVID-19 patients. <i>Critical Care</i> , 2022, 26, .	2.5	1
6213	All-cause and in-hospital mortality after aspirin use in patients hospitalized with COVID-19: a systematic review and meta-analysis. <i>Biology Methods and Protocols</i> , 2022, 7, .	1.0	1
6214	Use of chronic medications and risk of severe death due to COVID-19 in hospitalised patients. <i>European Journal of Hospital Pharmacy</i> , 0, , ejhpharm-2021-003186.	0.5	2
6215	Immune Modulation in Sepsis, ARDS, and Covid-19 " The Road Traveled and the Road Ahead. , 2022, 1, .		6
6216	Acute Kidney Injury and Blood Purification Techniques in Severe COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 6286.	1.0	2
6217	Protective role of vitamin D status against COVID-19: a mini-review. <i>Endocrine</i> , 2023, 79, 235-242.	1.1	3
6218	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
6219	Therapeutic advances in COVID-19. <i>Nature Reviews Nephrology</i> , 2023, 19, 38-52.	4.1	67
6220	Multi-Omics Reveals Mechanisms of Partial Modulation of COVID-19 Dysregulation by Glucocorticoid Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12079.	1.8	11
6221	Efficacy of COVID-HiGIV in animal models of SARS-CoV-2 infection. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
6222	Respiratory function and CT abnormalities among survivors of COVID-19 pneumonia: a nationwide follow-up study. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001347.	1.2	2

#	ARTICLE	IF	CITATIONS
6224	COVID-19-associated Guillain-Barré syndrome in the early pandemic experience in Lombardia (Italy). <i>Neurological Sciences</i> , 2023, 44, 437-446.	0.9	1
6225	Fluid restriction management in the treatment of COVID-19: a single-center observational study. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
6226	Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 883-891.	1.0	5
6227	COVID-19 Therapeutics and Considerations for Pregnancy. <i>Obstetrics and Gynecology Clinics of North America</i> , 2022, , .	0.7	0
6228	Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial. <i>Clinical Microbiology and Infection</i> , 2023, 29, 372-378.	2.8	24
6229	Shared features of pathogenetic aspects, autoimmunity and pharmacotherapy in coronavirus infection (COVID-19) and immunoinflammatory rheumatic diseases. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 82-87.	0.1	0
6231	Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARS-CoV-2. <i>Advanced Science</i> , 2022, 9, .	5.6	17
6232	Management of hyperinflammation in COVID-19 patients. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 6-9.	0.5	3
6233	Clinical and mycological investigations of <i>post-COVID-19</i> acute invasive fungal sinusitis. <i>Laryngoscope Investigative Otolaryngology</i> , 2022, 7, 1780-1789.	0.6	3
6234	Making better use of natural experimental evaluation in population health. <i>BMJ, The</i> , 0, , e070872.	3.0	10
6235	Predicting the risk of chest radiograph abnormality 12-weeks post hospitalisation with SARS CoV-2 PCR confirmed COVID-19. <i>Respiratory Research</i> , 2022, 23, .	1.4	1
6236	Treatment and case fatality rate of COVID-19 in Africa. <i>Journal of Public Health in Africa</i> , 2022, 13, .	0.2	1
6237	Machine learning-based scoring system to predict in-hospital outcomes in patients hospitalized with COVID-19. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 617-626.	0.7	6
6238	<i>Strongyloides stercoralis</i> : A Neglected but Fatal Parasite. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 310.	0.9	15
6239	Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19. <i>Annals of Pharmacotherapy</i> , 2023, 57, 769-775.	0.9	8
6241	Respiratory Physiology of COVID-19 and Influenza Associated Acute Respiratory Distress Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 6237.	1.0	3
6242	Efficacy and safety of polyherbal formulation as an add-on to standard-of-care in mild-to-moderate COVID-19: A randomized, double-blind, placebo-controlled trial. <i>Journal of Ayurveda and Integrative Medicine</i> , 2022, , 100653.	0.9	1
6243	Low incidence of severe bacterial infections in hospitalised patients with COVID-19: A population-based registry study. <i>Infectious Diseases</i> , 2023, 55, 132-141.	1.4	2

#	ARTICLE	IF	CITATIONS
6244	New Therapeutic Options in Mild Moderate COVID-19 Outpatients. <i>Microorganisms</i> , 2022, 10, 2131.	1.6	2
6246	Tâ€cell dysfunction as a potential contributing factor in <scp>postâ€COVID</scp>â€19 mucormycosis. <i>Mycoses</i> , 2023, 66, 202-210.	1.8	2
6247	Factors associated with the severity of <scp>COVID</scp>â€19 outcomes in people with neuromuscular diseases: Data from the International Neuromuscular <scp>COVID</scp>â€19 Registry. <i>European Journal of Neurology</i> , 2023, 30, 399-412.	1.7	1
6248	The Adverse Outcome Pathway Framework Applied to Neurological Symptoms of COVID-19. <i>Cells</i> , 2022, 11, 3411.	1.8	7
6249	Effect of methylprednisolone therapy on hospital stay and viral clearance in patients with moderate COVID-19. , 2022, , .		0
6250	Lung transplantation for coronavirus disease 2019 associated severe acute respiratory distress syndrome. <i>Current Opinion in Anaesthesiology</i> , 0, Publish Ahead of Print, .	0.9	0
6252	A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients. <i>Medicina Intensiva (English Edition)</i> , 2023, 47, 23-33.	0.1	4
6253	Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*. <i>Critical Care Medicine</i> , 2022, 50, 1788-1798.	0.4	13
6254	Willingness to Accept COVID-19 Vaccine and Associated Factors Among Adult Household Members in Dire Dawa City Administration, East Ethiopia. <i>Patient Preference and Adherence</i> , 0, Volume 16, 2977-2988.	0.8	1
6255	Pharmacological therapies and drug development targeting SARS-CoV-2 infection. <i>Cytokine and Growth Factor Reviews</i> , 2022, , .	3.2	6
6257	Molecular markers for early stratification of disease severity and progression in COVID-19. <i>Biology Methods and Protocols</i> , 2022, 7, .	1.0	2
6258	Glucocorticoids and COVID-19. <i>Pharmacological Research</i> , 2022, 185, 106511.	3.1	11
6259	Racial and ethnic variation in COVID-19 care, treatment, and outcomes: A retrospective cohort study from the MiCOVID-19 registry. <i>PLoS ONE</i> , 2022, 17, e0276806.	1.1	2
6260	Impact of Glucocorticoids on Cardiovascular Systemâ€”The Yin Yang Effect. <i>Journal of Personalized Medicine</i> , 2022, 12, 1829.	1.1	1
6261	Ventilatory Parameters Measured After One Week of Mechanical Ventilation and Survival in COVID-19â€Related ARDS. <i>Respiratory Care</i> , 2023, 68, 44-51.	0.8	0
6262	Differential effects of age, sex and dexamethasone therapy on ACE2/TMPRSS2 expression and susceptibility to SARS-CoV-2 infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
6263	A 9-mRNA signature measured from whole blood by a prototype PCR panel predicts 28-day mortality upon admission of critically ill COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
6264	B-cell malignancies and COVID-19: a narrative review. <i>Clinical Microbiology and Infection</i> , 2023, 29, 332-337.	2.8	7

#	ARTICLE	IF	CITATIONS
6265	Post-COVID-19 respiratory problems: burden and management. <i>Current Opinion in Supportive and Palliative Care</i> , 0, Publish Ahead of Print, .	0.5	2
6266	COMPREHENSIVE THERAPEUTIC INTERVENTIONS AGAINST SARS-COV-2: A REVIEW AND PROSPECTIVE. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 0, , 1-12.	0.3	0
6267	A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. <i>Life</i> , 2022, 12, 1758.	1.1	9
6268	Postexposureâ€vaccineâ€prophylaxis against COVIDâ€19. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	2
6269	Neutrophil activation and neutrophil extracellular traps (NETs) in COVIDâ€19 ARDS and immunothrombosis. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	26
6270	Association between prehospital medication and fatal outcomes in a cohort of hospitalized patients due to coronavirus disease-2019 in a referral hospital in Peru. <i>Travel Medicine and Infectious Disease</i> , 2022, 50, 102472.	1.5	1
6271	Mucormycosis an added burden to Covid-19 Patients: An in-depth systematic review. <i>Journal of Infection and Public Health</i> , 2022, 15, 1299-1314.	1.9	7
6272	Extreme obesity is a strong predictor for in-hospital mortality and the prevalence of long-COVID in severe COVID-19 patients with acute respiratory distress syndrome. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
6273	Editorial: Renal system section in current opinion in critical care: pathways forward for innovation in acute kidney injury. <i>Current Opinion in Critical Care</i> , 2022, 28, 581-582.	1.6	0
6274	Effect of corticosteroids in patients with COVID-19: a Bayesian network meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 125, 84-92.	1.5	6
6275	Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial. <i>EClinicalMedicine</i> , 2022, 54, 101703.	3.2	23
6276	Integrating non-concurrent controls in the analyses of late-entry experimental arms in multi-arm trials with a shared control group in the presence of parameter drift. <i>Contemporary Clinical Trials</i> , 2022, 123, 106972.	0.8	0
6277	Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality. <i>Pulmonary Pharmacology and Therapeutics</i> , 2022, 77, 102172.	1.1	3
6278	Clinical course of patients with severe SARS-CoV-2 infection co-treatment with Jin Si Herbal Tea in Eastern Taiwan: A retrospective cohort study. <i>Journal of Herbal Medicine</i> , 2022, 36, 100610.	1.0	2
6279	Cytokine Release Syndrome and Sepsis. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 735-748.	1.9	4
6280	Conventional and Kampo Medicine Treatment for Mild-to-moderate COVID-19: A Multicenter, Retrospective, Observational Study by the Integrative Management in Japan for Epidemic Disease (IMJEDI) Tj ETQq 1b30.78434 4 rgBT		
6281	AI for Drug Repurposing in the Pandemic Response. , 2022, , 59-84.		0
6282	Characteristics and outcomes of parturients with COVID-19, admitted to a critical care unit: A single-center retrospective observational study. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 6478.	0.3	2

#	ARTICLE	IF	CITATIONS
6283	The Metabolomics of Critical Illness. Handbook of Experimental Pharmacology, 2022, , .	0.9	0
6284	The similarities between severe COVID-19 infection and acute radiation syndrome: Literature review. AIP Conference Proceedings, 2022, , .	0.3	0
6285	Data and Computation: A Contemporary Landscape. , 2022, , 51-72.		0
6286	Mucormycosis and diabetes in the times of COVID-19: A Mumbai-based observational study. Journal of Family Medicine and Primary Care, 2022, 11, 6107.	0.3	2
6287	Outpatient surveillance programme for health workers with COVID 19 in Mexico: an observational study of ambulatory treatment and early hospitalization. Therapeutic Advances in Infectious Disease, 2022, 9, 204993612211302.	1.1	0
6288	Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: an international multi-centre observational cohort study. EClinicalMedicine, 2023, 55, 101724.	3.2	26
6289	V. Current Treatment Approach for COVID-19. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 2374-2382.	0.0	0
6290	Pituitary and COVID-19: review. Problemy Endokrinologii, 2022, 68, 14-23.	0.2	0
6291	Variability of Steroid Prescription for COVID-19 Associated Pneumonia in Real-Life, Non-Trial Settings. The Journal of Critical Care Medicine, 2022, 8, 259-265.	0.3	0
6292	The COVID-19 challenge. What have we learned?. Jornal Brasileiro De Pneumologia, 0, , e20220361.	0.4	0
6293	Significant risk of COVID-19 and related-hospitalization among patients with adrenal insufficiency: A large multinational survey. Frontiers in Endocrinology, 0, 13, .	1.5	4
6294	ROLE OF TOCILIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE COVID-19 PNEUMONIA. Asian Journal of Pharmaceutical and Clinical Research, 0, , 121-125.	0.3	0
6295	Prolonged higher dose methylprednisolone<i>versus</i>conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). European Respiratory Journal, 2023, 61, 2201514.	3.1	18
6297	Dietary nitrate supplementation for preventing and reducing the severity of winter infections, including COVID-19, in care homes (BEET-Winter): a randomised placebo-controlled feasibility trial. European Geriatric Medicine, 2022, 13, 1343-1355.	1.2	3
6298	Using national electronic health records for pandemic preparedness: validation of a parsimonious model for predicting excess deaths among those with COVID-19â€“a data-driven retrospective cohort study. Journal of the Royal Society of Medicine, 0, , 014107682211318.	1.1	3
6299	Factors Associated with Mortality in Patients with COVID-19 Receiving Prolonged Ventilatory Support. Surgical Infections, 0, , .	0.7	1
6300	COVID-19 in Russia: Evolution of Views on the Pandemic. Report II. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2022, 77, 291-306.	0.2	2
6301	Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. BMJ, The, 0, , e072175.	3.0	16

#	ARTICLE	IF	CITATIONS
6302	Thrombotic storm in coronavirus disease 2019: from underlying mechanisms to its management. <i>Journal of Medical Microbiology</i> , 2022, 71, .	0.7	3
6303	Reply to Yan. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	0
6304	Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19). <i>Journal of Clinical Medicine</i> , 2022, 11, 6545.	1.0	4
6305	Dexamethasone-induced hyperglycaemia in COVID-19: Glycaemic profile in patients without diabetes and factors associated with hyperglycaemia. <i>Diabetes Research and Clinical Practice</i> , 2022, 194, 110151.	1.1	7
6306	COVID-19: From Pathophysiology to Treatment. , 0, , .		0
6307	Mucolytic and Antioxidant Properties of Carbocysteine as a Strategy in COVID-19 Therapy. <i>Life</i> , 2022, 12, 1824.	1.1	2
6308	A persistent neutrophil-associated immune signature characterizes post-“COVID-19 pulmonary sequelae. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	43
6309	Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial. <i>Molecular Medicine</i> , 2022, 28, .	1.9	7
6310	Decrease in serum levels of autotaxin in COVID-19 patients. <i>Annals of Medicine</i> , 2022, 54, 3188-3199.	1.5	1
6311	Randomized Open Investigation Determining Steroid Dose in Severe COVID-19: The ROIDS-Dose Clinical Trial. <i>Cureus</i> , 2022, , .	0.2	1
6312	Four-compartment diffusion model of cortisol disposition: Comparison to three alternative models in current clinical use. <i>Journal of the Endocrine Society</i> , 0, , .	0.1	2
6313	Changing trends of patient characteristics and treatment pathways during the COVID-19 pandemic: A cross-sectional analysis of 72,459 inpatient cases from the German Helios database. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
6314	Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19. <i>Thrombosis Update</i> , 2022, , 100126.	0.4	0
6315	High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone. <i>Respiratory Research</i> , 2022, 23, .	1.4	2
6316	Therapeutic role of N-acetyl cysteine (NAC) for the treatment and/or management of SARS-CoV-2-induced lung damage in hamster model. <i>European Journal of Pharmacology</i> , 2023, 938, 175392.	1.7	1
6317	The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2022. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, , .	0.6	0
6318	Fit for the future: empowering clinical trials with digital technology. <i>European Heart Journal</i> , 2023, 44, 64-67.	1.0	8
6319	A country-based review in COVID-19 related research developments. <i>RAIRO - Operations Research</i> , 0, , .	1.0	0

#	ARTICLE	IF	CITATIONS
6320	Ensitrelvir as a potential treatment for COVID-19. Expert Opinion on Pharmacotherapy, 2022, 23, 1995-1998.	0.9	9
6321	Lung Transplantation for COVID-19 patients and COVID-19 in Lung Transplant Recipients. Clinics in Chest Medicine, 2022, .	0.8	0
6322	Clinical Findings and Outcomes From Subjects With COVID-19 Pneumonia in an Intermediate Respiratory Care Unit. Respiratory Care, 2023, 68, 67-76.	0.8	2
6323	Potential influence of COVID-19 and dexamethasone on the reproductive system: what we know and can expect. Human Fertility, 2023, 26, 38-49.	0.7	0
6324	Addressing Osteonecrosis: A preventable catastrophe - A multi-center study. Pakistan Journal of Medical Sciences, 2022, 39, .	0.3	0
6325	<i>Ganoderma lucidum</i> polysaccharides ameliorate lipopolysaccharide-induced acute pneumonia via inhibiting NRP1-mediated inflammation. Pharmaceutical Biology, 2022, 60, 2201-2209.	1.3	7
6327	Evaluation of the Prevalence of Barotrauma and Affecting Factors in Patients with COVID-19 during Follow-Up in the Intermediate Care Unit. Journal of Personalized Medicine, 2022, 12, 1863.	1.1	0
6329	COVID-19 Mixed Impact on Hospital Antimicrobial Stewardship Activities: A Qualitative Study in UK-Based Hospitals. Antibiotics, 2022, 11, 1600.	1.5	7
6330	A narrative review on drug development for the management of antimicrobial-resistant infection crisis in Japan: the past, present, and future. Expert Review of Anti-Infective Therapy, 2022, 20, 1603-1614.	2.0	2
6331	Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial. PLoS ONE, 2022, 17, e0277790.	1.1	3
6332	Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence. The Cochrane Library, 2022, 2022, .	1.5	14
6333	A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2023, 75, 253-265.	2.9	33
6334	Aging, inflammaging and immunosenescence as risk factors of severe COVID-19. Immunity and Ageing, 2022, 19, .	1.8	28
6335	Clinical Challenges of Emerging and Re-Emerging Yeast Infections in the Context of the COVID-19 Pandemic. Microorganisms, 2022, 10, 2223.	1.6	2
6336	Autoinflammatory manifestations in adult patients. Clinical and Experimental Immunology, 2022, 210, 295-308.	1.1	3
6337	Mortality of intubated patients with COVID-19 during first and subsequent waves: a meta-analysis involving 363,660 patients from 43 countries. Expert Review of Respiratory Medicine, 2022, 16, 1101-1108.	1.0	3
6339	Early antiviral and supervisory dexamethasone treatment improve clinical outcomes of nonsevere COVID-19 patients. Medicine (United States), 2022, 101, e31681.	0.4	2
6340	Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options. International Immunopharmacology, 2022, 113, 109428.	1.7	22

#	ARTICLE	IF	CITATIONS
6341	Life stressors significantly impact long-term outcomes and post-acute symptoms 12-months after COVID-19 hospitalization. <i>Journal of the Neurological Sciences</i> , 2022, 443, 120487.	0.3	13
6343	Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: An observational study of comparative effectiveness. <i>International Journal of Infectious Diseases</i> , 2022, , .	1.5	0
6344	Transcriptional reprogramming of infiltrating neutrophils drives lung pathology in severe COVID-19 despite low viral load. <i>Blood Advances</i> , 2023, 7, 778-799.	2.5	11
6345	Acute and chronic histopathological findings in renal biopsies in COVID-19. <i>Clinical and Experimental Medicine</i> , 2023, 23, 1003-1014.	1.9	6
6346	Estimated glomerular filtration rates are higher when creatinine-based equations are compared to a cystatin C-based equation in COVID-19. <i>Acta Anaesthesiologica Scandinavica</i> , 0, , .	0.7	2
6347	Inflammation in COVID-19: A Risk for Superinfections. <i>Covid</i> , 2022, 2, 1609-1624.	0.7	4
6348	Maintaining Momentum in Clinical Trials for Respiratory Viruses*. <i>Critical Care Medicine</i> , 2022, 50, 1840-1842.	0.4	0
6349	Clinical Outcomes and Prolonged SARS-CoV-2 Viral Shedding in ICU Patients with Severe COVID-19 Infection and Nosocomial Bacterial Pneumonia: A Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 6796.	1.0	4
6350	Severe COVID-19 with persistent respiratory failure—A retrospective cohort study in a tertiary centre in Malaysia. <i>PLoS ONE</i> , 2022, 17, e0276848.	1.1	0
6351	Prevalence of undiagnosed hepatitis B virus infection in patients with COVID-19: A single center retrospective study. <i>Medicine (United States)</i> , 2022, 101, e31385.	0.4	1
6352	Effects of Different Corticosteroid Doses in Elderly Unvaccinated Patients with Severe to Critical COVID-19. <i>Life</i> , 2022, 12, 1924.	1.1	1
6353	Hospital-acquired bloodstream infections in patients deceased with COVID-19 in Italy (2020–2021). <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
6354	Human Coronaviruses. , 2023, , 1167-1175.e6.		0
6355	Targeting G-quadruplexes to achieve antiviral activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2023, 79, 129085.	1.0	18
6357	COVID-19 Outbreak in Daegu City, Korea and Response to COVID-19: How Have We Dealt and What Are the Lessons?. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	6
6358	Recent advances in regenerative biomaterials. <i>Regenerative Biomaterials</i> , 2022, 9, .	2.4	54
6359	How We Have Treated Severe to Critically Ill Patients With Coronavirus Disease 2019 in Korea. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	4
6360	Potentially inappropriate medications based on TIME criteria and risk of in-hospital mortality in COVID-19 patients. <i>Revista Da Associação Médica Brasileira</i> , 2022, 68, 1730-1736.	0.3	1

#	ARTICLE	IF	CITATIONS
6361	Persistent Steroid Exposure Before Coronavirus Disease 2019 Diagnosis and Risk of Hospitalization in Patients With Chronic Obstructive Pulmonary Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 0, , .	0.5	0
6362	Long COVID in Patients with Rheumatologic Disease: A Single Center Observational Study. <i>Indian Journal of Rheumatology</i> , 2023, 18, 212-217.	0.2	3
6363	Integrated rapid-cycle comparative effectiveness trials using flexible point of care randomisation in electronic health record systems. <i>Journal of Biomedical Informatics</i> , 2023, 137, 104273.	2.5	0
6364	A case of amebic colitis and liver abscesses that occurred after treatment of coronavirus disease 2019 with dexamethasone. <i>IDCases</i> , 2023, 31, e01648.	0.4	1
6365	COVID-19 associated Mucormycosis (CAM): Implications for perioperative physicians â€“ A narrative review. <i>Saudi Journal of Anaesthesia</i> , 2023, 17, 58.	0.2	0
6366	Preventing acute lung injury from progressing to pulmonary fibrosis by maintaining ERS homeostasis through a multistage targeting nanomicelle. <i>Nano Today</i> , 2023, 48, 101719.	6.2	6
6367	Increases in stress hormone levels in a UK population during the COVID-19 pandemic: A prospective cohort study. <i>Psychoneuroendocrinology</i> , 2023, 148, 105992.	1.3	3
6368	Life-threatening pneumothorax after release from isolation with COVID-19 pneumonia. <i>Radiology Case Reports</i> , 2023, 18, 903-906.	0.2	0
6369	A tale of two waves: characteristics and outcomes of COVID-19 admissions during the Omicron-driven fourth wave in Cape Town, South Africa, and implications for the future. <i>IJID Regions</i> , 2023, 6, 42-47.	0.5	3
6370	Dexamethasone use and insulin requirements in coronavirus-19 (COVID-19) infection stratified by Hemoglobin A1c. <i>Diabetes Epidemiology and Management</i> , 2023, 10, 100123.	0.4	3
6371	Sars-Cov-2 Pandemic From The Ophthalmologist'S Perspective. A Review. <i>Ceska A Slovenska Oftalmologie</i> , 2022, 78, 217-224.	0.1	1
6372	Sarcopenia associated with COVID-19. <i>Profilakticheskaya Meditsina</i> , 2022, 25, 105.	0.2	1
6373	Damage to the cardiovascular system and complications in Covid-19 infection with a focus on the post-acute covid19 syndrome. <i>Timocki Medicinski Glasnik</i> , 2022, 47, 104-118.	0.0	0
6374	Sabizabulin for the Treatment of Patients Hospitalized with Moderateâ€“Severe COVID-19 (Requiring) Tj ETQq1 1 0.784314 rgBT /Over Pulmonary Diseases, 2022, 7, 32.	0.2	0
6375	Respiratory mechanics in late COVID-19 ARDS â€“ a restrictive pattern is strongly associated with death. A cohort study. <i>Anesthesiology Intensive Therapy</i> , 2022, 54, 295-301.	0.4	1
6376	Immune-Targeted Therapies for COVID-19. , 2022, , 451-468.		0
6377	Nirmatrelvir/Ritonavir Prescription Rate and Outcomes in Coronavirus Disease 2019: A Single Center Study. <i>Infection and Chemotherapy</i> , 2022, 54, 757.	1.0	6
6378	Randomized Trials Fit for the 21st Century. A Joint Opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation. <i>Global Heart</i> , 2022, 17, .	0.9	1

#	ARTICLE	IF	CITATIONS
6379	Cardiovascular implications of the COVID-19: Management of complications and drug safety concerns. <i>Journal of Research in Medical Sciences</i> , 2022, 27, 92.	0.4	0
6380	A 71-Year-Old Man From Ecuador With a History of Type 2 Diabetes Mellitus and Severe COVID-19 Pneumonia and Lung Cavitation Associated With Triple Infection With <i>Trichosporon Asahii</i> , <i>Klebsiella Pneumoniae</i> , and <i>Pseudomonas Aeruginosa</i> . <i>Journal of Investigative Medicine High Impact Case Reports</i> . 2022, 10, 232470962211402.	0.3	1
6382	Clinical Outcomes After Use of Inhaled Corticosteroids or Oral Steroids in a COVID-19 Telemedicine Clinic Cohort: Retrospective Chart Review. <i>JMIR Formative Research</i> , 0, 7, e36023.	0.7	0
6383	Severe Coronavirus disease (COVID)-19: from pathogenesis to therapy. <i>Shock</i> , 0, Publish Ahead of Print, .	1.0	0
6384	COMPARATIVE EVALUATION AND PROGNOSTIC UTILITY OF NEURONAL INJURY BIOMARKERS IN COVID-19 PATIENTS: A PROSPECTIVE STUDY. <i>Shock</i> , 2022, 58, 507-513.	1.0	1
6386	Coronavirus Disease-2019 in Pregnancy. <i>Clinics in Chest Medicine</i> , 2023, 44, 373-384.	0.8	0
6387	Lung Transplantation in Coronavirus-19 Patients. <i>Clinics in Chest Medicine</i> , 2023, 44, 347-357.	0.8	3
6388	High throughput bioluminescent assay to characterize and monitor the activity of SARS-CoV-2 methyltransferases. <i>PLoS ONE</i> , 2022, 17, e0274343.	1.1	0
6389	IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	7
6391	Honey and <i>Nigella sativa</i> against COVID-19 in Pakistan (<i>HNSâ€œCOVIDâ€œPK</i>): A multicenter placebo-controlled randomized clinical trial. <i>Phytotherapy Research</i> , 2023, 37, 627-644.	2.8	20
6392	The Role of VV-ECMO in Severe COVID-19 ARDS. , 0, , .		0
6393	Utility of the HScore for Predicting COVID-19 Severity. <i>Cureus</i> , 2022, , .	0.2	0
6394	Lessons learned from a global perspective of COVID-19. <i>Clinics in Chest Medicine</i> , 2022, , .	0.8	0
6395	Next-generation proteomics of serum extracellular vesicles combined with single-cell RNA sequencing identifies MACROH2A1 associated with refractory COVID-19. <i>Inflammation and Regeneration</i> , 2022, 42, .	1.5	1
6396	Higher- versus Lower-Dose Corticosteroids for Severe to Critical COVID-19: A Systematic Review and Doseâ€œResponse Meta-analysis. <i>Annals of the American Thoracic Society</i> , 2023, 20, 596-604.	1.5	4
6397	COVID-19 in patients with chronic lung disease. <i>Clinics in Chest Medicine</i> , 2022, , .	0.8	1
6398	Fatal Pyopneumothorax in a COVID-19 Patient. <i>Cureus</i> , 2022, , .	0.2	0
6399	Formulation, Device, and Clinical Factors Influencing the Targeted Delivery of COVID-19 Vaccines to the Lungs. <i>AAPS PharmSciTech</i> , 2023, 24, .	1.5	2

#	ARTICLE	IF	CITATIONS
6400	Corticosteroid treatment in severe patients with SARS-CoV-2 and chronic HBV co-infection: a retrospective multicenter study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	2
6401	Initial evaluation of extracorporeal immunomodulatory therapy for the treatment of critically ill COVID-19 infected patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
6402	Structured Benefit-Risk Assessments: An Illustrative Case Study of Paracetamol.. <i>Global Clinical and Translational Research</i> , 2022, , 8-15.	0.4	0
6403	Impact of COVID-19 on Non-Pulmonary Critical Illness: Prevalence, Clinical Manifestations, Management, and Outcomes. <i>Clinics in Chest Medicine</i> , 2022, , .	0.8	0
6404	Efficacy of Therapeutic Plasma Exchange in Severe Acute Respiratory Distress Syndrome in COVID-19 Patients from the Western Part of Romania. <i>Medicina (Lithuania)</i> , 2022, 58, 1707.	0.8	0
6405	Genetics, structure, transmission, epidemiology, immune response, and vaccine efficacies of the SARS-CoV-2 Delta variant: A comprehensive review. <i>Reviews in Medical Virology</i> , 0, , .	3.9	0
6406	Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14462.	1.8	1
6407	Could treatment with immunomodulatory agents targeting IL-1, IL-6, or JAK signalling improve outcomes in patients with severe influenza pneumonia? A systematic and narrative review. <i>HRB Open Research</i> , 0, 5, 77.	0.3	1
6408	Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective. <i>British Journal of Cancer</i> , 0, , .	2.9	0
6409	Hypercoagulability in critically ill patients with COVID 19, an observational prospective study. <i>PLoS ONE</i> , 2022, 17, e0277544.	1.1	5
6410	Ferulic acid derivatives block coronaviruses HCoV-229E and SARS-CoV-2 replication in vitro. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
6411	The Role of the Coagulation System in Peripheral Arterial Disease: Interactions with the Arterial Wall and Its Vascular Microenvironment and Implications for Rational Therapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14914.	1.8	5
6412	Heavy burden of COVID-19-related mortality among the elderly in Corsica, 2020-2021. <i>Clinical Microbiology and Infection</i> , 2022, , .	2.8	0
6413	Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	29
6414	Incidence and Microbiology of Hospital-Acquired Infections in COVID-19 Patients between the First and the Second Outbreak of the SARS-CoV-2 Pandemic: A Retrospective, Observational Study. <i>Microorganisms</i> , 2022, 10, 2372.	1.6	0
6415	Mepolizumab as a Potential Protective Factor of COVID-19 Mortality: A Case Report of Chronic Bronchitis and Asthma in an Elderly Patient. <i>American Journal of Case Reports</i> , 0, 23, .	0.3	1
6416	Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. <i>Pharmaceuticals</i> , 2022, 15, 1456.	1.7	0
6417	Comparison of machine learning methods with logistic regression analysis in creating predictive models for risk of critical in-hospital events in COVID-19 patients on hospital admission. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, .	1.5	7

#	ARTICLE	IF	CITATIONS
6418	Incidence, Outcomes and Risk Factors of Recurrent Ventilator Associated Pneumonia in COVID-19 Patients: A Retrospective Multicenter Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 7097.	1.0	4
6419	Infliximab as a potential treatment for COVID-19. <i>Expert Review of Anti-Infective Therapy</i> , 2023, 21, 1-5.	2.0	4
6420	Antcin A, a phytosterol regulates SARS-CoV-2 spike protein-mediated metabolic alteration in THP1 cells explored by the ¹ H-NMR-based metabolomics approach. <i>Phytotherapy Research</i> , 2023, 37, 885-902.	2.8	2
6421	Immunomodulatory agents for COVID-19 pneumonia. <i>Clinics in Chest Medicine</i> , 2022, , .	0.8	1
6422	Molecular Function of cGAS-STING in SARS-CoV-2: A Novel Approach to COVID-19 Treatment. <i>BioMed Research International</i> , 2022, 2022, 1-10.	0.9	3
6423	N-acetylcysteine Reduces Inflammasome Activation Induced by SARS-CoV-2 Proteins In Vitro. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14518.	1.8	11
6424	Comparison of methylprednisolone pulse vs conventional dexamethasone for adult cases of COVID-19 requiring oxygen; a Japanese retrospective cohort study. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	0.8	0
6425	Preparing for the next pandemic: Simulation-based deep reinforcement learning to discover and test multimodal control of systemic inflammation using repurposed immunomodulatory agents. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
6426	Increased KL-6 levels in moderate to severe COVID-19 infection. <i>PLoS ONE</i> , 2022, 17, e0273107.	1.1	0
6427	The Effects of the COVID Pandemic on Patients with IBD: Lessons Learned and Future Directions. <i>Journal of Clinical Medicine</i> , 2022, 11, 7002.	1.0	3
6428	Real-world Evidence of the Effects of Novel Treatments for COVID-19 on Mortality: A Nationwide Comparative Cohort Study of Hospitalized Patients in the First, Second, Third, and Fourth Waves in the Netherlands. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	4
6429	SARS-CoV-2 Infection and COVID-19 in Children. <i>Clinics in Chest Medicine</i> , 2023, 44, 359-371.	0.8	6
6430	Effect of Remote Ischaemic Conditioning on the Inflammatory Cytokine Cascade of COVID-19 (RIC in) Tj ETQq0 0 0 rgBT /Overlock 10 Tt	1.3	1
6431	FEATURES OF PATHOGENESIS, COURSE AND THERAPY OF PNEUMONIA UNDER COVID-19 (Literature Review). , 2022, 22, 220-225.	0.1	1
6432	SARS-CoV-2 infection and cardiac arrhythmias. , 2022, 1, 1109-1110.		7
6433	Clinical Characterization of the Three Waves of COVID-19 Occurring in Southern Italy: Results of a Multicenter Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 16003.	1.2	6
6434	Very Low Driving-Pressure Ventilation in Patients With COVID-19 Acute Respiratory Distress Syndrome on Extracorporeal Membrane Oxygenation: A Physiologic Study. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2023, 37, 423-431.	0.6	2
6435	Pathological Roles of Pulmonary Cells in Acute Lung Injury: Lessons from Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15027.	1.8	2

#	ARTICLE	IF	CITATIONS
6436	Academic and Community ICUs Participating in a Critical Care Randomized Trial: A Comparison of Patient Characteristics and Trial Metrics. , 2022, 4, e0794.		1
6437	Liposomal amphotericin Bâ€”the future. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, ii21-ii34.	1.3	5
6438	Pathological Lung Patterns of COVID-19 and its Clinical Correlation to Disease Severity. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 1285-1292.	0.3	2
6439	Study Protocol for a Randomized Double-blind Placebo-controlled Phase 2 Clinical Trial to Assess Anti-inflammatory Effect of Colchicine (DRC3633) in Mild to Moderately Severe COVIDâ€™19 Patients (DRC-06C). <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2022, 53, 199-205.	0.1	1
6440	Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 1716-1727.	2.0	2
6441	Annexin A1 Is Associated with Adverse Clinical Outcomes in Patients with COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 7486.	1.0	2
6442	Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care. <i>Lancet Respiratory Medicine</i> ,the, 2023, 11, 415-424.	5.2	16
6443	The Impact of Clostridioides Difficile Infection in Hospitalized Patients: What Changed during the Pandemic?. <i>Diagnostics</i> , 2022, 12, 3196.	1.3	6
6444	A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2023, 67, .	1.4	10
6445	Treatment of pregnant and early postpartum women with severe and critical COVID-19: experience at a tertiary center. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	1
6446	HIV-Associated Mycobacterium Avium Complex, Oral Candida, and SARS-CoV-2 Co-Infection: A Rare Case Report. <i>Infection and Drug Resistance</i> , 0, Volume 15, 7037-7042.	1.1	1
6447	Involvement of the STING signaling in COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
6448	COVID-19 in Patients with Rheumatic Disease Using Immunomodulatory Drugs: Imaging Findings and Predictors of Hospitalization. <i>Rheumatology and Therapy</i> , 0, , .	1.1	1
6449	COVIDâ€™19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and metaâ€™analysis. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	6
6450	Quality, integrity and utility of COVID-19 science: opportunities for public health researchers. <i>European Journal of Public Health</i> , 2023, 33, 157-158.	0.1	3
6451	Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients. <i>Viruses</i> , 2022, 14, 2728.	1.5	3
6452	COVID Associated Invasive Aspergillosis. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2023, 75, 557-562.	0.3	2
6453	Proteomic profiling of end-stage COVID-19 lung biopsies. <i>Clinical Proteomics</i> , 2022, 19, .	1.1	1

#	ARTICLE	IF	CITATIONS
6454	Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	17
6456	The origin of regulatory from the effector cells in LAG β -marked Th1 immunity against severe influenza virus infection. <i>Immunology</i> , 2023, 169, 167-184.	2.0	2
6457	Genicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial. <i>Journal of Global Antimicrobial Resistance</i> , 2023, 32, 44-47.	0.9	2
6458	Clinical Outcomes in COVID-19 Patients Treated with Immunotherapy. <i>Cancers</i> , 2022, 14, 5954.	1.7	0
6460	Inhaled Sargramostim (Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor) for COVID-19-Associated Acute Hypoxemia: Results of the Phase 2, Randomized, Open-Label Trial (iLeukPulm). <i>Military Medicine</i> , 2023, 188, e2629-e2638.	0.4	5
6461	Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease. <i>PLoS ONE</i> , 2022, 17, e0277646.	1.1	3
6462	Dysbiosis: An Indicator of COVID-19 Severity in Critically Ill Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15808.	1.8	2
6463	Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19. <i>JAMA Network Open</i> , 2022, 5, e2242918.	2.8	2
6464	The impact of Omicron pandemic and COVID-19 vaccination on the pancreatic adenocarcinoma patients. <i>Ageing and Cancer</i> , 0, , .	0.5	1
6466	Laboratory test trends within 72 hours of hospital admission associated with death among COVID-19 patients. <i>Medicine (United States)</i> , 2022, 101, e31154.	0.4	0
6467	COVID-19 Drug Development: Role of Drug Repurposing. , 0, , .		0
6469	Intensive care unit burden is associated with increased mortality in critically ill COVID-19 patients. <i>Acta Anaesthesiologica Scandinavica</i> , 2023, 67, 329-338.	0.7	3
6470	Influence of Nutritional Parameters on the Evolution, Severity and Prognosis of Critically Ill Patients with COVID-19. <i>Nutrients</i> , 2022, 14, 5363.	1.7	3
6471	How clinical research nursing is shaping the future of urology trials. <i>British Journal of Nursing</i> , 2022, 31, 1136-1142.	0.3	0
6472	A leap towards personalised therapy of acute lung injury. <i>European Respiratory Journal</i> , 2022, 60, 2201808.	3.1	1
6473	COVID-19-associated Pulmonary Mucormycosis Study from a Tertiary Care Hospital, Rajkot, Gujarat, India: A Case Series. <i>The Indian Journal of Chest Diseases & Allied Sciences</i> , 2022, 64, 173-176.	0.1	0
6474	Small molecules in the treatment of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	42
6475	Transplantation Amid a Pandemic: The Fall and Rise of Kidney Transplantation in the United States. <i>Transplantation Direct</i> , 2023, 9, e1423.	0.8	1

#	ARTICLE	IF	CITATIONS
6476	Safety and efficacy of prophylactic anticoagulation versus therapeutic anticoagulation in hospitalized admitted COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Respiratory Journal</i> , 2023, 17, 73-79.	0.6	3
6477	Predicting the response to methylprednisolone pulses in patients with SARS-COV-2 infection. <i>Medicina Clínica (English Edition)</i> , 2022, 159, 557-562.	0.1	0
6478	Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence. <i>Nature Communications</i> , 2022, 13, .	5.8	13
6479	Randomized Trials Fit for the 21st Century: A Joint Opinion From the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation. <i>Circulation</i> , 0, , .	1.6	1
6481	Corticosteroid Uptake For COVID-19 after Publication of RECOVERY: A Difference in Difference Model. <i>Annals of the American Thoracic Society</i> , 2023, 20, 473-476.	1.5	2
6482	Donor selection for adoptive cell therapy with CD45RA ^{hi} memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release. <i>Cytotherapy</i> , 2023, 25, 330-340.	0.3	2
6483	ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial. <i>Trials</i> , 2022, 23, .	0.7	4
6484	Effect of Dexamethasone on the Incidence and Outcome of COVID-19 Associated Pulmonary Aspergillosis (CAPA) in Critically Ill Patients during First- and Second Pandemic Wave—A Single Center Experience. <i>Diagnostics</i> , 2022, 12, 3049.	1.3	0
6485	Randomized trials fit for the 21st century. A joint opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation. <i>European Heart Journal</i> , 2023, 44, 931-934.	1.0	3
6486	Bioinformatics insights into the genes and pathways on severe COVID-19 pathology in patients with comorbidities. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	2
6488	Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19. <i>Current Issues in Molecular Biology</i> , 2023, 45, 33-50.	1.0	14
6489	Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?. <i>Drugs</i> , 2023, 83, 1-36.	4.9	4
6490	Nebulised interferon- β 1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study. <i>ERJ Open Research</i> , 2023, 9, 00605-2022.	1.1	5
6492	Antibiotics Use in COVID-19 Patients: A Systematic Literature Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 7207.	1.0	11
6493	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. <i>European Journal of Cancer</i> , 2023, 181, 102-118.	1.3	2
6494	Endothelial Damage and the Microcirculation in Critical Illness. <i>Biomedicines</i> , 2022, 10, 3150.	1.4	7
6495	Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	11
6496	Strategies Tackling Viral Replication and Inflammatory Pathways as Early Pharmacological Treatment for SARS-CoV-2 Infection: Any Potential Role for Ketoprofen Lysine Salt?. <i>Molecules</i> , 2022, 27, 8919.	1.7	2

#	ARTICLE	IF	CITATIONS
6498	Assessment of the pneumonia severity score in community-acquired and nursing and healthcare-associated pneumonia due to COVID-19. <i>Journal of Infection and Chemotherapy</i> , 2023, 29, 437-442.	0.8	2
6499	The role of ECMO in COVID-19 acute respiratory failure: Defining risk factors for mortality. <i>American Journal of Surgery</i> , 2023, 225, 1096-1101.	0.9	2
6500	Age and Comorbidities Predict COVID-19 Outcome, Regardless of Innate Immune Response Severity: A Single Institutional Cohort Study. , 2022, 4, e0799.		4
6501	Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review. <i>Expert Review of Hematology</i> , 2022, 15, 1045-1054.	1.0	4
6503	Therapeutic Approaches for Chronic Obstructive Pulmonary Disease (COPD) Exacerbations. <i>Pathogens</i> , 2022, 11, 1513.	1.2	8
6504	Nanoparticle Formulation Composition Analysis by Liquid Chromatography on Reversed-Phase Monolithic Silica. <i>Analytical Chemistry</i> , 0, , .	3.2	0
6505	Characteristics and risk factors for post-COVID-19 breathlessness after hospitalisation for COVID-19. <i>ERJ Open Research</i> , 2023, 9, 00274-2022.	1.1	6
6506	Circulating adipokine levels and COVID-19 severity in hospitalized patients. <i>International Journal of Obesity</i> , 2023, 47, 126-137.	1.6	13
6507	Magic bullets, magic shields, and antimicrobials in between. , 2023, 1, 100002.		2
6508	Comparing rehabilitation outcomes for patients admitted to the intensive care unit with COVID-19 requiring mechanical ventilation during the first two waves of the pandemic: A service evaluation. <i>Intensive and Critical Care Nursing</i> , 2023, 75, 103370.	1.4	1
6509	Eosinopenia as Predictor of Poor Outcome in Hospitalized COVID-19 Adult Patients from Waves 1 and 2 of 2020 Pandemic. <i>Microorganisms</i> , 2022, 10, 2423.	1.6	5
6510	Management of Coronavirus Disease-2019 Infection in Pregnancy. <i>Emergency Medicine Clinics of North America</i> , 2023, 41, 307-322.	0.5	0
6511	COVID-19 and Pulmonary Embolism Outcomes among Hospitalized Patients in the United States: A Propensity-Matched Analysis of National Inpatient Sample. <i>Vaccines</i> , 2022, 10, 2104.	2.1	4
6512	A B1aâ€œnatural IgGâ€œneutrophil axis is impaired in viral- and steroid-associated aspergillosis. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	14
6513	Potential therapeutic value of necroptosis inhibitor for the treatment of COVID-19. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	5
6514	Criteria for hyperinflammation developing in coronavirus diseaseâ€œ19: analysis of two cohorts from different periods of the pandemic. <i>Arthritis and Rheumatology</i> , 0, , .	2.9	1
6515	A comprehensive clinical guide for<i>Pneumocystis jirovecii</i>pneumonia: a missing therapeutic target in HIV-uninfected patients. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 1167-1190.	1.0	9
6516	COVIDâ€œ19â€œrelated medicine utilization study in pregnancy: The COVIâ€œPREG cohort. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 1560-1574.	1.1	2

#	ARTICLE	IF	CITATIONS
6517	Identification of two specific transcriptomic clusters of COVID-19 ARDS patients with different immune profiles and different outcomes. <i>European Respiratory Journal</i> , 0, , 2202008.	3.1	0
6518	Probing the Neuro-psychological Changes Observed with the Administration of COVID-19 Drugs. <i>Current Topics in Medicinal Chemistry</i> , 2023, 23, 143-154.	1.0	2
6519	Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study. <i>Wellcome Open Research</i> , 0, 6, 216.	0.9	0
6520	3D printed matrix solid forms: Can the drug solubility and dose customisation affect their controlled release behaviour?. <i>International Journal of Pharmaceutics: X</i> , 2023, 5, 100153.	1.2	3
6521	Use of therapeutic plasma exchange in COVID-19: A systematic review of current evidence. <i>Therapeutic Apheresis and Dialysis</i> , 0, , .	0.4	1
6522	Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation. <i>Health Research Policy and Systems</i> , 2022, 20, .	1.1	3
6523	Control of blood glucose levels by an artificial pancreas in patients with severe coronavirus disease 2019 pneumonia. <i>Artificial Organs</i> , 2023, 47, 990-998.	1.0	2
6524	Prolonged COVID-19 in a Multiple Sclerosis Patient Treated With Rituximab. <i>Cureus</i> , 2022, , .	0.2	1
6525	Predictors and Outcomes of Healthcare-Associated Infections among Patients with COVID-19 Admitted to Intensive Care Units in Punjab, Pakistan; Findings and Implications. <i>Antibiotics</i> , 2022, 11, 1806.	1.5	6
6526	Challenges of using external data in clinical trials- an illustration in patients with COVID-19. <i>BMC Medical Research Methodology</i> , 2022, 22, .	1.4	2
6527	Hypothesis: Efficacy of early treatments with some NSAIDs in COVID-19: Might it also depend on their direct and/or indirect zinc chelating ability?. <i>British Journal of Pharmacology</i> , 2023, 180, 279-286.	2.7	3
6528	Demographic and Clinical Profile of Patients Presenting with COVID-19-Associated Rhino-orbito-cerebral Mucormycosis at a Tertiary Care Center. <i>Annals of the National Academy of Medical Sciences (India)</i> , 0, , .	0.2	0
6529	Pulmonary function test results and radiological findings 90-120 days after COVID-19 pneumonia: a single-center retrospective study. <i>Medical Science Pulse</i> , 2022, 16, 1-8.	0.1	0
6530	Different treatment response to systemic corticosteroids according to white blood cell counts in severe COVID-19 patients. <i>Annals of Medicine</i> , 2022, 54, 2998-3006.	1.5	0
6531	Discharge to Post-Acute Care and Other Predictors of Prolonged Length of Stay During the Initial COVID-19 Surge: A Single Site Analysis. <i>International Journal for Quality in Health Care</i> , 0, , .	0.9	1
6532	Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	20
6533	Substance abuse and the risk of severe COVID-19: Mendelian randomization confirms the causal role of opioids but hints a negative causal effect for cannabinoids. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
6534	Hyperactive immature state and differential CXCR2 expression of neutrophils in severe COVID-19. <i>Life Science Alliance</i> , 2023, 6, e202201658.	1.3	9

#	ARTICLE	IF	CITATIONS
6535	COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Xenobiotics). <i>Journal of Medical Toxicology</i> , 2023, 19, 26-36.	0.8	5
6536	Selective CB2 Receptor Agonist, HU-308, Reduces Systemic Inflammation in Endotoxin Model of Pneumonia-Induced Acute Lung Injury. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15857.	1.8	4
6537	Approaches to enabling rapid evaluation of innovations in health and social care: a scoping review of evidence from high-income countries. <i>BMJ Open</i> , 2022, 12, e064345.	0.8	3
6538	Equitable well-being, social trust, and the economy: An integrated health system's perspectives on the long-term implications of COVID-19. <i>Progress in Cardiovascular Diseases</i> , 2023, 76, 57-60.	1.6	2
6539	Recent developments in the immunopathology of COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 369-388.	2.7	33
6540	Use of a simplified local guideline improves front door management of diabetes and hyperglycaemia in people admitted to hospital with COVID-19. <i>British Journal of Diabetes</i> , 2022, 22, 129-131.	0.1	0
6541	Anti-inflammatory effects of medications used for viral infection-induced respiratory diseases. <i>Respiratory Investigation</i> , 2022, , .	0.9	4
6542	Effectiveness of corticosteroids to treat coronavirus disease 2019 symptoms: A meta-analysis. <i>Medicina Clínica (English Edition)</i> , 2022, 159, 575-583.	0.1	1
6543	Immune-based therapy for hospitalized patients with COVID-19 and risk of secondary infections: A systematic review and meta-analysis. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	1
6544	Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial. <i>International Journal of Infectious Diseases</i> , 2023, 128, 223-229.	1.5	7
6545	Profil pasien COVID-19 rawat inap di Rumah Sakit Ari Canti, Gianyar, Bali, Indonesia. <i>Intisari Sains Medis</i> , 2022, 13, 684-689.	0.1	0
6547	Gaps and opportunities in sepsis translational research. <i>EBioMedicine</i> , 2022, 86, 104387.	2.7	6
6548	Factors associated with critical care requirements in diabetic patients treated with dexamethasone for COVID-19 infection in the first wave of the pandemic. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
6549	Influenza antivirals and their role in pandemic preparedness. <i>Antiviral Research</i> , 2023, 210, 105499.	1.9	17
6550	FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. <i>Nature</i> , 2023, 615, 134-142.	13.7	131
6551	Long-term Follow-up After Critical COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 0, , .	3.8	4
6552	Lymphopenia in sepsis an acquired immunodeficiency?. <i>Immunology and Cell Biology</i> , 2023, 101, 535-544.	1.0	12
6553	Early Short-Term Use of Different Doses of Corticosteroid in Hospitalized Pediatric Patients with Coronavirus Disease 2019 Pneumonia. <i>Journal of Pediatric Infectious Diseases</i> , 2023, 18, 001-009.	0.1	1

#	ARTICLE	IF	CITATIONS
6554	Interventions and outcomes of COVID-19 patients in a community hospital—A single center study comparing the first and second waves. <i>PLoS ONE</i> , 2022, 17, e0279208.	1.1	1
6555	Tolerogenic Dendritic Cells Induce Apoptosis-Independent T Cell Hyporesponsiveness of SARS-CoV-2-Specific T Cells in an Antigen-Specific Manner. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15201.	1.8	0
6556	The correlation between serum 25-hydroxy-vitamin D levels and anti-SARS-CoV-2 S-RBD IgG and neutralizing antibody levels among cancer patients receiving COVID-19 vaccines. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	4
6557	Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms. <i>Frontiers in Molecular Medicine</i> , 0, 2, .	0.6	2
6558	Effect of Tocilizumab on Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta or Omicron Variants: A Propensity-Matched Analysis in Nimes University Hospital, France. <i>Antibiotics</i> , 2023, 12, 88.	1.5	1
6559	Safety and outcomes of an early discharge strategy with oxygen home therapy in stable severe COVID-19 patients. <i>Infectious Diseases</i> , 2023, 55, 292-298.	1.4	6
6560	Inflammatory Bowel Disease in the Childbearing Adult and Newborn. <i>NeoReviews</i> , 2023, 24, 10-23.	0.4	0
6561	Proinflammatory and Thrombotic Manifestations and the Therapeutic Options of COVID-19. <i>Journal of Global Humanities and Social Sciences</i> , 2023, , 49-78.	0.3	0
6562	The Rationale for Using Corticosteroids in COVID-19 Encephalopathy: Lessons From a Case Report With Evidence From Literature. <i>Cureus</i> , 2023, , .	0.2	0
6563	Current and Emerging Knowledge in COVID-19. <i>Radiology</i> , 2023, 306, .	3.6	30
6564	Pituitary-Immune Interface. , 2022, , 375-384.		0
6565	Screening the binding affinity of bile acid derivatives for the glucocorticoid receptor ligand-binding domain. <i>Journal of the Serbian Chemical Society</i> , 2023, 88, 123-139.	0.4	3
6566	Outcome of patients receiving V-V ECMO for SARS-CoV-2 severe acute respiratory failure. <i>Pulmonology</i> , 2023, 29, 240-243.	1.0	1
6567	COVID-19 patients' clinical profile and outcome with respect to their vaccination status: A prospective observational multicentre cohort study during third wave in Western India. <i>Indian Journal of Medical Microbiology</i> , 2023, 41, 28-32.	0.3	2
6568	HIV and COVID-19 Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 035-049.	0.8	2
6569	Two-year follow-up of the COVID-19 pandemic in Mexico. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	8
6570	Microvascular significance of TGF- β 2 axis activation in COVID-19. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	11
6571	Distinct systemic immune networks define severe vs. mild COVID-19 in hematologic and solid cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0

#	ARTICLE	IF	CITATIONS
6572	A tale of two diseases. <i>Journal of Human Hypertension</i> , 0, , .	1.0	0
6573	Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. <i>Viruses</i> , 2023, 15, 175.	1.5	33
6574	A hyperinflammation clinical risk tool, HIS-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohort. <i>PLoS ONE</i> , 2023, 18, e0280079.	1.1	0
6575	Baricitinib or imatinib in hospitalized COVID-19 patients: Results from COVINIB, an exploratory randomized clinical trial. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	4
6576	Bayes's Theorem in Neurocritical Care: Principles and Practice. <i>Neurocritical Care</i> , 0, , .	1.2	0
6577	An Integrated Radiologic-Pathologic Understanding of COVID-19 Pneumonia. <i>Radiology</i> , 2023, 306, .	3.6	11
6578	Learning how to treat coronavirus disease 2019 in hematopoietic stem cell transplant patients. <i>Transplant Infectious Disease</i> , 2023, 25, .	0.7	0
6579	Refocus on Immunogenic Characteristics of Convalescent COVID-19 Challenged by Prototype SARS-CoV-2. <i>Vaccines</i> , 2023, 11, 123.	2.1	3
6580	Safety-Related Drug Label Changes Following Large Post-Marketing Cardiometabolic Trials: A Review of European Public Assessment Reports. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 859-866.	2.3	0
6581	The Outcome of COVID-19 Infection on Kidney Transplantation Recipients in Southern Saudi Arabia: Single-Center Experience. <i>Transplantation Proceedings</i> , 2023, 55, 521-529.	0.3	0
6582	Techniques for Oxygenation and Ventilation in Coronavirus Disease 2019. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 091-099.	0.8	1
6583	Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	10
6584	Modification of Sympathetic and Hypothalamic Responses to Prevent Complications of COVID-19: A Dam and Wall Concept's Stresses, 2023, 3, 153-166.	1.8	0
6585	Correlates of Coronavirus Disease 2019 Inpatient Mortality at a Southern California Community Hospital With a Predominantly Hispanic/Latino Adult Population. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	3
6586	Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation. <i>Nature Communications</i> , 2023, 14, .	5.8	2
6587	Covid-19: What the pandemic has taught us and the way forward. <i>The National Medical Journal of India</i> , 0, 35, 193-196.	0.1	0
6588	PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection. <i>Journal of the American College of Cardiology</i> , 2023, 81, 224-234.	1.2	32
6589	Pharmacological Activities of Fingerroot Extract and Its Phytoconstituents Against SARS-CoV-2 Infection in Golden Syrian Hamsters. <i>Journal of Experimental Pharmacology</i> , 0, Volume 15, 13-26.	1.5	3

#	ARTICLE	IF	CITATIONS
6590	Comparison of the efficacy of equivalent doses of dexamethasone, methylprednisolone, and hydrocortisone for treatment of COVID-19-related acute respiratory distress syndrome: a prospective three-arm randomized clinical trial. <i>Wiener Medizinische Wochenschrift</i> , 2023, 173, 140-151.	0.5	4
6591	Peptide-guided delivery improves the therapeutic efficacy and safety of glucocorticoid drugs for treating acute lung injury. <i>Molecular Therapy</i> , 2023, 31, 875-889.	3.7	3
6592	A Review of Coronavirus Disease 2019 in Pregnancy. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 050-065.	0.8	0
6593	Immuno-Modulatory Effects of Dexamethasone in Severe COVID-19—A Swedish Cohort Study. <i>Biomedicines</i> , 2023, 11, 164.	1.4	3
6594	Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea. <i>Pulmonary Pharmacology and Therapeutics</i> , 2023, , 102189.	1.1	0
6595	Early Stage Combination Treatment with Methylprednisolone Pulse and Remdesivir for Severe COVID-19 Pneumonia. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 1081.	1.2	1
6596	Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa. <i>Nature Communications</i> , 2023, 14, .	5.8	17
6597	Biological Markers to Predict Outcome in Mechanically Ventilated Patients with Severe COVID-19 Living at High Altitude. <i>Journal of Clinical Medicine</i> , 2023, 12, 644.	1.0	2
6598	Age-related Differences in Immune Reactions to SARS-CoV-2 Spike and Nucleocapsid Antigens. <i>In Vivo</i> , 2023, 37, 70-78.	0.6	3
6599	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities. <i>PLoS Pathogens</i> , 2023, 19, e1011063.	2.1	7
6600	Pathobiological bases of asthma-COVID-19 interaction: A theoretical viewpoint. , 0, .		0
6601	Multicenter Case—Control Study of COVID-19—Associated Mucormycosis Outbreak, India. <i>Emerging Infectious Diseases</i> , 2023, 29, 8-19.	2.0	33
6602	The need for COVID-19 clinical trials in LMICs. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
6604	Glucocorticoid Therapy in COVID-19. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 100-117.	0.8	6
6605	Acute kidney injury in Jamaicans with sickle cell disease hospitalized with COVID-19 infection. <i>EJHaem</i> , 0, , .	0.4	0
6606	Innate immune evasion strategies of SARS-CoV-2. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	31
6607	COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection. <i>Journal of Translational Autoimmunity</i> , 2023, 6, 100190.	2.0	0
6608	Ventilator Acquired Pneumonia in COVID-19 ICU Patients: A Retrospective Cohort Study during Pandemia in France. <i>Journal of Clinical Medicine</i> , 2023, 12, 421.	1.0	5

#	ARTICLE	IF	CITATIONS
6609	SARS-CoV-2 Z-RNA activates the ZBP1-RIPK3 pathway to promote virus-induced inflammatory responses. <i>Cell Research</i> , 2023, 33, 201-214.	5.7	22
6610	Pharmacokinetic/Pharmacodynamic Modeling of Dexamethasone Anti-Inflammatory and Immunomodulatory Effects in LPS-Challenged Rats: A Model for Cytokine Release Syndrome. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2023, 384, 455-472.	1.3	8
6611	Comparison of Efficacy and Safety of Low-Dose Versus High-Dose Dexamethasone in Hospitalized COVID-19 Patients: A Meta-Analysis. <i>Cureus</i> , 2023, , .	0.2	1
6612	Cross-immunity against SARS-CoV-2 variants of concern in naturally infected critically ill COVID-19 patients. <i>Heliyon</i> , 2023, 9, e12704.	1.4	2
6613	Obstruktív tüdőbetegségek súlyosbodása SARS-CoV-2-fertőzés hatására a marosvásárhelyi Pulmonológiai Klinika beteganyagában. <i>Orvosi Hetilap</i> , 2023, 164, 43-50.	0.1	0
6614	Secondary subcutaneous abscess due to mixed infections by <i>Peptoniphilus olseni</i> and <i>Gleimia europaea</i> after COVID-19. <i>Clinical Case Reports (discontinued)</i> , 2023, 11, .	0.2	2
6615	Which trial do we need? Management of elderly, fragile, fully vaccinated patients hospitalized for SARS-CoV-2 infection. <i>Clinical Microbiology and Infection</i> , 2023, 29, 419-421.	2.8	0
6616	Characteristics, outcomes, and risk factors for in-hospital mortality of COVID-19 patients: A retrospective study in Thailand. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
6617	Epidemiology and outcomes of early-onset AKI in COVID-19-related ARDS in comparison with non-COVID-19-related ARDS: insights from two prospective global cohort studies. <i>Critical Care</i> , 2023, 27, .	2.5	7
6618	Effects of dexamethasone use on viral clearance among patients with COVID-19: a multicenter cohort study. <i>International Journal of Infectious Diseases</i> , 2023, 128, 257-264.	1.5	0
6620	The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19. <i>Transplant Immunology</i> , 2023, 77, 101777.	0.6	0
6621	Acute Respiratory Distress Syndrome in Pregnancy: Updates in Principles and Practice. <i>Clinical Obstetrics and Gynecology</i> , 2023, 66, 208-222.	0.6	0
6622	Cytokine Storm, Immunomodulators and Mucormycosis in COVID-19: Bench To Bed Side. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 4871-4875.	0.2	3
6623	Gravité de la COVID-19 chez les receveurs d'une transplantation d'organe plein au Canada, 2020-2021 : Étude de cohorte prospective multicentrique. <i>Cmaj</i> , 2022, 194, E1578-E1586.	0.9	0
6624	Perspective Chapter: Cardiovascular Post-Acute COVID-19 Syndrome – Definition, Clinical Scenarios, Diagnosis, and Management. , 0, , .		1
6625	In vitro Antiviral Activity of Remdesivir Against SARS-CoV-2 and its Variants. <i>Journal of Bacteriology and Virology</i> , 2022, 52, 149-159.	0.0	0
6627	Drug-drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case-control study in the National COVID Cohort Collaborative (N3C). <i>BMJ Open</i> , 2022, 12, e066846.	0.8	2
6629	Prognostic values of baseline cortisol levels and neutrophil to lymphocyte ratio in COVID-19. <i>Journal of Medical Biochemistry</i> , 0, , .	0.7	1

#	ARTICLE	IF	CITATIONS
6632	The impact of the coronavirus pandemic on sedation in critical care: volatile anesthetics in the ICU. <i>Current Opinion in Critical Care</i> , 2023, 29, 14-18.	1.6	2
6633	A Clinical Case of Nosocomial Pneumonia as a Complication of COVID-19: How to Balance Benefits and Risks of Immunosuppressive Therapy?. <i>Antibiotics</i> , 2023, 12, 53.	1.5	3
6634	Impact of Early SARS-CoV-2 Antiviral Therapy on Disease Progression. <i>Viruses</i> , 2023, 15, 71.	1.5	18
6636	Evidence-based prescription of corticosteroids for COVID-19 patients: A comparison between general medicine and other specialty in Japan. <i>Journal of General and Family Medicine</i> , 0, , .	0.3	1
6637	Perforation of the Diverticulum in the Sigmoid Colon Following Administration of Tocilizumab for Treatment of Coronavirus Infection-Associated Pneumonia: A Case Report. <i>Japanese Journal of Gastroenterological Surgery</i> , 2022, 55, 780-785.	0.0	0
6638	Pharmacokinetic Study of Intranasal Dexamethasone and Methylprednisolone Compared with Intravenous Administration: Two Open-Label, Single-Dose, Two-Period, Two-Sequence, Cross-Over Study in Healthy Volunteers. <i>Pharmaceutics</i> , 2023, 15, 105.	2.0	5
6639	Manifestations of Mucormycosis and Its Complications in COVID-19 Patients: A Case Series Study. <i>Ear, Nose and Throat Journal</i> , 0, , 014556132211438.	0.4	0
6641	Changing epidemiology of acute kidney injury in critically ill patients with COVID-19: a prospective cohort. <i>Annals of Intensive Care</i> , 2022, 12, .	2.2	5
6642	Kinetics of Immune Subsets in COVID-19 Patients Treated with Corticosteroids. <i>Viruses</i> , 2023, 15, 51.	1.5	5
6643	Analysis of risk factors of fungal superinfections in viral pneumonia patients: A systematic review and meta-analysis. <i>Immunity, Inflammation and Disease</i> , 2023, 11, .	1.3	1
6644	Hospitalised COVID-19 outcomes are predicted by hypoxaemia and pneumonia phenotype irrespective of the timing of their emergence. <i>BMJ Open</i> , 2022, 12, e062453.	0.8	0
6645	Corticosteroid Therapy in Severe Cases of Pneumonia Caused by SARS-CoV-2. <i>Cureus</i> , 2022, , .	0.2	0
6646	Mortality and Associated Factors in Patients with COVID-19: Cross-Sectional Study. <i>Vaccines</i> , 2023, 11, 71.	2.1	0
6649	An Unfrequent Neurologic Complication of COVID-19 at the Critical Care Unit. <i>Infectious Diseases in Clinical Practice</i> , 2023, 31, .	0.1	0
6650	An in-hospital relapse case of an elderly COVID-19 patient on steroids. <i>Okayama Igakkai Zasshi</i> , 2022, 134, 171-175.	0.0	0
6651	Clinical follow up of renal transplant recipients with COVID-19: a case series. <i>Cukurova Medical Journal</i> , 2022, 47, 1746-1752.	0.1	0
6652	The impact of COVID-19 on multidrug-resistant organisms causing healthcare-associated infections: a narrative review. <i>JAC-Antimicrobial Resistance</i> , 2022, 5, .	0.9	15
6653	Pathomechanisms of SARS-CoV-2 infection and development of atherosclerosis in patients with COVID-19: A review. <i>Medicine (United States)</i> , 2022, 101, e31540.	0.4	7

#	ARTICLE	IF	CITATIONS
6654	Comparison with Spectrophotometric and Liquid Chromatographic Methods of Pharmaceutical Forms of Ivermectin. <i>Medical Records</i> , 2023, 5, 126-31.	0.4	1
6656	A Surveillance System Controlling Covid-19 in Office Environments. , 2022, , .		0
6657	Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review. <i>Biology</i> , 2023, 12, 177.	1.3	11
6658	The Impact of the Society of Critical Care Medicine's Flagship Journal: <i>Critical Care Medicine: Reflections of Critical Care Pioneers</i> . <i>Critical Care Medicine</i> , 2023, 51, 164-181.	0.4	0
6660	Sepsis presentation and pathophysiology. , 2023, , 489-501.		0
6661	Coronavirus disease 2019 and severe asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 0, Publish Ahead of Print, .	1.1	0
6662	Persistent Pneumonic Consolidations due to Secondary Organizing Pneumonia in a Patient Recovering from COVID-19 Pneumonia: A Case Report and Literature Review. <i>Infection and Chemotherapy</i> , 2023, 55, 121.	1.0	4
6663	Dynamic activity in cis-regulatory elements of leukocytes identifies transcription factor activation and stratifies COVID-19 severity in ICU patients. <i>Cell Reports Medicine</i> , 2023, 4, 100935.	3.3	2
6664	Variation of the COVID-19 characteristics between genders. , 2023, , 577-593.		0
6665	Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study. <i>PLoS Medicine</i> , 2023, 20, e1004086.	3.9	24
6666	Optimal palatability of a cup of tea: don't forget spoon bias. <i>BMJ, The</i> , 0, , p146.	3.0	0
6667	Functionally Collaborative Nanostructure for Direct Monitoring of Neurotransmitter Exocytosis in Living Cells. <i>Nano Letters</i> , 2023, 23, 2427-2435.	4.5	4
6668	Outcome of COVID-19 infections in patients with adrenal insufficiency and excess. <i>Endocrine Connections</i> , 2023, 12, .	0.8	5
6669	Inflammatory protection and management during extracorporeal membrane oxygenation. , 2023, , 1003-1020.		0
6670	Association between periodontitis and COVID-19 infection: a two-sample Mendelian randomization study. <i>PeerJ</i> , 0, 11, e14595.	0.9	4
6671	Clinical relevance of timing of assessment of ICU mortality in patients with moderate-to-severe Acute Respiratory Distress Syndrome. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
6673	Management of acute COVID-19 in the pediatric population and role of antimicrobial therapy. , 2023, , 99-139.		1
6674	The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19—Results from a pragmatic randomized clinical trial. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	2

#	ARTICLE	IF	CITATIONS
6675	Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome—An Extempore Game of Misfiring with Defense Arsenal. <i>Pathogens</i> , 2023, 12, 210.	1.2	3
6676	Mechanisms of impaired alveolar fluid clearance. <i>Anatomical Record</i> , 0, , .	0.8	2
6677	Non-Dexamethasone Corticosteroid Therapy's Effect on COVID-19 Prognosis in Cancer Patients: A Retrospective Study. <i>Vaccines</i> , 2023, 11, 290.	2.1	0
6678	Development of a multivariate model with desirability-based optimization for simultaneous determination of five co-administrated drugs for the management of COVID-19 infection in their dosage forms <i>via</i> validated RP-HPLC method. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2022, 45, 191-203.	0.5	1
6679	International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship. <i>ELife</i> , 0, 12, .	2.8	3
6680	SARS-CoV-2 Establishes a Productive Infection in Hepatoma and Glioblastoma Multiforme Cell Lines. <i>Cancers</i> , 2023, 15, 632.	1.7	3
6681	Long-term outcome of thyroid abnormalities in patients with severe Covid-19. <i>European Thyroid Journal</i> , 2023, 12, .	1.2	4
6682	Pulmonary Specific Ancillary Treatment for Pediatric Acute Respiratory Distress Syndrome: From the Second Pediatric Acute Lung Injury Consensus Conference. <i>Pediatric Critical Care Medicine</i> , 2023, 24, S99-S111.	0.2	4
6683	Validation of the RIM Score-COVID in the Spanish SEMI-COVID-19 Registry. <i>Internal and Emergency Medicine</i> , 2023, 18, 907-915.	1.0	1
6684	Enoxaparin Posology According to Prothrombotic Status and Bleeding Risk in Hospitalized Patients with SARS-CoV-2 Pneumonia. <i>Journal of Clinical Medicine</i> , 2023, 12, 928.	1.0	0
6685	Sustained Cytotoxic Response of Peripheral Blood Mononuclear Cells from Unvaccinated Individuals Admitted to the ICU Due to Critical COVID-19 Is Essential to Avoid a Fatal Outcome. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 1947.	1.2	0
6686	COVID-19: Diabetes Perspective—Pathophysiology and Management. <i>Pathogens</i> , 2023, 12, 184.	1.2	7
6687	Prevention and treatment for COVID-19 associated severe pneumonia in the Gambia (PaTS-COVID-19), a single-blinded randomized clinical trial: study protocol. <i>International Journal of Clinical Trials</i> , 2023, 10, 26-33.	0.0	0
6688	Efficacy and safety of ivermectin in patients with mild and moderate COVID-19: A randomized controlled trial. <i>Asian Pacific Journal of Tropical Medicine</i> , 2023, 16, 3-8.	0.4	0
6689	Applications of mathematical modeling and simulation in COVID-19. , 2023, , 275-290.		0
6690	Steroid exposure and outcome in COVID-19 pneumonia. , 2023, 5, 100128.		2
6691	A Literature Review on SARS-CoV-2 and Other Viruses in Thyroid Disorders: Environmental Triggers or No-Guilty Bystanders?. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 2389.	1.2	4
6692	Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study. <i>Viruses</i> , 2023, 15, 294.	1.5	2

#	ARTICLE	IF	CITATIONS
6693	Moderate-to-severe ARDS: COVID-19 patients compared to influenza patients for ventilator parameters and mortality. ERJ Open Research, 2023, 9, 00554-2022.	1.1	1
6694	Quality of Life in COVID-Related ARDS Patients One Year after Intensive Care Discharge (Odissea Study): A Multicenter Observational Study. Journal of Clinical Medicine, 2023, 12, 1058.	1.0	12
6695	Design, Synthesis, and Anti-Inflammatory Activities of 12-Dehydropyxinol Derivatives. Molecules, 2023, 28, 1307.	1.7	4
6696	Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2. Oxford Open Immunology, 2023, 4, .	1.2	3
6697	CytoSorb in patients with coronavirus disease 2019: A rapid evidence review and meta-analysis. Frontiers in Immunology, 0, 14, .	2.2	6
6698	The mechanisms of hyperglycemia and its management in new coronavirus infection. Sibirskij Å¾urnal KliniÄeskoj I ÅºksperimentalÉnoj Mediciny, 2023, 37, 22-30.	0.1	0
6699	Pulmonary hypertension due to pulmonary embolism secondary to COVID-19: A district general hospital experience from the UK. Journal of the Royal College of Physicians of Edinburgh, The, 0, , 147827152311526.	0.2	0
6700	COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation. Critical Care, 2023, 27, .	2.5	31
6701	Diagnostic significance of secondary bacteremia in patients with COVID-19. Journal of Infection and Chemotherapy, 2023, 29, 422-426.	0.8	2
6702	Safety and efficacy of glucocorticoids in the treatment of COVID-19: A meta-analysis of randomized control trials. Expert Review of Respiratory Medicine, 2023, 17, 81-96.	1.0	4
6703	Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia. Medicina ClÄnica (English Edition), 2023, , .	0.1	0
6705	Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19*. Critical Care Medicine, 2023, 51, 337-346.	0.4	11
6706	COVID-19 Pandemic and Vaccination. Reproductive Medicine for Clinicians, 2023, , 17-23.	0.2	0
6707	Infectious Disease Pearls for Maritime Surgical Teams. , 2023, , 267-285.		0
6708	COVID-19 ARDS in Pregnancy: Implications for the Non-COVID Era. Annual Update in Intensive Care and Emergency Medicine, 2023, , 489-501.	0.1	0
6710	A Study on the Impact of Diabetes Mellitus on the Severity of COVID-19-Associated Mucormycosis. Annals of the National Academy of Medical Sciences (India), 2023, 59, 027-035.	0.2	0
6711	Persistence of inflammatory and vascular mediators 5 months after hospitalization with COVID-19 infection. Frontiers in Medicine, 0, 10, .	1.2	2
6712	Organizing pneumonia: an unusual sequela of COVID-19 infection. European Journal of Case Reports in Internal Medicine, 0, , .	0.2	1

#	ARTICLE	IF	CITATIONS
6713	A Propensity-Matched Cohort Assessing Impact of a Neutralizing Monoclonal Antibody in Mild-to-Moderate Coronavirus Disease 2019. <i>Journal of Intensive Care Medicine</i> , 0, , 088506662311558.	1.3	0
6714	Emergence of Clonally-Related South Asian Clade I Clinical Isolates of <i>Candida auris</i> in a Greek COVID-19 Intensive Care Unit. <i>Journal of Fungi (Basel, Switzerland)</i> , 2023, 9, 243.	1.5	3
6715	COVID-19 and Heart Failure with Preserved and Reduced Ejection Fraction Clinical Outcomes among Hospitalized Patients in the United States. <i>Viruses</i> , 2023, 15, 600.	1.5	1
6716	Serious Clinical Outcomes of COVID-19 Related to Acetaminophen or NSAIDs from a Nationwide Population-Based Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 3832.	1.2	0
6717	Revitalising cancer clinical trials: definitely time for patient-centred reform. <i>British Journal of Cancer</i> , 2023, 128, 1407-1408.	2.9	0
6718	Dose-Response Meta-Analysis of Corticosteroid Effects in SARS Outbreak: A Model for Risk Stratification and Screening Strategy for Osteonecrosis of Femoral Head Post-Corticosteroid Therapy for COVID-19. <i>Life</i> , 2023, 13, 907.	1.1	1
6719	Pulmonary Aspergillosis in Critically Ill COVID-19 Patients Admitted to the Intensive Care Unit: A Retrospective Cohort Study. <i>Journal of Fungi (Basel, Switzerland)</i> , 2023, 9, 315.	1.5	4
6721	Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19. <i>Critical Care</i> , 2023, 27, .	2.5	3
6722	Mortality and risk factors of vaccinated and unvaccinated frail patients with COVID-19 treated with anti-SARS-CoV-2 monoclonal antibodies: A real-world study. <i>International Journal of Infectious Diseases</i> , 2023, 131, 155-161.	1.5	4
6723	Obliterative Endotheliitis Leading to Cystic Lung Necrosis in Severe COVID-19 during the First Wave of the Pandemic. <i>BioMed</i> , 2023, 3, 202-206.	0.6	0
6724	Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
6725	Anaesthetic challenges of coronavirus disease (COVID-19) associated mucormycosis: A case series. <i>Indian Journal of Clinical Anaesthesia</i> , 2023, 10, 89-97.	0.0	0
6726	Corticosteroid outcome may be dependent of duration of use in severe COVID-19. <i>Korean Journal of Internal Medicine</i> , 2023, 38, 382-392.	0.7	4
6727	Radiological lung sequelae, functional status and symptoms in older patients 3 and 6 months after hospitalization for COVID-19 pneumonia. <i>Internal and Emergency Medicine</i> , 2023, 18, 1075-1085.	1.0	3
6728	Comprehensive evaluation of six interventions for hospitalized patients with COVID-19: A propensity score matching study. <i>Saudi Pharmaceutical Journal</i> , 2023, 31, 517-525.	1.2	1
6729	Effect of an Immune-Boosting, Antioxidant and Anti-Inflammatory Food Supplement in Hospitalized COVID-19 Patients: A Prospective Randomized Pilot Study. <i>Nutrients</i> , 2023, 15, 1736.	1.7	7
6730	Physiological and transcriptional effects in the male western mosquitofish (<i>Gambusia affinis</i>) following exposure to dexamethasone. <i>Ecotoxicology and Environmental Safety</i> , 2023, 254, 114722.	2.9	1
6731	SARS-CoV-2-Induced Myocarditis: A State-of-the-Art Review. <i>Viruses</i> , 2023, 15, 916.	1.5	3

#	ARTICLE	IF	CITATIONS
6732	Explanatory predictive model for COVID-19 severity risk employing machine learning, shapley addition, and LIME. Scientific Reports, 2023, 13, .	1.6	9
6733	Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2023, 401, 1499-1507.	6.3	27
6734	SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo. Microorganisms, 2023, 11, 1015.	1.6	8
6735	Higher-dose dexamethasone for patients with COVID-19 and hypoxaemia?. Lancet, The, 2023, 401, 1474-1476.	6.3	1
6736	Long-term outcomes of COVID-19 infection in patients with solid tumors. The European Research Journal, 0, , 1-8.	0.1	0
6737	Stridor in Tuberculosis and COVID-19 Coinfection. Infectious Diseases in Clinical Practice, 2023, 31, .	0.1	0
6738	Analogies between COVID-19 and Preeclampsia: Focus on Therapies. International Journal of Translational Medicine, 2023, 3, 203-216.	0.1	0
6739	MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases. Current Opinion in Virology, 2023, 59, 101304.	2.6	2
6740	Pulmonary drug delivery for acute respiratory distress syndrome. Pulmonary Pharmacology and Therapeutics, 2023, 79, 102196.	1.1	5
6741	Is COVID-19 different from other causes of acute respiratory distress syndrome?. Journal of Intensive Medicine, 2023, 3, 212-219.	0.8	2
6742	Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia. , 2023, 11, 100167.		4
6743	Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection. International Immunopharmacology, 2023, 118, 110055.	1.7	3
6744	Methodology and design of platform trials: a meta-epidemiological study. Journal of Clinical Epidemiology, 2023, 157, 1-12.	2.4	4
6745	Fusion of Michael-acceptors enhances the anti-inflammatory activity of ginsenosides as potential modulators of the NLRP3 signaling pathway. Bioorganic Chemistry, 2023, 134, 106467.	2.0	1
6746	Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies. Thrombosis Research, 2023, 225, 47-56.	0.8	2
6747	Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19. European Journal of Pharmaceutical Sciences, 2023, 184, 106418.	1.9	1
6748	Incidence, risk factors and pre-emptive screening for COVID-19 associated pulmonary aspergillosis in an era of immunomodulant therapy. Journal of Critical Care, 2023, 76, 154272.	1.0	6
6749	Are foot and ankle corticosteroid injections safe during the COVID-19 pandemic? A single center prospective observational study. Foot, 2023, 56, 102001.	0.4	0

#	ARTICLE	IF	CITATIONS
6750	Effect of Methylprednisolone on Mortality and Clinical Courses in Patients with Severe COVID-19: A Propensity Score Matching Analysis. <i>Infectious Diseases & Immunity</i> , 2023, 3, 20-28.	0.2	0
6751	Procalcitonin Values Fail to Track the Presence of Secondary Bacterial Infections in COVID-19 ICU Patients. <i>Antibiotics</i> , 2023, 12, 709.	1.5	2
6752	Phase-separation: a possible new layer for transcriptional regulation by glucocorticoid receptor. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
6753	TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial. <i>Thorax</i> , 2023, 78, 816-824.	2.7	3
6754	Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial. <i>EClinicalMedicine</i> , 2023, 58, 101889.	3.2	9
6755	Simulation study for evaluating an adaptive-randomisation Bayesian hybrid trial design with enrichment. <i>Contemporary Clinical Trials Communications</i> , 2023, 33, 101141.	0.5	0
6758	Reduced circulating BMP9 and pBMP10 in hospitalized COVID-19 patients. <i>Pulmonary Circulation</i> , 2023, 13, .	0.8	2
6759	Rhinovirus/enterovirus identification by electron microscopy in lower respiratory tract infection in a patient with relapsed myelodysplastic syndrome after allogeneic hematopoietic cell transplantation and donor lymphocyte infusion. <i>Transplant Immunology</i> , 2023, 77, 101792.	0.6	1
6760	The Need for Speed and Efficiency: A Brief Review of Small Molecule Antivirals for COVID-19. <i>Frontiers in Drug Discovery</i> , 0, 2, .	1.1	7
6761	SARS-CoV-2 Nsp2 Contributes to Inflammation by Activating NF- κ B. <i>Viruses</i> , 2023, 15, 334.	1.5	9
6762	A comparative study of COVID-19 transcriptional signatures between clinical samples and preclinical cell models in the search for disease master regulators and drug repositioning candidates. <i>Virus Research</i> , 2023, 326, 199053.	1.1	2
6763	The development of COVID-19 treatment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	59
6764	SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report. , 2023, 11, e005957.		3
6765	Development of indolealkylamine derivatives as potential multi-target agents for COVID-19 treatment. <i>European Journal of Medicinal Chemistry</i> , 2023, 249, 115152.	2.6	1
6766	Review of the British Thoracic Society Winter Meeting 23 November 2022 23â€“25 November 2022. <i>Thorax</i> , 2023, 78, e1-e1.	2.7	0
6767	Death from COVID-19 of a 57-year-old man refusing medical care and self-medicating with ivermectin. <i>Central European Journal of Public Health</i> , 2022, 30, 265-267.	0.4	1
6768	Conducting Goals of Care Conversations: Lessons From the COVID-19 Pandemic. <i>Journal of Palliative Care</i> , 2024, 39, 13-20.	0.4	1
6769	Using risk factors and markers to predict bacterial respiratory co-/superinfections in COVID-19 patients: is the antibiotic stewardâ€™s toolbox full or empty?. <i>Acta Clinica Belgica</i> , 2023, 78, 418-430.	0.5	1

#	ARTICLE	IF	CITATIONS
6770	Assessing the Clinical Characteristics and Management of COVID-19 among Pediatric Patients in Ghana: Findings and Implications. <i>Antibiotics</i> , 2023, 12, 283.	1.5	3
6771	Glucocorticoide und Mineralocorticoide. , 2022, , 431-437.		0
6773	A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages. <i>International Journal of Infectious Diseases</i> , 2023, 129, 57-62.	1.5	1
6774	A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19. <i>Vaccines</i> , 2023, 11, 332.	2.1	4
6775	Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 0, , .	1.4	4
6776	The Personalised Randomized Controlled Trial: Evaluation of a new trial design. <i>Statistics in Medicine</i> , 2023, 42, 1156-1170.	0.8	0
6777	O que mudou entre os períodos de pico e de platô durante a primeira onda do SARS-CoV-2? Estudo multicêntrico português em unidades de cuidados intensivos. <i>Revista Brasileira De Terapia Intensiva</i> , 2022, 34, .	0.1	0
6778	Response to: "Corticosteroid Therapy in COVID-19 Associated With In-hospital Mortality in Geriatric Patients: A Propensity Matched Cohort Study". <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 0, , .	1.7	0
6779	Pleiotropic Functions of Nitric Oxide Produced by Ascorbate for the Prevention and Mitigation of COVID-19: A Reevaluation of Pauling's Vitamin C Therapy. <i>Microorganisms</i> , 2023, 11, 397.	1.6	0
6780	<scp>COVID</scp> vaccination status impact on mortality in end-stage kidney disease. <i>Hemodialysis International</i> , 2023, 27, 197-199.	0.4	1
6781	Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study. <i>Acute and Critical Care</i> , 2023, 38, 57-67.	0.6	0
6782	The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	17
6783	Drug Repurposing for COVID-19 Therapy: Pipeline, Current Status and Challenges. , 2023, , 451-478.		0
6784	Comment on: "Intravenous methylprednisolone pulses in hospitalized patients with severe COVID-19 pneumonia: a double-blind, randomized, placebo-controlled trial". <i>Gazzetta Medica Italiana Archivio Per Le Scienze Mediche</i> , 2023, 181, .	0.0	0
6785	Introducing helmet non-invasive ventilation during COVID-19 pandemic: Early experience of two centres. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
6786	An overview on the treatments and prevention against COVID-19. <i>Virology Journal</i> , 2023, 20, .	1.4	19
6787	Intravenous methylprednisolone pulse therapy and the risk of in-hospital mortality among acute COVID-19 patients: Nationwide clinical cohort study. <i>Critical Care</i> , 2023, 27, .	2.5	2
6788	Nucleoside Analogs That Inhibit SARS-CoV-2 Replication by Blocking Interaction of Virus Polymerase with RNA. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3361.	1.8	3

#	ARTICLE	IF	CITATIONS
6789	Pathogenicity and virulence of <i>Aspergillus fumigatus</i> . <i>Virulence</i> , 2023, 14, .	1.8	15
6790	Bronchoscopic Endobronchial Valve Therapy for Persistent Air Leaks in COVID-19 Patients Requiring Venovenous Extracorporeal Membrane Oxygenation. <i>Journal of Clinical Medicine</i> , 2023, 12, 1348.	1.0	1
6791	Dry powder formulation of azithromycin for COVID-19 therapeutics. <i>Journal of Microencapsulation</i> , 2023, 40, 217-232.	1.2	0
6792	The Role of Nutrition in Mitigating the Effects of COVID-19 from Infection through PASC. <i>Nutrients</i> , 2023, 15, 866.	1.7	5
6793	Therapeutic options in COVID-19. , 2023, , 647-672.		0
6794	The Impact of Multidrug-Resistant <i>Acinetobacter baumannii</i> Infection in Critically Ill Patients with or without COVID-19 Infection. <i>Healthcare (Switzerland)</i> , 2023, 11, 487.	1.0	7
6795	Palliative Care in a Pandemic: A Multicenter Cohort of Critically Ill Patients with Coronavirus Disease 2019. <i>Surgical Infections</i> , 2023, 24, 190-198.	0.7	0
6796	Oral ketone esters acutely improve myocardial contractility in post-hospitalized COVID-19 patients: A randomized placebo-controlled double-blind crossover study. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	0
6797	Effects of therapeutic plasma exchange on a cohort of patients with severe coronavirus infection: real world evidence from Brazil. <i>Hematology, Transfusion and Cell Therapy</i> , 2023, , .	0.1	0
6798	Clinical and pharmacological factors associated with mortality in patients with COVID-19 in a high complexity hospital in Manaus: A retrospective study. <i>PLoS ONE</i> , 2023, 18, e0280891.	1.1	1
6799	Use of COVID-19 Convalescent Plasma for Treatment of Symptomatic SARS-CoV-2 Infection at a Children's Hospital: A Contribution to a Still Inadequate Body of Evidence. <i>Children</i> , 2023, 10, 350.	0.6	1
6800	Pneumocystis pneumonia in COVID-19 patients: A comprehensive review. <i>Heliyon</i> , 2023, 9, e13618.	1.4	5
6801	Acute Kidney Injury with SARS-CoV-2 Infection in Pediatric Patients Receiving High-Dose Methotrexate Chemotherapy: A Report of Three Cases. <i>Children</i> , 2023, 10, 331.	0.6	1
6802	metaCOVID: A web application for living meta-analyses of COVID-19 trials. <i>Research Synthesis Methods</i> , 2023, 14, 479-488.	4.2	1
6803	Machine learning reveals STAT motifs as predictors for GR-mediated gene repression. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 1697-1710.	1.9	2
6804	Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis. <i>Annals of Hematology</i> , 2023, 102, 761-768.	0.8	5
6806	Impact of COVID-19 on Cardiovascular Disease. <i>Viruses</i> , 2023, 15, 508.	1.5	15
6807	Demographic and clinical characteristics and outcomes of COVID-19 patients admitted to a university hospital in the west of Iran: a retrospective study in the third wave. <i>Vacunas</i> , 2023, 24, 182-189.	1.1	2

#	ARTICLE	IF	CITATIONS
6808	Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial. <i>Infectious Agents and Cancer</i> , 2023, 18, .	1.2	2
6810	Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: Less is more. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	0
6811	Severe Acute Respiratory Syndrome and Particulate Matter Exposure: A Systematic Review. <i>Life</i> , 2023, 13, 538.	1.1	1
6812	STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol. <i>PLoS ONE</i> , 2023, 18, e0272472.	1.1	9
6813	Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches. <i>Journal of Personalized Medicine</i> , 2023, 13, 334.	1.1	13
6814	Artificial intelligence assessment of the potential of tocilizumab along with corticosteroids therapy for the management of COVID-19 evoked acute respiratory distress syndrome. <i>PLoS ONE</i> , 2023, 18, e0280677.	1.1	2
6815	Advancing Precision Medicine for the Diagnosis and Treatment of Acute Respiratory Distress Syndrome. <i>Journal of Clinical Medicine</i> , 2023, 12, 1563.	1.0	4
6816	Deep Learning With Chest Radiographs for Making Prognoses in Patients With COVID-19: Retrospective Cohort Study. <i>Journal of Medical Internet Research</i> , 0, 25, e42717.	2.1	4
6817	Severe Acute Respiratory Syndrome Coronaviruses-2 (SARS-CoV-2). , 2023, , 1-15.		0
6818	Safety and efficacy of methylprednisolone <i>versus</i> dexamethasone in critically ill patients with COVID-19 acute respiratory distress syndrome: a retrospective study. <i>Therapeutic Advances in Infectious Disease</i> , 2023, 10, 204993612311535.	1.1	2
6819	Current and Emerging Therapies for COVID-19 in Lung Transplantation. <i>Current Pulmonology Reports</i> , 2023, 12, 23-35.	0.5	1
6820	Comorbidities, multimorbidity and COVID-19. <i>Nature Medicine</i> , 2023, 29, 334-343.	15.2	89
6821	Modeling Heart Diseases on a Chip: Advantages and Future Opportunities. <i>Circulation Research</i> , 2023, 132, 483-497.	2.0	10
6822	Pulmonary embolism in COVID-19, risk factors and association with inflammatory biomarkers. <i>Medicine (United States)</i> , 2023, 102, e32887.	0.4	1
6823	SARS-CoV-2 infection in children: A 24 months experience with focus on risk factors in a pediatric tertiary care hospital in Milan, Italy. <i>Frontiers in Pediatrics</i> , 0, 11, .	0.9	2
6824	Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19. <i>Viruses</i> , 2023, 15, 549.	1.5	3
6825	Insights into COVID-19-associated critical illness: a narrative review. <i>Annals of Translational Medicine</i> , 2023, 11, 220-220.	0.7	2
6826	Data quality considerations for evaluating COVID-19 treatments using real world data: learnings from the National COVID Cohort Collaborative (N3C). <i>BMC Medical Research Methodology</i> , 2023, 23, .	1.4	4

#	ARTICLE	IF	CITATIONS
6827	Clinical outcomes of children and adolescents with sickle cell disease and COVID-19 infection: A year in review at a metropolitan tertiary pediatric hospital. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
6828	Severe COVID-19-associated hyperinflammatory syndrome versus classic hemophagocytic lymphohistiocytosis: similarities, differences, and the way forward. <i>Journal of Investigative Medicine</i> , 2023, 71, 244-253.	0.7	0
6830	Strongyloides and COVID-19: Challenges and Opportunities for Future Research. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 127.	0.9	2
6831	Risk of Underlying Diseases and Effectiveness of Drugs on COVID-19 Inpatients Assessed Using Medical Claims in Japan: Retrospective Observational Study. <i>International Journal of General Medicine</i> , 0, Volume 16, 657-672.	0.8	2
6832	Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients. <i>Hepatology Communications</i> , 2023, 7, e0034-e0034.	2.0	2
6833	The Interplay among Glucocorticoid Therapy, Platelet-Activating Factor and Endocannabinoid Release Influences the Inflammatory Response to COVID-19. <i>Viruses</i> , 2023, 15, 573.	1.5	3
6834	Transcranial direct current stimulation associated with pharmacological approaches in patients infected by SARS-CoV-2. <i>Revista Da Associação Médica Brasileira</i> , 2023, 69, 370-371.	0.3	0
6835	Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19). <i>BMJ Open</i> , 2023, 13, e064374.	0.8	5
6836	Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 453-464.	5.2	35
6837	Comparison of systemic inflammatory profiles in COVID-19 and community-acquired pneumonia patients: a prospective cohort study. <i>Respiratory Research</i> , 2023, 24, .	1.4	3
6838	Allogeneic hematopoietic stem cell transplantation in the COVID-19 era. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
6839	Drug Cocktail Formulation via Circuit Design. <i>IEEE Transactions on Molecular, Biological, and Multi-Scale Communications</i> , 2023, 9, 28-48.	1.4	1
6840	Anticipatory Antifungal Treatment in Critically Ill Patients with SARS-CoV-2 Pneumonia. <i>Journal of Fungi (Basel, Switzerland)</i> , 2023, 9, 288.	1.5	1
6841	Association Between Metabolic Syndrome Inflammatory Biomarkers and COVID-19 Severity. <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.1	0
6842	Rhino Orbital Cerebral Mucormycosis in Covid-19 Crisis. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2023, 75, 1014-1020.	0.3	2
6843	In silico prediction of potential inhibitors for SARS-CoV-2 Omicron variant using molecular docking and dynamics simulation-based drug repurposing. <i>Journal of Molecular Modeling</i> , 2023, 29, .	0.8	2
6844	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4401.	1.8	4
6845	Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19. <i>Science Immunology</i> , 2023, 8, .	5.6	7

#	ARTICLE	IF	CITATIONS
6847	Long-Term Evolution of Activities of Daily Life (ADLs) in Critically Ill COVID-19 Patients, a Case Series. <i>Healthcare (Switzerland)</i> , 2023, 11, 650.	1.0	0
6848	Comparison of patients admitted to an inner-city intensive care unit across 3 COVID-19 waves. <i>Medicine (United States)</i> , 2023, 102, e33069.	0.4	3
6849	<i>Infecties (COVID-19)</i> . , 2022, , 311-323.		0
6850	Effect of the chronic medication use on outcome measures of hospitalized COVID-19 patients: Evidence from big data. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	4
6851	Optimal Duration of Systemic Corticosteroids in Coronavirus Disease 2019 Treatment: A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	1
6852	Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia. <i>Respiratory Research</i> , 2023, 24, .	1.4	7
6854	Implementing pragmatic clinical trials in hepatology. <i>Hepatology</i> , 2024, 79, 704-712.	3.6	0
6855	Immunity to fungi in the lung. <i>Seminars in Immunology</i> , 2023, 66, 101728.	2.7	10
6856	Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. <i>BMJ Open</i> , 2023, 13, e067910.	0.8	7
6857	Clinical characteristics, diagnosis, outcomes and lung microbiome analysis of invasive pulmonary aspergillosis in the community-acquired pneumonia patients. <i>BMJ Open Respiratory Research</i> , 2023, 10, e001358.	1.2	3
6858	The role of interleukin-6 and janus kinases in the pathogenesis, and treatment of SARS-CoV-2. <i>Journal of Lung, Pulmonary & Respiratory Research</i> , 2022, 9, 17-32.	0.3	1
6859	Could the fibromyalgia syndrome be triggered or enhanced by COVID-19?. <i>Inflammopharmacology</i> , 2023, 31, 633-651.	1.9	9
6860	Sepsis: Past, Present, and Future—Lessons Learned from COVID-19. , 2023, , 1-6.		0
6861	Association of the structure of the glucocorticoid receptor and single nucleotide <i>NR3C1</i> gene polymorphisms with metabolic disorders. <i>Problemy Endokrinologii</i> , 2023, 69, 50-58.	0.2	0
6862	Plasma Apolipoprotein Concentrations Are Highly Altered in Severe Intensive Care Unit COVID-19 Patients: Preliminary Results from the LIPICOR Cohort Study. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4605.	1.8	3
6863	Clinical trials and future perspectives of antiinflammatory agents. , 2023, , 331-386.		0
6864	Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function. <i>PLoS ONE</i> , 2023, 18, e0279765.	1.1	5
6865	Rising Mortality in Coronavirus-19 Patients Supported With Extracorporeal Membrane Oxygenation. <i>ASAIO Journal</i> , 2023, 69, 254-259.	0.9	0

#	ARTICLE	IF	CITATIONS
6866	A Fungal P450 Enzyme from <i>Fusarium graminearum</i> with Unique 12 ¹² -Steroid Hydroxylation Activity. <i>Applied and Environmental Microbiology</i> , 2023, 89, .	1.4	4
6867	Thyroid Function Abnormalities and Outcomes in Hospitalized Patients with COVID-19 Infection: A Cross-Sectional Study. <i>Hormone and Metabolic Research</i> , 2023, 55, 169-175.	0.7	2
6868	What Is New in Pulmonary Mucormycosis?. <i>Journal of Fungi (Basel, Switzerland)</i> , 2023, 9, 307.	1.5	11
6869	Corticosteroids for non-severe COVID-19 infections? Too early to conclude. <i>Korean Journal of Internal Medicine</i> , 2023, 38, 144-146.	0.7	1
6870	COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study. <i>Cancers</i> , 2023, 15, 1497.	1.7	3
6871	Mechanical Circulatory Support in COVID-19. <i>Heart Failure Clinics</i> , 2023, 19, 205-211.	1.0	0
6872	Integrated Metabolic and Inflammatory Signatures Associated with Severity of, Fatality of, and Recovery from COVID-19. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	4
6873	Knowledge, Attitude and Practices of Self-Medication Including Antibiotics among Health Care Professionals during the COVID-19 Pandemic in Pakistan: Findings and Implications. <i>Antibiotics</i> , 2023, 12, 481.	1.5	4
6874	Acute management of pneumonia in adult patients. <i>Singapore Medical Journal</i> , 2023, 64, 209.	0.3	1
6875	Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease. <i>Brain</i> , 2023, 146, 2717-2722.	3.7	7
6876	Pulmonary Cryptococcosis and Pulmonary Fibrosis: A Complication of COVID-19 Pneumonia. <i>Cureus</i> , 2023, , .	0.2	0
6878	Inducible generalized activation of hSTING-N154S expression in mice leads to lethal hypercytokinemia: a model for "cytokine storm". <i>Journal of Leukocyte Biology</i> , 2023, 113, 326-333.	1.5	0
6879	Effects of 12Âmg vs. 6Âmg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial. <i>Annals of Intensive Care</i> , 2023, 13, .	2.2	1
6880	COVID-19 as a polymorphic inflammatory spectrum of diseases: a review with focus on the brain. <i>Acta Neuropsychiatrica</i> , 0, , 1-22.	1.0	1
6881	Incidence and clinical outcomes of bacterial superinfections in critically ill patients with COVID-19. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	6
6882	NPH Insulin Versus Insulin Glargine Versus NPH Insulin Plus Insulin Glargine for the Treatment of Dexamethasone-Induced Hyperglycemia in Patients With COVID-19: A Retrospective Cohort Study. <i>Journal of Pharmacy Technology</i> , 2023, 39, 68-74.	0.5	0
6883	Impact of variants of SARS-CoV-2 on obstetrical and neonatal outcomes. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2023, 52, 102566.	0.6	2
6884	Post-COVID Interstitial Lung Disease" The Tip of the Iceberg. <i>Immunology and Allergy Clinics of North America</i> , 2023, 43, 389-410.	0.7	3

#	ARTICLE	IF	CITATIONS
6885	New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention. <i>Materials Today Chemistry</i> , 2023, 29, 101478.	1.7	15
6886	A Novel Algorithm for the Management of Inpatient COVID-19 Glucocorticoid-Induced Hyperglycemia. <i>Clinical Diabetes</i> , 2023, 41, 378-385.	1.2	1
6887	The Defenders of the Alveolus Succumb in COVID-19 Pneumonia to SARS-CoV-2 and Necroptosis, Pyroptosis, and PANoptosis. <i>Journal of Infectious Diseases</i> , 2023, 227, 1245-1254.	1.9	6
6889	Risk of Coronavirus Disease 2019-associated Pulmonary Aspergillosis Based on Corticosteroid Duration in Intensive Care Patients. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	4
6890	Application of the PHENotype SIMulator for rapid identification of potential candidates in effective COVID-19 drug repurposing. <i>Heliyon</i> , 2023, 9, e14115.	1.4	1
6891	Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
6892	Dexamethasone and Dexamethasone Phosphate: Effect on DMPC Membrane Models. <i>Pharmaceutics</i> , 2023, 15, 844.	2.0	2
6893	Relationship of Extravascular Lung Water and Pulmonary Vascular Permeability to Respiratory Mechanics in Patients with COVID-19-Induced ARDS. <i>Journal of Clinical Medicine</i> , 2023, 12, 2028.	1.0	0
6894	Development of acute peptic ulcers complicated by gastrointestinal bleeding in patients with novel coronavirus infection. <i>Hirurg</i> , 2023, , 13-18.	0.0	0
6895	Acute COVID-19 Management in Heart Failure Patients: A Specific Setting Requiring Detailed Inpatient and Outpatient Hospital Care. <i>Biomedicines</i> , 2023, 11, 790.	1.4	4
6896	Synthesis of Microwave Functionalized, Nanostructured Poly(lactide Co-glycolic Acid (nfPLGA) for Incorporation into Hydrophobic Dexamethasone to Enhance Dissolution. <i>Nanomaterials</i> , 2023, 13, 943.	1.9	2
6897	A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet. <i>European Respiratory Journal</i> , 2023, 61, 2300270.	3.1	0
6898	Treating COVID-19: Targeting the Host Response, Not the Virus. <i>Life</i> , 2023, 13, 712.	1.1	2
6899	Pharmacological potential of <i>Withania somnifera</i> (L.) Dunal and <i>Tinospora cordifolia</i> (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
6900	Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19. <i>JCI Insight</i> , 2023, 8, .	2.3	1
6901	The use of prophylactic nebulized liposomal amphotericin B to reduce the risk of CAPA in mechanically ventilated COVID-19 patients on ICU in a large UK tertiary teaching hospital trust. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 1129-1131.	1.3	0
6902	A Letter to the Editor Regarding "Identifying Gaps in the Corticosteroid Treatment of COVID-19: We Need More Studies". <i>Infectious Diseases and Therapy</i> , 2023, 12, 1013-1016.	1.8	0
6903	Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX "REVOLUTION" trial. <i>The Lancet Regional Health Americas</i> , 2023, 20, 100466.	1.5	1

#	ARTICLE	IF	CITATIONS
6904	Factors related to the mortality risk of severe hand, foot, and mouth diseases (HFMD): a 5-year hospital-based survey in Guangxi, Southern China. <i>BMC Infectious Diseases</i> , 2023, 23, .	1.3	0
6905	“Reply on: statistics on steroids”how recognizing competing risks gets us closer to the truth about COVID-19-associated VAP” <i>Critical Care</i> , 2023, 27, .	2.5	0
6906	Safety of Tocilizumab and Remdesivir in Treating COVID-19 Pneumonia in Premature Twins. <i>Pediatrics</i> , 2023, 151, .	1.0	0
6907	COVID-19 and Pulmonary Angiogenesis: The Possible Role of Hypoxia and Hyperinflammation in the Overexpression of Proteins Involved in Alveolar Vascular Dysfunction. <i>Viruses</i> , 2023, 15, 706.	1.5	5
6908	Assessing the effects of therapeutic combinations on SARS-CoV-2 infected patient outcomes: A big data approach. <i>PLoS ONE</i> , 2023, 18, e0282587.	1.1	0
6909	5. Clinical Practice of Respiratory Infectious Diseases in the "with/after COVID-19 Era". <i>The Journal of the Japanese Society of Internal Medicine</i> , 2022, 111, 578-584.	0.0	0
6910	Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
6911	High incidence of barotrauma in patients admitted with COVID-19 to ICU and associated mortality in rural Appalachia: An observational study. <i>PLoS ONE</i> , 2023, 18, e0282735.	1.1	0
6912	Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine. <i>Medicina (Lithuania)</i> , 2023, 59, 541.	0.8	1
6913	Acute Kidney Injury Associated with Severe SARS-CoV-2 Infection: Risk Factors for Morbidity and Mortality and a Potential Benefit of Combined Therapy with Tocilizumab and Corticosteroids. <i>Biomedicines</i> , 2023, 11, 845.	1.4	1
6915	Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: A real-life cohort study. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	9
6916	Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone. <i>Infectious Diseases</i> , 2023, 55, 351-360.	1.4	3
6917	Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2023, 76, 555-563.	0.4	1
6918	Anti-cytokine Therapy in Critical Illness: Is There a Role?. <i>Lessons From the ICU</i> , 2023, , 277-297.	0.1	0
6919	Inflammation Related to Association of Low Uric Acid and Progression to Severe Disease in Patients Hospitalized for Non-Severe Coronavirus Disease 2019. <i>Biomedicines</i> , 2023, 11, 854.	1.4	0
6920	Cancer, more than a “COVID-19 co-morbidity” <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
6921	Predictors of Mortality among Patients Hospitalized with COVID-19 during the First Wave in India: A Multisite Case-Control Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2023, 108, 727-733.	0.6	1
6922	Mucormycosis in a Patient with Severe COVID-19 Disease”The First Case Report in Romania and a Literature Review. <i>Medicina (Lithuania)</i> , 2023, 59, 555.	0.8	1

#	ARTICLE	IF	CITATIONS
6923	Extreme Symptom Burden for Patients With COVID-19 at the End of Life; Extrapolation of Knowledge Gained to Achieve Sustained Comfort and Dignity for all Patients in Their Last Days of Life ^{<sup>1</sup>. American Journal of Hospice and Palliative Medicine, 0, , 104990912311641.}	0.8	0
6924	The role of corticosteroids may be different in patients with COVID-19. Reviews in Medical Virology, 2023, 33, .	3.9	0
6925	Hemophagocytic Syndrome and COVID-19: A Comprehensive Review. Cureus, 2023, , .	0.2	0
6926	Drug treatment of COVID-19 infection. Current Opinion in Pulmonary Medicine, 2023, 29, 174-183.	1.2	10
6927	Secondary infections in critically ill patients with viral pneumonia due to COVID-19 and influenza: a historical cohort study. Canadian Journal of Anaesthesia, 2023, 70, 374-383.	0.7	1
6928	Temporal Changes in SARS-CoV-2 Infection Pattern in Patients Admitted with Hematological Diseasesâ€”A Single Center Experience from North India. Hemato, 2023, 4, 100-111.	0.2	0
6929	The role of interleukin 13 and the type 2 immune pathway in COVID-19: A review. Annals of Allergy, Asthma and Immunology, 2023, 130, 727-732.	0.5	9
6931	Towards achieving transnational research partnership equity: lessons from implementing adaptive platform trials in low- and middle-income countries. Wellcome Open Research, 0, 8, 120.	0.9	3
6932	COVID-19-Associated Pulmonary Aspergillosis Complicated by Severe Coronavirus Disease: Is Detection of Aspergillus in Airway Specimens Before Disease Onset an Indicator of Antifungal Prophylaxis?. Cureus, 2023, , .	0.2	0
6933	Incidence of barotrauma in patients with COVID-19 (alpha- and beta-predominant period) requiring mechanical ventilation: Single-center retrospective study. SAGE Open Medicine, 2023, 11, 205031212311594.	0.7	1
6934	Pneumonia-Induced Inflammation, Resolution and Cardiovascular Disease: Causes, Consequences and Clinical Opportunities. Circulation Research, 2023, 132, 751-774.	2.0	3
6935	A 16-month-long experience of <scp>COVID</scp>-19 in allogeneic haematopoietic stem cell transplantation recipients: An <scp>SFGMâ€”C</scp> multicentre cohort study. British Journal of Haematology, 2023, 201, 1066-1071.	1.2	1
6936	Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial. PLoS ONE, 2023, 18, e0282688.	1.1	4
6937	Evaluation of Cellular Toxicity and Preclinical Safety of Using an Inhalable Liposomal form of Dexamethasone. Pharmaceutical Chemistry Journal, 2023, 56, 1573-1576.	0.3	0
6939	Concerted and multidisciplinary management of COVID-19 drug therapies during the first two epidemic waves in a tertiary hospital in Marseille, France: Results of the PHARMA-COVID study. PLoS ONE, 2023, 18, e0283165.	1.1	0
6940	Glucocorticoid exposure modifies the <scp>miRNA</scp> profile of sperm in the guinea pig: Implications for intergenerational transmission. FASEB Journal, 2023, 37, .	0.2	2
6941	High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge. Transplant Infectious Disease, 2023, 25, .	0.7	3
6942	COVID-19 in Elderly Patients Receiving Haemodialysis: A Current Review. Biomedicines, 2023, 11, 926.	1.4	2

#	ARTICLE	IF	CITATIONS
6944	To Compare the Maternal and Fetal Outcomes of COVID-19-Affected Expectant Mothers During the First and Second COVID-19 Waves: Data From a Tertiary Care Referral Hospital in Punjab. <i>Cureus</i> , 2023, , .	0.2	0
6945	Backgrounderâ€™Part 2. , 2023, , 27-64.		0
6946	Steroid Pulse Therapy as a Treatment for Patients With COVID-19 Pneumonia at an Intensive Care Unit: A Single-Center Retrospective Observational Study. <i>Cureus</i> , 2023, , .	0.2	0
6947	Caring for two in the <scp>ICU</scp> : Pharmacotherapy in the critically ill pregnant patient. <i>Pharmacotherapy</i> , 0, , .	1.2	0
6948	Clinical Characteristics of Strongyloidiasis during the COVID-19 Pandemic: Systematic Scoping Review. <i>American Journal of Tropical Medicine and Hygiene</i> , 2023, , .	0.6	0
6949	COVID-19 and the Genetics of Inflammation. <i>Critical Care Medicine</i> , 2023, 51, 817-825.	0.4	3
6950	Effect of pharmacological interventions for the treatment of people with postâ€™COVIDâ€™19 condition: A rapid review. , 2023, 1, .		1
6951	COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices. <i>Viruses</i> , 2023, 15, 787.	1.5	5
6952	Potency assessment of IFNÎ³-producing SARS-CoV-2-specific T cells from COVID-19 convalescent subjects. <i>Life Science Alliance</i> , 2023, 6, e202201759.	1.3	1
6953	Impact of an Early Warning System Protocol, for Patients Admitted to the Medical Floors with SARS-COV2 Pneumonia, on ICU Admission. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2023, 17, 117954842311567.	0.5	1
6954	Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> ,the, 2023, 11, 1051-1063.	5.2	9
6955	Angiotensin-converting enzyme 2 as a marker of endothelial dysfunction and a risk factor for acute kidney injury in patients with COVID-19: retrospective cohort study. <i>SeÄenovskij Vestnik</i> , 2023, 13, 33-44.	0.3	0
6956	Coronavirus Disease 2019 Management Strategies in Solid Organ Transplant Recipients. <i>Infectious Disease Clinics of North America</i> , 2023, 37, 475-493.	1.9	1
6957	Physiological and clinical variables identify ARDS classes and therapeutic heterogeneity to glucocorticoids: a retrospective study. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	0
6958	Biomarkers of Sepsis and a Focus on PCSK9. <i>Biomarkers in Disease</i> , 2023, , 785-812.	0.0	0
6959	Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
6960	CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	5
6961	The COVID-19 Pandemic and Adult Cardiac Transplantation: Impact, Interventions, and Implications. <i>Canadian Journal of Cardiology</i> , 2023, 39, 853-864.	0.8	1

#	ARTICLE	IF	CITATIONS
6962	Revitalising cancer trials post-pandemic: time for reform. <i>British Journal of Cancer</i> , 2023, 128, 1409-1414.	2.9	5
6963	Adaptive clinical trials in public health emergency contexts: ethics considerations. <i>Wellcome Open Research</i> , 0, 8, 130.	0.9	3
6964	Immune Response in COVID-19-associated Acute Kidney Injury and Maladaptive Kidney Repair. , 2023, 10, .		0
6965	Dimethylxalylglycine Attenuates Steroid-Associated Endothelial Progenitor Cell Impairment and Osteonecrosis of the Femoral Head by Regulating the HIF-1 α Signaling Pathway. <i>Biomedicines</i> , 2023, 11, 992.	1.4	2
6966	Evidence-Based Medical Therapy for the Treatment of Critically Ill COVID-19 Patients: A Primer for Cardiologists. <i>Canadian Journal of Cardiology</i> , 2023, 39, 849-852.	0.8	1
6967	Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study. <i>PLoS ONE</i> , 2023, 18, e0283529.	1.1	0
6968	Immune and ionic mechanisms mediating the effect of dexamethasone in severe COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
6969	What is really "Long COVID"? <i>Inflammopharmacology</i> , 2023, 31, 551-557.	1.9	7
6970	Corticosteroids reduce pathologic interferon responses by downregulating STAT1 in patients with high-risk COVID-19. <i>Experimental and Molecular Medicine</i> , 2023, 55, 653-664.	3.2	2
6971	Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
6972	Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance. <i>Journal of Inflammation</i> , 2023, 20, .	1.5	2
6973	Economic evaluation of strategies against coronavirus: a systematic review. <i>Health Economics Review</i> , 2023, 13, .	0.8	8
6974	Effect of a Three-Day Course of Dexamethasone on Acute Phase Response Following Treatment With Zoledronate: A Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 38, 631-638.	3.1	5
6975	Cytokine Storm Syndromes in Pediatric Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, , .	2.0	1
6977	Pulse Methylprednisolone Versus Dexamethasone in COVID-19: A Multicenter Cohort Study. , 2023, 5, e0886.		0
6978	Intrapulmonary and Intracardiac Shunts in Adult COVID-19 Versus Non-COVID Acute Respiratory Distress Syndrome ICU Patients Using Echocardiography and Contrast Bubble Studies (COVID-Shunt) Tj ETQq1 1 00784314 rgBT /Overlo		
6979	The origins of new SARS-COV-2 variants in immunocompromised individuals. <i>Current Opinion in HIV and AIDS</i> , 2023, 18, 148-156.	1.5	3
6980	The SARS-CoV-2 E protein induces Toll-like receptor 2-mediated neonatal lung injury in a model of COVID-19 viremia that is rescued by the glucocorticoid ciclesonide. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2023, 324, L722-L736.	1.3	1

#	ARTICLE	IF	CITATIONS
6981	Uneven resources threaten causal consistency in randomized trials. <i>Epidemiology</i> , 0, Publish Ahead of Print, .	1.2	0
6982	Introductory Chapter: Lessons from SARS-CoV-2/COVID-19 after Two Years of Pandemic. <i>Infectious Diseases</i> , 0, , .	4.0	0
6984	Editorial: Pulmonary sarcoidosis. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
6985	Ethnic minority representation in UK COVID-19 trials: systematic review and meta-analysis. <i>BMC Medicine</i> , 2023, 21, .	2.3	10
6986	Triple Trouble: Disseminated Penicilliosis in a Cancer patient with COVID-19. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.1	0
6987	Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19. <i>World Journal of Clinical Cases</i> , 0, 11, 2140-2159.	0.3	1
6988	Impact of dexamethasone on persistent symptoms of COVID-19: an observational study. <i>Wellcome Open Research</i> , 0, 8, 145.	0.9	0
6989	A review of cytokine-based pathophysiology of Long COVID symptoms. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	28
6990	Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. <i>Clinical Infectious Diseases</i> , 2023, 77, 186-193.	2.9	1
6992	Pathophysiology of COVID-19 pneumonia and respiratory treatment. <i>Minerva Anestesiologica</i> , 2023, 89, .	0.6	1
6993	Treatment of COVID-19 pneumonia with low-dose radiotherapy plus standard of care versus standard of care alone in frail patients. <i>Strahlentherapie Und Onkologie</i> , 2023, 199, 847-856.	1.0	2
6994	Respiratory and other systemic complications of coronavirus disease 2019 in adults: A narrative review. , 0, 2, .		0
6995	The role of the endothelium in severe acute respiratory syndrome coronavirus 2 infection and pathogenesis. <i>Current Opinion in Physiology</i> , 2023, 34, 100670.	0.9	3
6996	Modified SCOPE (mSCOPE) Score as a Tool to Predict Mortality in COVID-19 Critically Ill Patients. <i>Journal of Personalized Medicine</i> , 2023, 13, 628.	1.1	0
6997	Macronutrient and micronutrient requirements and therapeutic effects in critically ill patients with SARS-CoV-2: A narrative review. <i>Nutrition in Clinical Practice</i> , 2023, 38, 499-519.	1.1	1
6998	Incidence of deep venous thrombosis in COVID-19 critically ill patients treated with intermediate-dose of heparin for thromboprophylaxis: The COVIDOP-DVT observational study. <i>Vascular</i> , 0, , 170853812311650.	0.4	0
6999	Reduced IL-8 Secretion by NOD-like and Toll-like Receptors in Blood Cells from COVID-19 Patients. <i>Biomedicines</i> , 2023, 11, 1078.	1.4	1
7001	COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic. <i>Biology</i> , 2023, 12, 545.	1.3	2

#	ARTICLE	IF	CITATIONS
7002	Risk for Newly Diagnosed Type 2 Diabetes Mellitus after COVID-19 among Korean Adults: A Nationwide Matched Cohort Study. <i>Endocrinology and Metabolism</i> , 0, .	1.3	4
7003	AssociaÃ§Ã£o entre o Antagonismo do Sistema Renina-Angiotensina-Aldosterona e a Mortalidade Relacionada Ã COVID-19 em Pacientes com HipertensÃ£o Relacionada ao Sobrepeso/Obesidade: um Estudo Retrospectivo de Coorte. <i>Arquivos Brasileiros De Cardiologia</i> , 2023, 120, .	0.3	0
7004	Death is not the worst that can happen: risk scoring and outcomes in emergency laparotomy. <i>Anaesthesia</i> , 2023, 78, 1055-1057.	1.8	1
7005	Severe <scp>COVID</scp> â€19 pneumonia in pregnant woman treated with pulse corticosteroids therapy and thirdâ€™trimester caesarean section: A case report. <i>Respirology Case Reports</i> , 2023, 11, .	0.3	2
7006	Longitudinal Trends in Cardiovascular Risk Factor Profiles and Complications Among Patients Hospitalized for COVID-19 Infection: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2023, 16, .	0.9	2
7007	Host-Based Treatments for Severe COVID-19. <i>Current Issues in Molecular Biology</i> , 2023, 45, 3102-3121.	1.0	3
7008	Iniciativas Brasileiras Lideram com Forte CooperaÃ§Ã£o CientÃfica para Enfrentar QuestÃes da COVID-19: O Caso da CoalizÃ£o COVID-19 Brasil. <i>Arquivos Brasileiros De Cardiologia</i> , 2023, 120, .	0.3	0
7009	Therapeutics for COVID-19. , 2024, , 282-307.		0
7010	Fast tracking informative clinical trials: lessons for mental health. <i>Lancet Psychiatry</i> ,the, 2023, 10, 376-378.	3.7	0
7011	Impact of Maternal SARS-CoV-2 Infection on the Fetus and Newborn. , 2024, , 235-252.		0
7012	Comparing Clinical Outcomes of COVID-19 and Influenza-Induced Acute Respiratory Distress Syndrome: A Propensity-Matched Analysis. <i>Viruses</i> , 2023, 15, 922.	1.5	0
7013	Pulmonary Manifestations of COVID-19. , 2024, , 100-136.		0
7014	Immunology of COVID-19. , 2024, , 52-71.		0
7015	What Can We Still Learn from Brain Autopsies in COVID-19?. <i>Seminars in Neurology</i> , 2023, 43, 195-204.	0.5	1
7016	Kidney Manifestations of COVID-19. , 2024, , 203-217.		0
7017	COVID-19: Emergency Medicine Perspectives. , 2024, , 268-281.		0
7018	COVID-19: Natural History andÃSpectrum of Disease. , 2024, , 72-98.		0
7019	Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19. <i>JAMA Network Open</i> , 2023, 6, e237243.	2.8	8

#	ARTICLE	IF	CITATIONS
7020	COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery. <i>Genes and Diseases</i> , 2023, , .	1.5	3
7021	Treatment options for patients with severe COVID-19. <i>Global Health & Medicine</i> , 2023, 5, 99-105.	0.6	1
7022	<scp>SARSâ€CoV</scp>â€2 spike protein induces endothelial dysfunction in <scp>3D</scp> engineered vascular networks. <i>Journal of Biomedical Materials Research - Part A</i> , 2024, 112, 524-533.	2.1	1
7023	<i>Mycobacterium tuberculosis</i> and SARS-CoV-2 co-infections: The knowns and unknowns. <i>IScience</i> , 2023, 26, 106629.	1.9	3
7024	Adverse Tumour and Host Biology May Explain the Poorer Outcomes Seen in Emergency Presentations of Colon Cancer. <i>Annals of Surgery</i> , 0, Publish Ahead of Print, .	2.1	0
7025	Safety and efficacy of Siddha management as adjuvant care for COVID-19 patients admitted in a tertiary care hospital - An open-label, proof-of-concept Randomized Controlled Trial. <i>Journal of Ayurveda and Integrative Medicine</i> , 2023, 14, 100706.	0.9	0
7026	Investigational medications in 9,638 hospitalized patients with severe COVID-19: lessons from the â€fail-and-learnâ€ strategy during the first two waves of the pandemic in 2020. <i>Patient Safety in Surgery</i> , 2023, 17, .	1.1	0
7027	Lung transplantation for coronavirus disease 2019 acute respiratory distress syndrome/fibrosis: silver lining of a global pandemic. <i>Current Opinion in Organ Transplantation</i> , 0, Publish Ahead of Print, .	0.8	0
7028	The positive impact of COVID-19 on critical care: from unprecedented challenges to transformative changes, from the perspective of young intensivists. <i>Annals of Intensive Care</i> , 2023, 13, .	2.2	2
7029	NETosis induction reflects COVID-19 severity and long COVID: insights from a 2-center patient cohort study in Israel. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2569-2584.	1.9	14
7030	Post COVID Interstitial Lung Abnormalitiesâ€”Incidence and Management. <i>Current Pulmonology Reports</i> , 2023, 12, 64-69.	0.5	1
7031	Retrospective Comparison of Hospital Outcomes among Mechanically Ventilated COVID-19 Patients in ICU Who Received Methylprednisolone or Dexamethasone. <i>BioMed</i> , 2023, 3, 225-235.	0.6	0
7032	Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. <i>Viruses</i> , 2023, 15, 944.	1.5	19
7033	Drug-Induced Acute Pancreatitis in Hospitalized COVID-19 Patients. <i>Diagnostics</i> , 2023, 13, 1398.	1.3	2
7034	The Multifaceted Role of Annexin A1 in Viral Infections. <i>Cells</i> , 2023, 12, 1131.	1.8	1
7035	Endogenous Endophthalmitis in COVID-19 Patients: A Case Series and Literature Review. <i>Ocular Immunology and Inflammation</i> , 2023, 31, 1191-1197.	1.0	3
7036	Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies. <i>World Journal of Gastroenterology</i> , 0, 29, 2064-2077.	1.4	4
7037	Trends in management and outcomes of COVID patients admitted to a Swiss tertiary care hospital. <i>Scientific Reports</i> , 2023, 13, .	1.6	1

#	ARTICLE	IF	CITATIONS
7038	Drug evidence watch: a process to the benefit of public health. <i>Lancet, The</i> , 2023, , .	6.3	0
7039	Ongoing Uncertainties in Bleeding and Clotting Complications in Patients With COVID-19*. <i>Critical Care Medicine</i> , 2023, 51, 688-691.	0.4	0
7040	Drug effectiveness for COVID-19 inpatients inferred from Japanese medical claim data using propensity score matching. <i>F1000Research</i> , 0, 12, 398.	0.8	1
7042	Autochthonous Peruvian Natural Plants as Potential SARS-CoV-2 Mpro Main Protease Inhibitors. <i>Pharmaceuticals</i> , 2023, 16, 585.	1.7	4
7043	A Rare Side Effect of COVID-19 Treatment: Avascular Femoral Necrosis. , 0, , 33-37.		0
7044	Intervencionismo en dolor crÃ³nico y uso de corticoides en el riesgo de infecciÃ³n por SARS- Cov2. <i>Multidisciplinary Pain Journal</i> , 2023, , .	0.1	0
7045	A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions. <i>Npj Systems Biology and Applications</i> , 2023, 9, .	1.4	3
7046	Dexamethasone Modulates the Cytokine Response but Not COVID-19-Induced Coagulopathy in Critically Ill. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7278.	1.8	4
7047	Exploring m6Aâ€œRNA methylation as a potential therapeutic strategy for acute lung injury and acute respiratory distress syndrome. <i>Pulmonary Circulation</i> , 2023, 13, .	0.8	1
7048	Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives. <i>Advances in Therapy</i> , 2023, 40, 2626-2692.	1.3	8
7050	Dexamethasone for Inpatients With COVID-19 in a National Cohort. <i>JAMA Network Open</i> , 2023, 6, e238516.	2.8	4
7051	Severe COVID-19: Drugs and Clinical Trials. <i>Journal of Clinical Medicine</i> , 2023, 12, 2893.	1.0	0
7052	Effect of coronaviruses on blood vessel permeability: potential therapeutic targets. <i>Therapeutic Advances in Respiratory Disease</i> , 2023, 17, 175346662311622.	1.0	0
7053	Combination therapy with predicted body weight-based dexamethasone, remdesivir, and baricitinib in patients with COVID-19 pneumonia: A single-center retrospective cohort study during 5th wave in Japan. <i>Respiratory Investigation</i> , 2023, 61, 438-444.	0.9	0
7055	Anticoagulation strategy and safety in critically ill COVID-19 patients: a French retrospective multicentre study. <i>Thrombosis Journal</i> , 2023, 21, .	0.9	0
7056	Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
7057	Meta-Analysis of Glucocorticoids for Covid-19 Patients Not Receiving Oxygen. , 2023, 2, .		7
7058	Long COVID: pathophysiological factors and abnormalities of coagulation. <i>Trends in Endocrinology and Metabolism</i> , 2023, 34, 321-344.	3.1	42

#	ARTICLE	IF	CITATIONS
7059	Modern view on the etiology and immunological aspects of pneumonia. Meditsinskiy Sovet, 2023, , 141-153.	0.1	1
7060	Face mask integrated with flexible and wearable manganite oxide respiration sensor. Nano Energy, 2023, 112, 108460.	8.2	12
7061	Therapeutic strategies for COVID-19: progress and lessons learned. Nature Reviews Drug Discovery, 2023, 22, 449-475.	21.5	112
7062	Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review. Infectious Diseases of Poverty, 2023, 12, .	1.5	2
7063	Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patients's susceptibility to COVID-19 to the possible caution of future global diabetes tsunami. Inflammopharmacology, 2023, 31, 1029-1052.	1.9	4
7065	Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. European Journal of Clinical Pharmacology, 2023, 79, 723-751.	0.8	7
7066	Repurposed Drugs/Potential Pharmacological Agents Targeting Cytokine Release and Induction of Coagulation in COVID-19. , 2023, , 100-136.		0
7067	Age-related changes in plasma biomarkers and their association with mortality in COVID-19. European Respiratory Journal, 2023, 62, 2300011.	3.1	6
7069	Autopsy Findings of Severe COVID-19 Pneumonia Combined with Pulmonary Aspergillosis, Pneumothorax, and Pulmonary Thromboembolisms. American Journal of Case Reports, 0, 24, .	0.3	0
7070	Characterising biological mechanisms underlying ethnicity-associated outcomes in COVID-19 through biomarker trajectories: a multicentre registry analysis. British Journal of Anaesthesia, 2023, 131, 491-502.	1.5	1
7071	COVID-19 Developed During Systemic Steroid Therapy for Vogt-Koyanagi-Harada Disease: A Case Report. Ocular Immunology and Inflammation, 0, , 1-5.	1.0	1
7072	Severe COVID-19 Myocarditis in a Young Unvaccinated Patient. Cureus, 2023, , .	0.2	0
7073	Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia. Scientific Reports, 2023, 13, .	1.6	4
7074	Design and synthesis optimization of novel diimide indoles derivatives for ameliorating acute lung injury through modulation of NF- κ B signaling pathway. Bioorganic Chemistry, 2023, 136, 106557.	2.0	4
7077	Impact of systemic corticosteroids on hospital length of stay among patients with COVID-19. Farmacia Hospitalaria, 2023, 47, 55-63.	0.6	1
7078	COVID-19 and Multiorgan Response: The Long-Term Impact. Current Problems in Cardiology, 2023, 48, 101756.	1.1	2
7079	[Translated article] Efficacy and marginal cost of treatment with tocilizumab in COVID-19 patients. Farmacia Hospitalaria, 2023, 47, T10-T15.	0.6	0
7095	Osteonecrosis amid the COVID-19 pandemic. Rheumatology International, 2023, 43, 1377-1378.	1.5	6

#	ARTICLE	IF	CITATIONS
7130	Accelerating antiviral drug discovery: lessons from COVID-19. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 585-603.	21.5	25
7160	Intermediate- to high-dose dexamethasone versus low-dose dexamethasone in patients with COVID-19 requiring respiratory support: a systematic review and meta-analysis of randomized trials. <i>Inflammopharmacology</i> , 2023, 31, 2773-2779.	1.9	2
7184	COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma. <i>Annals of Hematology</i> , 2023, 102, 2635-2637.	0.8	2
7197	<i>Respiratory Viral Infections.</i> , 2023,, 161-176.		0
7199	<i>COVID-19 and Hematopoietic Stem Cell Transplantation.</i> , 2023,, 177-192.		0
7210	<i>Teaching Medical Statistics Within the Context of Evidence Based Medicine.</i> , 2023,, 19-29.		0
7223	<i>Therapeutic Interventions for COVID-19.</i> , 0,, .		0
7240	<i>The COVID-19â€™related neuroinflammation model may reveal relevant information on healthy longevity.</i> , 2023,, 47-73.		0
7244	Systemic Corticosteroids for Treating Respiratory Diseases: Less Is Better, butâ€¦ When and How Is It Possible in Real Life?. <i>Pulmonary Therapy</i> , 2023, 9, 329-344.	1.1	3
7262	Applications of single-cell RNA sequencing in drug discovery and development. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 496-520.	21.5	31
7283	The post-COVID stress syndrome: from the three-stage stress response of Hans Selye to COVID-19. <i>Inflammopharmacology</i> , 2023, 31, 2799-2806.	1.9	0
7284	Protein kinases: drug targets for immunological disorders. <i>Nature Reviews Immunology</i> , 2023, 23, 787-806.	10.6	11
7296	Case report: Fatal lung hyperinflammation in a preterm newborn with SARS-CoV-2 infection. <i>Frontiers in Pediatrics</i> , 0, 11, .	0.9	0
7301	<i>Antiviral Drugs for SARS-CoV-2 and COVID-19.</i> , 2023,, 211-223.		0
7308	Diabetes and COVID. <i>Contemporary Cardiology</i> , 2023,, 1025-1041.	0.0	0
7350	<i>ARF Mechanical Ventilation and History in Pandemics.</i> , 2023,, 3-9.		0
7372	Clinical Trial Design Innovations for Precision Medicine in Asthma. <i>Advances in Experimental Medicine and Biology</i> , 2023,, 395-412.	0.8	1
7407	<i>Corticosteroids in Emergency Pathologies.</i> , 0,, .		0

#	ARTICLE	IF	CITATIONS
7423	Respiratory Viruses and Atypical Bacteria. , 2024, , 254-267.		0
7440	COVID-19: Management of mild-moderate disease. , 2023, , 129-151.		0
7445	COVID-19 in Brazil: Overall Impact and Singularities. , 2023, , 513-536.		0
7446	Post-Viral Aspergillosis. Infectious Diseases, 0, , .	4.0	0
7467	Chronicling the 3-year evolution of the COVID-19 pandemic: analysis of disease management, characteristics of major variants, and impacts on pathogenicity. Clinical and Experimental Medicine, 0, , .	1.9	0
7473	Prolonged glucocorticoid treatment in ARDS: Pathobiological rationale and pharmacological principles. , 2024, , 289-324.e1.		0
7474	Steroid hormone receptors and regulation of ACE2 and COVID-19 disease outcomes. , 2024, , 129-145.		0
7479	Intrapartum Management of Moderate to Severe COVID-19: an Evidence-Based Update. Current Obstetrics and Gynecology Reports, 2023, 12, 165-172.	0.3	0
7484	Cancer management during the COVID-19 world pandemic. Cancer Immunology, Immunotherapy, 0, , .	2.0	1
7547	The role of SARS-CoV-2-mediated NF- κ B activation in COVID-19 patients. Hypertension Research, 2024, 47, 375-384.	1.5	2
7548	Awake prone positioning for patients with COVID-19-related respiratory failure: a systematic review and meta-analysis. Internal and Emergency Medicine, 0, , .	1.0	0
7554	Editorial: COVID-19 related acute vascular distress syndrome: from pathophysiology to treatment. Frontiers in Medicine, 0, 10, .	1.2	0
7565	Sensitivity and Subgroup Analysis. , 2023, , 55-64.		0
7599	Viral Infection. , 2023, , 181-211.		0
7604	Management of Acute Respiratory Distress Syndrome. , 2023, , 1-21.		0
7638	Severe Acute Respiratory Syndrome Coronaviruses-2 (SARS-CoV-2). , 2023, , 1529-1543.		0
7640	T cell responses to SARS-COV-2. Progress in Molecular Biology and Translational Science, 2023, , .	0.9	0
7731	The role of vitamin D in COVID-19. , 2024, , 1091-1108.		0

#	ARTICLE	IF	CITATIONS
7766	Management of Immunosuppressed Dermatology Patients During COVID-19. Updates in Clinical Dermatology, 2023, , 109-120.	0.1	0
7777	Corticosteroids in sepsis and community-acquired pneumonia. Medizinische Klinik - Intensivmedizin Und Notfallmedizin, 0, , .	0.4	1
7797	Editorial: Updates and new concepts in regulation of pro-inflammatory gene expression by steroid hormones, volume II. Frontiers in Endocrinology, 0, 14, .	1.5	0
7822	Clinical course and management of COVID-19 in the era of widespread population immunity. Nature Reviews Microbiology, 2024, 22, 75-88.	13.6	1
7823	Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review. Infection, 2024, 52, 43-58.	2.3	3
7832	Chemical and physiological effects of dexamethasone drug to hyperglycemia with Covid-19 patients. AIP Conference Proceedings, 2023, , .	0.3	0
7861	The pathophysiology of sepsis and precision-medicine-based immunotherapy. Nature Immunology, 2024, 25, 19-28.	7.0	1
7904	Inpatient Glucocorticoid-Induced Hyperglycemia. Contemporary Endocrinology, 2023, , 165-177.	0.3	0
7905	Diabetes and COVID-19. Contemporary Endocrinology, 2023, , 179-192.	0.3	0
7910	Steroid hormones and infection and immunity. , 2024, , 79-105.		0
7911	Pharmacotherapeutics for cytokine storm in COVID-19. , 2024, , 101-125.		0
7912	Metabolic syndrome and COVID-19: AnÂunholy alliance. , 2024, , 543-554.		0
7924	Impact of the coronavirus pandemic on living-donor organ transplantation. , 2024, , 1535-1544.		0
7943	Anti-inflammatory Drugs: Glucocorticoids. , 2023, , 265-275.		0
7947	Update in Pediatric Hospital Medicine. , 2023, , 449-477.		0
7987	Glucocorticoide und Mineralocorticoide. , 2023, , 463-469.		0